



**HAL**  
open science

# Generalizing a causal effect from a trial to a target population : methodological and theoretical contributions

Bénédicte Colnet

► **To cite this version:**

Bénédicte Colnet. Generalizing a causal effect from a trial to a target population : methodological and theoretical contributions. Statistics [math.ST]. Institut Polytechnique de Paris, 2023. English. NNT : 2023IPPAX048 . tel-04345484

**HAL Id: tel-04345484**

**<https://theses.hal.science/tel-04345484>**

Submitted on 14 Dec 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



INSTITUT  
POLYTECHNIQUE  
DE PARIS

NNT : 2023IPPAX048

Thèse de doctorat



*Inria*

# Generalizing a causal effect from a trial to a target population: methodological and theoretical contributions

Thèse de doctorat de l'Institut Polytechnique de Paris  
préparée à l'École polytechnique

École doctorale n°574 Ecole Doctorale de Mathématiques Hadamard (EDMH)  
Spécialité de doctorat : Spécialité de doctorat: Mathématiques appliquées

Thèse présentée et soutenue à Palaiseau, le Mercredi 28 Juin 2023, par

**BÉNÉDICTE COLNET**

Composition du Jury :

Erwan Le Pennec Professeur, École polytechnique	Président
Stijn Vansteelandt Professeur, Ghent	Rapporteur
Nicolai Meinshausen Professeur, ETH Zürich	Rapporteur
Trevor Hastie Professeur, Stanford	Examineur
Betsy Ogbrun Maître de conférences, Johns Hopkins	Examinatrice
Julie Josse Chercheur senior, Inria	Directrice de thèse
Erwan Scornet Maître de conférences, École polytechnique	Co-directeur de thèse
Philippe Ravaut Professeur, Assistance Public – Hôpitaux de Paris	Invité
Gaël Varoquaux Directeur de recherche, Inria	Invité



*“What has been is what will be,  
and what has been done is what will be done,  
and there is nothing new under the sun.*

*Is there a thing of which it is said, “See, this  
is new”?*

*It has been already in the ages before us.*

*There is no remembrance of former things,  
nor will there be any remembrance of later  
things*

*yet to be among those who come after.”*

Ecclesiastes, c. 450–330 BCE.

*“Ce qui a existé, c’est cela qui existera ;  
ce qui s’est fait, c’est cela qui se fera ;  
rien de nouveau sous le soleil.*

*Y a-t-il une seule chose dont on dise: “Voilà  
enfin du nouveau !”*

*– Non, cela existait déjà dans les siècles  
passés.*

*Mais, il ne reste pas de souvenir d’autrefois ;  
de même, les événements futurs ne laisseront  
pas de souvenir après eux.”*

L’Éclésiaste, env. IIIe siècle av. J.-C.





# Résumé en français

La médecine moderne, aussi dite médecine fondée sur les preuves, place les essais contrôlés randomisés (ECRs) au premier plan de la preuve clinique. En effet, la randomisation permet une estimation de l'effet causal du traitement, au lieu de la simple association ou corrélation. Cependant, de plus en plus de limites sont trouvées aux ECRs, du fait de leurs stricts critères d'éligibilité, des conditions de réalisation, des périodes de temps trop restreintes qu'ils couvrent, ou encore de leur petite taille d'échantillon. Toutes ces raisons entament ce que l'on appelle la validité externe des résultats. L'utilisation de données observationnelles – ou dites de vie réelle – constitue une potentielle solution. Les autorités sanitaires comme le régulateur américain (*Food and Drug Administration*) ou encore la *Haute Autorité de la Santé* (HAS) soutiennent ces nouvelles pratiques. Mais les données de vie réelle ne sont pas non plus une panacée, car leur analyse repose sur des hypothèses non vérifiables pour la plupart. Des travaux plus récents proposent de combiner les deux sources de données, afin de renforcer les faiblesses de l'une par les forces de l'autre. Ainsi, cette thèse propose d'abord une revue de toutes les méthodes existantes sur le sujet, que ce soit pour déconfondre une base de données observationnelles à partir de données expérimentales ou bien pour généraliser à d'autres populations une étude randomisée. Ce travail de thèse propose ensuite d'approfondir ce dernier aspect, en utilisant la représentativité des données de vie réelle pour re-pondérer les résultats d'un ECR. Cette thèse étudie les propriétés théoriques de ces méthodes, telles que les propriétés d'estimation à taille finie ou asymptotique (biais et variance). Ces résultats permettent d'obtenir des recommandations pratiques pour la recherche clinique, notamment concernant la sélection de covariables. Cette thèse propose également une analyse de sensibilité lorsque les covariables sont partiellement ou totalement observées. La plupart des travaux existants définissent l'effet d'un traitement comme une différence absolue. Pourtant, d'autres métriques, comme le ratio, sont préférées dans la recherche clinique. Par conséquent, cette thèse ouvre également la voie à la généralisation de toutes les mesures causales, et non pas seulement de l'une d'entre elles. Ce faisant, nous relient la généralisation à une préoccupation plutôt ancienne de la causalité, à savoir la collapsibilité d'une mesure. Nous proposons également une autre façon d'appréhender ce que l'on appelle l'hétérogénéité d'un effet. Ceci nous permet de montrer que les méthodes pour généraliser un effet causal dépendent de la nature de l'outcome (continu ou binaire) ainsi que de la nature de la mesure d'intérêt (ratio ou différence). Tous les travaux de cette thèse sont développés en lien avec la recherche clinique, notamment via le consortium français de la Traumabase.

# Abstract

Modern evidence-based medicine places Randomized Controlled Trials (RCTs) at the forefront of clinical evidence. Randomization enables the estimation of the average treatment effect (ATE) by eliminating the confounding effects of spurious or unwanted associated factors. More recently, concerns have been raised on the limited scope of RCTs: stringent eligibility criteria, unrealistic real-world compliance, short timeframe, limited sample size, etc. All these possible limitations threaten the external validity of RCT studies to other situations or populations. The usage of complementary non-randomized data, referred to as *observational* or from the *real world*, brings promises as additional sources of evidence. Today, there is a growing incentive to rely on this new data, which is also endorsed by health authorities such as the *Food and Drug Administration* (FDA) in the U.S. and the *Haute Autorité de la Santé* (HAS) in France. Combining both data types – randomized and observational – is a new venue that could make the most of both worlds. First, this thesis proposes a review of all the existing methods combining several data types to build clinical evidence. Then, the thesis is focused on improving the external validity of RCTs. In other words, how can we use representative sample of the target population of interest to *re-weight* or to *generalize* the trial's findings? Such methods are quite recent and have been proposed in the early 2010's. This thesis investigates theoretical properties of these methods, such as finite and large sample properties (bias and variance) of the estimation, which helps to provide practical guidelines about covariates selection and the impact of both samples' sizes. This thesis also proposes a sensitivity analysis when covariates are either partially or totally unobserved. Most – if not all – current statistical works concern the generalization of the effect on the scale of the absolute difference, while our clinicians collaborators pointed to us the need to encompass several causal measures (e.g. ratio, odds ratio, number needed to treat). Therefore, this thesis also opens the door to the generalization of all causal measures of interest. Doing so, we link generalization with a rather old concern of causality, namely collapsibility of a measure. We also propose a new framing to apprehend heterogeneity of a treatment effect. Finally, it turns out that assumptions required for generalization depend on the nature of the outcome and the causal measure of interest. All our research questions are motivated by clinical applications, and in particular by the Traumabase consortium.

# Remerciements

Ce travail de recherche n'aurait pas été le même sans la participation plus ou moins directe de toutes les personnes suivantes.

Tout d'abord je souhaite remercier mes trois directeurs de thèse – Julie Josse, Erwan Scornet, et Gaël Varoquaux. J'ai souvent dit autour de moi pendant ces trois dernières années que je n'aurais pas pu espérer meilleur encadrement. N'y voyez ici aucune flagornerie ni exagération de ma part. Julie, Gaël, Erwan: merci pour le temps que vous avez mis dans l'encadrement de cette thèse, pour votre soutien permanent, et pour avoir eu la générosité de partager vos savoirs, votre approche de la science, votre vision de ce qui est important et de ce qui l'est moins, et votre amour des raisonnements justes. L'aventure du doctorat ne me laisse pas indemne, et je repars changée et chargée de l'héritage de chacun de vous. Merci Julie de m'avoir conseillée sur toutes les étapes de la thèse, scientifiques mais aussi celles qui concernent la vie et le savoir-être. Merci pour ta présence quotidienne et ton encadrement exceptionnel. Merci Gaël de m'avoir appris à penser hors du cadre, et appris à chercher la bonne question tout en façonnant la bonne réponse. Enfin, merci Erwan pour les longues heures que tu as consacrées à refaire mes calculs, à clarifier le propos, à m'expliquer que le plus important est de trouver la bonne notation et la bonne question. Merci de m'avoir appris à être plus réfléchie. Merci aussi à tous les trois pour votre humour et la bonne humeur toujours présente. Trois directeurs c'est plus que d'ordinaire. Cet orchestre a su concerter ensemble, accordant des instruments différents, pour faire une composition unique. Nos rendez-vous hebdomadaires me manquent déjà.

J'aimerais désormais remercier les membres du jury, sans qui ce travail n'aurait pas reçu l'assentiment des pairs nécessaire et précieuse à la validation scientifique. Thank you to the reviewers, Prof. Nicolai Meinshausen and Prof. Stijn Vansteelandt for accepting to take the time to read the manuscript and for their high quality review. Thank you also to Prof. Elizabeth L. Ogburn, Prof. Trevor Hastie (whose book was the one in which I first discovered Machine-Learning), Prof. Erwan Le Pennec, and Prof. Philippe Ravaud for being part of the committee. I feel honored to present my work in front of incredible researchers who are inspiring me.

Pendant ces trois années j'ai eu la chance d'être accueillie par le laboratoire PARIETAL devenu depuis SODA · MIND. Ce lieu est une pépite de la recherche française. Merci à Bertrand Thirion pour avoir accepté et soutenu ma demande de candidature. Merci à tous ses membres qui insufflent la culture scientifique et la camaraderie singulière de ce lieu: Thomas, Jill-Jënn, Alexandre, Demian, Philippe, et puis tout le groupe des personnes sans HDR : Alexandre<sup>2</sup>, Matthieu<sup>2</sup> et Mathieu (désolé Mathieu d'être un co-bureau qui parle parfois trop et manque toujours de réserve de café), Thuthu (qui contrairement à moi, fait de la vraie science), Alexis, Lilian, Ambroise, Louis, Léo, Théo, Apolline, Riccardo, Cédric, Julia, Benoît, Samuel, Jun, Tomas, et tous les autres que j'oublie. Un clin d'œil particulier à Matthieu, avec qui nous partageons un directeur de thèse, une même thématique de thèse, un même numéro de promotion, et un début tardif de thèse commun. Nous avons progressé ensemble, et merci pour les heures de discussions à essayer de comprendre l'inférence causale, mais aussi les débats politiques autour du café matinal. Quel plaisir aussi de parler science et de partager les séminaires avec l'incroyable équipe scikit-learn (autre pépite française). Merci à Olivier, Guillaume, Loïc, Julien, Vincent, Franck, Jovan, François. J'ajoute ici une mention toute particulière à deux jeunes chercheuses exceptionnelles: Marine Le Morvan et Judith Abecassis. J'ai eu la chance de partager votre bureau et de voir votre passage de post-doctorantes à chercheuses. Merci infiniment

---

pour votre bonne humeur, vos conseils de vie, ou de survie en recherche. Le laboratoire a de la chance de vous avoir, et je suis ravie de connaître une relève aussi brillante.

Merci également à tous les étudiants et membres de PreMeDICAL: Aude, Maxime, Pan, Margaux, Paul, Imke. Quelle joie de voir cette nouvelle équipe se créer. Merci à Paul pour nos échanges et questionnements pendant la thèse. Je n'oublie pas ton expertise pour classer sans faux positifs le bon café du mauvais café. Merci Margaux pour les réflexions sur le but de la science, et puis les bons moments en conférence. Phong a aussi croisé la route de ce laboratoire. Je suis déçue de ne pas avoir pu partager de projet de recherche ensemble. Quelque chose me dit que nos routes vont continuer de se croiser. Enfin, j'ai eu la chance de débiter ma thèse au côté de Imke. Merci Imke de m'avoir littéralement prise sous ton aile, de m'avoir expliqué le quotidien de la recherche, d'avoir répondu à toutes mes questions. Merci de ton soutien, de ta sagesse, et de ta patience au quotidien. Bon courage à la relève: Ahmed, Rémi, Charlotte, Jeff. J'ai hâte de voir les merveilles que vous allez réaliser !

During this Ph.D. I had the chance to go to the U.S. for several months. Thank you to the Simons Institute for the invitation to the Causality semester. This was an incredible and invaluable opportunity as a young researcher to meet the community. Thank you also to the Stanford Department of Statistics and especially to Prof. Trevor Hastie for welcoming me as a visiting student. Thank you to all students (John, Dan, Michael, Shuangning and others) for the warm welcome. I found inspiration and confidence in these two wonderful places. Merci Adrien et Solène pour votre accueil sur le campus, les dumplings, et les récits photosynthétiques.

Pendant cette thèse j'ai eu la chance de travailler avec d'autres personnes que celles du laboratoire. Je remercie tous les médecins de la Traumabase – Tobias Gauss, Jean-Denis Moyer, François-Xavier Ageron – pour leur intérêt dans nos travaux et pour avoir toujours pris le temps de répondre à mes questions les plus naïves. Ce projet n'aurait pas été le même sans vous. Mes pensées vont à Sophie Hamada pour qui le chemin s'est arrêté trop tôt.

Rechercher c'est collaborer, et je remercie Gaël et Stanislas Dehaene d'avoir rendu possible un travail de recherche avec Pauline Martinot. Merci Pauline d'avoir accepté qu'une ingénieure parfois un peu psycho-rigide sur le traitement des données et sur les modèles utilisés arrive sur ton projet de thèse. J'ai beaucoup appris à tes côtés, et je te remercie pour ton dynamisme et ta motivation sans faille. Quel plaisir pour moi de voir nos rencontres R petit à petit remplacées par des moments d'amitié avec JB, Marc, le petit Charles, et Scarlett.

Merci également aux conseils de François Husson sur un projet d'analyse de données de Twitter. Nos trouvailles sur le panorama journalistique de notre pays resteront pour le moment entre nous. Qui sait, peut-être que ce projet ira plus loin ?

Le chemin vers la thèse n'a pas été une évidence pour moi. Je souhaite ici remercier les personnes qui m'ont aidée dans ce discernement. Merci en particulier à Johan Mathe, Nina Miolane, Claire Biot, Fanny Perraudeau, et Arnaud Echard. Nos échanges ont été de véritables moments décisifs dans mon choix.

La thèse, parce qu'elle demande beaucoup, envahit nécessairement son entourage amical. Merci les amis pour votre soutien sur ces trois années et vos encouragements alors même que la thèse nous fait douter de tout. Merci aux bouboux et à son adhérence : Augustin, Basile, Camille, Grégoire, Louis, Valentin, Marion, Solène, et Merlin. Merci de me rappeler à chaque fois l'auto-dérision et de prendre le temps. Merci à Denis. Merci aux Corbeliens, et plus particulièrement aux confinés Maudimaud, Tibo, Nathan, Emily, et Alexandre. J'ajoute bien sûr à la liste Olivia, quasi-confinée. Merci pour le soutien et tous les moments de camaraderie passés et à venir. Merci à Marie-Anne pour sa patience lorsque je lui explique ma question de recherche du moment ou alors ma dernière angoisse existentielle. Merci aussi pour tous ces moments d'évasion que nous prenons ensemble et qui sont des bulles

d'air nécessaires. Merci aux raideurs 14, et en particulier à Pou, Ki, Beau, Ba, La, Colin, Victor, et Mathilde, de toujours prendre des nouvelles. Merci aux amis d'enfance: Jeanne et Marine, qui doivent bien finir par se demander pourquoi je continue de souffrir autant (comme si nous n'avions pas déjà assez donné au collège). Je pense aussi aux autres compagnons de fortune qui ont débuté une thèse en même temps: Pierre, Corentin, Robin, Victor, El Mehdi et Rubing. Nos exposés respectifs ont été des moments de plaisir scientifique, me permettant à chaque fois de mesurer la chance de pouvoir faire des sciences au quotidien. Merci en particulier à Pierre d'avoir initié ces rendez-vous et de fédérer le groupe.

Merci à la team Kraaft pour son accueil dans leurs locaux lors de mes journées de télétravail. Vous avez littéralement illuminé mes journées et permis de ne pas trop m'enfoncer dans des méandres statistiques pour garder un lien avec le terrain !

Depuis des années, ils ont vu et supporté mes questionnements et errements dans le monde scolaire et professionnel. Ils ont supporté mon travail parfois trop intense. Papa et maman: le chemin aurait été bien différent et bien pénible sans votre soutien. Et si je tiens ce goût des sciences, ce n'est probablement pas par hasard. Merci.

Marc, merci d'être mon compagnon de route.

# Avant-propos

En tant que fonctionnaire – en particulier ingénieure du corps des mines – j’ai eu la chance d’effectuer ma thèse dans les meilleures conditions qui soient. Je remercie tout particulièrement mon employeur INRIA, ainsi que le corps des mines pour avoir accepté mon détachement. Merci à la commission scientifique et technique du corps des mines, présidée par Yannick d’Escatha, ainsi qu’à Catherine Lagneau de leur soutien et de leur confiance dans ce projet de recherche.

Beaucoup de nos concitoyens ne connaissent pas l’existence des grands corps d’État, en particulier les corps techniques. J’en ai moi-même découvert l’existence lors de ma scolarité à l’École polytechnique. En quelques mots, ils constituent un vivier de fonctionnaires-ingénieurs, généralement recrutés à la sortie des dites Grandes Écoles comme l’École polytechnique, les Mines de Paris, Telecom, ou encore les Écoles Normales Supérieures (ENS). Depuis quelques années, le recrutement tend à s’élargir légèrement, avec notamment l’ouverture d’une voie de recrutement sur doctorat.

Débuter par la recherche scientifique n’a pas été un chemin facile, à la fois pour la réflexion personnelle que cela implique, mais aussi parce que cette possibilité, si elle existe, n’est pas encouragée. À certains égards, faire le choix d’obtenir un doctorat est perçu par certains comme une perte de temps ou l’option du confort de rester un *éternel étudiant*. Demander à aller en institut de recherche ou à l’université pour quelques années alors que d’autres postes nous sont proposés peut donc passer pour un luxe. Consciente de la position privilégiée que j’occupe, ces questions me tiennent à coeur. J’ai donc moi-même ressenti l’embarras de prendre encore plus à un système qui me récompense déjà beaucoup.

Pourtant, après trois années d’immersion et de travail dans la recherche académique, je ne regrette en aucun cas cette décision. Au contraire ! Faire le choix de la recherche scientifique, c’est d’abord *pratiquer* la science. Alors que je me sentais vaguement ingénieure en sortie d’école, je me sens désormais scientifique. Le changement le plus visible est une connaissance dite experte sur un sujet et une légitimité nouvelle. Mais plus important: ma relation au savoir a changé. Désormais, ce que j’appelle savoir - ou connaissance - est quelque chose qui se découpe entre plusieurs notions: ce qui est écrit dans les livres, ce que les autres disent, ce qui est considéré comme une preuve, ce dont j’ai entendu parler, et ce que je maîtrise partiellement ou réellement. D’une certaine façon, me suis émancipée de mon rapport encyclopédique à la connaissance.

J’en mesure le bénéfice personnel. Mais était-ce de l’argent bien investi par la Nation? C’est aux citoyens d’apporter la réponse. Le recrutement, la formation, et la vocation des hauts-fonctionnaires est une question politique, qui évolue avec la société et les besoins qui la traversent.

Ces dernières années, la France a connu une phase de questionnement sur la légitimité de ses élites. Je pense notamment à la manifestation des gilets jaunes ou encore aux débats sur la (perte de) souveraineté énergétique française. À une époque bouleversée par le retour de la guerre aux portes de l’Europe, l’inflation, les conflits sociaux, et les prémices des bouleversements climatiques et écologiques à venir, l’expertise scientifique est nécessaire. Dans mes réflexions sur ces sujets, j’ai récemment découvert l’existence du décret Suquet (Figure 1 ci-dessous), paru au début de la Seconde Guerre Mondiale. Ce Décret résonne avec notre époque, indiquant une perte de compétences scientifiques et techniques en interne des corps techniques. Il pointe notamment le manque de temps pour se

former, les effectifs réduits, ou encore la pénurie de formation scientifique (et non pas scolaire) alors même que des vocations se présentent. En conséquence, ce Décret propose d'augmenter le nombre de recrutements de fonctionnaires ingénieurs pour permettre à une partie d'entre eux de débiter par une période de recherche de quatre ans minimum au côté d'un savant de son domaine. Le propos conclut ainsi que "Certes, ce remède excellent et d'un effet sûr nécessite quelques créations d'emplois dans certains corps dont l'effectif est déjà très réduit: il se traduit donc par une dépense nouvelle. Mais celle-ci est assurément faible eu égard aux services d'ordre national et aux économies que procurera l'organisation proposée."

**MINISTÈRE DE LA DÉFENSE NATIONALE  
ET DE LA GUERRE**

**Organisation de la recherche scientifique dans  
les corps techniques de l'Etat.**

**RAPPORT**  
AU PRÉSIDENT DE LA RÉPUBLIQUE FRANÇAISE

Paris, le 24 août 1939.

Monsieur le Président,

Les conditions dans lesquelles la recherche scientifique s'effectue actuellement dans les corps techniques de l'Etat sont particulièrement préjudiciables aux études intéressant la défense nationale et ont en outre de graves conséquences d'ordre financier et économique.

La cause de ces déficiences dans nos services de recherches ne peut être trouvée dans une insuffisance de la formation scolaire et technique de nos corps d'ingénieurs ou d'officiers, issus, en majeure partie, de nos grandes écoles, présentant les meilleures garanties de culture générale scientifique; ils acquièrent ensuite dans d'excellentes écoles d'application les notions techniques qui leur permettent de rendre des services dans leurs corps. La qualité du recrutement n'a pas fléchi.

Mais, il ne s'agit là que d'une formation scolaire. La formation scientifique supérieure, qui seule peut produire des chercheurs de qualité, ne s'acquiert que par un travail de recherches personnelles, poursuivies dans un laboratoire de formation scientifique. Ce sont de telles individualités, à culture hautement scientifique, dont on constate l'actuelle pénurie.

Cependant ce ne sont pas les vocations qui manquent. Ce qui fait défaut, en définitive, c'est la possibilité de suivre cette vocation. Et cette impossibilité est due au développement des tâches de l'Etat qui dirige vers l'administration pure l'activité des ingénieurs d'Etat. Les besoins du service sont tels qu'au sortir de l'école d'application, les jeunes ingénieurs reçoivent un poste d'affectation, sans qu'il soit possible de les en distraire pendant les quelques années qui seraient nécessaires pour leur assurer une formation scientifique supérieure.

Il a donc paru indispensable d'obliger certains corps techniques de l'Etat à affecter à des postes dits « de recherche scientifique » un petit nombre de leurs ingénieurs ou officiers. L'affectation à ces postes, entraînant la mise des titulaires à la disposition d'un savant éminent, pour une durée de quatre ans au minimum et en principe de six ans au maximum, permettrait à ceux-ci d'acquiescer une formation scientifique supérieure dont leurs corps en définitive seraient les bénéficiaires. Au terme de leur affectation aux postes de recherches scientifiques, ces ingénieurs ou officiers y seraient remplacés par d'autres plus jeunes de façon à assurer à la mesure adoptée un caractère de continuité.

Certes, ce remède excellent et d'un effet sûr nécessite quelques créations d'emplois dans certains corps dont l'effectif est déjà très réduit; il se traduit donc par une dépense nouvelle. Mais celle-ci est assurément faible eu égard aux services d'ordre national et aux économies que procurera l'organisation proposée. C'est pourquoi il a paru que l'adoption de la mesure envisagée, en vertu de la loi du 19 mars 1939, était indiscutablement légitime.

Le conseil des ministres entendu,

Décrète:

**TITRE I<sup>er</sup>**

**Organisation de la recherche scientifique dans les corps techniques de l'Etat.**

Art. 1<sup>er</sup>. — Les corps techniques de l'Etat énumérés ci-après sont tenus d'affecter à des postes de recherche scientifique le nombre d'ingénieurs ou d'officiers fixé pour chacun d'eux par le tableau ci-dessous:

Ingénieurs au corps national des mines...	6
Ingénieurs au corps national des ponts et chaussées .....	6
Ingénieurs des manufactures de l'Etat...	4
Ingénieurs des postes et télégraphes.....	6
Ingénieurs de l'aéronautique.....	6
Ingénieurs au corps du génie rural.....	3
Ingénieurs militaires du génie maritime...	6
Ingénieurs militaires de l'artillerie navale.	6
Ingénieurs militaires des fabrications d'armement .....	6
Ingénieurs militaires des poudres.....	2
Officiers des eaux et forêts.....	3
Officiers d'artillerie.....	4
Officiers du génie.....	4

Art. 2. — Les ingénieurs ou officiers affectés à ces postes sont mis, pendant une durée minimum de quatre ans à la disposition du directeur d'un laboratoire de recherche de l'enseignement supérieur ou de l'école polytechnique, avec l'agrément du ministre dont dépend ce laboratoire. Ils peuvent aussi, sur avis favorable de la section compétente du conseil supérieur de la recherche scientifique, être mis à la disposition d'un savant de notoriété reconnue.

Figure 1: Journal Officiel de la République Française en date du Mercredi 30 Août 1939 – Extraits du Décret relatif à l'organisation de la recherche scientifique dans les corps techniques de l'État, aussi appelé Décret Suquet.



# Contents

<b>1</b>	<b>Introduction</b>	<b>1</b>
1	The emergence of modern clinical evidence . . . . .	1
2	Rising concerns about external validity . . . . .	5
3	The promise of detailed and larger observational data . . . . .	9
4	Contributions . . . . .	16
1.A	L'émergence de l'évidence clinique dite moderne . . . . .	20
1.B	Limites des essais randomisés contrôlés dans la recherche clinique . . . . .	24
<b>2</b>	<b>Combining experimental and observational data: a review</b>	<b>29</b>
1	Introduction . . . . .	30
2	Problem setting . . . . .	31
3	When observational data have no treatment and outcome information . . . . .	35
4	When observational data contain treatment and outcome information . . . . .	42
5	Structural causal models (SCM) and transportability . . . . .	45
6	Software for combining RCT and observational data . . . . .	48
7	Application: Effect of Tranexamic Acid . . . . .	51
8	Conclusion . . . . .	55
2.A	Randomized controlled trial . . . . .	58
2.B	Estimation of ATE in observational data . . . . .	58
2.C	Identification formula . . . . .	59
2.D	Sources of formal statements of estimators described in Section 3.2 . . . . .	60
2.E	Nested study design . . . . .	61
2.F	Additional information on the SCM framework . . . . .	65
2.G	Additional simulation results . . . . .	69
2.H	Supplementary information on Traumabase and CRASH-3 . . . . .	73
<b>3</b>	<b>Sensitivity analysis</b>	<b>82</b>
1	Introduction . . . . .	83
2	Problem setting: generalizing a causal effect . . . . .	85
3	Impact of a missing key covariate for a linear CATE . . . . .	87
4	Synthetic and semi-synthetic simulations . . . . .	95
5	Application on critical care data . . . . .	99
3.A	Estimators of the target population ATE . . . . .	102
3.B	$L^1$ -convergence of G-formula, IPSW, and AIPSW . . . . .	103
3.C	Proofs for the missing covariate setting . . . . .	110
3.D	Toward a semi-parametric model . . . . .	114
3.E	Robinson procedure . . . . .	115
3.F	Synthetic simulation - Extension . . . . .	115
3.G	Homogeneity of the variance-covariance matrix . . . . .	117

---

<b>4</b>	<b>Finite sample error and variable selection</b>	<b>120</b>
1	Introduction . . . . .	121
2	Problem setting . . . . .	122
3	Notations and assumptions for causal identifiability . . . . .	126
4	Theoretical results . . . . .	131
5	Synthetic and semi-synthetic simulations . . . . .	139
6	Conclusion and future work . . . . .	143
4.A	Main proofs . . . . .	144
4.B	Extended adjustment set . . . . .	168
4.C	Semi-synthetic simulation's data preparation . . . . .	169
4.D	Useful results about RCTs under a Bernoulli design . . . . .	172
4.E	(Non-exhaustive) Review of the different IPSW versions in the literature . . . . .	182
<b>5</b>	<b>Which causal measure is easier to generalize?</b>	<b>183</b>
1	The age-old question of how to report effects . . . . .	184
2	Problem setting and key results . . . . .	185
3	Causal metrics and their properties . . . . .	190
4	Reverse the thinking: using working models . . . . .	195
5	Are some measures easier to generalize than others? . . . . .	200
6	Illustration through simulations . . . . .	202
7	Conclusion . . . . .	204
5.A	Treatment effect measures . . . . .	205
5.B	Definitions found in the literature . . . . .	208
5.C	Proofs . . . . .	210
5.D	Usual point of view for a binary outcome: logistic regression . . . . .	222
5.E	Complements on the intrication model . . . . .	224
5.F	Different points of view . . . . .	226
5.G	Comments and answers to related article . . . . .	230
5.H	Details about the simulations . . . . .	233
<b>6</b>	<b>Conclusion</b>	<b>237</b>
	<b>References</b>	<b>240</b>

# List of Figures

1	Extrait du Décret Suquet . . . . .	v
1.1	The pyramid of evidence in clinical research . . . . .	4
1.2	Cartoon by Jim Borgman in 1997 . . . . .	5
1.3	Univariate comparison of Glasgow score . . . . .	8
1.4	Hypothetical response to Tranexamic acid (TXA) . . . . .	8
1.5	Number of published IPW studies . . . . .	14
1.6	La pyramide des preuves dans la recherche clinique . . . . .	23
1.7	Caricature des sciences médicales modernes par Jim Borgman . . . . .	24
1.8	Distribution du score de Glasgow . . . . .	27
1.9	Schéma illustratif . . . . .	28
2.1	Schematics of the nested (left) and non-nested (right) designs . . . . .	34
2.2	Illustrative schematics for the estimation strategies . . . . .	37
2.3	Illustration of selection diagrams for transportability . . . . .	47
2.4	Post-treatment covariate adjustment . . . . .	48
2.5	Well-specified model . . . . .	51
2.6	Mis-specified models . . . . .	52
2.7	Structural causal diagram for the CRASH-3 / Traumabase application . . . . .	53
2.8	Distributional shift for the CRASH-3 / Traumabase application . . . . .	54
2.9	Estimation results of CRASH-3 findings transported on the Traumabase population . . . . .	56
2.10	Examples of Structural Causal Models . . . . .	66
2.11	Application of the backdoor criterion in large graphs . . . . .	67
2.12	Summary of identifiability results to control for confounding bias . . . . .	68
2.13	Cases with sample selection bias . . . . .	68
2.14	Covariates distributions differences . . . . .	70
2.15	Simulations: Weak versus strong distributional shift between experimental and observational data . . . . .	71
2.16	Simulations: Effect of strata number . . . . .	71
2.17	Simulations: Impact of the treatment-effect modifiers . . . . .	72
2.18	Simulations: Homogeneous treatment effect . . . . .	72
2.19	Percentage of missing values for a subset of Traumabase variables . . . . .	73
2.20	Causal graph for the Traumabase . . . . .	74
2.21	Traumabase / CRASH-3: Distributional shift for age . . . . .	76
2.22	Traumabase / CRASH-3: Distributional shift for the Glasgow score . . . . .	76
2.23	Traumabase / CRASH-3: Distributional shift for blood pressure . . . . .	77
2.24	Traumabase / CRASH-3: Gender imbalance . . . . .	77
2.25	Traumabase / CRASH-3: Distributional shift for pupils reactivity . . . . .	77
2.26	PCA of the data set combining CRASH-3 and Traumabase data. . . . .	78
2.27	Conditional odds histogram ( <code>glm</code> ) obtained with the <code>misaem</code> R package. . . . .	79
2.28	Conditional odds histogram ( <code>grf</code> ) obtained with random forests. . . . .	79
2.29	Scatter plot of the two conditional odds . . . . .	80
2.30	Generalization's results for the severe strata . . . . .	81

3.1	Typical data structure of Chapter 3 . . . . .	87
3.2	Sensitivity maps . . . . .	92
3.3	Variance-covariance preservation in the simulation set-up . . . . .	95
3.4	Illustration of Theorem 5 . . . . .	96
3.5	Simulations results when applying procedure 2 . . . . .	97
3.6	Empirical link between the logistic regression coefficient for sampling bias $\beta_{s,1}$ and the p-value of a Box-M test . . . . .	97
3.7	Impact of poor transportability of the variance-covariance matrix . . . . .	97
3.8	Simulated STAR data . . . . .	99
3.9	Sensitivity analysis of STAR data . . . . .	99
3.10	Sensitivity map if the Glasgow score covariate was missing . . . . .	101
3.11	Sensitivity map for TTT . . . . .	101
3.12	Simulations results when imputin . . . . .	116
3.13	Simulation results for proxy variable . . . . .	116
3.14	Pairwise data ellipses for the STAR data . . . . .	117
3.15	Pairwise data ellipses for the CRASH-3 and Traumabase data . . . . .	118
3.16	Effect of a different variance-covariance matrix on the ATE estimation . . . . .	119
4.1	Treatment effect estimates (toy example) . . . . .	122
4.2	Covariate shift along the genetic mutation $X$ (toy example) . . . . .	122
4.3	Toy example's simulations - General results under the minimal adjustment set, that is covariate $X$ . . . . .	123
4.4	Toy example's simulations – Extended adjustment set . . . . .	124
4.5	Summary of the data at hand . . . . .	127
4.6	Illustration of Corollary 5 . . . . .	135
4.7	Risks and different asymptotic regimes . . . . .	140
4.8	IPSW estimating $\pi$ or not . . . . .	141
4.9	Effect of non-necessary covariates on the variance . . . . .	142
4.10	Bar plot of categorized age in the semi-synthetic simulation . . . . .	170
4.11	Bar plot of categorized systolic blood pressure in the semi-synthetic simulation . . . . .	171
4.12	Bar plot of gender in the semi-synthetic simulation . . . . .	171
4.13	Bar plot of the glasgow score in the semi-synthetic simulation . . . . .	171
4.14	[Bar plot of pupil reactivity in the semi-synthetic simulation]Bar plot of pupil reactivity (−1 encoding not able to measure) in the semi-synthetic simulation . . . . .	172
4.15	Bar plot of categorized time-to-treatment in the semi-synthetic simulation . . . . .	172
5.1	Generalization in practice: data sets at hand . . . . .	193
5.2	Intuition behind Lemma 11 . . . . .	196
5.3	Intuition for a binary outcome . . . . .	196
5.4	Simulation's covariate shift . . . . .	201
5.5	Results of the simulations for a continuous outcomes . . . . .	202
5.6	Simulation with binary outcome $Y$ . . . . .	203
5.7	Plots of the ranges of the different metrics . . . . .	206
5.9	Heterogeneity of a treatment effect depends on the scale . . . . .	209
5.10	Implementation of the formulae from eq. 5.24 . . . . .	216
5.11	Illustration of the impossibility of having a constant $\tau_{RR}(x) > 1$ . . . . .	231
5.12	Illustration of the possibility to have a constant $\tau_{SR}(x) < 1$ . . . . .	231

# List of Tables

1.1	A typical Table 1 . . . . .	7
1.2	Un exemple de Table 1 . . . . .	26
2.1	Illustration of data structure . . . . .	33
2.2	List of notations. . . . .	33
2.3	Inventory of publicly available code for generalization . . . . .	50
2.4	ATE estimations from the Traumabase for TBI-related 28-day mortality . . . . .	53
2.5	Sample sizes for both studies. . . . .	54
2.6	Overview of generalization estimators with missing values . . . . .	55
2.7	ATE estimations from the Traumabase . . . . .	80
2.8	Results reproduction for CRASH-3 . . . . .	80
2.9	Sample sizes of both studies: CRASH-3 and Traumabase . . . . .	81
3.1	Summary of the assumptions of Chapter 3 . . . . .	89
3.2	Differences between Chapter 3's methods and existing methods . . . . .	90
3.3	Simulations parameters . . . . .	95
3.4	Simulations results when applying procedure 3 . . . . .	97
3.5	Coefficients estimated in the simulation . . . . .	115
4.1	Non-exhaustive review of the different IPSW versions . . . . .	182
5.1	Benefit of antihypertensive therapy ( $A$ ) against stroke ( $Y$ ) . . . . .	187
5.2	Non-collapsibility of the odds ratio on a toy example . . . . .	191
5.3	Causal measures and their properties (collapsibility, logic-respecting) . . . . .	193
5.4	Summary of the different values of the Russian roulette example . . . . .	225
5.5	Typical causal measures reported in clinical practice . . . . .	236

# Chapter 1

## Introduction

*“Statistical inference is an unusually wide-ranging discipline, located as it is at the triple-point of mathematics, empirical science, and philosophy.”*

Brad EFRON and Trevor HASTIE, *Computer Age Statistical Inference*

### Contents

---

1	The emergence of modern clinical evidence . . . . .	1
2	Rising concerns about external validity . . . . .	5
3	The promise of detailed and larger observational data . . . . .	9
4	Contributions . . . . .	16
1.A	L'émergence de l'évidence clinique dite moderne . . . . .	20
1.B	Limites des essais randomisés contrôlés dans la recherche clinique . . . .	24

---

## 1 The emergence of modern clinical evidence

Currently, medical recommendations made by clinicians or regulatory agencies (e.g. *Food and Drug Administration* (FDA) or *World Health Organization* (WHO)) are grounded on what is known as *evidence*. But over the past two centuries, the notion of evidence that would guide medical practices has evolved significantly, with a notable increase in the use of clinical data, particularly through statistical analysis. The idea of using data to address clinical questions has gained traction since the 19th century. Many methods, ways of thinking, and types of evidence that we use today were developed during this era. As illustration, we detail some of the following pioneers's contributions.

- **Pierre-Charles-Alexandre Louis (1787–1872)** was a doctor in the former Paris hospital called *La Charité*. He developed new methodologies on diseases (e.g., typhoid and tuberculosis), along with efficacy evaluation of a popular technic at the time: bloodletting (Morabia, 2006; Chemla and Abastado, 2012). His work on bloodletting contains many of the key elements that are today advocated as modern robust clinical research. Louis (1828) discusses the target population (i.e. patients suffering from a certain type of pneumonia), patients stratification (i.e. whether they had been bled early after the start of the disease or not), and the precise definition of an outcome (i.e. duration of disease), to name a few. What is striking in Pierre-Charles-Alexandre Louis's work is (i) the notion of comparing *similar* groups and (ii) the idea of a target population. These two elements are cornerstones of modern randomized controlled trials (RCTs), along with randomization.
- **William Farr (1807-1883)** was a pioneering demographer and civil servant at the *General Register Office* where he was first appointed as the compiler of statistical abstract before being appointed *Superintendent of the Statistical Department*. In parallel to his work as a civil servant, he was a regular contributor of the *Lancet* (Langmuir, 1976). His work involved a broad range

of topics, including normalization of datasets' nomenclature. He is also famous for improving the statistical definition of the life expectancy with his *British Life Table* (Farr, 1864), while also developing the tenets of what is today called *surveillance* (of disease, see Langmuir, 1976). According to Rothman (2011), William Farr also took a great place in the scientific discussion about the causes of cholera (see below with John Snow). William Farr was a social reformer, deeply concerned by the impacts of industrialization on public health. This could explain his data-based investigations about the causes of diseases, in order to *prevent* them from happening and to urge effective sanitary reforms (Farr, 1839; Langmuir, 1976; Rothman, 2011).

- **John Snow (1813-1858)** was a physician. He is known for his work about cholera, and is now introduced in every epidemiology lectures or books *as the founding father of epidemiology* (Rothman, 2011). In 1854, London faced a cholera outbreak. According to the textbooks describing the story, John Snow started recording the cases on a map of London, which corresponds to what we call today *descriptive statistics*. He tested the hypothesis of water as the vector of contamination, and therefore added the water pumps on the map. He could identify a correlation between the two: concentration of cholera cases was the highest around some water pumps (Tulchinsky, 2018). Snow is known for having convinced authorities to remove the handle from the pump suspected to be at the origin of the outbreak, and the spread of the disease ended<sup>1</sup>. A memorial in his honor is now standing at the location of this pump. Note that at the time another hypothesis was that cholera was transferred in the air: the miasma theory. This theory was shared by many – including William Farr (Eylar, 2004). Miasma theory was supported by the observations that people living in altitude – supposed to be exposed to fresh air – were less subject to cholera. But altitude is also related to the flow of water, with individuals living at lower altitudes being more likely to drink contaminated water. What made the difference at the time was Snow's intuition that, because the symptoms were gastrointestinal, the disease could only be transmitted by food or water. He somehow unraveled the hidden covariates while associating houses with their exact water suppliers. In other words, this allowed to clearly see the link between the water pump and the inhabitants suffering from cholera, and not only the spurious correlation with air quality through altitude (Rothman, 2011).
- **Janet Lane-Claypon (1877-1967)** was a physician, and was also the first woman ever to receive a research scholarship from the *British Medical Society*. Beyond many research works, one of her aim was to compare the benefits of breast feeding versus cow's milk feeding (she published a 60-pages report in 1912<sup>2</sup>). According to Winkelstein Jr (2004), she authored one of the first case-control study, which included a detailed discussion about sources of confounding, and finite sample random error. She applied a Student t-test to reject the assumption of random sampling explaining the difference associated with feeding in infants body weights. Note that the Student t-test had been proposed only four years before Janet Lane-Clayton's work (Student, 1908), illustrating how much this work using state-of-the-art's statistics. She also highlighted the social class as a possible unobserved confounding factor (Winkelstein Jr, 2004; Rothman, 2011). In 1926, she also worked on another case-control study unraveling risk factors of breast cancers, most of them being still accurate as of today (Lane-Claypon et al., 1926).

All these researchers and scientists derived their conclusions from collective empirical data, rather than from individual experiences. At the same period, mathematical concepts were evolving. A new mathematical science was emerging with probabilities and statistics. One can mention the book entitled *A Philosophical Essay on Probabilities* from Pierre-Simon Laplace (1749-1827) published in 1814, illustrating the premises of a new kind of reasoning: data collection, probabilistic thinking, and its application in medicine:

---

<sup>1</sup>Some recent works advocate that John Snow's intervention was too late, as the disease was already naturally decreasing. Therefore, his action was not what ended the cholera outbreak. See Chapter 4 of Rothman (2011), showing a reconstitution of the epidemic curve, already decreasing at the time of John Snow's intervention. Still, the whole process of going from description to hypothesis testing remains notable and novel.

<sup>2</sup>We have not found the original article.

“The calculation of probabilities can help appreciate the advantages and disadvantages of the methods used in conjectural sciences. For example, to recognize the best treatment used to cure a disease, it suffices to test each one on the same number of patients, while making all circumstances perfectly similar. The superiority of the most advantageous treatment will become increasingly apparent as this number grows, and calculation will reveal the corresponding probability of its advantage, and the ratio by which it is superior to the others.” – page 134, in [Marquis de Laplace \(1825\)](#)<sup>3</sup>

It is no coincidence that the term *epidemiology* could be traced back in 1850, with the creation of the *Royal Society of Medicine’s Epidemiological Society* in London. The objective of this institute was “to investigate the causes and conditions which influence the origin, propagation, mitigation, and prevention of epidemic disease” ([Evans, 2001](#)). The apparition of the term *epidemiology* indicates the birth and establishment of a new methodological approach to characterize disease propagation and public health. One of its typical characteristics: interdisciplinarity (at least with medicine, physiology, and mathematics). The *Royal Society of Medicine’s Epidemiological Society* was later incorporated into the *Royal Society of Medicine*, showing how epidemiology was not only shaped by clinicians, but also (if not mostly) by scientists. As an example of the spirit of the time, Claude Bernard (1813-1878) recalls a very witty anecdote to illustrate the urge to merge different scientific communities:

*The desire that I express here would roughly correspond to Laplace’s thought, when he was asked why he had proposed to include doctors in the Academy of Sciences since medicine is not a science: ‘It is,’ he replied, ‘so that they can be with scientists.’* – page 285, in [Bernard \(1865\)](#)<sup>4</sup>

An interesting parallel can be made with today’s situation, where interdisciplinary collaborations become more and more sought after, in fields such as data science (e.g. [Chambers \(2022\)](#)).

Note that the increasing role of statistics –also named *conjectural science* in the mid-19th century– to build evidence was discussed and challenged. For example, Claude Bernard is often quoted as an opponent to the use of statistics to build clinical evidence. [Bernard \(1865\)](#) indeed considered that true medical knowledge had to be acquired by individualization of cases and the understanding of variability across individuals, rather than hiding such differences in averages. His underlying idea being that if the mechanism is truly understood, then there should be no more uncertainty in the outcome and/or treatment effect. But reality is not binary, and Claude Bernard also recognized empirical data as an intermediate tool to build conjectures. For example, and as shown by [Morabia \(2018\)](#), Claude Bernard implicitly (i.e. without naming it) discusses experiments from Pierre-Charles-Alexandre Louis in his book, praising the experimental evaluation about bloodletting.

**Current practice** The use of statistics in clinical research, which was introduced in the 19<sup>th</sup> century, has continued to be widely disseminated. The modern approach to teaching statistics for public health and clinical research follows a clear framework and notation, as outlined in various textbooks ([Rothman and Greenland, 2000](#); [Rothman, 2011](#); [Guyatt et al., 2015](#)). Currently, researchers rely primarily on collecting data from multiple sources to build evidence and draw conclusions about diseases or risk factors. The strength of this evidence ranges from relatively weak to highly robust, depending on the *type* and *amount* of data collected. By *type* of data, we mean how the data were collected and whether or not data result from an observational or experimental design. There is also a broad

<sup>3</sup>Original French version: “Le calcul des probabilités peut faire apprécier les avantages et les inconvénients des méthodes employées dans les sciences conjecturales. Ainsi, pour reconnaître le meilleur des traitements en usage dans la guérison d’une maladie, il suffit d’éprouver chacun d’eux sur un même nombre de malades, en rendant toutes les circonstances parfaitement semblables : la supériorité du traitement le plus avantageux se manifesterá de plus en plus à mesure que ce nombre s’accroítra ; et le calcul fera connaître la probabilité correspondante de son avantage, et du rapport suivant lequel il est supérieur aux autres.”

<sup>4</sup>Original French version: “Le désir que j’exprime ici répondrait à peu près à la pensée de Laplace, à qui on demandait pourquoi il avait proposé de mettre des médecins à l’Académie des sciences puisque la médecine n’est pas une science : “C’est, répondit-il, afin qu’ils se trouvent avec des savants.””



variety of sources of evidence, that is to say of data collection and analysis: two-stage designs, ecologic studies, retrospective cohort, case-control studies, and randomized controlled trials (RCTs). Among these, RCTs are widely considered as the best evidence that can be obtained from a single study, earning them the title of “gold standard” for measuring causal effects:

*Because no other study design can provide the safeguards against bias associated with randomization, randomized controlled trials (RCTs) yield stronger evidence than other study designs.* – (Guyatt et al., 1995)

The RCT which assessed the efficacy of streptomycin (Crofton and Mitchison, 1948) is often quoted as the landmark RCT for modern guidelines. This trial was conducted in a context where the great success of penicillin spearheaded research to detect other potential antibiotics. Penicillin was found to be inefficient against a pathogen named *Mycobacterium tuberculosis* (or *Koch’s bacillus*) causing pulmonary tuberculosis. At the time, streptomycin was a promising new antibiotic with positive experiments in tubes and animals. Crofton (2006), one of the member of the Medical Research Council (MRC) Tuberculosis Unit at the time with Austin Bradford Hill (1897-1991), tells the story of how this landmark trial was designed and conducted. The current standard treatment (or control group) of pulmonary tuberculosis was bed rest. Bradford and the committee defined a trial following all the modern standards: eligibility criteria (for e.g. disease stage, age, etc), randomization (through envelopes with two options, control or treatment), double blinded treatment allocation (for patients and clinicians), confidentiality, collection of longitudinal clinical data for each patient during the whole trial.

*I like to believe that, together with the MRC Tuberculosis Research Unit, we helped to promote the adoption of a study design for which the MRC streptomycin trial is often seen as a symbol.* – Crofton (2006)

While streptomycin provided good results at first in this trial, investigators could observe side effects and a slow shrinking of efficacy with time. It turns out that to be efficient, streptomycin has to be combined to other treatments and requires a strict observance to avoid bacterial resistance. Note that Crofton, who was a clinician, proposes an interesting personal opinion which echos the one of Claude Bernard:

*Randomized trials like these were of great practical importance in developing effective treatment strategies, but they were not intellectually challenging. Our major intellectual challenge in tuberculosis research was to identify the causes of failed drug treatment.* – Crofton (2006)

As of today, Randomized Controlled Trials have a central place in pharmaceutical regulations. Trials are divided in different clinical phases, to assess first the toxicity, and then estimate efficacy on larger populations. Taxonomies of empirical studies are often presented in a hierarchical structure, which ranks the strength of evidence that each study can provide. This hierarchy is often depicted in a pyramid diagram that illustrates the various levels of evidence. (see Figure 1.6, where RCT corresponds to *Randomized Controlled Double Blind Studies*).


**Figure 1.1: Example of a typical pyramid of evidence;** this exact pyramid can be found in the SUNY Downstate Medical Research Library of Brooklyn (see Evidence-Based Medicine Course, available [online](#)). Several similar pyramids can be found in textbooks or research articles (e.g. Ahn and Kang (2018)), sometimes showing slightly different ranking or naming. Some sociological works question their origin, role, and usage, e.g. Blunt (2015).



What could be better than a single randomized controlled trial (RCT)? Multiple RCTs! In addition to studies conducted on a single population, systematic reviews and meta-analyses represent the final layer of modern clinical evidence according to the usual hierarchy promoted in clinical research. Systematic review is the approach of collecting and reviewing the available research about a specific question, and analyzing their results. A meta-analysis pools the different estimates from several trials (see a presentation of how to run a meta-analysis in [Ahn and Kang, 2018](#)). Pooling several studies estimate as an additional statistical layer is tempting, but require to ensure that the population of interest is clearly defined. The so-called PICO criteria are often mentioned (Population, Intervention, Comparison, Outcomes). Results of a meta-analysis are usually presented as a forest plots. Recently, in 2009, the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) ([Liberati et al., 2009](#)) has proposed updated guidelines for review and meta-analysis. The former ones were proposed in 1999 ([Moher et al., 1999](#)) (named *Quality Of Reporting Of Meta-analysis* (QUOROM)). Such guidelines contain a checklist to ensure review and meta-analysis are correctly performed. For example, authors have to report the protocol, to detail eligibility criteria, to provide the summary measures used (e.g. risk ratio, risk difference), or to attach a flow chart to describe the process.

Finally, note that the prevalent use of statistics to quantify the causes and effects of habits or drugs is also under some critics. To give one example, one manifestation of modern evidence is the proliferation of publications citing so-called risk factors. However, the approach of systematically breaking down an effect into sub-effects has its limitations ([Krieger, 1994](#)). Furthermore, there are concerns about how society and the media perceive and interpret these findings, as illustrated in Figure 1.7.

**Figure 1.2:** The cartoon by Jim Borgman in 1997, conveys several ideas, in particular that (i) many diseases are multifactorial and can hardly be decomposed in a single risk factor and that (ii) communicating key results in the media can be misleading due to the numerous scientific papers currently published.



## 2 Rising concerns about external validity

If modern *evidence-based* medicine (EBM) puts Randomized Controlled Trial (RCT) at the core of clinical evidence, there have been recent concerns about the limited scope of RCTs. One of the main current concerns is the *external validity* (or *generalizability*) of a trial. Generalizability of trial findings is crucial as, most often, clinicians use causal effects from published trials to (i) estimate the expected response to treatment for a specific patient based on his/her baseline risks, and therefore to (ii) choose the best treatment. Beyond each practitioner's point of view, the same reasoning is valid for regulatory agencies having to expose clear guidelines and promote a standard-of-care. While usually less pointed out in scientific papers, trial's conclusions have also an impact on pharmaceutical regulation, since the price of a drug is mainly driven by its efficacy (assessed through clinical studies).

The formalism and principle of a RCT is detailed below (see Sections 3), but for now, one can admit the idea that a RCT's output is an estimated so-called Average Treatment Effect (ATE), also named average *causal* effect of a treatment to emphasized that the effect reported is not an association. In practice, a RCT mainly aims to report one point estimate with its confidence intervals, for e.g. the risk ratio, usually highlighted in the abstract as the main results, along with population's size and confidence intervals. Hence, it is of main importance to understand how valid this number is when

considering other populations.

The issue of whether study results can be extrapolated to other populations is not a new concern. In 1957, [Campbell \(1957\)](#) introduced the concept of internal and external validity within social science. This concept – also referred to as generalizability or representativeness in the original paper – raises questions about *the populations, settings, and variables to which a given effect can be generalized*. This definition and naming have been promoted more recently by the *Consolidated Standards of Reporting Trials* (CONSORT) ([Altman et al., 2001](#)). Even if not shared by all (see, e.g. [Rothman et al., 2013](#)), generalizability is gaining interest in clinical research ([Concato et al., 2000](#); [Blanco et al., 2008](#); [Deeks, 2002](#); [Rothwell, 2007](#); [Green and Glasgow, 2006](#); [Frieden, 2017](#); [Berkowitz et al., 2018](#)):

“Neither Cochrane nor Bradford Hill were practising clinicians, but they understood the limitations of the methodology that they had pioneered. Although what little systematic evidence we now have confirms that RCTs do often lack external validity, this issue is neglected by current researchers, medical journals, funding agencies, ethics committees, the pharmaceutical industry, and governmental regulators alike.” – [Rothwell \(2007\)](#)

To ensure external validity, there must be a strong resemblance between the population used in the experiment and the target population of interest. This may explain why this concept is sometimes referred to as a *matter of judgment* ([Altman et al., 2001](#)). Below are some typical concerns that have been raised about the limit scope of RCTs:

- **Eligibility and exclusion criteria** help to define the population recruited in a randomized controlled trial, and are therefore part of the design. Usually a certain age limit and typology of diseases are required to be enrolled. Such criteria are both used to *(i)* protect the weak or at-risk population (e.g. pregnant women) and to *(ii)* conduct the study on a sufficiently homogeneous group of patients to maximize the estimated treatment effect. Beyond the exclusion criteria which define a limit on the typology of patients selected, there can also be some over- or under-representation of some population, due for example to the hospitals or places chosen to conduct the trials. Such biases are much harder to track and report than exclusion criteria.
- **Unrealistic real-world compliance** of trials is often reported as a limit to extend the validity of trials. In a RCT, individuals are carefully monitored, so that, during the trial, the treatment is given in optimal conditions with a very good observance: doses and treatment scheduling. Outside experimental conditions, individuals may deviate from the norm, for example forgetting to take a pill that was prescribed, or stopping the treatment earlier than expected. Beyond absent-mindedness, this can be for good reasons such as side effects or painful treatment administration. Therefore, the effect observed in practice may differ from the one evaluated during the trial, because the real-life treatment is no longer the same as than the one administrated during the trial. Some people refer to this phenomenon as effectiveness (real-world conditions) versus efficacy (experimental conditions) ([Singal et al., 2014](#)).
- The **short timeframe** of a trial, due to the associated financial cost, prevents individuals to be followed for many years, making results of randomized controlled trial potentially narrow.
- The **limited sample size**, a widely shared concern about RCT, prevents the estimation of conditional (or stratified) treatment effects due to a lack of statistical power.

Although guidelines, such as the ones provided by CONSORT ([Altman et al., 2001](#)), exist to outline eligibility and exclusion criteria, there is a widespread concern regarding the inadequate reporting provided in clinical publications ([Rothwell, 2007](#)). It should be noted that this lack of clarity is not necessarily intentional, but may be the consequence of willingness to present a concise message to readers. Below, we detail our motivating example and epitome we tackle in this research work. Finally, note that more recently, another type of RCT *pragmatic* trials are now more and more proposed. Those trials aim at maximizing the generalizability with smooth eligibility criteria and more flexibility in the intervention management ([Godwin et al., 2003](#)).

**An illustration from critical care** As highlighted by Rothwell (2007), the problem of the lack of external validity is even more concerning when the treatment is only moderately effective. In such situations, any small variation of experimental conditions may endanger the study main conclusions, especially when transferring this knowledge to another populations. To illustrate this phenomenon, consider a case addressed by our clinician collaborators, in which they try to cure patients suffering from a traumatic brain injury (TBI). TBI is a brain damage caused by a blow or jolt to the head. Tranexamic acid (TXA) is an antifibrinolytic agent that limits excessive bleeding, commonly given to surgical patients. Previous clinical trial showed that TXA decreases mortality in patients with traumatic *extracranial* bleeding (Shakur-Still et al., 2009). Consequently, TXA may also be effective in TBI, because *intracranial* hemorrhage is common in TBI patients, with risks of increased intracranial pressure, brain herniation, and death.

Following this intuition, a randomized controlled trial CRASH-3 has been launched to assess the question of the effectiveness of TXA in TBI (CRASH-3, 2019). CRASH-3 is a multi-centric randomized and placebo-controlled trial launched over 175 hospitals in 29 different countries (Dewan et al., 2012). This trial recruited 9,202 adults, which is unusually large for a medical RCT. All suffering from TBI without major extracranial bleeding. The summary of baseline demographic and clinical characteristics of study participants are usually presented at the beginning of each clinical study, under the name Table 1 (see Table 1.2 as a typical example). Here, six covariates are measured at baseline, being age, sex, time since injury, systolic blood pressure, Glasgow Coma Scale score (GCS)<sup>5</sup>, and pupil reaction. All participants were randomly administrated TXA. The primary outcome studied is head-injury-related death in hospital within 28 days of injury in patients included and randomized within 3 hours of injury. The study concludes that the risk of head-injury-related death is 18.5% in the TXA group versus 19.8% in the placebo group. The causal effect, measured as a Risk Ratio (RR) was not significant (RR = 0.94 [95% CI 0.86 - 1.02])). But CRASH-3 revealed a positive effect of TXA only when considering mild and moderate cases (i.e., moderate and high Glasgow scores). As trial reports usually include the baseline clinical and demographic characteristics of randomized patients (see Table 1.2), so that it is believed that clinicians can assess external validity by comparison with their target population and typical patients (Altman et al., 2001). How different is the CRASH-3 population compared to the patients encountered by our clinicians collaborators? To answer this question, we have at hand a large cohort: the **Traumabase**.

	Tranexamic acid (n=4649)	Placebo (n=4553)
<b>Sex*</b>		
Men	3742 (80%)	3660 (80)
Women	906 (19%)	893 (20)
<b>Age, years</b>		
Mean (SD)	41.7 (19.0)	41.9 (19.0)
<25	1042 (22%)	996 (22%)
25-44	1716 (37%)	1672 (37%)
45-64	1169 (25%)	1184 (26%)
≥65	722 (16%)	701 (15%)
<b>Time since injury, h</b>		
Mean (SD)	1.9 (0.7)	1.9 (0.7)
≤1	877 (19%)	869 (19%)
>1-2	2003 (43%)	1889 (41%)
>2-3	1769 (38%)	1795 (39%)
<b>Systolic blood pressure, mm Hg</b>		
<90	89 (2%)	85 (2%)
90-119	1508 (32%)	1490 (33%)
120-139	1461 (31%)	1504 (33%)
≥140	1576 (34%)	1466 (32%)
Unknown	15 (<1%)	8 (<1%)
<b>Glasgow Coma Scale score</b>		
3	495 (11%)	506 (11%)
4	213 (5%)	213 (5%)
5	163 (4%)	172 (4%)
6	221 (5%)	232 (5%)
7	311 (7%)	294 (6%)
8	354 (8%)	315 (7%)
9	335 (7%)	292 (6%)
10	371 (8%)	364 (8%)
11	375 (8%)	390 (9%)
12	476 (10%)	478 (10%)
13	297 (6%)	312 (7%)
14	526 (11%)	458 (10%)
15	484 (10%)	492 (11%)
Unknown	28 (1%)	35 (1%)
<b>Pupil reaction</b>		
None reacted	425 (9%)	440 (10%)
One reacted	374 (8%)	353 (8%)
Both reacted	3706 (80%)	3636 (80%)
Unable to assess or unknown	144 (3%)	124 (3%)

Data are n (%), unless otherwise indicated. \*In the tranexamic acid group, one patient's sex was unknown.

**Table 1: Baseline characteristics of patients before randomisation of those randomly assigned within 3 h of injury**

**Table 1.1:** Screenshot of the **Table 1** from CRASH-3 (2019).


The Traumabase regroups 23 French Trauma centers that collect detailed clinical data from major trauma patients, from the scene of the accident to hospital discharge, in the form of a registry. The

<sup>5</sup>The Glasgow Coma Scale (GCS) is a neurological scale which aims to assess a person's consciousness. The lower the score, the higher the severity of the trauma.




data, currently counting over 30,000 patient records, are of unique granularity and size in Europe. However, they are highly heterogeneous, with both categorical – sex, type of illness, ...– and quantitative – blood pressure, hemoglobin level, ...– features, multiple sources, and many missing data (98% of the records are incomplete). Within this data set, 8,270 patients are suffering from TBI. As stated, the Traumabase contains many missing values. Luckily some covariates are almost always observed, such as the Glasgow score. This enables the comparison of the CRASH-3 sample with the patients from TBI in the Traumabase. The barplot is presented in Figure 1.8, making clear that the two samples are different. While the CRASH-3 trial more or less homogeneously covers the full range of Glasgow scores, the Traumabase contains relatively more patients with either high or low Glasgow scores.

Now, considering that the response to the treatment is varying with the severity of the TBI (assessed through the Glasgow score), the *average* effect reported in the CRASH-3 report is necessarily anchored in the choice of population. Assume that the true probability to die from TBI is the one depicted in Figure 1.9 (hypothetical drawing). This drawing is supposed to depict a situation where low injured patients (high GCS) have a low probability to die from TBI, while severely injured patients (low GCS) have a high probability to die. In both cases, the treatment cannot drastically decrease the baseline risk, due to the extreme condition (either good or bad) of the patient. Under such situations, the average effect estimated in the CRASH-3 RCT would be higher than the actual effect observed in the Traumabase population, thus leading to erroneous conclusion when transferring directly conclusions from CRASH-3 onto a population similar to that of the Traumabase.



**Figure 1.3:** Univariate comparison of the Glasgow score distribution between the CRASH-3 sample (9,202 individuals) and the subsample of the Traumabase suffering from TBI (8,270 individuals, data extraction made in 2019).

**Figure 1.4:** Schematic of an hypothetical response to Tranexamic acid (TXA) when suffering from traumatic brain injury (TBI) as a function of the Glasgow score (GCS). This hypothetical drawing was imagined while talking to clinicians, and only aims to illustrate the problem.



**How can we generalize trial’s findings?** As far as we know, in the applied clinical research the question of the trial’s representativeness has mostly been asked through the lens of what endangers the validity. For example, some clinical works compare the baseline covariates of the individuals recruited in the trial with that of the target population (e.g. comparing the so-called Tables 1 such as

in Figure 1.8), or derive the ineligibility rates – that is the percentage of ineligible patients within the population suffering from the disease (Kennedy-Martin et al., 2015). For example Van Eijk et al. (2019) review that for some RCTs investigating treatments to cure amyotrophic lateral sclerosis, only 14% of the actual population affected by the disease could have been recruited.

Others methods have recently been proposed to quantify how the population’s shift impacts the treatment effect amplitude. Such methods – named *generalization* – have been introduced in the 2010’s (Stuart et al., 2011; Pearl and Bareinboim, 2011a), and have the particularity to rely on several data sources. Having one trial (e.g. CRASH-3) and a sample of the target population of interest (e.g. Traumabase) is a typical situation where those methods can apply.

This method can be found under other wordings, such as transportability (Pearl and Bareinboim, 2011a; Rudolph and van der Laan, 2017; Westreich et al., 2017b), portability (Xiao et al., 2022), or recoverability (Bareinboim and Pearl, 2012a; Bareinboim et al., 2014). This topic is also related to *covariate shift* and generalization in machine-learning. Links between causality and distributional robustness in machine-learning exist (Meinshausen, 2018), but are not tackled in this thesis. Note that this question is also termed as *selection bias*:

**“Definition of selection bias:** The systematic error in creating intervention groups, causing them to differ with respect to prognosis. That is, the groups differ in measured or unmeasured baseline characteristics because of the way in which participants were selected for the study or assigned to their study groups. The term is also used to mean that the participants are not representative of the population of all possible participants”. – Altman et al. (2001) (CONSORT)

CONSORT explicitly relates selection bias to external validity. In the literature, this can imply slightly different estimation strategies, in particular when the trial’s population is nested within the target population of interest (Dahabreh et al., 2020). We detail the difference in Chapter 2. All other chapters focus on the most standard design of one already conducted trial, for which someone wants to generalize the effect (e.g. CRASH-3 and Traumabase).

In this PhD thesis, the aim is to develop and improve statistical approaches to generalize trial’s findings to another population of interest. Applied to the Traumabase illustrative example, this means that we want to answer the following question: what would have been measured in the RCT if individuals were rather sampled from the Traumabase?

### 3 The promise of detailed and larger observational data

Data science has infused into every domain without exception, as Pearl and Mackenzie (2018) highlights: *Courses in “data science” are proliferating in our universities, and jobs for “data scientists” are lucrative in the companies that participate in the “data economy.”* This expansion is partly due to the digitization of information, which has made data collection, storage, and accessibility easier. In addition, computational power improvements have also transformed the way statistics are performed, with the invention of more computationally intensive *machine learning* technics.

Healthcare is no exception to this data tidal wave. Hospitals are adopting Electronic Health Records (EHRs) on a large scale. For example, in the U.S., nearly all reported hospitals of the American Hospital Association (96% of non-Federal acute care hospitals<sup>6</sup>) possessed a certified EHR technology in 2015, while this number was slightly below 10% in 2008 (Henry et al., 2016). France is another example, with a growing number of Clinical Data Warehouses starting in 2007, which is intensifying in the past five years (Doutreligne et al., 2023). While many of these data sets remain under private access, some are publicly available, like the MIMIC data set composed of almost 40,000 individuals

<sup>6</sup>Includes acute care general medical and surgical, general children’s, and cancer hospitals owned by private/not-for-profit, investor-owned/for-profit, or state/local government

(Johnson et al., 2016).

Collecting such large data sets can help to solve a variety of tasks: predicting (e.g. predicting the remission time or the probability to suffer from a disease), variable identification (e.g. screening for risk factors of multifactorial diseases such as diabete). But another purpose of such clinical data is policy evaluation via real-world treatment effect estimation, therefore enriching all the existing clinical evidence toolkits. Data collected in such disease registries, cohorts, biobanks, epidemiological studies, or electronic health records are promising as they are readily available, include large and representative samples, and are less cost-intensive than RCTs. Those data are of high external validity. However, data quality can be poor (e.g. many missing values), and they are collected without following a prespecified design study, which opens the door to *confounding biases*.

**Extracting causal information from observational samples** Statistical tools have been proposed to de-confound observational (i.e. non-experimental or non-randomized) data, and hopefully draw *causal* conclusions from such observational data sets. In non-randomized studies, the effect of treatment cannot be estimated by simply comparing outcomes between treatment groups as it is possible on a RCT. Below, we detail a formalization of the problem through the so-called potential outcomes framework. The potential outcomes framework was proposed by Neyman in 1923 (in polish) and further popularized by Rubin (1974) (see Imbens and Rubin (2015) for a review and the historical context). Another formalism is also commonly used: the Structural Causal Model (SCM) with causal diagrams and the do-operators (Pearl, 2009a). In this work, we adopt the former, while we also propose discussion about links with the latter (see Chapter 2).

Assume that we have access to  $n$  independent and identically distributed observations labeled  $i = 1, \dots, n$ , each one consisting in a feature vector  $X_i \in \mathcal{X}$ , a response  $Y_i \in \mathcal{Y}$ , and a binary treatment indicator  $A_i \in \{0, 1\}$ . We further denote  $\mathcal{D}_n = \{(X_i, A_i, Y_i), i \in \{1, \dots, n\}\}$  the data set at hand. Following the potential outcomes framework, we then posit the existence of potential outcomes  $Y_i^{(1)}$  and  $Y_i^{(0)}$  corresponding respectively to the response the  $i^{\text{th}}$  subject would have experienced with and without the treatment. This notation is based on our intuition about causality, which typically involves holding everything constant except for certain interventions. The goal is to understand how the counterfactual situation would differ from the actual state, that is

$$Y_i^{(1)} \stackrel{?}{=} Y_i^{(0)}. \quad (1.1)$$

As a consequence,  $Y_i$  is used to denote the *observed* outcome for individual  $i$ . The so-called consistency assumption (totally unrelated to estimator consistency) states that when treatment is assigned, the observed potential outcomes is the one corresponding to the treatment actually allocated, that is

$$Y_i = A_i Y_i^{(1)} + (1 - A_i) Y_i^{(0)}. \quad (1.2)$$

While this equation *seems* to hold in all cases, it truly encodes an assumption difficult to verify in practice, namely that individuals actually do what they were asked to do (taking treatment). There are famous examples where individuals swapped or shared their treatment, typically when the issue can be fatal (e.g. HIV, see Pool et al., 2010). Besides, eq. 1.2 also implicitly assumes that the output of any individual is not influenced by the treatments assigned to other individuals. Formally, for  $n$  observations, denoting  $\mathbf{A} = (A_1, A_2, \dots, A_n)$  the vector of treatment allocations of all the  $n$  units, then,

$$Y_i^{(\mathbf{A})} = Y_i^{(A_i)},$$

that is the output  $Y_i$  only depends on the treatment allocation  $A_i$  and not on all other assignments  $A_{j \neq i}$ . Again, this may seem quite obvious, but encodes the complex practical assumption of *no interference* between individuals. This assumption can be violated, especially when considering public policies impacting individual interactions due to social interactions, or when considering vaccine as

treatment. For instance, when someone is vaccinated, it can impact someone who isn't vaccinated by preventing the spread of the disease. Note that interference is not always a threat to validity, as it can be of interest in some cases. For example, in an educational setting, one may want to know the effect of acting positively on one child, and how this can spread to peers. There is a recent and increasing literature dealing with interference (Ogburn and VanderWeele, 2014; Aronow and Samii, 2017; Hu et al., 2022; Ogburn et al., 2022). Having both assumptions of consistency and no interference is equivalent to the so-called Stable Unit Treatment Value Assumption (SUTVA). In this work, we will always assume that SUTVA holds.

**Assumption 1** (SUTVA - page 33 of Imbens and Rubin (2015)). *Treatment assignments for other units do not affect the outcomes for unit  $i$ . Besides, each treatment defines a unique outcome for each unit.*

Unfortunately, one cannot observe the two worlds for a single individual, and thus comparing the potential outputs  $Y_i^{(0)}$  and  $Y_i^{(1)}$  for any individual  $i$  (as in eq. 1.1) is practically impossible. However, we can compare the *expected* values of each potential outcome  $Y^{(a)}$ , as it requires a population-level approach. In this case, the usual target quantity to infer is a distributional parameter called the Average Treatment Effect (ATE), corresponding to the average difference of the potential outcomes over the *entire* population,

$$\tau = \mathbb{E} \left[ Y_i^{(1)} - Y_i^{(0)} \right].$$

Another common quantity of interest is the conditional average treatment effect (CATE) or average effect across sub-populations of subjects<sup>7</sup>, defined as

$$\tau(x) = \mathbb{E} \left[ Y_i^{(1)} - Y_i^{(0)} \mid X_i = x \right].$$

The ATE is a *causal* effect because it compares what would happen if the same people were treated or not. Note that in general  $\mathbb{E}[Y^{(a)}] \neq \mathbb{E}[Y|A = a]$ , because  $\mathbb{E}[Y|A = a]$  reads as *the expected value of  $Y$  given  $A = a$* , which is a restriction to the sub-population that actually received the treatment  $A = a$ . To properly measure the causal effect, two *similar* groups of people are needed. Luckily, by design, we have access to such groups in a RCT: in such settings, because randomization is ensured, we have

$$\left\{ Y_i^{(0)}, Y_i^{(1)} \right\} \perp\!\!\!\perp A_i,$$

and thus

$$\begin{aligned} \mathbb{E}[Y \mid A = 1] &= \mathbb{E}[YA \mid A = 1] && \text{Binary nature of } A \\ &= \mathbb{E} \left[ Y^{(1)}A^2 \mid A = 1 \right] && \text{Consistency } Y_i = A_i Y_i^{(1)} + (1 - A_i) Y_i^{(0)} \\ &= \mathbb{E} \left[ Y^{(1)} \mid A = 1 \right] && \text{Binary nature of } A \\ &= \mathbb{E} \left[ Y^{(1)} \right] && \text{Randomization,} \end{aligned}$$

and similarly for  $A = 0$ , so that

$$\tau = \mathbb{E}[Y \mid A = 1] - \mathbb{E}[Y \mid A = 0].$$

The key assumption used in a RCT is randomization, which appears in the above derivation (those assumptions are sometimes qualified as causal). Being able to write a causal quantity – here  $\tau$  – as a function of distributional parameters that only involves observable quantities – here  $\mathbb{E}[Y \mid A = a]$  – is called *identification* or *identifiability*. Identifiability is a population-level property which is not related to any estimation issue. Therefore having more data does not help to solve identifiability problems.

<sup>7</sup>Doing so, the ATE corresponds to the integral of the CATE over  $x$ .



**Confounding variables** When extracting causal evidence from observational data, randomization usually does not hold. Most of the time, treatment has been assigned preferentially to some individuals (e.g. sick or aged individuals). This is typically what occurs in the Traumabase. Among patients suffering from Traumatic Brain Injury (TBI), mortality is much higher on individuals who received Tranexamic Acid (TXA) than those who did not (38% vs. 16%). This situation arises because patients who seemed to be in a more critical condition were both more likely to receive TXA treatment but also more likely to pass away, irrespective of whether they received the treatment or not (Mayer et al., 2020). In such situation, treatment effect is said to be confounded, and the severity of the trauma is said to be a confounding variable. Controlling or adjusting on all the confounding variables is a way to extract causal information in some simple cases<sup>8</sup>. A set  $X$  is said to de-confound the analysis when the following well-known and fundamental unconfoundedness assumption is satisfied.

**Assumption 2** (Unconfoundedness - Rosenbaum and Rubin (1983b); Rubin (1990)). *For all subject  $i$ ,*

$$\{Y_i^{(0)}, Y_i^{(1)}\} \perp\!\!\!\perp A_i \mid X_i.$$

This assumption can also be found under the name ignorability, or conditional independence assumption (Angrist and Pischke, 2008). Interestingly, this process of extracting causal information from observational data is usually presented as the *emulation of a randomized experiment* (Hernán and Robins, 2016). Assumption 2 corresponds to randomization, but conditional on the covariate  $X$ . Doing so, the spirit of the hierarchy exposed above (Figure 1.6) appears again, where the aim is to emulate the gold standard from observational data.

Another assumption is required to ensure that treatment assignment is not completely deterministic, that is the probability of receiving the treatment is different from 0 or 1, for any observation.

**Assumption 3** (Overlap or positivity). *For some  $\eta \in (0, 1)$ , and for any  $x \in \mathcal{X}$ ,*

$$\eta \leq \mathbb{P}[A = 1 \mid X = x] \leq 1 - \eta.$$

Indeed, would some individuals be certain to receive or not the treatment, then the counterfactual could not be estimated, and therefore the average effect would not be identifiable. One could be tempted to add as many covariates as possible (even non-necessary ones) into the set  $X$  to ensure ignorability (Assumption 2), but this is likely to break overlap due to the high dimensionality. D’Amour et al. (2021) detail this phenomenon.

Finally, note that for some public policies, the treatment assignment is completely deterministic, except for a subset of individuals close to the decision rule - for example, individuals near the public policy threshold for treatment allocation. This specific situation is called a regression discontinuity designs. Such set-up has been proposed by Thistlethwaite and Campbell (1960), while the modern formalism has been proposed more recently (Hahn et al., 2001).

**Estimation** Estimation is another challenge to properly estimate the causal parameters once this parameter is assumed to be identified (e.g. with randomization under a RCT design or with Assumptions 2 and 3 for observational data). Under a RCT design, the most intuitive and common estimator is the difference-in-means estimator.

**Definition 1** (Difference-in-means - Neyman (1923) and its English translation Splawa-Neyman et al. (1990)). *The Difference-in-means estimator is denoted  $\hat{\tau}_{DM,n}$  and defined as*

$$\hat{\tau}_{DM,n} = \frac{1}{n_1} \sum_{A_i=1} Y_i - \frac{1}{n_0} \sum_{A_i=0} Y_i, \quad \text{where } n_a = \sum_{i=1}^n \mathbb{1}_{A_i=a}.$$

<sup>8</sup>This corresponds to the simplest – or, let’s say standard – situations, also called *backdoor criterion* within the Structural Causal Model (SCM) literature. See also Pearl (2009b) for more complex identification situations such as the *front door criterion*.

The Difference-in-means is also referred to as the *simple difference estimator* (Miratrix et al., 2013) or *difference in the sample means of the observed outcome variable between the treated and control groups* (Imai et al., 2008). This estimator is consistent (see Chapter 4 for the proof under a Bernoulli design). Note that this is not the estimator with the lowest asymptotic variance that can be proposed to estimate causal effect  $\tau$  from RCT data. Using covariates - even if not needed for identification - can help precision. The intuition lies in the fact that even if randomized, the effective sample may suffer from little confounding simply due to the sample randomly deviating from the mean (Imai et al., 2008). Using covariates can help reduce large sample variance, for example using methods such as OLS regression of the outcome (Imbens and Rubin, 2015) or post-stratification (Miratrix et al., 2013). Note that this can be at the cost of a finite sample bias (Imbens and Rubin, 2015; Colnet et al., 2022b).

When it comes to the estimation of  $\tau$  from an observational sample, other estimation strategies have to be adopted. To do so, an important object is the propensity score. The propensity score is defined as the probability of treatment assignment, conditional on baseline covariates.

**Definition 2** (Propensity score). *For any  $x \in \mathcal{X}$ ,  $e(x) := \mathbb{P}[A = 1 \mid X = x]$ .*

Propensity scores were introduced by Rosenbaum and Rubin (1983b), who presented their property as a balancing score, that is conditional on propensity score, the baseline covariates are expected to be balanced between treated and untreated groups. The propensity score suggests a natural estimation strategy based on re-weighting. Currently, one of the most popular estimation tool is to re-weight individuals using propensity scores, a method called Inverse Propensity Weighting (IPW). IPW is also named the transformed outcomes regression in the medical community (Wendling et al., 2018) or IPTW (Austin and Stuart, 2015).

**Definition 3** (Inverse Propensity Weighting - IPW - Hirano et al. (2003)).

$$\hat{\tau}_{IPW} = \frac{1}{n} \sum_{i=1}^n \left( \frac{A_i Y_i}{\hat{e}(X_i)} - \frac{(1 - A_i) Y_i}{1 - \hat{e}(X_i)} \right),$$

where  $\hat{e}(\cdot)$  is the estimated propensity score  $e(\cdot)$  obtained using  $\mathcal{D}_n$ .

IPW can be interpreted as a simple difference-in-means (see Definition 1), but where individuals are weighted by the inverse of the propensity to be treated or untreated. Beyond the IPW estimator (Definition 3), once this probability is estimated, it can be used in several ways to estimate the ATE. Four methods of using the propensity score have been described in the statistical literature: covariate adjustment using the propensity score, stratification or subclassification on the propensity score, matching on the propensity score (and IPW). Another popular estimator is the plug-in G-formula.

**Definition 4** (Plug-in G-formula - Robins (1986)). *The plug-in G-formula estimator is denoted  $\hat{\tau}_G$ , and defined as*

$$\hat{\tau}_G = \frac{1}{n} \sum_{i=1}^n (\hat{\mu}_1(X_i) - \hat{\mu}_0(X_i)),$$

where  $\hat{\mu}_a(X_i)$  is an estimator of  $\mu_a(X_i) := \mathbb{E}[Y^{(a)} \mid X_i]$  obtained using the data  $\mathcal{D}_n$ .

The plug-in G-formula estimator is present under different names such as conditional mean regression (Wendling et al., 2018), G-standardization (Vansteelandt and Keiding, 2011), or even G-computation or simple substitution estimation. Note that, when using a logistic regression, and in particular in the epidemiology field, it has been named the Q-model (Snowden et al., 2011). Part of the literature does not recommend this estimator for two reasons. Because (i) the asymptotic properties of such estimator is unknown if there is no parametric assumption on the surface responses  $\mu_a$ , and (ii) because of a regularization bias when using non parametric estimators for the regressions (Künzel et al., 2017; Chernozhukov et al., 2018a; Athey et al., 2018). Finally, there is an increasing popularity of the doubly-robust approaches.

**Definition 5** (Augmented IPW (Robins et al., 1994)). The AIPW estimator is denoted  $\hat{\tau}_{AIPW}$  and defined as


$$\hat{\tau}_{AIPW} = \frac{1}{n} \sum_{i=1}^n \left( \hat{\mu}_1(X_i) - \hat{\mu}_0(X_i) + A_i \frac{Y_i - \hat{\mu}_1(X_i)}{\hat{e}(X_i)} - (1 - A_i) \frac{Y_i - \hat{\mu}_0(X_i)}{1 - \hat{e}(X_i)} \right)$$

where  $\hat{\mu}_a(X_i)$  (resp.  $\hat{e}(\cdot)$ ) is an estimator of  $\mu_a(X_i) := \mathbb{E}[Y^{(a)} | X_i]$  (resp.  $e(\cdot)$ ) obtained using the data  $\mathcal{D}_n$ .

Historically, the AIPW estimator was designed to tackle a problem of missing outcome variables when willing to learn a predictor of this outcome from covariates. Robins et al. (1994) identified the AIPW as the most efficient estimator for this purpose, that is having asymptotic normality property along with the smallest possible asymptotic variance. This missing value problem can be understood in the light of the causal inference problem, where Assumption 2 is equivalent to the missing at random assumption. The *doubly robust* adjective used to name this estimator refers to another interesting property: the AIPW estimator remains consistent if either the treatment model or the outcome model is correctly specified up to a parametric form (Scharfstein et al., 1999). Note that recent statistical works advocate to use flexible regression models (aka machine-learning) for nuisance parameters estimation such as the propensity score  $e(\cdot)$  and the so-called response surfaces  $\mu_a(\cdot)$  (Westreich et al., 2010; Laan and Rose, 2011; Kennedy, 2016; Athey and Imbens, 2017; Chernozhukov et al., 2018a; Kreif and DiazOrdaz, 2019). Such practices can considerably reduce the chance of misspecification as the flexible regression models is resilient to a variety of generative models. Finally, other promising estimation methods have been proposed for the CATE  $\tau(X)$  estimation such as the R-learner (Nie and Wager, 2020).

**Current practices in clinical research** In practice estimation methods relying on the propensity scores are the most common approaches for estimation within the medical community. In particular, Grose et al. (2020) discuss the approach of hundreds of surgical studies using the propensity score, showing a diversity of practices with propensity matching being the most used method. Ali et al. (2015) also reports a predominance of propensity score usage within the medical field, with the predominance of matching ( $\sim 69\%$ ) over inverse-propensity weighting ( $\sim 7\%$ ). Still, applications with IPW remains quite recent and Austin and Stuart (2015) document that no applied studies using IPW has been published before 2000, and an effective application has started in 2007 (see Figure 1.5).

**Figure 1.5:** Number of published IPW studies, showing an increase in the number of publications quite recently compared to the statistical invention of the method that can be grounded in 1983 with the propensity score's invention (Rosenbaum and Rubin, 1983b). Theoretical characterization of IPW can be traced back in 2003 (Hirano et al., 2003). The plot is taken from Austin and Stuart (2015).



**Combining data sources to strengthen clinical evidence** Most of the current literature focuses on estimation of causal effect either from observational data or from Randomized Controlled Trials (RCTs). In practice, it is possible that an observational analysis leads to an estimated treatment effect of  $\hat{\tau}_{\text{obs}}$ , while a previous RCT reported  $\hat{\tau}_{\text{exp}}$  for a certain treatment effect on an outcome. Facing such apparent paradox, which one should we trust? Three main reasons can be mentioned to explain such a difference:

1. The treatments and/or outcomes reported in both studies are not exactly the same. Typically, the conditions under which treatment is given in the observational sample does not follow the exact conditions of the RCT (Lodi et al., 2019). This can also be linked to poor compliance in the real-world condition (see external validity discussion above).
2. The population under which the treatment effect was assessed in the RCT is different from the one in the observational sample. Under treatment effect heterogeneity, it is very likely that both estimates are different (see Figures 1.8 and 1.9 above for an illustration). This reason is deeply linked to the lack of external validity we mentioned above, and in particular the population lack of representativeness.
3. The observational data analysis is undermined by an unobserved confounder (that is Assumption 2 does not hold).

The fear of an unobserved confounder (third hypothesis) is usually the ideal culprit in current applied literature. When a confounder is unobserved, solutions have been proposed at the price of additional assumptions, for example the *front-door criterion* (Pearl, 1993), instrumental variables (Angrist et al., 1996; Hernán and Robins, 2006; Imbens, 2014), and sensitivity analysis (Cornfield et al., 1959; Rosenbaum and Rubin, 1983a; Imbens, 2003).

In fact, to investigate whether assumptions two and three hold, we could leverage several data sources, in order to strengthen observational data against confounding, or correct trial's lack of representativeness. Indeed, a trial assessing the efficacy of a treatment  $A$  on an outcome  $Y$ , and an observational database recording individuals treated or not by  $A$  and the outcome  $Y$  could be jointly used to:

1. **Enrich external validity of the trial** As highlighted in the Section 1.B, and in particular in the critical care illustration (see Figure 1.8), one concern of randomized controlled trials is the **distributional shift** between the population recruited and the target population on which the trial's findings are applied. The idea is to use an observational sample to generalize or transport the trial's findings into the distribution of the target population of interest. Doing so, a large cohort could be used to re-weight the trial observations. Such approach has been proposed in the 2010's both by Pearl and Bareinboim (2011a) and Stuart et al. (2011). While Pearl and Bareinboim (2011a) proposed a framework to reason about the assumptions enabling such generalization (called transportability in this literature) through an enrichment of causal diagram into selection diagram, Stuart et al. (2011) has directly proposed an estimation strategy based on population re-weighting, extending the definition of the propensity score (Definition 2) into a sampling score. This method is usually called *Inverse Propensity Sampling Weighting* (IPSW). Since then, other estimators have been proposed to generalize a causal effect, following the spirit of what can be done on a single observational sample. Therefore an equivalent of the plug-in G-formula (Kern et al., 2016) has been proposed, and a doubly-robust approach (Dahabreh et al., 2020). One of the main difference with the classical situation is the fact that two samples are involved in the estimation process, preventing the theoretical results from the observational literature to directly apply to this situation. Note that to generalize trial's findings there is no need to observe the treatment in the target population, but only the covariates  $X$  (and sometimes the baseline outcome  $Y^{(0)}$  for some methods as presented in Chapter 5).
2. **Enrich internal validity of observational studies** Former RCTs can be used as *negative controls* to ensure the observational study does not suffer from confounding. The intuition is that the causal effect estimated on the trial should be recovered at least on a subpopulation of the observational sample. The term negative control comes from standard routine precaution in biological laboratory experiments, where such controls are used to – at least partially – check that the experiment is not undermined. For example, it can test the absence of reagents or components that are necessary for a detection of something particular. In particular, one of the two bars of covid antigenic tests is one of these controls. The analogy of this principle in causal inference is detailed in Lipsitch et al. (2010). For instance, in a recent observational study on a

COVID-19 vaccine, [Dagan et al. \(2021\)](#) use such approach to ensure that previous trial results could be retrieved. Recent methodological developments have also been proposed by [Kallus et al. \(2018\)](#)

Other practical applications of data sources combination exist (see Chapter 2 for all purposes of combining data sources), as, for example, enabling the usage of hybrid control arms. A hybrid control arm is a control arm constructed from a combination of randomized patients and patients receiving usual care in standard clinical practice, as introduced by [Pocock \(1976\)](#) and pursued by [Hobbs et al. \(2012\)](#); [Schmidli et al. \(2014\)](#). Recently, the FDA has detailed their usage in regulatory purposes ([FDA, 2018](#)).

Note that having data from different sources can also be used in the context of anchor regression ([Rothenhäusler et al., 2021](#)).

## 4 Contributions

This PhD thesis is motivated by the clinical situation presented in Section 1.B: are the findings of the CRASH-3 trial generalizable toward the Traumabase’s population?

**Contributions** This manuscript is divided into five chapters. Chapter 2 proposes a review of current statistical methods that combine several data sources in order to build or strengthen clinical evidence. As missing data are ubiquitous in observational data sets, we propose, in Chapter 3, a sensitivity analysis to deal with totally or partially missing covariates when generalizing a treatment effect. Going back to the complete case scenario where all covariates are observed, we carry out, in Chapter 4, a finite and large sample analysis of the *Inverse Propensity Sampling Weighting* (IPSW) estimator, along with a discussion about the impact of additional non-necessary covariates on the variance estimator. While Chapters 3 and 4 focus on the generalization of the risk difference (as most of the current literature), we question, in Chapter 5, the generalization of different causal metrics such as the ratio, number needed to treat, or odds ratio. Doing so, we also propose general considerations about causal measure, such as the collapsibility of causal effects.

The contributions of each chapter, which are summarized below, have led to four articles as first-authors:

- Chapter 2 published in *Statistical Science*, co-authored with Imke Mayer,
- Chapter 3 published in *Journal of Causal Inference*,
- Chapter 4 submitted to *Journal of the Royal Statistical Society: Series A*,
- Chapter 5 submitted to *Statistics in Medicine*.

Beyond these methodological works, contributions in applied fields have also been conducted, leading to two others research works. The first project is linked to educational public policy, and the second to climate change:

- **Schooling induces a gender gap in math: Evidence from two million children**, co-authored with Stanislas Dehaene and Pauline Martinot (et al.). This work has been submitted to *Nature* (second-position author).

On this project I helped all along the data cleaning and preparation process (in particular with missing values) and on the design and implementation of statistical analysis. This research work makes use of modern causal inference technics such as matching, propensity weighting, g-formula, and causal forests.

- **Decrease of the spatial variability and local dimension of the Euro-Atlantic eddy-driven jet stream with global warming**, co-authored with Robin Noyelle and Pascal Yiou



(et al.). This work is currently in a major review process to *Climate Dynamics* (middle-position author).

In this work, I contributed to the redaction of the methodological section along with the sensitivity analysis. Principal investigators were willing to estimate the effect of the temperature increase on the jet stream’s variability. Through our discussions, I helped them in explaining what is a causal graph and how to draw one, which was later used to identify a necessary set of covariates for identification. Estimation is done using a plug-in g-formula with linear assumptions on the generative process. I also applied a sensitivity analysis to assess the impact of a missing confounder on the conclusion (Cinelli and Hazlett, 2020).

These two works are mostly applications and do not require development of new statistical tools or theoretical guarantees. Therefore their content is not detailed in this manuscript.

**Chapter 2: Combining experimental and observational data, a review** This chapter reviews the current state of the art on combining experimental and observational sources. For now, most existing methods aim to (i) generalize trial’s findings to a target population or (ii) strengthen the observational data analysis with interventional data as a negative control. While this thesis is anchored in the potential outcomes framework, Chapter 2 also contains a review of the so-called structural causal model framework with a presentation of the selection diagram’s framework to encode transportability assumptions. Chapter 2 also contains the implementation of the different generalization estimators, along with a comparison on a simulation. Finally, an extensive discussion about the critical care application is provided, opening the door to current open methodological questions: covariate selection, missing values, finite and large sample behavior (to name a few). Some of these challenges motivate the research works presented in Chapters 3, 4, and 5.

**Chapter 3: A sensitivity analysis to handle missing covariates** While implementing the generalization of CRASH-3 trial’s findings, we faced an important identification problem. An important treatment effect modifier is missing in the Traumabase: the time between treatment (TTT) and the accident. There is already evidence that this covariate is a major treatment effect modulator, e.g. Mansukhani et al. (2020) reveal a 10% reduction in treatment effectiveness for every 20-min increase in TTT. As TTT is probably shifted between the two populations, this prevented to conclude on the generalized effect. Therefore our first methodological contribution is to develop a sensitivity analysis for this specific situation. In Chapter 3, we present and investigate the problem of a missing covariate that affects the identifiability of the target population average treatment effect (ATE) when generalizing trial’s findings to a target population, a common situation when combining different data sources. We propose a quantification of the bias due to unobserved covariates, assuming a semi-parametric generative process (linear conditional average treatment effect, CATE), and under a transportability assumption of links across covariates between the two populations. Our derivation of this bias is not estimator specific and remains valid for the three main estimators for generalization (IPSW, G-formula plug-in estimator, and AIPSW). We also prove that a linear imputation of a partially missing covariate cannot replace a sensitivity analysis. Relying on this result, we provide a sensitivity analysis framework. In practice, experts must usually provide *sensitivity parameters* that reflect plausible properties of the missing confounder. Classic sensitivity analyses, dedicated to ATE estimation from observational data, use as sensitivity parameters the *impact of the missing covariate on treatment assignment probability* along with the *strength on the outcome* of the missing confounder. However, given that these quantities are hardly directly transposable when it comes to generalization, these approaches cannot be directly applied to estimate the population treatment effect. Our sensitivity analysis deals with all the possible missing data patterns, including the case of a proxy variable that would replace the missing one. Therefore these results can be useful for users as they may be tempted to consider the intersection of common covariates between the RCT and the observational data. We detail how the different patterns involve either one or two sensitivity parameters. To give users an interpretable analysis, and due to the specificity of the sensitivity parameters at hands, we propose an adaptation of sensitivity maps that are commonly used to communicate sensitivity analysis results.

**Chapter 4: Finite sample error and variable selection when re-weighting a trial** When applying generalization’s estimator to our motivating example, we faced another open question. While theoretical results related to consistency exist in the literature, we have found no theoretical characterization of (i) the finite sample properties or (ii) the effect of the target sample size  $m$  relative to the trial sample size  $n$  on the estimators. We also questioned ourselves about the impact of adding non-necessary covariates for generalization in the adjustment set. Non-necessary covariates in the adjustment set is a widely known topic when facing a single observational sample (Lunceford and Davidian, 2004; Brookhart et al., 2006), but was an open research question when it comes to generalization. For instance, existing results on the IPW estimator (see Definition 3) can not be directly transferred to the generalization case as the equivalent for the generalization estimator (the *Inverse Propensity Sampling Weighting* - IPSW) implies different weights and two samples. In Chapter 4, we address simultaneously the impact of the two sample sizes on the IPSW estimator together with its dependence on adding additional covariates. Doing so, we consider several variants of the IPSW, for which the weights are oracle, semi-oracle, or estimated. In this context, we derive the asymptotic variance of all the variants of IPSW, and we show that several asymptotic regimes exist, depending on the relative size of the RCT compared to the target sample. Denoting  $\hat{\tau}_{n,m}$  the IPSW estimator, where weights are completely estimated, we show that this estimator is asymptotically unbiased when  $n$  tends to infinity, that is

$$\lim_{n \rightarrow \infty} \mathbb{E}[\hat{\tau}_{n,m}] = \tau.$$

Besides, letting  $\lim_{n,m \rightarrow \infty} m/n = \lambda \in [0, \infty]$ , the asymptotic variance of the estimated IPSW satisfies

$$\lim_{n,m \rightarrow \infty} \min(n, m) \text{Var}[\hat{\tau}_{n,m}] = \min(1, \lambda) \left( \frac{\text{Var}[\tau(X)]}{\lambda} + V_{so} \right),$$

where  $\tau(X)$  is the CATE previously introduced and  $V_{so}$  is a constant depending on (i) the distributional shift between the trial population and the target population, and on (ii) the variance of the potential outcomes. Interestingly, the variance is a function of both sample sizes, whereas the bias only depends on the trial sample size. Depending on the relative sample size of  $n$  and  $m$  (through  $\lambda$ ), different convergence regimes can be defined. We also provide finite sample expression of the bias and variance for all the IPSW variants introduced, allowing us to bound the risk on these estimators for any samples sizes (trial and target population). From these theoretical results, we explain why the addition of some additional but non-necessary covariates in the adjustment set has a large impact on precision, for the best or the worst. Indeed, while non-shifted treatment effect modifiers improve precision by lowering the variance, adding shifted covariates that are not treatment effect modifiers of the outcome considerably reduces the statistical power of the analysis by inflating the variance. For this latter situation, we provide an explicit formula of the variance inflation when the additional covariate set is independent of the necessary one. These results have important consequences for practitioners because they allow to give precise recommendations about how to select covariates. Note that we link our work to seminal works in causal inference, showing that semi-oracle estimation outperforms a completely oracle estimation, while the exact result on IPW on efficient estimation can not be completely extended to the case of generalization. All our results assume neither a parametric form of the outcome nor the sampling process, but are established at the cost of restricting the scope to categorical covariates for adjustment. Within the medical domain, scores or categories are often used to characterize individuals, which justifies this approach.

**Chapter 5: Risk ratio, odds ratio, risk difference... Which causal measure is easier to generalize?** We have noticed that very few works exist on which covariate sets are required to identify causal effects that are not the absolute difference, e.g. ratios or odds ratios. Huitfeldt et al. (2018) highlighted that the assumptions to generalize the causal effects depend on the causal measure of interest. In Chapter 5, we pave the way toward the generalization of other causal metrics such as the ratio, odds ratio, or number-needed-to-treat. This research question was motivated by our clinician collaborators, which are mostly interested in reporting ratios rather than absolute differences. While investigating the generalizability of the different causal measures led us toward a reviewing work

on causal measures. In particular we proposed a formalization of the so-called collapsibility properties, proposing three different definitions unifying different existing definitions in the literature. Besides reviewing and formalizing properties, our main contribution is to reverse the thinking: rather than starting from the causal measure, we propose to start from a non-parametric generative model of the outcome. This enable the following observations: depending on the nature of the outcome, some causal measures disentangle treatment modulations from baseline risk. For example, if the outcome is continuous, it is possible to disentangle baseline level with the treatment effect in a very general generative process. Assuming that  $\mathbb{E}[|Y^{(1)}| | X] < \infty$  and  $\mathbb{E}[|Y^{(0)}| | X] < \infty$ , we show that there exist two functions  $b, m : \mathcal{X} \rightarrow \mathbb{R}$  such that

$$Y^{(a)} = b(X) + a m(X) + \varepsilon_a,$$

where  $b(X) := \mathbb{E}[Y^{(0)} | X]$ ,  $m(X) := \mathbb{E}[Y^{(1)} - Y^{(0)} | X]$  and a noise  $\varepsilon_A$  satisfying  $\mathbb{E}[\varepsilon_A | X] = 0$  almost surely. This model allows interpreting the difference between the distributions of treated and control groups as the alteration  $m(X)$  of a generative model  $b(X)$  by the treatment. The function  $b$  corresponds to the **baseline**, and  $m$  to the **modifying function** due to treatment. It is then possible to notice that the difference and the ratio grasp different parts of the generative process:

$$\tau_{\text{RD}} = \mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}] = \mathbb{E}[m(X)], \quad \tau_{\text{RR}} = \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]} = 1 + \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}.$$

In these simple derivations, one can see that the ratio depends on both the baseline  $b$  and the modifying effect  $m$ , whereas the difference only depends on the modifying effect  $m(X)$ . Note that  $m(X) := \tau(X)$  previously introduced for the risk difference. We extend this idea to a binary outcome, for which the conclusion of the causal measure interpretation is different. In particular, the modifying effect function  $m(X)$  can no longer be written as an effect on the difference, making the ratio the more generalizable measure to use.

Our analysis outlines an understanding what heterogeneity and homogeneity of treatment effect mean, not through the lens of the measure, but through the lens of the covariates. As our goal is the generalization of causal measures, we show that different sets of covariates are needed to generalize an effect to a different target population depending on *(i)* the causal measure of interest, *(ii)* the nature of the outcome, and *(iii)* a conditional outcome model or local effects are used to generalize.



## Traduction en français du propos introductif

### 1.A L'émergence de l'évidence clinique dite moderne

Les recommandations médicales formulées par les cliniciens ou les organismes de réglementation (ex. *Food and Drug Administration* (FDA) ou l'*Organisation mondiale de la santé* (OMS)) sont fondées sur ce que l'on appelle les *la médecine par les preuves*. Toutefois, au cours des deux derniers siècles, la notion d'évidence clinique a considérablement évolué. Désormais, les données cliniques et l'analyse statistique sont centrales. L'idée d'utiliser des données pour répondre à des questions cliniques s'est progressivement imposée à partir du XIXe siècle. De nombreuses approches et méthodes que nous utilisons aujourd'hui ont été développées à cette époque. À titre d'illustration, nous détaillons certaines des contributions des pionniers suivants.

- **Pierre-Charles-Alexandre Louis (1787-1872)** était médecin dans l'ancien hôpital parisien *La Charité*. Il a développé de nouvelles méthodologies sur des maladies (par exemple, la typhoïde et la tuberculose), ainsi qu'une évaluation de l'efficacité d'une technique très populaire à l'époque: la saignée (Morabia, 2006; Chemla and Abastado, 2012). Son travail sur la saignée contient de nombreux éléments clés qui sont aujourd'hui préconisés comme relevant de la recherche clinique moderne. Par exemple, Louis (1828) restreint son étude à une population cible de la même façon que dans les études modernes, stratifie les patients selon la nature du traitement et la gravité de leur maladie, et enfin définit un *outcome* (ici la durée de la maladie). Ce qui frappe dans l'œuvre de Pierre-Charles-Alexandre Louis, c'est (i) la notion de comparaison de groupes *similaires* et (ii) la notion de population cible. Ces deux éléments sont des éléments standards des essais contrôlés randomisés (ECR) modernes.
- **William Farr (1807-1883)** était un démographe pionnier et un fonctionnaire du *General Register Office* où il a d'abord été nommé compilateur d'extraits statistiques avant d'être nommé *Superintendent of the Statistical Department* (surintendant du département statistique). Parallèlement à son travail de fonctionnaire, il était un collaborateur régulier de la revue *Lancet* (Langmuir, 1976). Ses travaux ont porté sur un large éventail de sujets, notamment la normalisation de la nomenclature des ensembles de données. Il est également célèbre pour avoir amélioré la définition statistique de l'espérance de vie avec sa *British Life Table* (Farr, 1864), tout en développant les principes de ce que l'on appelle aujourd'hui *surveillance* (de la maladie, voir Langmuir, 1976). Il s'est attaché à trouver les causes des maladies, tout en étant très préoccupé par l'impact de l'industrialisation sur la santé publique. Selon Rothman (2011), William Farr a également joué un rôle important dans la discussion scientifique sur les causes du choléra (voir ci-dessous avec John Snow). William Farr était un réformateur social, profondément préoccupé par les effets de l'industrialisation sur la santé publique. Cela pourrait expliquer ses enquêtes basées sur des données concernant les causes des maladies, afin de *prévenir* leur apparition et d'encourager des réformes sanitaires efficaces (Farr, 1839; Langmuir, 1976; Rothman, 2011).
- **John Snow (1813-1858)** était médecin. Il est connu pour ses travaux sur le choléra et est aujourd'hui présenté dans tous les cours ou livres d'épidémiologie *comme le père fondateur de l'épidémiologie* (Rothman, 2011). En 1854, Londres a été confrontée à une épidémie de choléra. Selon le récit communément raconté aujourd'hui, John Snow a commencé à reporter les cas sur une carte de Londres. Cette pratique correspond à ce que nous appelons aujourd'hui *les statistiques descriptives*. Il a testé l'hypothèse de l'eau comme vecteur de contamination du choléra, et a donc indiqué les pompes à eau sur la carte. Il a pu identifier une corrélation entre les deux : la concentration de cas de choléra était la plus élevée autour de certaines pompes à eau (Tulchinsky, 2018). Snow est connu pour avoir convaincu les autorités de retirer la poignée de la pompe suspectée d'être à l'origine de l'épidémie, entraînant la fin de l'épidémie<sup>9</sup>. L'emplacement

<sup>9</sup>Certains travaux récents défendent l'idée que l'intervention de John Snow a été trop tardive, car la maladie était déjà en régression naturelle. Ce n'est donc pas son action qui aurait mis seule fin à l'épidémie de choléra. Voir le chapitre 4 de Rothman (2011), montrant une reconstitution de la courbe épidémique, déjà en décroissance au moment de l'intervention

de la pompe est aujourd'hui marqué par une plaque en l'honneur de John Snow. Il convient de noter qu'à l'époque, une autre hypothèse voulait que le choléra soit transmis par l'air : la théorie dite des miasmes. Cette théorie était partagée par de nombreuses personnes, dont William Farr (Eyler, 2004). La théorie des miasmes était étayée par les observations selon lesquelles les personnes vivant en altitude - censées être exposées à l'air frais - étaient moins sujettes au choléra. Mais l'altitude est également liée à l'écoulement de l'eau, les personnes vivant à basse altitude étant plus susceptibles de boire de l'eau contaminée. Ce qui a fait la différence à l'époque, c'est l'intuition de Snow selon laquelle, les symptômes étant gastro-intestinaux, la maladie ne pouvait être transmise que par l'eau ou la nourriture. Il a réussi à démêler les covariables cachées en associant les maisons à leurs fournisseurs d'eau exacts. En d'autres termes, cela a permis de voir clairement le lien entre la pompe à eau et les habitants souffrant du choléra, et pas seulement la corrélation fallacieuse avec la qualité de l'air par le biais de l'altitude (Rothman, 2011).

- **Janet Lane-Clayton (1877-1967)** était médecin et fut également la première femme à recevoir une bourse de recherche de la *British Medical Society*. Outre ses nombreux travaux de recherche, l'un de ses objectifs était de comparer les avantages de l'allaitement maternel par rapport à l'alimentation au lait de vache (elle a publié un rapport de 60 pages en 1912). Selon Winkelstein Jr (2004), elle est l'auteur de l'une des premières études cas-témoins, qui comprend une discussion détaillée sur les sources de confusion et l'erreur aléatoire de l'échantillon fini. Elle a appliqué un test t de Student pour rejeter l'hypothèse d'un échantillonnage aléatoire expliquant la différence associée à l'alimentation dans le poids corporel des nourrissons. Il convient de noter que le test t de Student n'a été proposé que quatre ans avant les travaux de Janet Lane-Clayton (Student, 1908), ce qui montre à quel point ces travaux utilisent les statistiques les plus récentes. Elle a également mis en évidence la classe sociale comme un possible facteur de confusion non observé (Winkelstein Jr, 2004; Rothman, 2011). En 1926, elle a également travaillé sur une autre étude cas-témoins visant à déterminer les facteurs de risque des cancers du sein, dont la plupart sont encore valables aujourd'hui (Lane-Clayton et al., 1926).

Tous ces chercheurs et scientifiques ont tiré leurs conclusions de données empiriques collectives, plutôt que d'expériences individuelles. À la même époque, les concepts mathématiques évoluent. Une nouvelle science mathématique émerge alors avec les probabilités et les statistiques. L'ouvrage de Pierre-Simon Laplace (1749-1827) intitulé *Essai philosophique sur les probabilités* publié en 1814 est un bon exemple de ce mouvement. Ce livre illustre les prémisses d'un nouveau type de raisonnement : la collecte de données, la pensée probabiliste et son application en médecine :

*“Le calcul des probabilités peut faire apprécier les avantages et les inconvénients des méthodes employées dans les sciences conjecturales. Ainsi, pour reconnaître le meilleur des traitements en usage dans la guérison d'une maladie, il suffit d'éprouver chacun d'eux sur un même nombre de malades, en rendant toutes les circonstances parfaitement semblables : la supériorité du traitement le plus avantageux se manifestera de plus en plus à mesure que ce nombre s'accroîtra ; et le calcul fera connaître la probabilité correspondante de son avantage, et du rapport suivant lequel il est supérieur aux autres.”* – page 134, de l'ouvrage de l'Essai philosophique sur les probabilités du Marquis de Laplace.

On peut ainsi attribuer l'apparition du terme *épidémiologie* en 1850 à la création de la *Royal Society of Medicine's Epidemiological Society* à Londres. L'objectif de cet institut était “d'étudier les causes et les conditions qui influencent l'origine, la propagation, l'atténuation et la prévention des maladies épidémiques” (Evans, 2001). L'apparition du terme *épidémiologie* symbolise ainsi la naissance et l'établissement d'une nouvelle approche méthodologique pour caractériser la propagation des maladies, et plus généralement ce que l'on appelle aujourd'hui la santé publique. L'épidémiologie est par essence interdisciplinaire, comptant au moins la médecine, la physiologie et les mathématiques. Par la suite, la *Royal Society of Medicine's Epidemiological Society* a été intégrée à la *Royal Society of Medicine*, prenant ainsi toutes ses lettres de noblesse. L'épidémiologie n'a pas seulement été façonnée par des

---

de John Snow. Il n'en reste pas moins que l'ensemble du processus qui consiste à passer de la description à la vérification de l'hypothèse reste remarquable et inédit pour la période.

cliniciens, mais surtout par des scientifiques. Claude Bernard (1813-1878) souligne dans son livre comment cette nouvelle science suppose la fusion des différentes communautés scientifiques :

*Le désir que j'exprime ici répondrait à peu près à la pensée de Laplace, à qui on demandait pourquoi il avait proposé de mettre des médecins à l'Académie des sciences puisque la médecine n'est pas une science : "C'est, répondit-il, afin qu'ils se trouvent avec des savants." – page 285, dans Bernard (1865)*

Un parallèle intéressant peut être fait avec la situation actuelle, où les collaborations interdisciplinaires sont de plus en plus recherchées, dans des domaines tels que la science des données (Chambers, 2022).

A cette époque le rôle croissant des statistiques - également appelées *sciences conjecturales* au milieu du 19<sup>ème</sup> siècle - n'a pas été si naturel. Claude Bernard est souvent cité comme un opposant à l'utilisation des statistiques dans la science médicale. Bernard (1865) considérait en effet que la véritable connaissance médicale devait être acquise par l'individualisation des cas et la compréhension de la variabilité entre les individus, plutôt que par la dissimulation de ces dernières dans des moyennes. L'idée sous-jacente étant que si le mécanisme est vraiment compris, il ne devrait plus y avoir d'incertitude quant au résultat et/ou à l'effet du traitement. Ceci étant dit, une lecture plus précise des travaux de Claude Bernard montre une réalité moins caricaturale. Par exemple, Claude Bernard discute dans son *Introduction à l'étude de la médecine expérimentale* sans le nommer les expériences de Pierre-Charles-Alexandre Louis. Il y fait l'éloge de l'évaluation expérimentale et statistique de la saignée, reconnaissant ainsi les atouts de ces méthodologies nouvelles.

**La recherche clinique moderne et les données** L'utilisation des statistiques dans la recherche clinique, introduite au 19<sup>ème</sup> siècle, a continué à être largement diffusée. L'approche moderne de l'enseignement des statistiques pour la santé publique a désormais un cadre clair (Rothman and Greenland, 2000; Rothman, 2011; Guyatt et al., 2015). Ainsi, la pratique actuelle pour construire ce que l'on appelle "l'évidence clinique" est très encadrée. Les chercheurs s'appuient principalement sur la collecte de données provenant de sources multiples pour établir des preuves et tirer des conclusions sur les maladies ou les facteurs de risque. La force de ces preuves va de relativement faible à très robuste, en fonction du *type* et de la *la quantité* des données collectées. Par *type* de données, il faut comprendre la manière dont les données ont été collectées et le fait qu'elles résultent ou non d'un modèle observationnel ou d'un modèle expérimental. Il existe une grande variété de sources de preuves, c'est-à-dire de collecte et d'analyse de données : les études en deux étapes, les études écologiques, les cohortes rétrospectives, les études cas-témoins et les essais contrôlés randomisés (ECR). Actuellement, les essais contrôlés randomisés sont largement considérés comme la meilleure preuve pouvant être obtenue à partir d'une seule étude, ce qui leur vaut le titre d'*étalon-or* pour la mesure des effets causaux :

*Parce qu'aucun autre modèle d'étude ne peut offrir les garanties contre les biais associés à la randomisation, les essais contrôlés randomisés (ECR) fournissent des preuves plus solides que les autres modèles d'étude. – (Guyatt et al., 1995)<sup>10</sup>*

L'essai clinique randomisé qui a évalué l'efficacité de la streptomycine (Crofton and Mitchison, 1948) est souvent cité comme l'essai clinique randomisé fondateur des standards actuels. Cet essai clinique a été réalisé dans un contexte de recherche de nouveaux antibiotiques. La pénicilline s'avairait inefficace contre un agent pathogène appelé *Mycobacterium tuberculosis* (ou *bacille de Koch*) responsable de la tuberculose pulmonaire. Pourtant à l'époque, la streptomycine était un nouvel antibiotique prometteur ayant fait l'objet d'expériences positives sur des tubes et des animaux. Crofton (2006), l'un des membres de l'unité Tuberculose du Medical Research Council (MRC) de l'époque avec Austin Bradford Hill (1897-1991), raconte l'histoire de la conception et de la réalisation de cet essai historique. Le traitement standard (ou groupe de contrôle) de la tuberculose pulmonaire était le repos au lit. Bradford et le comité ont défini un essai respectant toutes les normes modernes : critères d'éligibilité (par

---

<sup>10</sup>Translated from English.

exemple, stade de la maladie, âge, etc.), randomisation (au moyen d'enveloppes avec deux options, contrôle ou traitement), répartition du traitement en double aveugle (pour les patients et les cliniciens), confidentialité, collecte de données cliniques longitudinales pour chaque patient pendant toute la durée de l'essai.

*Il me plaît de croire que, avec l'unité de recherche sur la tuberculose du MRC, nous avons contribué à promouvoir l'adoption d'un modèle d'étude pour lequel l'essai de l'essai de streptomycine du MRC est souvent considéré comme un symbole. – Crofton (2006)<sup>11</sup>*

Bien que la streptomycine ait donné de bons résultats au début de cet essai, les chercheurs ont pu observer des effets secondaires et une lente diminution de l'efficacité au fil du temps. Il s'avère que pour être efficace, la streptomycine doit être associée à d'autres traitements et nécessite une observation stricte pour éviter la résistance bactérienne. Notons que Crofton, qui était clinicien, propose une opinion personnelle intéressante qui fait écho à celle de Claude Bernard :

*Les essais randomisés de ce type ont été d'une grande importance pour développer des stratégies de traitement efficaces, mais ils n'étaient pas intellectuellement stimulants. Notre principal intellectuel dans la recherche sur la tuberculose était d'identifier d'identifier les causes de l'échec des traitements médicamenteux. – Crofton (2006)<sup>12</sup>*

À l'heure actuelle, les essais contrôlés randomisés (ECRs) occupent une place centrale dans les réglementations pharmaceutiques. Les essais sont divisés en différentes phases cliniques selon leur amplitude et objectifs, et on parle ainsi de différentes "phases", allant de un à trois. Les études empiriques sont souvent présentées dans une structure hiérarchique, qui classe la force des preuves que chaque étude peut fournir. Cette hiérarchie est souvent représentée par un diagramme pyramidal qui illustre les différents niveaux de preuve. (voir Figure 1.6, où RCT correspond à *Études randomisées contrôlées en double aveugle*).

**Figure 1.6: Exemple d'une pyramide de l'évidence clinique** ; cette pyramide exacte se trouve à la SUNY Downstate Medical Research Library de Brooklyn (voir Evidence-Based Medicine Course, disponible [online](#)). Plusieurs pyramides similaires peuvent être trouvées dans des manuels ou des articles de recherche (par exemple [Ahn and Kang \(2018\)](#)), parfois avec un classement ou une dénomination légèrement différents. Certains travaux sociologiques remettent en question leur origine, leur rôle et leur utilisation, par exemple [Blunt \(2015\)](#).



Qu'y a-t-il de mieux qu'un seul essai contrôlé randomisé (ECR) ? Plusieurs essais contrôlés randomisés ! Outre les études menées sur une seule population, les examens systématiques et les méta-analyses représentent la dernière couche de preuves cliniques modernes selon la hiérarchie actuellement promue dans la recherche clinique. La méta analyse est une approche qui consiste à collecter et à examiner les recherches disponibles sur une question spécifique et à en analyser les résultats ([Ahn and Kang, 2018](#)). La mise en commun des estimations de plusieurs études comme couche statistique supplémentaire est tentante, mais nécessite de s'assurer que la population d'intérêt est clairement définie. Les critères dits PICO sont souvent mentionnés (Population, Intervention, Comparaison, Résultats). Les résultats d'une méta-analyse sont généralement présentés sous forme de *forest plots*. En 2009, le *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) ([Liberati et al., 2009](#)) a proposé des lignes directrices actualisées concernant les méta-analyses. Les premières avaient été proposées en 1999 ([Moher et al., 1999](#)) (appelées *Quality Of Reporting Of Meta-analysis* (QUOROM)). Ces lignes directrices contiennent une liste de bonnes pratiques visant à garantir que les méta-analyses sont effectués correctement. Par exemple, les auteurs doivent rapporter le protocole, détailler les critères

<sup>11</sup>Translated from English.


<sup>12</sup>Translated from English



d'éligibilité, fournir les mesures sommaires utilisées (par exemple, le rapport de risque, la différence de risque) et joindre un organigramme pour décrire le processus.

Enfin, il convient de noter que l'utilisation courante de statistiques pour quantifier les causes et les effets des habitudes ou des drogues fait également l'objet de critiques, du fait de la prolifération d'études mesurants un effet ou un autre, sans forcément apporter un recul global (Krieger, 1994). En outre, la façon dont la société et les médias perçoivent et interprètent ces résultats suscite des inquiétudes, comme l'illustre la Figure 1.7.

**Figure 1.7:** La caricature de Jim Borgman en 1997, véhicule plusieurs idées, en particulier que (i) de nombreuses maladies sont multifactorielles et peuvent difficilement être décomposées en un seul facteur de risque et que (ii) la communication de résultats clés dans les médias peut être trompeuse en raison des nombreux articles scientifiques actuellement publiés.



## 1.B Limites des essais randomisés contrôlés dans la recherche clinique

Si la médecine moderne *fondée sur des preuves* (*evidence-based medicine, EBM*) place les essais contrôlés randomisés (ECRs) au cœur de la preuve clinique, des préoccupations ont récemment été exprimées quant à la portée limitée de ces études. L'une des principales préoccupations actuelles concerne ce que l'on appelle la *validité externe* (ou *généralisabilité*) d'un essai. La généralisation des résultats des essais est cruciale car, le plus souvent, les cliniciens utilisent les effets causaux des essais publiés pour (i) estimer la réponse attendue au traitement pour un patient spécifique en fonction de ses risques de base, et donc pour (ii) choisir le meilleur traitement. Au-delà du point de vue de chaque praticien, le même raisonnement est valable pour les organismes de réglementation qui doivent exposer des lignes directrices claires et promouvoir une norme de soins. Bien qu'elles soient généralement moins soulignées dans les articles scientifiques, les conclusions des essais ont également un impact sur la réglementation pharmaceutique, puisque le prix d'un médicament dépend principalement de son efficacité (évaluée au moyen d'études cliniques).

Le formalisme et le principe d'un ECR sont détaillés ci-dessous (voir Sections 3), mais pour l'instant, on peut admettre l'idée que le résultat d'un ECR est une estimation de ce que l'on appelle l'effet moyen du traitement (*ATE, average treatment effect*), également appelé effet moyen *causal* d'un traitement afin de souligner que l'effet rapporté n'est pas une association. Dans la pratique, un ECR vise principalement à présenter une estimation ponctuelle avec ses intervalles de confiance, par exemple le rapport de risque, généralement mis en évidence dans le résumé en tant que résultats principaux, avec la taille de la population et les intervalles de confiance. Il est donc essentiel de comprendre la validité de ce chiffre si l'on considère d'autres populations.

La question de savoir si les résultats d'une étude peuvent être extrapolés à d'autres populations n'est pas nouvelle. En 1957, **Campbell (1957)** a introduit le concept de validité interne et externe dans les sciences sociales. Ce concept - également appelé généralisation ou représentativité dans l'article original - soulève des questions sur *les populations, les contextes et les variables auxquels un effet donné peut être généralisé*. Cette définition et cette dénomination ont été promues plus récemment par les

*Consolidated Standards of Reporting Trials* (CONSORT) (Altman et al., 2001). Même si ce souci n'est pas partagée par tous (voir, par exemple Rothman et al., 2013), cette question gagne en intérêt dans la recherche clinique (Concato et al., 2000; Blanco et al., 2008; Deeks, 2002; Rothwell, 2007; Green and Glasgow, 2006; Frieden, 2017; Berkowitz et al., 2018) :

“Ni Cochrane ni Bradford Hill n'étaient cliniciens, mais ils comprenaient les limites de la de la méthodologie dont ils étaient les pionniers. Le peu de preuves dont nous disposons aujourd'hui confirme que les que les essais contrôlés randomisés manquent souvent de validité externe, or cette question est négligée par les chercheurs actuels, les revues médicales, les chercheurs en médecine, les agences de financement, les comités d'éthique, l'industrie pharmaceutique, ainsi que les régulateurs gouvernementaux.” – Rothwell (2007)<sup>13</sup>

Pour garantir la validité externe, il doit y avoir une forte ressemblance entre la population utilisée dans l'expérience et la population cible. Cela inclut : l'efficacité de la population, la définition des résultats, la manière dont le traitement a été administré, l'importance des lieux et la chronologie. Cela explique peut-être pourquoi ce concept est parfois qualifié de *matière de jugement* (Altman et al., 2001). (même si les deux concepts ne sont pas strictement équivalents, ce qui conduit à des notations mathématiques différentes). Voici quelques préoccupations typiques qui ont été soulevées au sujet de la portée limitée des ECRs :

- **Les critères d'éligibilité et d'exclusion** permettent de définir la population recrutée dans le cadre d'un ECR et font donc partie de la conception. En général, une certaine limite d'âge et une certaine typologie de maladies sont requises pour être recruté. Ces critères servent à la fois à (i) protéger la population faible ou à risque (par exemple, les femmes enceintes) et à (ii) mener l'étude sur un groupe de patients suffisamment homogène pour maximiser l'effet estimé du traitement. Au-delà des critères d'exclusion qui définissent une limite à la typologie des patients sélectionnés, il peut également y avoir une sur- ou sous-représentation de certaines populations, en raison par exemple des hôpitaux ou des lieux choisis pour mener les essais. Ces biais sont beaucoup plus difficiles à repérer et à signaler que les critères d'exclusion.
- **La conformité irréaliste au monde réel** des essais est souvent considérée comme une limite à l'extension de la validité des essais. Dans un essai clinique randomisé, les individus sont soigneusement suivis, de sorte que, pendant l'essai, le traitement est administré dans des conditions optimales avec une très bonne observance : doses et calendrier de traitement. En dehors des conditions expérimentales, les individus peuvent s'écarter de la norme, par exemple en oubliant de prendre une pilule prescrite ou en arrêtant le traitement plus tôt que prévu. Au-delà de l'étourderie, cela peut être pour de bonnes raisons telles que des effets secondaires ou une administration douloureuse du traitement. Par conséquent, l'effet observé en pratique peut différer de celui évalué lors de l'essai, car le traitement en vie réelle n'est plus le même que celui administré lors de l'essai. Certains appellent ce phénomène l'efficacité (conditions réelles) par opposition à l'efficacité (conditions expérimentales) (Singal et al., 2014).
- Le **court délai** d'un essai, en raison du coût financier associé, empêche les individus d'être suivis pendant de nombreuses années, ce qui rend les résultats d'un ECR potentiellement étroits.
- La **taille limitée de l'échantillon**, une préoccupation largement partagée au sujet des essais contrôlés randomisés, empêche l'estimation des effets conditionnels (ou stratifiés) du traitement en raison d'un manque de puissance statistique.

Bien qu'il existe des lignes directrices, telles que celles fournies par CONSORT (Altman et al., 2001), existent pour définir les critères d'éligibilité et d'exclusion, il existe une inquiétude généralisée concernant les rapports inadéquats fournis dans les publications cliniques (Rothwell, 2007). Il convient de noter que ce manque de clarté n'est pas nécessairement intentionnel, mais peut être la conséquence de la volonté de présenter un message concis aux lecteurs. Nous détaillons ci-dessous notre exemple

<sup>13</sup>Translated from English

motivant et l'épitomé que nous abordons dans ce travail de recherche. Enfin, il convient de noter que, plus récemment, un autre type d'essais contrôlés randomisés (ECR) *pragmatiques* est de plus en plus proposé. Ces essais visent à maximiser la généralisabilité avec des critères d'éligibilité plus souples et une plus grande flexibilité dans la gestion de l'intervention (Godwin et al., 2003).

### Illustration du problème avec un exemple de la médecine de réanimation

Comme le souligne Rothwell (2007), le problème du manque de validité externe est encore plus préoccupant lorsque le traitement n'est que modérément efficace. Dans de telles situations, toute petite variation des conditions expérimentales peut invalider les conclusions de l'étude, en particulier lorsqu'il s'agit de transférer ces connaissances à d'autres populations. Pour illustrer ce phénomène, considérons le cas traité par nos collaborateurs cliniciens, dans lequel ils tentent de sauver des patients souffrant d'une lésion cérébrale traumatique (TBI). Le traumatisme cérébral est une lésion cérébrale causée par un coup ou une secousse à la tête. L'acide tranexamique (TXA) est un agent antifibrinolytique qui limite les saignements excessifs et qui est couramment administré aux patients en chirurgie. Des essais cliniques antérieurs ont montré que le TXA réduisait la mortalité chez les patients souffrant d'une hémorragie traumatique *extracrânienne* (Shakur-Still et al., 2009). Par conséquent, le TXA est suspecté comme potentiellement efficace dans le traitement des lésions crâniennes, car les hémorragies *intracrâniennes* sont généralement associées aux traumatismes crâniens, avec des risques d'augmentation de la pression intracrânienne, d'hernie cérébrale et de décès.

Suite à cette intuition, un essai randomisé contrôlé CRASH-3 a été lancé pour estimer l'effet causal (CRASH-3, 2019). CRASH-3 est un essai multicentrique randomisé et contrôlé par placebo lancé dans 175 hôpitaux de 29 pays différents (Dewan et al., 2012). Cet essai a recruté 9 202 adultes, ce qui est inhabituellement important pour un essai clinique randomisé médical. Tous souffraient d'un traumatisme crânien sans hémorragie extracrânienne majeure. Le résumé des caractéristiques démographiques et cliniques de base des participants à l'étude est généralement présenté au début de chaque étude clinique, sous le nom de tableau 1, et l'étude CRASH-3 ne fait pas défaut à cette pratique (voir le tableau 1.2 comme exemple typique). Ici, six covariables sont mesurées lors de l'entrée dans l'étude, à savoir l'âge, le sexe, le temps écoulé depuis la blessure, la pression artérielle systolique, le score de l'échelle de coma de Glasgow (GCS)<sup>14</sup>, et la réaction de la pupille. Tous les participants ont reçu au hasard du TXA. Le principal résultat étudié est le décès lié à un traumatisme crânien survenu à l'hôpital dans les 28 jours suivant la blessure chez les patients inclus et randomisés dans les 3 heures suivant la blessure. L'étude conclut que le risque de décès lié à un traumatisme crânien est de 18,5% dans le groupe TXA contre 19,8 % dans le groupe placebo. L'effet causal, reporté via le rapport des risques (RR), n'est pas significatif (RR = 0,94 [IC 95 % 0,86 - 1,02]). Ceci dit CRASH-3 a révélé un effet positif de l'acide tranexamique sur des sous-populations, et notamment pour les cas légers et modérés (c'est-à-dire avec des scores de Glasgow modérés et élevés). Mais dans quelle mesure la

	Tranexamic acid (n=4649)	Placebo (n=4553)
<b>Sex*</b>		
Men	3742 (80%)	3660 (80)
Women	906 (19%)	893 (20)
<b>Age, years</b>		
Mean (SD)	41.7 (19.0)	41.9 (19.0)
<25	1042 (22%)	996 (22%)
25-44	1716 (37%)	1672 (37%)
45-64	1169 (25%)	1184 (26%)
≥65	722 (16%)	701 (15%)
<b>Time since injury, h</b>		
Mean (SD)	1.9 (0.7)	1.9 (0.7)
≤1	877 (19%)	869 (19%)
>1-2	2003 (43%)	1889 (41%)
>2-3	1769 (38%)	1795 (39%)
<b>Systolic blood pressure, mm Hg</b>		
<90	89 (2%)	85 (2%)
90-119	1508 (32%)	1490 (33%)
120-139	1461 (31%)	1504 (33%)
≥140	1576 (34%)	1466 (32%)
Unknown	15 (<1%)	8 (<1%)
<b>Glasgow Coma Scale score</b>		
3	495 (11%)	506 (11%)
4	213 (5%)	213 (5%)
5	163 (4%)	172 (4%)
6	221 (5%)	232 (5%)
7	311 (7%)	294 (6%)
8	354 (8%)	315 (7%)
9	335 (7%)	292 (6%)
10	371 (8%)	364 (8%)
11	375 (8%)	390 (9%)
12	476 (10%)	478 (10%)
13	297 (6%)	312 (7%)
14	526 (11%)	458 (10%)
15	484 (10%)	492 (11%)
Unknown	28 (1%)	35 (1%)
<b>Pupil reaction</b>		
None reacted	425 (9%)	440 (10%)
One reacted	374 (8%)	353 (8%)
Both reacted	3706 (80%)	3636 (80%)
Unable to assess or unknown	144 (3%)	124 (3%)

Data are n (%), unless otherwise indicated. \*In the tranexamic acid group, one patient's sex was unknown.

**Table 1:** Baseline characteristics of patients before randomisation of those randomly assigned within 3 h of injury


**Table 1.2:** Exemple d'une **Table 1**, ici issue CRASH-3 (2019).

<sup>14</sup>L'échelle de coma de Glasgow (GCS) est une échelle neurologique qui vise à évaluer l'état de conscience d'une personne. Plus le score est bas, plus le traumatisme est grave

population de CRASH-3 est-elle représentatives des patients qui entrent en soin dans les hôpitaux de la Traumabase ? Pour répondre à cette question, nous disposons d'une vaste cohorte: la Traumabase.

La base de données Traumabase regroupe 23 centres de traumatologie français qui recueillent des données cliniques détaillées sur les patients souffrant de traumatismes majeurs, depuis le lieu de l'accident jusqu'à la sortie de l'hôpital, sous la forme d'un registre. Les données, qui comptent actuellement plus de 30 000 dossiers de patients, sont d'une granularité et d'une taille uniques en Europe. Cependant, elles sont très hétérogènes, avec des caractéristiques catégorielles (sexe, type de maladie, ...) et quantitatives (tension artérielle, taux d'hémoglobine, ...), des sources multiples et de nombreuses données manquantes (98 Dans cet ensemble de données, 8270 patients souffrent de TBI. Comme indiqué, la base de données Traumabase contient de nombreuses valeurs manquantes. Heureusement, certaines covariables sont presque toujours observées, comme le score de Glasgow. Cela permet de comparer l'échantillon CRASH-3 avec les patients souffrant de TBI dans la base de données Traumabase. Il est par exemple possible de comparer les patients selon le score de Glasgow lors de l'entrée en centre de réanimation (Figure 1.8), indiquant que les deux populations sont différentes. Alors que l'essai CRASH-3 couvre de manière plus ou moins homogène l'ensemble des scores de Glasgow, la base de données Traumabase contient relativement plus de patients avec des scores de Glasgow élevés ou faibles.

Or, si l'on considère que la réponse au traitement varie en fonction de la gravité du traumatisme crânien (évaluée par le score de Glasgow), l'effet *moyen* rapporté dans le rapport CRASH-3 dépend nécessairement de la population dans laquelle il est estimé. Supposons que la véritable probabilité de mourir d'un traumatisme crânien soit celle décrite dans la Figure 1.9 (dessin hypothétique). Ce dessin est censé illustrer une situation dans laquelle les patients faiblement blessés (GCS élevé) ont une faible probabilité de mourir d'un traumatisme crânien, tandis que les patients gravement blessés (GCS faible) ont une forte probabilité de mourir. Dans les deux cas, le traitement ne peut pas réduire radicalement le risque de base, en raison de l'état extrême (bon ou mauvais) du patient. Dans de telles situations, l'effet moyen estimé dans l'essai clinique randomisé CRASH-3 serait plus élevé que l'effet réel observé dans la population de la base de données Traumabase, ce qui conduirait à des conclusions erronées si l'on transposait directement les conclusions de l'essai CRASH-3 à une population similaire à celle de la base de données Traumabase.




**Figure 1.8:** Comparaison univariée de la distribution du score de Glasgow entre l'échantillon CRASH-3 (9 202 individus) et le sous-échantillon de la Traumabase souffrant de TBI (8 270 individus, extraction des données effectuée en 2019).

**Comment pouvons-nous généraliser les résultats d'un essai ?** En recherche clinique, la question de la représentativité de l'essai est souvent posée sous l'angle de ce qui la compromet. Par exemple, certains travaux cliniques comparent les covariables des personnes recrutées dans l'essai avec celles de la population cible (par exemple, en comparant ce que l'on appelle les tableaux 1, comme dans la Figure 1.8), ou dérivent les taux d'inéligibilité - c'est-à-dire le pourcentage de patients inéligibles au



**Figure 1.9:** Schéma d'une réponse hypothétique à l'acide tranexamique (TXA) en cas de lésion cérébrale traumatique (TBI) en fonction du score de Glasgow (GCS). Ce dessin hypothétique a été imaginé en discutant avec des cliniciens et ne vise qu'à illustrer le problème.



sein de la population souffrant de la maladie (Kennedy-Martin et al., 2015). Par exemple, Van Eijk et al. (2019) examine que pour certains ECR portant sur des traitements visant à guérir la sclérose latérale amyotrophique, seuls 14% de la population réellement touchée par la maladie aurait pu être recrutée.

Pourtant, d'autres méthodes ont récemment été proposées pour directement quantifier l'impact du changement population sur l'effet du traitement. Ces méthodes - appelées *généralisation* - ont été introduites par Stuart et al. (2011); Pearl and Bareinboim (2011a) aux alentours des années 2010, et ont la particularité de s'appuyer sur plusieurs sources de données. L'existence d'un essai (par exemple CRASH-3) et d'un échantillon de la population cible (par exemple Traumabase) est une situation typique dans laquelle ces méthodes peuvent s'appliquer.

On retrouve cette méthode sous d'autres appellations, comme transportabilité (Pearl and Bareinboim, 2011a; Rudolph and van der Laan, 2017; Westreich et al., 2017b), portabilité (Xiao et al., 2022), ou récupérabilité (Bareinboim and Pearl, 2012a; Bareinboim et al., 2014). Ce sujet est également lié à ce que l'on appelle le problème du *covariate shift* dans le machine-learning. Si il existe des liens entre la causalité et les changements de distribution en machine-learning (Meinshausen, 2018), ces derniers ne sont pas abordés dans cette thèse. Il convient de noter que cette question est également en lien avec ce que l'on appelle le *biais de sélection* en statistique.

Dans cette thèse de doctorat, l'objectif est de développer et d'améliorer les approches statistiques pour généraliser les résultats des essais à une autre population d'intérêt. Du fait de leur relative nouveauté, ces méthodes ne sont pas complètement caractérisées théoriquement, et de nombreuses questions pratiques sont encore en suspens. Ce travail de recherche propose de nouvelles clefs de compréhension de ce problème, sur un plan théorique et méthodologique.

## Chapter 2

# Combining experimental and observational data: a review

This chapter corresponds to the article entitled *Causal inference methods for combining randomized trials and observational studies: a review* accepted for publication in *Statistical Science*,

co-authored with Imke MAYER<sup>a</sup>, Guanhua CHEN, Awa DIENG, Ruohong LI, Gaël VAROQUAUX, Jean-Philippe VERT, Julie JOSSE, Shu YANG.

---

<sup>a</sup>equal contribution as first authors.

### ***Chapter's content***

---

In this chapter, we review the growing literature on methods for causal inference combining experimental and observational data. We first discuss identification and estimation methods that improve generalizability of trial using the representativeness of observational data. Classical estimators include weighting, difference between conditional outcome models, and doubly robust estimators. We then discuss methods using trial to ensure uncounfoundedness of the observational analysis or to improve (conditional) average treatment effect estimation. We also connect and contrast works developed in both the potential outcomes literature and the structural causal model literature. We compare the main methods using a simulation study and real world data to analyze the effect of tranexamic acid on the mortality rate in major trauma patients. A review of available codes and new implementations is also provided.

---

## Contents

1	Introduction . . . . .	30
2	Problem setting . . . . .	31
3	When observational data have no treatment and outcome information .	35
4	When observational data contain treatment and outcome information .	42
5	Structural causal models (SCM) and transportability . . . . .	45
6	Software for combining RCT and observational data . . . . .	48
7	Application: Effect of Tranexamic Acid . . . . .	51
8	Conclusion . . . . .	55
2.A	Randomized controlled trial . . . . .	58
2.B	Estimation of ATE in observational data . . . . .	58
2.C	Identification formula . . . . .	59
2.D	Sources of formal statements of estimators described in Section 3.2 . . .	60
2.E	Nested study design . . . . .	61
2.F	Additional information on the SCM framework . . . . .	65
2.G	Additional simulation results . . . . .	69
2.H	Supplementary information on Traumabase and CRASH-3 . . . . .	73

## 1 Introduction

*Experimental data*, collected through carefully designed and randomized protocols, are usually considered the gold standard approach for assessing the causal effect of an intervention or a treatment on an outcome of interest. In particular, the intensive use of randomized controlled trials (RCTs) grounds the so-called “evidence-based medicine”, a keystone of modern medicine. In an RCT, the treatment allocation is under control, ensuring a *balanced* distribution of treated and control individuals; as a consequence, simple estimators can be used to measure the treatment effect, e.g., with the difference in mean effect between the treated and control individuals (Imbens and Rubin, 2015). Still, RCTs come with practical drawbacks such as cost and time, but also with methodological issues such as restrictive inclusion/exclusion criteria which can lead to a trial sample that differs markedly from the population potentially eligible for the treatment. Therefore, the findings from RCTs can lack generalizability to a target population of interest. This concern is related to the aim of *external validity*, central in medical research (Concato et al., 2000; Rothwell, 2007; Green and Glasgow, 2006; Frieden, 2017) policy research (Martel Garcia and Wantchekon, 2010; Deaton and Cartwright, 2018; Deaton et al., 2019; Jeong and Namkoong, 2022), and other fields such as advertising (Gordon et al., 2019). In contrast, *observational data* – collected without systematically designed interventions, such as disease registries, cohorts, biobanks, epidemiological studies, or electronic health records – are promising as they are readily available, include large and representative samples, and are less cost-intensive than RCTs. However, there are often concerns about the quality of these “big data”, given that the lack of a controlled experimental intervention opens the door to *confounding bias*. This concern is referred to as a lack of *internal validity*. Under assumptions such as unconfoundedness it is possible to estimate a causal treatment effect from observational data. In practice, methods such as matching, inverse propensity weighting (IPW), or augmented IPW (AIPW) are used (Imbens and Rubin, 2015). Even when a confounder is unobserved, solutions exist at the price of additional assumptions, for example the *front-door criterion* (Pearl, 1993), instrumental variables (Angrist et al., 1996; Hernán and Robins, 2006; Imbens, 2014), and sensitivity analysis (Cornfield et al., 1959; Rosenbaum and Rubin, 1983a; Imbens, 2003).

Combining information gathered from experimental and observational data opens the door to new tools for,

1. accounting for the lack of representativeness of RCT, as observational data can constitute an external representative sample of a target population of interest;
2. making observational evidence more credible using RCT ground observational analysis, such as detecting a confounding bias;
3. improving statistical efficiency, for example to better estimate heterogeneous treatment effects as RCTs are often under-powered in such settings.

As of today, there is abundant literature about the different ways and purposes of combining both sources of information. Terms used to refer to similar problems are *generalizability* (Cole and Stuart, 2010; Stuart et al., 2011; Hernán and VanderWeele, 2011; Tipton, 2013; O’Muircheartaigh and Hedges, 2014; Stuart et al., 2015; Keiding and Louis, 2016; Dahabreh et al., 2019; Buchanan et al., 2018; Cinelli and Pearl, 2020; Dahabreh et al., 2020), *representativeness* (Campbell, 1957), *external validity* (Rothwell, 2007; Stuart et al., 2018; Westreich et al., 2018), *transportability* (Pearl and Bareinboim, 2011a; Rudolph and van der Laan, 2017; Westreich et al., 2017b), *recoverability* (Bareinboim and Pearl, 2012a; Bareinboim et al., 2014) and finally *data fusion* (Bareinboim and Pearl, 2016); this review will explain the commonalities or differences between the terminologies. They have connections to inference from non-probability samples in survey sampling (Yang et al., 2020a; Yang and Kim, 2020) and to the covariate shift problem in machine learning (Sugiyama and Kawanabe, 2012). This problem of data integration for causal inference is tackled by two main bodies of literature, namely the potential outcomes (PO) framework (Neyman, 1923; Rubin, 1974), and the work on structural causal models (SCM) using directed acyclic graphs (DAGs), pioneered by Pearl (1995) and his collaborators.

The present paper reviews this literature on combining experimental and observational data. Section 2 introduces the notations from the PO literature, as well as the common designs. Section 3 details how an observational sample can be used to generalize RCT findings to another population point (a). We detail the corresponding identifiability assumptions and present the main estimation methods that have been suggested to account for distributional shifts. In this section, only baseline covariates are required in the observational data. In Section 4, we consider the case where observational data also contain treatment and outcome data. This setting in particular provides the opportunity to tackle different scientific questions such as hidden confounding or statistical efficiency (oints (b) and (c)). In Section 5, we present the SCM literature, using different notations and ways to formulate assumptions, thus capturing richer and more diverse identifiability scenarios. In Section 6, we first present existing implementations and software and then we illustrate the properties of the generalization estimators on simulated data with new implementations. In Section 7, we apply the various methods presented in Section 3 on a medical application involving major trauma patients. The aim of this study is to assess the effect of the drug tranexamic acid on mortality in head trauma patients. Both an RCT (the CRASH-3 trial) and an observational database (the Traumabase registry) are available. In this section, we also review methods for addressing data quality issues such as missing values.

## 2 Problem setting

### 2.1 Notations in the PO framework

Each individual in the RCT or observational population is described by  $(X, Y(0), Y(1), A, S)$ , a random tuple with distribution  $P$ , where  $X$  is a  $p$ -dimensional vector of covariates,  $A$  the binary treatment assignment (with  $A = 0$  for the control and  $A = 1$  for the treated individuals),  $Y(a)$  is the binary or continuous outcome had the subject been given treatment  $a$  (for  $a \in \{0, 1\}$ ), and  $S$  a binary variable indicating trial eligibility and willingness to participate<sup>1</sup>. We model the individuals belonging to an RCT sample of size  $n$  and to an observational data sample of size  $m$  by  $n + m$  independent random tuples:  $\{X_i, Y_i(0), Y_i(1), A_i, S_i\}_{i=1}^{n+m}$ , where the RCT samples  $i = 1, \dots, n$  are identically distributed

<sup>1</sup>Note that in the literature,  $S$  can have a slightly different meaning, for example other works use two separate indicators, one for participation and one for eligibility (Nguyen et al., 2018; Dahabreh et al., 2019).

according to  $P(X, Y(0), Y(1), A, S \mid S = 1)$ , and the observational data samples  $i = n + 1, \dots, n + m$  are identically distributed according to  $P(X, Y(0), Y(1), A, S)$ . The sampling mechanisms of the RCT and observational samples are assumed to be independent, which corresponds to a so-called non-nested design as explained in Section 2.2.1. We also denote  $\mathcal{R} = \{1, \dots, n\}$  the set of indices of units observed in the RCT study, and  $\mathcal{O} = \{n + 1, \dots, n + m\}$  the set of indices of units observed in the observational study. For each RCT sample  $i \in \mathcal{R}$ , we observe  $(X_i, A_i, Y_i, S_i = 1)$ , while for observational data  $i \in \mathcal{O}$ , we consider two settings: (i) we only observe the covariates  $X_i$  (Section 3), (ii) we also observe the treatment and outcome  $(X_i, A_i, Y_i)$  (Section 4).

In this review we consider the absolute difference, and do not consider other contrast measures<sup>2</sup>. Doing so, we denote respectively by  $\tau(x)$  and  $\tau_1(x)$  the conditional average treatment effect (CATE) in the observational population and the RCT population:

$$\forall x \in \mathcal{P}, \quad \tau(x) = \mathbb{E}[Y(1) - Y(0) \mid X = x], \quad \tau_1(x) = \mathbb{E}[Y(1) - Y(0) \mid X = x, S = 1].$$

We also denote  $\tau$  and  $\tau_1$  the population average treatment effect (ATE) in the observational population and the RCT one:

$$\tau = \mathbb{E}[Y(1) - Y(0)] = \mathbb{E}[\tau(X)], \quad \tau_1 = \mathbb{E}[Y(1) - Y(0) \mid S = 1],$$

where the population ATE can be different from the RCT ATE, i.e.,  $\tau \neq \tau_1$  in general.

We denote respectively by  $e(x)$  and  $e_1(x)$  the propensity score in the observational population and in the RCT population:

$$e(x) = P(A = 1 \mid X = x), \quad e_1(x) = P(A = 1 \mid X = x, S = 1),$$

where  $e_1(x)$  is usually known in an RCT. We also denote by  $\mu_a(x)$  and  $\mu_{a,1}(x)$  the conditional mean outcome under treatment  $a \in \{0, 1\}$  in the observational population and in the RCT population, respectively:

$$\mu_a(x) = \mathbb{E}[Y(a) \mid X = x], \quad \mu_{a,1}(x) = \mathbb{E}[Y(a) \mid X = x, S = 1].$$

Finally, we denote by  $\alpha(x)$  the conditional odds that an individual with covariates  $x$  is in the RCT or in the observational sample:

$$\alpha(x) = \frac{\mathbb{P}(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{\mathbb{P}(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} = \frac{\pi_{\mathcal{R}}(x)}{\pi_{\mathcal{O}}(x)} = \frac{\pi_{\mathcal{R}}(x)}{1 - \pi_{\mathcal{R}}(x)},$$

where  $\pi_{\mathcal{R}}(x)$  (resp.  $\pi_{\mathcal{O}}(x)$ ) is the probability that an individual with covariates  $x$  known to be in the concatenated data (RCT sample and observational sample) is in the RCT (resp. in the observational sample). In the literature another widely used quantity is the selection score – or sampling propensity score (in particular this name was proposed by [Tipton \(2013\)](#)) – denoted  $\pi_S(x)$  and defined as

$$\pi_S(x) = \mathbb{P}(S = 1 \mid X = x).$$

Because  $\pi_S(x)$  is the probability of being *sampled* in the trial given covariates values  $x$ , it is different from  $\pi_{\mathcal{R}}(x)$ .  $\pi_S(x)$  is often used with a nested design (see Section 2.2.1 for a definition), but is not of interest in our setup (non-nested design) because it cannot be identified. Indeed,

$$\pi_S(x) = \mathbb{P}(S = 1) \times \frac{\mathbb{P}(X = x \mid S = 1)}{\mathbb{P}(X = x)} = \mathbb{P}(S = 1) \times \frac{\mathbb{P}(X_i = x \mid i \in \mathcal{R})}{\mathbb{P}(X_i = x \mid i \in \mathcal{O})} = \underbrace{\mathbb{P}(S = 1)}_{\text{Not known}} \times \underbrace{\frac{n}{m} \frac{\pi_{\mathcal{R}}(x)}{\pi_{\mathcal{O}}(x)}}_{= \alpha(x)}.$$

derivations can be found in the appendix (see Section 2.C). The quantity  $\mathbb{P}(S = 1)$  is unknown because, individuals in the target population could have participated in the RCT or not:  $S$  can be equal to 1 and 0 in the observational sample but this information is not known. Table 2.1 illustrates the considered type of data, and Table 2.2 summarizes the notations.

<sup>2</sup>Considering other measures such as the ratio or odds ratio can have an impact on the assumptions considered, for example in generalization ([Huitfeldt et al., 2019](#)). As the large majority of the literature is focused on the absolute difference, this review reflects the practices, and therefore considers the absolute difference.

**Table 2.1: Illustration of data structure** of RCT data (Set  $\mathcal{R}$ ) and observational data (Set  $\mathcal{O}$ ) with covariates  $X$ , trial eligibility  $S$ , binary treatment  $A$  and outcome  $Y$ . Left: with observed outcomes, Right: with potential outcomes. Note that the  $S$  covariate can be either 0 or 1 in the observational data set (it is unknown in the non-nested design, hence the NA for not available), and is always equal to 1 for observations in the RCT. In the nested design (cf. Appendix 2.E),  $S = 0$  for all individuals in the observational data set.

	$S$	Set	Covariates			Treatment	Outcome	$S$	Set	Covariates			Treatment	Outcome(s)	
			$X_1$	$X_2$	$X_3$	$A$	$Y$			$X_1$	$X_2$	$X_3$	$A$	$Y(0)$	$Y(1)$
1	1	$\mathcal{R}$	1.1	20	F	1	1	1	$\mathcal{R}$	1.1	20	F	1	NA	1
	1	$\mathcal{R}$	-6	45	F	0	1	1	$\mathcal{R}$	-6	45	F	0	1	NA
$n$	1	$\mathcal{R}$	0	15	M	1	0	1	$\mathcal{R}$	0	15	M	1	NA	1
$n+1$	NA	$\mathcal{O}$	...			...	...	NA	$\mathcal{O}$	...			...	...	...
	NA	$\mathcal{O}$	-2	52	M	0	1	NA	$\mathcal{O}$	-2	52	M	0	1	NA
	NA	$\mathcal{O}$	-1	35	M	1	1	NA	$\mathcal{O}$	-1	35	M	1	NA	1
$n+m$	NA	$\mathcal{O}$	-2	22	M	0	0	NA	$\mathcal{O}$	-2	22	M	0	0	NA


**Table 2.2: List of notations.**

Symbol	Description
$X$	Covariates (also known as baseline covariates when measured at inclusion of the patient)
$A$	Treatment indicator ( $A = 1$ for treatment, $A = 0$ for control)
$Y$	Outcome of interest
$S$	Trial eligibility ( $S = 1$ for eligibility, $S = 0$ for non-eligibility)
$n$	Size of the RCT study
$m$	Size of the observational study
$\mathcal{R}$	Index set of units observed in the RCT study; $\mathcal{R} = \{1, \dots, n\}$
$\mathcal{O}$	Index set of units observed in the observational study; $\mathcal{O} = \{n+1, \dots, n+m\}$
$\pi_{\mathcal{R}}(x)$	Probability that a unit in $\mathcal{R} \cup \mathcal{O}$ with covariate $x$ is in $\mathcal{R}$
$\pi_{\mathcal{O}}(x)$	Probability that a unit in $\mathcal{R} \cup \mathcal{O}$ with covariate $x$ is in $\mathcal{O}$
$\alpha(x)$	Conditional odds $\alpha(x) = \pi_{\mathcal{R}}(x)/\pi_{\mathcal{O}}(x)$
$\tau$	Population average treatment effect (ATE) defined as $\tau = \mathbb{E}[Y(1) - Y(0)]$
$\tau_1$	Trial (or sample) average treatment effect defined as $\tau_1 = \mathbb{E}[Y(1) - Y(0)   S = 1]$
$\tau(x)$	Conditional average treatment effect (CATE) defined as $\tau(x) = \mathbb{E}[Y(1) - Y(0)   X = x]$
$\tau_1(x)$	Trial conditional average treatment effect defined as $\tau_1(x) = \mathbb{E}[Y(1) - Y(0)   X = x, S = 1]$
$e(x)$	Propensity score defined as $e(x) = \mathbb{P}(A = 1   X = x)$
$e_1(x)$	Propensity score in the trial defined as $e_1(x) = \mathbb{P}(A = 1   X = x, S = 1)$ , known by design
$\mu_a(x)$	Outcome mean defined as $\mu_a(x) = \mathbb{E}[Y(a)   X = x]$ for $a = 0, 1$
$\mu_{a,1}(x)$	Outcome mean in the trial defined as $\mu_{a,1}(x) = \mathbb{E}[Y(a)   X = x, S = 1]$ for $a = 0, 1$
$\pi_S(x)$	Selection score defined as $\pi_S(x) = \mathbb{P}(S = 1   X = x)$
$f(X)$	Covariate distribution in the target population
$f(X S = 1)$	Covariate distribution conditional to trial-eligible individuals ( $S = 1$ )

## 2.2 Study designs and goals

### 2.2.1 Nested and non-nested study designs

Following [Dahabreh et al. \(2021\)](#) and [Dahabreh et al. \(2020\)](#), the study design to obtain the trial and observational samples can be categorized into two types: *nested* study designs and *non-nested* study designs as illustrated on Figure 2.1. Designs imply different identifiability conditions and therefore estimators. This review focuses on what is called the non-nested design, as the trial sample and the observational sample are obtained separately. On the contrary the nested design involves a two-stage nested sampling. For example it can correspond to an embedded trial in a broader health system. As a concrete example one can mention the Women Health Initiative, or the recent study on Medicaid where part of the participants are randomized ([Degtiar et al., 2021](#)). In this situation, data are not really combined as the overall data comes from one initial sampling in which two treatment assignment regimes (randomized or not) coexist. The nested design estimators are detailed in Appendix 2.E.



**Figure 2.1: Schematics of the nested (left) and non-nested (right) designs**, a similar schematic can be found in [Josey et al. \(2021\)](#).

## 2.2.2 Transportability, generalizability, and recoverability

Several terms are currently present in the literature to describe the process of predicting the effect of the treatment from an RCT to another population: generalization ([Stuart et al., 2011](#); [Buchanan et al., 2018](#); [Dahabreh et al., 2019](#)), transportability ([Hernán and VanderWeele, 2011](#); [Bareinboim and Pearl, 2016](#); [Westreich et al., 2017b](#)), or recoverability ([Bareinboim et al., 2014](#)). Differences in the definitions can be found in the literature, underlying a specific design such as the existence of a common superpopulation or assumptions such as the support overlap between different populations. For example, [Dahabreh et al. \(2020\)](#) highlights that several definitions are given,

*We use the term generalizability when the target population coincides or is a subset of the trial-eligible population and transportability when the target population includes at least some individuals who are not trial-eligible (and who, by definition, cannot be trial participants) (others have proposed different definitions).*

Due to different definitions in the literature, several terms can be found to describe the same scientific goal. In this review, we call *generalization* the task that extends the RCT result to *its* larger population, where it was sampled with a bias (detailed in Section 3). The SCM literature also uses different terminologies corresponding to different assumptions –and corresponding diagrams– as detailed in Section 5. For example what is called transportability refers to two distinct populations, and not necessarily about different covariate supports as suggested by [Dahabreh et al. \(2020\)](#). In particular, in this literature the task that we study in Section 3 is termed recoverability from a sampling bias, rather than generalization. This terminology has the merit of indicating that generalization can have a much broader coverage, including other types of problems. Note that granting some assumptions about a common support or non-zero probability to be sampled, then the two problems – namely recovering from a sampling bias and transportability – rely on the same estimators and procedure, as highlighted in Section 3.1.3 and in [Pearl \(2015\)](#).



### 3 When observational data have no treatment and outcome information

We start by considering the case where only the covariates from the observational study are available or used. We consider the observational data as a random sample from the target population. Considering this set-up, the question tackled in this section is how to generalize or transport the trial findings toward a target population of interest. Applied examples can be found in [Dong et al. \(2020\)](#); [Lesko et al. \(2016\)](#); [Tipton et al. \(2016\)](#); [Li et al. \(2021\)](#); [Yang and Wang \(2022\)](#). In particular [He et al. \(2020\)](#) review current practice, revealing that generalization’s implementation is still at the stage of prototyping without real usage for clinical and public health decisions yet.

#### 3.1 Assumptions needed to identify the ATE on the target population

A fundamental problem in causal inference is that we can observe at most one of the potential outcomes for an individual subject. In order to identify nonetheless the ATE from RCT and observational covariate data, we require some of the following assumptions.

##### 3.1.1 Internal validity of the RCT

**Assumption 4** (Consistency).  $Y = AY(1) + (1 - A)Y(0)$ .

Assumption 4 implies that the observed outcome is the potential outcome under the actual assigned treatment.

**Assumption 5** (Randomization).  $\{Y(0), Y(1)\} \perp\!\!\!\perp A \mid S = 1, X$

Assumption 5 corresponds to internal validity. It holds by design in a completely randomized experiment, where the treatment is independent of all the potential outcomes and covariates. The more general case of conditional randomization is assumed throughout this review.

If Assumptions 4 and 5 hold, then the RCT is said to be compliant. In addition, in an RCT, it is common that the probability of treatment assignment,  $e_1(x)$ , is known. In a complete randomized trial, the propensity score is fixed as a constant, and usually  $e_1(x) = 0.5$  for all  $x$ .

##### 3.1.2 Assumptions ensuring generalizability of the RCT to the target population

The literature proposes different assumptions to generalize trial’s findings to a target population.

**Assumption 6** (Ignorability assumption on trial participation).  $\{Y(0), Y(1)\} \perp\!\!\!\perp S \mid X$ . ([Hotz et al., 2005](#); [Stuart et al., 2011](#); [Tipton, 2013](#); [Hartman et al., 2015](#); [Buchanan et al., 2018](#); [Degtiar and Rose, 2023](#); [Egami and Hartman, 2021](#))

A parallel can be made with the *strong ignorability condition* in causal inference with observational data (see Assumption 14 in Appendix), but applied to the sample selection rather than treatment assignment. In other words, these assumptions require to control for all covariates being shifted and predictive of  $Y$ . We call shifted covariates, all the baseline covariates along which the two populations – trial and target – do not follow the same distribution. A weaker version of Assumption 6 can be found in [Dahabreh et al. \(2019, 2020\)](#):

**Assumption 7** (Mean exchangeability).  $\mathbb{E}[Y(a) \mid X = x, S = 1] = \mathbb{E}[Y(a) \mid X = x]$  (*mean exchangeability over trial participation*), for all  $x$  and  $a = 0, 1$ .

Another assumption can be found, relying on the transportability of treatment effect rather than the potential outcomes.

**Assumption 8** (Sample ignorability for treatment effects - [Kern et al. \(2016\)](#); [Nguyen et al. \(2018\)](#)).  $Y(1) - Y(0) \perp\!\!\!\perp S \mid X$ .



A weaker version can be found:

**Assumption 9** (Transportability of the CATE).  $\tau_1(x) = \tau(x)$  for all  $x$ .

To meet these last two assumptions, one requires variables that are both *treatment effects modifiers* and *shifted*. Epidemiologists often use the term “effect modification” to indicate that the treatment effect varies across strata of baseline covariates, such baseline covariates being treatment effect modifiers. These assumptions are implied by Assumption 6, but this is not reciprocal as all covariates predictive of the outcome are not necessarily treatment effect modifiers. Note that a treatment effect modifier depends on the chosen scale, here we focus on the absolute difference, but if we had considered a risk ratio the variables being treatment effects modifiers would not be the same. Mathematical definitions of a treatment effect modifier are hard to find, but we quote one from [VanderWeele and Robins \(2007\)](#) for the absolute scale.

**Definition 6** (Treatment effect modifier). *We say that a variable  $X$  is a treatment effect modifier for the causal risk difference of  $A$  on  $Y$  if  $X$  is not affected by  $A$  and if there exist two levels of  $A$ ,  $a_0$  and  $a_1$ , such that  $\mathbb{E}[Y^{(a_1)} | X = x] - \mathbb{E}[Y^{(a_0)} | X = x]$  is not constant in  $x$ .*

In this work, we only rely on Assumption 8 for identification formula. Finally a last assumption is needed, the *positivity of trial participation* assumption.

**Assumption 10** (Positivity of trial participation, also called overlap). *There exists a constant  $c > 0$  such that, almost surely,  $\mathbb{P}(S = 1 | X) \geq c$ .*

Assumption 10 requires adequate overlap of the covariate distribution between the trial sample and the target population (in other words, all members of the target population have non-zero probability of being selected into the trial). Other formulation of this assumption can be found under the assumption of the target population’s support included in the trial sample support ([Nie et al., 2021](#); [Colnet et al., 2022b](#))

### 3.1.3 Identifications formulae

Under Assumptions 4, 5, 9, and 10 the ATE can be identified based on the following formulas (derivations in Appendix 2.C):

1. Reweighting formulation:

$$\tau = \mathbb{E} \left[ \frac{n}{m\alpha(X)} \tau_1(X) | S = 1 \right] = \mathbb{E} \left[ \frac{n}{m\alpha(X)} \left( \frac{A}{e_1(X)} - \frac{1-A}{1-e_1(X)} \right) Y | S = 1 \right]. \quad (2.1)$$

Note that Equation 2.1 can be understood as a transportability problem considering two distributions  $P_1$  and  $P$ , and transporting evidence from population  $P_1$  to population  $P$ ,


$$\tau = \mathbb{E}_P [\tau(X)] = \underbrace{\int_{\mathcal{X}} \tau(x) f(x) dx}_{\text{Integral on } P} = \underbrace{\int_{\mathcal{X}} \tau_1(x) \frac{f(x)}{f_1(x)} f_1(x) dx}_{\text{Integral on } P_1} = \int_{\mathcal{X}} \tau_1(x) \frac{n}{m} \frac{1}{\alpha(x)} f_1(x) dx,$$

noting that  $\alpha(x) = \frac{\mathbb{P}(i \in \mathcal{R} | \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{\mathbb{P}(i \in \mathcal{O} | \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} = \frac{\mathbb{P}(i \in \mathcal{R})}{\mathbb{P}(i \in \mathcal{O})} \times \frac{\mathbb{P}(X_i = x | i \in \mathcal{R})}{\mathbb{P}(X_i = x | i \in \mathcal{O})} = \frac{n}{m} \times \frac{f_1(x)}{f(x)}$ , and using the transportability assumption (see Assumption 9) stating that  $\tau(x) = \tau_1(x)$ .

2. Regression formulation:

$$\tau = \mathbb{E} [\mu_{1,1}(X) - \mu_{0,1}(X)] = \mathbb{E} [\tau_1(X)]. \quad (2.2)$$

Different identification formulas motivate different estimation strategies as discussed next. These strategies are illustrated in Figure 2.2.



**Figure 2.2: Illustrative schematics for the estimation strategies:** On this drawing the trial findings  $\hat{\tau}_{1,n}$  would over-estimate the target treatment effect  $\tau$  (on an absolute scale). On the left, the IPSW (Definition 7) strategy, relying on weighting the RCT observations; on the right, the plug-in g-formula (Definition 9) strategy, relying on modeling the response using the RCT observations. Notations are the same as introduced in Table 2.2, i.e.,  $f_X$  ( $f_{X|S=1}$ ) denotes the density of the target (resp. trial) population, and  $\hat{\mu}_{a,n}(\cdot)$  denotes the fitted response surface using the  $n$  trial observations.

### 3.2 Estimation methods to generalize trial findings to a target population of interest

All along this review, estimators are indexed with the number of observations used for estimation. For example,  $\hat{\tau}_n$  indicates that the finite sample estimator only relies on the RCT individuals, or  $\hat{\tau}_{n,m}$  if it depends on both data sets.

#### 3.2.1 IPSW and stratification: modeling the probability of trial participation

To overcome the bias due to covariate shift between populations, most existing methods rely on direct modeling of the selection score previously introduced. The selection score adjustment methods include IPSW (Cole and Stuart, 2010; Stuart et al., 2011; Lesko et al., 2017; Buchanan et al., 2018; Colnet et al., 2022b) and stratification (Stuart et al., 2011; Tipton, 2013; O’Muircheartaigh and Hedges, 2014).

**Inverse probability of sampling weighting (IPSW).** The IPSW approach can be seen as the counterpart of IPW methods for estimating the ATE from observational studies by controlling for confounding (see Appendix 2.B for details on IPW). Based on the identification formula eq. 2.1, the IPSW estimator of the ATE is defined as the weighted difference of average outcomes between the treated and control group in the trial. The observations are weighted by the inverse odds  $1/\alpha(x) = \pi_{\mathcal{O}}(x)/\pi_{\mathcal{R}}(x)$  to account for the shift of the covariate distribution from the RCT sample to the target population. The larger  $\alpha(X_i)$ , the smaller the weight of the observation  $i$  (as illustrated on Figure 2.2). The shape of the IPSW estimator is slightly different from the shape of the IPW estimator. In the latter, each observation is weighted by the inverse of the probability to be treated whereas in the former it is weighted by the inverse of the odds of the probability to be in the trial sample. This is due to the non-nested sampling design (see the IPSW estimator for the nested design eq. 2.14), as highlighted by Kern et al. (2016) and Nguyen et al. (2018).

**Definition 7** (Inverse probability of sampling weighting - IPSW). *The IPSW estimator is defined as follows:*

$$\hat{\tau}_{IPSW,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{n}{m} \frac{Y_i}{\hat{\alpha}_{n,m}(X_i)} \left( \frac{A_i}{e_1(X_i)} - \frac{1 - A_i}{1 - e_1(X_i)} \right),$$

where  $\hat{\alpha}_{n,m}$  is an estimate of the odds of the indicatrix of being in the RCT.

The IPSW estimator is consistent when the quantity  $\alpha$  is consistently estimated by  $\hat{\alpha}_{n,m}$  (Buchanan et al., 2018; Colnet et al., 2022a). In practice, various methods are used to estimate  $\alpha$ : for e.g. by logistic regression (Stuart, 2010), while recent works rely on non-parametric methods such as random

forest and Gradient boosting (Kern et al., 2016) or Hájek-style estimator to target the density ratio (Huang et al., 2021; Nie et al., 2021). Similar to IPW estimators, IPSW estimators are known to be highly unstable, especially when the weights are extreme. This can occur if the observational study contains units with very small probabilities of being in the trial. Normalized weights can be used to overcome this issue (Dahabreh et al., 2020). Still, the major challenge remains that IPSW estimators require a correct model specification of the weights. Avoiding this problem requires either very strong domain expertise or turning to doubly robust methods (Section 3.2.4). Current theoretical guarantees and theorems are detailed in Appendix (see Section 2.D). For example Buchanan et al. (2018) propose a derivation of the asymptotic variance under parametric assumptions in the nested case, while Zivich et al. (2022) extends this to a non-nested design. Dahabreh et al. (2019) propose the use of sandwich-type variance estimators (for both nested and non-nested design) or non-parametric bootstrap approaches, and note that the latter may be preferred in practice. Colnet et al. (2022a) has formalized consistency results for any consistent estimator of  $\alpha$ , including non-parametric estimators.

**Assumption 11** (Consistency assumptions for  $\alpha$ ). Denoting by  $\frac{n}{m\hat{\alpha}_{n,m}(x)}$  the estimated weights on the set  $X$ , the following conditions hold,

- $\sup_{x \in \mathcal{X}} \left| \frac{n}{m\hat{\alpha}_{n,m}(x)} - \frac{f_X(x)}{f_{X|S=1}(x)} \right| = \epsilon_{n,m} \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- for all  $n, m$  large enough  $\mathbb{E}[\varepsilon_{n,m}^2]$  exists and  $\mathbb{E}[\varepsilon_{n,m}^2] \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- $Y$  is square integrable.

**Theorem 1** (IPSW consistency - Colnet et al. (2022a)). Under causal assumptions (Assumptions 4, 5, 9, 10), (identifiability), and Assumption 11 (consistency), then,  $\hat{\tau}_{IPSW,n,m}$  converges toward  $\tau$  in  $L^1$  norm,

$$\hat{\tau}_{IPSW,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

More recently Colnet et al. (2022b) has proposed a finite sample characterization of IPSW when  $X$  only contains categorical covariates.

**Stratification.** The stratification approach – or subclassification – is introduced by Cochran (1968) for a single observational data set, and has been further extended by Stuart et al. (2011), Tipton (2013), and O’Muircheartaigh and Hedges (2014) for the generalization’s context. It is proposed as a solution to mitigate the risks of extreme weights in the IPSW formula. First, one has to estimate the conditional odds  $\hat{\alpha}_{n,m}$  in the same manner as for the IPSW detailed above. Then, based on the values of the conditional odds obtained,  $L$  strata are defined (usually 5 as reported in (O’Muircheartaigh and Hedges, 2014), following the empirical seminal work of (Cochran, 1968)). In the trial, for each strata  $l$  one has to compute the average effect on this strata defined as  $\overline{Y(1)}_l - \overline{Y(0)}_l$ , where  $\overline{Y(a)}_l$  denotes the average value of the outcome for units with treatment  $a$  in stratum  $l$  in the RCT. The generalized ATE is defined by the aggregation of the treatment effect estimates on each strata  $l$  weighted by the proportion of the strata in the target population  $\frac{m_l}{m}$ , where  $m_l$  is the number of individuals in strata  $l$  in the target sample.

**Definition 8** (Stratification). The stratification estimator denoted  $\hat{\tau}_{n,m}$  is defined as,

$$\hat{\tau}_{n,m} = \sum_{l=1}^L \frac{m_l}{m} \underbrace{\left( \overline{Y(1)}_l - \overline{Y(0)}_l \right)}_{\text{from RCT}}.$$

Buchanan et al. (2018) has proposed asymptotic normality result for this estimator. Theoretical results for the stratification estimator are detailed in the appendix (Section 2.D).

### 3.2.2 Plug-in g-formula estimators: modeling the conditional outcome in the trial

Other estimators to generalize RCT findings to a target population leverage the regression formulation eq. 2.2, in the inspiration of (Robins, 1986). Known as plug-in  $g$ -formula estimators, they fit a model of the conditional outcome mean among trial participants, rather than modeling the probability of trial participation (as illustrated on Figure 2.2). Then a marginalization is done over the empirical covariate distribution of the target population.

**Definition 9** (Plug-in  $g$ -formula). *The plug-in  $g$ -formula (or outcome model-based) estimator is then defined as:*

$$\hat{\tau}_{G,n,m} = \frac{1}{m} \sum_{i=n+1}^{n+m} (\hat{\mu}_{1,1,n}(X_i) - \hat{\mu}_{0,1,n}(X_i)),$$

where  $\hat{\mu}_{a,1,n}(X_i)$  is an estimator of  $\mu_{a,1}(X_i)$  fitted using the RCT data.

In practice, any model can be used to fit  $\mu_{a,1}(X_i)$ , for e.g. standard ordinary least squares (OLS). Dahabreh et al. (2020) announce<sup>3</sup> consistency of the plug-in  $g$ -formula for parametric estimator of the response model  $\mu_a(X)$ . Note that derivations are made in the context of a nested design but said to extend to a non-nested design. They also recommend the use of sandwich-type variance for confidence intervals estimation when correctly specified parametric models are used. Machine-learning algorithms such as random forests can also be used to estimate  $\mu_{a,1}(X_i)$  (Kern et al., 2016). As shown by Colnet et al. (2022a) if the model is correctly specified (see Assumption 12 below), the estimator is consistent.

**Assumption 12** (Consistency of surface response estimators). *Denote  $\hat{\mu}_{0,n}$  (respectively  $\hat{\mu}_{1,n}$ ) an estimator of  $\mu_0$  (respectively  $\mu_1$ ). Let  $\mathcal{D}_n$  the RCT sample, so that*

*For  $a \in \{0, 1\}$ ,  $\mathbb{E}[|\hat{\mu}_{a,n}(X) - \mu_a(X)| \mid \mathcal{D}_n] \xrightarrow{P} 0$  when  $n \rightarrow \infty$ ,*

*For  $a \in \{0, 1\}$ , there exist  $C_1, N_1$  so that for all  $n \geq N_1$ , a.s.,  $\mathbb{E}[\hat{\mu}_{a,n}^2(X) \mid \mathcal{D}_n] \leq C_1$ .*

**Theorem 2** (Consistency of the plug-in  $g$ -formula - Colnet et al. (2022a)). *Under causal assumptions (Assumptions 4, 5, 9, 10), and Assumption 12 the plug-in  $g$ -formula converges toward  $\tau$  in  $L^1$  norm,*

$$\hat{\tau}_{G,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

### 3.2.3 Calibration weighting: balancing covariates

Beyond propensity scores, other schemes use sample reweighting. Dong et al. (2020) propose a calibration weighting approach, similar to the idea of entropy balancing weights introduced by Hainmueller (2012). They calibrate subjects in the RCT sample in such a way that after calibration, the covariate distribution of the RCT sample empirically matches the target population.

**Definition 10** (Calibration weighting - CW). *Let  $\mathbf{g}(X)$  be a vector of functions of  $X$  to be calibrated, e.g., the moments, interactions, and non-linear transformations of components of  $X$ . Then, assign a weight  $\omega_i$  to each subject  $i$  in the RCT sample by solving the following optimization problem:*

$$\begin{aligned} & \min_{\omega_1, \dots, \omega_n} \sum_{i=1}^n \omega_i \log \omega_i, \\ & \text{subject to } \omega_i \geq 0, \text{ for all } i, \\ & \sum_{i=1}^n \omega_i = 1, \sum_{i=1}^n \omega_i \mathbf{g}(X_i) = \tilde{\mathbf{g}}, \text{ (the balancing constraint)} \end{aligned}$$

<sup>3</sup>see their Appendix, Section A, pages 6-7.

where  $\tilde{\mathbf{g}} = m^{-1} \sum_{i=n+1}^{m+n} \mathbf{g}(X_i)$  is a consistent estimator of  $\mathbb{E}[\mathbf{g}(X)]$  from the observational sample. Based on the calibration weights, the CW estimator is then

$$\hat{\tau}_{CW,n,m} = \sum_{i=1}^n \hat{\omega}_{n,m}(X_i) Y_i \left( \frac{A_i}{e_1(X_i)} - \frac{1 - A_i}{1 - e_1(X_i)} \right),$$

where  $\hat{\omega}_{n,m}(\cdot)$  is the estimated  $\omega(\cdot)$  using the RCT and observational data.

The optimization problem in Definition 10 corresponds to the negative entropy of the calibration weights; thus, minimizing this criterion ensures that the empirical distribution of calibration weights is not too far away from the uniform distribution. This aims at minimizing the variability due to heterogeneous weights. This optimization problem can be solved using convex optimization with Lagrange multipliers. For an intuitive understanding of the calibration weighting framework, consider  $\mathbf{g}(X) = X$ . In such a setting, the balancing constraint is forcing the means of the observational data and of the RCT to be equal after reweighting. More complex constraints can enforce balance on higher-order moments. The calibration algorithm is inherently imposing a log-linear model on the sampling propensity score and solving the corresponding parameters by a set of estimating equations induced by covariate balance. Other objective functions of the weights correspond to different models for the sampling propensity score (Chu et al., 2022). Wu and Yang (2022b) propose a cross-validation procedure to select the calibration weights that target at the smallest mean squared error of the resulting estimator.

The CW estimator  $\hat{\tau}_{CW,n,m}$  is doubly robust in that it is a consistent estimator for  $\tau$  if the selection score of RCT participation follows a log-linear model, i.e.,  $\pi_S(X) = \exp\{\gamma_0^\top \mathbf{g}(X)\}$  for some  $\gamma_0$ , or if the CATE is linear in  $\mathbf{g}(X)$ , i.e.,  $\tau(X) = \gamma_0^\top \mathbf{g}(X)$ , though not necessarily both. The authors suggest a bootstrap approach to estimate its variance.

### 3.2.4 Doubly-robust estimators

The model for the expectation of the outcomes among randomized individuals (used for the plug-in  $g$ -formula estimator in Definition 9) and the model for the probability of trial participation (used in the IPSW estimator in Definition 7) can be combined to form an Augmented IPSW estimator (AIPSW).

**Definition 11** (Augmented IPSW -AIPSW). *The augmented IPSW estimator, denoted  $\hat{\tau}_{AIPSW,n,m}$ , is defined as*

$$\begin{aligned} \hat{\tau}_{AIPSW,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{n}{m \hat{\alpha}_{n,m}(X_i)} & \left( \frac{A_i (Y_i - \hat{\mu}_{1,1,n}(X_i))}{e_1(X_i)} - \frac{(1 - A_i) (Y_i - \hat{\mu}_{0,1,n}(X_i))}{1 - e_1(X_i)} \right) \\ & + \frac{1}{m} \sum_{i=n+1}^{m+n} (\hat{\mu}_{1,1,n}(X_i) - \hat{\mu}_{0,1,n}(X_i)), \end{aligned}$$

where  $\hat{\mu}_{a,1}$ , are estimated on the RCT sample (see Definition 9), and  $\hat{\alpha}_{n,m}$  (see Definition 7) on the concatenated RCT and observational samples.

It can be shown that this estimator is doubly robust, i.e., consistent when either one of the two models for  $\hat{\alpha}_{n,m}(\cdot)$  and  $\hat{\mu}_{a,1}(\cdot)$  ( $a = 0, 1$ ) is correctly specified. Dahabreh et al. (2020) has proposed a proof in the nested-case (see their appendix, Section A) said to follow the same principle in the non-nested design (Section B page 25). In the plain text we recall the results from Colnet et al. (2022a).

**Assumption 13** (Consistency assumptions - AIPSW). *The nuisance parameters are bounded, and more particularly*

- There exists a function  $\alpha_0$  bounded from above and below (from zero), satisfying

$$\lim_{m,n \rightarrow \infty} \sup_{x \in \mathcal{X}} \left| \frac{n}{m \hat{\alpha}_{n,m}(x)} - \frac{1}{\alpha_0(x)} \right| = 0,$$

- There exist two bounded functions  $\xi_1, \xi_0 : \mathcal{X} \rightarrow \mathbb{R}$ , such that  $\forall a \in \{0, 1\}$ ,

$$\lim_{n \rightarrow +\infty} \sup_{x \in \mathcal{X}} |\xi_{a,1}(x) - \hat{\mu}_{a,1,n}(x)| = 0.$$

**Theorem 3** (AIPSW consistency - Colnet et al. (2022a)). *Assuming causal assumptions (Assumptions 4, 5, 9, 10), and Assumption 25 (consistency), and considering that estimated surface responses  $\hat{\mu}_{a,1,n}(\cdot)$  where  $a \in \{0, 1\}$  are obtained following a cross-fitting estimation, then if Assumption 12 or Assumption 11 also holds then,  $\hat{\tau}_{AIPSW,n,m}$  converges toward  $\tau$  in  $L^1$  norm,*

$$\hat{\tau}_{AIPSW,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

This estimator is also shown to be asymptotically normal when both the outcome mean and conditional odds model are consistently estimated at least at rate  $n^{1/4}$  in Dahabreh et al. (2020) and Li et al. (2021). Note that machine-learning tools are tempting to avoid model mis-specification when estimating nuisance parameters. Still, this practice requires specific caution, such as using cross-fitting, due to overfitting and regularization. These issues are well described in the situation of a single observational data set. We refer to Chernozhukov et al. (2018b) for a detailed explanation, and to Zhong et al. (2021); Bach et al. (2021, 2022) for implementations.

More recently, Dong et al. (2020) propose an augmented calibration weighting (ACW) estimator.

**Definition 12** (Augmented CW - ACW). *The ACW estimator, denoted  $\hat{\tau}_{ACW,n,m}$ , is defined as*

$$\begin{aligned} \hat{\tau}_{ACW,n,m} = \sum_{i=1}^n \hat{\omega}_{n,m}(X_i) & \left( \frac{A_i (Y_i - \hat{\mu}_{1,1,n}(X_i))}{e_1(X_i)} - \frac{(1 - A_i) (Y_i - \hat{\mu}_{0,1,n}(X_i))}{1 - e_1(X_i)} \right) \\ & + \frac{1}{m} \sum_{i=n+1}^{m+n} (\hat{\mu}_{1,1,n}(X_i) - \hat{\mu}_{0,1,n}(X_i)), \end{aligned}$$

where the estimation of  $\hat{\omega}_{n,m}(\cdot)$  is detailed in Definition 10, and where  $\hat{\mu}_{a,1,n}$  are estimated on the RCT sample (see Definition 9).

They show that  $\hat{\tau}_{ACW,n,m}$  achieves double robustness and local efficiency, i.e., its asymptotic variance achieves the semiparametric efficiency bound when both the calibration weights and the outcome mean model are correctly specified. Moreover, the convergence rate of the ACW estimator corresponds to the product of the convergence rates of the nuisance estimators, enabling the use of machine-learning estimation of nuisance functions while preserving the  $\sqrt{n}$ -consistency of the ACW estimator, when both the outcome mean and calibration weights model are consistently estimated at rate  $n^{1/4}$  (Dong et al., 2020). Furthermore, Lee et al. (2022) and Lee et al. (2022) extend the framework for handling survival outcomes.

### 3.2.5 Practical issues: non-parametric estimation, overlap and unobserved covariates

**Lack of overlap.** The overlap assumption (see Assumption 10) is restrictive because RCT inclusion and exclusion criteria can be strict as the goal of RCTs (at least in early stages) is to show a clear effect even on a restricted population. Whenever Assumption 10 does not hold, it is still possible to generalize on a different target population, such as the subset of the target population for which eligibility criteria of the trial are ensured. This has also been suggested before, for e.g. by Tipton (2013) (p.245). The question asked would rather be ‘‘What would have been the estimated treatment effect in a situation where the trial has sampled individuals from the target population who meet the trial eligibility criteria?’’. Another approach has been proposed by Chen et al. (2021). Similarly to the idea of trimming propensity scores for dealing with limited overlap between treated and control groups, they propose a generalizability score: a function of participation probability and propensity score, to select subpopulations from the observational data for causal generalization when the overlap is limited.



**Unobserved treatment effect modifiers.** Finally, we point out the important caveat that all methods assume the ignorability conditions (see Assumptions 6, 7, 8, or 9): given the covariates  $X$ , the conditional treatment effect must be the same in the observational data and the RCT. In particular, this assumption could be violated if some shifted treatment effect modifiers are not captured in the concatenated data, which is a plausible scenario given that data are seldom collected jointly and thus typically measure different covariates.

In case of a richer set of covariates in the RCT than in the observational study (which doesn't necessarily mean that a sufficient set of pre-treatment covariates can be chosen, see for e.g. M-bias, see Pearl (2000), page 186), Egami and Hartman (2021) propose a method to select a sufficient set of covariates. But in the case of a low number of common covariates, standard practice is to consider the subset of covariates present in both data sets, but this violates the identifiability condition. Recently, sensitivity analyses have been proposed to mitigate the consequences of missing covariates in the RCT, or in the observational sample or even in both data sets (Nguyen et al., 2017; Andrews and Oster, 2019; Nguyen et al., 2018; Dahabreh et al., 2019; Colnet et al., 2022a; Nie et al., 2021; Huang, 2022).

## 4 When observational data contain treatment and outcome information

Section 3 studied how to correct RCT selection bias (with respect to the target population) while leveraging covariate distribution of an observational sample. When the observational sample also contains treatment and outcome information ( $Y, A$ ), efficiency improvements can be obtained (Huang et al., 2021). But beyond the generalization question, such additional covariates enable different questions of interest. These questions are the purpose of Section 4. Indeed, RCTs can make causal conclusions from the observational sample more trustworthy, either by removing confounding bias (detailed in Section 4.1) or via more efficient estimation (detailed in Section 4.2). For completeness, we recall in Appendix 2.B how to perform causal inference from purely observational data.

### 4.1 Dealing with unmeasured confounders in observational data

**Motivation.** Unmeasured confounding implies that  $\{Y(1), Y(0)\} \not\perp\!\!\!\perp A \mid X$ , where  $X$  are the observed covariates. In such situations, standard causal inference estimators  $\hat{\tau}_m^{\mathcal{O}}(x)$  (resp.  $\hat{\tau}_m^{\mathcal{O}}$ ) of the CATE  $\tau(X)$  (resp. ATE  $\tau$ ), that are designed for purely observational data of size  $m$ , face a so-called hidden confounding bias for these quantities, i.e.,

$$\lim_{m \rightarrow +\infty} \hat{\tau}_m^{\mathcal{O}}(x) \neq \tau(x), \quad \text{and} \quad \lim_{m \rightarrow +\infty} \hat{\tau}_m^{\mathcal{O}} \neq \tau.$$

In practice, former RCTs can be used as *negative controls*<sup>4</sup>, to ensure the observational study does not suffer from confounding. For example, in a recent observational study on a COVID-19 vaccine, Dagan et al. (2021) use such approach to ensure that previous trial results conclusion could be retrieved. When confounding remains, solutions such as sensitivity analysis have been developed to handle such situations (Rosenbaum, 2005; Imbens, 2003), but they typically rely on sensitivity parameters which are difficult to set. Including additional experimental data brings interesting promises to handle such identification bias. Recent works described below propose to use an RCT to *ground* the observational analysis and debias the estimator that would be obtained on purely confounded observational data.

**Using an assumption on secondary outcomes or surrogates.** The use of surrogate outcomes arises in different contexts, for example in clinical studies (Prentice, 1989; Begg and Leung, 2000), where it may be difficult to observe long-term outcomes, e.g., the effect of early childhood medical or economic interventions. Athey et al. (2020) observe that the effect of class size reduction leads

<sup>4</sup>The term negative controls comes from usual routine precaution in biological laboratory experiments, where such controls are used to – at least partially – check that the experiment is not undermined. For example it can test the absence of reagents or components that are necessary for a detection of something particular. For example one of the two bars of the covid antigenic test is one of these controls. The analogy of this principle in causal inference is detailed in (Lipsitch et al., 2010).



to a decrease in children 3<sup>rd</sup> grades in the observational data, while a famous RCT, the Tennessee Student/Teacher Achievement Ratio (STAR) study (Krueger, 1999a), concludes on a positive effect. This difference could come from the fact that the two populations are different, but they assume the apparent difference can be entirely explained by confounding<sup>5</sup>. In their set-up, they consider two outcomes, a primary long-term outcome  $Y^{1st}$  (8<sup>th</sup> grades) and a secondary short-term outcome  $Y^{2nd}$  (3<sup>rd</sup> grades). The RCT contains information on the surrogate but not the long-term outcome while this is the opposite for the observational sample. Their central assumption to recover identifiability is called *latent unconfoundedness*, i.e.,

$$A \perp\!\!\!\perp Y^{1st}(a) \mid Y^{2nd}(a), i \in \mathcal{R}, \text{ , for } a = 0, 1,$$

which corresponds to the assumption that hidden confounders violating identification of the effect on  $Y^{1st}$  are the same than for  $Y^{2nd}$ . In other words, their method consists in adjusting the estimates of the treatment effects on the primary outcome using the differences observed on the secondary outcome. Their assumptions can be understood as a missing data problem, i.e., the missing data in the primary outcomes are missing at random in the concatenated data (Rubin, 1976). For estimation, they suggest three methods, namely, *i*) imputing the missing primary outcome in the RCT, *ii*) weighting the units in the observational sample, and *iii*) using control function methods.

**Deconfound using the bias/confounding function.** Kallus et al. (2018) propose to use an RCT sample to deconfound the CATE estimated on a single observational data set, denoted  $\hat{\tau}_m^{\mathcal{O}}(x)$ . Due to possible unmeasured confounding,  $\hat{\tau}_m^{\mathcal{O}}(x)$  may be biased for  $\tau(x)$ , that is  $\eta(x) \neq 0$  where  $\eta(x) := \tau(x) - \hat{\tau}_m^{\mathcal{O}}(x)$  is the bias function. To correct for this bias, they assume they have at hand a narrow RCT (as it is usually the case with strict eligibility criteria in trial) with high internal validity, and with covariate support included in the observational sample support. Given that  $\hat{\tau}_m^{\mathcal{O}}(x)$  is obtained from the observational data, one can estimate  $\eta(\cdot)$  on the common support between the RCT and the observational data using the (unconfounded) RCT data. Another assumption is required, being that the bias can be well approximated by a function with low complexity, e.g., a linear function of the covariates  $x$ :  $\eta(x) = \theta^T x$ . Kallus et al. (2018) then propose to estimate the bias as  $\hat{\eta}_{m,n}(x) = \hat{\theta}_{m,n}^T x$  by solving the following minimization:

$$\hat{\theta}_{m,n} = \operatorname{argmin}_{\eta} \sum_{i=1}^n (Y_i^* - \hat{\tau}_m^{\mathcal{O}}(X_i) - \eta(X_i))^2 = \operatorname{argmin}_{\theta} \sum_{i=1}^n (Y_i^* - \hat{\tau}_m^{\mathcal{O}}(X_i) - \theta^T X_i)^2,$$

where  $Y_i^* = \left( e(X_i)^{-1} A_i - \{1 - e(X_i)\}^{-1} (1 - A_i) \right) Y_i$ , which satisfies  $\mathbb{E}[Y_i^* \mid X_i] = \tau(X_i)$ .

Note that the linear assumption guarantees the validity of the framework even if the observational data does not fully overlap with the experimental data as the bias, i.e, the confounding error is assumed to be extrapolable. Finally,  $\hat{\tau}_{m,n}(x) = \hat{\tau}_m^{\mathcal{O}}(x) + \hat{\eta}_{m,n}(x)$  is the estimated conditional average treatment effect. They prove that under conditions of parametric identification of  $\eta$ ,  $\hat{\tau}_{m,n}(x)$  is a consistent estimate of  $\tau(x)$  which converges at a rate governed by the rate of estimating  $\mathbb{E}[\hat{\tau}_m^{\mathcal{O}}(x)]$  by  $\hat{\tau}_m^{\mathcal{O}}(x)$ . More recently, Yang et al. (2020) proposed another approach. Rather than  $\eta(x)$ , they consider what they call the *confounding function*  $\lambda(x)$ ,

$$\lambda(x) = \mathbb{E}[Y(0) \mid A = 1, X = x] - \mathbb{E}[Y(0) \mid A = 0, X = x],$$

summarizing the impact of unmeasured confounders on the potential outcome distribution between the treated and untreated patients. In the absence of unmeasured confounding,  $\lambda(x)$  is zero for any  $x \in \mathcal{X}$ , while if there is unmeasured confounding,  $\lambda(x) \neq 0$  for some  $x$ . Assuming a parametric model assumption for the CATE  $\tau(x) := \tau_{\varphi_0}(x)$  with  $\varphi_0 \in \mathcal{P}^1$ , and for  $\lambda(x) := \lambda_{\phi_0}(x)$  with  $\phi_0 \in \mathcal{P}^2$ , the coupling of RCT and observational data allows identifiability of  $\tau(x)$  and  $\lambda(x)$ . The key insight is to introduce the following random variable

$$H_{\psi_0} = Y - \tau_{\varphi_0}(X)A - (1 - S)\lambda_{\phi_0}(X)\{A - e(X)\},$$

<sup>5</sup>Assuming the bias comes from an unobserved confounder and not from inherent differences between populations can be stated as,  $S \perp\!\!\!\perp \{Y(1), Y(0)\}$ , which means that the two samples come from comparable populations (see Section 3).

where  $\psi_0 = (\varphi_0, \phi_0)$  is the full vector of model parameters in the CATE and confounding function, and where here  $S = 1$  (resp.  $S = 0$ ) denotes trial participation (resp. observational study participation). By separating the treatment effect  $\tau_{\varphi_0}(X)A$  and  $(1 - S)\lambda_{\phi_0}(X)\{A - e(X)\}$  from the observed  $Y$ ,  $H_{\psi_0}$  mimics the potential outcome  $Y(0)$ . They then derive the semiparametric efficient score of  $\psi_0$ :

$$S_{\psi_0}(V) = \begin{pmatrix} \frac{\partial \tau_{\varphi_0}(X)}{\partial \varphi_0} \\ \frac{\partial \lambda_{\phi_0}(X)}{\partial \phi_0} (1 - S) \end{pmatrix} (\sigma_S^2(X))^{-1} (H_{\psi_0} - \mathbb{E}[H_{\psi_0} | X, S]) (A - e(X)), \quad (2.3)$$

where  $\sigma_S^2(X) = \mathbb{V}[Y(0) | X, S]$ . A semiparametric efficient estimator of  $\psi_0$  can be obtained by solving the estimating equation based on (2.3). If the predictors in  $\tau_{\varphi_0}(X)$  and  $\lambda_{\phi_0}(X)$  are not linearly dependent, they show that the integrative estimator of the CATE is strictly more efficient than the RCT estimator. As a by-product, this framework can be used to generalize the ATEs from the RCT to a target population without requiring an overlap covariate distribution assumption between the RCT and observational data. [Wu and Yang \(2022a\)](#) propose an integrative R-learner that extends the framework of [Yang et al. \(2020\)](#) to allow flexible machine learning methods for approximating CATE, confounding function, and nuisance functions.

## 4.2 Toward more efficient estimation

Under Assumptions 4, 5, and 9, the CATE can be estimated based on the RCT, while under the classical unconfoundedness assumption (see Appendix 14), the CATE can be estimated using the observational sample. Therefore when both sets of assumptions are met, the two data sources can be pooled to improve estimation efficiency.

Toward this end, [Yang et al. \(2022\)](#) use the semiparametric efficiency theory to derive the semiparametrically efficient integrative estimator of  $\varphi_0$  for the CATE  $\tau_{\varphi_0}(X)$ . However, if the unconfoundedness assumption is violated, integrating the observational sample would bias the CATE estimation. Leveraging the design advantage of RCTs, [Yang et al. \(2022\)](#) derive a preliminary test statistic for the comparability and reliability assessment of the observational data and decide whether to use it in an integrative analysis. Denote the efficient score based solely on the RCT and observational data as  $S_{\text{rct}, \varphi_0}(V)$  and  $S_{\text{os}, \varphi_0}(V)$ , respectively, where  $V$  is a full vector of variables. Their basic idea is to derive an RCT estimator  $\hat{\varphi}_{\text{rct}}$  for  $\varphi_0$  and construct the preliminary test statistics based on  $S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V)$ . The rationale is that if the observational sample is comparable to the RCT sample for estimating  $\varphi_0$ ,  $S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V)$  is expected to be close to zero; otherwise,  $S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V)$  is expected to deviate from zero. This thought process leads to the test statistics

$$T = \left\{ n^{-1/2} \sum_{i=n+1}^{n+m} S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V_i) \right\}^T \hat{\Sigma}_{SS}^{-1} \left\{ n^{-1/2} \sum_{i=n+1}^{n+m} S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V_i) \right\}, \quad (2.4)$$

where  $\hat{\Sigma}_{SS}$  is a consistent estimator for the asymptotic variance of  $n^{-1/2} \sum_{i=n+1}^{n+m} S_{\text{os}, \hat{\varphi}_{\text{rct}}}(V_i)$ . Under  $H_0$  that the observational sample is comparable to the RCT sample,  $T \rightarrow \chi_p^2$ , a Chi-square distribution with degrees of freedom  $\dim(\varphi_0)$ , as  $n \rightarrow \infty$ . This result serves to detect the violation of the assumption required for the observational data.

[Yang et al. \(2022\)](#) propose the elastic integrative estimator by solving

$$\sum_{i=1}^n \hat{S}_{\text{rct}, \varphi}(V_i) + \mathbb{I}(T < c_\gamma) \sum_{i=n+1}^{n+m} \hat{S}_{\text{os}, \varphi}(V_i) = 0, \quad (2.5)$$

where  $c_\gamma$  is the  $100(1 - \gamma)$ th percentile of  $\chi_p^2$ , serving as a switch to decide combining or not. The methodological contribution of [Yang et al. \(2022\)](#) is to derive a data-adaptive selection of  $c_\gamma$  such that the resulting estimator has the smallest mean squared error and thus performs at least similar to the RCT-only estimator, if not better. Moreover, the elastic integrative estimator is non-regular and belongs to pre-test estimation by construction. The theoretical contributions of [Yang et al. \(2022\)](#) include characterizing the distribution of the elastic integrative estimator under local alternatives, which better approximates the finite-sample behaviors, and providing data-adaptive confidence intervals that are uniformly valid.

### 4.3 Other use cases

Beyond generalizability or overcoming confounding, there are other purposes motivating the combination of experimental and observational data. We provide a brief list of these purposes and methodologies. A detailed or exhaustive survey is beyond the scope of this review.

**Using hybrid controls.** A hybrid control arm is a control arm constructed from a combination of randomized patients and patients receiving usual care in standard clinical practice, as introduced by Pocock (1976) and pursued by Hobbs et al. (2012); Schmidli et al. (2014). Recently the FDA has detailed their usage in the regulatory purposes (FDA, 2018). Using hybrid controls has the potential to decrease the cost of randomized trials, and to reduce ethic constraints on control groups.

**Case-control studies.** In certain applications, e.g., in epidemiology, the observational data at hand comes from a case-control study where the selection of observations is driven by the outcome of interest  $Y$ . Thus, the RCT and observational data differ in terms of the outcome distribution, typically a preferential selection on the outcome for the observational data set. Several solutions have been proposed to handle this type of selection bias. Robins (2000) and Hernán et al. (2005) propose marginal structural model approaches to eliminate this bias given sufficient knowledge of the selection model given treatment. Guo et al. (2021) propose a control variates technique (Tan, 2006; Yang and Ding, 2020) identifying and estimating an estimand that is sufficiently correlated with the target estimand of interest for the observational cohort.

**Encouragement design intervention** An encouragement design intervention is a design in which some individuals or groups are randomly assigned to receive encouragement to take up the program. (Rudolph and van der Laan, 2017) provide a semiparametric efficiency score for transporting the ATE from one study following an encouragement design, to another population. Due to the design, their set-up is a variant of the generalization work from Section 3, but with treatment allocation information in the target population.

## 5 Structural causal models (SCM) and transportability

Within the SCM framework (Pearl, 1995, 2009b), Bareinboim and Pearl (2016) have proposed answers for transportability and combination of different data-sources – also called *data fusion*. This section is split off from the previous section as it builds on additional concepts.

Let us first briefly introduce the SCM framework, using as much as possible the notations of Section 2.1 that we introduced for the PO framework (Appendix 2.F gives a more general primer on the SCM framework, and in particular the *do*-operator). The covariates  $X$ , treatment  $A$ , and response  $Y$  are modeled in the SCM framework as random variables with joint distribution  $P(X, A, Y)$ . Each intervention, such as setting  $A$  to  $a = 0$  or  $a = 1$ , defines an alternative distribution over  $(X, A, Y)$  that can be systematically deduced from the no-intervention (or observational) distribution  $P$  using the SCM model, and which is written  $P(X, A, Y | do(A = a))$ . In this framework, the CATE is written:

$$\tau(x) = \mathbb{E}[Y | do(A = 1), X = x] - \mathbb{E}[Y | do(A = 0), X = x];$$

and the ATE:

$$\tau = \mathbb{E}[Y | do(A = 1)] - \mathbb{E}[Y | do(A = 0)].$$

These expressions mirror the corresponding expressions in the PO framework (Table 2.2) when one identifies the variable  $Y(a)$  in the PO framework to the variable  $Y$  under the intervention  $do(A = a)$  in the SCM framework, namely when we set  $P(Y(a), X) = P(Y, X | do(A = a))$ . In fact this analogy is valid in the sense that any theorem that holds for SCM counterfactuals holds in the PO framework, and vice-versa (Pearl, 2009b, Chapter 7; Pearl, 2009a, Chapter 4). In spite of this formal equivalence, the two frameworks differ in how they allow practitioners to express causal assumptions, and to derive corresponding estimands of causal effects. The SCM framework provides a convenient graphical

representation known as causal diagram to encode potentially complex causal assumptions between variables, and provides a complete language known as *do*-calculus to express causal effects (i.e., some expectation under the  $do(A = a)$  probability) as a function of observational data (i.e., some expectation under the no-intervention distribution) (Pearl, 1995, 2009b). When this reduction is possible, the causal effect is called *identifiable*. In addition, the *do*-calculus is complete in the sense that a causal effect is identifiable if and only if it can be reduced to a function of observational data using *do*-calculus (Huang and Valtorta, 2006; Shpitser and Pearl, 2006). Interestingly, this provides a variety of formulas to correctly infer causal effects even in the presence of unmeasured confounders, which cannot be handled by the PO framework (without additional structural and modeling assumptions), such as the front-door adjustment formula (Pearl, 1995).

## 5.1 Formulating transportability in the SCM framework


The SCM literature and *do*-calculus naturally cover the problem of generalizing an RCT experiment to a different target population. Following our notations in the PO setting (Section 2.1), we again denote by  $S$  a binary random variable that indicates which individuals can be in the RCT. The RCT population then follows the distribution  $P(X, Y, A | S = 1)$ , and by design the RCT allows estimating the conditional distributions  $P(Y | do(A = a), X, S = 1)$  for  $a = 0, 1$ . The problem of generalization to the target population in this setting is then to deduce the distributions of  $P(Y | do(A = a), X)$  for  $a = 0, 1$  from these two distributions and the observed distribution of the covariates  $P(X)$  in the target distribution (as in Section 3), or of the covariates, treatments and responses  $P(X, A, Y)$  in the target population (as in Section 4). If this deduction (using *do*-calculus) is possible, then the causal effect on the target population is identifiable, and the deduction provides a formula for the causal effect that can then be estimated from a finite population using some consistent estimator.

Interestingly, this formalism covers two important situations: (i) the *sample selection bias* problem, when the RCT population is a subset of the target population that fulfills some eligibility criterion<sup>6</sup>, and (ii) the *transportability* problem, where the RCT population differs more drastically from the target, e.g., when one wants to generalize an RCT conducted in one country to a population in another country (Pearl, 2015). To model sample selection bias, on the one hand, one typically adds a node  $S$  with incoming edges to a causal graph in order to capture the eligibility conditions that may depend on pre- or post-treatment variables. It is then possible to derive conditions under which one can recover from selection bias when the probability of selection is available (Cooper, 1995; Lauritzen and Richardson, 2008; Geneletti et al., 2008) or when no quantitative knowledge is available about probability of selection (Didelez et al., 2010; Bareinboim and Pearl, 2012a). We provide examples of such conditions in Appendix 2.F.1.2. To model transportability to a different population, on the other hand, the node  $S$  has typically no incoming edge, and instead points to variables that differ between the RCT and the target population, either in their functional dependency to their parents in the causal graph, or in the distribution of their exogenous variables. The resulting graph is called a *selection diagram* and allows to encode graphically detailed assumptions about the differences between populations (Pearl and Bareinboim, 2011a; Bareinboim and Pearl, 2012b; Pearl and Bareinboim, 2014; Bareinboim and Pearl, 2013). Note that even if the two situations imply different causal diagrams, the problem of selection bias “*has some unique features, but can also be viewed as a nuance of the transportability problem, thus inheriting all the theoretical results of transportability*” (Pearl, 2015); this remark is connected to the discussion from Section 2.2.

The SCM approach thus provides powerful machinery to generalize causal effect across populations, and entails a detailed description of the causal assumptions between variables in the selection diagram, including the selection variable  $S$ . The two selection diagrams of Figure 2.3 represent for example transportability problems with a distributional change of covariates  $X$  between the RCT and target populations (with an arrow from  $S$  to  $X$ ), and where the interventional nature of the RCT versus the target population is also represented with an arrow from  $S$  to  $A$ .

In addition, in Figure 2.3(a) the arrow from  $S$  to  $Y$  indicates that the conditional distribution of  $Y$  given  $X$  and  $A$  differs between the two populations, which in general prevents any transporta-

<sup>6</sup>This setting has been termed as *generalizability* in the introduction of the different study designs in Section 2.2.



**Figure 2.3: Illustration of selection diagrams depicting differences between source and target populations:** In (a) and (b), the two populations differ by covariate distributions (indicated by  $S$  pointing to  $X$ ) and the two populations differ in their interventional nature ( $S$  pointing to  $A$ ). Assumption 9 (transportability assumption) is assumed on (b), but not on (a) (since  $S$  points to  $Y$  in (a)). These two examples are inspired by [Pearl and Bareinboim \(2011a\)](#).

bility of causal effect, while the lack of arrow from  $S$  to  $A$  in Figure 2.3(b) encodes the independence assumption  $\mathbb{P}(Y | X, A) = \mathbb{P}(Y | X, A, S = 1)$ , which implies the transportability assumption  $\mathbb{P}(Y | do(A = a), X, S = 1) = \mathbb{P}(Y | do(A = a), X)$  (which itself implies Assumption 9 in the PO framework).

In that case, one easily deduces by simple conditioning on  $X$  that the distribution of  $Y$  under intervention on the whole population is given by

$$\mathbb{P}(Y | do(A = a)) = \sum_x \underbrace{\mathbb{P}(Y | do(A = a), X = x, S = 1)}_{RCT} \underbrace{\mathbb{P}(X = x)}_{Obs.} . \quad (2.6)$$

This transport formula, also known as *re-calibration*, *re-weighting* or *post-stratification* formula ([Pearl, 2015](#)), thus combines experimental results obtained in the RCT population and the observational description of the target population to estimate the causal effect in the target population. In particular, we easily deduce the ATE on the target population by integrating (2.6) in  $Y$  to get


$$\tau = \sum_x \underbrace{\tau_1(x)}_{RCT} \underbrace{\mathbb{P}(X = x)}_{Obs.} , \quad (2.7)$$

where

$\tau_1(x)$  is by design identifiable by conditioning on treatment in the RCT population. This formula (2.7) is equivalent to the regression formula (2.2) in the PO framework, which is valid under Assumption 9. Interestingly, ([Pearl and Bareinboim, 2011a](#)) show that the transport formula (2.6) holds more generally as soon as  $X$  is a set of pre-treatment variables which is *S-admissible*, i.e., if  $S \perp\!\!\!\perp Y | X, do(A = a)$  for  $a = 0, 1$ . Graphically, *S-admissibility* holds whenever  $X$  blocks all paths from  $S$  to  $Y$  after deleting from the graph all incoming arrows into  $A$ . We note that *S-admissibility* implies the mean exchangeability assumption (Assumption 7) and is equivalent to the *S-ignorability* assumption  $S \perp\!\!\!\perp Y(a) | X$  (Assumption 6) used in the PO literature when  $X$  and  $S$  are pre-treatment variables, and entails similar transport formula in that situation.

However, the two notions differ for treatment-dependent selection and covariates, as discussed by [Pearl \(2015\)](#), where several examples illustrate how the *S-admissibility* assumption can lead to different transport formulas when both pre- and post-treatment variables are leveraged. Such an example is presented on Figure 2.4, where the covariate  $X$  is a post-treatment variable, for example a biomarker, believed to mediate between treatment and outcome.





**Figure 2.4: Post-treatment covariate adjustment:** On this selection diagram the arrow from  $S$  to  $X$  indicates the assumption of different effect of  $A$  on  $X$  in the two populations. Here,  $X$  is  $S$ -admissible but not  $S$ -ignorable, and the corresponding transport formula is  $\mathbb{P}(Y \mid do(A = a)) = \sum_x \mathbb{P}(Y \mid do(A = a), X = x, S = 1) \mathbb{P}(X = x \mid A = a)$ , where it invokes an unconventional average of the CATE weighted by a conditional probability in the target population. This example is taken from Pearl (2015).

Here, we presented how Assumptions 5, 6 and 7 are translated in the SCM literature and how another scenario with post-treatment covariates can be identified. More identifiability scenarios have been discussed in the SCM literature (Huang and Valtorta, 2006; Bareinboim et al., 2013; Pearl, 2015; Lee et al., 2020b), and to our knowledge we have found no similar identifiability scenario in the PO literature. It is worth mentioning that the transportation problem discussed so far, to export a causal effect estimated in an RCT to a general population is only one specific instance of the more general problem of *data fusion* (Pearl and Bareinboim, 2011a; Bareinboim and Pearl, 2012b, 2016; Hünernmund and Bareinboim, 2019; Lee et al., 2020a), which simultaneously accounts for confounding issues of observational data, sample selection issues, as well as extrapolation of causal claims across heterogeneous environments. The SCM framework, with its elegant way of formalizing the problem, helps practitioners formulate and discuss causal assumptions across variables and environments. In particular, subject to a good knowledge of the graph, it helps selecting sets of variables that are sufficient to establish identifiability and exclude variables that would bias the analysis. As we will see in Section 7, already in the early phase of a study, the causal and selection diagrams offer a very convenient tool to discuss with clinicians and explicitly lay out conditional independence assumptions. Once a diagram encodes assumptions about a system, algorithmic solutions implementing the *do*-calculus are available to determine whether non-parametric identifiability holds, and to provide correct formula if it holds (Correa et al., 2018; Tikka et al., 2019).

While the SCM literature provides powerful and versatile sets of concepts and tools to *identify* causal effects, practical estimators with publicly available implementations and detailed consistency, convergence rates or robustness results are still scarce. Some recent work has proposed solutions for this estimation task in the context of either experimental or observational data by extending weighting-based methods developed for the back-door case to more general settings (Jung et al., 2020a,b), or extending the double/debiased machine learning (DML) approach proposed by Chernozhukov et al. (2018b) under ignorability assumption to any identifiable causal effect (Jung et al., 2021). In the same spirit, Karvanen et al. (2020) propose combination of data from a survey and a meta-analysis of 34 trials, where identifiability and transport formula are the output of the algorithm *do-search* (see Section 6), and estimation is performed with the real data at hand. Additionally, even if a causal effect is not identifiable, partial-identifiability techniques have been proposed for deriving bounds for the causal effect (Tian and Pearl, 2000; Dawid et al., 2019). Cinelli and Pearl (2020) give an example illustrating partial identifiability on real data, with experiments assessing the effect of the Vitamin A supplementation. In this setting the existence of experimental data from one source population leads to identify bounds on the transported causal effect, but the availability of two trials instead of one leads to a point estimate. Finally, Dahabreh et al. (2019, 2020) propose an alternative approach for generalizability and integrative analyses of trials and observational studies using structural equation models under weaker error assumptions and represented using single world intervention graphs (Richardson and Robins, 2013).

## 6 Software for combining RCT and observational data

### 6.1 Review of available implementations

An important point to bridge the gap between theory and practice is the availability of software. In recent years, there have been more and more solutions for users interested in causal inference and causation, see Tikka and Karvanen (2017); Guo et al. (2020); Yao et al. (2021) for surveys and Mayer et al. (2022) for a task view of R implementations. Regarding the specific subject of

this article, we present in Table 2.3 the implementations available about both identifiability and estimators. The available implementations are often dedicated to specific sampling designs and, as mentioned, estimators are different from nested and non-nested framework. As a consequence, a new user has to pay attention to all of these practical – but fundamental – details.

## 6.2 Simulation study of generalization estimators

This part presents simulations results to illustrate the different estimators introduced in Section 3 and their behavior under several mis-specifications patterns. The code to reproduce the results is available on [Github](#)<sup>7</sup>. We implement in R ([R Core Team, 2021](#)) our own version of the estimators to match exactly the formulas introduced in the review (IPSW and `IPSW.normd` see Definition 7, stratification; Definition 8, plug-in g-formula; Definition 9, and AIPSW; Definition 21), except for the CW and ACW estimators (Definitions 10) and 12) for which we use the `genRCT` package.

**Scenario 1: well-specified models.** Similarly to [Dong et al. \(2020\)](#), We generate non-nested trial settings as follow. First, we draw a sample of size 50,000 from a covariate distribution with four covariates are generated independently as with  $X_j \sim \mathcal{N}(1, 1)$  for each  $j = 1, \dots, 4$ . From this sample, we then select an RCT sample of size  $n \sim 1000$  with trial selection scores defined using a logistic regression model:

$$\text{logit} \{ \pi_S(X) \} = -2.5 - 0.5 X_1 - 0.3 X_2 - 0.5 X_3 - 0.4 X_4. \quad (2.8)$$

Then, we generate the treatment according to a Bernoulli distribution with probability equals to 0.5,  $e_1(x) = e_1 = 0.5$  and the outcome according to a linear model:

$$Y(a) = -100 + 27.4 a X_1 + 13.7 X_2 + 13.7 X_3 + 13.7 X_4 + \epsilon \text{ with } \epsilon \sim \mathcal{N}(0, 1). \quad (2.9)$$

This outcome model implies a target population ATE of  $\tau = 27.4$ , and  $\mathbb{E}[X_1] = 27.4$ . Finally, we generate an observational sample by drawing a new sample of size  $m = 10,000$  from the distribution of the covariates.

Figure 2.5 presents estimated ATE over 100 simulations. The true ATE is represented with a dash line. The ATE estimated only with the RCT sample is also displayed as a baseline. As expected it is biased downward (its mean is equal to 14.24) as the distribution of the covariates and in particular the treatment effect modifiers such as  $X_1$  is not the same in the trial sample and in the population (as illustrated in Table 2.14 in Appendix 2.G). Note that in this simulation all the estimators are unbiased. The variability of the two IPSW estimators are larger than the others. The number of strata in the stratification estimator plays an important role. As shown in Figure 2.16 in Appendix 2.G, the results are biased when the number of strata is smaller than 10.

**Scenario 2: mis-specification of the sampling propensity score or outcome model.** To study the impact of mis-specification of the sampling propensity score model, we generate the RCT selection according to the model

$$\text{logit} \{ \pi_S(X) \} = -2.5 - 0.5 e^{X_1} - 0.3 e^{X_2} - 0.5 e^{X_3} - 0.4 e^{X_4} + 3,$$

and outcome according to the model

$$Y(a) = -100 + 27.4 a X_1 X_2 + 13.7 X_2 + 13.7 X_3 + 13.7 X_4 + \epsilon.$$

The analysis is then performed using classical logistic and linear estimators on the four covariates. As shown in Figure 2.6, when the sampling propensity score model is mis-specified, the IPSW estimators are biased; whereas when the outcome model is mis-specified, the plug-in g-estimator is biased. In both settings, the double robust estimator (AIPSW) is unbiased and robust to mis-specification. In the case where both models are mis-specified, all estimators are biased except the CW and ACW estimators. This demonstrates some robust properties of calibration against slight model mis-specification. Appendix 2.G investigates the effect of a missing covariate, homogeneous treatment effect, and the impact of a stronger covariate shift, i.e., poorly satisfied Assumption 10.


<sup>7</sup><https://github.com/BenedicteColnet/combine-rct-rwd-review>



**Table 2.3:** Inventory of publicly available code for generalization (top: software for identification; bottom: software for estimation).

Name	Method - Setting	Source & Reference
<i>Identification</i>		
causaleffect	Identification and transportation of causal effects, e.g., conditional causal effect identification algorithm	R package on CRAN, <a href="#">Tikka and Karvanen (2017)</a>
dosearch	Identification of causal effects from arbitrary observational and experimental probability distributions via do-calculus	R package on CRAN, <a href="#">Tikka et al. (2019)</a>
Causal Fusion	Identifiability in data fusion framework, (Section 5)	Browser beta version upon request <a href="#">Bareinboim and Pearl (2016)</a>
<i>Estimation</i>		
ExtendingInferences	IPSW (Definition 7), plug-in g-formula equation eq. 2.16 - Nested AIPSW eq. 2.18 - Nested Continuous outcome	R code on <a href="#">GitHub</a> , <a href="#">Dahabreh et al. (2020)</a>
generalize	IPSW (Definition 7), TMLE (Section 3.2.4)	R package on <a href="#">GitHub</a> <a href="#">Ackerman et al. (2021)</a>
genRCT	IPSW (Definition 7), calibration weighting (Section 3.2.4) Continuous and binary outcome	R package <a href="#">Dong et al. (2020)</a>
IntegrativeHTE	Integrative HTE (Section 4.1)	R package on <a href="#">GitHub</a> , <a href="#">Yang et al. (2022)</a>
IntegrativeHTEcf	Includes confounding functions (Section 4.1)	R package on <a href="#">GitHub</a> , <a href="#">Yang et al. (2022)</a>
generalizing	SCM with probabilistic graphical model for Bayesian inference Binary outcome	R package on <a href="#">GitHub</a> , <a href="#">Cinelli and Pearl (2020)</a>
RemovingHiddenConfounding	Unmeasured confounder (Section 4.1)	R package on <a href="#">GitHub</a> , <a href="#">Kallus et al. (2018)</a>
senseweight	Sensitivity analysis (IPSW Definition 7)	R package on <a href="#">Github</a> <a href="#">Huang (2022)</a>
transport	Targeted maximum likelihood estimators (TMLEs) Transport	R package on <a href="#">GitHub</a> , <a href="#">Rudolph et al. (2018)</a>
combine-rct-rwd-review	Generalization estimators of Section 3	R code on <a href="#">GitHub</a>

**Figure 2.5: Well-specified model** Estimated ATE with the inverse propensity of sampling weighting with and without weights normalization (IPSW and IPSW.norm; Definition 7), stratification (with 10 strata; Definition 8), plug-in g-formula (Definition 9), calibration weighting (CW; Definition 10), augmented IPSW (AIPSW; Definition 21) and ACW (Definition 12)) over 100 simulations.



## 7 Application: Effect of Tranexamic Acid


To illustrate the methodological question of combining experimental and observational data and demonstrate some of the previously discussed methods, we consider an open medical question about major trauma patients. We focus on trauma patients suffering from a traumatic brain injury (TBI): brain damage caused by a blow or jolt to the head. Tranexamic acid (TXA) is an antifibrinolytic agent that limits excessive bleeding, commonly given to surgical patients. Previous clinical trials showed that TXA decreases mortality in patients with traumatic *extracranial* bleeding (Shakur-Still et al., 2009). Such prior result raises the possibility that it might also be effective in TBI, because *intracranial* hemorrhage is common in TBI patients, with risks of raised intracranial pressure, brain herniation, and death. Therefore the aim here is to assess the potential decrease of mortality in patients with intracranial bleeding when using TXA. To answer this question, we have at our disposal both an RCT, *CRASH-3*, and an observational study, the *Traumabase*. Both data have previously been analyzed separately in *CRASH-3* (2019) (for the RCT) and in Mayer et al. (2020) (for the observational study) and the medical teams of both studies want to share their respective data to answer both medical and methodological questions. Such initiatives allow to: (1) collate the results from the observational study with the RCT findings; (2) assess the generalizability methods, considering the *Traumabase* as the target population, and assess the estimators presented in this review in a real application. We first present the two data sources, treatment effect analyses and findings from these, before turning to the combined analysis in Section 7.2. The code to reproduce all these analyses is available on [Github](https://github.com/BenedicteColnet/combine-rct-rwd-review)<sup>8</sup>, however the medical data cannot be publicly shared for privacy concerns.

### 7.1 The observational data: Traumabase

#### 7.1.1 Context

The *Traumabase* regroups 23 French Trauma centers that collect detailed clinical data from major trauma patients from the scene of the accident to hospital discharge in form of a registry. The data, currently counting over 30,000 patient records, are of unique granularity and size in Europe. However, they are highly heterogeneous, with both categorical – sex, type of illness, ... – and quantitative – blood pressure, hemoglobin level, ... – features, multiple sources, and many missing data (98% of the records are incomplete). Here, we use 8,270 patients suffering from TBI extracted from the *Traumabase*. Mayer et al. (2020) performed a first, purely observational, study to assess the effect of TXA on mortality for traumatic brain injury patients from this data: the treatment variable is the administration of

<sup>8</sup><https://github.com/BenedicteColnet/combine-rct-rwd-review>



**Figure 2.6: Mis-specified models** Estimated ATE when selection in RCT and/or outcome models are mis-specified. Estimators used being IPSW (IPSW and IPSW.norm; Def. 7), stratification (with 10 strata; Def. 8), plug-in g-formula (Def. 9), calibration weighting (CW; Def. 10), augmented IPSW (AIPSW; Def. 21), and ACW (Def. 12) over 100 simulations.

TXA during pre-hospital care or on admission to a Trauma Center<sup>9</sup> within three hours of the initial trauma. The Traumabase analysis contains many missing values (see Appendix 2.H.1), which implies additional assumptions to perform causal inference.

### 7.1.2 Purely-observational results from two different estimation strategies

The direct causal effect of TXA on 28-day intra-hospital TBI-related mortality and on all cause intra-hospital mortality among traumatic brain injury patients is estimated by adjusting for confounding using 17 confounding variables. In addition, 21 variables predictive of the outcome but not related to the treatment are included (see Mayer et al. (2020) for the detailed adjustment set). We recall the results from this study which put a focus on how to estimate treatment effects in the presence of incomplete data. The presented methods rely either on logistic regressions or generalized random forests (Athey et al., 2019) for the nuisance components, denoted respectively by *GLM* and *GRF* in Table 2.4. The doubly robust results (AIPW) in Table 2.4 show that from this study there is no evidence for an effect of TXA on mortality of TBI patients. These findings—obtained prior to the publication of CRASH-3—are consistent with the main conclusion of the CRASH-3 study. However, the results from IPW conclude on a possible deleterious effect. In such a situation, the possibility to generalize the treatment effect from the RCT is also a step to comfort the results. In Appendix 2.H.4, we additionally recall results on sub-groups obtained by stratifying along trauma severity.

<sup>9</sup>More precisely, to the resuscitation room of a hospital equipped to treat major trauma patients.

**Table 2.4: ATE estimations from the Traumabase** for TBI-related 28-day mortality. Red cells conclude on deteriorating effect, white cells can not reject the null hypothesis of no effect. GLM stands for Generalized Linear Models and GRF for Generalized Random Forests to estimate nuisance components. Two estimators of the treatment effect are considered: IPW and AIPW, as well as two methods to deal with missing values: multiple imputation or missing incorporated in attribute (MIA) in GRF.


	Multiple imputation (MICE)		GRF-MIA		Unadjusted ATE $\times 10^2$
	IPW (95% CI) $\times 10^2$	AIPW (95% CI) $\times 10^2$	IPW (95% CI) $\times 10^2$	AIPW (95% CI) $\times 10^2$	
Total (n=8248)	GLM 15 (-6.8, 23) GRF 11 (6.0, 16)	GLM 3.4 (-9.0, 16) GRF -0.1 (-4.7, 4.4)	9.3 (4.0, 15)	-0.4 (-5.2, 4.4)	16

### 7.1.3 Context

CRASH-3 is a multi-centric randomized and placebo-controlled trial launched over 175 hospitals in 29 different countries (Dewan et al., 2012). This trial recruited 9,202 adults –unusually large for a medical RCT–, all suffering from TBI with only intracranial bleeding, i.e., without major extracranial bleeding. All participants were randomly administrated TXA (CRASH-3, 2019; ?). The primary outcome studied is head-injury-related death in hospital within 28 days of injury in patients included and randomized within 3 hours of injury. The study concludes that the risk of head-injury-related death is 18.5% in the TXA group versus 19.8% in the placebo group. The causal effect, measured as a Risk Ratio (RR) was not significant (RR = 0.94 [95% CI 0.86 - 1.02]). Note that CRASH-3 revealed a positive effect of TXA only when considering mild and moderate cases. In the Appendix 2.H.4, we provide a complementary analysis to study this sub-group.

### 7.1.4 RCT selection

Six covariates are present at baseline, being age, sex, time since injury, systolic blood pressure, Glasgow Coma Scale score (GCS)<sup>10</sup>, and pupil reaction. The inclusion criteria of the trial are patients with a GCS score of 12 or lower or any intracranial bleeding on CT scan (computed tomography), and no major extracranial bleeding. We provide a DAG summarizing the trial selection and predictors of the outcome present in CRASH-3 in Figure 2.7.



**Figure 2.7: Structural causal diagram** representing treatment, outcome, inclusion criteria with  $S$  and other predictors of outcome (Figure generated using the Causal Fusion software presented in Section 6 from Bareinboim and Pearl (2016)).

## 7.2 Transporting the ATE on the observational data

With the two separate analyses in mind, we can now turn to the combined analysis, more specifically, the generalization from the RCT results to the target population defined by the observational Traumabase registry. Before any analysis aiming to compare and combine two data sets an important step is to assess that baseline covariates, treatment, and outcome are the same (for details, see Appendix 2.H.2).

<sup>10</sup>The Glasgow Coma Scale (GCS) is a neurological scale which aims to assess a person’s consciousness. The lower the score, the higher the severity of the trauma.

	majorExtracranial	Glasgow_initial	age	pupilReact_num	systolicBloodPressure	sexe	TBI_Death
Control.Observational	0.65	10.81	43.29	1.67	130.18	0.22	0.16
Treated.Observational	0.99	8.42	41.73	1.27	100.14	0.33	0.32
Control.RCT	0	9.58	41.9	1.65	129.64	0.2	0.2
Treated.RCT	0	9.62	41.75	1.64	130.41	0.19	0.18

**Figure 2.8: Distributional shift** and difference in terms of univariate means of the trial inclusion criteria (red: group mean greater than overall mean, blue: group mean less than overall mean, white: no significant difference with overall mean, numeric values: group mean (resp. proportion for binary variables)). Graph obtained with the `catdes` function of the `FactoMineR` package (Lê et al., 2008).

### 7.2.1 Descriptive analyses

**Missing values.** The RCT contains almost no missing values, whereas the variables for determining eligibility in the observational data contain important fractions of missing values, ranging from 0.27 to 29 %. Thus the methods discussed in this review must be adapted to account for missing values<sup>11</sup>. In order to estimate the nuisance components, i.e., the conditional odds and the outcome model(s), despite the missing data, we explore two alternative strategies: (1) logistic regression with incomplete covariates using an expectation maximization algorithm (Dempster et al., 1977), a computationally efficient variant of this method using stochastic approximation is implemented in the R package `misaem` (Jiang et al., 2020); (2) generalized regression forest with missing incorporated in attributes (Twala et al., 2008; Josse et al., 2019), this method is implemented in the R package `grf` (Tibshirani et al., 2020).

**Table 2.5:** Sample sizes for both studies.

Traumabase			CRASH-3		
m	#treated	#death	n	#treated	#death
8248	683	1411	9168	4632	1745

**Distribution shift.** Simple comparisons of the means of the covariates between the treatment groups of the two studies –Figure 2.8– reveal the fundamental difference between the two studies, namely the treatment assignment bias in the observational study and the balanced treatment groups in the RCT. In Appendix 2.H.3.1 we further explore the distribution shift with univariate histograms (Figures 2.21–2.25).

### 7.2.2 Analyses

**Notations and estimator details.** We use two consistent ATE estimators from the CRASH-3 data, namely the difference in mean estimator (**Difference in means**; Section 2.A) and the difference in

<sup>11</sup>If we assumed the missing values being missing completely at random (MCAR), we could “throw away” the incomplete observations and perform the analyses on the complete observations, but this would reduce the total sample size to 917 observations. And as explained in Section 7.1, the MCAR assumption is not plausible for the present observational data, thus such a *complete case analysis* would be biased.

conditional mean relying on OLS (**Difference in conditional means**). We also present the results from the purely observational study outlined earlier: AIPW coupled with multiple imputation (MI AIPW) and AIPW based on nuisance parameters estimated via generalized random forest (GRF AIPW) that can directly handle missing values when needed with missing incorporated in attribute strategy. To generalize the ATE to the target population, we apply the estimators discussed in this review while implementing strategies to handle the missing values. The resulting estimators are presented in Table 2.6.

**Table 2.6:** Overview of generalization estimators based on different missing values handling strategies used in the data analysis.

		Missing values strategy	
		Logistic regression with missing values	Generalized random forests (grf) - MIA
$\hat{\tau}_{n,m}$	IPSW	EM IPSW	GRF IPSW
	Plug-in g-formula	EM Plug-in g-formula	GRF Plug-in g-formula
	AIPSW	EM AIPSW	GRF AIPSW

The confidence intervals of these estimators are computed with a stratified bootstrap in the RCT and the observational data set in order to maintain the ratio of relative size of the two studies (with 100 bootstrap samples). Note that the Calibration Weighting estimators (CW and ACW) are not used in this analysis as they would require a specific adaptation to the case of the missing values.

**Results of the combined analysis.** Figure 2.9 gives the generalization from the RCT to the target population using all the observations from both data sets, showing certain discrepancies with respect to the separate analysis results. On the one hand, one half of the generalization estimators support the CRASH-3 conclusion about the treatment effect: no significant effect. On the other hand, some estimators point towards a deleterious treatment effect. Recall that the AIPW ATE estimations from the purely observational data study do not reject the null hypothesis of no treatment effect. Note that these results are to be interpreted carefully due to the potential impact of missing values on the performance of the chosen estimators. For example, the large confidence intervals for the GRF estimators when used to estimate weights are likely to be due to the imbalanced proportions of missing values in the RCT and the observational data. Indeed, the variance is much smaller using the plug-in g-formula with GRF. Dealing with missing values when generalizing a treatment effect remains an open research question.


Here we present the results transported onto the total TBI Traumabase population, but the CRASH-3 study highlights a specific subgroup of patients (mild and moderate patients) for which a positive effect of the tranexamic acid is measured. The generalization of the CRASH-3 findings onto this subgroup in the Traumabase raises multiple methodological issues that still need to be addressed in future works (detailed in Appendix 2.H.4.3).

Overall this data analysis highlights the interest of combining two different data sets, but also some challenges: the need for a good understanding of the common covariates, exposure, and outcome of interest before combining the data sets, different missing data patterns, and poor overlap when considering specific target (sub-)populations.

## 8 Conclusion

Combining observational data and RCTs can improve many aspects of causal inference, from increased statistical power to better external validity. A large part of this review is dedicated to generalizability and transportability of RCT from one population to another. The corresponding rich and prolific literature answers a real practical concern: external validity. Indeed, questions about external validity arise as soon as there are treatment effect heterogeneities in the populations under study. We find that, as any growing scientific field, the ideas are in flux: notations differ, implementations are scattered, and the proposed methods proposed still lack real-world benchmarks, generated hand in hand with practitioners. In addition, many open questions still remain as detailed below.





**Figure 2.9: Juxtaposition of different estimation results** with ATE estimators computed on the Traumabase (observational data set), on the CRASH-3 trial (RCT), and transported from CRASH-3 to the Traumabase target population. All the observations are used. Number of variables used in each context is given in the legend.

**Discrepancies between RCTs and observational data.** The application on tranexamic acid effect hinted to moderate external validity of the RCT as the generalized ATE is concordant with the findings from the RCT, at least for half of the estimators. Additionally, the purely observational data study also supports the results from the RCT. Determining which analysis to trust depends on the assumptions we are willing to make – either related to transportability or unconfoundedness – as well as the suitability of the selected variables. Beyond these assumptions, caution is needed when interpreting the results, as observing the methods in action reveals threats to validity. The target population of interest and overlap also raise concerns. Considering certain strata revealed violated positivity, which leads to a non-transportable treatment effect on the strata of interest: mild and moderate patients. Therefore, further discussions and analyses with the medical expert committee are necessary to re-define a target population of interest on which generalization is possible and medically relevant. As it is generally the case, beyond methodological and theoretical guarantees, a major step to be taken before applying a set of methods is to clearly state the causal question and estimand(s) and the associated identifiability requirements. This task is even more complex when combining data sets. A primary and fundamental concern is whether outcome, treatment, and covariates are comparable in the two studies (Lodi et al., 2019).

**Right choice of covariates to answer the question.** Domain expertise can be used to postulate a causal graph: a directed acyclic graph representing the mechanisms (as Figure 2.7). The SCM framework is then convenient to assess whether the question of interest can be formulated in an identifiable way. This approach offers a principled way of selecting variables needed for identification of the causal effect and to avoid biased causal effect estimates. Without such an approach, identifiability claims are limited. A common practical recommendation is to include as many variables as possible to avoid violation of any assumption as proposed for e.g. by Stuart and Rhodes (2017); Ling et al. (2022) and Dahabreh et al. (2020): “it is probably best to include as many outcome predictors as possible in

regression models for the expectation of the outcome or the probability of trial participation”. On the contrary, a recent work alerts about the bad consequences of adding covariates that are shifted between the two populations while not being treatment effect modifiers, resulting in variance inflation (Colnet et al., 2022b). In its current state, the field probably lacks work on covariate selection and its impact on bias and variance. Some recent works propose the use of causal graphs to select optimal adjustment sets that allow the reduction of the variance of the final estimation (Smucler et al., 2021; Witte et al., 2020; Guo and Perković, 2022), but such methods have not yet been developed for generalization or data fusion.

**Challenges in handling missing values.** In our data analysis, we have seen the need to account for missing values, and in particular different missing value patterns between data sources. Missing values typically occur more often in observational data since in RCTs, investigators typically deploy significant efforts to avoid them. RCTs may however suffer from participants missing scheduled visits or completely dropping out from the study. The literature for RCT mainly focuses on missing outcome data and calls for sensitivity analysis given that available strategies to handle such missing data (weighting, multiple imputation) rely on untestable assumptions about the missing values mechanism (Carpenter and Kenward, 2007; National Research Council, 2012; Kenward, 2013; O’Kelly and Ratitch, 2014; Li and Stuart, 2019; Cro et al., 2020). Missing values may lead to subtle biases in the inferences, as they are seldom uniformly distributed across both data sets – occurring more in one than in the other. While a recent research work proposes an assessment of the effect of different missing data patterns (Mayer et al., 2021), further research is needed to clarify identifiability conditions and estimators in this setting in order to better understand the scope of each method.

## Appendix of Chapter 2

### 2.A Randomized controlled trial

This section recalls assumptions and estimators for average treatment estimation in the case of a single RCT. The assumptions for average treatment effect identifiability in RCTs are the SUTVA assumption and assumptions 4 (consistency) and 5 (random treatment assignment within the RCT). These assumptions allow the average treatment effect to be identifiable. The most intuitive estimators coming from these assumptions is the difference-in-means estimators:

$$\hat{\tau}_{\text{DM},n} = \frac{1}{n_1} \sum_{A_i=1} Y_i - \frac{1}{n_0} \sum_{A_i=0} Y_i \quad (2.10)$$

With  $n_1$  being the number of individuals in the trial that have been treated and  $n_0$  the number of individuals in the trial who have not been treated ( $n_0 + n_1 = n$ ). This estimator is unbiased and  $\sqrt{n}$ -consistent if the trial is a random sample of the target population. If not, it is a biased estimation of the population average treatment effect.

### 2.B Estimation of ATE in observational data

Under classical identifiability assumptions, it is possible to estimate the ATE and CATE based only on the observational data. In what follows, we briefly recall the usual assumptions, which can be seen as an introduction to Section 4.

**Assumption 14** (Unconfoundedness).  $Y(a) \perp\!\!\!\perp A \mid X$  for  $a = 0, 1$ .

Assumption 14 (also called *ignorability* assumption) states that treatment assignment is as good as random conditionally on the attributes  $X$ . In other words, all confounding factors are measured. Unlike the RCT, in observational studies, its plausibility relies on whether or not the observed covariates  $X$  include all the confounders that affect the treatment as well as the outcome.

**Assumption 15** (Overlap). *There exists a constant  $\eta > 0$  such that for almost all  $x$ ,  $\eta < e(x) < 1 - \eta$ .*

Assumption 15 (also called *positivity* assumption) states that the propensity score  $e(\cdot)$  is bounded away from 0 and 1 almost surely.

Under Assumptions 14 and 15, the ATE can be identified based on the following formulas from the observational data:

1. Reweighting formulation:

$$\tau = \mathbb{E}\left[\frac{AY}{e(X)} - \frac{(1-A)Y}{1-e(X)}\right]; \quad (2.11)$$

2. Regression formulation:

$$\tau = \mathbb{E}[\tau(X)] = \mathbb{E}[\mu_1(X) - \mu_0(X)]. \quad (2.12)$$

For example the identification formulas, and more particularly the reweighting formulation, motivates the Inverse Propensity Weighting (IPW) estimator (Hirano et al., 2003),

$$\hat{\tau}_{,m} = \frac{1}{m} \sum_{i=1}^m \left\{ \frac{A_i Y_i}{e(X_i)} - \frac{(1-A_i) Y_i}{1-e(X_i)} \right\}, \quad (2.13)$$

where  $e(x) = P(A = 1 \mid X = x)$  is the propensity score, i.e., the probability to be treated given the covariates. The rationale of IPW is to upweight treated observations with a small propensity score (and the other way around) to balance the two groups, treated and non treated, with respect to their covariates. These identification formula motivate also the regression estimators or doubly

robust estimators based solely on the observational data. Efficient estimation of the ATE with one single observational data set and non-parametric models is detailed in [Laan and Rose \(2011\)](#); [Kennedy \(2016\)](#); [Chernozhukov et al. \(2018b\)](#). There are also many available methods to estimate the CATE, based on the observational data such as causal forests ([Wager and Athey, 2018](#)), causal BART ([Hill, 2011](#); [Hahn et al., 2020](#)), or causal boosting ([Powers et al., 2018](#)). There are also meta-learners such as the S-Learner ([Künzel et al., 2019](#)), T-learner ([Künzel et al., 2019](#)), X-Learner ([Künzel et al., 2019](#)), and R-learner ([Nie and Wager, 2020](#)), which build upon any base learners for regression or supervised classification. [Knaus et al. \(2021\)](#) and [Powers et al. \(2018\)](#) conduct comprehensive simulation studies to compare these methods.

## 2.C Identification formula

This part focuses on the non-nested design only, as it corresponds to the central design of this review.

### Identification by the g-formula or regression formula in the target population

*Proof.*

$$\begin{aligned}
\mathbb{E}[Y(a)] &= \mathbb{E}[\mathbb{E}[Y(a) \mid X]] && \text{Law of total expectation} \\
&= \mathbb{E}[\mathbb{E}[Y(a) \mid X, S = 1]] && \text{Assump. 7} \\
&= \mathbb{E}[\mathbb{E}[Y(a) \mid X, S = 1, A = a]] && \text{Assump. 5} \\
&= \mathbb{E}[\mathbb{E}[Y \mid X, S = 1, A = a]] && \text{Assump. 4} \quad \square
\end{aligned}$$

This last quantity can be expressed as a function of the distribution of  $X$  in the target population:

$$\mathbb{E}[Y(a)] = \int \mathbb{E}[Y \mid X = x, S = 1, A = a] df(x),$$

where  $f(X)$  denotes the distribution of  $X$  in the target population.

### Identification by weighting

*Proof.*

$$\begin{aligned}
\tau &= \mathbb{E}[\tau(X)] && \text{Law of total expectation} \\
&= \mathbb{E}[\tau_1(X)] && \text{Assump. 9} \\
&= \mathbb{E}\left[\frac{f(X)}{f(X \mid S = 1)} \tau_1(X) \mid S = 1\right] && \text{Assump. 10.}
\end{aligned}$$

□

Using Bayes' rule, we note that

$$\frac{f(x)}{f(x \mid S = 1)} = \frac{\mathbb{P}(S = 1)}{\mathbb{P}(S = 1 \mid X = x)} = \frac{\mathbb{P}(S = 1)}{\pi_S(x)}.$$

In this expression, however, it is important to notice that neither  $\pi_S(x)$  nor  $\mathbb{P}(S = 1)$  can be estimated from the data, because we do not observe the  $S$  indicator in the observational study (Figure 2.1). On the other hand, the conditional odds  $\alpha(x)$  can be estimated by fitting a logistic regression model that discriminates RCT versus observational samples, and Bayes' rule gives:

$$\begin{aligned}
\alpha(x) &= \frac{\mathbb{P}(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{\mathbb{P}(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)} \\
&= \frac{\mathbb{P}(i \in \mathcal{R})}{\mathbb{P}(i \in \mathcal{O})} \times \frac{\mathbb{P}(X_i = x \mid i \in \mathcal{R})}{\mathbb{P}(X_i = x \mid i \in \mathcal{O})} \\
&= \frac{n}{m} \times \frac{f(x \mid S = 1)}{f(x)},
\end{aligned}$$

and therefore

$$\tau = \mathbb{E} \left[ \frac{n}{m\alpha(X)} \tau_1(X) \mid S = 1 \right].$$

This quantity can be further developed, underlying  $\tau_1(X)$  identification as presented in the following proof 2.C.

*Proof.*

$$\begin{aligned} \tau_1(x) &= \mathbb{E}[Y(1) - Y(0) \mid X = x, S = 1] \\ &= \mathbb{E}[Y(1) \mid X = x, S = 1] - \mathbb{E}[Y(0) \mid X = x, S = 1] \\ &= \frac{\mathbb{E}[A \mid X = x, S = 1] \mathbb{E}[Y(1) \mid X = x, S = 1]}{e_1(x)} \\ &\quad - \frac{\mathbb{E}[1 - A \mid X = x, S = 1] \mathbb{E}[Y(0) \mid X = x, S = 1]}{1 - e_1(x)} \\ &= \frac{\mathbb{E}[AY(1) \mid X = x, S = 1]}{e_1(x)} - \frac{\mathbb{E}[(1 - A)Y(0) \mid X = x, S = 1]}{1 - e_1(x)} && \text{Assump. 5} \\ &= \frac{\mathbb{E}[AY \mid X = x, S = 1]}{e_1(x)} - \frac{\mathbb{E}[(1 - A)Y \mid X = x, S = 1]}{1 - e_1(x)} && \text{Assump. 4} \\ &= \mathbb{E} \left[ \frac{A}{e_1(x)} Y - \frac{1 - A}{1 - e_1(x)} Y \mid X = x, S = 1 \right]. \end{aligned}$$

□

## 2.D Sources of formal statements of estimators described in Section 3.2

This section proposes formal statements on the statistical properties of the exposed estimators in the form of theorems. As part of a review work, this section only reports results that are stated along a Theorem environment and with explicit proof in the original papers.

### 2.D.1 Inverse Propensity of Sampling Weighting

Beyond the result from [Colnet et al. \(2022a\)](#) recalled in plain document, other theoretical results on the IPSW can be found in:

- [Egami and Hartman \(2021\)](#), which provides finite sample unbiasedness, consistency and asymptotic normality of an oracle version of the IPSW, that is an estimator where the true  $\alpha$  is known (see their appendix, Section SM-2).
- [Buchanan et al. \(2018\)](#), which provides consistency and asymptotic normality assuming that the conditional odds are well approached by a parametric model (for e.g. a logistic regression). Results are detailed both in the main paper (p.7) and in appendix for detailed derivations. Note that they also obtain asymptotic normality and consistency for an oracle version of the IPSW. Their proof rely on M-estimation methods ([Stefanski and Boos, 2002](#); [Lunceford and Davidian, 2004](#)), writing the estimation problem as a stacked equation, with the specificity that the observations are not necessarily identically distributed. The authors retrieve a well-known result in causal inference: estimating the weights leads to a gain in variance. Note that the proof is done in the context of a nested design, which is not exactly the purpose of the review. Without stating theoretical results, [Zivich et al. \(2022\)](#) extends this work to non-nested design showing how to compute the sandwich type confidence intervals. [Buchanan et al. \(2018\)](#) also propose sandwich-type estimation of variance, while noting that estimation of the variance of the oracle version of IPSW would provide conservative but valid confidence intervals.

- [Dahabreh et al. \(2020\)](#), which announces consistency of the IPSW for parametric estimator of the RCT selection model  $\alpha(X)$ , and sketches the proof in Appendix for both a normalized and non-normalized version of the IPSW (see Section A). Note that derivations are made in the context of a nested design but said to extend to a non-nested design.
- [Colnet et al. \(2022a\)](#), which provides consistency (i.e. asymptotically unbiased) for any consistent parametric or non-parametric method to estimate  $\alpha$ .
- [Colnet et al. \(2022b\)](#), which provides finite and large sample bias and variance when the adjustment set is constituted of categorical covariates. The consistency is a by-product of their results. To our knowledge, their results is the only one characterizing different variance regimes depending on the size of the two data sample (RCT and observational). They also recommend to estimate the probability to be treated in the trial  $e_1(X)$  to decrease the asymptotic variance.

### 2.D.2 Stratification

- [O’Muircheartaigh and Hedges \(2014\)](#) provide a formula of the variance under the situation where the strata estimates are assumed independent and the estimation of the strata proportion  $m_l/m$  is without error (i.e. infinite target sample).
- [Buchanan et al. \(2018\)](#) provide asymptotic normality for the stratification estimator, assuming that the estimator is the average of  $L$  independent, within-stratum, treatment effect estimators ([Lunceford and Davidian, 2004](#); [Tipton, 2013](#)). They propose a formula for the asymptotic variance.

### 2.D.3 Calibration Weighting

[Dong et al. \(2020\)](#) provide regularity conditions and theoretical properties of the CW and ACW estimators in terms of consistency, asymptotic normality, and inference procedures. The proof can be found in the supplementary material of [Dong et al. \(2020\)](#).

## 2.E Nested study design

The nested trial design has different impacts on the estimators expressions previously introduced, and even on the causal quantity of interest. In a nested trial design the randomized trial is embedded in a cohort (e.g. a large cohort - considered as a sample from the target population - in which eligible people are proposed to participate in the trial, but if they refuse they are still included in the cohort study). **As a consequence,  $S$  is the binary indicator for trial participation, with  $S = 1$  for participants and  $S = 0$  for non-participants.** Therefore the sampling probability of non-randomized individuals is known in nested trial designs ([Lesko et al., 2017](#); [Buchanan et al., 2018](#); [Dahabreh et al., 2021](#)). Mathematically it means that the quantity  $\mathbb{P}(S = 1)$  is identifiable. In addition, two causal quantities can be identified:  $\mathbb{E}[Y(1) - Y(0)]$  and  $\mathbb{E}[Y(1) - Y(0) | S = 0]$ . It is important to note that the second quantity can have a scientific interest in order to better understand heterogeneities within the cohort, and variables that influence the sampling selection and/or the treatment effect on the outcome.

### 2.E.1 When observational data have no outcome and treatment information

Main estimators, such as IPSW, plug-in g-formula, and doubly-robust estimators are presented for the specific case of nested trial design.

#### 2.E.1.1 IPSW

In this design the weights in the IPSW estimators are different, because the quantity  $\pi_S$  can be estimated directly from the observed data as the indicator  $S$  is observed. This allows the IPSW formula to be closer to the classic IPW expression without the need to use the odds to weight data. The IPSW expression is the following:



$$\hat{\tau}_{\text{IPSW-nested},n,m} = \frac{1}{n} \sum_{i=1}^n \frac{n}{n+m} \frac{A_i Y_i}{\hat{\pi}_{S,n,m}(X_i) e_1(X_i)} - \frac{1}{n} \sum_{i=1}^n \frac{n}{n+m} \frac{(1-A_i) Y_i}{\hat{\pi}_{S,n,m}(X_i) (1-e_1(X_i))}. \quad (2.14)$$

The normalized version is the following one:

$$\begin{aligned} \hat{\tau}_{\text{IPSW-nested norm.},n,m} &= \frac{\sum_{i=1}^n (\hat{\pi}_{S,n,m}(X_i) e_1(X_i))^{-1} A_i Y_i}{\sum_{i=1}^n (\hat{\pi}_{S,n,m}(X_i) e_1(X_i))^{-1} A_i} \\ &\quad - \frac{\sum_{i=1}^n (\hat{\pi}_{S,n,m}(X_i) (1-e_1(X_i)))^{-1} (1-A_i) Y_i}{\sum_{i=1}^n (\hat{\pi}_{S,n,m}(X_i) (1-e_1(X_i)))^{-1} (1-A_i)}. \end{aligned} \quad (2.15)$$

*Proof.*

$$\begin{aligned} \tau &= \mathbb{E}[\tau(X)] && \text{Law of total expectation} \\ &= \mathbb{E}[\tau_1(X)] && \text{Assump. 9} \\ &= \mathbb{E}\left[\frac{f(X)}{f(X|S=1)} \tau_1(X) \mid S=1\right] && \text{Assump. 10} \\ &= \mathbb{E}\left[\frac{P(S=1)}{\pi_S(X)} \tau_1(X) \mid S=1\right] && \text{Bayes law} \\ &= \mathbb{E}\left[\frac{n}{n+m} \pi_S(X_i)^{-1} \tau_1(X) \mid S=1\right] && P[S=1] = \frac{n}{n+m} \text{ in the nested design} \end{aligned}$$

□

Where  $\pi_S$  can be estimated directly using the randomized and the non randomized data.  $\tau_1$  is further derived as presented in proof 2.C.

### 2.E.1.2 G-formula

The g-formula formulation in the case of nested trial design depends on the causal quantity of interest. When the target population is the causal quantity of interest, then the identification expression is the same as in the non-nested design. But, because  $f \neq f_{|S=0}$ , the estimator's expression is slightly different:

$$\hat{\tau}_{g\text{-nested},n,m} = \frac{1}{n+m} \sum_{i=1}^{n+m} (\hat{\mu}_{1,1,n}(X_i) - \hat{\mu}_{0,1,n}(X_i)), \quad (2.16)$$

In the case where the population of interest is the non-randomized one, the identification of the causal quantity of interest is the following:

$$\mathbb{E}[Y^a \mid S=0] = \mathbb{E}[\mathbb{E}[Y \mid X, S=1, A=a] \mid S=0] = \mathbb{E}[\mu_{1,1}(X) - \mu_{0,1}(X) \mid S=0] \quad (2.17)$$

The Proof 2.E.1.2 details the calculus. And the estimator is the same as given in Definition 9 as the integration is done on the law  $f_{|S=0}$ .

*Proof.*

$$\begin{aligned} \mathbb{E}[Y(a)|S=0] &= \mathbb{E}[\mathbb{E}[Y(a) \mid X] \mid S=0] && \text{Law of total expectation} \\ &= \mathbb{E}[\mathbb{E}[Y(a) \mid X, S=1] \mid S=0] && \text{Assump. 7} \\ &= \mathbb{E}[\mathbb{E}[Y(a) \mid X, S=1, A=a] \mid S=0] && \text{Assump. 7} \\ &= \mathbb{E}[\mathbb{E}[Y \mid X, S=1, A=a] \mid S=0] && \text{Assump. 4} \end{aligned} \quad \square$$

This last quantity can be expressed as a function of the distribution of  $X$  in the non-randomized population:

$$\mathbb{E}[Y(a)] = \int \mathbb{E}[Y \mid X=x, S=1, A=a] f(x|S=0) dx$$

where  $f(X|S=0)$  denotes the density function of  $X$  in the non-randomized population.

### 2.E.1.3 Doubly-robust estimator

Similarly to the doubly-robust estimation in the non-nested case (Section 3.2.4), the g-formula and the IPSW methods can be leveraged into a doubly-robust estimator. The AIPSW expression for the nested case is the following:

$$\begin{aligned} \hat{\tau}_{\text{AIPSW-nested},n,m} = & \frac{1}{n+m} \sum_{i=1}^{n+m} \frac{S_i A_i}{\hat{\pi}_{S,n,m}(X_i) e_1(X_i)} (Y_i - \hat{\mu}_{1,1,n}(X_i)) \\ & - \frac{1}{n+m} \sum_{i=1}^{n+m} \frac{S_i (1 - A_i)}{\hat{\pi}_{S,n,m}(X_i) (1 - e_1(X_i))} (Y_i - \hat{\mu}_{0,1,n}(X_i)) \\ & + \frac{1}{m+m} \sum_{i=1}^{m+n} \{\hat{\mu}_{1,1,n}(X_i) - \hat{\mu}_{0,1,n}(X_i)\}. \end{aligned} \quad (2.18)$$

### 2.E.2 Combining treatment-effect estimates from both sources of data

Under Assumptions 4, 5 and 6 for the RCT and Assumptions 14 and 15 for the observational data, separate estimators of the ATEs from the two data sources can be constructed. [Lu et al. \(2019\)](#) considered the ATEs for the comprehensive cohort studies (CCS) which include participants who would like to be randomized, constituting the RCT, and participants who would like to choose the treatment by their preference, constituting the observational sample. In particular, they considered the ATE over the CCS study population  $\tau_2$  and the ATE over the trial population  $\tau_1$ . Note that  $\tau_2$  is different from  $\tau$  in our setting because  $\tau_2$  is defined with respect to the combined RCT and observational sample; while  $\tau$  is defined with respect to the observational sample only. In order to construct improved estimators by combining study-specific estimators, they derived the optimal influence functions for  $\tau_1$  and  $\tau_2$ , which suggest that the efficient estimators of  $\tau_1$  and  $\tau_2$  can be obtained by

$$\begin{aligned} \hat{\tau}_{1,\text{eff}} = & \frac{1}{n} \sum_{i=1}^{n+m} \left[ \frac{\hat{\pi}_S(X_i) A_i Y_i}{\hat{e}(X_i)} + \left\{ S_i - \frac{A_i \hat{\pi}_S(X_i)}{\hat{e}(X_i)} \right\} \hat{\mu}_1(X_i) \right. \\ & \left. - \frac{\hat{\pi}_S(X_i) (1 - A_i) Y_i}{1 - \hat{e}(X_i)} - \left\{ S_i - \frac{(1 - A_i) \hat{\pi}_S(X_i)}{1 - \hat{e}(X_i)} \right\} \hat{\mu}_0(X_i) \right], \end{aligned}$$

and

$$\hat{\tau}_{2,\text{eff}} = \frac{1}{n+m} \sum_{i=n}^{n+m} \frac{A_i \{Y_i - \hat{\mu}_1(X_i)\}}{\hat{e}(X_i)} - \frac{(1 - A_i) \{Y_i - \hat{\mu}_0(X_i)\}}{1 - \hat{e}(X_i)} + \{\hat{\mu}_1(X_i) - \hat{\mu}_0(X_i)\},$$

where  $\hat{e}_1(X_i)$ ,  $\hat{\mu}_{0,1}(X_i)$ , and  $\hat{\mu}_{1,1}(X_i)$  for units in the RCT are simplified as  $\hat{e}(X_i)$ ,  $\hat{\mu}_0(X_i)$ , and  $\hat{\mu}_1(X_i)$ .

### 2.E.3 Softwares: Examples of implementations

This part completes Section 6 and proposes specific examples of implementations, such as identifiability questions with the package `causaleffect`, the beta version of `causalfusion`, and implementation examples for the nested case.

#### 2.E.3.1 R package `causaleffect`

The R packages `causaleffect` ([Tikka and Karvanen, 2017](#)) and `dosearch` ([Tikka et al., 2019](#)) can be used for causal effect identification, with the later handling transportability, selection bias and missing values (bivariates) issues simultaneously. In this package, the `dosearch` function takes the observable distributions, a query, and a semi-Markovian causal graph as the input and outputs a formula for the query over the input distributions, or decides that it is not identifiable. It is based on a search algorithm that directly applies the rules of do-calculus. Their general identification procedure is not necessary complete given an arbitrary query and an arbitrary set of input distributions. In order to retrieve the backdoor criterion in theorem 4, one can write:

```

1 data <- "P(Y, X,Z)"
2 query <- "P(Y|do(X))"
3 graph <- "X -> Y
4           Z -> X
5           Z -> Y"
6 dosearch(data, query, graph)

1 $identifiable
2 [1] TRUE
3 $formula
4 [1] "[sum_{Z} [p(Z)*p(Y|X,Z)]]"

```

### 2.E.3.2 Beta version of causalfusion

The beta version of causal fusion ([Bareinboim and Pearl, 2016](#)) can be used, with a user-friendly interface requiring no coding skills. For example, if uploading the selection diagrams from Figure 2.3 onto this interface, it will state that diagram (a) is not transportable, while (b) is transportable along with the correct transport formula. The authors also propose to load their diagrams from previous publications and research works, some of which have been discussed in this review.

### 2.E.3.3 IPSW for the nested case

The IPSW estimator can be implemented using the available code from [Dahabreh et al. \(2019\)](#). It requires as input a `data.frame` (here called `study`) which columns represent treatment, denoted by  $A$  (binary), the RCT indicator, denoted as  $S$  (binary), the outcome as  $Y$  (continuous), and the quantitative covariates. The current available code for 3 quantitative covariates denoted  $X_1, X_2, X_3$  is presented below. A first function `generate_weights()` estimates the sampling propensity score and the propensity score as logistic regressions, and compute the according weights to each data point. The variance is estimated with the `geex` library ([Saul and Hudgens, 2020](#)) through the `m_estimate` function which computes the empirical sandwich variance estimator.

```

1 # Compute selection score model and propensity score in the trial (logit)
2 weights <- generate_weights(Smod = S~X1+X2+X3, Amod = A~X1+X2+X3, study)
3
4 # Use these scores to compute IPSW
5 IOW1 <- IOW1_est(data = weights$dat)
6
7 # Compute the empirical sandwich variance
8 param_start_IOW1 <- c(coef(weights$$Smod) , coef(weights$Amod),
9                       m1 = IOW1$IOW1_1, m0 = IOW1$IOW1_0, ate = IOW1$IOW1)
10 IOW1_mest <- m_estimate( estFUN = IOW1_EE, data = study,
11 root_control = setup_root_control(start = param_start_IOW1))
12
13 # Format the output
14 IOW1_ate <- extractEST(geex_output = IOW1_mest,
15 est_name ="ate",
16 param_start = param_start_IOW1)

```

The output is:

```

1 print(IOW1_ate)
2 >   ate      SE
3 > -0.16961 0.02751

```

### 2.E.3.4 G-formula for the nested case

The G-formula can also be implemented in the nested design using the available code from [Dahabreh et al. \(2019\)](#). It takes a similar entry as the IPSW previously presented. The variance is estimated with the `geex` library ([Saul and Hudgens, 2020](#)) through the `m_estimate` function which computes the empirical sandwich variance estimator.

```

1 # Linear regression cond. outcome mean as a function of covariates on the RCT
2 # Compute ATE on the observational data
3 OM <- OM_est(data = study)
4
5 # Compute the empirical sandwich variance
6 param_start_OM <- c(coef(OM$OM1mod), coef(OM$OM0mod),
7                     m1=OM$OM_1, m0=OM$OM_0, ate=OM$OM)
8 OM_mest <- m_estimate( estFUN = OM_EE, data = study,
9                       root_control = setup_root_control(start = param_start_OM))
10
11 # Format the output
12 OM_ate <- extractEST(geex_output = OM_mest, est_name = "ate",
13 param_start = param_start_OM)

```

The output is:

```

1 >   ate      SE
2 > -0.1934  0.0300

```

## 2.F Additional information on the SCM framework

### 2.F.1 Notations and Assumptions

This supplementary introduction aims to provide an introduction to the whole SCM framework, and introduce the graphical representation, along with the do-calculus concepts and notations.


**Structural Causal Models.** Formally (Pearl, 2009b, p.203), an SCM is a 4-tuple  $M = (U, V, F, P)$  where:

1.  $U$  is a set of *background* or *exogenous* variables, which are not explicitly modeled but which can affect relationships within the model.
2.  $V = \{V_1, \dots, V_n\}$  is a set of *endogenous* variables, that are deterministically determined by variables in  $U \cup V$ ; in the setting of this paper, one typically chooses  $V = \{X, A, Y\}$  or  $V = \{X, A, Y, S\}$  to respectively model covariates, treatment, outcome and selection.
3.  $F$  is a set of functions  $\{f_1, \dots, f_n\}$  such that each  $f_i$  uniquely determines the value of  $V_i \in V$  by the so-called *structural equation*  $v_i = f(pa_i, u_i)$ , where  $PA_i \subset V \setminus \{V_i\}$  are called the *parents* of  $V_i$  and  $U_i \subset U$ .
4.  $P$  is a probability distribution for  $U$ .

The *causal diagram* corresponding to an SCM is a graph with  $V$  as vertices, directed edges from each parent to its children, and undirected dotted edges between vertices  $V_i$  and  $V_j$  such that  $U_i \cap U_j \neq \emptyset$ . Alternatively, the  $U$  can be explicitly represented, with directed dotted edges from  $U_i$  to  $V_i$ , as in Figure 2.10 which represents the SCM with  $V = (X, A, Y)$ ,  $U = (U_x, U_a, U_y)$ , and structural equations:

$$\begin{aligned}
 x &\leftarrow f_x(u_x) \\
 a &\leftarrow f_a(x, u_a), \\
 y &\leftarrow f_y(a, x, u_y).
 \end{aligned}$$

Often, no parametric assumptions is made on the function  $F$  or the distribution  $\mathbb{P}[U]$ . The distribution  $P(U)$  induces a distribution  $P_M(V)$  through  $V = F(U)$ , and in the case where the causal diagram is a directed acyclic graph and variables in  $U$  are independent, then the distribution  $P_M(V)$  is a Bayesian network. In particular, the causal diagram encodes the conditional independence relationships among variables in  $V$ .



**Figure 2.10:** Left: (a) example of an SCM  $M$  and corresponding DAG; right: (b) Post-intervention graph of  $M$  for  $do(A = a_0)$ .

**Interventions.** At the core of the SCM framework is the *do-operator* which enables the use of structural equations to represent causal effects and counterfactuals. The  $do(A = a_0)$  operation marks the replacements of the mechanism  $f_a$  with a constant  $a_0$ , while keeping the rest of the model unchanged, resulting in the following post-treatment model for our toy example:

$$\begin{aligned} x &\leftarrow f_x(u_x) \\ a &\leftarrow a_0 \\ y &\leftarrow f_y(a, x, u_y) \end{aligned}$$

In the causal graph, this corresponds to deleting all incoming arrows in  $A$  (Figure 2.10(b)). We denote  $Q = \mathbb{P}[Y \mid do(A = a_0)]$  the post-intervention distribution, i.e., the distribution of a random variable  $Y$  after a manipulation on  $A$ . From this distribution, the ATE can be written as:

$$\begin{aligned} \tau &= \mathbb{E}[Y \mid do(A = a_1)] - \mathbb{E}[Y \mid do(A = a_0)] \\ &= \sum_y y (\mathbb{P}[(Y = y \mid do(A = a_1))] - \mathbb{P}[Y = y \mid do(A = a_0)]). \end{aligned}$$

Note that the post-intervention distribution can also be denoted in counterfactual notation as

$$\mathbb{P}[Y = y \mid do(A = a)] = \mathbb{P}[Y(a) = y].$$


The distinction between  $\mathbb{P}[Y \mid A = a]$  and  $\mathbb{P}[Y \mid do(a)]$  corresponds in the PO framework to the difference between  $\mathbb{P}[Y \mid A = a]$  and  $\mathbb{P}[Y(a)]$ .

**D-separation.** Conditional independences between variables can be read from the DAG induced by an SCM using a graphical criterion known as *d-separation*. This criterion will be useful in identifying the causal effect.

**Definition 13** (d-separation). *A set  $X$  of nodes is said to block a path  $p$  if either*

- *$p$  contains at least one arrow-emitting node that is in  $X$ , or*
- *$p$  contains at least one collision node that is outside  $X$  and has no descendant in  $X$ .*

If  $X$  blocks all paths from set  $A$  to set  $Y$ , it is said to “d-separate  $A$  and  $Y$ ” and then it can be shown that  $A \perp\!\!\!\perp Y \mid X$ . As an illustration, let us consider a path with  $A \rightarrow D \leftarrow B \rightarrow C$ . Since  $B$  emits arrows on that path, it blocks the path between  $A$  and  $C$ , and  $A \perp\!\!\!\perp C \mid B$ .  $D$  is a collider (two arrows incoming) and consequently it blocks the path without conditioning  $A \perp\!\!\!\perp C$ ; but conditioning on  $D$  would open the path and thus would imply that  $A \not\perp\!\!\!\perp C \mid D$ . Furthermore, in the SCM framework it is generally assumed that *faithfulness* holds, i.e., that all conditional independences are encoded in the graph, allowing to infer dependencies from the graph structure (Peters et al., 2017). In other words, if the Global Markov property (i.e., *d-separation* implies conditional independence), and faithfulness hold, then the resulting equivalence between conditional independences and *d-separation* allows to move back and forth between the graphical and the probabilistic model.



**Figure 2.11: Application of the backdoor criterion in large graphs:** Based on the admissible set definition 15, eq. 2.19 present all the following sets that are admissible and can be used for adjustment. For example, the set  $\{W_2, W_3\}$  blocks all backdoor paths between  $A$  and  $Y$ .  $W_2$  block the path  $A \leftarrow W_2 \rightarrow W_3 \rightarrow W_5 \rightarrow Y$ .

**Identifiability.** We are interested in answering the *identifiability* question: *can the post-intervention distribution  $Q$  be estimated using observed data (such as pre-intervention distribution)?*

**Definition 14** (identifiability). *A causal query  $Q$  is identifiable from distribution  $P(y)$  compatible with a causal graph  $G$ , if for any two (fully specified) models  $M_1$  and  $M_2$  that satisfy the assumptions in  $G$ , we have*

$$\mathbb{P}_1[V] = \mathbb{P}_2[V] \implies Q(M_1) = Q(M_2).$$

Specifically, if a causal query  $Q$  in the form of a *do*-expression can be *reduced* to an expression no longer containing the *do*-operator (i.e, containing only estimable expressions using nonexperimental, observed data) by iteratively applying the inference rules of *do-calculus*, then  $Q$  is identifiable. The language of *do-calculus* is proved to be *complete* for queries in the form  $Q = \mathbb{P}[Y = y \mid do(A = a), X = x]$  meaning that if no reduction can be obtained using these rules,  $Q$  is not identifiable.

The application of previous rules and the backdoor criterion in the graph of Figure 2.11 allows to list all possible admissible adjustment sets for identifying  $P(y \mid do(a))$ :

$$X = \{W_2\}, \{W_2, W_3\}, \{W_2, W_4\}, \{W_3, W_4\}, \{W_2, W_3, W_4\}, \{W_2, W_5\}, \{W_2, W_3, W_5\}, \\ \{W_4, W_5\}, \{W_2, W_4, W_5\}, \{W_3, W_4, W_5\}, \{W_2, W_3, W_4, W_5\} \quad (2.19)$$

The analyst can select from this list which is preferable. Note that conditioning on  $W_1$  would induce bias as it is a collider.

### 2.F.1.1 Confounding bias

In order to estimate the causal effect  $\mathbb{P}[Y \mid do(A = a)]$  using only available observational data, following the observational distribution  $P(A, X, Y)$ , the idea is to identify—on the basis of the causal graph—a set of *admissible variables* such that measuring and adjusting for these variables removes any bias due to confounding. The *backdoor criterion* defined below provides a graphical method for selecting admissible sets for adjustment.

**Definition 15** (Admissible sets - the backdoor criterion). *Given an ordered pair of treatment and outcome variables  $(A, Y)$  in a causal DAG  $G$ , a set  $X$  is backdoor admissible if it blocks every path between  $A$  and  $Y$  in the graph  $G_{\underline{A}}$ , with  $G_{\underline{A}}$  the graph that is obtained when all edges emitted by node  $A$  are deleted in  $G$ .*

The backdoor criterion can be seen as the counterpart of unconfoundedness in Assumption 14: If a set  $X$  of variables satisfies the backdoor condition relative to  $(A, Y)$ , then  $Y(a) \perp\!\!\!\perp A \mid X$ . Identifying backdoor admissible variables is important because it allows to estimate causal effects from observational data as follows:


**Theorem 4** (Backdoor adjustment criterion). *If a set of variables satisfies the backdoor criterion relative to  $(A, Y)$ , the causal effect of  $A$  on  $Y$  can be identified from observational data by the adjustment formula:*

$$\mathbb{P}[Y = y \mid do(A = a)] = \sum_x \mathbb{P}[Y = y \mid A = a, X = x] \mathbb{P}[X = x] .$$

The adjustment formula can be seen as part of the identifiability formula in Equation 2.12.

The backdoor criterion is one of the graphical methods for identifying admissible sets. In cases where it is not applicable, an extended definition called the *frontdoor criterion* can be applied using mediators in the graph.


Figure 2.12 provides a summary of the identifiability conditions when the available data is either observational data or data from surrogate experiments.



**Figure 2.12: Summary of identifiability results to control for confounding bias:** If there exists a set of observed variables that satisfies the backdoor criterion, then the causal effect of  $A$  on  $Y$  can be identified using nonexperimental data alone. In the case where no set of observed variables satisfies the backdoor condition but the effect of  $A$  can be mediated by an observed variable  $M$  (mediator), if there exists a set of observed variables that satisfies the frontdoor criterion, then the causal effect is also identifiable from observational data alone. If none of these conditions holds, the query is not identifiable. If, in addition to observational data, RCTs through surrogate experiments are available, the  $z$ -identifiability condition is sufficient to determine if the query is identifiable or not.

### 2.F.1.2 Sample selection bias

To tackle sample selection bias, i.e., preferential selection of units, the authors consider an indicator variable  $S$  such that  $S = 1$  identifies units in the sample. The data at hand can be seen as  $\mathbb{P}[A, Y, X \mid S = 1]$  and the target is  $\mathbb{P}[Y \mid do(A = a)]$ .



**Figure 2.13: Cases with sample selection bias:**  $A$  is the treatment and  $Y$  the outcome,  $S$  is the selection process and the aim is to estimate  $P(y \mid do(a))$  when data available come from  $\mathbb{P}[a, y \mid S = 1]$  in (a) and (b).

Figure 2.13 (b) presents a case where the selection process is  $d$ -separated (definition in Appendix 2.F) from  $Y$  by  $A$ , then  $\mathbb{P}[Y \mid A] = \mathbb{P}[Y \mid A, S = 1]$ ; since  $A$  and  $Y$  are unconfounded,  $\mathbb{P}[A \mid do(A)] =$



$\mathbb{P}[Y | A]$  so that the experimental distribution is recoverable from observed data. This is not the case for Figure 2.13 (a) without further assumptions. When both confounding bias and selection bias are present in the data (Figure 2.13 (c)), the graphical framework can help selecting among the list of adjustment sets,  $\{W_1, W_2\}$ ,  $\{W_1, W_2, X\}$ ,  $\{W_1, X\}$ ,  $\{W_2, X\}$ , and  $X$ , (these sets control for confounding), the one that can be used as available from biased data; here it will be  $X$  as it is the only one separated from  $S$ , leading to  $\mathbb{P}[Y | do(A)] = \sum_x \mathbb{P}[Y | A, X, S = 1] \mathbb{P}[X | S = 1]$ . This ability to select relevant covariates for identifiability is presented as an important advantage of the SCM framework.

**Combined biased and unbiased data.** Note that the previous examples in Figure 2.13 concern only one set of data but the approach is extended to combine data, biased (with a selection) data, and unbiased data (for example covariates from the target population) as follows. To do so, [Bareinboim and Pearl \(2016\)](#) define the  **$S$ -backdoor admissible criterion** which is a sufficient condition but not necessary. It states that if  $X$  is backdoor admissible,  $A$  and  $X$  block all paths between  $S$  and  $Y$ , i.e.  $Y \perp\!\!\!\perp S | A, X$ , and that  $X$  is measured in both population-level data and biased data, then, the causal effect can be identified as

$$\mathbb{P}[Y | do(A = a)] = \sum_x \mathbb{P}[Y | do(A = a), X = x, S = 1] \mathbb{P}[X = x],$$

where  $\mathbb{P}[X = x]$  denotes the probability in the target population. If the set  $X$  contains post-treatment covariates, then this formula is generally wrong. Indeed  $S$ -ignorability is rarely satisfied in that case, as illustrated with several examples by [Pearl \(2015\)](#). This formula is called the post-stratification formula, to define this action of re-calibrate or re-weight ([Pearl, 2015](#)). This expression shows that one can generalize what is observed on the selected sample by reweighting or recalibrating by  $\mathbb{P}[X = x]$  that is available from the target population (unbiased data). More complex setting can be handled, such as dealing with post-treatment variables. In such a case, they show that generalizability can be obtained by another weighting strategy (not by  $\mathbb{P}[X = x]$ ), which can also be seen as a benefit of this framework.

## 2.F.2 Proof of the transport formula (2.6)

We compute:

$$\begin{aligned} \mathbb{P}[Y | do(A = a)] &= \sum_x \mathbb{P}[Y | do(A = a), X = x] \mathbb{P}[X = x | do(A = a)] \\ &= \sum_x \mathbb{P}[Y | do(A = a), X = x, S = 1] \mathbb{P}[X = x | do(A = a)] \\ &= \sum_x \mathbb{P}[Y | do(A = a), X = x, S = 1] \mathbb{P}[X = x], \end{aligned}$$

where the first equation follows by conditioning, the second one by  $S$ -admissibility assumption of  $X$ , and the third one from the fact  $X$  are pre-treatment variables.


## 2.G Additional simulation results

This section follows Section 6.2 and provides additional results for the simulations.

### 2.G.1 Distributional shift between RCT and observational samples

The simulation design proposed simulates a situation where the RCT data reveals a distributional shift with the observational sample. In the RCT all the covariates tend to have lower values than in the observational sample. Still, the overlap assumption (Assumption 10) is valid as each observation in the target sample has a non-zero probability to be included in the experimental sample. Summary statistics obtained for a simulation with  $\sim 1000$  observations in the RCT and 10 000 observations in

	Observational (N=10000)	RCT (N=1023)	Total (N=11023)
<b>X1</b>			
Mean (SD)	1.01 (0.996)	0.552 (0.980)	0.968 (1.00)
Median [Min, Max]	1.01 [-2.84, 4.43]	0.535 [-2.51, 3.62]	0.972 [-2.84, 4.43]
<b>X2</b>			
Mean (SD)	1.00 (0.984)	0.652 (0.991)	0.970 (0.990)
Median [Min, Max]	0.996 [-2.48, 5.02]	0.679 [-2.81, 3.49]	0.963 [-2.81, 5.02]
<b>X3</b>			
Mean (SD)	1.00 (1.01)	0.485 (1.02)	0.954 (1.02)
Median [Min, Max]	1.01 [-2.91, 5.05]	0.468 [-2.32, 3.88]	0.961 [-2.91, 5.05]
<b>X4</b>			
Mean (SD)	0.991 (1.00)	0.616 (1.01)	0.956 (1.01)
Median [Min, Max]	0.988 [-2.77, 4.94]	0.615 [-2.14, 4.17]	0.960 [-2.77, 4.94]



**Figure 2.14: Covariates distributions differences** between experimental sample and observational sample when simulating according to eq.3.7 as detailed in Section 6.2 (left), with a focus on the  $X_1$  distributional shift with histograms overlap for the two samples (right).

the observational sample is given on Figure 2.14, in addition with an histogram illustrating overlaps and the distributional shift for the covariate  $X_1$ .

The sampling propensity score model used to generate the simulated data eq. 3.7 implies a weak covariate shift between the RCT sample and the observational sample. A stronger shift can be obtained, at least on covariate  $X_1$ , swapping the coefficient  $-0.5X_1$  with  $-1.5X_1$ . Figure 2.15 shows that the variance of the weighted and CW estimators have increased in the setting with a stronger covariate shift.



## 2.G.2 Stratification

Within the weighted estimators, the stratification estimator (Section 3.2.1) supposes to choose an additional parameter being the number of strata used. Simulations are launched with the number of strata varying from 3 to 15, and the results are presented on Figure 2.16. We observed that the number of strata has an impact on the results, the higher the number of strata used, the better the prediction.

## 2.G.3 Impact of a hidden treatment effect modifier


In this part, we consider a heterogeneous treatment effect setting where  $X_1$  impacts the RCT sampling while also being a treatment effect modifier. We consider the IPSW estimator and its variations without using  $X_1$  (labeled as IPSW.without.X1) and using only  $X_1$  (labeled as IPSW.X1). As shown in Figure 2.17, IPSW.X1 is still unbiased when using only  $X_1$  in the sampling propensity score estimation, as it is the only covariate being the shifted treatment effect modifier. However, if  $X_1$  is missing, the resulting estimator IPSW.without.X1 is strongly biased. Therefore, by including all variables that affect both sampling and outcome one can ensure identifiability. A recent work suggests to add non-shifted treatment effect modifier for precision (Colnet et al., 2022b).

Note also that if the treatment effect were homogeneous (does not depend on  $X_1$ ), then the estimated ATE on the RCT would be unbiased (as shown Figure 2.18 in the section below, Section 2.G.4) so in this setting there is no need to use the observational data and associated methods to transport the ATE from the trial to the target population as the causal effect investigated is on the absolute different scale.




**Figure 2.15: Weak versus strong distributional shift between experimental and observational data with estimated ATE when RCT is weakly or strongly shifted from the target population distribution.** Estimators used being IPSW (IPSW and IPSW.norm; Def. 7), stratification (with 10 strata; Def. 8), g-formula (Def. 9), calibration weighting (CW; Def. 10), augmented IPSW (AIPSW; Def. 21), and ACW (Def. 12) over 100 simulations.

**Figure 2.16: Effect of strata number** Estimated ATE obtained while varying the number of strata  $L \in \{3, 5, 7, 9, 11, 13, 15\}$  with 100 repetitions each time. All others simulation parameters being the same as the standard case described in 6.2 and in Figure 2.5.



**Figure 2.17: Impact of the treatment-effect modifiers** Estimated ATE when IPSW estimator includes all covariates, only  $X_1$ , or all covariates except  $X_1$  (IPSW; Section 3.2.1), with g-formula (Section 3.2.2) presented as a control, over 100 simulations. Simulations are still performed with eq. 3.7 for RCT eligibility and eq. 3.8 for outcome modeling.




### 2.G.4 Homogeneous treatment effect

It is always interesting to note that in the case of an homogeneous treatment effect the RCT sample contains all the information to estimate the population ATE, in other words  $\tau_1$  is a consistent estimator of the ATE. We performed simulation with an homogeneous treatment effect (results are presented on Figure eq. 2.18) such as:

$$Y(a) | X = -100 + X_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + 27.4a + \epsilon$$

**Figure 2.18: Homogeneous treatment effect** Estimated ATE with a homogeneous treatment effect  $Y(a) | X = -100 + X_1 + 13.7X_2 + 13.7X_3 + 13.7X_4 + 27.4a + \epsilon$ . All others simulation parameters being the same as the standard case described in eq. 6.2 and in Figure 2.5.




## 2.H Supplementary information on Traumabase and CRASH-3

### 2.H.1 Additional information on the Traumabase

#### 2.H.1.1 Missing values

The problem of missing values is ubiquitous in data analysis practice and particularly present in observational data, as they are not necessarily collected for research purposes. The Traumabase is a high-quality data set but, nevertheless, missing values occur. Figure 2.19 represents the percentage of missing values for the covariates selected by the medical doctors from the Traumabase. It varies from 0 to nearly 60% for some features. In addition, there are different codes for missing values giving hints on the reason of their occurrence, e.g., not available (NA), impossible (imp), not made (NM), etc. Some of these values can be seen as missing completely at random (MCAR), e.g., the information has not been recorded simply because the form was not filled out, but they can be informative and missing not at random (MNAR), e.g., when the state of the patient is such that it was impossible to take a measurement.




**Figure 2.19: Percentage of missing values for a subset of Traumabase variables** relevant for traumatic brain injury. Different encodings of missing values are available such as: *NA* (not available), but also *not informed*, *not made*, *not applicable*, *impossible*.

There is an abundant literature available on how to deal with missing values in a general context and Mayer et al. (2019) identify more than 150 R (R Core Team, 2021) packages available on the topic. Missing values add a layer of complexity to conducting causal analyses as they require coupling conventional hypotheses of causal effect identifiability in the complete case with hypotheses about the mechanism that generated the missing data (Rubin, 1976), or defining new hypotheses, to establish conditions of causal effect identifiability with missing data. Mayer et al. (2020) survey available works, classify the methods in three families that differ with respect to the different assumptions and provide associated estimators to estimate the ATE from an observational data set with missing values in the covariates. More precisely, they advocate the use of multiple imputation (van Buuren, 2018) by IPW or doubly robust estimators when missing values can be considered to be missing (completely) at random (M(C)AR) and the classical unconfoundedness assumption (Assump. 14) holds (Seaman and White, 2014). As an alternative, they recommend using a doubly robust estimator adapted to missing values.

More specifically an estimator that makes use of random forests with a missing incorporate in attributes splitting criterion (Twala et al., 2008; Josse et al., 2019) to estimate the generalized propensity scores (Rosenbaum and Rubin, 1984) and the regression function with missing values<sup>12</sup>; this approach does not require a particular missing values mechanism but an adapted unconfoundedness hypothesis with missing data. Finally, when covariates can be seen as noisy incomplete proxies of true confounders, latent variable models can be a solution to estimate causal effect with missing values (Kallus et al., 2018; Louizos et al., 2017). Note that for the generalization task, IPSW weights are also computed after imputation in Susukida et al. (2016).

### 2.H.1.2 Covariate adjustment

Since the Traumabase is an observational registry, straightforward treatment effect estimation on these data is not possible due to confounding. The causal graph in Figure 2.20 is the result of a two-stage Delphi method (Linstone and Turoff, 1975) in which six anesthetists and resuscitators specialized in critical care—and therefore familiar with the allocation process for TXA—first select covariates related to either treatment or outcome or both, and second classify these covariates into confounders and predictors of only outcome. Even though it is not possible to test for unobserved confounding, this Delphi procedure is an attempt to gather as much expert knowledge about the studied question as possible to manually identify possible confounders and qualitatively assess the plausibility of the unconfoundedness assumption. Note that this approach is an explicit example where we leverage the advantages of the SCM and PO frameworks: the causal graph helps to select relevant variables during the conception phase of the study and to assess identifiability of the target estimand, and the treatment effect analysis uses different estimation methods from the PO framework.



**Figure 2.20: Causal graph** representing treatment, outcome, confounders and other predictors of outcome (Figure generated using DAGitty (Textor et al., 2011); NAs indicates variables that have missing values).

<sup>12</sup>This doubly robust method is implemented in the R package grf (Athey et al., 2019).

## 2.H.2 Common covariates description between CRASH-3 and Traumabase

In the following, we discuss definitions of common variables, outcome, treatment, and designs in order to leverage both sources of information. We recall the causal question of interest: “What is the effect of the TXA on head-injury related death in patients suffering from TBI?” This part is important for the alignment of the study protocol.

**Treatment exposure.** The treatment protocol of CRASH-3 precisely frames the timing and mean of administration (a first dose given by intravenous injection shortly after randomization, i.e., within 3 hours of the accident, and a maintenance dose given afterwards (Dewan et al., 2012)). For consistency with the original CRASH-3 study described above, we also only keep observations from the RCT with administration within 3 hours. The Traumabase study being a retrospective analysis, this level of granularity concerning TXA is not available. Neither the exact timing, nor the type of administration are specified for patients who received the drug. However, the expert committee agreed that the assumption of treatment within 3 hours of the accident is plausible since this drug is administered in pre-hospital phase or within the first 30 minutes at the hospital.

**Outcome of interest.** The CRASH-3 trial defines its primary outcome as head injury related death in hospital within 28 days of injury. For the Traumabase data we also look at death in hospital within 28 days but with a wider range of possible causes of death, namely TBI, brain death, multiple organ failure, brain death, or withdrawal of life-sustaining therapy.

**Multi-centered design.** Both studies are multi-centered, but while the Traumabase is a French registry with over 20 participating Trauma Centers, the CRASH-3 trial enrolled patients in various countries on different continents. This large spectrum of participating centers is likely to contribute to external validity of the CRASH-3 trial, it should nevertheless be noted that more than 65% of the patients included are from developing countries; regions of the world that differ from developed countries by a prolonged pre-hospital care period, limited access to brain imaging tests and neurosurgery within short periods of time, and the absence of expert centers for major trauma and neuro-intensive care. Thus, on top of the restrictive inclusion criteria of the RCT, this aspect of large heterogeneity in the participating Trauma centers motivates the combination of both studies to estimate the effect for a population with access to a specific high level of care, here represented by the French Trauma centers.

**Covariates accounting for trial eligibility.** In total, four criteria depending on five variables determined inclusion in the CRASH-3 trial: age (only adults were eligible), presence of TBI (defined as presence of intracranial bleeding on the CT scan, or a GCS of less than 13 in the case of no available CT scan), absence of major extracranial bleeding (defined explicitly in CRASH-3 and defined via the number of packed red blood cells transfused in the first 6 hours of admission or by colloid injection in the Traumabase), and delay of less than 8 hours (later reduced to 3 hours) between the injury and the randomization. The necessary variables are also available in the Traumabase, either exactly or in form of close proxies, which allows the estimation of the trial inclusion model on the combined data.

**Additional covariates.** Note that other covariates are available in both data sets, while not directly related to trial inclusion according to CRASH-3 investigators. But as they could be covariates moderating the treatment effect, we include them. According to the two studies, we can add three of them: sex (binary), systolic blood pressure (continuous), and pupils reactivity (categorical, ranging from 0 to 2, being the number of active pupils). Note that these three covariates are all mentioned as baselines for the CRASH3 study (CRASH-3, 2019), where the authors argue that they are likely to impact the outcome.



### 2.H.3 Additional analysis

This part proposes additional analysis to the data analysis part (Section 7). We first propose additional visualization of the distributional shift between CRASH-3 and the Traumabase, then we present a principal component analysis of the combined database. Propensity scores obtained either with the logistic regression or the forest are analyzed with histograms and scatter plots. Finally, a focus on the different patients strata, based on the severity of the injury, is presented.

#### 2.H.3.1 Distributional shift between CRASH-3 and Traumabase

Distributional shift between CRASH-3 and the Traumabase data can be illustrated with histograms. Figures 2.21 – 2.25 presents the empirical distribution shift between the Traumabase and CRASH-3 for age, Glasgow score, systolic blood pressure, sex and pupils reactivity (respectively). Differences can be observed, and for example the fact that the CRASH-3 study contains more young patients, while the Traumabase contains more moderate case (corresponding to a high Glasgow score). It is interesting to notice that the overlaps assumption seems to hold in our situation.




Figure 2.21: Distributional shift of Age between the Traumabase and the CRASH-3 studies.




Figure 2.22: Distributional shift of the Glasgow score between the Traumabase and the CRASH-3 studies.




Figure 2.23: Distributional shift of the systolic blood pressure between the Traumabase and the CRASH-3 studies.




Figure 2.24: Distributional shift of the sex between the Traumabase and the CRASH-3 studies.





Figure 2.25: Distributional shift of the pupils reactivity between the Traumabase and the CRASH-3 studies.

### 2.H.3.2 Principal component analysis

A principal component analysis is performed on the combined data set for the Traumabase and the CRASH-3 data using the FactoMineR package (Lê et al., 2008), results are presented on Figure 2.26. As expected the Glasgow coma scale score and the pupils reactivity are related (paralysis of the cranial

nerves leading to pupillary anomalies being closely related to the presence of an intracranial lesion, itself linked to the state of consciousness encoded in the Glasgow.). Additionally, the link between age and systolic blood pressure can be explained by the fact that atherosclerosis of the arteries is the source of an increase in blood pressure and is related to age.



**Figure 2.26:** PCA of the data set combining CRASH-3 and Traumabase data.

### 2.H.3.3 Conditional odds

The conditional odds obtained while performing the generalization from the CRASH-3 patients to the observational data are presented on Figures 2.27 (logistic regression) and 2.28 (forest). We observe that extreme coefficient values are obtained, and that the forest `grf` strengthens this trend. We can further investigate the differences in between the two methods to infer the propensity scores noticing that the forest method uses the NAs from the Traumabase to learn the propensity scores model. Figure 2.29 shows that the NAs present in the systolic blood pressure covariate are used by the random forest to predict  $S$ , leading to more extreme values at the end. This importance of different missing values patterns when combining two data sets are of importance and highlight the need for a better understanding of the impact of missing values in the present framework.

## 2.H.4 Evidence on other patient strata

The data analysis part only focuses on all the patients from the two studies CRASH-3 and Traumabase. This part proposes a focus on different patients type, based on the severity of the brain trauma (measured either with the Glasgow score or the pupils reactivity).

### 2.H.4.1 Traumabase: evidence on different strata

When stratifying along different criteria of severity as in the CRASH-3 study, namely pupil reactivity and the Glasgow Coma Scale as illustrated in Table 2.7 with Mild/moderate and Severe strata, the two studies provide different evidence: no average treatment effect in any of the strata for the Traumabase, while the CRASH-3 study finds a beneficial effect for mild forms of TBI.




Figure 2.27: Conditional odds histogram (glm) obtained with the `misaem` R package.





Figure 2.28: Conditional odds histogram (grf) obtained with random forests.

#### 2.H.4.2 CRASH-3: evidence on different strata

The CRASH-3 trial presents a significant treatment effect only on some strata (in particular on less severe injured patients). As the brain-injury gravity has an effect on the outcome—most patients with TBI with a GCS score of 3 (corresponding to a coma or unconsciousness state) and those with bilateral non-reactive pupils have a very poor prognosis regardless of treatment—, the treatment effect is likely to be biased towards the null. Therefore the CRASH-3 authors observe the maximal treatment effect and statistical strength on mild to moderate injured patients, which is what we retrieve from the data. This evidence is computed from the data, with a link between the risk ratio (RR) and the average treatment effect (ATE) on Table 2.8.



**Figure 2.29:** Scatter plot of the two conditional odds obtained with `glm` in x-axis and `grf` in the y-axis. Color is set according to the systolic blood pressure covariate values (while missing values are in grey).

**Table 2.7:** ATE estimations from the Traumabase for TBI-related 28-day mortality. Red cells conclude on deteriorating effect, white cells conclude on no effect.

	Multiple imputation (MICE)				MIA		Unad-justed ATE $\times 10^2$
	IPW (95% CI) $\times 10^2$		AIPW (95% CI) $\times 10^2$		IPW (95% CI) $\times 10^2$	AIPW (95% CI) $\times 10^2$	
	GLM	GRF	GLM	GRF			
Total ( $n = 8248$ )	15 (6.8, 23)	11 (6.0, 16)	3.4 (-9.0, 16)	-0.1 (-4.7, 4.4)	9.3 (4.0, 15)	-0.4 (-5.2, 4.4)	16
Mild/moderate ( $GCS > 8$ , $n = 5228$ )	17 (-7.9, 42)	11 (3.3,18)	15 (-47, 77)	2.1 (-8.5, 13)	6.8 (2.6, 11)	-0.1 (-4.9, 4.7)	8.7
Severe ( $GCS \leq 8$ , $n = 2855$ )	10 (-7.0, 27)	7.7 (-6.6, 22)	2.2 (-14, 18)	-1.3 (-14, 11)	7.1 (-1.0, 15)	-0.3 (-4.6, 4.0)	9.5

**Table 2.8:** Results reproduction for CRASH-3, with four possible stratifications based on the gravity level of the injury. Results are both presented as risk ratio (in accordance with CRASH-3 (2019)) and as ATE (in accordance with our framework, Section 2.1).

	Relative risk		Average Treatment Effect	
	RR	95% CI	ATE	95% CI
Total (within 3 hours)	0.94	(0.855, 1.02)	-0.12	(-0.28, 0.004)
$GCS > 3$ or at least 1 pupil reacts	0.90	(0.78, 1.01)	-0.02	(-0.03, 0.0005)
Mild/moderate ( $GCS > 8$ )	0.78	(0.59, 0.98)	-0.2	(-0.03, -0.003)
Severe ( $GCS \leq 8$ )	0.99	(0.91, 1.07)	-0.004	(-0.04, 0.03)
Both pupils react	0.87	(0.74, 1.00)	-0.015	(-0.03, -0.001)


### 2.H.4.3 Generalizing treatment effect on patient strata

As found by the CRASH-3 study, the group with potential benefit from TXA seems to be mild to moderate TBI patients (Table 2.1), defined as patients with a Glasgow Coma Scale between 9 and 15, while the evidence obtained from the Traumabase has not found a significant treatment effect for this group. However, in this stratum, for the CRASH-3 study, none of the patients has major extracranial bleeding, leading to a constant variable for this group. Conversely, in the Traumabase, in this stratum,

**Table 2.9: Sample sizes of both studies** and different strata along the Glasgow Coma Scale. #maj.Ex corresponds to the number of patients with a major extracranial bleeding.

	Traumabase				CRASH-3			
	m	#treated	#death	#maj.Ex	n	#treated	#death	#maj.Ex
Total (within 3 hours)	8248	683	1411	5583	9168	4632	1745	5
Mild/moderate ( $GCS > 8$ )	5456	535	527	3392	5844	3075	600	0
Severe ( $GCS \leq 8$ )	3083	596	1322	2224	3717	1985	1601	5

only four patients without major extracranial bleeding are treated (while 1867 are not treated with TXA). Since the practitioners are interested in the treatment effect transported on patients with mild to moderate TBI and with major extracranial bleeding, we cannot restrict the target population to those patients without major extracranial bleeding. The current methodology does not allow to satisfy the necessary assumptions for transporting the effect using the presented estimation strategies and defining a clinically relevant target population. Further methodological investigations are required to transport the effect on the stratified subpopulations (see Table 2.9 for the corresponding sample sizes). This issue does not apply to the complementary stratum of severe TBI patients (corresponding to a low Glasgow score,  $GCS \leq 8$ ). We can thus provide the results for this stratum in Figure 2.30. We observe that on this strata discrepancies between the solely Traumabase estimators and the generalized estimators are presents. The generalization supports either no-effect or a deleterious effect, while the RCT and the observational estimators support the no-effect hypothesis.



**Figure 2.30: Juxtaposition of different estimation results for target population corresponding to the severe Traumabase patients** with ATE estimators computed on the Traumabase (observational data set), on the CRASH-3 trial (RCT), and transported from CRASH-3 to the Traumabase target population (severe TBI patients). Number of variables used in each context is given in the legend.

## Chapter 3

# A sensitivity analysis to handle missing covariates

This chapter corresponds to the article entitled *Causal effect on a target population: A sensitivity analysis to handle missing covariates* published in *Journal of Causal Inference*,

co-authored with Julie JOSSE, Gaël VAROQUAUX, and Erwan SCORNET.

### *Chapter's content*

---

The previous Chapter contains a review of existing methods and theoretical guarantees of all the standard generalization's estimators to transport trial's findings to a target population: namely weighting (IPSW), outcome modeling (plug-in g-formula), or doubly robust approaches (AIPSW). All the consistency results we found for these estimators were done under the assumption of a certain parametric generative process. This Chapter proposes  $L^1$ -consistency results for these three estimators when no parametric assumptions is made. Chapter 2 ends on an application: the generalization of CRASH-3 findings to the Traumabase's population. In this application, there are good reasons to fear that the target causal effect can not be correctly identified due to a missing covariate in the Traumabase's data sets: the time between injury and treatment's allocation. As generalization's technics are recent, very few work existed on how to deal with such a situation through a sensitivity analysis, In this chapter, we derive the expected bias induced by a missing covariate, assuming a Gaussian distribution, a continuous outcome, and a semi-parametric model. Under this setting, we propose a sensitivity analysis for each missing covariate pattern and compute the sign of the expected bias. We also show that there is no gain in linearly imputing a partially unobserved covariate. Finally, we study the substitution of a missing covariate by a proxy. We illustrate all these results on simulations, as well as semi-synthetic benchmarks using data from the Tennessee student/teacher achievement ratio (STAR). This method is also implemented on our motivating example from critical care medicine.

---



---

**Contents**

1	<b>Introduction</b>	83
2	<b>Problem setting: generalizing a causal effect</b>	85
3	<b>Impact of a missing key covariate for a linear CATE</b>	87
4	<b>Synthetic and semi-synthetic simulations</b>	95
5	<b>Application on critical care data</b>	99
3.A	<b>Estimators of the target population ATE</b>	102
3.B	<b><math>L^1</math>-convergence of G-formula, IPSW, and AIPSW</b>	103
3.C	<b>Proofs for the missing covariate setting</b>	110
3.D	<b>Toward a semi-parametric model</b>	114
3.E	<b>Robinson procedure</b>	115
3.F	<b>Synthetic simulation - Extension</b>	115
3.G	<b>Homogeneity of the variance-covariance matrix</b>	117

---

## 1 Introduction

**Context** Randomized Controlled Trials (RCTs) are often considered the gold standard for estimating causal effects (Imbens and Rubin, 2015). Yet, they may lack external validity, when the population eligible to the RCT is substantially different from the target population of the intervention policy (Rothwell, 2007). Indeed, if there are treatment effect modifiers with a different distribution in the target population than that in the trial, some form of adjustment of the causal effects measured on the RCT is necessary to estimate the causal effect in the target population. Using covariates present in both RCT and an observational sample of the target population, this target population average treatment effect (ATE) can be identified and estimated with a variety of methods (Hotz et al., 2005; Cole and Stuart, 2010; Stuart et al., 2011; Pearl and Bareinboim, 2011b; Tipton, 2013; Bareinboim et al., 2014; Pearl and Bareinboim, 2014; Kern et al., 2016; Bareinboim and Pearl, 2016; Buchanan et al., 2018; Stuart et al., 2018; Dong et al., 2020), reviewed in Colnet et al. (2020) and Degtiar and Rose (2023).

In this context, two main approaches exist to estimate the target population ATE from a RCT. The *Inverse Probability of Sampling Weighting* (IPSW) reweights the RCT sample so that it resembles the target population with respect to the necessary covariates for generalization, while the *G-formula* models the outcome, using the RCT sample, with and without treatment conditionally on the same covariates, and then marginalizes the model to the target population of interest. These two methods can be combined in a doubly-robust approach—*Augmented Inverse Probability of Sampling Weighting* (AIPSW)—which enjoys better statistical properties. These methods rely on covariates to capture the heterogeneity of the treatment and the population distributional shift. But the datasets describing the RCT and the target population are seldom acquired as part of a homogeneous effort and as a result they come with different covariates (Pearl and Bareinboim, 2011b; Susukida et al., 2016; Lesko et al., 2016; Stuart and Rhodes, 2017; Egami and Hartman, 2021; Li et al., 2021). Restricting the analysis to the covariates in common raises the risk of omitting an important one leading to identifiability issues. Controlling biases due to unobserved covariates is of crucial importance for causal inference, where it is known as *sensitivity analysis* (Cornfield et al., 1959; Imbens, 2003; Rosenbaum, 2005).

**Prior work** The problem of missing covariates is central in causal inference as, in an observational study, one can never prove that there is no hidden confounding. In that setting, sensitivity analysis strives to assess how far confounding would affect the conclusion of a study (for example, would the ATE be of a different sign with such a hidden confounder). Such approaches date back to a study on the effect of smoking on lung cancer (Cornfield et al., 1959), and have been further developed for both parametric (Imbens, 2003; Rosenbaum, 2005; Dorie et al., 2016; Ichino et al., 2008; Cinelli and Hazlett, 2020) and semi-parametric situations (Franks et al., 2019; Veitch and Zaveri, 2020). Typically,

the analysis translates expert judgment into mathematical expression of how much the confounding affects treatment assignment and the outcome, and finally how much the estimated treatment effect is biased. In practice the expert must usually provide *sensitivity parameters* that reflect plausible properties of the missing confounder. Classic sensitivity analysis, dedicated to ATE estimation from observational data, use as sensitivity parameters the *impact of the missing covariate on treatment assignment probability* along with the *strength on the outcome* of the missing confounder. However, given that these quantities are hardly directly transposable when it comes to generalization, these approaches cannot be directly applied to estimating estimate the population treatment effect. These parameters have to be respectively replaced by the *covariate shift* and the *strength of a treatment effect modifier*. Existing sensitivity analysis methods for generalization usually consider a completely unobserved covariate. [Andrews and Oster \(2019\)](#) rely on a logistic model for sampling probability and a linear generative model of the outcome. [Dahabreh et al. \(2019\)](#) propose a sensitivity analysis assuming a model on the identification bias of the conditional average treatment effect. Very recent works propose two other approaches: (i) [Nie et al. \(2021\)](#) rely on the IPSW estimator and bound the error on the the density ratio and then derive the bias on the ATE following the spirit of [Rosenbaum \(2005\)](#); (ii) [Huang et al. \(2021\)](#) present a method with very few assumptions on the data generative process leading to three sensitivity parameters, including the variance of the treatment effect. As the analysis starts from two data sets, the missing covariate can also be partially observed in one of the two data set, which opens the door to new dedicated methods, in addition to sensitivity methods for totally-missing covariates. Following this observation, [Nguyen et al. \(2017, 2018\)](#) handle the case where a covariate is present in the RCT but not in the observational data set, and establish a sensitivity analysis under the hypothesis of a linear generative model for the outcome. When the missing covariate is partially observed, practitioners sometimes impute missing values based on other observed covariates, though this approach is poorly documented. For example, [Lesko et al. \(2016\)](#) impute a partially-observed covariate in a clinical study using a range of plausible distributions. Imputation has also been used in the context of individual participant data in meta-analysis ([Resche-Rigon et al., 2013](#); [Jolani et al., 2015](#)).

**Contributions** In this work we investigate the problem of a missing covariate that affects the identifiability of the target population average treatment effect (ATE), a common situation when combining different data sources. This work comes after the identifiability assessment, that is we consider that the necessary set of covariates to generalize is known, but a necessary covariate is totally or partially missing. Section 2 recalls the context along with the generic notations and assumptions used when coming to generalization. In Section 3, we quantify the bias due to unobserved covariates under the assumption of a semi-parametric generative process, considering a linear conditional average treatment effect (CATE), and under a transportability assumption of links between covariates in both populations. This bias is not estimator-specific and remains valid for the IPSW, G-formula, and AIPSW estimators. We also prove that a linear imputation of a partially missing covariate can not replace a sensitivity analysis. As mentioned in the introduction, and unlike classic sensitivity analysis, several missing data patterns can be observed: either totally missing or missing in one of the two sets. Therefore Section 3 provides sensitivity analysis frameworks for all the possible missing data patterns, including the case of a proxy variable that would replace the missing one. These results can be useful for users as they may be tempted to consider the intersection of common covariates between the RCT and the observational data. We detail how the different patterns involve either one or two sensitivity parameters. To give users an interpretable analysis, and due to the specificity of the sensitivity parameters at hands, we propose an adaptation of sensitivity maps ([Imbens, 2003](#)) that are commonly used to communicate sensitivity analysis results. Section 4 presents an extensive synthetic simulation analysis that illustrates theoretical results along with a semi-synthetic data simulation using the Tennessee Student/Teacher Achievement Ratio (STAR) experiment evaluating the effect of class size on children performance in elementary schools ([Krueger, 1999b](#)). Finally, Section 5 provides a real-world analysis to assess the effect of acid tranexomic on the Disability Rating Score (DRS) for trauma patients when a covariate is totally missing.

## 2 Problem setting: generalizing a causal effect

This section recalls the complete case context and identification assumptions. Any reader familiar with the notations and willing to jump to the sensitivity analysis can directly go to Section 3.

### 2.1 Notations

Notations are grounded on the potential outcome framework (Imbens and Rubin, 2015). We model each observation in the RCT or observational population as described by  $(X_i, Y_i(0), Y_i(1), A_i, S_i)$ , a random tuple for  $i \in \{1, \dots, n\}$  drawn from a distribution  $(X, Y(0), Y(1), A, S) \in \mathbb{R}^p \times \mathbb{R}^2 \times \{0, 1\}^2$ , such that the observations are *iid*. For each observation,  $X_i$  is a  $p$ -dimensional vector of covariates,  $A_i$  denotes the binary treatment assignment (with  $A_i = 1$  if treated and  $A_i = 0$  otherwise),  $Y_i(a)$  is the continuous outcome had the subject been given treatment  $a$  (for  $a \in \{0, 1\}$ ), and  $S_i$  is a binary indicator for RCT eligibility (i.e., meet the RCT inclusion and exclusion criteria) and willingness to participate if being invited to the trial ( $S_i = 1$  if eligible and  $S_i = 0$  if not). Assuming *consistency of potential outcomes*, and no interference between treated and non-treated subject (SUTVA assumption), we denote by  $Y_i = A_i Y_i(1) + (1 - A_i) Y_i(0)$  the observed outcome under treatment assignment  $A_i$ . Assuming the potential outcomes are integrable, we define the conditional average treatment effect (CATE):

$$\forall x \in \mathcal{X}, \quad \tau(x) = \mathbb{E}[Y(1) - Y(0) \mid X = x],$$

and the population average treatment effect (ATE):

$$\tau = \mathbb{E}[Y(1) - Y(0)] = \mathbb{E}[\tau(X)].$$

Unless explicitly stated, all expectations are taken with respect to all variables involved in the expression. We model the patients belonging to an RCT sample of size  $n$  and in an observational data sample of size  $m$  by  $n + m$  independent random tuples:  $\{X_i, Y_i(0), Y_i(1), A_i, S_i\}_{i=1}^{n+m}$ , where the RCT samples  $i = 1, \dots, n$  are identically distributed according to  $\mathcal{P}(X, Y(0), Y(1), A, S \mid S = 1)$ , and the observational data samples  $i = n + 1, \dots, n + m$  are identically distributed according to  $\mathcal{P}(X, Y(0), Y(1), A, S)$ . We also denote  $\mathcal{R} = \{1, \dots, n\}$  the index set of units observed in the RCT study, and  $\mathcal{O} = \{n + 1, \dots, n + m\}$  the index set of units observed in the observational study.

For each RCT sample  $i \in \mathcal{R}$ , we observe  $(X_i, A_i, Y_i, S_i = 1)$ , while for observational data  $i \in \mathcal{O}$ , we consider the setting where *we only observe the covariates*  $X_i$ , which is a common case in practice. A typical data set is presented on Table 3.1.

Because the RCT sample and observational data do not follow the same covariate distribution, the ATE  $\tau$  is different from the RCT's (or sample<sup>1</sup>) average treatment effect  $\tau_1$  which can be expressed as:

$$\tau \neq \tau_1, \quad \text{where } \tau_1 := \mathbb{E}[Y(1) - Y(0) \mid S = 1].$$

This difference is the core of the *lack of external validity* introduced in the beginning of the work, but formalized with a mathematical expression<sup>2</sup>. Throughout the paper, we denote  $\mu_a(x) := \mathbb{E}[Y(a) \mid X = x]$  the conditional mean outcome under treatment  $a \in \{0, 1\}$  (also called responses surfaces). and  $e_1(x) := \mathbb{P}(A = 1 \mid X = x, S = 1)$  the propensity score in the RCT population. This function is imposed by the trial characteristics and is usually a constant denoted by  $e_1$  (other cases include stratified RCT trials).

<sup>1</sup>Usually  $\tau_1$  is also called the Sample Average Treatment Effect (SATE), when  $\tau$  is named the Population Average Treatment Effect (PATE) (Stuart et al., 2011; Miratrix et al., 2017; Egami and Hartman, 2021; Degtiar and Rose, 2023).

<sup>2</sup>We would like to emphasize the fact that the target quantity is not  $\mathbb{E}[Y(1) - Y(0) \mid S = 0]$ , but  $\tau := \mathbb{E}[Y(1) - Y(0)]$ . This notation highlights that the trial sample is a biased sample from a superpopulation, while the observational data is an unbiased sample of this population. In other words, the target population contains individuals with  $S = 1$  or  $S = 0$ . Note that the generalizability problem tackled in this work - aiming to recover from a sampling bias - can also be equivalently seen as a transportability problem with two separate populations and a common support. See Colnet et al. (2020) for a discussion, or Nie et al. (2021) for a similar sensitivity analysis method, presented as a transportability problem.

For notational clarity, estimators are indexed by the number of observations used for their computation. For instance, response surfaces can be estimated using controls and treated individuals in the RCT to obtain respectively  $\hat{\mu}_{0,n}$  and  $\hat{\mu}_{1,n}$ . Similarly, we denote by  $\hat{\tau}_n$  an estimator of  $\tau$  depending only on the RCT samples (for example the difference-in-means estimator), and by  $\hat{\tau}_{n,m}$  an estimator computed using both datasets.

## 2.2 Identifiability (or causal) assumptions

The *consistency of treatment assignment* assumption ( $Y = AY(1) + (1 - A)Y(0)$ ) has already been introduced in Section 2. To ensure the internal validity of the RCT, we need to assume randomization of treatment assignment and positivity of trial treatment assignment.

**Assumption 16** (Treatment randomization within the RCT).  $\forall a \in \{0, 1\}, Y(a) \perp\!\!\!\perp A \mid S = 1, X$ .

In some cases, the trial is said to be completely randomized, that is  $\forall a \in \{0, 1\}, Y(a) \perp\!\!\!\perp A \mid S = 1$ , thus removing any potential stratification of the treatment assignment.

**Assumption 17** (Positivity of trial treatment assignment).  $\exists \eta_1 > 0, \forall x \in \mathcal{X}, \eta_1 \leq e_1(x) \leq 1 - \eta_1$

Under these two assumptions, along with the SUTVA assumption (see, e.g., [Imbens and Rubin \(2015\)](#)), the most classical difference-in-means estimator is consistent for  $\tau_1$ . In order to generalize the RCT estimate to the target population, three additional assumptions are required for identification of the target population ATE  $\tau$ .

**Assumption 18** (Representativity of observational data). *For all  $i \in \mathcal{O}, X_i \sim \mathcal{P}(X)$  where  $\mathcal{P}$  is the target population distribution.*

Then, a key assumption concerns the set of covariates that allows the identification of the target population treatment effect. This implies a conditional independence relation being called the *ignorability assumption on trial participation* or *S-ignorability* ([Hotz et al., 2005](#); [Stuart et al., 2011](#); [Tipton, 2013](#); [Hartman et al., 2015](#); [Pearl, 2015](#); [Kern et al., 2016](#); [Stuart and Rhodes, 2017](#); [Nguyen et al., 2018](#); [Egami and Hartman, 2021](#)).

**Assumption 19** (Ignorability assumption on trial participation - [Stuart et al. \(2011\)](#)).

$$Y(1) - Y(0) \perp\!\!\!\perp S \mid X.$$

Assumption 19 indicates that covariates  $X$  needed to generalize correspond to covariates being *both* treatment effect modifiers *and* subject to a distributional shift between the RCT sample and the target population.

Different strategies have been proposed to assess whether a treatment effect is constant or not, and usually relies on marginal variance, CDFs or quantiles comparison ([Ding et al., 2016](#)). Other techniques are possible such as comparing  $\text{Var}[Y \mid X_{obs}, A = 1, S = 1]$  to  $\text{Var}[Y \mid X_{obs}, A = 0, S = 1]$ , in order to assess whether or not an important treatment effect modifier is missing. In our work, we assume that the user is aware of which variables are treatment effect modifiers and subject to a distributional shift. We call these covariates as *key covariates*.

**Assumption 20** (Positivity of trial participation - [Stuart et al. \(2011\)](#)). *There exists a constant  $c$  such that for all  $x$  with probability 1,  $\mathbb{P}(S = 1 \mid X = x) \geq c > 0$*

## 2.3 Estimation strategies

To transport the ATE, several methods exist: the G-formula ([Lesko et al., 2017](#); [Pearl and Bareinboim, 2011b](#); [Dahabreh et al., 2019](#)), Inverse Propensity Weighting Score (IPSW) ([Cole and Stuart, 2010](#); [Lesko et al., 2017](#); [Buchanan et al., 2018](#)), and the Augmented IPSW (AIPSW) estimators. Note that other methods exist, such as calibration ([Dong et al., 2020](#); [Chattopadhyay et al., 2022](#)). For example the G-formula estimator consists in modeling the expected values for each potential outcome, conditional on the covariates.

**Definition 16** (G-formula - Dahabreh et al. (2019)). The G-formula is denoted  $\hat{\tau}_{G,n,m}$ , and defined as

$$\hat{\tau}_{G,n,m} = \frac{1}{m} \sum_{i=n+1}^{n+m} (\hat{\mu}_{1,n}(X_i) - \hat{\mu}_{0,n}(X_i)), \quad (3.1)$$

where  $\hat{\mu}_{a,n}(X_i)$  is an estimator of  $\mu_a(X_i)$  obtained on the RCT sample. These intermediary estimates are called nuisance components.

Beyond causal assumptions stated above, the behavior of the G-formula estimator strongly depends on that of the surface response estimators  $\hat{\mu}_{a,n}$  for  $a \in \{0, 1\}$ . To analyze the G-formula, we introduce below assumptions on the consistency of the nuisance parameters  $\hat{\mu}_{0,n}$  and  $\hat{\mu}_{1,n}$ .

**Assumption 21** (Consistency of surface response estimators). Denote  $\hat{\mu}_{0,n}$  (respectively  $\hat{\mu}_{1,n}$ ) an estimator of  $\mu_0$  (respectively  $\mu_1$ ). Let  $\mathcal{D}_n$  the RCT sample, so that

(H1-G) For  $a \in \{0, 1\}$ ,  $\mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)| | \mathcal{D}_n] \xrightarrow{P} 0$  when  $n \rightarrow \infty$ ,

(H2-G) For  $a \in \{0, 1\}$ , there exist  $C_1, N_1$  so that for all  $n \geq N_1$ , almost surely,  $\mathbb{E} [\hat{\mu}_{a,n}^2(X) | \mathcal{D}_n] \leq C_1$ .

**Proposition 1** (Informal -  $L^1$ -consistency of G-formula, IPSW, and AIPSW). Under causal assumptions (Assumptions 16, 17, 18, 19, and 20) and Assumption 21, the G-formula is  $L^1$ -consistent (asymptotically unbiased). In appendix we recall definitions of IPSW and AIPSW estimators and give the precise conditions under which  $L^1$ -consistency of those estimators is achieved (see Section 3.A).

Proofs and a more formal statement are in Section 3.B. The sensitivity analysis presented below holds for any  $L^1$ -consistent estimator.

### 3 Impact of a missing key covariate for a linear CATE

#### 3.1 Situation of interest: a missing covariate in one dataset

We study the common situation where both data sets (RCT and observational) contain a different subset of the total covariates  $X$ .  $X$  can be decomposed as  $X = X_{mis} \cup X_{obs}$  where  $X_{obs}$  denotes the covariates that are present in both data sets, the RCT and the observational study.  $X_{mis}$  denotes the covariates that are either partially observed in one of the two data sets or totally unobserved in both data sets. We do not consider (sporadic) missing data problems as in Mayer et al. (2021), but only cases where the covariate is totally observed or not per data sources. We denote by *obs* (resp. *mis*) the index set of observed (resp. missing) covariates. An illustration of a typical data set is presented in Table 3.1, with an example of two missing data patterns.

	Set	Covariates				
		$X_1$	$X_2$	$X_3$	$A$	$Y$
1	$\mathcal{R}$	1.1	20	5.4	1	10.1
	$\mathcal{O}$	-6	45	8.3	0	8.4
$n$	$\mathcal{R}$	0	15	6.2	1	14.5
$n+1$	$\mathcal{O}$	...			...	...
	$\mathcal{O}$	-2	52	NA	NA	NA
	$\mathcal{O}$	-1	35	NA	NA	NA
$n+m$	$\mathcal{O}$	-2	22	NA	NA	NA

	Set	Covariates				
		$X_1$	$X_2$	$X_3$	$A$	$Y$
1	$\mathcal{R}$	1.1	20	NA	1	10.1
	$\mathcal{O}$	-6	45	NA	0	8.4
$n$	$\mathcal{R}$	0	15	NA	1	14.5
$n+1$	$\mathcal{O}$	...			...	...
	$\mathcal{O}$	-2	52	3.4	NA	NA
	$\mathcal{O}$	-1	35	3.1	NA	NA
$n+m$	$\mathcal{O}$	-2	22	5.7	NA	NA

**Figure 3.1: Typical data structure**, where a covariate would be available in the RCT, but not in the observational data set (left) or the reverse situation (right). In this specific example,  $obs = \{1, 2\}$  ( $mis = \{3\}$ ), corresponds to common (resp. different) covariates in the two datasets.

In our context, due to (partially-)unobserved covariates, estimators of the target population ATE may be implemented on  $X_{obs}$  only.



To make the notations clear, we add a subscript *obs* on any estimator applied on the set  $X_{obs}$  rather than  $X$ . Such estimators may suffer from bias due to Assumption 19 violation, that is:

$$Y(1) - Y(0) \perp\!\!\!\perp S \mid X \quad \text{but} \quad Y(1) - Y(0) \not\perp\!\!\!\perp S \mid X_{obs}$$

We denote  $\hat{\tau}_{n,m,obs}$  any generalization estimator (G-formula, IPSW, AIPSW) applied on the covariate set  $X_{obs}$  rather than  $X$ .

## 3.2 Expression of the missing-covariate bias

### 3.2.1 Model and hypothesis

To analyze the effect of a missing covariate, we introduce a nonparametric generative model. In particular, we focus on zero-mean additive-error representation, where the CATE depends linearly on  $X$ . We admit that there exist  $\delta \in \mathbb{R}^p$ ,  $\sigma \in \mathbb{R}^+$ , and a function  $g : \mathcal{X} \rightarrow \mathbb{R}$ , such that:

$$Y = g(X) + A\langle X, \delta \rangle + \varepsilon, \quad \text{where } \varepsilon \sim \mathcal{N}(0, \sigma^2), \quad (3.2)$$

assuming  $\tau(X) := \langle X, \delta \rangle$ . In appendix (see Section 3.D) we prove why this assumption on the generative model for  $Y$  does not come with a loss of generality.

Under this model, the Average Treatment Effect (ATE) takes the following form:

$$\tau = \int \mathbb{E}[Y(1) - Y(0) \mid X = x] f(x) dx = \int \langle \delta, x \rangle f(x) dx = \delta^T \mathbb{E}[X].$$

Only variables that are both treatment effect modifier ( $\delta_j \neq 0$ ) and subject to a distributional change between the RCT and the target population are necessary to generalize the ATE. If some of these key covariates are missing, the estimation of the target population ATE will be biased. Our goal here is to express the bias of a missing variable on the transported ATE. But first, we have to specify a context in which a certain permanence of the relationship between  $X_{obs}$  and  $X_{mis}$  in the two data sets holds. Therefore, we introduce the *Transportability of covariate relationship* assumption.

**Assumption 22** (Transportability of covariate relationship). *The distribution of  $X$  is Gaussian, that is,  $X \sim \mathcal{N}(\mu, \Sigma)$ , and transportability of  $\Sigma$  is true, that is,  $X \mid S = 1 \sim \mathcal{N}(\mu_{RCT}, \Sigma)$ .*

This assumption, and in particular, the transportability of  $\Sigma$ , is of major importance for the sensitivity analysis develop below. Indeed, as soon as the correlation pattern changes in amplitude and sign between the two populations, the sensitivity analysis can be invalidated. The plausibility of Assumption 22 can be partially assessed through a statistical test on  $\Sigma_{obs,obs}$  for example a Box's M test (Box, 1949), supported with visualizations (Friendly and Sigal, 2020). A discussion can be found in the experimental study (Section 4) and in appendix (Section 3.G), showing that this assumption is plausible in many situations.

### 3.2.2 Main result

**Theorem 5.** *Assume that Assumptions 16, 17, 18, 19, 20 (identifiability) hold, along with Model eq. 3.2 and Assumption 22 (sensitivity model). Let  $B$  be the following quantity:*

$$B = - \sum_{j \in mis} \delta_j \left( \mathbb{E}[X_j] - \mathbb{E}[X_j \mid S = 1] - \Sigma_{j,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} \mid S = 1]) \right), \quad (3.3)$$

where  $\Sigma_{obs,obs}$  is the submatrix of  $\Sigma$  composed of rows and columns corresponding to variables present in both data sets. Similarly,  $\Sigma_{j,obs}$  is composed of the  $j$ th row of  $\Sigma$  and has columns corresponding to variables present in both data sets. Consider a procedure  $\hat{\tau}_{n,m}$  that estimates  $\tau$  with no asymptotic bias (for example the G-formula introduced in Definition 16 under Assumption 21). Let  $\hat{\tau}_{n,m,obs}$  be the same procedure but trained on observed data only. Then

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{n,m,obs}] - \tau = B. \quad (3.4)$$

Proof is given in appendix (see Section 3.C).

**Comment on  $L^1$ -consistency** Theorem 5 is valid for any  $L^1$ -consistent generalization estimator. In particular, we provide in appendix the detailed assumptions (similar as Assumption 21) under which two other popular estimators, IPSW and AIPSW, are asymptotically unbiased (see Section 3.A). Note that most of the existing works on estimating the target population causal effect focus on identification or establish consistency for parametric models or oracle estimators which are not bona fide estimation procedures as they require knowledge of some population data-generation mechanisms (Cole and Stuart, 2010; Stuart et al., 2011; Lunceford and Davidian, 2004; Buchanan et al., 2018; Dahabreh et al., 2019; Egami and Hartman, 2021). To our knowledge, no general  $L^1$ -consistency results for the G-formula, IPSW, and AIPSW procedures are available in a non-parametric case, when either the CATE or the weights are estimated from the data without prior knowledge.

**What if outcomes are also available in the observational sample?** Who can do more can do less, therefore this outcome covariate could be dropped and the analysis conducted without it. But alternative strategies exist. First, the outcome in the observational data – even if present in only one of the treatment group – would allow to test for the presence or absence of a missing treatment effect modifier (Degtiar and Rose, 2023) (see their Section 4.2), and therefore its strength. Moreover this would allow to rely on strategies to diminish the variance of the estimates (Huang et al., 2021). Finally, the assumption of a linear CATE could be reconsidered and softened, but we let this question to future work.

### 3.3 Sensitivity analysis

The above theoretical bias  $B$  (see equation 3.3) can be used to translate expert judgments about the strength of missing covariates, which corresponds to sensitivity analysis. In the rest of our work, we exemplify Theorem 5 in scenarios for which there is a totally unobserved covariate (Section 3.3.1), a missing covariate in RCT (Section 3.3.2), or a missing covariate in the observational sample (Section 3.3.2). Section 3.3.3 completes the previous sections presenting an adaptation to sensitivity maps. Finally Section 3.3.4 details the imputation case, and Section 3.3.5 the case of a proxy variable. All these methods rely on different assumptions recalled in Table 3.1.

Missing covariate pattern	Assumption(s) required	Procedure's label
Totally unobserved covariate	$X_{mis} \perp\!\!\!\perp X_{obs}$	1
Partially observed in observational study	Assumption 22	2
Partially observed in RCT	No assumption	3
Proxy variable	Assumptions 22 and 23	5

**Table 3.1: Summary of the assumptions and results pointer for all the sensitivity methods** according to the missing covariate pattern when the generative outcome is semi-parametric with a linear CATE eq. 3.2.

#### 3.3.1 Sensitivity analysis when a key covariate is totally unobserved

When a covariate is totally unobserved, a common and natural assumption is to assume independence between this covariate and the observed ones (Imbens, 2003). Although strong, this assumption allows us to estimate the identification bias.

**Corollary 1** (Sensitivity model). *Assume that Model eq. 3.2 holds, along with Assumptions 16, 17, 18, 19, 20, and 22. Assume also that  $X_{mis} \perp\!\!\!\perp X_{obs}$ ,  $X_{mis} \perp\!\!\!\perp X_{obs} \mid S = 1$ . Consider a procedure  $\hat{\tau}_{n,m}$  that estimates  $\tau$  with no asymptotic bias. Let  $\hat{\tau}_{n,m,obs}$  be the same procedure but trained on observed data only. Then*

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{n,m,obs}] - \tau = -\delta_{mis} \Delta_m$$

where  $\Delta_m = \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} \mid S = 1]$ .

Corollary 1 is a direct consequence of Theorem 5, particularized for the case where  $X_{obs} \perp\!\!\!\perp X_{mis}$  and  $X_{obs} \perp\!\!\!\perp X_{mis} \mid S = 1$ . In this expression,  $\Delta_m$  and  $\delta_{mis}$  are called the sensitivity parameters. To estimate the bias implied by an unobserved covariate, we have to determine how strongly  $X_{mis}$  is a



treatment effect modifier (through  $\delta_{mis}$ ), and how strongly it is linked to the trial inclusion (through the shift between the trial sample and the target population  $\Delta_m = \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1]$ ). Table 3.2 summarizes the similarities and differences with [Imbens \(2003\)](#), [Andrews and Oster \(2019\)](#)'s approaches, and our approach.

	<a href="#">Imbens (2003)</a>	<a href="#">Andrews and Oster (2019)</a>	Sensitivity model
Assumption on covariates	$X_{mis} \perp\!\!\!\perp X_{obs}$	$X_{mis} \perp\!\!\!\perp X_{obs}$	$X_{mis} \perp\!\!\!\perp X_{obs}$
Model on $Y$	Linear model	Linear model	Linear CATE eq. 3.2
Other assumption	Model on $A$ ( <b>logit</b> )	Model on $S$ ( <b>logit</b> )	-
First sensitivity parameter	Strength on $Y$ , using $\delta_{mis}$	Strength on $Y$ , using $\delta_{mis}$	Strength on $Y$ , using $\delta_{mis}$
Second sensitivity parameter	Strength on $A$ ( <b>logit</b> 's coefficient)	Strength on $S$ ( <b>logit</b> 's coefficient)	$\Delta_m$ : shift of $X_{mis}$

**Table 3.2:** Summary of the differences between [Imbens \(2003\)](#)'s method, being a prototypical method for sensitivity analysis for observational data and hidden confounding, [Andrews and Oster \(2019\)](#)'s method and our method.

In the setting of Corollary 1, sensitivity analysis can be carried out using Procedure 1 described below. To represent the bias magnitude as a function of the sensitivity parameters, we develop a graphical aid adapted from sensitivity maps ([Imbens, 2003](#); [Veitch and Zaveri, 2020](#)).

---

**Procedure 1:** A totally-unobserved covariate

---

```

init   :  $\delta_{mis} := [\dots]$ ;           // Define a range for plausible  $\delta_{mis}$  values
init   :  $\Delta_m := [\dots]$ ;         // Define arange for plausible  $\Delta_m$  values
Compute all possible bias  $-\delta_{mis}\Delta_m$  (see Lemma 1)
return Sensitivity map

```

---

A partially-observed covariate could always be removed so that this sensitivity analysis could be conducted for every missing data patterns (the variable being missing in the RCT or in the observational data). However dropping a partially-observed covariate (*i*) is inefficient as it discards available information, (*ii*) amounts to considering the variable as totally unobserved which, in turn, leads us to assume independence between observed and unobserved covariates, a very strong hypothesis. Therefore, in the following subsections, we propose methods that use the partially-observed covariate – when available – to improve the bias estimation.

### 3.3.2 Sensitivity analysis when a key covariate is partially unobserved

When partially available, we propose to use  $X_{mis}$  to have a better estimate of the bias. Unlike the above, this approach does not need the partially observed covariate to be independent of all other covariates, but rather captures the dependencies from the data.

**Observed in observational study** Suppose one key covariate  $X_{mis}$  is observed in the observational study, but not in the RCT. Under Assumption 22, the asymptotic bias of any  $L^1$ -consistent estimator  $\hat{\tau}_{n,m,obs}$  is derived in Theorem 5. The quantitative bias is informative as it depends only on the regression coefficients  $\delta$ , and on the shift in expectation between covariates. Indeed, the bias term can be decomposed as follows:

$$B = - \underbrace{\delta_{mis}}_{X_{mis}'s\ strength} \left( \underbrace{\mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1]}_{\text{Shift of } X_{mis}: \Delta_m} - \underbrace{\Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} | S = 1])}_{\text{Can be estimated from the data}} \right).$$

Using the observational study where the necessary covariates are all observed, one can estimate the covariance term  $\Sigma_{mis,obs} \Sigma_{obs,obs}^{-1}$  together with the shift for the observed set of covariates. Unfortunately, the remaining parameters  $\delta_{mis}$ , corresponding to the coefficient of the missing covariates in the complete linear model, and  $\Delta_m = \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1]$  are not identifiable from the observed data. These two parameters correspond respectively to the strength of the treatment effect modifier and the distributional shift of the missing covariate. These two quantities are used as sensitivity parameters to estimate a plausible range of the bias (see Procedure 2). Simulations illustrate how these

sensitivity parameters can be used, along with graphical visualization derived from sensitivity maps (see Section 4).

---

**Procedure 2:** Observed in observational

---

```

init   :  $\delta_{mis} := [\dots]$ ;           // Define a range for plausible  $\delta_{mis}$  values
init   :  $\Delta_{mis} := [\dots]$ ;         // Define a range for plausible  $\Delta_{mis}$  values
Estimate  $\Sigma_{obs,obs}$ ,  $\Sigma_{mis,obs}$ , and  $\mathbb{E}[X_{obs}]$  on the observational dataset;
Estimate  $\mathbb{E}[X_{obs} | S = 1]$  on the RCT dataset;
Compute all possible biases for the predefined ranges of  $\delta_{mis}$  and  $\Delta_{mis}$ , according to
Theorem 5.
return Sensitivity map

```

---

**Data-driven approach to determine sensitivity parameter** Note that guessing a good range for the shift  $\Delta_{mis}$  is probably easier than giving a range for the coefficients  $\delta_{mis}$ . We propose a data-driven method to estimate  $\delta_{mis}$ . First, learn a linear model of  $X_{mis}$  from observed covariates  $X_{obs}$  on the observational data, then impute the missing covariate in the trial, and finally obtain  $\hat{\delta}_{mis}$  with a Robinson procedure on the imputed trial data (Robinson, 1988; Wager, 2020; Nie and Wager, 2020). The Robinson procedure is recalled in Appendix (see Section 3.E). This method is used in the semi-synthetic simulation (see Section 4.2).

**Observed in the RCT** The method we propose here was already developed by Nguyen et al. (2017, 2018), and we briefly recall its principle in this part. Note that we extend this method by considering a semi-parametric model eq. 3.2, while they considered a completely linear model. For this missing covariate pattern, only one sensitivity parameter is necessary. As the RCT is the complete data set, the regression coefficients  $\delta$  of eq. 3.2 can be estimated for all the key covariates, leading to an estimate  $\hat{\delta}_{mis}$  for the partially unobserved covariate. Nguyen et al. (2017, 2018) showed that:

$$\tau = \langle \delta_{obs}, \mathbb{E}[X_{obs}] \rangle + \langle \delta_{mis}, \underbrace{\mathbb{E}[X_{mis}]}_{\text{Unknown}} \rangle. \quad (3.5)$$

In this case, and as the influence of  $X_{mis}$  as a treatment effect modifier can be estimated from the data through  $\hat{\delta}_{mis}$ , only one sensitivity parameter is needed, namely  $\mathbb{E}[X_{mis}]$ . Therefore, we assume to be given a range of plausible values for  $\mathbb{E}[X_{mis}]$ , for example according to a domain expert prior. Note that  $\delta_{mis}$  can be estimated following a Robinson procedure. This allows extending Nguyen et al. (2018)’s work to the semi-parametric case. Softening even more the parametric assumption where only  $X_{mis}$  is additive in the CATE is a natural extension, but out of the scope of the present work.

---

**Procedure 3:** Observed in RCT

---

```


init   :  $\mathbb{E}[X_{mis}] := [\dots]$ ;         // Define a range for plausible values of  $\mathbb{E}[X_{mis}]$ 
Estimate  $\delta$  with the Robinson procedure, that is:
Run a non-parametric regression  $Y \sim X$  on the RCT, and denote
 $\hat{m}_n(x) = \mathbb{E}[Y | X = x, S = 1]$  the obtained estimator;
Define the transformed features  $\tilde{Y} = Y - \hat{m}_n(X)$  and  $\tilde{Z} = (A - e_1(X))X$ .
Estimate  $\hat{\delta}$  running the OLS regression on  $\tilde{Y} \sim \tilde{Z}$ ;
Estimate  $\mathbb{E}[X_{obs}]$  on the observational dataset;
Compute all possible biases for yhe range of  $\mathbb{E}[X_{mis}]$  according to eq. 3.5.
return Sensitivity map

```

---

### 3.3.3 Vizualization: sensitivity maps

From now on, each of the sensitivity method suppose to translate sensitivity parameter(s) and to compute the range of bias associated. A last step is to communicate or visualize the range of biases, which is slightly more complicated when there are two sensitivity parameters. Sensitivity map is a way to aid such judgement (Imbens, 2003; Veitch and Zaveri, 2020). It consists in having a two-dimensional plot, each of the axis representing the sensitivity parameter, and the solid curve is the set



**Figure 3.2: Sensitivity maps:** On this figure  $X_3$  is supposed to be a missing covariate. (Left) Regular sensitivity map showing how strong an key covariate would need to be to induce a bias of  $\sim 6$  in function of the two sensitivity parameters  $\Delta_m$  and partial  $R^2$  when a covariate is totally unobserved. (Right) The exact same simulation data are represented, while using rather  $\delta_{mis}$  than the partial  $R^2$ , and superimposing the heatmap of the bias which allows to reveal the general landscape along with the sign of the bias.

of sensitivity parameters that leads to an estimate that induces a certain bias' threshold. Here, we adapt this method to our settings with several changes. Because coefficients interpretation is hard, a typical practice is to translate a regression coefficient into a partial  $R^2$ . For example, [Imbens \(2003\)](#) prototypical example proposes to interpret the two parameters with partial  $R^2$ . In our case, a close quantity can be used:

$$R^2 \sim \frac{\mathbb{V}[\delta_{mis} X_{mis}]}{\mathbb{V}[\sum_{j \in obs} \hat{\delta}_j X_j]} \quad (3.6)$$

where the denominator term is obtained when regressing  $Y$  on  $X_{obs}$ . If this  $R^2$  coefficient is close to 1, then the missing covariate has a similar influence on  $Y$  compared to other covariates. On the contrary, if  $R^2$  is close to 0, then the impact of  $X_{mis}$  on  $Y$  as a treatment effect modifier is small compared to other covariates. But in our case one of the sensitivity parameter is really palpable as it is the covariate shift  $\Delta_m$ .

We advocate keeping the regression coefficient and shift as sensitivity parameter rather than a  $R^2$  to help practitioners as it allows to keep the sign of the bias, than can be in favor of the treatment or not and help interpreting the sensitivity analysis. Furthermore, even if postulating an hypothetical value of a coefficient is tricky, when the covariate is partially observed an imputation procedure can be proposed to have a grasp of the coefficient true value.

On Figure 3.2 we present a glimpse of the simulation result, to introduce the principle of the sensitivity map, with on the left the representation using  $R^2$  and on the right a representation keeping the raw sensitivity parameters. In this plot, we consider the covariate  $X_3$  to be missing, so that we represent *what would be the bias if we missed  $X_3$ ?* The associated sensitivity parameters are represented on each axis. In other word, the sensitivity map shows how strong an unobserved key covariate would need to be to induce a bias that would force to reconsider the conclusion of the study because the bias is above a certain threshold, that is represented by the blue line. For example in our simulation set-up,  $X_3$  is below the threshold as illustrated on Figure 3.2. The threshold can be proposed by expert, and here we proposed the absolute difference between  $\hat{\tau}_{n,m,obs}$  and the RCT estimate  $\hat{\tau}_1$  as a natural quantity. In particular, we observe that keeping the sign of the sensitivity parameter allows to be even more confident on the direction of the bias.

### 3.3.4 Partially observed covariates: imputation

Another practically appealing solution is to impute the partially-observed covariate, based on the complete data set (whether it is the RCT or the observational one) following Procedure 4. We analyse theoretically in this section the bias of such procedure in Corollary 2, and show there is no gain in linearly imputing the partially-observed covariate.

To ease the mathematical analysis, we focus on a G-formula estimator based on oracles quantities: the best imputation function and the surface responses are assumed to be known. While these are not

available in practice, they can be approached with consistent estimates of the imputation functions and the surface responses. The precise formulations of our oracle estimates are given in Definition 17 and Definition 18.

**Definition 17** (Oracle estimator when covariate is missing in the observational data set). *Assume that the RCT is complete and that the observational sample contains one missing covariate  $X_{mis}$ . We assume that we know*

- (I) the true response surfaces  $\mu_1$  and  $\mu_0$ ,
- (II) the true linear relation between  $X_{mis}$  as a function of  $X_{obs}$ .

Our oracle estimate  $\hat{\tau}_{G,\infty,m,imp}$  consists in applying the G-formula with the true response surfaces  $\mu_1$  and  $\mu_0$  (I) on the observational sample, in which the missing covariate has been imputed by the best (linear) function (II).

**Definition 18** (Oracle estimator when covariate is missing in the RCT data set). *Assume that the observational sample is complete and that the RCT contains one missing covariate  $X_{mis}$ . We assume that we know*

- (I) the true linear relation between  $X_{mis}$  as a function of  $X_{obs}$ , which leads to the optimal imputation  $\hat{X}_{mis}$ ,
- (II) the conditional expectations,  $\mathbb{E} \left[ Y(a) | X_{obs}, \hat{X}_{mis}, S = 1 \right]$ , for  $a \in \{0, 1\}$ .

Our oracle estimate  $\hat{\tau}_{G,\infty,\infty,imp}$  consists in optimally imputing the missing variable  $X_{mis}$  in the RCT (I). Then, the G-formula is applied to the observational sample, with the surface responses that have been perfectly fitted on the completed RCT sample.

**Corollary 2** (Oracle bias of imputation in a Gaussian setting). *Assume that the CATE is linear eq. 3.2 and that Assumption 22 holds. Let  $B$  be the following quantity:*

$$B = \delta_{mis} \left( \mathbb{E} [X_{mis}] - \mathbb{E} [X_{mis} | S = 1] - \Sigma_{j,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E} [X_{obs}] - \mathbb{E} [X_{obs} | S = 1]) \right).$$

- **Complete RCT.** *Assume that the RCT is complete and that the observational data set contains a missing covariate  $X_{mis}$ . Consider the oracle estimator  $\hat{\tau}_{G,\infty,m,imp}$  in Definition 17. Then,*

$$\tau - \lim_{m \rightarrow \infty} [\hat{\tau}_{G,\infty,m,imp}] = B$$

- **Complete Observational.** *Assume that the observational data set is complete and that the RCT contains a missing covariate  $X_{mis}$ . Consider the oracle estimator  $\hat{\tau}_{G,\infty,\infty,imp}$  in Definition 18. Then,*

$$\tau - \mathbb{E} [\hat{\tau}_{G,\infty,\infty,imp}] = B$$

Derivations are detailed in appendix (see Subsection 3.C.2). Corollary 2 highlights that there is no gain in linearly imputing the missing covariate compared to dropping it. Simulations (Section 3.F) show that the average bias of a finite-sample imputation procedure is similar to the bias of  $\hat{\tau}_{G,\infty,\infty,obs}$ .

---

**Procedure 4:** Linear imputation

---

- Model  $X_{mis}$  a linear combination of  $X_{obs}$  on the complete data set;
  - Impute the missing covariate with  $\hat{X}_{mis}$  with the previous fitted model;
  - Compute  $\hat{\tau}$  with the G-formula using the imputed data set  $X_{obs} \cup \hat{X}_{mis}$ ;
  - return**  $\hat{\tau}$
-

### 3.3.5 Using a proxy variable in place of the missing covariate

Another solution is to use a so-called proxy variable. The impact of a proxy in the case of a linear model is documented in econometrics (Chen et al., 2005, 2007; Angrist and Pischke, 2008; Wooldridge, 2015). An example of a proxy variable is the height of children as a proxy for their age. Note that in this case, even if the age is present in one of the two datasets, only the children's height is kept in for this method. Here, we propose a framework to handle a missing key covariate with a proxy variable and estimate the bias reduction accounting for the additional noise brought by the proxy.

**Assumption 23** (Proxy framework). *Assume that  $X_{mis} \perp\!\!\!\perp X_{obs}$ , and that there exists a proxy variable  $X_{prox}$  such that,*

$$X_{prox} = X_{mis} + \eta,$$

where  $\mathbb{E}[\eta] = 0$ ,  $\text{Var}[\eta] = \sigma_{prox}^2$ , and  $\text{Cov}(\eta, X_{mis}) = 0$ . In addition we suppose that  $\text{Var}[X_{mis}] = \text{Var}[X_{mis} | S = 1] = \sigma_{mis}^2$ .

**Definition 19.** *Let  $\hat{\tau}_{G,n,m,prox}$  be the G-formula estimator where  $X_{mis}$  is substituted by  $X_{prox}$  as detailed in assumption 23.*

**Lemma 1.** *Assume that the generative linear model eq. 3.2 holds, along with Assumption 22 and the proxy framework eq. 23. Then the asymptotic bias of  $\hat{\tau}_{G,n,m,prox}$  is:*

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{G,n,m,prox}] - \tau = -\delta_{mis} \Delta_m \left( 1 - \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} \right)$$

We denote  $\hat{\delta}_{prox}$  the estimated coefficient for  $X_{prox}$ . Such an estimation can be obtained using a Robinson procedure when regressing  $Y$  on the set  $X_{obs} \cup X_{prox}$ .

**Corollary 3.** *The asymptotic bias in lemma 1 can be estimated using the following expression:*

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{G,n,m,prox}] - \tau = -\hat{\delta}_{prox} (\mathbb{E}[X_{prox}] - \mathbb{E}[X_{prox} | S = 1]) \frac{\sigma_{prox}^2}{\sigma_{mis}^2}.$$

Proofs of Lemma 1 and Corollary 3 are detailed in Appendix (Proof 3.C.3). Note that, as expected, the average bias reduction strongly depends on the quality of the proxy. In the limit case, if  $\sigma_{prox} \sim 0$  so that the correlation between the proxy and the missing variable is one, then the bias is null. In general, if  $\sigma_{prox} \gg \sigma_{mis}$  then the proxy variable does not diminish the bias. Finally, we propose a practical approach in Procedure 5. Note that it requires to have a range of possible  $\sigma_{prox}$  values. We recommend to use the data set on which the proxy along with the partially-unobserved covariate are present, and to obtain an estimation of this quantity on this subset.

---

#### Procedure 5: Proxy variable

---

```

init   :  $\sigma_{prox} := [\dots]$ ;           // Define a range for plausible  $\sigma_{prox}$  values
if  $X_{mis}$  is in RCT then
  | init   :  $\Delta_{mis} := [\dots]$ ;           // Define a range for plausible  $\Delta_{mis}$  values
  | Estimate  $\delta_{mis}$  with the Robinson procedure (see Procedure 3 for details);
  | Compute all possible biases for the range of  $\sigma_{prox}$  according to Lemma 3.C.3.
else
  | Estimate  $\delta_{prox}$  with the Robinson procedure (see Procedure 3 for details);
  | Estimate  $\mathbb{E}[X_{prox}]$  and  $\mathbb{E}[X_{prox} | S = 1]$ ;
  | Compute all possible bias for range of  $\sigma_{prox}$  according to Corollary 3.
return Biases's range

```

---

## 4 Synthetic and semi-synthetic simulations

More information on simulation settings can be found in Appendix see Section 3.F.

### 4.1 Synthetic simulations

While results presented in Section 3 apply to any function  $g$  (see eq. 3.2), we choose  $g$  as a linear function to illustrate our findings. All simulations are available on [github](#)<sup>3</sup>, and include non-linear forms for  $g$ .

**Simulations parameters** We use a similar simulation framework as in [Dong et al. \(2020\)](#) and [Colnet et al. \(2020\)](#), where 5 covariates are generated independently, except for  $X_1$  and  $X_5$  whose correlation is set at 0.8, except when explicitly mentioned. We simulate marginals as  $X_j \sim \mathcal{N}(1, 1)$  for all  $j = 1, \dots, 5$ . The trial selection process is defined using a logistic regression model, such that:

$$\text{logit} \{P(S = 1 | X)\} = \beta_{s,0} + \beta_{s,1} X_1 + \dots + \beta_{s,5} X_5. \quad (3.7)$$

This selection process implies that the variance-covariance matrix in the RCT sample and in the target population *may be different* depending on the (absolute) value of the coefficients  $\beta_s$ . In our simulation set-up, the overall variance-covariance structure is kept identical as visualized on Figure 3.3. The outcome is generated according to a linear model, following Model 3.2, that is

$$Y(a) = \beta_0 + \beta_1 X_1 + \dots + \beta_5 X_5 + a(\delta_1 X_1 + \dots + \delta_5 X_5) + \varepsilon \text{ with } \varepsilon \sim \mathcal{N}(0, 1). \quad (3.8)$$

In this simulation, we set  $\beta = (5, 5, 5, 5, 5)$ , and other parameters as described in Table 3.3.


Covariates	$X_1$	$X_2$	$X_3$	$X_4$	$X_5$
Treatment effect modifier	Yes	Yes	Yes	No	No
Linked to trial inclusion	Yes	No	Yes	Yes	No
$\delta$	$\delta_1 = 30$	$\delta_2 = 30$	$\delta_3 = -10$	$\delta_4 = 0$	$\delta_5 = 0$
$\beta_s$	$\beta_{s,1} = -0.4$	$\beta_{s,2} = 0$	$\beta_{s,3} = -0.3$	$\beta_{s,4} = -0.3$	$\beta_{s,5} = 0$
$\perp\!\!\!\perp X_1$	-	$X_2 \perp\!\!\!\perp X_1$	$X_3 \perp\!\!\!\perp X_1$	$X_4 \perp\!\!\!\perp X_1$	$X_5 \not\perp\!\!\!\perp X_1$

**Table 3.3: Simulations parameters.**

First a sample of size 10,000 is drawn from the covariate distribution. From this sample, the selection model eq. 3.7 is applied which leads to an RCT sample of size  $n \sim 2800$ . Then, the treatment is generated according to a Bernoulli distribution with probability equal to  $e_1 = 0.5$ . Finally, the outcome is generated according to eq. 3.8. The observational sample is obtained by drawing a new sample of size  $m = 10,000$  from the covariate distribution. In this setting, the ATE equals  $\tau = \sum_{j=1}^5 \delta_j \mathbb{E}[X_j] = \sum_{j=1}^5 \delta_j = 50$ . Besides, the sample selection ( $S = 1$ ) in eq. 3.7 is biased toward lower values of  $X_1$  (and indirectly  $X_5$ ), and higher values of  $X_3$ . This situation illustrates a case where  $\tau_1 \neq \tau$ . Empirically, we obtain  $\tau_1 \sim 44$ .

**Illustration of Theorem 5** Figure 3.4 presents results of a simulation with 100 repetitions with no missing covariates (on the Figure see `none`), and the impact of missing covariate(s) when using the G-formula or the IPSW to generalize. The theoretical bias from Theorem 5 is also represented.


<sup>3</sup>[BenedicteColnet/unobserved-covariate](#)



**Figure 3.3: Variance-covariance** preservation in the simulation set-up highlighted with pairwise covariance ellipses for one realization of the simulation (package `heplots`).



**Figure 3.4: Illustration of Theorem 5:** Simulation results for the linear model with missing covariate(s) when generalizing the treatment effect using the G-formula (Definition 16) or IPSW (see Definition 20 in appendix) estimators on the set of observed covariates. Missing covariate are indicated on the x-axis. The theoretical bias (orange dot) is obtained from Theorem 5. Simulations are repeated 100 times.



The absence of covariates  $X_2, X_4$  and/or  $X_5$  does not affect ATE generalization because these covariates are not simultaneously treatment effect modifiers and shifted (between the RCT sample and the target population). In addition, the signs of the biases depend on the signs of the coefficients associated to the missing variables, as highlighted by settings for which  $X_1$  and  $X_3$  are missing. As shown in Theorem 5, variables acting on  $Y$  without being treatment effect modifiers and linked to trial inclusion can help to reduce the bias, if correlated to a (partially-) unobserved key covariate. This is stressed out in our experiment by comparing the settings for which  $X_1, X_5$  are missing and the one where only  $X_1$  is missing.


**A totally-unobserved covariate (from Section 3.3.1)** To illustrate this case, the missing covariate has to be supposed independent of all the others. For this paragraph we consider  $X_3$ . Then, according to Lemma 1, the two sensitivity parameters  $\delta_{mis}$  and the shift  $\Delta_m$  can be used to produce a sensitivity map for the bias on the transported ATE. The procedure 1 summarizes the different steps, and the sensitivity map's output result was presented in Figure 3.2.

**A missing covariate in the RCT (from Section 3.3.2)** In this case, we need to specify ranges of values for the two sensitivity parameters  $\delta_{mis}$  and  $\Delta_m$ . The experimental protocol is designed such that all covariates are successively partially missing in the RCT. Because each missing variable implies a different landscape due to the dependence relation to other covariates (as stated in Theorem 5), each variable requires a different heatmap (except if covariates are all independent). Results are depicted in Figure 3.5. Figure 3.5 illustrates the benefit of Protocol 2 accounting for other correlated covariates, and compared to a protocol assuming independent covariates. Indeed,  $X_1$  and  $X_2$  are strong treatment effect modifiers (see Table 3.3, where  $\delta_1 = \delta_2$ ), but  $X_1$  is correlated to other completely observed covariates, which allows to "lower" the bias if  $X_1$  is completely removed from the analysis compared to a similar covariate that would be independent of all other covariates. This is highlighted with a non-symmetric bias landscape for  $X_1$  on Figure 3.5. As a consequence, for a same value of  $\delta_{mis}$  value, a guessed shift of  $\Delta_{mis} = 0.25$  allows to conclude on a lower bias on the map for  $X_1$ , while it would not be the case for covariate  $X_2$  (which is completely independent).

**A missing covariate in the observational data (from Section 3.3.2)** In this case, we need to specify a range for the values of only one sensitivity parameter, namely  $\mathbb{E}[X_{mis}]$  (see eq. 3.5). In our experimental protocol, we assume that  $X_1$  is missing and apply Procedure 3. Results are presented in Table 3.4.

Simulations illustrating imputation (Corollary 2) and usage of a proxy (Lemma 1) are available in appendix, in Section 3.F.






**Figure 3.5: Simulations results when applying procedure 2:** Heatmaps with a blue curve showing how strong an unobserved key covariate would need to be to induce a bias of  $\tau_1 - \tau \sim -6$  in function of the two sensitivity parameters  $\Delta_m$  and  $\delta_{mis}$  when a covariate is totally unobserved. Each heatmap illustrates a case where the covariate would be missing (indicated on the top of the map), given all other covariates. The cross indicate the coordinate of true sensitivity parameters, in adequation with the bias empirically observed in Figure 3.4. The bias landscape depends on the dependence of the covariate with other observed covariates, as illustrated with an asymmetric heatmap when  $X_1$  is partially observed, due to the presence of  $X_5$ .

Sensitivity parameter $\mathbb{E}[X_{mis}]$	0.8	0.9	1.0	1.1	1.2
Empirical average $\hat{\tau}_{G,n,m,obs}$	44	47	50	53	56
Empirical standard deviation $\hat{\tau}_{G,n,m,obs}$	0.4	0.4	0.3	0.3	0.4

**Table 3.4: Simulations results when applying procedure 3:** Results of the simulation considering  $X_1$  being partially observed in the RCT, and using the sensitivity method of [Nguyen et al. \(2017\)](#), but with a Robinson procedure to handle semi-parametric generative functions. When varying the sensitivity parameters, the estimated ATE is close to the true ATE ( $\tau = 50$ ) when the sensitivity parameter is closer to the true one ( $\mathbb{E}[X_{mis}] = 1$ ). The results are presented for 100 repetitions.

$\beta_{s,1}$	Averaged p-value
0	0.44
-0.2	0.37
-0.4	0.31
-0.6	0.14
-0.8	0.04
-1	0.012
-1.2	0.0001
-1.4	$1 \cdot 10^{-9}$
-1.6	$1 \cdot 10^{-10}$
-1.8	$3 \cdot 10^{-15}$
-2	$1.4 \cdot 10^{-23}$

**Figure 3.6: Empirical link between the logistic regression coefficient for sampling bias  $\beta_{s,1}$  and the p-value of a Box-M test.** The average p-value is computed by repeating 50 times the simulation. We recall that in Figure 3.4,  $\beta_{s,1} := -0.4$ .



**Figure 3.7: Impact of poor transportability of the variance-covariance matrix** which is simulated with a decreasing coefficient  $\beta_{s,1}$ , responsible of the covariate shift between the RCT sample and the observational sample. The lower  $\beta_{s,1}$ , the higher the absolute empirical bias (boxplots), and the higher the difference between the predictions given by Theorem 5 (orange dots) compared to the effective empirical biases (boxplots).

**Violation of Assumption 22** To assess the impact of a lack of transportability of the variance-covariance matrix (Assumption 22) we propose to observe the effect of an increasing (in absolute value) coefficient involved in the sampling process (Equation 3.7). We observe that the bigger the coefficient, the bigger the deviations from the theory, as expected. To illustrate this phenomenon, we associate the logistic regression coefficient (the further away from the zero, the more Assumption 22 is unvalidated) to the p-value of a Box-M test assessing if the variance covariance matrix from the two sources are different. Empirically, the bias is still well estimated by procedures described in Section 3 even if the p-value is lower than 0.05. Results are available on Figures 3.6 and 3.7.

## 4.2 A semi-synthetic simulation: the STAR experiment

The semi-synthetic experiment is a mean to evaluate the methods on (semi) real data where neither the data generation process nor the distribution of the covariates are under control.

### 4.2.1 Simulation details

We use the data from a randomized controlled trial, the Tennessee Student/Teacher Achievement Ratio (STAR) study. This RCT is a pioneering randomized study from the domain of education (Angrist and Pischke, 2008), started in 1985, and designed to estimate the effects of smaller classes in primary school, on the children’s grades. This experiment showed a strong payoff to smaller classes (Krueger, 1999b). In addition, the effect has been shown to be heterogeneous, where class sizes have a larger effect for minority students and those on subsidized lunch. For our purposes, we focus on the same subgroup of children, same treatment (small versus regular classes), and same outcome (average of all grades at the end) as in Kallus et al. (2018).


4218 children are concerned by the treatment randomization, with treatment assignment at first grade only. On the whole data, we estimated an average treatment effect of 12.80 additional points on the grades (95% CI [10.41-15.2]) with the difference-in-means estimator. We consider this estimate as the ground truth  $\tau$  as it is the global RCT. Then, we generate a random sample of 500 children to serve as the observational study. From the rest of the data, we sample a biased RCT according to a logistic regression that defines probability for each class to be selected in the RCT, and using only the variable `g1surban` informing on the neighborhood of the school, which can be considered as a proxy for the socioeconomic status. The final selection is performed using a Bernoulli procedure, which leads to 563 children in the RCT. The resulting RCT is such that  $\hat{\tau}_1$  is 4.85 (95% CI [-2.07-11.78]) which is underestimated. This is due to the fact that the selection is performed toward children that benefit less from the class size reduction according to previous studies (Krueger, 1999b; Kallus et al., 2018). When generalizing the ATE with the G-formula on the full set of covariates, estimating the nuisance components with a linear model, and estimating the confidence intervals with a stratified bootstrap (1000 repetitions), the target population ATE is recovered with an estimate of 13.05 (95% CI [5.07-22.11]) Not including the covariate on which the selection is performed (`g1surban`) leads to a biased generalized ATE of 5.87 (95% CI [-1.47-12.82]). These results are represented on Figure 3.8, along with AIPSW estimates. The IPSW is not represented due to a too large variance.

### 4.2.2 Application of the sensitivity methods

We now successively consider two different missing covariate patterns to apply the methods from Section 3.3.2.

**Considering `g1surban` is missing in the observational study** Nguyen et al. (2017)’s method (recalled in Section 3.3.2) can be applied, if we are given a set of plausible values for  $\mathbb{E}[\text{g1surban}]$ . Specifying the following range ]2.1, 2.7[ (containing the true value for  $\mathbb{E}[\text{g1surban}]$ ) leads to a range for the generalized ATE of ]9.5, 16.7[. Recalling that the *ground truth* is 12.80 (95% CI[10.41-15.2]), the estimated range has a good overlap with the ground truth. In other words, with this specification of the range, a user would correctly conclude that without this key variable, the generalized ATE is probably underestimated.


**Figure 3.8: Simulated STAR data:** True target population ATE estimation using all the STAR’s RCT data is represented (difference-in-means). This is highlighted with a red dashed line to represent the ground truth. The ATE estimate of a biased RCT (difference-in-means) is also represented showing a lower treatment effect due to a covariate shift along the covariate  $g1surban$ . Two estimators are used for the generalization, the G-formula (Definition 16) and the AIPSW (Definition 21); both relying on linear or logistic models for the nuisance components. The generalized ATE is either estimated with all covariates (blue) or with all covariates *except*  $g1surban$  (orange). The confidence intervals are estimated with a stratified bootstrap (1000 repetitions). Similar results are obtained when nuisance components are estimated with random forest.



**Considering  $g1surban$  is missing in the RCT** Figure 3.9 illustrates the method when the missing covariate is in the RCT data set (see Procedure 2). This method relies on Assumption 22, which we test with a Box M-test on  $\Sigma$  (though in practice such a test could only be performed on  $\Sigma_{obs,obs}$ ). Including only numerical covariates would reject the null hypothesis ( $p$ -value = 0.034). Note that beyond violating Assumption 22, some variables are categorical (eg **race** and **gender**). Further discussions about violation of this assumption are available in appendix (Section 3.G).

In this application, applying recommendations from Section 3.3.2 (see paragraph entitled *Data-driven approach to determine sensitivity parameter*) allow us to get  $\delta_{g1surban} \sim 11$ . We consider that the shift is correctly given by domain expert, and so the true shift is taken with uncertainty corresponding to the 95% confidence interval of a difference in mean. Finally, Figure 3.9 allows to conclude on a negative bias, that is  $\mathbb{E}[\hat{\tau}_{n,m,obs}] \leq \tau$ . Note that our method underestimate a bit the true bias, with an estimated bias of  $-6.4$  when the true bias is  $-7.08$ , delimited with the continue red curve on the top right.

**Figure 3.9: Sensitivity analysis of STAR data:** considering the covariate  $g1surban$  is missing in the RCT. The black cross indicates the point estimate value for the bias would an expert have the true sensitivity values ( $-6.4$ ) and the true bias value is represented with the red line ( $-7.08$ ). Dashed lines corresponds to the 95% confidence intervals around the estimated sensitivity parameters.



## 5 Application on critical care data

A motivating application of our work is the generalization to a French target population – represented by the **Traumabase** registry – of the CRASH-3 trial (CRASH-3, 2019), evaluating Tranexamic Acid (TXA) to prevent death from Traumatic Brain Injury (TBI).

**CRASH-3** A total of 175 hospitals in 29 different countries participated to the randomized and placebo-controlled trial, called CRASH-3 (Dewan et al., 2012), where adults with TBI suffering from intracranial bleeding were randomly administrated TXA (CRASH-3, 2019). The inclusion criteria

of the trial are patients with a Glasgow Coma Scale (GCS)<sup>4</sup> score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding. The outcome we consider in this application is the Disability Rating Scale (DRS) after 28 days of injury in patients treated within 3 hours of injury. Such an index is a composite ordinal indicator ranging from 0 to 29, the higher the value, the stronger the disability. This outcome can be considered as a secondary outcome. This outcome has some drawbacks in the sense that TXA diminishes the probability to die from TBI, and therefore may increase the number of high DRS values (Brenner et al., 2018). Therefore, to avoid a censoring or truncation due to death, we keep all individuals and set the DRS score of deceased ones to 30. The difference-in-means estimators gives an ATE of -0.29 with [95% CI -0.80 0.21]), therefore not giving a significant evidence of an effect of TXA on DRS.

**Traumabase** To improve decisions and patient care in emergency departments, the Traumabase group, comprising 23 French Trauma centers, collects detailed clinical data from the scene of the accident to the release from the hospital. The resulting database, called the Traumabase, comprises 23,000 trauma admissions to date, and is continually updated. In this application, we consider only the patients suffering from TBI, along with considering an imputed database. The Traumabase comprises a large number of missing values, this is why we used a multiple imputation via chained equations (MICE) (van Buuren, 2018) prior to applying our methodology.


**Predicting the treatment effect on the Traumabase data** We want to generalize the treatment effect to the French patients - represented by the Traumabase data base. Six covariates are present at baseline, with age, sex, time since injury, systolic blood pressure, Glasgow Coma Scale score (GCS), and pupil reaction. Sex is not considered in the final sensitivity analysis as a non-continuous covariate, and pupil reaction is considered as continuous ranging from 0 to 2. However an important treatment effect modifier is missing, that is the time between treatment and the trauma. For example, Mansukhani et al. (2020) reveal a 10% reduction in treatment effectiveness for every 20-min increase in time to treatment (TTT). In addition TTT is probably shifted between the two populations. Therefore this covariate breaks assumption 19 (ignorability on trial participation), and we propose to apply the methods developed in Section 3.

**Sensitivity analysis** The concatenated data set with the RCT and observational data contains 12496 observations (with  $n = 8977$  and  $m = 7743$ ). Considering a totally-missing covariate, we apply Procedure 1. We assume that time-to-treatment (TTT) is independent of all other variables, for example the ones related to the patient baseline characteristics (e.g. age) or to the severity of the trauma (e.g. the Glasgow score). Clinicians support this assumption as the time to receive the treatment depends on the time for the rescuers to come to the accident area, and not on the other patient characteristics. We first estimated the target population treatment effect with the set of observed variables and the G-formula estimator, leading to an estimated ATE  $\hat{\tau}_{n,m,obs}$  of -0.08 (95% CI [-0.50 0.44]). The nuisance parameters are estimated using random forests, and the confidence interval with non-parametric stratified bootstrap. As the omission of the TTT variable could affect this conclusion, the sensitivity analysis gives insights on the potential bias.


We apply the method relative to a completely missing covariate (Section 3.3.1). A common practice in sensitivity analysis is to use observed covariates as benchmark to guess the impact of an unobserved covariates. For example, the Glasgow score is also suspected to be a treatment effect modifier and is shifted between the two populations. We place it on a sensitivity map (Figure 3.10) along with the true corresponding values for  $\delta_{glasgow}$  and  $\Delta_{glasgow}$ . As the Traumabase contain more individuals with a higher Glasgow score, a positive shift is reported. In addition, the higher the Glasgow score the higher the effect (low DRS), so that  $\delta_{glasgow} < 0$ . Finally, removing the Glasgow score from the analysis would lead to  $\hat{\tau}_{obs,n,m} > \tau$ . The sensitivity map does not allow to conclude that this bias is big enough compared to the confidence intervals previously mentioned for  $\hat{\tau}_{obs,n,m}$ . Is the TTT a stronger or more shifted covariate than the Glasgow score? Previous publications have suggested a huge impact

<sup>4</sup>The Glasgow Coma Scale (GCS) is a neurological scale which aims to assess a person's consciousness. The lower the score, the higher the gravity of the trauma.

of TTT, and therefore one could expect a bigger impact on the bias. On Figure 3.11 we represent a sensitivity map for TTT that could be drawn by domain experts. Here, sensitivity parameters are guessed. For example, one can suspect that treatment is given on average 20 minutes earlier in the Traumabase (for example interviewing nurses and doctors in Trauma centers), and the coefficient  $\delta_{\text{TTT}}$  is inferred from a previous work on TXA. On Figure 3.11, one can see that not observing TTT has a bigger impact on the bias than not observing the Glasgow score (almost 10 times bigger), suggesting another conclusion: a positive and significant effect of TXA on the Traumabase population, if the sensitivity parameters are correctly guessed. Also, as soon as there is a risk of a treatment given later than in the CRASH3 trial, this sensitivity map would help raising an alarm on a negative effect on the Traumabase population.



**Figure 3.10: Sensitivity map if the Glasgow score covariate was missing:** the true corresponding values for  $\delta_{\text{glasgow}}$  and  $\Delta_{\text{glasgow}}$  are computed with respectively a Robinson procedure and a mean difference. Intervals correspond to 95% confidence intervals.



**Figure 3.11: Sensitivity map for TTT:** Intervals represent *plausible* parameters range, with a treatment given on average 10 to 30 minutes earlier in the Traumabase, and an heterogeneous coefficient inspired from Mansukhani et al. (2020).

## Conclusion

In this work, we have studied sensitivity analyses for causal-effect generalization to assess the impact of a partially-unobserved confounder (either in the RCT or in the observational data set) on the ATE estimation. In particular:

1. To go beyond the common requirement that the unobserved confounder is independent from the observed covariates, we instead assume that their covariance is transported (Assumption 22). Our simulation study (4) shows that even with a slightly deformed covariance, the proposed sensitivity analysis procedure gives useful estimates of the bias.
2. Leveraging the high interpretability of our sensitivity parameter, our framework concludes on the sign of the estimated bias. This sign is important as accepting a treatment effect highly depends on the direction of the generalization shift. We integrate the above methods into the existing sensitivity map visualization, using a heatmap to represent the sign of the estimated bias.
3. Our procedures use a sensitivity parameter with a direct interpretation: shift in expectation  $\Delta_m$  of the missing covariate between the RCT and the observational data. We hope that this will ease practical applications of sensitivity analyses by domain experts.

Our proposal inherits limitations from the more standard sensitivity analysis methods with observational data, namely the semi-parametric assumption of the outcome model along with an hypothesis on covariate structures (Gaussian inputs). Therefore, future extensions of this work could explore ways to relax either the parametric assumption or the distributional assumption to support more robust sensitivity analyses. Another possible extension to a missing binary covariate could be deduced from this work, in the case where this covariate is independent of the others in both populations.

## Appendix of Chapter 3

### 3.A Estimators of the target population ATE

In this section, we grant assumptions presented in Section 2.1 and study the asymptotic behavior – and in particular the  $L^1$ -consistency – of three estimators: the G-formula, the IPSW, and the AIPSW.

#### 3.A.1 G-formula

The G-formula procedure and its consistency assumption are detailed in the core text, see Section 3, and in particular Definition 16 and Assumption 21. Here, we present the Theorem for consistency.

**Theorem 6** (G-formula consistency). *Consider the G-formula estimator in Definition 16 along with Assumptions 16, 17, 18, 19, 20 (identifiability), and Assumption 21 (consistency), then the G-formula estimator converges toward  $\tau$  in  $L^1$  norm,*

$$\hat{\tau}_{G,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

#### 3.A.2 IPSW

Another approach, called Inverse Propensity Weighting Score (IPSW), consists in weighting the RCT sample so that it resembles the target population distribution.

**Definition 20** (Inverse Propensity Weighting Score - IPSW - [Stuart et al. \(2011\)](#); [Buchanan et al. \(2018\)](#)). *The IPSW estimator is denoted  $\hat{\tau}_{IPSW,n,m}$ , and defined as*

$$\hat{\tau}_{IPSW,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{n}{m} \frac{Y_i}{\hat{\alpha}_{n,m}(X_i)} \left( \frac{A_i}{e_1(X_i)} - \frac{1 - A_i}{1 - e_1(X_i)} \right), \quad (3.9)$$

where  $\hat{\alpha}_{n,m}$  is an estimate of the odd ratio of the indicatrix of being in the RCT:

$$\alpha(x) = \frac{(i \in \mathcal{R} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}{(i \in \mathcal{O} \mid \exists i \in \mathcal{R} \cup \mathcal{O}, X_i = x)}.$$

This intermediary quantity to estimate,  $\alpha(\cdot)$ , is called a nuisance component.

Similarly to the G-formula, we introduce here an assumption on the behavior of the nuisance component  $\alpha$  to carry out the mathematical analysis of the IPSW.

**Assumption 24** (Consistency assumptions - IPSW). *Denoting by  $\frac{n}{m\hat{\alpha}_{n,m}(x)}$  the estimated weights on the set of observed covariates  $X$ , the following conditions hold,*

- (H1-IPSW)  $\sup_{x \in \mathcal{X}} \left| \frac{n}{m\hat{\alpha}_{n,m}(x)} - \frac{f_X(x)}{f_{X|S=1}(x)} \right| = \epsilon_{n,m} \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- (H2-IPSW) for all  $n, m$  large enough  $\mathbb{E}[\epsilon_{n,m}^2]$  exists and  $\mathbb{E}[\epsilon_{n,m}^2] \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- (H3-IPSW)  $Y$  is square integrable.

**Theorem 7** (IPSW consistency). *Consider the IPSW estimator in Definition 20 along with Assumptions 16, 17, 18, 19, 20 (identifiability), and Assumption 24 (consistency). Then,  $\hat{\tau}_{IPSW,n,m}$  converges toward  $\tau$  in  $L^1$  norm,*

$$\hat{\tau}_{IPSW,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

Theorem 7 establishes the consistency of IPSW in a more general framework than that of [Cole and Stuart \(2010\)](#); [Stuart et al. \(2011\)](#); [Buchanan et al. \(2018\)](#); [Egami and Hartman \(2021\)](#), assuming neither oracle estimator, nor parametric assumptions on  $\alpha(\cdot)$ .



### 3.A.3 AIPSW

The model for the expectation of the outcomes among randomized individuals (used in the G-estimator in Definition 16) and the model for the probability of trial participation (used in IPSW estimator in Definition 20) can be combined to form an Augmented IPSW estimator (AIPSW) that has a doubly robust statistical property.

**Definition 21** (Augmented IPSW - AIPSW - Dahabreh et al. (2019)). *The AIPSW estimator is denoted  $\hat{\tau}_{AIPSW,n,m}$ , and defined as*

$$\hat{\tau}_{AIPSW,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{n}{m \hat{\alpha}_{n,m}(X_i)} \left[ \frac{A_i (Y_i - \hat{\mu}_{1,n}(X_i))}{e_1(X_i)} - \frac{(1 - A_i) (Y_i - \hat{\mu}_{0,n}(X_i))}{1 - e_1(X_i)} \right] + \frac{1}{m} \sum_{i=n+1}^{m+n} (\hat{\mu}_{1,n}(X_i) - \hat{\mu}_{0,n}(X_i)).$$

Recently, it has been shown that the AIPSW estimator can be derived from the influence function of the parameter  $\tau$  (see Dahabreh et al., 2019). Under additional conditions on the rate of convergence of the nuisance parameters, it is possible to obtain asymptotic normality results<sup>5</sup>. As in this work we only require  $L^1$ -consistency for the sensitivity analysis to hold, we therefore do not detail asymptotic normality conditions.

To prove AIPSW consistency, we make the following assumptions on the nuisance parameters.

**Assumption 25** (Consistency assumptions - AIPSW). *The nuisance parameters are bounded, and more particularly*

- (H1-AIPSW) *There exists a function  $\alpha_0$  bounded from above and below (from zero), satisfying*

$$\lim_{m,n \rightarrow \infty} \sup_{x \in \mathcal{X}} \left| \frac{n}{m \hat{\alpha}_{n,m}(x)} - \frac{1}{\alpha_0(x)} \right| = 0,$$

- (H2-AIPSW) *There exist two bounded functions  $\xi_1, \xi_0 : \mathcal{X} \rightarrow \mathbb{R}$ , such that  $\forall a \in \{0, 1\}$ ,*

$$\lim_{n \rightarrow +\infty} \sup_{x \in \mathcal{X}} |\xi_a(x) - \hat{\mu}_{a,n}(x)| = 0.$$

**Theorem 8** (AIPSW consistency). *Consider the AIPSW estimator in Definition 21, along with Assumptions 16, 17, 18, 19, 20 hold (identifiability), and Assumption 25 (consistency). Considering that estimated surface responses  $\hat{\mu}_{a,n}(\cdot)$  where  $a \in \{0, 1\}$  are obtained following a cross-fitting estimation, then if Assumption 21 **or** Assumption 24 also holds then,  $\hat{\tau}_{AIPSW,n,m}$  converges toward  $\tau$  in  $L^1$  norm,*

$$\hat{\tau}_{AIPSW,n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

## 3.B $L^1$ -convergence of G-formula, IPSW, and AIPSW

This appendix contains the proofs of theorems given in Section 3.A. We recall that this work completes and details existing theoretical work performed by Buchanan et al. (2018) on IPSW (but focused on a so called nested-trial design and assuming parametric model for the weights) and from Dahabreh et al. (2020) developing results within the semi-parametric theory.

<sup>5</sup>A primer for semiparametric theory can be found in Kennedy (2016).



### 3.B.1 $L^1$ -convergence of G-formula

This section contains the proof of Theorem 6, which assumes Assumption 21. For the state of clarity, we recall here Assumption 21. Denoting  $\hat{\mu}_{0,n}(\cdot)$  and  $\hat{\mu}_{1,n}(\cdot)$  estimators of  $\mu_0(\cdot)$  and  $\mu_1(\cdot)$  respectively, and  $\mathcal{D}_n$  the RCT sample, so that

- (H1-G) For  $a \in \{0, 1\}$ ,  $\mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)| \mid \mathcal{D}_n] \xrightarrow{P} 0$  when  $n \rightarrow \infty$ ,
- (H2-G) For  $a \in \{0, 1\}$ , there exist  $C_1, N_1$  so that for all  $n \geq N_1$ , almost surely,  $\mathbb{E}[\hat{\mu}_{a,n}^2(X) \mid \mathcal{D}_n] \leq C_1$ .

*Proof of Theorem 6.* In this proof, we largely rely on a oracle estimator  $\hat{\tau}_{G,\infty,m}^*$  (built with the true response surfaces), defined as

$$\hat{\tau}_{G,\infty,m}^* = \frac{1}{m} \sum_{i=n+1}^{n+m} \mu_1(X_i) - \mu_0(X_i).$$

The central idea of this proof is to compare the actual G-formula  $\hat{\tau}_{G,n,m}$  - on which the nuisance parameters are estimated on the RCT data - with the oracle.

#### $L^1$ -convergence of the surface responses

For the proof, we will require that the estimated surface responses  $\hat{\mu}_{1,n}(\cdot)$  and  $\hat{\mu}_{0,n}(\cdot)$  converge toward the true ones in  $L^1$ . This is implied by assumptions (H1-G) and (H2-G). Indeed, for all  $n > 0$  and all  $a \in \{0, 1\}$ , thanks to the triangle inequality and linearity of expectation, we have

$$\begin{aligned} \mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)| \mid \mathcal{D}_n] &\leq \mathbb{E} [|\hat{\mu}_{a,n}(X)| \mid \mathcal{D}_n] + \mathbb{E} [|\mu_a(X)| \mid \mathcal{D}_n] \\ &= \underbrace{\mathbb{E} [|\hat{\mu}_{a,n}(X)| \mid \mathcal{D}_n]}_{(*)} + \underbrace{\mathbb{E} [|\mu_a(X)|]}_{(**)}. \end{aligned}$$

First, note that the quantity (\*) is upper bounded thanks to assumption (H2-G), using Jensen's inequality. Also note that the quantity (\*\*) is upper bounded because the potential outcomes are integrables, that is  $\mathbb{E}[Y(1)]$  and  $\mathbb{E}[Y(0)]$  exist (see Section 2.1).

Therefore  $\mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)| \mid \mathcal{D}_n]$  is upper bounded. Consequently, using (H2-G) and a generalization of the dominated convergence theorem, one has

$$\mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)|] = \mathbb{E} [\mathbb{E} [|\hat{\mu}_{a,n}(X) - \mu_a(X)| \mid \mathcal{D}_n]] \xrightarrow[n \rightarrow \infty]{} 0,$$

which implies

$$\forall a \in \{0, 1\}, \hat{\mu}_{a,n}(X) \xrightarrow[n \rightarrow \infty]{L^1} \mu_a(X).$$

#### $L^1$ -convergence of $\hat{\tau}_{G,n,m}$ toward $\tau$

For all  $m, n > 0$ ,

$$\begin{aligned} \hat{\tau}_{G,n,m} - \hat{\tau}_{G,\infty,m}^* &= \frac{1}{m} \sum_{i=n+1}^{n+m} (\hat{\mu}_{1,n}(X_i) - \hat{\mu}_{0,n}(X_i)) - (\mu_1(X_i) - \mu_0(X_i)) \\ &= \frac{1}{m} \sum_{i=n+1}^{n+m} (\hat{\mu}_{1,n}(X_i) - \mu_1(X_i)) - (\hat{\mu}_{0,n}(X_i) - \mu_0(X_i)). \end{aligned}$$

Therefore, taking the expectation of the absolute value on both side, and using the triangle inequality and the fact that observations are iid,

$$\begin{aligned} \mathbb{E} [|\hat{\tau}_{G,n,m} - \hat{\tau}_{G,\infty,m}^*|] &= \mathbb{E} \left[ \left| \frac{1}{m} \sum_{i=n+1}^{n+m} (\hat{\mu}_{1,n}(X_i) - \mu_1(X_i)) - (\hat{\mu}_{0,n}(X_i) - \mu_0(X_i)) \right| \right] \\ &\leq \mathbb{E} [|\hat{\mu}_{1,n}(X) - \mu_1(X)|] + \mathbb{E} [|\hat{\mu}_{0,n}(X) - \mu_0(X)|]. \end{aligned}$$

Note that this last inequality can be obtained because different observations are used to (i) build the estimated surface responses  $\hat{\mu}_{a,n}$  (for  $a \in \{0, 1\}$ ) and (ii) to evaluate these estimators. Indeed, the proof would be much more complex if the sum was taken over the  $n$  observations used to fit the models. Due to the  $L^1$ -convergence of each of the surface response when  $n \rightarrow \infty$  (see the first part of the proof), we have

$$\lim_{n \rightarrow \infty} \mathbb{E} \left[ \left| \hat{\tau}_{G,n,m} - \hat{\tau}_{G,\infty,m}^* \right| \right] = 0.$$

In other words,

$$\forall m, \hat{\tau}_{G,n,m} \xrightarrow[n \rightarrow \infty]{L^1} \hat{\tau}_{G,\infty,m}^*. \quad (3.10)$$

This equality is true for any  $m$ , and intuitively can be understood as the fitted response surfaces  $\hat{\mu}_{a,n}(\cdot)$  can be very close to the true ones as soon as  $n$  is large enough. Then, the G-formula estimator, no matter the size of the observational data set, is close to the oracle one in  $L^1$ . Hence one can deduce a result on the difference between  $\tau$  and the G-formula,

$$\mathbb{E} \left[ \left| \hat{\tau}_{G,n,m} - \tau \right| \right] \leq \mathbb{E} \left[ \left| \hat{\tau}_{G,n,m} - \hat{\tau}_{G,\infty,m}^* \right| \right] + \mathbb{E} \left[ \left| \hat{\tau}_{G,\infty,m}^* - \tau \right| \right].$$

According to the weak law of large number, we have

$$\hat{\tau}_{G,\infty,m}^* \xrightarrow[m \rightarrow \infty]{L^1} \tau$$

Combining this result with equation eq. 3.10, we have

$$\hat{\tau}_{G,n,m} \xrightarrow[n, m \rightarrow \infty]{L^1} \tau,$$

which concludes the proof.  $\square$

### 3.B.2 $L^1$ -convergence of IPSW

This section provides the proof of Theorem 7, and for the sake of clarity, we recall Assumption 24. Denoting  $\frac{n}{m\hat{\alpha}_{n,m}(x)}$ , the estimated weights on the set of covariates  $X$ , the following conditions hold,

- (H1-IPSW)  $\sup_{x \in \mathcal{X}} \left| \frac{n}{m\hat{\alpha}_{n,m}(x)} - \frac{f_X(x)}{f_{X|S=1}(x)} \right| = \varepsilon_{n,m} \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- (H2-IPSW) we have for all  $n, m$  large enough  $\mathbb{E}[\varepsilon_{n,m}^2]$  exists and  $\mathbb{E}[\varepsilon_{n,m}^2] \xrightarrow{a.s.} 0$ , when  $n, m \rightarrow \infty$ ,
- (H3-IPSW)  $Y$  is square integrable.

*Proof of Theorem 7.* First, we consider an oracle estimator  $\hat{\tau}_{\text{IPSW},n}^*$  that is based on the true ratio  $\frac{f_X(x)}{f_{X|S=1}(x)}$ , that is

$$\hat{\tau}_{\text{IPSW},n}^* = \frac{1}{n} \sum_{i=1}^n Y_i \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \left( \frac{A_i}{e_1(X_i)} - \frac{1 - A_i}{1 - e_1(X_i)} \right).$$

Note that [Egami and Hartman \(2021\)](#) also consider such an estimator and document its consistency (see their appendix). Indeed, assuming the finite variance of  $Y$ , the strong law of large numbers (also called Kolmogorov's law) allows us to state that:

$$\hat{\tau}_{\text{IPSW},n}^* \xrightarrow{a.s.} \mathbb{E} \left[ Y \frac{f_X(X)}{f_{X|S=1}(X)} \left( \frac{A}{e_1(X)} - \frac{1 - A}{1 - e_1(X)} \right) \mid S = 1 \right] = \tau, \quad \text{as } n \rightarrow \infty. \quad (3.11)$$

Now, we need to prove that this result also holds for the estimate  $\hat{\tau}_{\text{IPSW},n,m}$  where the weights are estimated from the data. To this aim, we first use the triangle inequality comparing  $\hat{\tau}_{\text{IPSW},n,m}$  with the oracle IPSW:

$$\begin{aligned}
 \left| \hat{\tau}_{\text{IPSW},n,m} - \hat{\tau}_{\text{IPSW},n}^* \right| &= \left| \frac{1}{n} \sum_{i=1}^n \left( \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right) \left( \frac{n}{\hat{\alpha}_{n,m}(X_i)m} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right) \right| \\
 &\leq \frac{1}{n} \sum_{i=1}^n \left| \left( \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right) \left( \frac{n}{\hat{\alpha}_{n,m}(X_i)m} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right) \right| \quad \text{Triangular inequality} \\
 &= \frac{1}{n} \sum_{i=1}^n \left| \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right| \left| \frac{n}{\hat{\alpha}_{n,m}(X_i)m} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right| \\
 &\leq \frac{\epsilon_{n,m}}{n} \sum_{i=1}^n \left| \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right|,
 \end{aligned}$$

where last row uses Assumption 24 (H1-IPSW).

Taking the expectation on the previous inequality gives,

$$\begin{aligned}
 \mathbb{E} \left[ \left| \hat{\tau}_{\text{IPSW},n,m} - \hat{\tau}_{\text{IPSW},n}^* \right| \right] &\leq \mathbb{E} \left[ \epsilon_{n,m} \frac{1}{n} \sum_{i=1}^n \left| \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right| \right] \\
 &\leq \sqrt{\mathbb{E} [\epsilon_{n,m}^2]} \sqrt{\mathbb{E} \left[ \left( \frac{1}{n} \sum_{i=1}^n \left| \frac{A_i Y_i}{e_1(X_i)} - \frac{(1-A_i)Y_i}{1-e_1(X_i)} \right| \right)^2 \right]} \quad \text{C.S., square integ, H3-IPSW} \\
 &\leq \sqrt{\mathbb{E} [\epsilon_{n,m}^2]} \sqrt{\mathbb{E} \left[ \left( \frac{1}{n} \sum_{i=1}^n \frac{2|Y|}{\min(\eta_1, 1-\eta_1)} \right)^2 \right]} \quad \text{Assumption 17} \\
 &\leq \sqrt{\mathbb{E} [\epsilon_{n,m}^2]} \sqrt{\mathbb{E} \left[ \frac{1}{n} \sum_{i=1}^n \frac{4|Y|^2}{\min(\eta_1^2, (1-\eta_1)^2)} \right]} \quad \text{Jensen} \\
 &= \sqrt{\mathbb{E} [\epsilon_{n,m}^2]} \frac{2\sqrt{\mathbb{E} [Y^2]}}{\min(\eta_1, (1-\eta_1))} \quad \text{iid}
 \end{aligned}$$

Therefore, using (H2-IPSW),

$$\mathbb{E} \left[ \left| \hat{\tau}_{\text{IPSW},n,m} - \hat{\tau}_{\text{IPSW},n}^* \right| \right] \rightarrow 0, \quad \text{as } n, m \rightarrow \infty. \quad (3.12)$$

Finally, note that

$$\mathbb{E} \left[ \left| \hat{\tau}_{\text{IPSW},n,m} - \tau \right| \right] \leq \mathbb{E} \left[ \left| \hat{\tau}_{\text{IPSW},n,m} - \hat{\tau}_{\text{IPSW},n}^* \right| \right] + \mathbb{E} \left[ \left| \hat{\tau}_{\text{IPSW},n}^* - \tau \right| \right].$$

The second right-hand side term tends to zero by the weak law of large numbers (same reasoning as for the G-formula) and the first term tends to zero using eq. 3.12, which leads to

$$\hat{\tau}_{\text{IPSW},n,m} \xrightarrow[n, m \rightarrow \infty]{L^1} \tau.$$

□

### 3.B.3 $L^1$ convergence of AIPSW

The proof of Theorem 8 is based on Assumption 25 and either Assumption 21 or Assumption 24. Therefore the proof contains two parts. for clarity, we recall here Assumption 25:

- (H1-AIPSW) There exists a function  $\alpha_0$  bounded from above and below (from zero), satisfying

$$\lim_{m, n \rightarrow \infty} \sup_{x \in \mathcal{X}} \left| \frac{n}{m \hat{\alpha}_{n,m}(x)} - \frac{1}{\alpha_0(x)} \right| = 0,$$

- (H2-AIPSW) There exist two bounded functions  $\xi_1, \xi_0 : \mathcal{X} \rightarrow \mathbb{R}$ , such that  $\forall a \in \{0, 1\}$ ,

$$\lim_{n \rightarrow +\infty} \sup_{x \in \mathcal{X}} |\xi_a(x) - \hat{\mu}_{a,n}(x)| = 0,$$

and, for all  $i \in \{1, \dots, n\}$ ,

$$\lim_{n \rightarrow +\infty} \sup_{x \in \mathcal{X}} |\xi_a(x) - \hat{\mu}_{a,n}^{-k(i)}(x)| = 0.$$

*Proof of Theorem 8.* Note that the cross-fitting procedure supposes to divide the data into  $K$  evenly sized folds, where  $K$  is typically set to 5 or 10 (for example see Chernozhukov et al. (2017)). Let  $k(\cdot)$  be a mapping from the sample indices  $i = 1, \dots, n$  to the  $K$  evenly sized data folds, and fit  $\hat{\mu}_{0,n}(\cdot)$  and  $\hat{\mu}_{1,n}(\cdot)$  with cross-fitting over the  $K$  folds using methods tuned for optimal predictive accuracy. For  $i \in \{1, \dots, n\}$ ,  $\hat{\mu}_{0,n}^{-k(i)}(\cdot)$  and  $\hat{\mu}_{1,n}^{-k(i)}(\cdot)$  denote response surfaces fitted on all folds except the  $k(i)$ -th. Let us also denote by  $\hat{\mu}_{0,n}(\cdot)$  and  $\hat{\mu}_{1,n}(\cdot)$ , the surface responses estimated using the whole data set.

### First case - Assumption 21.

Grant Assumption 21. In this part, we show that, due to this assumption, surface responses are consistently estimated. Recall that the AIPSW estimator  $\hat{\tau}_{\text{AIPSW},n,m}$  is defined as

$$\begin{aligned} \hat{\tau}_{\text{AIPSW},n,m} &= \frac{1}{n} \sum_{i=1}^n \frac{n}{m\hat{\alpha}_{n,m}(X_i)} \frac{A_i \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)}{e_1(X_i)} && A_{n,m} \\ &\quad - \frac{1}{n} \sum_{i=1}^n \frac{n}{m\hat{\alpha}_{n,m}(X_i)} \frac{(1 - A_i) \left( Y_i - \hat{\mu}_{0,n}^{-k(i)}(X_i) \right)}{1 - e_1(X_i)} && B_{n,m} \\ &\quad + \frac{1}{m} \sum_{i=n+1}^{m+n} (\hat{\mu}_{1,n}(X_i) - \hat{\mu}_{0,n}(X_i)) && C_{n,m} \end{aligned}$$

Note that  $\hat{\tau}_{\text{AIPSW},n,m}$  is composed of three terms, where the last  $C_{n,m}$  corresponds to the G-formula  $\hat{\tau}_{\text{G},n,m}$ .

Now, considering  $\mathbb{E}[|\hat{\tau}_{\text{AIPSW},n,m} - \tau|]$ , and using the triangle inequality and linearity of the expectation,

$$\mathbb{E}[|\hat{\tau}_{\text{AIPSW},n,m} - \tau|] \leq \mathbb{E}[|A_{n,m}|] + \mathbb{E}[|B_{n,m}|] + \mathbb{E}[|\hat{\tau}_{\text{G},n,m} - \tau|]. \quad (3.13)$$

Because Assumption 21 holds and according to Theorem 6, we have

$$\mathbb{E}[|\hat{\tau}_{\text{G},n,m} - \tau|] \rightarrow 0, \text{ when } n, m \rightarrow \infty. \quad (3.14)$$

Now, consider the term  $A_{n,m}$ , so that,

$$\begin{aligned} A_{n,m} &= \frac{1}{n} \sum_{i=1}^n \left( \frac{n}{m\hat{\alpha}_{n,m}(X_i)} - \frac{1}{\alpha_0(X_i)} \right) \frac{A_i \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)}{e_1(X_i)} && A_{n,m,1} \\ &\quad + \frac{1}{n} \sum_{i=1}^n \frac{1}{\alpha_0(X_i)} \frac{A_i \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)}{e_1(X_i)} && A_{n,m,2}. \end{aligned}$$

Regarding  $A_{n,m,1}$ , we have

$$\begin{aligned} \mathbb{E}[|A_{n,m,1}|] &\leq \frac{1}{\eta_1} \sup_{x \in \mathcal{X}} \left| \frac{n}{m\hat{\alpha}_{n,m}(x)} - \frac{1}{\alpha_0(x)} \right| \left( \mathbb{E} \left[ |A_i Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i)| \right] \right) \\ &\leq \frac{1}{\eta_1} \sup_{x \in \mathcal{X}} \left| \frac{n}{m\hat{\alpha}_{n,m}(x)} - \frac{1}{\alpha_0(x)} \right| (\mathbb{E}[|Y(1)|] + \mathbb{E}[|\xi_1(X)|] + \varepsilon), \end{aligned}$$

which tends to zero according to (H1-AIPSW). Regarding  $A_{n,m,2}$ , by the weak law of large numbers,

$$\begin{aligned} \frac{1}{n} \sum_{i=1}^n \frac{1}{\alpha_0(X_i)} \frac{A_i \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)}{e_1(X_i)} &\xrightarrow[n \rightarrow \infty]{L^1} \mathbb{E} \left[ \frac{1}{\alpha_0(X_i)} \frac{A_i \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)}{e_1(X_i)} \right] \\ &= \mathbb{E} \left[ \frac{1}{\alpha_0(X_i)} \mathbb{E} \left[ \left( Y_i - \hat{\mu}_{1,n}^{-k(i)}(X_i) \right) \mid X_i, \mathcal{D}_n^{-k(i)} \right] \right] \\ &= \mathbb{E} \left[ \frac{1}{\alpha_0(X_i)} \mathbb{E} \left[ \mu_1(X) - \hat{\mu}_{1,n}^{-k(i)}(X) \mid \mathcal{D}_n^{-k(i)} \right] \right], \end{aligned}$$

where

$$\left| \mathbb{E} \left[ \frac{1}{\alpha_0(X_i)} \mathbb{E} \left[ \mu_1(X) - \hat{\mu}_{1,n}^{-k(i)}(X) \mid \mathcal{D}_n^{-k(i)} \right] \right] \right| \leq \sup_{x \in \mathcal{X}} \left( \frac{1}{\alpha_0(x)} \right) \mathbb{E} \left[ \mathbb{E} \left[ \left| \mu_1(X) - \hat{\mu}_{1,n}^{-k(i)}(X) \right| \mid \mathcal{D}_n^{-k(i)} \right] \right],$$

which tends to zero according to Assumption 21. Therefore

$$A_{n,m} \xrightarrow[n \rightarrow \infty]{L^1} 0. \quad (3.15)$$

Using equations eq. 3.14 and eq. 3.15 in eq. 3.13 along with the  $L^1$ -convergence of the G-formula toward  $\tau$  allows us to conclude that

$$\hat{\tau}_{\text{AIPSW},n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \tau.$$

### Second case - Assumption 24.

Grant Assumption 24. In this part, we show that, due to this assumption, weights are consistently estimated. Note that the AIPSW estimate can be rewritten as

$$\begin{aligned} \hat{\tau}_{\text{AIPSW},n,m} &= \frac{1}{n} \sum_{i=1}^n \frac{n}{m \hat{\alpha}_{n,m}(X_i)} \left( \frac{A_i Y_i}{e_1(X_i)} - \frac{(1 - A_i) Y_i}{1 - e_1(X_i)} \right) && D_{n,m} \\ &\quad - \frac{1}{n} \sum_{i=1}^n \left( \frac{n}{m \hat{\alpha}_{n,m}(X_i)} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right) \left( \frac{A_i \hat{\mu}_{1,n}^{-k(i)}(X_i)}{e_1(X_i)} \right) && E_{n,m} \\ &\quad + \frac{1}{n} \sum_{i=1}^n \left( \frac{n}{m \hat{\alpha}_{n,m}(X_i)} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right) \left( \frac{(1 - A_i) \hat{\mu}_{0,n}^{-k(i)}(X_i)}{1 - e_1(X_i)} \right) && F_{n,m} \\ &\quad - \frac{1}{n} \sum_{i=1}^n \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \left( \frac{A_i \hat{\mu}_{1,n}^{-k(i)}(X_i)}{e_1(X_i)} - \frac{(1 - A_i) \hat{\mu}_{0,n}^{-k(i)}(X_i)}{1 - e_1(X_i)} \right) && G_n \\ &\quad + \frac{1}{m} \sum_{i=n+1}^{m+n} (\hat{\mu}_{1,n}(X_i) - \hat{\mu}_{0,n}(X_i)). && C_{n,m} \end{aligned}$$

Again, using the expectation and the triangle inequality, one has,

$$\mathbb{E} [|\hat{\tau}_{\text{AIPSW},n,m} - \tau|] \leq \mathbb{E} [|D_{n,m} - \tau|] + \mathbb{E} [|E_{n,m}|] + \mathbb{E} [|F_{n,m}|] + \mathbb{E} [|G_n + C_{n,m}|] \quad (3.16)$$

Note that the term  $D_{n,m}$  corresponds to the IPSW estimator (Definition 20). According to Assumption 24 and Theorem 7,  $\mathbb{E} [|D_{n,m} - \tau|]$  converges to 0 as  $n, m \rightarrow \infty$ . Now, we study the convergence of each of the remaining terms in equation eq. 3.16.

**Considering  $E_{n,m}$  and  $F_{n,m}$** 

Let us now consider the term  $E_{n,m}$ . First, note that, according to Assumption 25 (H2-AIPSW), the estimated surface responses are uniformly bounded for  $n$  large enough, that is, there exists  $\mu_M > 0$  such that, for all  $a \in \{0, 1\}$ , for all  $n$  large enough,

$$\sup_{x \in \mathcal{X}} |\hat{\mu}_{a,n}(x)| \leq \mu_M.$$

It follows that, for all  $n$  large enough,

$$\begin{aligned} |E_{n,m}| &\leq \frac{1}{n} \sqrt{\sum_{i=1}^n \left( \frac{n}{m\hat{\alpha}_{n,m}(X_i)} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right)^2} \sqrt{\sum_{i=1}^n \left( \frac{A_i \hat{\mu}_{1,n}^{-k(i)}(X_i)}{e_1(X_i)} \right)^2} && \text{Cauchy-Schwarz} \\ &\leq \frac{1}{n} \sqrt{\sum_{i=1}^n \left( \frac{n}{m\hat{\alpha}_{n,m}(X_i)} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right)^2} \frac{1}{\eta_1} \sqrt{\sum_{i=1}^n \left( \hat{\mu}_{1,n}^{-k(i)}(X_i) \right)^2} && \text{Assumption 17} \\ &\leq \frac{1}{\sqrt{n}} \sqrt{\sum_{i=1}^n \left( \frac{n}{m\hat{\alpha}_{n,m}(X_i)} - \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \right)^2} \frac{\mu_M}{\eta_1} && \text{Assumption 25 (H2-AIPSW)} \\ &\rightarrow 0, \text{ when } n, m \rightarrow \infty. && \text{Assumption 24} \end{aligned}$$

The reasoning is the same for the term  $F_{n,m}$ , which also converges uniformly toward 0 when  $n, m \rightarrow \infty$ .

**Considering  $G_n$  and  $C_{n,m}$** 

By Assumption (H2-AIPSW), for all  $\varepsilon > 0$ , for all  $n$  large enough, for all  $x \in \mathcal{X}$ ,

$$\hat{\mu}_{1,n}(x) \in [\xi_1(x) - \varepsilon, \xi_1(x) + \varepsilon].$$

Therefore, for all  $n$  large enough, and for all  $m$ ,

$$\begin{aligned} \left| \frac{1}{m} \sum_{i=n+1}^{m+n} \hat{\mu}_{1,n}(X_i) - \frac{1}{m} \sum_{i=n+1}^{m+n} \xi_1(X_i) \right| &\leq \frac{1}{m} \sum_{i=n+1}^{m+n} |\hat{\mu}_{1,n}(X_i) - \xi_1(X_i)| \\ &\leq \varepsilon. \end{aligned}$$

Consequently,

$$\left| C_{n,m} - \frac{1}{m} \sum_{i=n+1}^{m+n} \xi_1(X_i) + \frac{1}{m} \sum_{i=n+1}^{m+n} \xi_0(X_i) \right| \leq 2\varepsilon.$$

Therefore,

$$|C_{n,m} - \mathbb{E}[\xi_1(X)] + \mathbb{E}[\xi_0(X)]| \leq 2\varepsilon + \left| \frac{1}{m} \sum_{i=n+1}^{m+n} \xi_1(X_i) - \mathbb{E}[\xi_1(X)] \right| + \left| \frac{1}{m} \sum_{i=n+1}^{m+n} \xi_0(X_i) - \mathbb{E}[\xi_0(X)] \right|.$$

Hence, by the law of large numbers,

$$C_{n,m} \xrightarrow[n, m \rightarrow \infty]{L^1} \mathbb{E}[\xi_1(X)] - \mathbb{E}[\xi_0(X)].$$

We can apply the same reasoning for the term  $G_n$ , by taking into account the fact that it uses a cross-fitting strategy. By Assumption 25 (H2-AIPSW), for all  $\varepsilon > 0$ , for all  $n$  large enough, for all  $x \in \mathcal{X}$ , for all  $i \in \{1, \dots, n\}$ ,

$$\hat{\mu}_{1,n}^{-k(i)}(x) \in [\xi_1(x) - \varepsilon, \xi_1(x) + \varepsilon].$$

Using this inequality, we obtain

$$\left| \frac{1}{n} \sum_{i=1}^n \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \frac{A_i}{e_1(X_i)} \hat{\mu}_{1,n}^{-k(i)}(X_i) - \frac{1}{n} \sum_{i=1}^n \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \frac{A_i}{e_1(X_i)} \xi(X_i) \right| \leq \frac{\varepsilon}{\eta_1} \sup_{x \in \mathcal{X}} \left( \frac{1}{\alpha_0(x)} \right).$$

Besides, by the law of large numbers,

$$\lim_{n \rightarrow \infty} \frac{1}{n} \sum_{i=1}^n \frac{f_X(X_i)}{f_{X|S=1}(X_i)} \frac{A_i}{e_1(X_i)} \xi_1(X_i) = \mathbb{E} \left[ \frac{f_X(X)}{f_{X|S=1}(X)} \frac{A}{e_1(X)} \xi_a(X) \right] = \mathbb{E}[\xi_a(X)].$$

Consequently, as above

$$G_{n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} \mathbb{E}[\xi_0(X)] - \mathbb{E}[\xi_1(X)].$$

Finally,

$$C_{n,m} + G_{n,m} \xrightarrow[n,m \rightarrow \infty]{L^1} 0,$$

which concludes the proof. □

### 3.C Proofs for the missing covariate setting

This section gathers proofs related to the case where key covariates (treatment effect modifiers with distributional shift) are missing. In particular this appendix contains the proofs of results presented in Section 3.

#### 3.C.1 Proof of Theorem 5

*Proof.* The Theorem 5 is essentially a statement about the observed distribution. One can first derived what is the partial-identification of  $\tau$  under the observed distribution  $\tau_{obs}$ , that is,

$$\begin{aligned} \tau_{obs} &= \mathbb{E}[\mathbb{E}[Y(1) - Y(0) \mid X_{obs} = x_{obs}, S = 1]] \\ &= \mathbb{E}[\mathbb{E}[\langle \delta, X \rangle \mid X_{obs} = x_{obs}, S = 1]] && \text{Linear CATE} \\ &= \mathbb{E}[\mathbb{E}[\langle \delta, X_{obs} \rangle + \langle \delta, X_{mis} \rangle \mid X_{obs} = x_{obs}, S = 1]] && X = (X_{mis}, X_{obs}) \\ &= \mathbb{E}[\langle \delta, X_{obs} \rangle] + \mathbb{E}[\mathbb{E}[\langle \delta, X_{mis} \rangle \mid X_{obs} = x_{obs}, S = 1]] && \text{Ignorability} \end{aligned}$$

As the covariates  $X$  are assumed to be a Gaussian vector distributed as  $\mathcal{N}(\mu, \Sigma)$ , and considering the assumption on the variance-covariance matrix (Assumption 22), one can have an explicit expression of the conditional expectation (Ross, 2020).

$$\mathbb{E}[X_{mis} \mid X_{obs} = x_{obs}] = \mathbb{E}[X_{mis}] + \Sigma_{mis,obs} (\Sigma_{obs,obs})^{-1} (x_{obs} - \mathbb{E}[X_{obs}]).$$

Therefore, plugging this expression into  $\tau_{obs}$  and comparing it to  $\tau$ ,

$$\begin{aligned} \tau - \tau_{obs} &= \langle \delta, \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} \mid S = 1] - \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} \mid S = 1]) \rangle \\ &= \sum_{j \in mis} \delta_j \left( \mathbb{E}[X_j] - \mathbb{E}[X_j \mid S = 1] - \Sigma_{j,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} \mid S = 1]) \right) \end{aligned}$$

Note that the last row is only a different way to write the scalar product into a sum.

Then, any  $L^1$ -consistent estimator  $hat{\tau}_{n,m,obs}$  of  $\tau$  on the observed set of covariates will follow

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{n,m,obs}] - \tau = - \sum_{j \in mis} \delta_j \left( \mathbb{E}[X_j] - \mathbb{E}[X_j \mid S = 1] - \Sigma_{j,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} \mid S = 1]) \right).$$

□



### 3.C.2 Imputation

This part contains the proof of Corollary 2.

*Proof.* This proof is divided into two parts, depending on the missing covariate pattern.

**Consider the RCT as the complete dataset** We assume that the linear link between the missing covariate  $X_{mis}$  and the observed one  $X_{obs}$  in the trial population is known, so is the true response surfaces  $\mu_1(\cdot)$  and  $\mu_0(\cdot)$ . We consider the estimator  $\hat{\tau}_{G,\infty,m,imp}$  based on the two previous oracles quantities. We denote by  $c_0, \dots, c_{\#obs}$  the coefficients linking  $X_{obs}$  and  $X_{mis}$  in the trial, so that, on the event  $S = 1$ ,

$$X_{mis} = c_0 + \sum_{j \in obs} c_j X_j + \varepsilon, \quad (3.17)$$

where  $\varepsilon$  is a Gaussian noise satisfying  $[\varepsilon \mid X_{obs}] = 0$  almost surely. Since we assume that the true link between  $X_{mis}$  and  $X_{obs}$  is known (that is we know the coefficients  $c_0, \dots, c_d$ ), the imputation of the missing covariate on the observational sample writes

$$\hat{X}_{mis} := c_0 + \sum_{j \in obs} c_j X_j. \quad (3.18)$$

We denote  $\tilde{X}$  the imputed data set composed of the observed covariates and the imputed one in the observational sample. The expectation of the oracle estimator  $\hat{\tau}_{G,\infty,m,imp}$  is defined as,

$$\begin{aligned} \mathbb{E}[\hat{\tau}_{G,\infty,m,imp}] &= \mathbb{E} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \mu_1(\tilde{X}_i) - \mu_0(\tilde{X}_i) \right] && \text{By definition of } \hat{\tau}_{G,\infty,m,imp} \\ &= \mathbb{E} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \langle \delta, \tilde{X}_i \rangle \right] && \text{Linear CATE eq. 3.2} \\ &= \mathbb{E} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \left( \left( \sum_{j \in obs} \delta_j X_{j,i} \right) + \delta_{mis} \hat{X}_{mis,i} \right) \right] \end{aligned}$$

Because of the finite variance of  $X_{obs}$  and  $\hat{X}_{mis}$  the law of large numbers allows to state that:

$$\lim_{m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{G,\infty,m,imp}] = \left( \sum_{j \in obs} \delta_j \mathbb{E}[X_j] \right) + \delta_{mis} \mathbb{E}[\hat{X}_{mis}].$$

Due to Assumption 22, the distribution of the vector  $X$  is Gaussian in both populations, and one can use the conditional expectation for a multivariate gaussian law to write the conditional expectation in the trial population, that is

$$\mathbb{E}[X_{mis} \mid X_{obs}, S = 1] = \mathbb{E}[X_{mis} \mid S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (X_{obs} - \mathbb{E}[X_{obs} \mid S = 1]). \quad (3.19)$$

Combining eq. 3.17 and eq. 3.19, one can obtain:

$$c_0 + \sum_{j \in obs} c_j X_j = \mathbb{E}[X_{mis} \mid S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (X_{obs} - \mathbb{E}[X_{obs} \mid S = 1]). \quad (3.20)$$

Now, we can compute,

$$\begin{aligned} \mathbb{E}[\hat{X}_{mis}] &= \mathbb{E}[c_0 + \sum_{j \in obs} c_j X_j] \\ &= \mathbb{E} \left[ \mathbb{E}[X_{mis} \mid S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (X_{obs} - \mathbb{E}[X_{obs} \mid S = 1]) \right] && \text{eq. 3.20} \\ &= \mathbb{E}[X_{mis} \mid S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} \mid S = 1]). \end{aligned}$$

This last result allows to conclude that,

$$\lim_{m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{G,\infty,m,imp}] = \left( \sum_{j \in obs} \delta_j \mathbb{E}[X_j] \right) + \delta_{mis} \left( \mathbb{E}[X_{mis} | S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[[X_{obs} | S = 1]]) \right).$$

Finally, as  $\tau = \sum_{j=1}^p \delta_j \mathbb{E}[X_j]$ ,

$$\tau - \lim_{m \rightarrow \infty} \mathbb{E}[\hat{\tau}_{G,\infty,m,imp}] = \delta_{mis} \left( \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1] - \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} | S = 1]) \right),$$

which concludes this part of the proof.

**Consider the observational data as the complete data set** We assume here that the true relations between  $X_{mis}$  and  $X_{obs}$  is known and the true response model is also known. We denote by  $\tau_{G,\infty,\infty,imp}$  the estimator based on these two quantities. More precisely, we denote by  $c_0, \dots, c_{\#obs}$  the coefficients linking  $X_{obs}$  and  $X_{mis}$  in the observational population, so that

$$X_{mis} = c_0 + \sum_{j \in obs} c_j X_j + \varepsilon, \quad (3.21)$$

where  $\varepsilon$  is a Gaussian noise satisfying  $\mathbb{E}[\varepsilon | X_{obs}] = 0$  almost surely.

As the estimator is an oracle, the relation in eq. 3.21 is used to impute the missing covariate in the observational sample, so that

$$\hat{X}_{mis} := c_0 + \sum_{j \in obs} c_j X_j. \quad (3.22)$$

We denote  $\tilde{X}$  the imputed data set composed of the observed covariates and the imputed one in the trial population. Note that the  $\hat{X}_{mis}$  is a linear combination of  $X_{obs}$  in the trial population, and thus a measurable function of  $X_{obs}$ . This property is used below and labelled as eq. 3.22. As  $\tau_{G,\infty,\infty,imp}$  is an oracle, one have:

$$\begin{aligned} \mathbb{E}[\tau_{G,\infty,\infty,imp}] &= \mathbb{E} \left[ \mathbb{E}[Y(1) - Y(0) | \tilde{X}, S = 1] \right] \\ &= \mathbb{E} \left[ \mathbb{E}[Y(1) - Y(0) | \hat{X}_{mis}, X_{obs}, S = 1] \right] \\ &= \mathbb{E} \left[ \mathbb{E}[Y(1) - Y(0) | X_{obs}, S = 1] \right] \quad \text{eq. 3.22} \\ &= \mathbb{E} \left[ \left( \sum_{j \in obs} \delta_j X_j \right) + \delta_{mis} \mathbb{E}[X_{mis} | X_{obs}, S = 1] \right] \quad \text{eq. 3.2} \\ &= \left( \sum_{j \in obs} \delta_j \mathbb{E}[X_j] \right) + \delta_{mis} \mathbb{E} \left[ \mathbb{E}[X_{mis} | X_{obs}, S = 1] \right] \\ &= \left( \sum_{j \in obs} \delta_j \mathbb{E}[X_j] \right) \\ &\quad + \delta_{mis} \left( \mathbb{E}[X_{mis} | S = 1] + \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[[X_{obs} | S = 1]]) \right). \quad \text{eq. 3.19} \end{aligned}$$

Finally, as  $\tau = \sum_{j=1}^p \delta_j \mathbb{E}[X_j]$ ,

$$\tau - \mathbb{E}[\tau_{G,\infty,\infty,imp}] = \delta_{mis} \left( \mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1] - \Sigma_{mis,obs} \Sigma_{obs,obs}^{-1} (\mathbb{E}[X_{obs}] - \mathbb{E}[X_{obs} | S = 1]) \right),$$

which concludes this part of the proof. □

### 3.C.3 Proxy variable

*Proof of Lemma 1.* Recall that we denote  $\hat{\tau}_{G,n,m,prox}$  the G-formula estimator using  $X_{prox}$  instead of  $X_{mis}$  in the G-formula. The derivations of  $\hat{\tau}_{G,n,m,prox}$  give:

$$\begin{aligned}
 \mathbb{E}[\hat{\tau}_{G,n,m,prox}] &= \mathbb{E}[\mathbb{E}[Y \mid X_{obs}, X_{prox}, S = 1, A = 1] - \mathbb{E}[Y \mid X_{obs}, X_{prox}, S = 1, A = 0]] \\
 &\quad \text{Definition of } \hat{\tau}_{G,n,m,prox} \\
 &= \mathbb{E}[\mathbb{E}[g(X) + \langle \delta, X \rangle \mid X_{obs}, X_{prox}, S = 1] - \mathbb{E}[g(X) \mid X_{obs}, X_{prox}, S = 1]] \\
 &= \mathbb{E}[\mathbb{E}[\langle \delta, X \rangle \mid X_{obs}, X_{prox}, S = 1]] \\
 &= \sum_{j \in obs} \delta_j \mathbb{E}[X_j] + \delta_{mis} \mathbb{E}[\mathbb{E}[X_{mis} \mid X_{obs}, X_{prox}, S = 1]] \\
 &\quad \text{Linearity of } Y \text{ eq. 3.2} \\
 &= \sum_{j \in obs} \delta_j \mathbb{E}[X_j] + \delta_{mis} \mathbb{E}[\mathbb{E}[X_{mis} \mid X_{prox}, S = 1]] \\
 &\quad X_{mis} \perp\!\!\!\perp X_{obs} \text{ eq. 23 and Assumption 16}
 \end{aligned}$$

The framework of the proxy variable eq. 23 allows to have an expression of the conditional expectation of  $X_{mis}$  (Ross, 2020):

$$\mathbb{E}[\mathbb{E}[X_{mis} \mid X_{prox}, S = 1]] = \mathbb{E}[X_{mis} \mid S = 1] + \frac{(X_{mis}, X_{prox})}{\mathbb{V}[X_{prox}]} (X_{prox} - \mathbb{E}[X_{prox} \mid S = 1]),$$

where

$$\begin{aligned}
 \mathbb{V}[X_{prox}] &= \mathbb{V}[X_{mis} + \eta] \\
 &= \mathbb{V}[X_{mis}] + \mathbb{V}[\eta] + 2 \underbrace{\text{Cov}(\eta, X_{mis})}_{=0 \text{ eq. 23}} \\
 &= \sigma_{mis}^2 + \sigma_{prox}^2
 \end{aligned}$$

and

$$\begin{aligned}
 (X_{mis}, X_{prox}) &= \mathbb{E}[X_{mis} X_{prox}] - \mathbb{E}[X_{prox}]^2 & \mathbb{E}[X_{mis}] &= \mathbb{E}[X_{prox}] \\
 &= \mathbb{E}[X_{prox}^2 - \eta X_{prox}] - \mathbb{E}[X_{prox}]^2 \\
 &= \mathbb{E}[X_{prox}^2] - \mathbb{E}[X_{prox}]^2 - \mathbb{E}[\eta X_{prox}] \\
 &= \mathbb{V}[X_{prox}] - \mathbb{E}[\eta X_{mis}] - \mathbb{E}[\eta^2] \\
 &= \sigma_{mis}^2 + \sigma_{prox}^2 - 0 - \sigma_{prox}^2 \\
 &= \sigma_{mis}^2
 \end{aligned}$$

Therefore, we have

$$\mathbb{E}[\mathbb{E}[X_{mis} \mid X_{prox}, S = 1]] = \mathbb{E}[X_{mis} \mid S = 1] + \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} (X_{prox} - \mathbb{E}[X_{prox} \mid S = 1]),$$

which allows us to complete the first derivation:

$$\begin{aligned}
 \mathbb{E}[\hat{\tau}_{G,n,m,prox}] &= \sum_{j \in obs} \delta_j \mathbb{E}[X_j] + \delta_{mis} \mathbb{E} \left[ \mathbb{E}[X_{mis} \mid S = 1] + \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} (X_{prox} - \mathbb{E}[X_{prox} \mid S = 1]) \right] \\
 &= \sum_{j \in obs} \delta_j \mathbb{E}[X_j] + \delta_{mis} \left( \mathbb{E}[X_{mis} \mid S = 1] + \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} (\mathbb{E}[X_{prox}] - \mathbb{E}[X_{prox} \mid S = 1]) \right) \\
 &= \sum_{j \in obs} \delta_j \mathbb{E}[X_j] + \delta_{mis} \left( \mathbb{E}[X_{mis} \mid S = 1] + \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} (\mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} \mid S = 1]) \right),
 \end{aligned}$$

since  $\mathbb{E}[X_{prox} | S = 1] = \mathbb{E}[X_{mis} | S = 1]$  and  $\mathbb{E}[X_{prox}] = \mathbb{E}[X_{mis}]$ . Recalling that  $\tau = \sum \delta_j \mathbb{E}[X_j]$ , the final form of the bias of  $\hat{\tau}_{G,n,m,prox}$  can be obtained as

$$\tau - \mathbb{E}[\hat{\tau}_{G,n,m,prox}] = \delta_{mis} (\mathbb{E}[X_{mis}] - \mathbb{E}[X_{mis} | S = 1]) \left( 1 - \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2} \right).$$

□

*Proof of Corollary 3.* Note that the final expression of the bias obtained in the previous proof can not be estimated in all missing covariate patterns. For example, if  $X_{mis}$  is partially observed in the RCT, then an estimate of  $\delta_{mis}$  can be computed, and therefore the bias can be estimated. But in all other missing covariate pattern, a temptation is to estimate  $\delta_{prox}$  from the regression of  $Y$  against  $X = (X_{obs}, X_{prox})$  with an OLS procedure. [Wooldridge \(2015\)](#) details the infinite sample estimate of such a coefficient:

$$\lim_{n,m \rightarrow \infty} \mathbb{E}[\hat{\delta}_{prox}] = \delta_{mis} \frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2}$$

Note that the quantity  $\frac{\sigma_{mis}^2}{\sigma_{mis}^2 + \sigma_{prox}^2}$  is always lower than 1, therefore if  $\delta_{mis} \geq 1$ , then  $\hat{\delta}_{prox}$  underestimates  $\delta_{mis}$ . This phenomenon is called the attenuation bias. This point is documented by [Wooldridge \(2015\)](#), and is due to heteroscedasticity in the plug-in regression:

$$\text{Cov}[X_{prox}, \varepsilon] = \text{Cov}[X_{mis} + \eta, \varepsilon - \delta_{mis}\eta] = -\delta_{mis}\sigma_{\eta}^2 \neq 0$$

This asymptotic estimate can be plugged-in into the previous bias estimation:

$$\tau - \mathbb{E}[\hat{\tau}_{G,n,m,prox}] = \hat{\delta}_{prox} (\mathbb{E}[X_{prox}] - \mathbb{E}[X_{prox} | S = 1]) \frac{\sigma_{prox}^2}{\sigma_{mis}^2}$$

□

### 3.D Toward a semi-parametric model

This section completes Model 3.2, and justifies why this the assumption of a linear CATE is somewhat natural when considering a continuous outcome  $Y$ .

For a continuous outcome  $Y$ , the outcome model can be written with two terms, a baseline and the CATE. Indeed, when focusing on zero-mean additive-error representations leads to assume that the potential outcomes are generated according to:

$$Y(A) = \mu(A, X) + \varepsilon_A, \tag{3.23}$$

for some function  $\mu \in \mathbf{L}^2(\{0, 1\} \times \mathcal{X} \rightarrow \mathbb{R})$  and a noise  $\varepsilon_A$  satisfying  $\mathbb{E}[\varepsilon_A | X] = 0$  almost surely.

**Lemma 2.** *Assume that the nonparametric generative model of Equation eq. 3.23 holds, then there exists a function  $g : \mathcal{X} \rightarrow \mathbb{R}$  such that*

$$Y(A) = g(X) + A\tau(X) + \varepsilon_A, \quad \text{where } \tau(X) := \mathbb{E}[Y(1) - Y(0) | X]. \tag{3.24}$$

Lemma 2 follows from rewriting Equation eq. 3.23, accounting for the fact that  $A$  is binary and  $Y \in \mathbb{R}$ . Such a decomposition is often used in the literature ([Nie and Wager, 2020](#)). This model allows to have a simpler expression of the treatment effect without any additional assumptions, due to the discrete nature of  $A$ .

In other words, this model enables placing independent functional form on the CATE  $\tau(X)$ , sometimes relying on the idea that the CATE is smoother, while the baseline response can be more complex ([Gao and Hastie, 2021](#)). In the context of the sensitivity analysis, this model has the interest of highlighting treatment effect modifier variables, such as variables that intervene in the CATE  $\tau(X)$ .

### 3.E Robinson procedure

This appendix recall the so-called Robinson procedure that aims at estimating the CATE coefficients  $\delta$  in a semi-parametric equation such as eq. 3.2. This method was developed by [Robinson \(1988\)](#) and has been further extended ([Chernozhukov et al., 2017](#); [Wager, 2020](#); [Nie and Wager, 2020](#)). Such a procedure is called a R-learner, where the  $R$  denotes *Robinson* or *Residuals*. We recall the procedure,

1. Run a non-parametric regressions  $Y \sim X$  using a parametric or non parametric method. The best method can be chosen with a cross-validation procedure. We denote  $\hat{m}_n(x) = \mathbb{E}[Y | X = x]$  the estimator obtained.
2. Define the transformed features  $\tilde{Y} = Y - \hat{m}_n(X)$  and  $\tilde{Z} = (A - e_1(X))X$ , using the previous procedure  $\hat{m}_n$ .
3. Estimate  $\hat{\delta}_n$  running the OLS regression on the transformed features  $\tilde{Y} \sim \tilde{Z}$ .

If the non-parametric regressions of  $m(x)$  satisfies  $\mathbb{E} [(\hat{m}(X) - m(X))^2]^{\frac{1}{2}} = o_P\left(\frac{1}{n^{1/4}}\right)$ , then the procedure to estimate  $\delta$  is  $\sqrt{n}$ -consistent and asymptotically normal,

$$\sqrt{n}(\hat{\delta} - \delta) \Rightarrow \mathcal{N}(0, V_R), \quad V_R = \text{Var}[\tilde{Z}]^{-1} \text{Var}[\tilde{Z}\tilde{Y}] \text{Var}[\tilde{Z}]^{-1}$$

See [Chernozhukov et al. \(2017\)](#); [Wager \(2020\)](#) for details.

### 3.F Synthetic simulation - Extension

This section completes the synthetic simulation presented in Section 4.


**Simulation parameters** Parameters chosen highlight different covariate roles and strength importance. In this setting, covariates  $X_1, X_2, X_3$  are the so-called treatment effect modifiers due to a non-zero  $\delta$  coefficients, and  $X_1, X_3, X_4$  are shifted from the RCT sample and the target population distribution due to a non-zero  $\beta_s$  coefficient. Therefore covariates  $X_1$  and  $X_3$  are necessary to generalize the treatment effect, because in both groups. Because in the simulation  $X_2$  and  $X_4$  are independent, the set  $X_1$  and  $X_3$  is also sufficient to generalize. Only  $X_2$  has the same marginal distribution in the RCT sample and in the observational study. Note that the amplitude and sign of different coefficients used, along with dependence between variables allows to illustrate several phenomenons. For example  $X_3$  is less shifted in between the two samples compared to  $X_1$  because  $|\beta_{s,1}| \leq |\beta_{s,3}|$ .

**Additional comments on Figure 3.4** Note that depending on the correlation strength between  $X_1$  and  $X_5$ , the missingness of  $X_1$  can lead to different coefficients estimations when using the G-formula estimation, and different bias on the ATE. Table 3.5 illustrates this situation, where the higher the correlation, the higher the error on the coefficients estimations, but the lower the bias on the ATE when only  $X_1$  is missing.

**Table 3.5: Coefficients estimated in the simulation:** Simulation with  $X_1$  as the missing covariate repeated 100 times, means of estimated coefficients for  $X_5$  and bias on ATE using the Robinson procedure.


$\rho_{X_1, X_5}$	$\delta_5 - \hat{\delta}_5$	$\hat{\tau}_{G,obs} - \tau$
0.05	6.34	-8.32
0.5	16.83	-6.29
0.95	28.53	-0.81

**Imputation** When a covariate is partially observed, at temptation is to imputed the missing part with a model learned on the complete part as detailed in procedure 4. Section 3 illustrates Corollary 2, as it shows that linear imputation does not diminish the bias compared to a case where the generalization is performed using only the restricted set of observed covariates. On Figure 3.12 we simulated all the missing covariate patterns (in RCT or in observational) considering  $X_1$  is partially missing, with varying correlation strength between  $X_5$  and  $X_1$ , and fitting a linear imputation model. Imputation does not lead to a lower bias than totally removing the partially observed covariate. Therefore, in case of a partially missing covariate we advocate running a sensitivity analysis rather than a linear imputation.



**Figure 3.12: Simulations results when imputing** (procedure 4): Results when imputing  $X_1$  with a linear model fitted on the complete data set (either the RCT or the observational). All the missing covariate pattern are simulated using either the G-formula or the IPSW estimators. The impact of the correlation between  $X_1$  and  $X_5$  is investigated. Each simulation is repeated 100 times. All procedures have a similar bias as the procedure ignoring the partially-missing covariate (`totally.missing`), so that a linear imputation (procedure 4) improves neither the bias nor the variance.

**Proxy variable** Finally and to illustrate Lemma 1, the simulation is extended to replace  $X_1$  by a proxy variable, generated following eq. 23 with a varying  $\sigma_{prox}$ . The generalized ATE is estimated with the G-formula. The experiments is repeated 20 times per  $\sigma_{prox}$  values. Results are presented on Figure 3.13. Whenever  $\sigma_{prox}$  is small compared to  $\sigma_{mis}$  (which is equal to one in this simulation), therefore the bias is small.



**Figure 3.13: Simulation results for proxy variable** (procedure 5) Simulation when a key covariate is replaced by a proxy following the proxy-framework (see Assumption 23). The theoretical bias eq. 1 is represented along with the empirical values obtained when generalizing the ATE with the plugged-in G-formula estimator.

### 3.G Homogeneity of the variance-covariance matrix


Recall that Assumption 22 states that the covariance matrices in both data sets are identical. This assumption, which may appear to be very restrictive, can be partially tested on the set of observed covariates. In this section, we present such a test (Box’s M-test [Box, 1949](#)), which illustrates the validity of Assumption 22 on some particular data set. Taking one step further, we study the impact of Assumption 22 violation on the resulting estimate.

#### 3.G.1 Statistical test and visualizations

[Friendly and Sigal \(2020\)](#) detail available tests to assess if covariance matrices from two data sample are equal. Despite its sensitivity to violation, Box’s M-test ([Box, 1949](#)) can be used to test the equality. In particular the package `heplots` contains the tests and visualizations in R. The command line to perform the test is detailed below.

```
1 library(heplots)
2 boxM(data[, c("X1", "X2", "X3", "X4")], group = data$S)
```

Even if we cannot bring a general rule to know if the covariance matrices are equal, we can display some examples in which Assumption 22 holds. For instance, [Friendly and Sigal \(2020\)](#) report that the `skull` data is an example of a real data set with multiple sources where there are substantial differences among the means of groups, but little evidence for heterogeneity of their covariance matrices.



**Figure 3.14: Pairwise data ellipses for the STAR data**, centered at the origin. This view allows to compare the variances and covariances for all pairs of variables.

##### 3.G.1.1 Semi-synthetic experiment: STAR

While doing the semi-synthetic experiment on the STAR data set, the Box M-test rejects the null hypothesis when considering only numerical covariates (`age`, `g1freelunch`, `gkfreelunch`, and `g1surban`) with a p-value of 0.022. This indicates that the preservation of the variance-covariance structure between the two simulated sources does not hold.

To help support conclusions, one can visualize how the variance covariance matrix vary in between the two sources, as presented on Figure 3.14, supporting that the changes in the variance-covariance are not very strong.

##### 3.G.1.2 Traumabase and CRASH-3

*Note that this part’s purpose is only to illustrate the principle as the application performed in Section 5 relies on the independence between the time to treatment and all other covariates, and not Assumption 22.*


One can inspect how far the variance and covariance change in between the two sources. Pairwise data ellipses are presented on Figure 3.15 for CRASH-3 and Traumabase patients, suggesting rather strong difference in the variance-covariance matrix. As expected Box M-test largely rejects the null hypothesis.

It is interesting to note that in some cases the variance covariance matrix is identical in between two populations. For example we tested whether the two major trauma centers in France present heterogeneity in the variance-covariance matrix, and the Box M test does not reject the null hypothesis.

#### 3.G.2 Extension of the simulations

Simulations presented in Section 4 can be extended to illustrate empirically the consequences of a poorly specified Assumption 22. Suppose  $X_1$  is the unobserved covariate, and that the variance-covariance matrix is not the same in the randomized population ( $S = 1$ ) as in the target population. But the heterogeneities in between the two sources can be different in their nature, affecting covariates





**Figure 3.15: Pairwise data ellipses for the CRASH-3 and Traumabase data**, centered at the origin. CRASH-3 data are in blue and Traumabase data in red. This view allows to compare the variances and covariances for all pairs of variables. While the means are really different in the two sources, the variances and covariances are not so different.


depending or not from  $X_1$ . We can imagine two situations, a situation (A) where the link in between  $X_1$  and  $X_5$  is different in the two sources, and another situation (B) where the link in between  $X_2$  and  $X_3$  is not the same. The situation is illustrated on Figures 3.16a and 3.16b with pairwise data ellipses. Note that with  $n = 1000$  and  $m = 10000$  a Box-M test largely rejects the null-hypothesis with a similar statistic value for both situations. When computing the bias according to Theorem 5 and repeating the experiment 50 times, empirical evidence is made that the localization of the heterogeneity impacts or not the bias computation. As presented on Figure 3.16c, situation A affects the bias computation, when situation B keeps the bias estimation valid.

### 3.G.3 Recommendations

Our current recommendations when considering the Assumption 22 is, first, to visualize the heterogeneity of variance-covariance matrix with pairwise data ellipses on  $\Sigma_{obs,obs}$ . A statistical test such as a Box-M test can be applied on  $\Sigma_{obs,obs}$ . We also want to emphasize that a statistical test depends on the size of the data sample, when what really matters in this assumption for the sensitivity analysis to be valid is the permanence of covariance structure of the missing covariates with the strongly correlated observed covariates. Simulations presented on Figure 3.16c is somehow an empirical pathological case where the variance-covariance matrix are equivalently different when considering a statistical test, but leads to different consequences on the validity of Theorem 5, and therefore the sensitivity analysis.


### 3.G.4 Comment about the notations

The notations used in this work inherits from the generalization literature and reflects the idea of a plausibility to be sampled from a target superpopulation. The point of view of two population with support inclusion is equivalent for our purpose. Still, thinking to the problem of a sampling bias, then Assumption 22 imposes unusual restrictions for  $P(X | S = 0)$ , that is a subpopulation of the target population. As we do not do any inference on that population and as it has no practical interpretation, we do not discuss this in this work.



(a) Situation A - Centered pairwise data ellipses

(b) Situation B - Centered pairwise data ellipses



(c) ATE estimation in the two situations where  $\hat{\tau}_{G,obs}$  is estimated considering  $X_1$  is missing and denoted ATE.uncomplete, while the bias  $B$  is estimated following Theorem 5 giving ATE.corrected ( $\hat{\tau}_{G,obs} + \hat{B}$ ).

**Figure 3.16: Effect of a different variance-covariance matrix on the ATE estimation**, where heterogeneity between the two variance-covariance matrix is introduced as presented in (a) and (b), and on (c) the impact on the estimated average treatment effect (ATE). Situations A and B result in a similar statistics when using a Box-M test, but leads to very different impact on the bias estimation as visible on (c). The simulation are repeated 50 times, with a similar outcome generative model as in eq. 3.8, and  $n = 1000$  and  $m = 10000$ .

## Chapter 4

# Reweighting the RCT for generalization: finite sample error and variable selection

This chapter corresponds to the article entitled *Reweighting the RCT for generalization: finite sample error and variable selection* submitted to the *Journal of the Royal Statistical Society: Series A*,

co-authored with Julie JOSSE, Gaël VAROQUAUX, and Erwan SCORNET.

### *Chapter's content*

---

This Chapter proposes to investigate properties of one of the seminal estimator proposed to generalize trial's findings to a target population: the *Inverse Propensity Weighting Estimator* (IPSW). While Chapter 2 reviews how this estimator was proposed and Chapter 3 proposes a large sample consistency results, this Chapter aims to propose stronger guarantees for any sample size. The results proposed are made under one assumption: the adjustment set being constituted of categorical covariates only. In this work, we establish the exact expressions of the finite and large samples bias and variance of IPSW. Results also reveal that IPSW performances are improved when the trial probability to be treated is estimated (rather than using its oracle counterpart). In addition, we study choice of variables: how including covariates that are not necessary for identifiability of the causal effect may impact the asymptotic variance. Including covariates that are shifted between the two samples but not treatment effect modifiers increases the variance while non-shifted but treatment effect modifiers do not. We illustrate all the takeaways in a didactic example, and on a semi-synthetic simulation inspired from critical care medicine.

---

---

**Contents**

<b>1</b>	<b>Introduction</b>	<b>121</b>
<b>2</b>	<b>Problem setting</b>	<b>122</b>
<b>3</b>	<b>Notations and assumptions for causal identifiability</b>	<b>126</b>
<b>4</b>	<b>Theoretical results</b>	<b>131</b>
<b>5</b>	<b>Synthetic and semi-synthetic simulations</b>	<b>139</b>
<b>6</b>	<b>Conclusion and future work</b>	<b>143</b>
<b>4.A</b>	<b>Main proofs</b>	<b>144</b>
<b>4.B</b>	<b>Extended adjustment set</b>	<b>168</b>
<b>4.C</b>	<b>Semi-synthetic simulation’s data preparation</b>	<b>169</b>
<b>4.D</b>	<b>Useful results about RCTs under a Bernoulli design</b>	<b>172</b>
<b>4.E</b>	<b>(Non-exhaustive) Review of the different IPSW versions in the literature</b>	<b>182</b>

---

## 1 Introduction

**Motivation** Modern *evidence-based* medicine puts Randomized Controlled Trial (RCT) at the core of clinical evidence. Indeed, randomization enables to estimate the average treatment effect (called ATE) by avoiding confounding effects of spurious or undesirable associated factors. But more recently, concerns have been raised on the limited scope of RCTs: stringent eligibility criteria, unrealistic real-world compliance, short timeframe, limited sample size, etc. All these possible limitations threaten the external validity of RCT studies to other situations or populations (Rothwell, 2007; Gatsonis and Sally, 2017; Deaton and Cartwright, 2018). The usage of complementary non-randomized data, referred to as *observational* or from the *real world*, brings promises as additional sources of evidence, in particular combined to trials (Kallus et al., 2018; Athey et al., 2020; Liu et al., 2021). For example, assume policy makers are studying an RCT which comes with great promises about a new treatment. But when reading the report, they may discover that the RCT is composed of substantially younger people than the target population of interest. Such a situation can be uncovered from the so-called *Table 1* of this newly published trial, which summarizes the demographics of the study population. In case of treatment effect heterogeneities, e.g. if the younger individuals respond better to the treatment, the ATE estimated from the trial is over-estimated and then biased. Now, assume these policy makers have also at disposal a sample of the actual patients in the district, being a representative sample of the true distribution of age in this population (typically without information on the outcome or the treatment). Can they use this representative sample of the target population of interest to *re-weight* or to *generalize* the trial’s findings? The answer is *yes*: the strategy has been formalized and popularized lately (Stuart et al., 2011; Pearl and Bareinboim, 2011a; Bareinboim and Pearl, 2012a,b; Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Hartman et al., 2015; Kern et al., 2016; Dahabreh et al., 2020) (reviewed in Colnet et al. (2020); Degtiar and Rose (2023)) and can come under many variants named *generalization*, *transportability*, *recoverability*, and *data-fusion*. In fact, the idea of re-weighting a trial can be traced back before the 2010’s. Several epidemiology books had already presented the core idea under the name *standardization* (Rothman and Greenland, 2000; Rothman, 2011).

In this work, we focus on one estimator used to generalize RCTs: the *Inverse Propensity of Sampling Weighting* (IPSW) (Cole and Stuart, 2010; Stuart et al., 2011), also named *Inverse Odds of Sampling Weights* (IOSW) (Westreich et al., 2017a; Josey et al., 2021) or *Inverse probability of participation weighting* (IPPW) (Degtiar and Rose, 2023). Despite an increasing literature on *generalization*, important practical questions remain open (Kern et al., 2016; Tipton et al., 2016; Stuart and Rhodes, 2017; Ling et al., 2022). For instance, which covariates – for e.g. age, and others – should be used to build the weights? Are some covariates increasing or lowering the overall precision? What is the impact of the size of the two samples (trial and representative sample) on the IPSW’s properties?

**Outline** We start by illustrating the principles of trial re-weighting and some key results of this article on a toy example (Section 2). Section 2 ends with related works. Then Section 3 introduces the mathematical notations, assumptions, and the precise definition of the IPSW estimator. In particular, we present several versions of the IPSW estimator: whether the covariates probability of the trial or the target population are estimated from the data or assumed as an oracle. This links our results to classic work in causal inference and epidemiology. Section 4 contains all the theoretical results, such as finite sample bias, variance, bounds on the risk, consistency, and large sample variance. We also detail why another version of the IPSW, where the probability of treatment assignment in the trial is also estimated, has a lower variance. Finally, we discuss in Section 4 how additional and non-necessary covariates can either improve or damage variance, depending on their status: whether they are only shifted between the two populations or only treatment-effect modifiers. Section 5 completes the toy example and illustrates all theoretical results on an extensive semi-synthetic example inspired from the medical domain. Finally, Section 6 summarizes all practical takeaways for this research and discusses it.

## 2 Problem setting


### 2.1 Toy example

#### 2.1.1 Context and intuitive estimation strategy

Assume that we would like to measure the average effect of a treatment (ATE)  $A$  on a outcome  $Y$  in a target population of interest  $\mathcal{P}_T$  (for target), and that an existing Randomized Controlled Trial (RCT) had already been conducted on  $n = 150$  individuals, sampled from a population  $\mathcal{P}_R$  (for randomized), to assess the average effect of  $A$  on  $Y$ . Usually, the average treatment effect is estimated from a trial via an Horvitz-Thomson estimator (Horvitz and Thompson, 1952),

$$\hat{\tau}_{\text{HT},n} = \frac{1}{n} \sum_{i \in \text{Trial}} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right), \quad (4.1)$$

where  $\pi$  is the probability of treatment allocation in the trial (in most applications,  $\pi = 0.5$ ). Figure 4.1 presents results of a simulated trial with an average treatment effect around 8.2. In addition, assume that the trial provides evidence that the treatment effect is heterogeneous with respect to a certain genetic mutation denoted  $X$  (with  $X = 1$  for the mutation, and  $X = 0$  if no mutation). More specifically, the average treatment effect conditional to  $X$  is larger for individuals with  $X = 1$  than for those with  $X = 0$ . This situation is illustrated on Figure 4.1 where the average effect per strata  $X$  is also represented. We have at hand a representative sample of  $m = 1000$  individuals from the target population we are interested in (for example from an existing observational database). We observe that individuals with the genetic mutation ( $X = 1$ ) are over-represented in the trial compared to the target population of interest (see Figure 4.2). As a consequence, the trial overestimates the target population's ATE we are interested in.



**Figure 4.1: Treatment effect estimates** (absolute difference) measured on a simulated trial of size  $n = 150$  sampled according to the trial population  $\mathcal{P}_R$ . On the left the estimate on **all individuals**, and on the right the two estimate stratified ( $X = 0$  and  $X = 1$ ) showing treatment effect heterogeneities along the genetic mutation  $X$ .

**Figure 4.2: Covariate shift along the genetic mutation**  $X$  between the trial population  $\mathcal{P}_R$  and target population  $\mathcal{P}_T$ , highlighting the distributional shift between the two data sources. Such population's difference questions what is named the external validity of a trial.


	Target ( $\mathcal{P}_T$ )	Trial ( $\mathcal{P}_R$ )
$X = 1$	30%	75%
$X = 0$	70%	25%

Fortunately, the representative sample of the target population can be used to learn weights, and re-weight the trial data in the following way,


$$\hat{\tau}_{n,m} = \frac{1}{n} \sum_{i \in \text{Trial}} \underbrace{\hat{w}_{n,m}(X_i)}_{\text{Weights}} \underbrace{\left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right)}_{\text{Horvitz-Thomson}}. \quad (4.2)$$

As detailed later on, the weights  $\hat{w}_{n,m}$  aims at estimating the probability ratio  $\frac{p_T(x)}{p_R(x)}$ , where  $p_T(x)$  (resp.  $p_R(x)$ ) is the probability of observing an individual with characteristics  $X = x$  in the target (resp. randomized) population. The weights  $\hat{w}_{n,m}$  depend on the sizes of the randomized and observational data sets, namely  $n$  and  $m$ . Consequently, the ATE estimator  $\hat{\tau}_{n,m}$  depends on the size of two data sets, raising questions on how this estimator behaves (bias and variance) as function of  $n$  and  $m$ .


### 2.1.2 Simulations and first observations



(a) **Toy example's data generative model:** where individuals with  $X = 1$  have a higher average treatment effect compared to individuals with  $X = 0$ . The baseline, centered on 0, is the same for both stratum.



(b) **Re-weighting in action:** Simulations's results with a trial of size  $n = 150$ , a target sample of size  $m = 1,000$  with 1,000 repetitions, where the naive trial estimate corresponds Equation 4.1, and **re-weighted trial** to Equation 4.2. As expected re-weighting allows to recover the ATE of the target population (red dashed line). It is also possible to **estimate**  $\pi$  from the data, giving another re-weighting estimator with lower variance (later introduced in Definition 31).



(c) **Two data sets leading to two asymptotic regimes:** where two situations are considered, one with a large target sample ( $m = 2000$ ) or a small target sample ( $m = 50$ ). Then, increasing  $n$  leads to a variance stagnation if  $m$  is small, while increasing  $n$  allows to further gain in precision if  $n \leq m$ .

**Figure 4.3:** Toy example's simulations - **Minimal** adjustment set.

To investigate empirically how  $\hat{\tau}_{n,m}$  behaves, we run simulations following the Data Generative Process (DGP) described in Section 2.1.1 and represented in Figure 4.3a. Figure 4.3b shows the different

estimators in action, showing that the re-weighted trial compensates for the distribution shift as expected.


Figure 4.3b also shows that estimating  $\pi$  from the data and plugging it in Equation 4.2 leads to a clear gain in variance. This phenomenon is linked to seminal works in causal inference, and is further demonstrated in Section 4.2. Finally, Figure 4.3c shows that if  $m$  remains small compared to  $n$  or if  $n$  remains small compared to  $m$ , then the asymptotic variance regime differs (see Corollary 5 for a formal statement, and Figure 4.6 for an illustration of the theoretical results).

For correct trial generalization, all shifted treatment effect modifier baseline covariates (see Definition 32 and 33, Section 4.3), such as the genetic mutation  $X$ , are necessary (Stuart et al., 2011). But, in practice *one may be tempted to add as many covariates  $V$  as available to account for all possible sources of external validity bias.*

Doing so, we may add covariates  $V$  that are not needed to properly estimates the weights. This is the case if (i)  $V$  is shifted between the two data sets, but in reality is not a treatment effect modifier or if (ii)  $V$  is a treatment effect modifier, but not shifted between the two data sets. Figure 4.4a shows that in (i), the covariate  $V$  should not be added, as it can considerably inflate the variance and therefore damage the precision (see Corollary 7 for a formal statement);

while in (ii), Figure 4.4b highlights that the covariate  $V$  should be added as

the precision can be augmented by adding such covariates (see Corollary 8 for a formal statement).



(a) Adding shifted covariate that is not a treatment effect modifier leads to a variance inflation. Simulation represents the situation of a binary shifted covariate  $V$  added or not in the adjustment set. The  $y$ -axis represents how much the variance with the minimal set is multiplied compared to a situation with this additional shifted covariate. The plain lines comes from the Theory (see Corollary 7) while dots are empirical variance (obtained from 1,000 repetitions with  $n = 150$  and  $m = 1,000$ ). The more shifted the covariate, the higher the inflation. The phenomenon is amplified if the covariate is imbalanced in the trial (in opposition with a balanced).

(b) Adding non-shifted treatment effect modifier leads to a gain in precision compared to a situation with only the necessary covariate. In this plot DGP from Figure 4.3a is adapted to add one non-shifted treatment effect modifier. Adding such covariate (extended set) compared to an adjustment set with only  $X$  (minimal set) lowers the variance.

Figure 4.4: Toy example's simulations - Extended adjustment set.

In Section 4, we prove these phenomenons, deriving explicit finite sample and asymptotic results to characterize the re-weighting process.

## 2.2 Related work

The estimator  $\hat{\tau}_{n,m}$  introduced in the toy example (Equation 4.2) is an exact implementation of the so-called *Inverse Propensity of Sampling Weighting* (IPSW) where the word *sampling* comes from



the popular habit of modeling the problem as the one of a randomized trial suffering from selection bias (Cole and Stuart, 2010; Bareinboim and Pearl, 2012a; Tipton, 2013; Dahabreh et al., 2019). Note that the estimator introduced in Equation 4.2 can also be linked to post-stratification (Imbens, 2011; Miratrix et al., 2013), where post-stratification belongs to the family of adjustment methods on a single RCT. Note that beyond trial re-weighting, other estimation strategies can be chosen when it comes to generalization, for example stratification (Tipton, 2013; O’Muircheartaigh and Hedges, 2013), modeling the response (G-formula or Outcome Modeling) (Kern et al., 2016; Dahabreh et al., 2019), using both strategies in a so-called doubly-robust approach (AIPSW) (Dahabreh et al., 2019, 2020), or entropy balancing (Josey et al., 2021; Dong et al., 2020).

**Link with IPW** The IPSW can be related – to a certain extent – to the well-known *Inverse Propensity Weighting* (IPW) estimator in the context of a single observational data set (Hirano et al., 2003). Indeed, this corresponds to a mirroring situation, where the weights are no longer the probability ratio, but the probability to be treated (propensity score, Rosenbaum and Rubin, 1983b). Robins et al. (1992); Hahn (1998); Hirano et al. (2003) showed that IPW is more efficient when weights are estimated, rather than relying on oracle weights. This curious phenomenon can even be found in other areas of statistics (Efron and Hinkley, 1978). Beyond efficient estimation with a minimal adjustment set, it is known that additional and non-necessary baseline covariates in the adjustment set of the IPW can either increase the variance (the so-called instruments) (Velentgas et al., 2013; Schnitzer et al., 2015; Wooldridge, 2016), while another class of covariates (the ones linked only to the outcome – and also called *outcome-related covariates* or *risk factors* or *precision covariates*) improves precision (Hahn, 2004; Lunceford and Davidian, 2004; Brookhart et al., 2006; Lefebvre et al., 2008; Witte and Didelez, 2018). A recent crash-course about good and bad controls recalls this phenomenon (Cinelli et al., 2022). Finally, another very recent line of research consists in determining – given a Directed Acyclic Graph (DAG) – the asymptotically-efficient adjustment set for ATE estimation. This is also named ‘optimal’ valid adjustment set (O-set), corresponding to the adjustment set ensuring the smallest asymptotic variance compared to other adjustment sets. Henckel et al. (2019) propose a result for linear model, and Rotnitzky and Smucler (2020) extend this work for any non-parametrically adjusted estimator. Such methods are meant for complex DAGs where several possible adjustment sets can be used.

**Theoretical results on IPSW** Expression of the variance has been proposed for an estimator related to the IPSW: the stratification estimator (O’Muircheartaigh and Hedges, 2013; Tipton, 2013). These results only consider the situation of an infinite target sample. Similar expressions can also be found in Rothman and Greenland (2000), also assuming an infinite target sample compared to the trial sample size. Buchanan et al. (2018) propose theoretical properties such as asymptotic variance of a variant of IPSW under a parametric model, using M-estimation methods for the proof (Stefanski and Boos, 2002). *Why a variant?* Because their proof is under the situation of a so-called nested design, that is a trial embedded in a larger observational population, so that there is only one single data set to consider and not two. In addition, we have found no discussion - neither empirical nor theoretical - about the impact of adding non-necessary covariates on the IPSW (or any other generalization’s estimator) properties (e.g., bias, variance). Egami and Hartman (2021) propose a method to estimate a separating set – *i.e.* a set of variables affecting both the sampling mechanism and treatment effect heterogeneity – and in particular when the trial contains many more covariates than the target population sample. However, their work focus on identification. Huitfeldt et al. (2019) also consider covariate selection for generalization, but focus on which covariates are necessary depending on the causal measure chosen (ratio, difference, or other). Yang et al. (2020b) addresses a similar problem (for non-probability sample and mean estimation), where they advocate selecting all variables, even instrumental variables, for robustness, although it may come at the cost of drop in efficiency. Note that some existing practical recommendations advocate to add as many covariates as possible (Stuart and Rhodes, 2017).

**Contributions** This work considers several variants of the IPSW, whether or not the weights are oracle, semi-oracle, or estimated. In this context, we derive the asymptotic variance of all the variants of IPSW and we show that several asymptotic regimes exist, depending on the relative size of the RCT compared to the target sample. We also provide finite sample expression of the bias and variance for all the IPSW variants introduced, allowing to bound the risk on this estimator for any samples sizes (trial and target population). From these theoretical results, we explain why the addition of some additional but non-necessary covariates in the adjustment set has a large impact on precision, for the best or the worst. Indeed, while non-shifted treatment effect modifiers improve precision by lowering the variance, adding shifted covariates that are not predictive of the outcome considerably reduces the statistical power of the analysis by inflating the variance. For this latter situation, we provide an explicit formula of the variance inflation when the additional covariate set is independent of the necessary one. These results have important consequences for practitioners because they allow to give precise recommendations about how to select covariates. Note that we link our work to seminal works in causal inference, showing that semi-oracle estimation outperforms a completely oracle estimation, while the exact result on IPW on efficient estimation can not be completely extended to the case of generalization.

All our results assume neither a parametric form of the outcome nor the sampling process, but are established at the cost of restricting the scope to categorical covariates for adjustment. Within the medical domain, scores or categories are often used to characterize individuals, which justifies this approach.

### 3 Notations and assumptions for causal identifiability

#### 3.1 Notations

##### 3.1.1 Problem setting

The notations and assumptions used in this work are grounded in the potential outcome framework (Imbens and Rubin, 2015). We assume to have at hand two data sets:


**A randomized controlled trial** denoted  $\mathcal{R}$  (for randomized), assessing the efficacy of a binary treatment  $A$  on an outcome  $Y$  (ordinal, binary, or continuous) conducted on  $n$  *iid* observations. Each observation  $i$  is labelled from 1 to  $n$  and can be modelled as sampled from a distribution  $P_{\mathcal{R}}(X, Y^{(1)}, Y^{(0)}, A) \in \mathbb{X} \times \mathbb{R}^2 \times \{0, 1\}$ , where  $\mathbb{X}$  is a categorical support. For any observation  $i$ ,  $A_i$  denotes the binary treatment assignment (with  $A_i = 0$  if no treatment and  $A_i = 1$  if treated), and  $Y_i^{(a)}$  is the outcome had the subject been given treatment  $a$  (for  $a \in \{0, 1\}$ ), which is assumed to be squared integrable.  $Y_i$  denotes the observed outcome, defined as  $Y_i = A_i Y_i^{(1)} + (1 - A_i) Y_i^{(0)}$ . In addition, this trial is assumed to be a Bernoulli trial with a constant probability of treatment assignment for all units and independence of treatment allocation between units (see in appendix Definition 34)<sup>1</sup>. We denote  $\mathbb{P}_{\mathcal{R}}[A_i = 1] = \pi$ .  $X_i$  is a  $p$ -dimensional vector of categorical covariates accounting for individual characteristics on the observation  $i$ ;

**A sample of the target population of interest** denoted  $\mathcal{T}$  (for target), containing  $m$  *iid* individuals samples drawn from a distribution  $P_{\mathcal{T}}(X, Y^{(1)}, Y^{(0)}, A) \in \mathbb{X} \times \mathbb{R}^2 \times \{0, 1\}$ , labelled from  $n + 1$  to  $n + m$ . In this data set, we only observe individual categorical characteristics  $X_i$ . For simplicity, we further use the notation  $P_{\mathcal{T}}(X)$  for the marginal of  $X$  on distribution  $P_{\mathcal{T}}$ .

Finally, the probability of  $X$  in the target population (resp. trial population) is denoted  $p_{\mathcal{T}}(x)$  (resp.  $p_{\mathcal{R}}(x)$ ). Mathematically, a covariate shift between the two populations occurs when there exists  $x \in \mathbb{X}$  such that  $p_{\mathcal{R}}(x) \neq p_{\mathcal{T}}(x)$ . The setting and notations are summarized on Figure 4.5.

<sup>1</sup>For a review of trial designs, in particular explaining the difference between a Bernoulli and a completely randomized design, we refer the reader to Chapter 2 of Imbens and Rubin (2015).

**Figure 4.5: Summary of the data at hand:** on the left, a randomized controlled trial  $\mathcal{R}$  of size  $n$  sampled according to  $P_{\mathcal{R}}$  and informing about the effect of a treatment  $A$  on the outcome  $Y$ . On the right, a sample  $\mathcal{T}$  of size  $m$  sampled from the target population of interest  $P_{\mathcal{T}}$ , containing only information on covariates  $X$ . As suggested on the drawing,  $n$  is often smaller than  $m$ , as trials are usually of limited size compared to large national data base or cohort.



**Comments on the notations** Note that a large part of the literature models the problem with a sampling mechanism from a super population. Doing so, the target and the trial samples are assumed sampled from this super population, with different mechanisms leading to a distributional shift of the trial (e.g. the framing in [Stuart et al., 2011](#); [Hartman, 2021](#)). Still, as soon as we are not working with a nested trial (that is a trial embedded in the target sample) and if only baseline covariates are considered for adjustment, the framing with a sampling model is equivalent to the problem setting introduced above ([Colnet et al., 2020](#); [Westreich et al., 2017a](#)). Note that the literature is increasing adopting the framing that we use here ([Kern et al., 2016](#); [Nie et al., 2021](#); [Chattopadhyay et al., 2022](#)).

### 3.1.2 Target quantity of interest

Recall that two distributions, indexed by  $\mathcal{R}$  and  $\mathcal{T}$  are involved in our problem setting (Section 3.1.1). Therefore, we will use these indices to denote quantities (expectations, probabilities) taken with respect to these distributions, for example  $\mathbb{E}_{\mathcal{R}}[\cdot]$  (resp.  $\mathbb{E}_{\mathcal{T}}[\cdot]$ ) for an expectation over  $P_{\mathcal{R}}$  (resp.  $P_{\mathcal{T}}$ ).

We define the target population average treatment effect ATE (sometimes called **TATE** for **T**arget):

$$\tau := \mathbb{E}_{\mathcal{T}} \left[ Y^{(1)} - Y^{(0)} \right]. \quad (4.3)$$

Because the randomized controlled data  $\mathcal{R}$  are not sampled from the target population of interest, the sample average treatment effect  $\tau_{\mathcal{R}}$  (sometimes called **SATE** for **S**ample) estimated from this population,

$$\tau_{\mathcal{R}} := \mathbb{E}_{\mathcal{R}} \left[ Y^{(1)} - Y^{(0)} \right],$$

may be biased, that is  $\tau_{\mathcal{R}} \neq \tau$ . While not being the target quantity of interest, we also introduce the so-called Conditional Average Treatment Effect (CATE), as

$$\forall x \in \mathbb{X}, \tau(x) := \mathbb{E}_{\mathcal{T}} \left[ Y^{(1)} - Y^{(0)} \mid X = x \right].$$

## 3.2 Identification assumptions

Assumptions are needed to be able to generalize the findings from the population data  $P_{\mathcal{R}}$  toward the population  $P_{\mathcal{T}}$ .

**Assumptions on the trial** We first need validity of the trial, also called *internal validity*. These assumptions are the usual ones formulated in causal inference, and in particular for randomized controlled trials within the potential outcomes framework ([Imbens and Rubin, 2015](#); [Hernan, 2020](#)).

**Assumption 26** (Representativity of the randomized data). *For all  $i \in \mathcal{R}$ ,  $X_i \sim P_{\mathcal{R}}(X)$  where  $P_{\mathcal{R}}$  is the population distribution from which the RCT was sampled.*

**Assumption 27** (Trial's internal validity). *The RCT at hand  $\mathcal{R}$  is assumed to be internally valid, such that*

(i) Consistency and no interference hold, that is:  $\forall i \in \mathcal{R}, Y_i = A_i Y_i^{(1)} + (1 - A_i) Y_i^{(0)}$  –an assumption often termed SUTVA (stable unit treatment value);

(ii) Treatment randomization holds, that is:  $\forall i \in \mathcal{R}, \{Y_i^{(1)}, Y_i^{(0)}\} \perp A_i$ ;

(iii) Positivity of trial treatment assignment holds, that is:  $0 < \pi < 1$  (usually  $\pi = 0.5$ ).

**Assumptions for generalization** The two following assumptions are specific to generalization or transportability.

**Assumption 28** (Transportability).  $\forall x \in \mathbb{X}, \mathbb{P}_R(Y^{(1)} - Y^{(0)} | X = x) = \mathbb{P}_T(Y^{(1)} - Y^{(0)} | X = x)$ .

The transportability assumption (Stuart et al., 2011; Pearl and Bareinboim, 2011a), also called *sample ignorability for treatment effects* (Kern et al., 2016) or *Conditional Ignorability* (Hartman, 2021), is probably the most important assumption to generalize or transport the trial findings to the target population, as this requires to have access to all shifted covariates being treatment modifiers. In other words, it assumes that all the systematic variations in the treatment effect are captured by the covariates  $X$  (O’Muircheartaigh and Hedges, 2013). The covariates  $X$  are usually named the adjustment or separating set. Note that the concept of treatment effect modifiers depends on the causal measure chosen; in this paper, we only consider the absolute difference most common for a continuous outcome as detailed in Equation 4.3. Would we have chosen the log-odd-ratio, for instance, then the covariates being treatment effect modifiers could be different. Finally, note that Pearl and Bareinboim (2011a) introduces *selection* diagram to formalize this assumption relying on causal diagrams. Pearl (2015) details why diagrams can contain more identification scenarii. But in this work, we only consider baseline covariates for the transportability assumption (i.e no *front-door* adjustment).

**Assumption 29** (Support inclusion).  $\forall x \in \mathbb{X}, p_R(x) > 0$ , and  $\text{supp}(P_T(X)) \in \text{supp}(P_R(X))$ .

Note that this last assumption is sometimes referred as the positivity of trial participation and can also be viewed as a sampling process with non-zero probability for all individuals.

### 3.3 Estimators

In this work, we denote any estimator targeting a quantity  $\tau$  as  $\hat{\tau}_{n,m}$  where the the index  $n$  or  $m$  is employed to characterise which data were used in the estimation strategy. For example, an estimator  $\hat{\tau}_n$  (resp.  $\hat{\tau}_m$ ) only uses the trial data (resp. observational data) whereas  $\hat{\tau}_{n,m}$  uses both data sets.

#### 3.3.1 Within-trial estimators of ATE

Two classical estimators targeting  $\tau_R$  from trial data are the Horvitz-Thomson and Difference-in-means estimators.

**Definition 22** (Horvitz-Thomson - Horvitz and Thompson (1952)). *The Horvitz-Thomson estimator is denoted  $\hat{\tau}_{HT,n}$  and defined as,*

$$\hat{\tau}_{HT,n} = \frac{1}{n} \sum_{i=1}^n \left( \frac{A_i Y_i}{\pi} - \frac{(1 - A_i) Y_i}{1 - \pi} \right).$$

Under a Bernoulli design (constant and independent probability to be treated  $\pi$ ) the Horvitz-Thomson estimator  $\hat{\tau}_{HT,n}$  is an unbiased and consistent estimator of  $\tau_R$ , and its variance satisfies, for all  $n$ ,

$$n \text{Var} [\hat{\tau}_{HT,n}] = \mathbb{E}_R \left[ \frac{(Y^{(1)})^2}{\pi} \right] + \mathbb{E}_R \left[ \frac{(Y^{(0)})^2}{1 - \pi} \right] - \tau_R^2 := V_{HT}. \quad (4.4)$$

**Definition 23** (Difference-in-means - Neyman (1923) and its English translation Splawa-Neyman et al. (1990)). *The Difference-in-means estimator is denoted  $\hat{\tau}_{DM,n}$  and defined as*

$$\hat{\tau}_{DM,n} = \frac{1}{n_1} \sum_{A_i=1} Y_i - \frac{1}{n_0} \sum_{A_i=0} Y_i, \quad \text{where } n_a = \sum_{i=1}^n \mathbb{1}_{A_i=a}.$$

The Difference-in-means is also referred to as the *simple difference estimator* for e.g. in Miratrix et al. (2013) or *difference in the sample means of the observed outcome variable between the treated and control groups* for e.g. in Imai et al. (2008). Under a Bernoulli design, the difference-in-means estimator is a consistent estimator of  $\tau_R$ , and its finite sample variance is bounded by

$$n \text{Var} [\hat{\tau}_{DM,n}] \leq \frac{\text{Var} [Y^{(1)}]}{\pi} + \frac{\text{Var} [Y^{(0)}]}{1 - \pi} + \mathcal{O} \left( n^{-1/2} \right), \quad (4.5)$$

and its large sample variance satisfies,

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{DM,n}] = \frac{\text{Var} [Y_i^{(1)}]}{\pi} + \frac{\text{Var} [Y_i^{(0)}]}{1 - \pi} := V_{DM,\infty}. \quad (4.6)$$

An explicit expression of the finite sample bias and variance of  $\hat{\tau}_{DM,n}$  are given in appendix (see Lemma 4). What will be used later on, is the fact that the Difference-in-Means estimator can be viewed as a variant of the Horvitz-Thomson estimator, where the probability to be treated  $\pi$  (or propensity score) is estimated, that is,

$$\hat{\tau}_{DM,n} = \frac{1}{n} \sum_{i=1}^n \left( \frac{A_i Y_i}{\hat{\pi}} - \frac{(1 - A_i) Y_i}{1 - \hat{\pi}} \right), \quad \text{where } \hat{\pi} = \frac{\sum_{i=1}^n A_i}{n}.$$

Counter-intuitively, the benefit of estimating  $\pi$  is to lower the variance. Even if the true probability is  $\pi = 0.5$ , the actual treatment allocation in the sample can be different (e.g.,  $\hat{\pi} = 0.48$ ), and using  $\hat{\pi}$  rather than  $\pi$  leads to a smaller large sample variance by adjusting to the exact observed probability to be treated in the trial. In particular, it is possible to be convinced of this phenomenon when comparing the two variances,

$$V_{DM,\infty} = V_{HT} - \left( \sqrt{\frac{1 - \pi}{\pi}} \mathbb{E}_R[Y^{(1)}] + \sqrt{\frac{\pi}{1 - \pi}} \mathbb{E}_R[Y^{(0)}] \right)^2 \leq V_{HT}. \quad (4.7)$$

Appendix 4.D recalls derivations to obtain eq. 4.4 to eq. 4.7.

Other estimators of  $\tau_R$  exist, and rely on prognostic covariates (also called adjustment) such as outcome-modeling or post-stratification. Below (Section 4.2), we introduce the post-stratification estimator, corresponding to the Horvitz-Thomson estimator where  $\pi$  is estimated according to different stratum.

### 3.3.2 Re-weighting estimator for generalizing the trial findings

As mentioned in Subsection 2.2, in this work we focus on the reweighting strategy, that is the *Inverse Propensity of Sampling Weighting* (IPSW) estimator (Cole and Stuart, 2010; Stuart et al., 2011).

**Definition 24** (Completely oracle IPSW). *The completely oracle IPSW estimator is denoted  $\hat{\tau}_{\pi,T,R,n}^*$  and defined as*

$$\hat{\tau}_{\pi,T,R,n}^* = \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{p_R(X_i)} Y_i \left( \frac{A_i}{\pi} - \frac{1 - A_i}{1 - \pi} \right), \quad (4.8)$$

where  $\frac{p_T(X_i)}{p_R(X_i)}$  are called the *weights* or the *nuisance components*.

Definition 24 corresponds to a completely oracle IPSW, where  $p_T$ ,  $p_R$ , and the trial allocation probability  $\pi$  are known.

### 3.3.3 Probability ratio estimation

In practice neither  $p_R$  nor  $p_T$  are known, and therefore one needs to estimate these probabilities. As explained in Subsection 3.1.1, we consider the case where  $X$  is composed of categorical covariates only. In such a situation, a practical IPSW estimator can be built from Definition 24 by estimating each probability  $p_T$  and  $p_R$  by their empirical counterpart (that is counting how many observations fall in each categories in the trial and target samples).

**Definition 25** (Probability estimation). *Under the setting defined in Subsection 3.1.1,*

$$\forall x \in \mathcal{X}, \hat{p}_{T,m}(x) := \frac{1}{m} \sum_{i \in \mathcal{T}} \mathbb{1}_{X_i=x} \quad \text{and,} \quad \hat{p}_{R,n}(x) := \frac{1}{n} \sum_{i \in \mathcal{R}} \mathbb{1}_{X_i=x}.$$

Having defined a method for probability estimation, one can build practical IPSW variants.

**Definition 26** (Semi-oracle IPSW). *The semi-oracle IPSW estimator  $\hat{\tau}_{\pi,T,n}^*$  is defined as*

$$\hat{\tau}_{\pi,T,n}^* = \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left( \frac{A_i}{\pi} - \frac{1 - A_i}{1 - \pi} \right), \quad (4.9)$$

where  $\hat{p}_{R,n}$  is estimated according to Definition 25.

Note that this semi-oracle estimator corresponds to the so-called standardization procedure described in Rothman and Greenland (2000).

**Definition 27** (IPSW). *The (estimated) IPSW estimator  $\hat{\tau}_{\pi,n,m}$  is defined as*

$$\hat{\tau}_{\pi,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left( \frac{A_i}{\pi} - \frac{1 - A_i}{1 - \pi} \right), \quad (4.10)$$

where  $\hat{p}_{R,n}$  and  $\hat{p}_{T,m}$  are estimated according to Definition 25.

Definition 27 corresponds to the classical implementation of the IPSW since, practically, the probabilities  $\hat{p}_{R,n}$  and  $\hat{p}_{T,m}$  are not known and must be estimated.

**Another interpretation of IPSW** Note that the IPSW can be understood differently, thanks to the fact that covariates used to adjust are categorical. Indeed, it is possible to re-write the IPSW estimator from Definition 27 as,

$$\hat{\tau}_{\pi,n,m} = \sum_{x \in \mathcal{X}} \frac{m_x}{m} \sum_{i=1}^n \mathbb{1}_{X_i=x} \frac{1}{n_x} \left( \frac{A_i Y_i^{(1)}}{\pi} - \frac{(1 - A_i) Y_i^{(1)}}{1 - \pi} \right) = \sum_{x \in \mathcal{X}} \frac{m_x}{m} \hat{\tau}_{\text{HT},n_x},$$

where  $m_x = \sum_{i=n+1}^m \mathbb{1}_{X_i=x}$  and  $n_x = \sum_{i=1}^n \mathbb{1}_{X_i=x}$ . This corresponds to a procedure where stratum average treatment effects are estimated with an Horvitz-Thomson procedure, and then aggregated with weights corresponding to the target sample proportions. Miratrix et al. (2013) also discusses a similar approach in their section 5, but where the sample proportions corresponds to the true target population of interest. In a way, our work extends this situation to a more general case, considering the noise due to the sampling process from two populations.

**Comment about oracle and semi-oracle interest** The completely-oracle and the semi-oracle estimators are not used in practice, as usually none of the true probabilities are known. Still, they both correspond to some asymptotic situations that are of interest to understand the IPSW. For instance:

- Studying  $\hat{\tau}_{\pi,T,R,n}^*$  allows us to observe the effect of averaging over the trial sample  $\mathcal{R}$ , without the variability due to covariates probabilities estimation ( $\hat{p}_{R,n}$  and  $\hat{p}_{T,m}$ );
- Studying  $\hat{\tau}_{\pi,T,n}^*$  allows to understand the situation where the target sample  $\mathcal{T}$  is infinite ( $m \rightarrow \infty$ ).



In addition, studying these estimators allows us to link our results with seminal works in causal inference showing that the estimated propensity score can lead to better properties than an oracle one (Robins et al., 1992; Hahn, 1998; Hirano et al., 2003). Note that we could introduce another semi-oracle estimator, where  $p_R$  is known but not  $p_T$ . This specific estimator does not correspond to a limit situation helping to figuring out the results, as it is as if the covariates probabilities in the trial are learned on a infinite data sample, but where the treatment effect estimate is still averaged on a finite sample. Finally, since all covariates are assumed to be categorical in our framework, trial and observational densities (continuous covariates) turn into trial and observational probabilities (categorical covariates). Oracles and semi-oracles will be different when considering continuous covariates as the weights will be replaced by density estimation or estimation of the probability of being in the target population (instead of the experimental sample) (e.g. see Kern et al., 2016; Nie et al., 2021)), sometimes directly estimating the ratio by binding the two data sources and therefore making the notion of semi-oracle outdated.

## 4 Theoretical results

### 4.1 Bias and variance of IPSW variants in finite-sample regime

In this section, we expose our main theoretical results on the three variants of the IPSW estimator (Definition 24, 26 and 27). The following results rely on the variance of the Horvitz-Thomson estimator on a given strata  $x$  (see Definition 22), denoted  $V_{HT}(x)$ , and defined as ,

$$V_{HT}(x) := \mathbb{E}_R \left[ \frac{(Y^{(1)})^2}{\pi} \mid X = x \right] + \mathbb{E}_R \left[ \frac{(Y^{(0)})^2}{1 - \pi} \mid X = x \right] - \tau(x)^2. \quad (4.11)$$

In this equation, we removed the index  $R$  of  $\tau(x)$  as  $\tau_R(x) = \tau_T(x) = \tau(x)$ , thanks to Assumption 28. Removing the index on the two conditional expectations would require to go beyond the classical transportability assumption, by assuming that

$$\forall a \in \{0, 1\}, P_R(Y^{(a)} \mid X = x) = P_T(Y^{(a)} \mid X = x),$$

*i.e.*  $X$  contains all the covariates being shifted and predictive of the outcome, which is stronger than Assumption 28.

#### 4.1.1 Properties of the completely oracle IPSW

The following result establishes consistency and finite sample bias and variance for the oracle IPSW, which extends the preceding results from Egami and Hartman (2021) (see their appendix, Section SM-2).

**Theorem 9** (Properties of the completely oracle IPSW). *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the completely oracle IPSW is unbiased and has an explicit variance expression, that is, for all  $n$ ,*

$$\mathbb{E} [\hat{\tau}_{\pi, T, R, n}^*] = \tau, \quad \text{and} \quad \text{Var} [\hat{\tau}_{\pi, T, R, n}^*] = \frac{V_o}{n}, \quad \text{where} \quad V_o := \text{Var}_R \left[ \frac{p_T(X)}{p_R(X)} \tau(X) \right] + \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{HT}(X) \right].$$

As a consequence, for all  $n$ , the quadratic risk of the completely oracle IPSW is given by,

$$\mathbb{E} \left[ (\hat{\tau}_{\pi, T, R, n}^* - \tau)^2 \right] = \frac{V_o}{n},$$

which implies its  $L^2$ -consistency as  $n$  tends to infinity, that is,

$$\hat{\tau}_{\pi, T, R, n}^* \xrightarrow{L^2} \tau.$$



The finite-sample variance  $V_o$  depends on the probability ratio, the amplitude of the heterogeneity of treatment effect (through  $\tau(x)$ ), and variances of the potential outcomes. In particular if for some category  $x$ , the  $p_T(x)$  and  $p_R(x)$  are very different implies a large variance when generalizing the trial's findings. Note that the convergence rate is a usual one in  $\propto \frac{1}{n}$ . Although it is not our main contribution, Theorem 9 is of primary importance for comparing the impact of sample sizes on the performances of the different IPSW variants. Appendix 4.A.1 provides a detailed proof of Theorem 9 and sheds light on the technical tools used for more complex IPSW variants.

### 4.1.2 Properties of the semi-oracle IPSW

In this section, we study the behaviour of the semi-oracle IPSW (Definition 26), for which the probability  $p_T$  is known but the probability  $p_R$  is estimated. One can obtain for a certain  $x$ ,  $\hat{p}_{R,n}(x) = 0$  for some  $x \in \mathbb{X}$ , even if the true probability is non-negative  $p_R(x) > 0$ . This phenomenon, occurring when no observations in the trial correspond to the covariate vector  $x$ , induces a finite sample bias of the IPSW estimate. The performance of the semi-oracle IPSW estimate is thus closely related to  $\mathbb{1}_{Z_n(x) > 0}$  where  $Z_n(x) = \sum_{i=1}^n \mathbb{1}_{X_i=x}$ , as stated in our next results.

**Proposition 2.** *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the bias of the semi-oracle IPSW satisfies, for all  $n$ ,*

$$\mathbb{E} [\hat{\tau}_{\pi,T,n}^*] - \tau = - \sum_{x \in \mathbb{X}} p_T(x) (1 - p_R(x))^n \tau(x),$$

and 
$$\left| \mathbb{E} [\hat{\tau}_{\pi,T,n}^*] - \tau \right| \leq \left( 1 - \min_x p_R(x) \right)^n \mathbb{E}_T [|\tau(X)|].$$

Moreover, under the same set of assumptions, the variance of the semi-oracle IPSW satisfies, for all  $n$ ,

$$n \text{Var} [\hat{\tau}_{\pi,T,n}^*] = \sum_{x \in \mathbb{X}} p_T(x)^2 V_{HT}(x) \mathbb{E}_R \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\hat{p}_{R,n}(x)} \right] + n \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]],$$

and 
$$\text{Var} [\hat{\tau}_{\pi,T,n}^*] \leq \frac{2V_{so}}{n+1} + \left( 1 - \min_{x \in \mathbb{X}} p_R(x) \right)^n \mathbb{E}_T [\tau(X)^2],$$

with 
$$V_{so} := \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{HT}(X) \right].$$

The proof is detailed in Subsection 4.A.2.1. Proposition 2 establishes the exact finite-sample bias and variance of the semi-oracle IPSW estimate. Unlike the completely oracle IPSW, the semi-oracle IPSW is biased for small trials (*i.e.* small  $n$ ), which can be understood by undercoverage of some categories in the trial. Indeed, for small trials, the probability that a category is not represented at all in the RCT may not be negligible. Fortunately, as shown in Proposition 2, this bias converges to zero exponentially with the trial size  $n$ . Note that, as soon as  $\tau(x)$  is of constant sign, the sign of the bias is known and opposite to that of  $\tau(x)$ . In fact, because of potentially empty categories in the trial, the expectation of the semi-oracle IPSW estimate  $\mathbb{E} [\hat{\tau}_{\pi,T,n}^*]$  is pushed toward zero, if  $\tau(x)$  is of constant sign. Proposition 2 also gives the exact finite-sample expression of the variance for the semi-oracle IPSW estimate. Corollary 4 provides asymptotic results derived from these finite-sample expressions:

**Corollary 4** (Asymptotics). *Under the same assumptions as in Proposition 2, the semi-oracle IPSW is asymptotically unbiased, and its asymptotic variance satisfies,*

$$\lim_{n \rightarrow \infty} \mathbb{E} [\hat{\tau}_{\pi,T,n}^*] = \tau, \quad \text{and} \quad \lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi,T,n}^*] = V_{so}.$$

The proof is detailed in Subsection 4.A.2.2. The quantity  $V_{so}$  already exist in the literature, for example in Rothman and Greenland (2000), where a form of semi-oracle IPSW was introduced under the name *standardization*. Here, we clarify the fact that this formula is valid only for large sample and

we provide detailed derivations. Therefore, Corollary 4 is the first theoretical result establishing the asymptotic variance of the semi-oracle IPSW. One can observe from the explicit derivations that the semi-oracle estimator  $\hat{\tau}_{\pi,T,n}^*$  has a lower asymptotic variance than the oracle IPSW  $\hat{\tau}_{\pi,T,R,n}^*$  recalled in Theorem 2. In particular,

$$V_{so} = V_o - \text{Var}_R \left[ \frac{p_T(X)}{p_R(X)} \tau(X) \right].$$

Always positive

This phenomenon has similar explanations<sup>2</sup> with the common (and often surprising) result stating that an estimated propensity score lowers the variance when re-weighting observational data compared to an estimator relying on oracle propensity score (see [Robins et al., 1992](#); [Hahn, 1998](#); [Hirano et al., 2003](#); [Lunceford and Davidian, 2004](#), regarding IPW estimator). Intuitively, we only need to generalize from the actual sample to the target population, and not from a source trial population to a target population.

The semi oracle estimate has a lower asymptotic variance compared to the estimated IPSW but is also biased. One can thus wonder how the risk of the two estimates compare. Theorem 10 upper bounds the risk of the semi-oracle estimate:

**Theorem 10** (Properties of the semi-oracle IPSW). *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the quadratic risk of the completely oracle IPSW satisfies,*

$$\mathbb{E} \left[ (\hat{\tau}_{\pi,T,n}^* - \tau)^2 \right] \leq \frac{2V_{so}}{n+1} + 2 \left( 1 - \min_x p_R \right)^n \mathbb{E}_T [\tau(X)^2],$$

which implies its  $L^2$ -consistency as  $n$  goes to infinity, that is,

$$\hat{\tau}_{\pi,T,n}^* \xrightarrow{L^2} \tau.$$

Subsection 4.A.2.3 details the proof. The second term in the upper bound of Theorem 10 decreases exponentially with  $n$ , whereas the first term decreases at rate  $1/n$ . At first, it is not easy to compare this upper bound to the risk of the completely oracle IPSW, due to the factor two before  $V_{so}$ . Close inspection of the proof of Theorem 10 reveals that the factor 2 can be replaced by  $(1 + \varepsilon)$ , for all  $\varepsilon$ , assuming that  $n$  is large enough (see Lemma 5). The bound presented here is valid for all  $n$  and can be improved if  $n$  is taken large enough. Therefore, for all  $n$  large enough, the first term in the upper bound is close to  $V_{so}/(n+1)$  which is smaller than  $V_o/(n+1)$  (see above), which makes the risk of the semi-oracle smaller than that of the completely oracle, for  $n$  large enough. This bound opens the doors to guarantees even on small sample size. Also note that, unlike  $V_o$ ,  $V_{so}$  can be estimated with the data.

### 4.1.3 Properties of the (estimated) IPSW

Previous results on IPSW are valid when the size of the target population goes to infinity. In this subsection, we establish theoretical guarantees for the estimated IPSW in a more complex setting: we consider finite trial and target population datasets and establish bounds depending on both sample sizes ( $n$  and  $m$ ).

**Proposition 3.** *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the bias of the estimated IPSW is the same as that of the semi-oracle IPSW, that is, for all  $n, m$ ,*

$$\mathbb{E} [\hat{\tau}_{\pi,n,m}] - \tau = - \sum_{x \in \mathbb{X}} p_T(x) (1 - p_R(x))^n \tau(x).$$

<sup>2</sup>In fact, similar considerations appear outside causal inference, for example [Efron and Hinkley \(1978\)](#) argued that the observed information rather than the expected Fisher information should be used to characterize the distribution of maximum-likelihood estimates.

Moreover, under the same set of assumptions, the variance of the estimated IPSW satisfies, for all  $n, m$ ,

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m}] &= \text{Var} [\hat{\tau}_{\pi,\tau,n}^*] + \frac{1}{m} (\text{Var}_T [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] - \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]]) \\ &\quad + \frac{1}{nm} \sum_{x \in \mathbf{X}} V_{HT}(x) p_T(x) (1 - p_T(x)) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{R,n}(x)} \right] \end{aligned}$$

and

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m}] &\leq \frac{2V_{so}}{n+1} + \frac{\text{Var}_T [\tau(X)]}{m} + \frac{2}{m(n+1)} \mathbb{E}_R \left[ \frac{p_T(X) (1 - p_T(X))}{p_R(X)^2} V_{HT}(X) \right] \\ &\quad + \left( 1 - \min_x p_R(x) \right)^{n/2} \mathbb{E}_T [\tau(X)^2] \left( 1 + \frac{4}{m} \right). \end{aligned} \quad (4.12)$$

A proof is given in Subsection 4.A.3.1. Note that the term  $\text{Var}_T [\tau(X)]$  can be replaced by  $\text{Var} [\tau(X)]$  thanks to Assumption 28. Proposition 3 is the first result to establish the bias and variance of the estimated IPSW in a finite-sample setting. A first observation is that the bias of the (estimated) IPSW is the same as that of the semi-oracle, showing that only a limited trial sample size can explain a finite sample bias. On the other side, the variance terms differ, due to the additional estimation of the target probability  $p_T$  in the estimated IPSW. All additional terms compared to the variance of the semi-oracle  $\hat{\tau}_{\tau,\pi,n}$  therefore depend on  $m$ . The explicit expression of the variance shows that  $n$  and  $m$  must go to infinity for the variance to go to zero.

In this setting, the variance is dominated by the first two terms in inequality 4.12. If  $m \gg n$ , the variance is dominated by the first term, which is the dominant term of the semi-oracle variance. Following this idea, Corollary 5 establishes the asymptotic bias and variance of the estimated IPSW in different sample size regimes.

**Corollary 5.** *Under the same assumptions as in Proposition 3, the estimated IPSW is asymptotically unbiased when  $n$  tends to infinity, that is*

$$\lim_{n \rightarrow \infty} \mathbb{E} [\hat{\tau}_{\pi,n,m}] = \tau.$$

Besides, letting  $\lim_{n,m \rightarrow \infty} m/n = \lambda \in [0, \infty]$ , the asymptotic variance of the estimated IPSW satisfies

$$\lim_{n,m \rightarrow \infty} \min(n, m) \text{Var} [\hat{\tau}_{\pi,n,m}] = \min(1, \lambda) \left( \frac{\text{Var} [\tau(X)]}{\lambda} + V_{so} \right).$$

A proof is detailed in Subsection 4.A.3.2.

As highlighted in Corollary 5, there is not a unique asymptotic variance for the estimated IPSW. Its asymptotic variance depends on how the sample sizes  $n$  and  $m$  compare to each other asymptotically. For example,

- If  $m/n \rightarrow \infty$ , (i.e.,  $\lambda = \infty$ ) then the asymptotic variance of the estimated IPSW corresponds to the semi-oracle's one;
- If we consider an asymptotic regime where the observational sample is about ten times bigger than the trial ( $\lambda = 10$ ), then the asymptotic variance is equal to  $\lim_{n,m \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi,n,m}] = \text{Var} [\tau(X)] / 10 + V_{so} > V_{so}$ ;
- Finally, if  $m/n \rightarrow 0$ , (i.e.,  $\lambda = 0$ ) then the asymptotic variance of the estimated IPSW has no more link to that of the semi-oracle IPSW, and  $\lim_{n,m \rightarrow \infty} m \text{Var} [\hat{\tau}_{\pi,n,m}] = \text{Var} [\tau(X)]$ .

This formula can be used to guide data collection. For example, and using the formula, one could say that at some point gathering  $N$  additional individuals information in the target population (which has a cost) could lead to less gain in precision than gathering a bit more data on the trial (if possible). This phenomenon is illustrated on Figure 4.6.

Upper bound on the risk of the estimated IPSW can be established, based on Proposition 3.


**Theorem 11** (Properties of the IPSW). *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the quadratic risk of the estimated IPSW satisfies,*

$$\begin{aligned} \mathbb{E} \left[ (\hat{\tau}_{\pi,n,m} - \tau)^2 \right] &\leq \frac{2V_{so}}{n+1} + \frac{\text{Var}[\tau(X)]}{m} + \frac{2}{m(n+1)} \mathbb{E}_R \left[ \frac{p_T(X)(1-p_T(X))}{p_R(X)^2} V_{HT}(X) \right] \\ &\quad + 2 \left( 1 - \min_x p_R(x) \right)^n \mathbb{E}_T[\tau(X)^2] \left( 1 + \frac{2}{m} \right), \end{aligned} \quad (4.13)$$

which implies its  $L^2$ -consistency as  $m, n$  tends to infinity, that is,

$$\hat{\tau}_{\pi,n,m} \xrightarrow{L^2} \tau.$$

Proof is detailed in Subsection 4.A.3.3. The first and fourth terms in inequality eq.4.13 correspond to the bound of the semi-oracle estimator (see Theorem 10). Following the intuition, the bound on the risk of the estimated IPSW is larger than the one of the semi-oracle. This is due to the cost of estimating  $p_T$  from a finite sample of size  $m$ . However, when  $m \gg n$ , the dominant terms in the risk of the estimated and semi-oracle IPSW are the same. Indeed, consistency of the (estimated) IPSW for continuous covariates has been proven in the literature, for e.g. [Buchanan et al. \(2018\)](#) demonstrate consistency and asymptotic normality under a nested-design and assuming a parametric selection process. [Colnet et al. \(2022a\)](#) demonstrate consistency assuming uniform convergence of the probability ratio under a cross-fitting procedure and no parametric assumption. Our results are the first to establish the bias and the variance of the estimated IPSW in finite and asymptotic regimes, with an explicit dependence on both sample sizes.



**Figure 4.6: Illustration of Corollary 5**

**What if the probability to be treated depends on  $x$ ?** In some trials, the probability to receive treatment depends on the strata (for e.g. for ethical reason). If so, all the previous results are kept unchanged, replacing  $\pi$  by  $\pi(x)$ , and the proofs are written with  $\pi(x)$ , even if the main results are reported with a constant  $\pi$  for brevity. In particular, all the covariates used to stratify the propensity to receive treatment in the trial should be used in the IPSW.

## 4.2 Estimating the probability to be treated in the trial?

So far, we have considered an estimation procedure where  $\pi$ , the probability to be treated in the trial, is plugged in the formula. Still, one may want to estimate it for the purpose of precision. This idea follows the same spirit of what can be done with the Horvitz-Thomson (Definition 22) and the Difference-in-means (Definition 23), where the large-sample gain in variance is recalled in Equation eq.4.7. To our knowledge, different version of IPSW are currently present in the literature, with or without an estimated  $\pi$  (see Table 4.1 in appendix for a non-exhaustive review). In our work, we propose to estimate  $\pi$  per strata, and then adapt the semi-oracle IPSW (Definition 26) and the estimated IPSW (Definition 27).

**Definition 28** (Estimation of  $\hat{\pi}$  for each strata). *Under the setting defined in Subsection 3.1.1,*

$$\forall x \in \mathbf{X}, \hat{\pi}_n(x) = \frac{\sum_{i \in \mathcal{R}} \mathbb{1}_{X_i=x} \mathbb{1}_{A_i=1}}{\sum_{i \in \mathcal{R}} \mathbb{1}_{X_i=x}}.$$

Strange as it may seem, estimating  $\pi$  per strata and not on the whole sample can also be beneficial in RCTs to improve precision. [Imbens \(2011\)](#); [Miratrix et al. \(2013\)](#) introduce the post-stratification procedure, a technique aiming to use covariate information for precision when estimating the ATE from a single trial. These two research works detail why a so-called post-stratification estimator yields a lower variance compared to the Difference-in-Means – and therefore a Horvitz-Thomson – as soon as the covariates used for stratification are predictive of the outcome. More particularly, the post-stratification estimator on a single trial is defined as follows.

**Definition 29** (Post-stratification - [Imbens \(2011\)](#); [Miratrix et al. \(2013\)](#)). *The post-stratification estimator is denoted  $\hat{\tau}_{PS,n}$  and defined as,*

$$\hat{\tau}_{PS,n} = \frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\hat{\pi}_n(x)} - \frac{(1 - A_i) Y_i}{1 - \hat{\pi}_n(x)},$$

where  $\pi$  is estimated according to [Definition 28](#).

The different displays of the post-stratification estimator  $\hat{\tau}_{PS,n}$  in literature are recalled in [Section 4.D](#). The gain in efficiency of an IPSW version with estimated  $\pi$  follows this intuition.

**Definition 30** (Semi-oracle IPSW with  $\hat{\pi}$ ). *The semi-oracle IPSW estimator  $\hat{\tau}_{T,n}^*$  with estimated propensity scores  $\hat{\pi}_n$  is defined as*

$$\hat{\tau}_{T,n}^* = \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left( \frac{A_i}{\hat{\pi}_n(X_i)} - \frac{1 - A_i}{1 - \hat{\pi}_n(X_i)} \right), \quad (4.14)$$

with  $\hat{p}_{R,n}(x)$  and  $\hat{\pi}_n(x)$  defined in [Definitions 25 and 28](#).

**Definition 31** (IPSW with  $\hat{\pi}$ ). *The completely-estimated IPSW estimator  $\hat{\tau}_{n,m}$  with estimated propensity scores  $\hat{\pi}_n$  is defined as*

$$\hat{\tau}_{n,m} = \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left( \frac{A_i}{\hat{\pi}_n(X_i)} - \frac{1 - A_i}{1 - \hat{\pi}_n(X_i)} \right), \quad (4.15)$$

where  $\hat{p}_{T,m}(x)$ ,  $\hat{p}_{R,n}(x)$ , and  $\hat{\pi}_n(x)$  defined in [Definitions 25 and 28](#).

Before stating the formal results, and following the spirit of what was done with the variance of the Horvitz-Thomson per strata [eq. 4.11](#), we introduce  $V_{DM,n}(x)$ :

$$V_{DM,n}(x) = n \text{Var}_{\mathbb{R}} [\hat{\tau}_{DM,n} | X = x]. \quad (4.16)$$

The explicit variance of the Difference-in-Means under a Bernoulli design is provided in [Appendix](#) (see [Lemma 4](#)), and not displayed here for conciseness.

**Proposition 4** (IPSW's properties when also estimating  $\pi$ ). *Under the general setting defined in [Subsection 3.1.1](#), granting [Assumptions 26-29](#), the bias of the estimated IPSW with estimated  $\hat{\pi}_n$  (see [Definition 28](#)) is given by*

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{n,m}] - \tau &= \sum_{x \in \mathbf{X}} p_T(x) \mathbb{E} [Y^{(0)} | X = x] \left( 1 - p_R(x) (1 - \pi(x)) \right)^n \\ &\quad - \sum_{x \in \mathbf{X}} p_T(x) \mathbb{E} [Y^{(1)} | X = x] (1 - p_R(x) \pi(x))^n. \end{aligned}$$

Besides, the variance of the estimated IPSW with estimated  $\hat{\pi}_n$  satisfies, for all  $n$

$$\begin{aligned} \text{Var} [\hat{\tau}_{n,m}] &= \frac{1}{m} \text{Var} [\tau(X) - C_n(X)] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \\ &\quad + \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1-p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{DM,n}(x), \end{aligned}$$

$$\text{where} \quad C_n(X) = \mathbb{E} [Y^{(1)} | X] (1 - \pi(X))^{Z_n(X)} - \mathbb{E} [Y^{(0)} | X] \pi(X)^{Z_n(X)}.$$

$$\begin{aligned} \text{Furthermore,} \quad \text{Var} [\hat{\tau}_{n,m}] &\leq \frac{2\tilde{V}_{so}}{n+1} + \frac{\text{Var} [\tau(X)]}{m} + \frac{2}{(n+1)m} \mathbb{E}_R \left[ \frac{p_T(X)(1-p_T(X))}{p_R(X)^2} V_{DM}(X) \right] \\ &\quad + 2 \left(1 + \frac{3}{m}\right) \left(1 - \min_x ((1 - \tilde{\pi}(x)^2)p_R(x))\right)^{n/2} \mathbb{E} [(Y^{(1)})^2 + (Y^{(0)})^2], \end{aligned}$$

$$\text{where} \quad \tilde{\pi}(x) = \max(\pi(x), 1 - \pi(x)) \quad \text{and} \quad \tilde{V}_{so} := \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{DM,n}(X) \right].$$

Proof is detailed in Subsection 4.A.4.1. Note that the bias takes a simpler form in the most usual case if  $\pi(x) = 1/2$ ,

$$\mathbb{E} [\hat{\tau}_{n,m}] - \tau = - \sum_{x \in \mathbb{X}} p_T(x) \tau(x) \left(1 - \frac{p_R(x)}{2}\right)^n.$$

In this case, the bias of the estimated IPSW with estimated  $\hat{\pi}_n$  is larger than the one of all three previous IPSW (completely oracle, semi-oracle and estimated with oracle  $\pi$ ), but still decreases exponentially with  $n$ . Another difference comes from the fact that the sign and magnitude of the bias no longer depends on the sign and magnitude of  $\tau(x)$  but also of  $\mathbb{E}[Y^{(0)}]$  and  $\mathbb{E}[Y^{(1)}]$ . The bound on the variance of  $\hat{\tau}_{n,m}$  is very close to the one of  $\hat{\tau}_{\pi,n,m}$ , and in particular for any fixed  $m$ ,

$$\text{Var} [\hat{\tau}_{n,m}] \leq \frac{2\tilde{V}_{so}}{n+1} + \frac{\text{Var} [\tau(X)]}{m} + \frac{2}{(n+1)m} \mathbb{E}_R \left[ \frac{p_T(X)(1-p_T(X))}{p_R(X)^2} V_{DM}(X) \right] + o\left(\frac{1}{n}\right),$$

where the main difference comes from  $\tilde{V}_{so}$  that contains  $V_{DM,n}(X)$  rather than  $V_{HT}(X)$ . Combining eq. 4.6 and eq. 4.7 allows to have

$$n \text{Var} [\hat{\tau}_{DM,n}] \leq V_{HT}(x) + \mathcal{O}\left(n^{-1/2}\right),$$

which allows to conclude that for all  $n$  large enough, the bound on the variance of  $\hat{\tau}_{n,m}$  is tighter than the bound on the variance of  $\hat{\tau}_{\pi,n,m}$ . This can also be observed on the large sample variance.

**Corollary 6.** *Under the same assumptions as in Proposition 4, the completely estimated IPSW is asymptotically unbiased when  $n$  tends to infinity, that is*

$$\lim_{n \rightarrow \infty} \mathbb{E} [\hat{\tau}_{n,m}] = \tau.$$

Besides, letting  $\lim_{n,m \rightarrow \infty} m/n = \lambda \in [0, \infty]$ , the asymptotic variance of completely estimated IPSW satisfies

$$\lim_{n,m \rightarrow \infty} \min(n, m) \text{Var} [\hat{\tau}_{n,m}] = \min(1, \lambda) \left( \frac{\text{Var} [\tau(X)]}{\lambda} + \tilde{V}_{so,\infty} \right),$$

$$\text{where} \quad \tilde{V}_{so,\infty} := \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{DM,\infty}(X) \right],$$

$$\text{and} \quad V_{DM,\infty}(x) := \frac{\text{Var}_R [Y^{(1)} | X = x]}{\pi} + \frac{\text{Var}_R [Y^{(0)} | X = x]}{1 - \pi}.$$

Proof is detailed in Subsection 4.A.4.2. Because  $\forall x \in \mathbb{X}$ ,  $V_{DM,\infty}(x) \leq V_{HT}(x)$ , then  $\tilde{V}_{so,\infty} \leq V_{so}$ , so that the large sample variance of the semi-oracle and completely estimated IPSW are smaller than with an oracle  $\pi$ , regardless of the regime at which  $n$  and  $m$  tend to infinity. Similarly to the result on  $\hat{\tau}_{\pi,n,m}$ , upper bound on the risk of the completely estimated IPSW can be established, based on Proposition 4.

**Theorem 12** (Properties of the IPSW). *Under the general setting defined in Subsection 3.1.1, granting Assumptions 26-29, the quadratic risk of the completely estimated IPSW with estimated  $\hat{\pi}$  satisfies,*

$$\begin{aligned} \mathbb{E} \left[ (\hat{\tau}_{n,m} - \tau)^2 \right] &\leq \frac{2\tilde{V}_{so}}{n+1} + \frac{\text{Var}[\tau(X)]}{m} + \frac{2}{m(n+1)} \mathbb{E}_R \left[ \frac{p_T(X)(1-p_T(X))}{p_R(X)^2} V_{DM}(X) \right] \\ &\quad + 2 \left( 2 + \frac{3}{m} \right) \left( 1 - \min_x ((1 - \hat{\pi}(x))p_R(x)) \right)^{n/2} \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right]. \end{aligned} \quad (4.17)$$

Consequently, the estimator  $\hat{\tau}_{n,m}$  is  $L^2$ -consistent as  $m, n$  tends to infinity, that is,

$$\hat{\tau}_{n,m} \xrightarrow{L^2} \tau.$$

Proof is detailed in Subsection 4.A.4.3. For the risk, and for the same arguments than for the bound on the variance, it can be shown that for a reasonable  $n$ , the bound on the risk of  $\hat{\tau}_{n,m}$  is tighter than for  $\hat{\tau}_{\pi,n,m}$ . All the previous results establish theoretical guidance explaining why an estimator also estimating  $\pi$  per strata should be preferred in practice, at least for a reasonable trial sample size  $n$ . To our knowledge we have not found work explicitly stating that estimating  $\pi$  in the IPSW should be preferred, even if Dahabreh et al. (2020) uses a logistic regression to estimate the propensity to receive treatment in the trial.

### 4.3 Extended adjustment set: when using extra covariates

In this section, we detail the impact of adding covariates that are not necessary for adjustment – for example being only shifted or only treatment effect modifiers – on the IPSW performances. Indeed, in the literature, one of the natural approach is to adjust on all shifted covariates, also named the *sampling set* (Cole and Stuart, 2010; Tipton, 2013). Another adjustment set is also possible, being the *heterogeneity set* comprising all the treatment effect modifiers (Hartman, 2021), even if, knowing which covariate is treatment effect modifier is harder. As mentioned in the related work (Subsection 2.2), there is an important literature about optimal adjustment set for precision in the causal inference literature, but to our knowledge the topic has not been tackled yet when it comes to efficiency in generalization. Egami and Hartman (2021) discuss extensively the usage of these two sets for identification but do not study their impact on the asymptotic variance.

In this section the theoretical results hold for a specific regime, where the target sample is bigger than the trial sample, that is  $m \gg n$ . In other word, this situation is equivalent as considering the semi-oracle IPSW with estimated  $\pi$  (Definition 30).

**Formalization** Consider that the user has at disposal an external set of baseline categorical covariates denoted  $V$ . We assume that Assumptions 28 and 29 are preserved when adding  $V$  to the adjustment set  $X$  previously considered<sup>3</sup>. As mentioned above, this external covariates set can be of two different natures.

**Definition 32** ( $V$  is not a treatment effect modifier).  *$V$  does not modulate treatment effect modifier, that is*

$$\forall v \in \mathbb{V}, \forall s \in \{T, R\}, \quad \mathbb{P}_s(Y^{(1)} - Y^{(0)} \mid X = x, V = v) = \mathbb{P}_s(Y^{(1)} - Y^{(0)} \mid X = x).$$

<sup>3</sup>Note that if preserving transportability is pretty straightforward as  $V$  is a baseline covariate too (for e.g. no collider bias), the support inclusion's assumption can be more challenging when adding too many covariates (see D'Amour et al. (2017) for a discussion).



**Definition 33** ( $V$  is not shifted).  $V$  is not shifted, that is

$$\forall v \in \mathbb{V}, \quad p_T(v) = p_R(v).$$

To distinguish estimator using the set  $X$  or the extended set  $X, V$ , we denote  $\hat{\tau}(X)$  and  $\hat{\tau}(X, V)$  the two estimations strategies. One can show that adding only shifted covariates  $V$  leads to a loss of precision, when the set  $V$  is independent of the set  $X$ .

**Corollary 7** (Adding shifted and independent covariates). *Consider the semi-oracle IPSW estimator  $\hat{\tau}_{T,n}^*$  (Definition 30), and a set of additional shifted covariates  $V$  (Definition 32) independent of  $X$ , which are not treatment effect modifiers. Then,*

$$\lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X, V)] = \left( \sum_{v \in \mathcal{V}} \frac{p_T(v)^2}{p_R(v)} \right) \lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X)].$$

Proof is detailed in Subsection 4.B.1. This results states that the asymptotic variance of the semi-oracle estimator is always bigger if an additional independent shifted covariate set  $V$  is added in the adjustment. Moreover, the stronger the shift, the bigger the variance inflation. Note that this specific rule was retrieved in the toy example, where the plain line (corresponding to Corollary 7) matches the empirical dots on Figure 4.4a.

On the contrary, adding an additional treatment effect modifier covariate set leads to a gain in precision.

**Corollary 8** (Adding non-shifted treatment effect modifiers). *Consider the semi-oracle IPSW estimator  $\hat{\tau}_{T,n}^*$  (Definition 30). Consider an additional non-shifted treatment effect modifier set (Definition 33) independent of  $X$ . Then,*

$$\lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X, V)] = \lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X)] - \mathbb{E}_R \left[ \frac{p_T(X)}{p_R(X)} \text{Var} [\tau(X, V) \mid X] \right].$$

In particular,

$$\lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X, V)] \leq \lim_{n \rightarrow \infty} n \text{Var}_R [\hat{\tau}_{T,n}^*(X)].$$

Proof is detailed in Subsection 4.B.2. This result follows a similar spirit as [Rotnitzky and Smucler \(2020\)](#) due to the comparison of two asymptotic variances, even though the context and the theoretical tools are different.

## 5 Synthetic and semi-synthetic simulations


In this section, one additional analysis based on the toy example is provided to illustrate the different asymptotic regimes from Section 4. In addition, results are also illustrated on a semi-synthetic simulation aiming to mimic a medical scenario. The code to reproduce the simulations and the different figures is available on [Github](#)<sup>4</sup>.

### 5.1 Synthetic: additional experiment from the toy example

While most of the results are illustrated at the beginning of the article through the toy example, here we more thoroughly investigate empirically the different asymptotic regimes of the IPSW and its variants. In particular we complete Figure 4.3c that highlights the phenomenon of different asymptotic regimes, with a complete visualization of risks and variances allowing to more precisely illustrate the theoretical results, and in particular Corollary 5. More precisely, the quadratic risk is depicted in Figure 4.7b, while the variance via  $\min(n, m) \text{Var} [\hat{\tau}_{n,m}]$  is displayed in Figure 4.7a. In both figures, different estimators (oracle or not) are considered with different regimes for  $m$ , as  $n$  grows to infinity. In particular, this simulation confirms that

<sup>4</sup>[BenedicteColnet/IPSW-categorical](#).

- (i) all IPSW variants are consistent, even though their convergence speeds depend on the regime (Figure 4.7b),
- (ii) the completely oracle IPSW has a bigger variance than the semi-oracle IPSW (Figure 4.7a),
- (iii) the asymptotic variance depends on the asymptotic regime (Figure 4.7a),
- (iv) the completely estimated IPSW reaches the variance of the semi-oracle one if the target population sample is bigger than the trial (Figure 4.7a).



**Figure 4.7: Risks and different asymptotic regimes:** Based on the toy example simulation (see Section 2 and data-generative process from Figure 4.3a) where empirical variance from either the completely oracle (Definition 24), the semi-oracle (Definition 26) or the estimated IPSW (Definition 27) are estimated repeating 6,000 times each simulation for each trial sample size ( $x$ -axis). Simulations cover different regimes of size  $n$  and  $m$ . On the  $y$ -axis the empirical variance  $\min(n,m) \text{Var}[\hat{\tau}_{n,m}]$  is plotted (with the exception of  $\min(n,m) = n$  for completely- and semi-oracle variants, represented in plain lines). Each color represents one specific estimator and regime.

## 5.2 Semi-synthetic

In the semi-synthetic simulation, the data are taken from an application in critical care medicine, and only the outcome generative model is simulated, such that the covariate distribution and in particular the distribution shift between populations is inherited from a real situation.

### 5.2.1 Design

Two data-sets are used to generate two sources:

1. A randomized controlled trial (RCT), called CRASH-3 (Dewan et al., 2012), aiming to measure the effect of Tranexamic Acide (TXA) to prevent death from Traumatic Brain Injury (TBI). A total of 175 hospitals in 29 different countries participated to the RCT, where adults with TBI suffering from intracranial bleeding were randomly administrated TXA (CRASH-3, 2019). The inclusion criteria of the trial are patients with a Glasgow Coma Scale (GCS)<sup>5</sup> score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding.
2. An observational cohort, called Traumabase, comprising 23 French Trauma centers, collects detailed clinical data from the scene of the accident to the release from the hospital. The resulting database, called the Traumabase, comprises 23,000 trauma admissions to date, and is continually updated, representing a fair, almost-exhaustive data base about actual individuals taken in charge in France and suffering from trauma.

<sup>5</sup>The Glasgow Coma Scale (GCS) is a neurological scale which aims to assess a person's consciousness. The lower the score, the higher the gravity of the trauma.

These two data sources are turned into two source populations representing a real-world situation with six covariates so that the distribution structure and, in particular, the distributional shift mimics a real-world situation. The six covariates kept in common are: GCS (categorical), gender (categorical), pupil reactivity (categorical), age (continuous), systolic blood pressure (continuous), and time-to-treatment (TTT) (continuous). The continuous covariates are then turned into categories. Additional details about data preparation are available in Appendix (see Section 4.C). In this semi-synthetic simulation, only the outcome model is completely synthetic, and follows


$$Y := f(\text{GCS}, \text{Gender}) + A\tau(\text{TTT}, \text{Blood Pressure}) + \epsilon_{\text{TTT}}, \quad (4.18)$$

where  $f$  and  $\tau$  are two functions of the covariates, and  $\epsilon_{\text{TTT}}$  is a gaussian noise such that  $\mathbb{E}[\epsilon_{\text{TTT}} | X] = 0$ , but where heteroscedasticity is observed along the covariate TTT. The higher the time-to-treatment, the higher  $\text{Var}[\epsilon_{\text{TTT}} | \text{TTT}]$ , and so the noise on  $Y$  (see Section 4.C for the detailed generated function). This outcome model is such that only time-to-treatment (TTT) and blood pressure are effect modifiers, while other covariates only affects the baseline value or have no impact. Each time a simulation is conducted observations are sampled from the two populations with replacement, and the outcome is created following equation eq. 4.18. The trial is such that  $\pi = 0.5$ .

### 5.2.2 Results

**Minimal adjustment set is sufficient to generalize** The minimal adjustment set to generalize the trial results is constituted of the time-to-treatment (TTT) and the systolic blood pressure (blood). Using only these two covariates, the simulations illustrate how the re-weighting procedure allows to correct for the population shift between the trial and the target population as presented on Figure 4.8 (1,000 repetitions).

**Figure 4.8: IPSW estimating  $\pi$  or not:** Simulations with  $n = 500$ ,  $m = 10\,000$  where the IPSW estimator from Definitions 27 and 31 are compared to the estimates of the non-reweighted trials (Definitions 22 and 23) showing that the IPSW allow to recover the true ATE on the target population represented by the red dashed line (illustrating consistency from Theorem 11). Estimating  $\pi$  leads to a lower variance as expected (Corollary 6).



**Estimating  $\pi$  lowers the variance** Simulations also illustrate the fact that estimating  $\pi$  (Definition 31) compared to not estimating it (Definition 27) lowers the variance, as shown on Figure 4.8. This is expected from Corollary 6.

**The generalized (or re-weighted) estimate is not necessarily noisier than the trial's estimate** Note that the variance of the IPSW - with estimation of  $\pi$  or not - has a similar variance as the estimates coming from the RCT only (Horvitz-Thomson or difference-in-means). This is due to the presence of heteroscedasticity in the generative model (see equation eq. 4.18). Indeed, we would like to emphasize that re-weighting the trial does not necessarily lead to wider confidence intervals. This somehow challenges a common and intuitive idea present in the literature and stating that a re-weighted trial always has a larger variance than the trial itself (Gatsonis and Sally, 2017; Ling et al., 2022). This intuition comes from the multiplication of weights that can take large values (in


particular if, for some  $x$ ,  $p_R(x) \ll p_T(x)$ , making this idea valid as soon as the outcome noise is homoscedastic. However, the asymptotic variance of the semi-oracle IPSW from Corollary 4 highlights that this intuitive and reasonable idea is not necessarily true, as soon as there is heteroscedasticity, which occurs if some categories for which potential outcomes have higher uncertainty (larger noise) are more represented in the trial than in the target population:

$$V_{so} = \sum_{x \in \mathcal{X}} \underbrace{\frac{p_T^2(x)}{p_R(x)}}_{\text{Weights}} \left( \underbrace{\frac{\text{Var}[Y^{(1)}|X=x]}{\pi} + \frac{\text{Var}[Y^{(0)}|X=x]}{1-\pi}}_{\text{Can be small for some } x \text{ with high weights } \frac{p_T^2(x)}{p_R(x)}} \right)$$

In particular in this simulation, having a variance of the IPSW estimate smaller than that of the treatment effect estimator on the trial is possible because individuals treated earlier have less uncertainty in the response than individuals with high TTT (encoded in  $\epsilon_{TTT}$ ), and the simulation is made such that in the target population such individuals are more present than in the trial.

**Shifted and not treatment effect modifier covariate increases variance: the example of Glasgow score (GCS)** It is possible to illustrate the results from Section 4.3 with the semi-synthetic simulation. For example, the Glasgow score (GCS) can be added to the minimal adjustment set previously used (see Figure 4.8), and leads to a loss of precision as this covariate is relatively strongly shifted between the two data sets and is not a treatment effect modifier (even if in the simulation this covariate has an impact on the outcome). The increase in variance can be observed on Figure 4.9, where the green boxplot on the left represents such situation.

**Figure 4.9: Effect of non-necessary covariates on the variance:** IPSW (Definition 31) with  $n = 3000$  and  $m = 10000$  showing that the addition of the covariate GCS (shifted covariate not being a treatment effect modifier) increases the variance of the IPSW, while the addition of a non-shifted treatment effect modifier (here simulated as no covariates from the actual data base where not shifted) leads to an improvement in variance, compared to the minimal set. Simulations are repeated 1,000 times.



**While a non-shifted but treatment effect modifier lowers the variance** To illustrate a gain in precision due to the addition of a non-shifted treatment effect modifier, it was not possible to use the natural covariates from the two original data sets as a distributional shift was always present in all covariates. To model such a situation, we added a categorical covariate `X_sup` (5 levels), independent with all other covariates and without shift, in the data generative model to represent such a situation:

$$Y := f(\text{GCS}, \text{Gender}) + A \tau(\text{TTT}, \text{Blood Pressure}, \text{X\_sup}) + \epsilon_{TTT}. \tag{4.19}$$

Doing so, it is possible to illustrate that adding `X_sup` in the adjustment set allows to lower the variance, and Figure 4.9 presents such situation with the purple boxplot on the right.

## 6 Conclusion and future work

In this work, we establish finite-sample and asymptotic results on different versions of the so-called *Inverse Propensity Sampling Weights* estimator, when the adjustment set is constituted of categorical covariates. We give the explicit expressions of the biases and variances for all estimates, together with their quadratic risk. Our detailed analysis allows us to compare this different estimate in different finite-sample regimes. Indeed, to the best of our knowledge, our work is the first to study the impact of finite trial and observational data sets on IPSW performance in the context of generalization, by providing rate of convergence for several IPSW estimates. By doing so, we link these results with previous results in epidemiology where one data source was considered infinite, and also explain how certain observations can be seen through the eyes of seminal work in causal inference (efficient estimation with IPW).

**Which covariate to include?** This work also reveals that care should be taken when selecting the covariates to generalize. From applied literature, we have noticed that practitioners usually select almost all available covariates to build the weights, which is encouraged by the fear of missing an important shifted treatment effect modifier. We show that inclusion of many covariates comes with the risk of adjusting on shifted covariates that are not treatment effect modifiers, which can drastically damage the precision. On the contrary, even though adding some non-shifted covariates may sound counterintuitive, we show that such practice improves asymptotic precision, as soon as the non-shifted additional covariate set modulates treatment effect. Still, adding too many covariates endangers overlap and therefore can lead to finite sample bias. In light of these theoretical results, we believe that physicians and epidemiologists have an important role to play in selecting a limited number of covariates when generalizing trial's findings.

**Future work** Studying only categorical covariates is probably the main restriction of this work, as data can be hybrid and composed of continuous and categorical information. However, even when facing a hybrid set of covariates - continuous and categorical - the user can still create bins for continuous covariates. Even if such data-processing is not necessarily recommended, for a limited number of covariates this should allow to extend the analysis. Indeed, binning covariate leads to within-stratum confounding, that is a residual confounding due to rough bins, and therefore to an asymptotic bias due to factors that are poorly controlled on. To avoid within-stratum residual confounding, it is desirable to create more bins and split the data into more strata, but stratifying too finely with a finite sample may lead to (i) a variance inflation and (ii) the support inclusion assumption's invalidity. Indeed, the performances of the IPSW in a high-dimensional setting can be limited. For example, if all input variables are binary, the finite-sample bias and variance can be rewritten as a function of  $n/2^d$  (where  $d$  is the number of input variables) and can thus spin out of control if the sample sizes are too small compared to the dimension of the problem. Future work should investigate how our conclusion on the different asymptotic regimes and the covariates selection's impact on variance can be extended to settings with mixed-type covariates (for e.g. a smoother version of IPSW with density ratio estimation).

In practice, the limitation due to categorical covariates is balanced by the fact that within the medical field, clinical indicators and covariates are often scores and categories. For example, [Berkowitz et al. \(2018\)](#) apply the IPSW to generalize the effect of blood pressure control relying on many categorical covariates such as health insurance status (insured, uninsured), tobacco smoking status (never, current, former), and so on. When facing continuous covariates in practice, and having in mind the current theoretical understanding of the different generalization estimators, this IPSW version has interests. A solution would be found at the crossroads between identification bias (due to imprecise bins) and variance inflation or finite sample bias (due to numerous bins). Quantifying such a tradeoff in specific settings would definitely help the practitioners by providing clear guidelines.

## Appendix of Chapter 4

### 4.A Main proofs

#### 4.A.1 Proof of Theorem 9 - Completely oracle estimator $\hat{\tau}_{\pi, \mathbb{T}, \mathbb{R}, n}^*$

We first recall the expression of the completely oracle estimator introduced in Definition 24,

$$\hat{\tau}_{\pi, \mathbb{T}, \mathbb{R}, n}^* = \frac{1}{n} \sum_{i=1}^n \frac{p_{\mathbb{T}}(X_i)}{p_{\mathbb{R}}(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right).$$

This estimator can be rewritten as,

$$\hat{\tau}_{\pi, \mathbb{T}, \mathbb{R}, n}^* = \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right),$$

since  $X_i$  take values in a categorical set  $\mathbb{X}$ . This rewriting is extensively used in the proof.

#### Bias

Recall that, for all  $x \in \mathbb{X}$ ,  $p_{\mathbb{R}}(x)$  and  $p_{\mathbb{T}}(x)$  are not random variables. We have

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, \mathbb{R}, n}^*] &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right] && \text{By definition} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right] && \text{Linearity of } \mathbb{E}[\cdot] \\ &= \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \mathbb{E} \left[ \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right] && p_{\mathbb{R}}(x) \text{ and } p_{\mathbb{T}}(x) \text{ are not random} \\ &= \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \mathbb{E}_{\mathbb{R}} \left[ \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right] && \text{Linearity \& iid trial} \\ &= \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{p_{\mathbb{R}}(x)} \mathbb{E}_{\mathbb{R}} \left[ \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right] && \text{SUTVA (see Assumption 27).} \end{aligned}$$

Noting that,

$$p_{\mathbb{R}}(x) = \mathbb{P}_{\mathbb{R}}[X = x] = \mathbb{P}_{\mathbb{R}}[X_i = x] = \mathbb{E}_{\mathbb{R}} [\mathbb{1}_{X_i=x}],$$

one can condition on the random variable  $X_i$ , yielding

$$\mathbb{E}_{\mathbb{R}} \left[ \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right] = \mathbb{E}_{\mathbb{R}} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid X_i = x \right] \underbrace{\mathbb{E}_{\mathbb{R}} [\mathbb{1}_{X_i=x}]}_{=p_{\mathbb{R}}(x)}.$$

Then,

$$\begin{aligned}
\mathbb{E} [\hat{\tau}_{\pi, T, R, n}^*] &= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E}_R \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \mid X_i = x \right] && \text{From previous derivations} \\
&= \sum_{x \in \mathbb{X}} p_T(x) \left( \frac{\mathbb{E}_R [Y_i^{(1)} A_i \mid X_i = x]}{\pi} - \frac{\mathbb{E}_R [Y_i^{(0)} (1 - A_i) \mid X_i = x]}{1 - \pi} \right) && \pi \text{ is constant} \\
&= \sum_{x \in \mathbb{X}} p_T(x) \left( \frac{\mathbb{E}_R [Y_i^{(1)} \mid X_i = x] \mathbb{E}_R [A_i \mid X_i = x]}{\pi} \right. \\
&\quad \left. - \frac{\mathbb{E}_R [Y_i^{(0)} \mid X_i = x] \mathbb{E}_R [(1 - A_i) \mid X_i = x]}{1 - \pi} \right) && \text{Assumption 27} \\
&= \sum_{x \in \mathbb{X}} p_T(x) \left( \mathbb{E}_R [Y_i^{(1)} \mid X_i = x] - \mathbb{E}_R [Y_i^{(0)} \mid X_i = x] \right) && \mathbb{E}_R [A_i \mid X_i = x] = \pi \\
&= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E}_R [Y_i^{(1)} - Y_i^{(0)} \mid X_i = x] && \text{Linearity of } \mathbb{E}[\cdot] \\
&= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E}_T [Y_i^{(1)} - Y_i^{(0)} \mid X_i = x] && \text{Assumption 28} \\
&= \tau, && \text{Law of total probability}
\end{aligned}$$

which concludes the first part of the proof.

Note that the previous derivations, relying on *iid*, Assumption 27 (Trial internal validity with SUTVA, definition of  $\pi$ , and randomization), Assumption 28, and the law of total probability, lead to the following intermediary result,

$$\mathbb{E}_R \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \mid X_i = x \right] = \mathbb{E}_T [Y_i^{(1)} - Y_i^{(0)} \mid X_i = x] = \tau(x). \quad (4.20)$$

eq. 4.20 will be used in other proofs.

### Variance

To shorten notation, we denote by  $\mathbf{X}_n \in \mathbb{X}^n$  the vector composed of the  $n$  observations in the trial. We then use the law of total variance, conditioning on  $\mathbf{X}_n$ ,

$$\text{Var} [\hat{\tau}_{\pi, T, R, n}^*] = \text{Var} [\mathbb{E} [\hat{\tau}_{\pi, T, R, n}^* \mid \mathbf{X}_n]] + \mathbb{E} [\text{Var} [\hat{\tau}_{\pi, T, R, n}^* \mid \mathbf{X}_n]]. \quad (4.21)$$

Considering the first term in the right-hand side of eq. 4.21,

$$\begin{aligned}
\mathbb{E} [\hat{\tau}_{\pi, T, R, n}^* \mid \mathbf{X}_n] &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] && \text{By definition (and SUTVA)} \\
&= \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \frac{1}{n} \mathbb{E} \left[ \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right]. && \text{Linearity of } \mathbb{E}[\cdot]
\end{aligned}$$

Note that this last derivation also uses the fact that neither  $p_T(x)$  nor  $p_R(x)$  are random variables.



$$\begin{aligned}
 \mathbb{E} [\hat{\tau}_{\pi, T, R, n}^* | \mathbf{X}_n] &= \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \sum_{i=1}^n \frac{\mathbb{1}_{X_i=x}}{n} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \mid X_i \right] \quad \text{iid individuals} \\
 &= \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \sum_{i=1}^n \frac{\mathbb{1}_{X_i=x}}{n} \tau(X_i) \\
 &= \frac{1}{n} \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \tau(x) \sum_{i=1}^n \mathbb{1}_{X_i=x} \quad \text{Transportability (see Assumption 28)}
 \end{aligned}$$

Now, this last term can be written as a unique sum on  $i \in \{1, \dots, n\}$ , that is,

$$\frac{1}{n} \sum_{x \in \mathbb{X}} \frac{p_T(x)}{p_R(x)} \tau(x) \sum_{i=1}^n \mathbb{1}_{X_i=x} = \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{p_R(X_i)} \tau(X_i).$$

Taking the variance of this term leads to,

$$\begin{aligned}
 \text{Var} [\mathbb{E}_R [\hat{\tau}_{\pi, T, R, n}^* | \mathbf{X}_n]] &= \text{Var} \left[ \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{p_R(X_i)} \tau(X_i) \right] \\
 &= \frac{1}{n} \text{Var}_R \left[ \frac{p_T(X)}{p_R(X)} \tau(X) \right]. \quad \text{iid observations on trial (Assumption 27)}
 \end{aligned} \tag{4.22}$$

Regarding the second term,

$$\begin{aligned}
 \text{Var} [\hat{\tau}_{\pi, T, R, n}^* | \mathbf{X}_n] &= \text{Var}_R \left[ \frac{1}{n} \sum_{i=1}^n \frac{p_T(X_i)}{p_R(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] \\
 &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_T(X_i)}{p_R(X_i)} \right)^2 \text{Var}_R \left[ \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] \\
 &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_T(X_i)}{p_R(X_i)} \right)^2 \text{Var}_R \left[ \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid X_i \right].
 \end{aligned} \tag{4.23}$$

Recall that the variance of the Horvitz-Thomson estimator (see Definition 22) conditioned on  $X_i$  is given by

$$\text{Var}_R [\hat{\tau}_{\text{HT}, n} | X_i] = \frac{1}{n} \text{Var}_R \left[ \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid X_i \right]. \tag{4.24}$$

Then, one can use Lemma 3 (see Section 4.D) to have

$$n \text{Var} [\hat{\tau}_{\text{HT}, n} | X_i] = \mathbb{E}_R \left[ \frac{(Y^{(1)})^2}{\pi} \mid X_i \right] + \mathbb{E}_R \left[ \frac{(Y^{(0)})^2}{1 - \pi} \mid X_i \right] - \tau(X_i)^2 := V_{\text{HT}}(X_i). \tag{4.25}$$

Then, coming back to eq. 4.23,

$$\begin{aligned}
\mathbb{E}_R [\text{Var} [\hat{\tau}_{\pi, T, R, n}^* \mid \mathbf{X}_n]] &= \mathbb{E}_R \left[ \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_T(X_i)}{p_R(X_i)} \right)^2 V_{\text{HT}}(X_i) \right] \\
&= \mathbb{E}_R \left[ \frac{1}{n^2} \sum_{i=1}^n \left( \sum_{x \in \mathbb{X}} \mathbb{1}_{X_i=x} \right) \left( \frac{p_T(X_i)}{p_R(X_i)} \right)^2 V_{\text{HT}}(X_i) \right] \\
&= \mathbb{E}_R \left[ \sum_{x \in \mathbb{X}} \frac{1}{n^2} \left( \frac{p_T(x)}{p_R(x)} \right)^2 V_{\text{HT}}(x) \sum_{i=1}^n \mathbb{1}_{X_i=x} \right] \\
&= \sum_{x \in \mathbb{X}} \frac{1}{n^2} \left( \frac{p_T(x)}{p_R(x)} \right)^2 V_{\text{HT}}(x) \mathbb{E}_R \left[ \sum_{i=1}^n \mathbb{1}_{X_i=x} \right] \\
&= \sum_{x \in \mathbb{X}} \frac{1}{n} \left( \frac{p_T(x)}{p_R(x)} \right)^2 V_{\text{HT}}(x) \mathbb{E}_R \left[ \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n} \right] \\
&= \sum_{x \in \mathbb{X}} \frac{1}{n} \left( \frac{p_T(x)}{p_R(x)} \right)^2 V_{\text{HT}}(x) p_R(x) && \text{Assumption 26} \\
&= \sum_{x \in \mathbb{X}} \frac{1}{n} \frac{p_T^2(x)}{p_R(x)} V_{\text{HT}}(x) \\
&= \frac{1}{n} \sum_{x \in \mathbb{X}} \frac{p_T^2(x)}{p_R(x)} \left( \mathbb{E}_R \left[ \frac{(Y^{(1)})^2}{\pi} \mid X = x \right] \right) \\
&= \frac{1}{n} \sum_{x \in \mathbb{X}} \frac{p_T^2(x)}{p_R(x)} \left( \mathbb{E}_R \left[ \frac{(Y^{(0)})^2}{1-\pi} \mid X = x \right] - \tau(x)^2 \right), && (4.26)
\end{aligned}$$

Combining eq. 4.26 and eq. 4.22 into eq. 4.21 leads to, for all  $n$ ,

$$\text{Var} [\hat{\tau}_{\pi, T, R, n}^*] = \frac{V_o}{n}$$

where

$$V_o = \text{Var} \left[ \frac{p_T(X_i)}{p_R(X_i)} \tau(X_i) \right] + \sum_{x \in \mathbb{X}} \frac{p_T^2(x)}{p_R(x)} V_{\text{HT}}(x).$$

Note that it is also possible to write the result such as,

$$V_o = \text{Var} \left[ \frac{p_T(X)}{p_R(X)} \tau(X) \right] + \mathbb{E}_R \left[ \frac{p_T^2(X)}{p_R^2(X)} V_{\text{HT}}(X) \right],$$

noting that

$$\sum_{x \in \mathbb{X}} \frac{p_T^2(x)}{p_R(x)} V_{\text{HT}}(x) = \mathbb{E}_R \left[ \frac{p_T^2(X)}{p_R^2(X)} V_{\text{HT}}(X) \right]$$

### Quadratic risk and consistency

For any estimate  $\hat{\tau}$ , we have

$$\mathbb{E} [(\hat{\tau} - \tau)^2] = (\mathbb{E} [\hat{\tau}] - \tau)^2 + \text{Var} [\hat{\tau}].$$

Therefore, the risk of the completely oracle IPSW estimate satisfies

$$\mathbb{E} [(\hat{\tau} - \tau)^2] = \frac{V_o}{n}.$$

The  $L^2$  consistency holds by letting  $n$  tend to infinity.

## 4.A.2 Proofs for the semi-oracle IPSW $\hat{\tau}_{\pi, \mathbb{T}, n}^*$

### 4.A.2.1 Proof of Proposition 2

*Proof.* We first recall the definition of the semi-oracle estimator introduced in Definition 26:

$$\hat{\tau}_{\pi, \mathbb{T}, n}^* = \frac{1}{n} \sum_{i=1}^n \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right),$$

where, for all  $x \in \mathbb{X}$ ,

$$\hat{p}_{\mathbb{R}, n}(x) = \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n}. \quad (4.27)$$

Similarly to the completely oracle estimator, the semi-oracle estimator can be written as,

$$\hat{\tau}_{\pi, \mathbb{T}, n}^* = \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right),$$

since  $X_i$  take values in a categorical set  $\mathbb{X}$ .

### Bias

To shorten notation, we denote the full vector of covariates  $\mathbf{X}_n \in \mathbb{X}^n$ , comprising the  $n$  observations  $X_1, X_2, \dots, X_n \in \mathbb{X}$  in the trial. We have

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, n}^*] &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right) \right] && \text{By definition} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right) \right] && \text{Linearity and SUTVA} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right) \mid \mathbf{X}_n \right] \right] && \text{Law of total expect.} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ p_{\mathbb{T}}(x) \mathbb{E} \left[ \frac{1}{\hat{p}_{\mathbb{R}, n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right) \mid \mathbf{X}_n \right] \right] && p_{\mathbb{T}}(x) \text{ is deterministic} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \mathbb{E} \left[ \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \right) \right) \mid \mathbf{X}_n \right] \right] \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid \mathbf{X}_n \right] \right] \end{aligned}$$

This last line uses the fact that  $\frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n}$  is measurable with respect to  $\mathbf{X}_n$ . Then, note that,

$$\mathbb{1}_{X_i=x} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid \mathbf{X}_n \right] = \mathbb{1}_{X_i=x} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid X_i \right] \quad \text{iid observations.}$$

Then, recall from the proof in Subsection 4.A.1, and in particular from eq. 4.20 that

$$\begin{aligned} \mathbb{1}_{X_i=x} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid \mathbf{X}_n \right] &= \mathbb{1}_{X_i=x} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)}(1 - A_i)}{1 - \pi} \mid X = x \right] && \text{Indicator forcing } X = x. \\ &= \mathbb{1}_{X_i=x} \tau(x) && \text{Transportability.} \end{aligned}$$

Therefore,

$$\begin{aligned}\mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, n}^*] &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n} \tau(x) \right] \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_{\mathbb{T}}(x)}{\frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n}} \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n} \tau(x) \right] \quad \text{Estimation procedure - Equation 4.27}\end{aligned}$$

Let  $Z_n(x) = \sum_{i=1}^n \mathbb{1}_{X_i=x}$  distributed as  $\mathfrak{B}(n, p_{\mathbb{R}}(x))$ . Note that, by convention, the term inside the expectation is null if  $Z_n(x) = 0$ .<sup>6</sup> This leads to the following equality,

$$\begin{aligned}\mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, n}^*] &= \sum_{x \in \mathbb{X}} \mathbb{E} [p_{\mathbb{T}}(x) \tau(x) \mathbb{1}_{Z_n(x) > 0}] \\ &= \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) \mathbb{E} [\mathbb{1}_{Z_n(x) > 0}] \\ &= \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) (1 - (1 - p_{\mathbb{R}}(x))^n).\end{aligned}$$

### Upper bound of the bias.

If  $p_{\mathbb{R}}(x) = 0$ , then  $p_{\mathbb{T}}(x) = 0$  (due to the support inclusion assumption, see Assumption 29). Therefore, for all  $x \in \mathbb{X}, 0 < p_{\mathbb{R}}(x)$ . Then, it is possible to bound the bias for any sample size  $n$ , noting that,

$$\begin{aligned}|\mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, n}^*] - \tau| &= \left| \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) (1 - (1 - p_{\mathbb{R}}(x))^n) - \tau \right| \\ &= \left| \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) (1 - (1 - p_{\mathbb{R}}(x))^n) - \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) \right| \\ &= \left| \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) (1 - p_{\mathbb{R}}(x))^n \right| \\ &\leq \left(1 - \min_x p_{\mathbb{R}}(x)\right)^n \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) |\tau(x)| \\ &\leq \left(1 - \min_x p_{\mathbb{R}}(x)\right)^n \mathbb{E}_{\mathbb{T}} [|\tau(X)|].\end{aligned}$$

### Variance

The proof follows the same track as that of the completely oracle IPSW, conditioning on  $\mathbf{X}_n$ , and using the law of total variance,

$$\text{Var} [\hat{\tau}_{\pi, \mathbb{T}, n}^*] = \text{Var} [\mathbb{E} [\hat{\tau}_{\pi, \mathbb{T}, n}^* | \mathbf{X}_n]] + \mathbb{E} [\text{Var} [\hat{\tau}_{\pi, \mathbb{T}, n}^* | \mathbf{X}_n]]. \quad (4.28)$$

<sup>6</sup>Note that to be clearer we could have introduced the multiplication by  $\mathbb{1}_{Z_n(x) > 0}$  in the formula summing over the categories from the beginning. Indeed, this was implicit as it is the re-writing of a sum on the trial's observations. But this also leads to heavy notations.

For the first inside term,

$$\begin{aligned}
 \mathbb{E} [\hat{\tau}_{\pi, \tau, n}^* | \mathbf{X}_n] &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] && \text{By definition (and SUTVA)} \\
 &= \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{E} \left[ \left( \frac{Y_i^{(1)} A_i}{\pi} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] && \text{Linearity of } \mathbb{E}[\cdot] \\
 &= \sum_{x \in \mathbb{X}} \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \tau(X_i) \\
 &= \sum_{x \in \mathbb{X}} p_{\mathbb{T}}(x) \tau(x) \mathbb{1}_{Z_n(x) > 0} && \text{Equation 4.27} \\
 &= \mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) > 0} | \mathbf{X}_n] && \text{Re-writing the sum as expectancy}
 \end{aligned}$$

Note that

$$\begin{aligned}
 \text{Var} [\mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) > 0} | \mathbf{X}_n]] &= \text{Var} [\mathbb{E}_{\mathbb{T}} [\tau(X)] - \mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \\
 &= \text{Var} [\tau - \mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \\
 &= \text{Var} [\mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]],
 \end{aligned} \tag{4.29}$$

as the only source of randomness comes from  $\mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]$ .

Therefore, the first inside term of eq. 4.28 corresponds to,

$$\text{Var} [\mathbb{E} [\hat{\tau}_{\pi, \tau, n}^* | \mathbf{X}_n]] = \text{Var} [\mathbb{E}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]]. \tag{4.30}$$

On the other hand,

$$\begin{aligned}
 \text{Var} [\hat{\tau}_{\pi, \tau, n}^* | \mathbf{X}_n] &= \text{Var} \left[ \frac{1}{n} \sum_{i=1}^n \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] \\
 &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \right)^2 \text{Var} \left[ \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_n \right] \\
 &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \right)^2 \text{Var} \left[ \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid X_i \right] \\
 &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \right)^2 V_{\text{HT}}(X_i),
 \end{aligned}$$

where the last row comes from intermediary results in the completely oracle proof (see equation eq. 4.25), with

$$V_{\text{HT}}(x) := \mathbb{E}_{\mathbb{R}} \left[ \left( \frac{Y^{(1)}}{\pi} \right)^2 \mid X_i \right] + \mathbb{E}_{\mathbb{R}} \left[ \left( \frac{Y^{(0)}}{1 - \pi} \right)^2 \mid X_i \right] - \tau(X)^2.$$

Then,

$$\begin{aligned}
 \mathbb{E} [\text{Var} [\hat{\tau}_{\pi, \tau, n}^* | \mathbf{X}_n]] &= \mathbb{E} \left[ \frac{1}{n^2} \sum_{i=1}^n \left( \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \right)^2 V_{\text{HT}}(X_i) \right] && \text{From previous derivations} \\
 &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \left( \frac{1}{n^2} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{p_{\mathbb{T}}(X_i)}{\hat{p}_{\mathbb{R}, n}(X_i)} \right)^2 V_{\text{HT}}(X_i) \right) \right] && \text{Categorical } X \\
 &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{1}{n^2} \left( \frac{p_{\mathbb{T}}(x)}{\hat{p}_{\mathbb{R}, n}(x)} \right)^2 V_{\text{HT}}(x) \left( \sum_{i=1}^n \mathbb{1}_{X_i=x} \right) \right] \\
 &= \sum_{x \in \mathbb{X}} \frac{1}{n^2} p_{\mathbb{T}}(x)^2 V_{\text{HT}}(x) \mathbb{E} \left[ \left( \frac{1}{\hat{p}_{\mathbb{R}, n}(x)} \right)^2 \left( \sum_{i=1}^n \mathbb{1}_{X_i=x} \right) \right].
 \end{aligned}$$

Replacing  $\hat{p}_{R,n}(x)$  by its explicit expression,

$$\mathbb{E} [\text{Var} [\hat{\tau}_{\pi,T,n}^* | \mathbf{X}_n]] = \frac{1}{n} \sum_{x \in \mathbb{X}} p_T(x)^2 V_{\text{HT}}(x) \mathbb{E} \left[ \left( \frac{1}{\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x}} \right)^2 \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \right) \right]. \quad (4.31)$$

As in the study of the bias, we introduce  $Z_n(x) = \sum_{i=1}^n \mathbb{1}_{X_i=x}$ , distributed as  $\mathfrak{B}(n, p)$ . One can then write,

$$\mathbb{E} [\text{Var} [\hat{\tau}_{\pi,T,n}^* | \mathbf{X}_n]] = \frac{1}{n} \sum_{x \in \mathbb{X}} p_T(x)^2 V_{\text{HT}}(x) \mathbb{E}_{\mathbb{R}} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x}} \right].$$

Recalling eq. 4.28 and eq. 4.30, we have

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,T,n}^*] &= \text{Var} [\mathbb{E} [\hat{\tau}_{\pi,T,n}^* | \mathbf{X}_n]] + \mathbb{E} [\text{Var} [\hat{\tau}_{\pi,T,n}^* | \mathbf{X}_n]] \\ &= \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] + \frac{1}{n} \sum_{x \in \mathbb{X}} p_T(x)^2 V_{\text{HT}}(x) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x}} \right]. \end{aligned} \quad (4.32)$$

### Upper bound on the variance

According to [Arnould et al. \(2021\)](#) (see page 27), since  $Z_n(x)$  is distributed as  $\mathfrak{B}(n, p_R(x))$ , we have

$$\forall x \in \mathbb{X}, \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{Z_n(x)} \right] \leq \frac{2}{(n+1)p_R(x)}.$$

Besides,

$$\begin{aligned} \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] &\leq \mathbb{E}_T [\tau(X)^2 \mathbb{1}_{Z_n(X)=0}] \\ &\leq \mathbb{E}_T [\tau(X)^2 (1 - p_R(X))^n] \\ &\leq \mathbb{E}_T [\tau(X)^2] \left( 1 - \min_{x \in \mathbb{X}} p_R(x) \right)^n. \end{aligned}$$

Combining these inequalities with eq. 4.32 yields, for all  $n$ ,

$$\text{Var} [\hat{\tau}_{\pi,T,n}^*] \leq \mathbb{E}_T [\tau(X)^2] \left( 1 - \min_{x \in \mathbb{X}} p_R(x) \right)^n + \frac{2}{n+1} \sum_{x \in \mathbb{X}} \frac{p_T(x)^2}{p_R(x)} V_{\text{HT}}(x).$$

This expression can be further simplified in,

$$\text{Var} [\hat{\tau}_{\pi,T,n}^*] \leq \frac{2V_{so}}{n+1} + \left( 1 - \min_{x \in \mathbb{X}} p_R(x) \right)^n \mathbb{E}_T [\tau(X)^2],$$

where

$$V_{so} := \sum_{x \in \mathbb{X}} \frac{p_T(x)^2}{p_R(x)} V_{\text{HT}}(x) = \mathbb{E}_T \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{\text{HT}}(X) \right].$$

□

#### 4.A.2.2 Proof of Corollary 4

*Proof. Asymptotically unbiased*

Recall the expression of the semi-oracle IPSW bias from Proposition 2.

$$\mathbb{E} [\hat{\tau}_{\pi,T,n}^*] = \sum_{x \in \mathbb{X}} p_T(x) \tau(x) (1 - (1 - p_R(x))^n).$$

According to Assumption 29, we have  $\forall x \in \mathbb{X}$ ,  $0 < p_{\text{R}}(x) < 1$ . As a consequence,

$$\lim_{n \rightarrow \infty} (1 - (1 - p_{\text{R}}(x))^n) = 1,$$

which leads to

$$\lim_{n \rightarrow \infty} \mathbb{E} [\hat{\tau}_{\pi, \text{T}, n}^*] = \tau.$$

### Asymptotic variance

Recall the expression of the variance of the semi-oracle IPSW from Proposition 2:

$$n \text{Var} [\hat{\tau}_{\pi, \text{T}, n}^*] = n \text{Var} [\mathbb{E} [\hat{\tau}_{\pi, \text{T}, n}^* \mid \mathbf{X}_n]] + \sum_{x \in \mathbb{X}} p_{\text{T}}(x)^2 V_{\text{HT}}(x) \mathbb{E}_{\text{R}} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i = x}} \right]. \quad (4.33)$$

Note that the first term tends to zero since

$$0 \leq n \text{Var} [\mathbb{E} [\hat{\tau}_{\pi, \text{T}, n}^* \mid \mathbf{X}_n]] \leq \mathbb{E}_{\text{T}} [\tau(X)^2] \left( 1 - \min_{x \in \mathbb{X}} p_{\text{R}}(x) \right)^n.$$

Therefore,

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi, \text{T}, n}^*] = \lim_{n \rightarrow \infty} \sum_{x \in \mathbb{X}} p_{\text{T}}(x)^2 V_{\text{HT}}(x) \mathbb{E}_{\text{R}} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i = x}} \right]. \quad (4.34)$$

The next part of the proof consists in characterizing how the term  $\mathbb{E}_{\text{R}} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right]$  converges. Let  $\varepsilon > 0$ . Since, for all  $x$ ,  $p_{\text{R}}(x) > 0$ , we have

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \right] = \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| \geq \varepsilon} \right] + \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| < \varepsilon} \right]. \quad (4.35)$$

Regarding the first term in eq. 4.35, we have

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| \geq \varepsilon} \right] \leq n \mathbb{P} \left[ \left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| \geq \varepsilon \right],$$

since, on the event  $Z_n(x) > 0$ ,  $Z_n(x) \geq 1$ . Now, by Chernoff's inequality,

$$\mathbb{P} \left[ \left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| \geq \varepsilon \right] \leq 2 \exp(-2\varepsilon^2 n),$$

which yields

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| \geq \varepsilon} \right] \leq 2n \exp(-2\varepsilon^2 n). \quad (4.36)$$

Regarding the second term in equation eq. 4.35, since

$$\frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| < \varepsilon}$$

is bounded above, for  $\varepsilon < p_{\text{R}}(x)/2$  and converges in probability to  $1/p_{\text{R}}(x)$ , we have

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{\frac{Z_n(x)}{n}} \mathbb{1}_{\left| \frac{Z_n(x)}{n} - p_{\text{R}}(x) \right| < \varepsilon} \right] \rightarrow \frac{1}{p_{\text{R}}(x)}, \quad \text{as } n \rightarrow \infty. \quad (4.37)$$

Combining eq. 4.36 and eq. 4.37, we have

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right] \rightarrow \frac{1}{p_{\text{R}}(x)}, \quad \text{as } n \rightarrow \infty.$$

Using equation eq. 4.34, we finally obtain

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi, \text{T}, n}^*] = \sum_{x \in \mathbb{X}} \frac{p_{\text{T}}(x)^2}{p_{\text{R}}(x)} V_{\text{HT}}(x) = \mathbb{E} \left[ \left( \frac{p_{\text{T}}(X)}{p_{\text{R}}(X)} \right)^2 V_{\text{HT}}(X) \right] := V_{\text{so}}.$$

□



### 4.A.2.3 Proof of Theorem 10

*Proof.* For any estimate  $\hat{\tau}$ , we have

$$\mathbb{E} [(\hat{\tau} - \tau)^2] = (\mathbb{E} [\hat{\tau}] - \tau)^2 + \text{Var} [\hat{\tau}].$$

Therefore, the risk of the semi-oracle IPSW estimate can be bounded using results from Subsection 4.A.2.1 (or Proposition 2), and in particular the bounds on the variance and the bias,

$$\begin{aligned} \mathbb{E} [(\hat{\tau} - \tau)^2] &\leq \left(1 - \min_x p_{\text{R}}(x)\right)^{2n} \mathbb{E}_{\text{T}} [|\tau(X)|^2] + \frac{2V_{so}}{n+1} + \left(1 - \min_{x \in \mathbb{X}} p_{\text{R}}(x)\right)^n \mathbb{E}_{\text{T}} [\tau(X)^2] \\ &\leq \frac{2V_{so}}{n+1} + 2 \left(1 - \min_{x \in \mathbb{X}} p_{\text{R}}(x)\right)^n \mathbb{E}_{\text{T}} [\tau(X)^2], \end{aligned}$$

In particular thanks to the fact that,

$$\text{Var}_{\text{T}} [|\tau(X)|] = \mathbb{E}_{\text{T}} [\tau(X)^2] - \mathbb{E}_{\text{T}} [|\tau(X)|]^2,$$

so that,

$$\mathbb{E}_{\text{T}} [|\tau(X)|]^2 \leq \mathbb{E}_{\text{T}} [\tau(X)^2].$$

The  $L^2$  consistency holds by letting  $n$  tend to infinity. □

### 4.A.3 Proofs for (estimated) IPSW $\hat{\tau}_{\pi,n,m}$

We first recall the definition of a fully estimated estimator introduced in Definition 27.

$$\hat{\tau}_{\pi,n,m} = \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{\text{T},m}(X_i)}{\hat{p}_{\text{R},n}(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right),$$

where, for all  $x \in \mathbb{X}$ ,

$$\hat{p}_{\text{R},n}(x) = \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n}, \quad \text{and} \quad \hat{p}_{\text{T},m}(x) = \frac{\sum_{i=n+1}^{n+m} \mathbb{1}_{X_i=x}}{m}. \quad (4.38)$$

Similar to the completely oracle estimator, this estimated IPSW can be written as,

$$\hat{\tau}_{\pi,n,m} = \sum_{x \in \mathbb{X}} \frac{\hat{p}_{\text{T},m}(x)}{\hat{p}_{\text{R},n}(x)} \left( \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1 - A_i)}{1 - \pi} \right) \right).$$

All the proofs below rely on this decomposition.

#### 4.A.3.1 Proof of Proposition 3

*Proof.* **Expression of the bias**

Using the exact same derivations as in Subsection 4.A.2.1 (Bias), **but** using the law of total expectation when conditioning on  $\mathbf{X}_{n+m} \in \mathbb{X}^{n+m}$  (i.e. comprising the  $n$  and  $m$  observations  $X_1, X_2, \dots, X_n, X_{n+1} \dots X_{n+m} \in \mathbb{X}$  in the trial and target population, one has,

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{\pi,n,m}] &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{\hat{p}_{\text{T},m}(x)}{\hat{p}_{\text{R},n}(x)} \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n} \tau(x) \right] \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{\hat{p}_{\text{T},m}(x)}{\frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n}} \frac{\sum_{i=1}^n \mathbb{1}_{X_i=x}}{n} \tau(x) \right] \quad \text{Estimation procedure - Equation 4.38} \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} [\hat{p}_{\text{T},m}(x) \tau(x) \mathbb{1}_{Z_n(x) \neq 0}]. \end{aligned}$$

Note that  $Z_n(x)$  only depend on the trial sample  $\mathcal{R}$  and  $\hat{p}_{T,m}(x)$  on the observational sample. In addition,  $\tau(x)$  is deterministic, therefore

$$\mathbb{E}[\hat{\tau}_{\pi,n,m}] = \sum_{x \in \mathbb{X}} \tau(x) \mathbb{E}[\hat{p}_{T,m}(x)] \mathbb{E}[\mathbb{1}_{Z_n(x) \neq 0}].$$

Note that  $\mathbb{E}[\hat{p}_{T,m}(x)] = p_T(x)$ . Besides, according to the proof of the semi-oracle IPSW,

$$\mathbb{E}[\mathbb{1}_{Z_n(x) \neq 0}] = (1 - (1 - p_R(x))^n).$$

Therefore,

$$\mathbb{E}[\hat{\tau}_{\pi,n,m}] = \sum_{x \in \mathbb{X}} p_T(x) \tau(x) (1 - (1 - p_R(x))^n),$$

that is

$$\mathbb{E}[\hat{\tau}_{\pi,n,m}] - \tau = - \sum_{x \in \mathbb{X}} p_T(x) \tau(x) (1 - p_R(x))^n.$$

### Upper bound on the bias

It is possible to bound the bias for any sample size  $n$ , using the exact same derivations than for the semi-oracle IPSW.

### Expression of the variance

The proof follows a similar spirit as the proof for the completely oracle estimator, conditioning on all observations  $\mathbf{X}_{n+m}$ .

$$\text{Var}[\hat{\tau}_{\pi,n,m}] = \text{Var}[\mathbb{E}[\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] + \mathbb{E}[\text{Var}[\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]]. \quad (4.39)$$

$$\begin{aligned} \mathbb{E}[\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}] &= \mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \left(\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right)\right) \mid \mathbf{X}_{n+m}\right] \\ &= \sum_{x \in \mathbb{X}} \mathbb{E}\left[\frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \left(\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right)\right) \mid \mathbf{X}_{n+m}\right] \quad \text{Linearity of } \mathbb{E}[\cdot] \\ &= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \mathbb{E}\left[\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right) \mid \mathbf{X}_{n+m}\right]. \end{aligned}$$

Indeed,  $\hat{p}_{R,n}(x)$  and  $\hat{p}_{T,m}(x)$  are measurable with respect to  $\mathbf{X}_{n+m}$ .

Pursuing the computation, we have

$$\begin{aligned} \mathbb{E}[\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}] &= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \mathbb{E}\left[\frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right) \mid \mathbf{X}_{n+m}\right] \\ &= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{E}\left[\mathbb{1}_{X_i=x} \left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right) \mid \mathbf{X}_{n+m}\right] \quad \text{Linearity of } \mathbb{E}[\cdot] \\ &= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{E}\left[\left(\frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi}\right) \mid \mathbf{X}_{n+m}\right] \quad \text{Conditioning on } \mathbf{X}_n \\ &= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \tau(x) \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \quad \text{Transportability} \\ &= \sum_{x \in \mathbb{X}} \hat{p}_{T,m}(x) \tau(x) \mathbb{1}_{Z_n(x) \neq 0}, \end{aligned}$$

where  $Z_n(x) = \sum_{i=1}^n \mathbb{1}_{X_i=x}$ . Then,

$$\begin{aligned} \text{Var} [\mathbb{E} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] &= \text{Var} \left[ \sum_{x \in \mathbb{X}} \hat{p}_{T,m}(x) \tau(x) \mathbb{1}_{Z_n(x) \neq 0} \right] \\ &= \text{Var} \left[ \sum_{x \in \mathbb{X}} \frac{\sum_{i=n+1}^{n+m} \mathbb{1}_{X_i=x} \tau(x)}{m} \mathbb{1}_{Z_n(x) \neq 0} \right] \\ &= \text{Var} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \tau(X_i) \mathbb{1}_{Z_n(X_i) \neq 0} \right] \end{aligned}$$

Note that, contrary to the semi-oracle IPSW, this term is non-null due to estimation of  $\hat{p}_{T,m}$ . By the law of total variance,

$$\begin{aligned} \text{Var} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \tau(X_i) \mathbb{1}_{Z_n(X_i) \neq 0} \right] &= \mathbb{E} \left[ \text{Var} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \tau(X_i) \mathbb{1}_{Z_n(X_i) \neq 0} \mid \mathbf{X}_n \right] \right] \\ &\quad + \text{Var} \left[ \mathbb{E} \left[ \frac{1}{m} \sum_{i=n+1}^{n+m} \tau(X_i) \mathbb{1}_{Z_n(X_i) \neq 0} \mid \mathbf{X}_n \right] \right] \\ &= \frac{1}{m} \mathbb{E} [\text{Var} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0} \mid \mathbf{X}_n]] + \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0} \mid \mathbf{X}_n]] \\ &= \frac{1}{m} \text{Var} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0} \mid \mathbf{X}_n]], \end{aligned}$$

where the last line comes from the law of total variance applied to  $\text{Var} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}]$ . Recalling similar derivations from the semi-oracle IPSW proof, and in particular eq. 4.29, one has

$$\text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0} \mid \mathbf{X}_n]] = \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} \mid \mathbf{X}_n]],$$

so that

$$\text{Var} [\mathbb{E} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_n]] = \frac{1}{m} \text{Var} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E}_T [\tau(X) \mathbb{1}_{Z_n(X)=0} \mid \mathbf{X}_n]]. \quad (4.40)$$

For the other term of eq. 4.39,

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}] &= \text{Var} \left[ \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \left( \frac{Y_i A_i}{\pi} - \frac{Y_i (1 - A_i)}{1 - \pi} \right) \mid \mathbf{X}_{n+m} \right] \\ &= \frac{1}{n^2} \sum_{i=1}^n \left( \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \right)^2 V_{\text{HT}}(X_i). \end{aligned}$$

Derivations are very similar to the semi-oracle estimator, using the fact that  $\hat{p}_{R,n}(x)$  and  $\hat{p}_{T,m}(x)$  are measurable with respect to  $\mathbf{X}_{n+m}$ . We have

$$\begin{aligned} \mathbb{E} [\text{Var} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] &= \mathbb{E} \left[ \frac{1}{n^2} \sum_{i=1}^n \left( \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \right)^2 V_{\text{HT}}(X_i) \right] && \text{From previous derivations} \\ &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \left( \frac{1}{n^2} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \right)^2 V_{\text{HT}}(X_i) \right) \right] && \text{Categorical } X \\ &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{1}{n^2} \left( \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \right)^2 V_{\text{HT}}(x) \left( \sum_{i=1}^n \mathbb{1}_{X_i=x} \right) \right] \\ &= \sum_{x \in \mathbb{X}} \frac{1}{n^2} V_{\text{HT}}(x) \mathbb{E} \left[ \left( \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \right)^2 \left( \sum_{i=1}^n \mathbb{1}_{X_i=x} \right) \right] \\ &= \sum_{x \in \mathbb{X}} \frac{1}{n} V_{\text{HT}}(x) \mathbb{E}_R \left[ \frac{(\hat{p}_{T,m}(x))^2}{\hat{p}_{R,n}(x)} \mathbb{1}_{Z_n(x) \neq 0} \right]. \end{aligned}$$

In particular, the last term can be simplified in

$$\mathbb{E} [\text{Var} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] = \sum_{x \in \mathbb{X}} \frac{1}{n} V_{\text{HT}}(x) \mathbb{E} [(\hat{p}_{\text{T},m}(x))^2] \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\text{R},n}(x)} \right]. \quad (4.41)$$

This last derivation is possible because  $\hat{p}_{\text{T},m}(x)$ , which depends on  $\mathcal{T}$ , and  $\hat{p}_{\text{R},n}(x)$ , which depends on  $\mathcal{R}$ , are independent. The difference from the semi-oracle estimator comes from the term

$$\begin{aligned} \mathbb{E} [(\hat{p}_{\text{T},m}(x))^2] &= \mathbb{E} \left[ \left( \frac{\sum_{i=n+1}^m \mathbb{1}_{X_i=x}}{m} \right)^2 \right] \\ &= \frac{1}{m^2} \mathbb{E} \left[ \left( \sum_{i=n+1}^m \mathbb{1}_{X_i=x} \right)^2 \right] \\ &= \frac{1}{m^2} (mp_{\text{T}}(x)(1-p_{\text{T}}(x)) + m^2 p_{\text{T}}^2(x)) \\ &= \frac{p_{\text{T}}(x)(1-p_{\text{T}}(x))}{m} + p_{\text{T}}^2(x). \end{aligned} \quad (4.42)$$

Using eq. 4.40 and eq. 4.42 in eq. 4.39, we have

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m}] &= \text{Var} [\mathbb{E} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] + \mathbb{E} [\text{Var} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] \\ &= \frac{1}{m} \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} \mid \mathbf{X}_n]] \\ &\quad + \frac{1}{n} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) \frac{p_{\text{T}}(x)(1-p_{\text{T}}(x))}{m} \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\text{R},n}(x)} \right] + \frac{1}{n} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\text{T}}^2(x) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\text{R},n}(x)} \right] \\ &= \frac{1}{m} (\text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] - \text{Var} [\mathbb{E}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0} \mid \mathbf{X}_n]]) + \text{Var} [\hat{\tau}_{\pi,\text{T},n}^*] \\ &\quad + \frac{1}{nm} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\text{T}}(x)(1-p_{\text{T}}(x)) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\text{R},n}(x)} \right]. \end{aligned} \quad (4.43)$$

### Upper bound on the variance.

We first bound eq. 4.40, corresponding to

$$\text{Var} [\mathbb{E} [\hat{\tau}_{\pi,n,m} \mid \mathbf{X}_{n+m}]] = \frac{1}{m} \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} \mid \mathbf{X}_{n+m}]].$$

We have

$$\begin{aligned} \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] &= \text{Var}_{\text{T}} [\tau(X) - \tau(X) \mathbb{1}_{Z_n(X)=0}] \\ &= \text{Var}_{\text{T}} [\tau(X)] - 2 \text{Cov}_{\text{T}} (\tau(X), \tau(X) \mathbb{1}_{Z_n(X)=0}) + \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0}] \\ &\leq \text{Var}_{\text{T}} [\tau(X)] + 2 (\text{Var}_{\text{T}} [\tau(X)] \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0}])^{1/2} + \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0}], \end{aligned}$$

with

$$\begin{aligned} \text{Var}_{\text{T}} [\tau(X) \mathbb{1}_{Z_n(X)=0}] &\leq \mathbb{E} [\tau(X)^2 \mathbb{1}_{Z_n(X)=0}] \\ &\leq \mathbb{E} [\tau(X)^2 \mathbb{E} [\mathbb{1}_{Z_n(X)=0} \mid X]] \\ &\leq \mathbb{E} [\tau(X)^2 (1-p_{\text{R}}(X))^n] \\ &\leq \left(1 - \min_x p_{\text{R}}(x)\right)^n \mathbb{E}_{\text{T}} [\tau(X)^2]. \end{aligned}$$

Consequently,

$$\begin{aligned} \text{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] &\leq \text{Var}_{\mathbb{T}} [\tau(X)] + 2\mathbb{E}_{\mathbb{T}} [\tau(X)^2] \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2} + \left(1 - \min_x p_{\mathbb{R}}(x)\right)^n \mathbb{E}_{\mathbb{T}} [\tau(X)^2] \\ &\leq \text{Var}_{\mathbb{T}} [\tau(X)] + 4\mathbb{E}_{\mathbb{T}} [\tau(X)^2] \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2}. \end{aligned}$$

One can also bound the other term of eq. 4.40 following the same derivations as the semi-oracle IPSW,

$$\begin{aligned} \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_{n+m}]] &\leq \mathbb{E} [\tau(X)^2 \mathbb{1}_{Z_n(X)=0}] \\ &= \mathbb{E} [\tau(X)^2 \mathbb{E} [\mathbb{1}_{Z_n(X)=0} | X]] \\ &= \mathbb{E} [\tau(X)^2 \mathbb{P} [Z_n(X) = 0 | X]] \\ &\leq \mathbb{E} [\tau(X)^2] \left(1 - \min_x p_{\mathbb{R}}(x)\right)^n. \end{aligned} \quad (4.44)$$

The first bound is obtained using the fact that the variance of a random variable is bounded by the expectancy of the squared random variables, and either the law of total variance or Jensen inequality. Then, using the fact that  $1 - \frac{1}{m} \leq 1$ ,

$$\begin{aligned} \text{Var} [\mathbb{E}_{\mathbb{T}} [\hat{\tau}_{\pi,n,m} | \mathbf{X}_{n+m}]] &\leq \frac{\text{Var}_{\mathbb{T}} [\tau(X)]}{m} + \frac{4\mathbb{E}_{\mathbb{T}} [\tau(X)^2]}{m} \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2} + \mathbb{E}_{\mathbb{T}} [\tau(X)^2] \left(1 - \min_x p_{\mathbb{R}}(x)\right)^n \\ &\leq \frac{\text{Var}_{\mathbb{T}} [\tau(X)]}{m} + \mathbb{E}_{\mathbb{T}} [\tau(X)^2] \left(\frac{4}{m} + 1\right) \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2}. \end{aligned} \quad (4.45)$$

Then, for the other term of the asymptotic variance, one can use the results from [Arnould et al. \(2021\)](#) (see page 27) to bound the variance, which leads to

$$\begin{aligned} \mathbb{E} [\text{Var} [\hat{\tau}_{\pi,n,m} | \mathbf{X}_{n+m}]] &= \sum_{x \in \mathbb{X}} \frac{1}{n} g(x) \mathbb{E} [(\hat{p}_{\mathbb{T},m}(x))^2] \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\frac{Z_n(x)}{n}} \right] \\ &\leq \sum_{x \in \mathbb{X}} g(x) \mathbb{E} [(\hat{p}_{\mathbb{T},m}(x))^2] \frac{2}{(n+1)p_{\mathbb{R}}(x)} \quad \text{Arnould et al. (2021) (p.27)} \\ &= \sum_{x \in \mathbb{X}} g(x) \left( \frac{p_{\mathbb{T}}(x)(1-p_{\mathbb{T}}(x))}{m} + p_{\mathbb{T}}(x)^2 \right) \frac{2}{(n+1)p_{\mathbb{R}}(x)} \end{aligned}$$

Finally, using eq. 4.45, and eq. 4.43,

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m}] &\leq \frac{\text{Var}_{\mathbb{T}} [\tau(X)]}{m} + \mathbb{E}_{\mathbb{T}} [\tau(X)^2] \left(\frac{4}{m} + 1\right) \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2} \\ &\quad + \frac{2}{n+1} \left( \mathbb{E}_{\mathbb{R}} \left[ \left(\frac{p_{\mathbb{T}}(X)}{p_{\mathbb{R}}(X)}\right)^2 V_{\text{HT}}(X) \right] + \frac{1}{m} \mathbb{E}_{\mathbb{R}} \left[ \frac{p_{\mathbb{T}}(X)(1-p_{\mathbb{T}}(X))}{p_{\mathbb{R}}(X)^2} V_{\text{HT}}(X) \right] \right). \end{aligned} \quad (4.46)$$

□

### 4.A.3.2 Proof of Corollary 5

#### Asymptotic bias

The proof is exactly the same as for the semi-oracle IPSW, see Subsection 4.A.2.2.

#### Asymptotic variance

We recall that the explicit expression of the variance is

$$\begin{aligned} \text{Var} [\hat{\tau}_{\pi,n,m}] &= \frac{1}{m} \text{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \\ &\quad + \frac{1}{n} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) \frac{p_{\mathbb{T}}(x)(1-p_{\mathbb{T}}(x))}{m} \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R},n}(x)} \right] + \text{Var} [\hat{\tau}_{\pi,\mathbb{T},n}^*]. \end{aligned}$$

Let's consider a slightly different quantity, multiplying by  $\min(n, m)$ ,

$$\begin{aligned} \min(n, m) \text{Var} [\hat{\tau}_{\pi,n,m}] &= \frac{\min(n, m)}{m} \text{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \min(n, m) \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \\ &\quad + \frac{\min(n, m)}{nm} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\mathbb{T}}(x)(1-p_{\mathbb{T}}(x)) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R},n}(x)} \right] + \min(n, m) \text{Var} [\hat{\tau}_{\pi,\mathbb{T},n}^*]. \end{aligned}$$

Now, we study an asymptotic regime where  $n$  and  $m$  can grow toward infinity but at different paces.

Let  $\lim_{n,m \rightarrow \infty} \frac{m}{n} = \lambda \in [0, \infty]$ , where  $\lambda$  characterizes the regime.

**Case 1:** If  $\lambda \in [1, \infty]$ , one can replace  $\min(n, m)$  by  $n$ , so that

$$\begin{aligned} \lim_{n,m \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi,n,m}] &= \lim_{n,m \rightarrow \infty} \left( \underbrace{\frac{n}{m}}_{\frac{1}{\lambda}} \text{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + n \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \right) \\ &\quad + \lim_{n,m \rightarrow \infty} \underbrace{\left( \frac{1}{m} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\mathbb{T}}(x)(1-p_{\mathbb{T}}(x)) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R},n}(x)} \right] \right)}_{=0} \\ &\quad + \underbrace{\lim_{n,m \rightarrow \infty} (n \text{Var} [\hat{\tau}_{\pi,\mathbb{T},n}^*])}_{=V_{\text{so}}}, \end{aligned}$$

where we also used Corollary 4 and from former proof, eq. 4.36 and eq. 4.37 stating that

$$\mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right] \rightarrow \frac{1}{p_{\mathbb{R}}(x)}, \quad \text{as } n \rightarrow \infty.$$

Recalling eq. 4.44,

$$0 \leq \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \leq \tau \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{2n},$$

due to the exponential convergence one has,

$$\lim_{n \rightarrow \infty} n \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] = 0,$$

and therefore,

$$\lim_{n,m \rightarrow \infty} n \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] = 0. \quad (4.47)$$

Besides,

$$\lim_{n \rightarrow \infty} \text{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] = \text{Var}_{\mathbb{T}} [\tau(X)],$$

To summarize, if  $\lambda \in [1, \infty]$ , one can conclude that

$$\lim_{n,m \rightarrow \infty} n \text{Var} [\hat{\tau}_{\pi,n,m}] = \frac{\text{Var} [\tau(X)]}{\lambda} + V_{\text{so}}. \quad (4.48)$$

**Case 2:** If  $\lambda \in [0, 1]$ , one can replace  $\min(n, m)$  by  $m$ , so that

$$\begin{aligned} \lim_{n, m \rightarrow \infty} m \operatorname{Var} [\hat{\tau}_{\pi, n, m}] &= \lim_{n, m \rightarrow \infty} \operatorname{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] + \lim_{n, m \rightarrow \infty} m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \\ &\quad + \lim_{n, m \rightarrow \infty} \frac{1}{n} \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\mathbb{T}}(x) (1 - p_{\mathbb{T}}(x)) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R}, n}(x)} \right] \\ &\quad + \lim_{n, m \rightarrow \infty} \lambda \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\mathbb{T}}^2(x) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R}, n}(x)} \right]. \end{aligned}$$

In particular,

$$\lim_{n, m \rightarrow \infty} \operatorname{Var}_{\mathbb{T}} [\tau(X) \mathbb{1}_{Z_n(X) \neq 0}] = \operatorname{Var}_{\mathbb{T}} [\tau(X)].$$

As above, we have

$$\lim_{n, m \rightarrow \infty} m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] = 0,$$

because,

$$0 \leq m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]] \leq n \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [\tau(X) \mathbb{1}_{Z_n(X)=0} | \mathbf{X}_n]].$$

In addition, eq. 4.36 and eq. 4.37 ensure that

$$\lim_{n, m \rightarrow \infty} \lambda \sum_{x \in \mathbb{X}} V_{\text{HT}}(x) p_{\mathbb{T}}^2(x) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) \neq 0}}{\hat{p}_{\mathbb{R}, n}(x)} \right] = \lambda V_{so}.$$

As an intermediary conclusion, if  $\lambda \in [0, 1]$ ,

$$\lim_{n, m \rightarrow \infty} \min(n, m) \operatorname{Var} [\hat{\tau}_{\pi, n, m}] = \operatorname{Var} [\tau(X)] + \lambda V_{so} \quad (4.49)$$

**General conclusion:** It is possible to gather equations eq. 4.48 and eq. 4.49 in one single conclusion. Therefore, letting  $\lim_{n, m \rightarrow \infty} m/n = \lambda \in [0, \infty]$ , the asymptotic variance of estimated IPSW satisfies

$$\lim_{n, m \rightarrow \infty} \min(n, m) \operatorname{Var} [\hat{\tau}_{\pi, n, m}] = \min(1, \lambda) \left( \frac{\operatorname{Var} [\tau(X)]}{\lambda} + V_{so} \right).$$

#### 4.A.3.3 Proof of Theorem 11

*Proof.* For any estimate  $\hat{\tau}$ , we have

$$\mathbb{E} [(\hat{\tau} - \tau)^2] = (\mathbb{E} [\hat{\tau}] - \tau)^2 + \operatorname{Var} [\hat{\tau}].$$

Therefore, the risk of the (estimated) IPSW estimate can be bounded using results from Subsection 4.A.3.1 (or Proposition 3), and in particular the bounds on the variance and the bias,

$$\begin{aligned} \mathbb{E} [(\hat{\tau} - \tau)^2] &\leq (1 - \min_x p_{\mathbb{R}}(x))^{2n} \mathbb{E}_{\mathbb{T}} [\tau(X)^2] + \frac{\operatorname{Var}_{\mathbb{T}} [\tau(X)]}{m} + \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2} \left( \frac{4\mathbb{E}_{\mathbb{T}} [\tau(X)^2]}{m} + \tau \right) \\ &\quad + \frac{2}{n+1} \left( \mathbb{E}_{\mathbb{R}} \left[ \left( \frac{p_{\mathbb{T}}(X)}{p_{\mathbb{R}}(X)} \right)^2 V_{\text{HT}}(X) \right] + \frac{1}{m} \mathbb{E}_{\mathbb{R}} \left[ \frac{p_{\mathbb{T}}(X) (1 - p_{\mathbb{T}}(X))}{p_{\mathbb{R}}(X)^2} V_{\text{HT}}(X) \right] \right) \\ &\leq \frac{2V_{so}}{n+1} + \frac{\operatorname{Var}_{\mathbb{T}} [\tau(X)]}{m} + \frac{2}{m(n+1)} \mathbb{E}_{\mathbb{R}} \left[ \frac{p_{\mathbb{T}}(X) (1 - p_{\mathbb{T}}(X))}{p_{\mathbb{R}}(X)^2} V_{\text{HT}}(X) \right] \\ &\quad + \left(1 - \min_x p_{\mathbb{R}}(x)\right)^{n/2} \left( 1 + \mathbb{E}_{\mathbb{T}} [\tau(X)^2] + \frac{4\mathbb{E}_{\mathbb{T}} [\tau(X)^2]}{m} \right). \end{aligned}$$

The  $L^2$  consistency holds by letting  $n$  and  $m$  tend to infinity. □



#### 4.A.4 Estimated IPSW with estimated $\hat{\pi}_n(x)$

##### 4.A.4.1 Proof of Proposition 4

*Proof. Bias*

We start by computing the bias of

$$\begin{aligned}
 \mathbb{E}[\hat{\tau}_{n,m}] &= \mathbb{E}\left[\frac{1}{n}\sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left(\frac{A_i}{\hat{\pi}_n(X_i)} - \frac{1-A_i}{1-\hat{\pi}_n(X_i)}\right)\right] \\
 &= \frac{1}{n}\mathbb{E}\left[\mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i \left(\frac{A_i}{\hat{\pi}_n(x)} - \frac{1-A_i}{1-\hat{\pi}_n(x)}\right) \mid \mathbf{X}_n, \mathbf{A}_n, \mathbf{Y}_n\right]\right] \\
 &= \frac{1}{n}\mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{\mathbb{E}[\hat{p}_{T,m}(x) \mid \mathbf{X}_n, \mathbf{A}_n, \mathbf{Y}_n]}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i \left(\frac{A_i}{\hat{\pi}_n(x)} - \frac{1-A_i}{1-\hat{\pi}_n(x)}\right)\right] \\
 &= \frac{1}{n}\mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i \left(\frac{A_i}{\hat{\pi}_n(x)} - \frac{1-A_i}{1-\hat{\pi}_n(x)}\right)\right].
 \end{aligned}$$

This derivation is possible as  $\hat{p}_{T,m}$  is estimated on a different data set than the trial.

Using SUTVA (Assumption 27), one can replace observed outcomes by potential outcomes, and

$$\begin{aligned}
 \mathbb{E}[\hat{\tau}_{n,m}] &= \frac{1}{n}\mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left(\frac{Y_i^{(1)} A_i}{\hat{\pi}_n(x)} - \frac{Y_i^{(0)}(1-A_i)}{1-\hat{\pi}_n(x)}\right)\right] \\
 &= \frac{1}{n}\mathbb{E}\left[\sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{E}\left[\left(\frac{Y_i^{(1)} A_i}{\hat{\pi}_n(x)} - \frac{Y_i^{(0)}(1-A_i)}{1-\hat{\pi}_n(x)}\right) \mid \mathbf{X}_n, \mathbf{Y}_n^{(1)}, \mathbf{Y}_n^{(0)}\right]\right].
 \end{aligned}$$

Let us consider, for any fixed  $x \in \mathbb{X}$ ,

$$\mathbb{E}\left[\frac{Y_i^{(1)} A_i}{\hat{\pi}_n(x)} \mid \mathbf{X}_n, \mathbf{Y}_n^{(1)}, \mathbf{Y}_n^{(0)}\right] = Y_i^{(1)} \mathbb{E}\left[\frac{A_i}{\hat{\pi}_n(x)} \mid \mathbf{X}_n\right].$$

Up to reordering the  $X_i$ 's, we have

$$\begin{aligned}
 \mathbb{E}\left[\frac{A_i}{\hat{\pi}_n(x)} \mid \mathbf{X}_n\right] &= \mathbb{E}\left[\frac{A_i}{\frac{\sum_{j=1}^{Z_n(x)} A_j}{Z_n(x)}} \mid \mathbf{X}_n\right] \\
 &= Z_n(x) \mathbb{E}\left[\frac{A_i}{\sum_{j=1}^{Z_n(x)} A_j} \mid \mathbf{X}_n\right] \\
 &= Z_n(x) \pi(x) \mathbb{E}\left[\frac{1}{1 + \sum_{j=2}^{Z_n(x)} A_j} \mid \mathbf{X}_n\right].
 \end{aligned}$$

The last rows uses the law of total probability. According to Lemma 11 (i) in [Biau \(2012\)](#), and considering  $B_n(x) \sim \mathfrak{B}(n, p)$ , for any  $x \in \mathbb{X}$ ,

$$\mathbb{E}\left[\frac{1}{1 + B_n(x)}\right] = \frac{1}{(n+1)p} - \frac{(1-p)^{n+1}}{(n+1)p}.$$

Since, conditional on  $\mathbf{X}_n$ ,  $\sum_{j=2}^{Z_n(x)} A_j$  is distributed as  $\mathfrak{B}(Z_n(x) - 1, \pi(x))$ ,

$$\begin{aligned}
 \mathbb{E}\left[\frac{A_i}{\hat{\pi}_n(x)} \mid \mathbf{X}_n\right] &= Z_n(x) \pi(x) \left(\frac{1}{Z_n(x) \pi(x)} - \frac{(1-\pi(x))^{Z_n(x)}}{Z_n(x) \pi(x)}\right) \\
 &= 1 - (1-\pi(x))^{Z_n(x)}.
 \end{aligned}$$

Similarly,

$$\mathbb{E} \left[ \frac{(1 - A_i)}{1 - \hat{\pi}_n(x)} \mid \mathbf{X}_n \right] = 1 - \pi(x)^{Z_n(x)}.$$

Consequently,

$$\begin{aligned} \mathbb{E} \left[ \left( \frac{Y_i^{(1)} A_i}{\hat{\pi}_n(x)} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \hat{\pi}_n(x)} \right) \mid \mathbf{X}_n, \mathbf{Y}_n^{(1)}, \mathbf{Y}_n^{(0)} \right] &= Y_i^{(1)} \left( 1 - (1 - \pi(x))^{Z_n(x)} \right) - Y_i^{(0)} \left( 1 - \pi(x)^{Z_n(x)} \right) \\ &= \left( Y_i^{(1)} - Y_i^{(0)} \right) - Y_i^{(1)} (1 - \pi(x))^{Z_n(x)} + Y_i^{(0)} \pi(x)^{Z_n(x)}. \end{aligned}$$

Therefore,

$$\mathbb{E} [\hat{\tau}_{n,m}] = \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} (Y_i^{(1)} - Y_i^{(0)}) \right] \quad (4.50)$$

$$+ \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i^{(0)} \pi(x)^{Z_n(x)} \right] \quad (4.51)$$

$$- \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i^{(1)} (1 - \pi(x))^{Z_n(x)} \right]. \quad (4.52)$$

On one hand, considering eq. 4.50,

$$\begin{aligned} \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} (Y_i^{(1)} - Y_i^{(0)}) \right] &= \frac{1}{n} \sum_{x \in \mathbb{X}} \mathbb{E} \left[ \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} (Y_i^{(1)} - Y_i^{(0)}) \right] \\ &= \sum_{x \in \mathbb{X}} \mathbb{E} [p_T(x) \mathbb{1}_{Z_n(x) > 0} \tau(x)], \end{aligned}$$

corresponding to the bias in the semi-oracle and the estimated IPSW. Indeed, we recall from the semi-oracle IPSW proof that,

$$\sum_{x \in \mathbb{X}} \mathbb{E} [p_T(x) \mathbb{1}_{Z_n(x) > 0} \tau(x)] = \sum_{x \in \mathbb{X}} p_T(x) (1 - (1 - p_R(x))^n) \tau(x).$$

On the other hand, considering eq. 4.51,

$$\begin{aligned} \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i^{(0)} \pi(x)^{Z_n(x)} \right] &= \frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{E} [Y_i^{(0)} \mid X_i = x] \pi(x)^{Z_n(x)} \right] \\ &= \mathbb{E} \left[ \sum_{x \in \mathbb{X}} p_T(x) \mathbb{1}_{Z_n(x) > 0} \mathbb{E} [Y_i^{(0)} \mid X_i = x] \pi(x)^{Z_n(x)} \right] \\ &= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} [Y_i^{(0)} \mid X_i = x] \mathbb{E} [\mathbb{1}_{Z_n(x) > 0} \pi(x)^{Z_n(x)}] \\ &= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} [Y_i^{(0)} \mid X_i = x] \mathbb{E} [(1 - \mathbb{1}_{Z_n(x)=0}) \pi(x)^{Z_n(x)}] \\ &= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} [Y_i^{(0)} \mid X_i = x] \left( \mathbb{E} [\pi(x)^{Z_n(x)}] - \mathbb{E} [\mathbb{1}_{Z_n(x)=0}] \right). \end{aligned}$$

Now, note that  $\mathbb{P}[Z_n(x) = 0] = (1 - p_R(x))^n$  and

$$\begin{aligned} \mathbb{E} [\pi(x)^{Z_n(x)}] &= \prod_{j=1}^n \mathbb{E} [\pi(x)^{\mathbb{1}_{X_j=x}}] \\ &= (\pi(x) p_R(x) + (1 - p_R(x)))^n. \\ &= (1 - p_R(x) (1 - \pi(x)))^n. \end{aligned}$$

Therefore,

$$\frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i^{(0)} \pi(x)^{Z_n(x)} \right] = \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(0)} \mid X_i = x \right] \left( (1 - p_R(x)(1 - \pi(x)))^n - (1 - p_R(x))^n \right).$$

Similarly, considering eq. 4.52,

$$-\frac{1}{n} \mathbb{E} \left[ \sum_{x \in \mathbb{X}} \frac{p_T(x)}{\hat{p}_{R,n}(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} Y_i^{(1)} (1 - \pi)^{Z_n(x)} \right] = - \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(1)} \mid X_i = x \right] \left( (1 - p_R(x)\pi(x))^n - (1 - p_R(x))^n \right).$$

Finally, the bias of the estimated IPSW with estimated treatment proportion is given by

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{n,m}] - \tau &= - \sum_{x \in \mathbb{X}} p_T(x) \tau(x) (1 - p_R(x))^n \\ &\quad + \sum_{x \in \mathbb{X}} p_T(x) \left( \mathbb{E} \left[ Y_i^{(1)} \mid X_i = x \right] - \mathbb{E} \left[ Y_i^{(0)} \mid X_i = x \right] \right) (1 - p_R(x))^n \\ &\quad + \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(0)} \mid X_i = x \right] (1 - p_R(x)(1 - \pi(x)))^n \\ &\quad - \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(1)} \mid X_i = x \right] (1 - p_R(x)\pi(x))^n, \end{aligned}$$

such that,

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{n,m}] - \tau &= \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(0)} \mid X_i = x \right] (1 - p_R(x)(1 - \pi(x)))^n \\ &\quad - \sum_{x \in \mathbb{X}} p_T(x) \mathbb{E} \left[ Y_i^{(1)} \mid X_i = x \right] (1 - p_R(x)\pi(x))^n. \end{aligned}$$

## Variance

As above, we have

$$\text{Var} [\hat{\tau}_{n,m}] = \text{Var} [\mathbb{E} [\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}]] + \mathbb{E} [\text{Var} [\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}]]. \quad (4.53)$$

Let us examine the first term. We have

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}] &= \mathbb{E} \left[ \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} Y_i \left( \frac{A_i}{\hat{\pi}_n(X_i)} - \frac{1 - A_i}{1 - \hat{\pi}_n(X_i)} \right) \mid \mathbf{X}_{m+n} \right] \\ &= \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\hat{\pi}_n(X_i)} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \hat{\pi}_n(X_i)} \mid \mathbf{X}_{m+n} \right] \\ &= \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \mathbb{E} \left[ \mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\hat{\pi}_n(X_i)} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \hat{\pi}_n(X_i)} \mid \mathbf{X}_{m+n}, \mathbf{Y}_n^{(1)}, \mathbf{Y}_n^{(0)} \right] \mid \mathbf{X}_{m+n} \right]. \end{aligned}$$

A similar computation as the one used in the derivation of the bias above shows that

$$\mathbb{E} \left[ \frac{Y_i^{(1)} A_i}{\hat{\pi}_n(X_i)} - \frac{Y_i^{(0)} (1 - A_i)}{1 - \hat{\pi}_n(X_i)} \mid \mathbf{X}_{m+n}, \mathbf{Y}_n^{(1)}, \mathbf{Y}_n^{(0)} \right] = \left( Y_i^{(1)} - Y_i^{(0)} \right) - Y_i^{(1)} (1 - \pi(X_i))^{Z_n(X_i)} + Y_i^{(0)} \pi(X_i)^{Z_n(X_i)},$$

which leads to

$$\begin{aligned} \mathbb{E} [\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}] &= \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \mathbb{E} \left[ \left( Y_i^{(1)} - Y_i^{(0)} \right) - Y_i^{(1)} (1 - \pi(X_i))^{Z_n(X_i)} + Y_i^{(0)} \pi(X_i)^{Z_n(X_i)} \mid \mathbf{X}_{m+n} \right] \\ &= \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \left( \tau(X_i) - \mathbb{E} \left[ Y_i^{(1)} \mid X_i \right] (1 - \pi(X_i))^{Z_n(X_i)} + \mathbb{E} \left[ Y_i^{(0)} \mid X_i \right] \pi(X_i)^{Z_n(X_i)} \right). \end{aligned}$$

Rewriting the previous sum yields

$$\begin{aligned}
\mathbb{E}[\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}] &= \frac{1}{n} \sum_{x \in \mathbb{X}} \sum_{i=1}^n \mathbb{1}_{X_i=x} \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} (\tau(X_i) - \mathbb{E}[Y_i^{(1)} \mid X_i]) (1 - \pi(X_i))^{Z_n(X_i)} \\
&\quad + \mathbb{E}[Y_i^{(0)} \mid X_i] \pi(X_i)^{Z_n(X_i)} \\
&= \sum_{x \in \mathbb{X}} \hat{p}_{T,m}(x) \left( \tau(x) - \mathbb{E}[Y_i^{(1)} \mid X_i = x] \right) (1 - \pi(x))^{Z_n(x)} + \mathbb{E}[Y_i^{(0)} \mid X_i = x] \pi(x)^{Z_n(x)} \\
&= \frac{1}{m} \sum_{i=n+1}^{n+m} U_n(X_i),
\end{aligned}$$

where

$$U_n(X_i) := \left( \tau(X_i) - \mathbb{E}[Y_i^{(1)} \mid X_i] \right) (1 - \pi(X_i))^{Z_n(X_i)} + \mathbb{E}[Y_i^{(0)} \mid X_i] \pi(X_i)^{Z_n(X_i)}.$$

By the law of total variance,

$$\begin{aligned}
&\text{Var}[\mathbb{E}[\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}]] \\
&= \text{Var}\left[\frac{1}{m} \sum_{i=n+1}^{n+m} U_n(X_i)\right] \\
&= \mathbb{E}\left[\text{Var}\left[\frac{1}{m} \sum_{i=n+1}^{n+m} U_n(X_i) \mid \mathbf{X}_n\right]\right] + \text{Var}\left[\mathbb{E}\left[\frac{1}{m} \sum_{i=n+1}^{n+m} U_n(X_i) \mid \mathbf{X}_n\right]\right] \\
&= \frac{1}{m} \mathbb{E}[\text{Var}[U_n(X) \mid \mathbf{X}_n]] + \text{Var}[\mathbb{E}[U_n(X) \mid \mathbf{X}_n]] \\
&= \frac{1}{m} \text{Var}[U_n(X)] + \left(1 - \frac{1}{m}\right) \text{Var}[\mathbb{E}[U_n(X) \mid \mathbf{X}_n]],
\end{aligned}$$

where the last line comes from the law of total variance applied to  $\text{Var}[U_n(X)]$ . Since

$$\begin{aligned}
&\text{Var}[\mathbb{E}[U_n(X) \mid \mathbf{X}_n]] \\
&= \text{Var}\left[\mathbb{E}\left[\left(\tau(X) - \mathbb{E}[Y^{(1)} \mid X]\right) (1 - \pi(X))^{Z_n(X)} + \mathbb{E}[Y^{(0)} \mid X] \pi(X)^{Z_n(X)} \mid \mathbf{X}_n\right]\right] \\
&= \text{Var}\left[\mathbb{E}\left[\mathbb{E}[Y^{(0)} \mid X] \pi(X)^{Z_n(X)} - \mathbb{E}[Y^{(1)} \mid X] (1 - \pi(X))^{Z_n(X)} \mid \mathbf{X}_n\right]\right],
\end{aligned}$$

as the only source of randomness comes from  $Z_n(X)$  (and not from  $\tau(X)$ ), we have

$$\text{Var}[\mathbb{E}[\hat{\tau}_{n,m} \mid \mathbf{X}_{m+n}]] = \frac{1}{m} \text{Var}[\tau(X) - C_n(X)] + \left(1 - \frac{1}{m}\right) \text{Var}[\mathbb{E}[C_n(X) \mid \mathbf{X}_n]], \quad (4.54)$$

where

$$C_n(X) = \mathbb{E}[Y^{(1)} \mid X] (1 - \pi(X))^{Z_n(X)} - \mathbb{E}[Y^{(0)} \mid X] \pi(X)^{Z_n(X)}.$$

Regarding the other term, and first re-writing  $\hat{\tau}_{n,m}$ ,

$$\begin{aligned}
\hat{\tau}_{n,m} &= \frac{1}{n} \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{\hat{p}_{R,n}(X_i)} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(X_i)} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}_n(X_i)} \right) \\
&= \sum_{i=1}^n \frac{\hat{p}_{T,m}(X_i)}{Z_n(X_i)} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(X_i)} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}_n(X_i)} \right) \\
&= \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{Z_n(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}_n(x)} \right).
\end{aligned}$$

Hence,

$$\begin{aligned}
 & \text{Var} [\hat{\tau}_{n,m} \mid \mathbf{X}_{n+m}] \\
 &= \text{Var} \left[ \sum_{x \in \mathbb{X}} \frac{\hat{p}_{T,m}(x)}{Z_n(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right) \mid \mathbf{X}_{n+m} \right] \\
 &= \sum_{x \in \mathbb{X}} (\hat{p}_{T,m}(x))^2 \text{Var} \left[ \frac{1}{Z_n(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right) \mid \mathbf{X}_{n+m} \right] + \\
 & \quad + \sum_{x,y \in \mathbb{X}, x \neq y} \text{Cov} \left[ \frac{\hat{p}_{T,m}(x)}{Z_n(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right), \frac{\hat{p}_{T,m}(y)}{Z_n(y)} \sum_{j=1}^n \mathbb{1}_{X_j=y} \left( \frac{A_j Y_j^{(1)}}{\hat{\pi}_n(y)} - \frac{(1-A_j) Y_j^{(0)}}{1-\hat{\pi}_n(y)} \right) \mid \mathbf{X}_{n+m} \right].
 \end{aligned}$$

Note that the term

$$\text{Var} \left[ \frac{1}{Z_n(x)} \sum_{i=1}^n \mathbb{1}_{X_i=x} \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right) \mid \mathbf{X}_{n+m} \right]$$

corresponds to the variance of the difference-in-means estimator on the strata  $X = x$  (where  $n$  is replaced by  $Z_n(x)$ ) and therefore equals

$$V_{\text{DM},n}(x) \mathbb{1}_{Z_n(x) > 0} / Z_n(x),$$

where (see Lemma 4),

$$V_{\text{DM}}(x) = \left( \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] \text{Var} [Y_i^{(1)}] + \mathbb{E} \left[ \frac{\mathbb{1}_{(1-\hat{\pi}) > 0}}{1-\hat{\pi}} \right] \text{Var} [Y_i^{(0)}] \right) + \mathcal{O}(Z_n(x) \max(\pi, 1-\pi)^n).$$

Consequently,

$$\begin{aligned}
 & \text{Var} [\hat{\tau}_{n,m} \mid \mathbf{X}_{n+m}] \\
 &= \sum_{x \in \mathbb{X}} \frac{(\hat{p}_{T,m}(x))^2 V_{\text{DM},n}(x) \mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \\
 & \quad + \sum_{x,y \in \mathbb{X}, x \neq y} \frac{\hat{p}_{T,m}(x)}{Z_n(x)} \frac{\hat{p}_{T,m}(y)}{Z_n(y)} \sum_{i,j} \mathbb{1}_{X_i=x} \mathbb{1}_{X_j=y} \text{Cov} \left[ \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right), \left( \frac{A_j Y_j^{(1)}}{\hat{\pi}_n(y)} - \frac{(1-A_j) Y_j^{(0)}}{1-\hat{\pi}_n(y)} \right) \mid \mathbf{X}_{n+m} \right].
 \end{aligned}$$

Note that for  $x \neq y$ ,  $\hat{\pi}_n(x) \perp\!\!\!\perp \hat{\pi}_n(y)$ . Consequently, for  $i \neq j$ ,

$$\left( \frac{A_i Y_i^{(1)}}{\hat{\pi}_n(x)} - \frac{(1-A_i) Y_i^{(0)}}{1-\hat{\pi}_n(x)} \right) \perp\!\!\!\perp \left( \frac{A_j Y_j^{(1)}}{\hat{\pi}_n(y)} - \frac{(1-A_j) Y_j^{(0)}}{1-\hat{\pi}_n(y)} \right).$$

Consequently,

$$\text{Var} [\hat{\tau}_{n,m} \mid \mathbf{X}_{n+m}] = \sum_{x \in \mathbb{X}} \frac{(\hat{p}_{T,m}(x))^2 V_{\text{DM},n}(x) \mathbb{1}_{Z_n(x) > 0}}{Z_n(x)},$$

and, taking the expectation with respect to  $\mathbf{X}_{n+m}$ , we have

$$\begin{aligned}
 \mathbb{E} [\text{Var} [\hat{\tau}_{n,m} \mid \mathbf{X}_{n+m}]] &= \sum_{x \in \mathbb{X}} \mathbb{E} [(\hat{p}_{T,m}(x))^2] \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{\text{DM},n}(x) \\
 &= \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1-p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{\text{DM},n}(x). \tag{4.55}
 \end{aligned}$$

Gathering eq. 4.54 and eq. 4.55, we finally obtain,

$$\begin{aligned}
 & \text{Var} [\hat{\tau}_{n,m}] \\
 &= \frac{1}{m} \text{Var} [\tau(X) - C_n(X)] + \left( 1 - \frac{1}{m} \right) \text{Var} [\mathbb{E} [C_n(X) \mid \mathbf{X}_n]] \\
 & \quad + \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1-p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{\text{DM},n}(x),
 \end{aligned}$$

where

$$C_n(X) = \mathbb{E} \left[ Y^{(1)} \mid X \right] (1 - \pi(X))^{Z_n(X)} - \mathbb{E} \left[ Y^{(0)} \mid X \right] \pi(X)^{Z_n(X)}.$$

Note that, by Jensen's inequality,

$$\begin{aligned} & \text{Var} [\mathbb{E} [C_n(X) \mid \mathbf{X}_n]] \\ & \leq \mathbb{E} [C_n(X)^2] \\ & \leq 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} \mid X \right]^2 (1 - \pi(X))^{2Z_n(X)} \right] + 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(0)} \mid X \right]^2 \pi(X)^{2Z_n(X)} \right] \\ & \leq 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} \mid X \right]^2 \mathbb{E} \left[ (1 - \pi(X))^{2Z_n(X)} \mid X \right] \right] + 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(0)} \mid X \right]^2 \mathbb{E} \left[ \pi(X)^{2Z_n(X)} \mid X \right] \right] \\ & \leq 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} \mid X \right]^2 (1 - (1 - \pi(X)^2) p_R(X))^n \right] + 2\mathbb{E} \left[ \mathbb{E} \left[ Y^{(0)} \mid X \right]^2 (1 - (1 - (1 - \pi(X)^2) p_R(X))^n) \right] \\ & \leq 2 \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^n \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right], \end{aligned}$$

where  $\tilde{\pi}(x) = \max(\pi(x), 1 - \pi(x))$ , and we have used the fact that

$$\begin{aligned} \mathbb{E} \left[ \pi(X)^{2Z_n(X)} \mid X \right] &= (\pi(X)^2 p_R(X) + 1 - p_R(X))^n \\ &= (1 - (1 - \pi(X)^2) p_R(X))^n. \end{aligned}$$

Besides, we have

$$\text{Var} [\tau(X) - C_n(X)] \leq \text{Var}_T [\tau(X)] + 2 (\text{Var}_T [\tau(X)] \text{Var}_T [C_n(X)])^{1/2} + \text{Var}_T [C_n(X)],$$

where

$$\begin{aligned} \text{Var}_T [C_n(X)] &\leq \mathbb{E} [C_n(X)^2] \\ &\leq 2 \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^n \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right]. \end{aligned}$$

Consequently,

$$\begin{aligned} \text{Var} [\tau(X) - C_n(X)] &\leq \text{Var}_T [\tau(X)] + 4 \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^{n/2} \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right] \\ &\quad + 2 \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^n \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right] \\ &\leq \text{Var}_T [\tau(X)] + 6 \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^{n/2} \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right]. \end{aligned}$$

Finally,

$$\begin{aligned} \text{Var} [\hat{\tau}_{n,m}] &\leq \frac{2}{n+1} \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{\text{DM}}(X) \right] + \frac{\text{Var} [\tau(X)]}{m} + \frac{2}{(n+1)m} \mathbb{E}_R \left[ \frac{p_T(X) (1 - p_T(X))}{p_R(X)^2} V_{\text{DM},n}(X) \right] \\ &\quad + 2 \left( 1 + \frac{3}{m} \right) \left( 1 - \min_x ((1 - \tilde{\pi}(x)^2) p_R(x)) \right)^{n/2} \mathbb{E} \left[ (Y^{(1)})^2 + (Y^{(0)})^2 \right]. \end{aligned}$$

□

#### 4.A.4.2 Proof of Corollary 6

*Proof.* The proof follows exactly the same structure as that of the proof of Corollary 5.

*Proof.* We recall the explicit expression of the variance of  $\hat{\tau}_{n,m}$ ,

$$\begin{aligned} & \text{Var} [\hat{\tau}_{n,m}] \\ &= \frac{1}{m} \text{Var} [\tau(X) - C_n(X)] + \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \\ & \quad + \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1 - p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{\text{DM}}(x), \end{aligned}$$

where

$$C_n(X) = \mathbb{E} [Y^{(1)} | X] (1 - \pi(X))^{Z_n(X)} - \mathbb{E} [Y^{(0)} | X] \pi(X)^{Z_n(X)}.$$

Recall that using eq. 4.36 and eq. 4.37, one has

$$\lim_{n \rightarrow \infty} \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right] = \frac{1}{p_R(x)},$$

and we also have

$$\lim_{n \rightarrow \infty} \text{Var}_T [\tau(X) - C_n(X)] = \text{Var}_T [\tau(X)] = \text{Var} [\tau(X)].$$

Finally, note that the term  $\text{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]]$  can be bounded by a term proportional to  $(1 - \min(\pi, 1 - \pi))^n$ , so that the convergence toward 0 it at an exponential pace with  $n$ .

Multiplying the explicit variance by  $\min(n, m)$  one has,

$$\begin{aligned} & \min(n, m) \text{Var} [\hat{\tau}_{n,m}] \\ &= \frac{\min(n, m)}{m} \text{Var} [\tau(X) - C_n(X)] + \min(n, m) \left(1 - \frac{1}{m}\right) \text{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \\ & \quad + \frac{\min(n, m)}{n} \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1 - p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right] V_{\text{DM}}(x). \end{aligned}$$

Now, we study an asymptotic regime where  $n$  and  $m$  can grow toward infinity but at different paces. Let  $\lim_{n, m \rightarrow \infty} \frac{m}{n} = \lambda \in [0, \infty]$ , where  $\lambda$  characterizes the regime.

**Case 1:** If  $\lambda \in [1, \infty]$ , one can replace  $\min(n, m)$  by  $n$ , so that

$$\begin{aligned} \min(n, m) \text{Var} [\hat{\tau}_{n,m}] &= n \text{Var} [\hat{\tau}_{n,m}] \\ &= \frac{1}{\lambda} \text{Var} [\tau(X) - C_n(X)] + \left(n - \frac{1}{\lambda}\right) \text{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \\ & \quad + \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1 - p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)} \right] V_{\text{DM}}(x), \end{aligned}$$

such that

$$\lim_{n, m \rightarrow \infty} n \text{Var} [\hat{\tau}_{n,m}] = \frac{\text{Var} [\tau(X)]}{\lambda} + \tilde{V}_{so},$$

where

$$\tilde{V}_{so} := \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{\text{DM}, \infty}(X) \right].$$

**Case 2:** If  $\lambda \in [0, 1]$ , one can replace  $\min(n, m)$  by  $m$ , so that,



$$\begin{aligned}
& \min(n, m) \operatorname{Var} [\hat{\tau}_{n,m}] = m \operatorname{Var} [\hat{\tau}_{n,m}] \\
& = \operatorname{Var} [\tau(X) - C_n(X)] + m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \\
& \quad + \lambda \sum_{x \in \mathbb{X}} \left( \frac{p_T(x)(1 - p_T(x))}{m} + p_T^2(x) \right) \mathbb{E} \left[ \frac{\mathbb{1}_{Z_n(x) > 0}}{Z_n(x)/n} \right] V_{\text{DM}}(x).
\end{aligned}$$

Because  $m \leq n$ , then

$$m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \leq n \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]],$$

so that

$$\lim_{n, m \rightarrow \infty} m \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] \leq \lim_{n, m \rightarrow \infty} n \left(1 - \frac{1}{m}\right) \operatorname{Var} [\mathbb{E} [C_n(X) | \mathbf{X}_n]] = 0.$$

Finally,

$$\lim_{n, m \rightarrow \infty} m \operatorname{Var} [\hat{\tau}_{n,m}] = \operatorname{Var} [\tau(X)] + \lambda \tilde{V}_{so}.$$

□

□

#### 4.A.4.3 Proof of Theorem 12

*Proof.* According to Proposition 4, the bias of the IPSW estimator with estimated  $\hat{\pi}_n$  can be upper bounded via

$$\begin{aligned}
|\mathbb{E} [\hat{\tau}_{n,m}] - \tau| & \leq \sum_{x \in \mathbb{X}} p_T(x) \left| \mathbb{E} [Y^{(0)} | X = x] \right| (1 - p_R(x)(1 - \pi(x)))^n \\
& \quad + \sum_{x \in \mathbb{X}} p_T(x) \left| \mathbb{E} [Y^{(1)} | X = x] \right| (1 - p_R(x)\pi(x))^n \\
& \leq \left(1 - \min_x ((1 - \tilde{\pi}(x))p_R(x))\right)^n \mathbb{E}_T \left[ \left| \mathbb{E} [Y^{(1)} | X] \right| + \left| \mathbb{E} [Y^{(0)} | X] \right| \right].
\end{aligned}$$

Therefore, the risk of the (estimated) IPSW estimate with estimated  $\hat{\pi}_n$  satisfies,

$$\begin{aligned}
& \mathbb{E} [(\hat{\tau}_{n,m} - \tau)^2] \\
& \leq \left(1 - \min_x ((1 - \tilde{\pi}(x))p_R(x))\right)^{2n} \mathbb{E}_T \left[ \left| \mathbb{E} [Y^{(1)} | X] \right| + \left| \mathbb{E} [Y^{(0)} | X] \right| \right]^2 + \frac{2}{n+1} \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{\text{DM}}(X) \right] \\
& \quad + \frac{\operatorname{Var} [\tau(X)]}{m} + \frac{2}{(n+1)m} \mathbb{E}_R \left[ \frac{p_T(X)(1 - p_T(X))}{p_R(X)^2} V_{\text{DM}}(X) \right] \\
& \quad + 2 \left(1 + \frac{3}{m}\right) \left(1 - \min_x ((1 - \tilde{\pi}(x)^2)p_R(x))\right)^{n/2} \mathbb{E} [(Y^{(1)})^2 + (Y^{(0)})^2] \\
& \leq \frac{2}{n+1} \mathbb{E}_R \left[ \left( \frac{p_T(X)}{p_R(X)} \right)^2 V_{\text{DM}}(X) \right] + \frac{\operatorname{Var} [\tau(X)]}{m} + \frac{2}{m(n+1)} \mathbb{E}_R \left[ \frac{p_T(X)(1 - p_T(X))}{p_R(X)^2} V_{\text{DM}}(X) \right] \\
& \quad + 2 \left(2 + \frac{3}{m}\right) \left(1 - \min_x ((1 - \tilde{\pi}(x))p_R(x))\right)^{n/2} \mathbb{E} [(Y^{(1)})^2 + (Y^{(0)})^2].
\end{aligned}$$

□

## 4.B Extended adjustment set

### 4.B.1 Proof of Corollary 7

*Proof.* According to Corollary 4, we have

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{T,n}^*(X)] = V_{\text{so}}, \quad (4.56)$$

where

$$V_{\text{so}} := \mathbb{E}_{\mathbb{R}} \left[ \left( \frac{p_{\text{T}}(X)}{p_{\text{R}}(X)} \right)^2 V_{\text{HT}}(X) \right],$$

with

$$V_{\text{HT}}(x) = \mathbb{E}_{\mathbb{R}} \left[ \frac{(Y^{(1)})^2}{\pi} \mid X = x \right] + \mathbb{E}_{\mathbb{R}} \left[ \frac{(Y^{(0)})^2}{1 - \pi} \mid X = x \right] - \tau(x)^2.$$

Since, by assumption,  $V$  is composed of covariates that are not treatment effect modifiers, using Definition 32, we have, for all  $(x, v)$ ,

$$V_{\text{HT}}(x, v) = V_{\text{HT}}(x). \quad (4.57)$$

Now, considering the set  $(X, V)$  instead of  $X$  in the expression eq. 4.56 leads to

$$\begin{aligned} \lim_{n \rightarrow \infty} n \text{Var}_{\mathbb{R}} [\hat{\tau}_{T,n}^*(X, V)] &= \mathbb{E}_{\mathbb{R}} \left[ \left( \frac{p_{\text{T}}(X, V)}{p_{\text{R}}(X, V)} \right)^2 V_{\text{HT}}(X, V) \right] \\ &= \sum_{x, v \in \mathcal{X}, \mathcal{V}} \frac{p_{\text{T}}^2(x, v)}{p_{\text{R}}(x, v)} V_{\text{HT}}(x, v) \\ &= \sum_{x, v \in \mathcal{X}, \mathcal{V}} \frac{p_{\text{T}}^2(x, v)}{p_{\text{R}}(x, v)} V_{\text{HT}}(x) && \text{Equation. eq. 4.57} \\ &= \sum_{x, v \in \mathcal{X}, \mathcal{V}} \frac{p_{\text{T}}^2(x) p_{\text{T}}^2(v)}{p_{\text{R}}(x) p_{\text{R}}(v)} V_{\text{HT}}(x) && V \perp\!\!\!\perp X \\ &= \left( \sum_{v \in \mathcal{V}} \frac{p_{\text{T}}(v)^2}{p_{\text{R}}(v)} \right) \sum_{x \in \mathcal{X}} \frac{p_{\text{T}}^2(x)}{p_{\text{R}}(x)} V_{\text{HT}}(x) \\ &= \left( \sum_{v \in \mathcal{V}} \frac{p_{\text{T}}(v)^2}{p_{\text{R}}(v)} \right) \lim_{n \rightarrow \infty} n \text{Var}_{\mathbb{R}} [\hat{\tau}_{T,n}^*(X)], \end{aligned}$$

Now, note that

$$\begin{aligned} \sum_{v \in \mathcal{V}} \frac{p_{\text{T}}(v)^2}{p_{\text{R}}(v)} &= \mathbb{E}_{\mathbb{R}} \left[ \frac{p_{\text{T}}(V)^2}{p_{\text{R}}(V)^2} \right] \\ &\geq \left( \mathbb{E}_{\mathbb{R}} \left[ \frac{p_{\text{T}}(V)}{p_{\text{R}}(V)} \right] \right)^2 \\ &\geq \left( \sum_{v \in \mathcal{V}} p_{\text{T}}(v) \right)^2 \\ &\geq 1, \end{aligned}$$

where the first inequality results from Jensen's inequality. Consequently,

$$\lim_{n \rightarrow \infty} n \text{Var}_{\mathbb{R}} [\hat{\tau}_{T,n}^*(X, V)] \geq \lim_{n \rightarrow \infty} n \text{Var}_{\mathbb{R}} [\hat{\tau}_{T,n}^*(X)].$$

□

### 4.B.2 Proof of Corollary 8

*Proof.* By the law of total variance, we have, for all  $x$ ,

$$V_{\text{DM}}(x) = \mathbb{E} [V_{\text{DM}}(x, V)] + \text{Var} [\tau(x, V)]. \quad (4.58)$$

Indeed, according to the law of total variance, for all random variables  $Z, X_1, X_2$ , we have, a.s.,

$$\text{Var} [Z | X_1] = \mathbb{E} [\text{Var} [Z | X_1, X_2] | X_1] + \text{Var} [\mathbb{E} [Z | X_1, X_2] | X_1].$$

Letting  $X_1 = X, X_2 = V$  and  $Z = (YA/\pi) - (Y(1-A)/\pi)$  yields equation eq. 4.58. Now, we can write

$$\begin{aligned} \lim_{n \rightarrow \infty} n \text{Var}_{\text{R}} [\hat{\tau}_{\text{T},n}^*(X, V)] &= \mathbb{E}_{\text{R}} \left[ \left( \frac{p_{\text{T}}(X, V)}{p_{\text{R}}(X, V)} \right)^2 V_{\text{DM}}(X, V) \right] \\ &= \sum_{x,v \in \mathcal{X}, \mathcal{V}} \frac{p_{\text{T}}^2(x, v)}{p_{\text{R}}(x, v)} V_{\text{DM}}(x, v) \\ &= \sum_{x,v \in \mathcal{X}, \mathcal{V}} \frac{p_{\text{T}}^2(x) p_{\text{T}}^2(v)}{p_{\text{R}}(x) p_{\text{R}}(v)} V_{\text{DM}}(x, v) && V \perp\!\!\!\perp X \\ &= \sum_{x \in \mathcal{X}} \frac{p_{\text{T}}^2(x)}{p_{\text{R}}(x)} \sum_{v \in \mathcal{V}} \frac{p_{\text{T}}^2(v)}{p_{\text{R}}(v)} V_{\text{DM}}(x, v) \\ &= \sum_{x \in \mathcal{X}} \frac{p_{\text{T}}^2(x)}{p_{\text{R}}(x)} \sum_{v \in \mathcal{V}} p_{\text{T}}(v) V_{\text{HT}}(x, v) && \text{by Definition 33} \\ &= \sum_{x \in \mathcal{X}} \frac{p_{\text{T}}^2(x)}{p_{\text{R}}(x)} (V_{\text{DM}}(x) - \text{Var} [\tau(x, V)]) && \text{Equation eq. 4.58} \\ &= \lim_{n \rightarrow \infty} n \text{Var}_{\text{R}} [\hat{\tau}_{\text{T},n}^*(X)] - \mathbb{E}_{\text{R}} \left[ \frac{p_{\text{T}}(X)}{p_{\text{R}}(X)} \text{Var} [\tau(X, V) | X] \right], \end{aligned}$$

which concludes the proof.  $\square$

## 4.C Semi-synthetic simulation's data preparation

### 4.C.1 Context

The semi-synthetic simulation is made of real world data, a trial called CRASH-3 (Dewan et al., 2012; CRASH-3, 2019) and an observational data base called Traumabase. The covariates of both data sources are used to generate the true distribution from which the simulated data are generated. This part details the pre-treatment performed on the covariates, which is contained in the R notebook entitled `Prepare-semi-synthetic-simulation.Rmd`. As explained in the main document, in this semi-synthetic simulation we only consider six baseline covariates:

- Glasgow Coma Scale score<sup>7</sup> (GCS) (categorical);
- Gender (categorical);
- Pupil reactivity (categorical);
- Age (continuous);
- Systolic blood pressure (continuous);
- Time-to-treatment (continuous), being the time between the trauma and the administration of the treatment.

<sup>7</sup>The GCS is a neurological scale which aims to assess a person's consciousness. The lower the score, the higher the severity of the trauma.

As three covariates out of 6 are continuous, we categorize them to obtain a completely categorical data. The time-to-treatment is categorized in 4 levels, systolic blood pressure in 3 levels, and age in 3 levels. To further reduce the number of categories, and follow the CRASH-3 trial stratification, the Glasgow score is also gathered in 3 levels, from severe to moderately injured individuals, based on their Glasgow score.

**CRASH-3 trial** The CRASH-3 trial data contains information on 12,737 individuals. Over the six covariates of interest and the 12,737 individuals, 108 values are missing. We imputed them using the R package `missRanger`.

**Traumabase observational data** The complete Traumabase data contains 20,037 observations, but when keeping only the individuals suffering from Traumatic Brain Injury (TBI) as it is the case in the CRASH-3 trial, only 8,289 observations could be kept. Many data are missing, in particular 2,660 missing values for 8,289 individuals and along 5 baseline covariates considered. We impute them with the R package `missRanger`, using 35 other available baseline covariates. Because the time to treatment is not observed in the Traumabase this covariate is generated following a beta law, and considering a shifted distribution compared to the trial, in particular toward lower time-to-treatment values than in the trial.

**Ensuring overlap** When binding the two data sets, we had to ensure that the support inclusion assumption (Assumption 29) was verified. Out of the 586 modalities present in the target data, only 192 are also present in the trial data. Therefore only these observations are kept, such that the observational sample finally contains 8,058 observations (8,289 at the beginning). All the observations in the trial are kept as there is no restriction for the trial to contain a larger support as presented in Assumption 29.

#### 4.C.1.1 Covariate shift vizualization

For each of the six baseline and categorical considered, visualization of the covariate shift between the two data source is represented on Figures 4.10, 4.11, 4.12, 4.13, 4.14, and 4.15.






Figure 4.10: Bar plot of categorized age in the semi-synthetic simulation

#### 4.C.2 Synthetic outcome model


As detailed above, for now the covariate support reflects a true situation, where only the time-to-treatment covariate was created as it is missing in the target population sample (Colnet et al., 2022a).



**Figure 4.11:** Bar plot of categorized systolic blood pressure in the semi-synthetic simulation




**Figure 4.12:** Bar plot of gender in the semi-synthetic simulation




**Figure 4.13:** Bar plot of the Glasgow score in the semi-synthetic simulation

For the purpose of simulation, the outcome model is completely synthetic, and for each strata a number is affected, from 1 to the number of strata, starting to the lowest category (for example youngest strata, or lowest Glasgow score, or lower systolic blood pressure), to the highest one.



**Figure 4.14:** [Bar plot of pupil reactivity in the semi-synthetic simulation] Bar plot of pupil reactivity ( $-1$  encoding not able to measure) in the semi-synthetic simulation



**Figure 4.15:** Bar plot of categorized time-to-treatment in the semi-synthetic simulation

Doing so, the outcome model considered is such as,

$$Y = 10 - \text{Glasgow} + (\text{if Girl: } -5 \text{ else: } 0) + A(15(6 - \text{TTT}) + 3 * (\text{Systolic.blood.pressure} - 1)^2) + \varepsilon_{\text{TTT}},$$

where  $\varepsilon_{\text{TTT}}$  is a random Gaussian noise with a standard deviation depending on the value of the covariate TTT. In particular if the treatment is given later, then the noise is stronger.

#### 4.D Useful results about RCTs under a Bernoulli design

Here we recall the definition of a Bernoulli trial (see Definition 34) and results such as variance expression of the Horvitz-Thomson and difference-in-means estimators under this design. We also provide details about variance inequality between the variance of the Horvitz-Thomson compared to the variance of the difference-in-means. In the literature we have not found detailed derivations about the finite sample bias and variance of the difference-in-means under a Bernoulli design. Extensively detailed derivations are available in Chapter two of [Imbens and Rubin \(2015\)](#), but for a completely randomized design. Also note that in this work we assume a superpopulation framework, and a large part of the existing literature focuses on inference on a finite population. Indeed, when considering a finite sample, bias and variance of the Horvitz-Thomson and difference-in-means are not the same

as when inferring the superpopulation treatment effect (Splawa-Neyman et al., 1990; Imbens, 2011; Miratrix et al., 2013; Harshaw et al., 2021).

Note that all the results in this section considers one population, and not two populations with two distributions (target and randomized), therefore no index is placed on the expectation. When the following results on RCTs are used in the main paper and/or in the proofs, we use the index  $R$  in the expectation as the trial in the main paper is sample according to  $P_R$ .

#### 4.D.1 Bernoulli trial

A Bernoulli trial is a trial where the treatment assignment vector, being  $\mathbf{A} = (A_1, \dots, A_n)$  follows a Bernoulli law with a constant probability. More formally,

**Definition 34** (Assignment mechanism for a Bernoulli Trial). *If the assignment mechanism is a Bernoulli trial with a probability  $\pi$ , then*

$$\forall i, \mathbb{P}[A_i] = \pi,$$

and considering a sample for  $n$  units,

$$\mathbb{P}[\mathbf{A} \mid i \in \mathcal{R}] = \prod_{i=1}^n \left[ \pi^{A_i} \cdot (1 - \pi)^{1-A_i} \right],$$

where  $\mathbf{A}$  denotes the vector of treatment allocation for the trial sample  $\mathcal{R}$ .

In this design the treatment allocation is independent of all other treatment allocations. A disadvantage of such design is the fact that there is always a small probability that all units receive the treatment or no treatment. This is why other designs are possible, such as the so-called completely randomized design, where the number of treated units is selected prior to treatment allocation (usually  $n/2$  units are given treatment). The interest is to ensure a balanced group of treated and controls, and avoid a possible pathological case of high unbalance between the number of treated and control individuals.

Mathematically, treating the situation of a completely randomized design is different than a Bernoulli design, as in the former the probability of treatment is not independent between units, for example

$$\forall i, j \in \mathcal{R}, \mathbb{P}_{\text{Comp. rand.}}[A_i = 1 \mid A_j = 1] \neq \mathbb{P}_{\text{Comp. rand.}}[A_i = 1] = \pi.$$

#### 4.D.2 Horvitz-Thomson's

The Horvitz-Thomson estimator is unbiased and has an explicit finite sample variance.

**Lemma 3** (Finite sample bias and variance of the Horvitz-Thomson estimator). *Assuming trial internal validity (Assumption 27), then*

$$\forall n, \quad \mathbb{E}[\hat{\tau}_{HT}] - \tau = 0,$$

and

$$\forall n, \quad n \text{Var}[\hat{\tau}_{HT,n}] = \mathbb{E} \left[ \frac{(Y^{(1)})^2}{\pi} \right] + \mathbb{E} \left[ \frac{(Y^{(0)})^2}{1 - \pi} \right] - \tau^2.$$

Note that the following proof can be extended to any  $\pi(x)$  depending on baseline covariates, and therefore extends to the oracle IPW in the causal inference literature.

*Proof.* **Bias**

$$\begin{aligned}
 \mathbb{E}[\hat{\tau}_{\text{HT}}] &= \frac{\mathbb{E}[A_i Y_i^{(1)}]}{\pi} - \frac{\mathbb{E}[(1 - A_i) Y_i^{(0)}]}{1 - \pi} && \text{Linearity \& SUTVA} \\
 &= \frac{\mathbb{E}[A_i] \mathbb{E}[Y_i^{(1)}]}{\pi} - \frac{\mathbb{E}[(1 - A_i)] \mathbb{E}[Y_i^{(0)}]}{1 - \pi} && \text{Randomization} \\
 &= \frac{\pi \mathbb{E}[Y_i^{(1)}]}{\pi} - \frac{(1 - \pi) \mathbb{E}[Y_i^{(0)}]}{1 - \pi} && \text{Def. of } \pi \text{ - Bernoulli design} \\
 &= \tau, && \text{Linearity.}
 \end{aligned}$$

**Variance**

$$\begin{aligned}
 \text{Var}[\hat{\tau}_{\text{HT},n}] &= \text{Var}\left[\frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\pi} - \frac{(1 - A_i) Y_i}{1 - \pi}\right] \\
 &= \frac{1}{n^2} \text{Var}\left[\sum_{i=1}^n \frac{A_i Y_i^{(1)}}{\pi} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \pi}\right] && \text{Assumption 27} \\
 &= \frac{1}{n} \text{Var}\left[\frac{AY^{(1)}}{\pi} - \frac{(1 - A)Y^{(0)}}{1 - \pi}\right]. && \text{iid}
 \end{aligned}$$

Then,

$$\text{Var}[\hat{\tau}_{\text{HT},n}] = \frac{1}{n} \left( \text{Var}\left[\frac{AY^{(1)}}{\pi}\right] + \text{Var}\left[\frac{(1 - A)Y^{(0)}}{1 - \pi}\right] - 2 \text{Cov}\left[\frac{AY^{(1)}}{\pi}, \frac{(1 - A)Y^{(0)}}{1 - \pi}\right] \right). \quad (4.59)$$

The first two terms can be simplified, noting that

$$\begin{aligned}
 \mathbb{E}\left[\left(\frac{AY^{(1)}}{\pi}\right)^2\right] &= \mathbb{E}\left[\mathbb{1}_{\{A_i=1\}} \left(\frac{Y^{(1)}}{\pi}\right)^2\right] && \text{A is binary} \\
 &= \mathbb{E}\left[\frac{(Y^{(1)})^2}{\pi^2}\right] \mathbb{E}_{\text{R}}[\mathbb{1}_{\{A_i=1\}}] && \text{Randomization of trial} \\
 &= \mathbb{E}\left[\frac{(Y^{(1)})^2}{\pi}\right] && \text{Definition of } \pi
 \end{aligned}$$

Similarly,

$$\mathbb{E}\left[\left(\frac{(1 - A)Y^{(0)}}{1 - \pi}\right)^2\right] = \mathbb{E}\left[\frac{(Y^{(0)})^2}{1 - \pi}\right].$$

So,

$$\begin{aligned}
 \text{Var}\left[\frac{AY^{(1)}}{\pi}\right] &= \mathbb{E}\left[\left(\frac{AY^{(1)}}{\pi}\right)^2\right] - \mathbb{E}\left[\frac{AY^{(1)}}{\pi}\right]^2 \\
 &= \mathbb{E}\left[\frac{(Y^{(1)})^2}{\pi}\right] - \mathbb{E}[Y^{(1)}]^2.
 \end{aligned}$$

Similarly,

$$\text{Var}\left[\frac{(1 - A)Y^{(0)}}{1 - \pi}\right] = \mathbb{E}\left[\frac{(Y^{(0)})^2}{1 - \pi}\right] - \mathbb{E}[Y^{(0)}]^2.$$

The third term in equation eq. 4.59 can also be decomposed, so that,



$$\begin{aligned} \text{Cov} \left[ \frac{AY^{(1)}}{\pi}, \frac{(1-A)Y^{(0)}}{1-\pi} \right] &= \mathbb{E}_R \left[ \left( \frac{AY^{(1)}}{\pi} - \mathbb{E} [Y^{(1)}] \right) \left( \frac{(1-A)Y^{(0)}}{1-\pi} - \mathbb{E}_R [Y^{(0)}] \right) \right] \\ &= \mathbb{E}_R \left[ \underbrace{\frac{AY^{(1)}}{\pi} \frac{(1-A)Y^{(0)}}{1-\pi}}_{=0} \right] - \mathbb{E}_R [Y^{(0)}] \mathbb{E}_R [Y^{(1)}]. \end{aligned}$$

Finally,

$$n \text{Var} [\hat{\tau}_{\text{HT},n}] = \mathbb{E}_R \left[ \frac{(Y^{(1)})^2}{\pi} \right] + \mathbb{E}_R \left[ \frac{(Y^{(0)})^2}{1-\pi} \right] - \tau^2 := V_{\text{HT}}.$$

□

### 4.D.3 General results about the Difference-in-means

First, note that the Difference-in-Means estimator (in Definition 23) can be re-written as,

$$\hat{\tau}_{\text{DM},n} = \frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\frac{\sum_{i=1}^n A_i}{n}} - \frac{1}{n} \sum_{i=1}^n \frac{(1-A_i) Y_i}{\frac{\sum_{i=1}^n (1-A_i)}{n}},$$

which corresponds to the Horvitz-Thomson where the probability to be treated is estimated with the data.

This estimator is always defined, even if due to the Bernoulli design it possible that all observations were allocated treatment or control. For example, if all units are given control, then

$$\sum_{i=1}^n A_i = 0,$$

and because for all  $i$ ,  $A_i = 0$ , the ratio  $\frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\frac{\sum_{i=1}^n A_i}{n}}$  is defined and equal to  $\frac{0}{0} = 0$  by convention.

**Lemma 4** (Finite sample and large sample properties of the difference-in-means estimator). *Assuming trial internal validity (Assumption 27), then*

$$\forall n, \quad \mathbb{E} [\hat{\tau}_{\text{DM},n}] - \tau = \pi^n \mathbb{E} [Y_i^{(0)}] - (1-\pi)^n \mathbb{E} [Y_i^{(1)}],$$

and

$$\forall n, \quad \text{Var} [\hat{\tau}_{\text{DM},n}] = \frac{1}{n} \left( \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] \text{Var} [Y_i^{(1)}] + \mathbb{E} \left[ \frac{\mathbb{1}_{(1-\hat{\pi}) > 0}}{1-\hat{\pi}} \right] \text{Var} [Y_i^{(0)}] \right) + D_n,$$

where  $D_n = \mathbb{E} [Y_i^{(1)}]^2 (1-\pi)^n + \mathbb{E} [Y_i^{(0)}]^2 \pi^n - \left( \mathbb{E} [Y_i^{(1)}] (1-\pi)^n + \mathbb{E} [Y_i^{(0)}] \pi^n \right)^2$ .

Asymptotically, the difference-in-means is unbiased

$$\lim_{n \rightarrow \infty} \mathbb{E} [\hat{\tau}_{\text{DM},n}] = \tau,$$

and has the following variance

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{\text{DM},n}] = \frac{\text{Var} [Y^{(1)}]}{\pi} + \frac{\text{Var} [Y^{(0)}]}{1-\pi} := V_{\text{DM},\infty}.$$

The difference-in-means under a Bernoulli design has a finite sample bias due to the possibility of a sample where everyone receive treatments or control. But the bias is exponentially decreasing with  $n$ . Also note that,

$$D_n = \mathcal{O}(\max(\pi, 1 - \pi)^n)$$

The asymptotic variance of the difference-in-means is the variance usually reported in textbooks, and corresponds to the finite sample of the Difference-in-Means estimator under a completely randomized trial. Note that we could also show that the Difference-in-Means is asymptotically normally distributed, for example using M-estimation technics (Stefanski and Boos, 2002). As this result is not used in this paper, we do not detail the proof.

Note that for a completely randomized design, the difference-in-means is unbiased and its finite sample variance is,

$$\text{Var}[\hat{\tau}_{\text{DM},n}] = \frac{\text{Var}[Y^{(1)}]}{n_1} + \frac{\text{Var}[Y^{(0)}]}{n_0},$$

where  $n_1$  is the number of treated units ( $\sim \pi n$ ) and  $n_0$  is the number of control units ( $\sim (1 - \pi)n$ ). This formula is extensively used in the literature, but under a Bernoulli design this formula is true only in large sample as detailed in Lemma 4.

*Proof. Bias*

One can use the law of total expectation, conditioning on the treatment assignment vector denoted  $\mathbf{A}$ ,

$$\begin{aligned} \mathbb{E}[\hat{\tau}_{\text{DM}}] &= \mathbb{E}[\mathbb{E}[\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] \\ &= \mathbb{E}\left[\frac{\frac{1}{n} \sum_{i=1}^n A_i}{\frac{1}{n} \sum_{i=1}^n A_i} \mathbb{E}[Y_i^{(1)} \mid \mathbf{A}] - \frac{\frac{1}{n} \sum_{i=1}^n (1 - A_i)}{\frac{1}{n} \sum_{i=1}^n (1 - A_i)} \mathbb{E}[Y_i^{(0)} \mid \mathbf{A}]\right] \\ &= \mathbb{E}\left[\frac{\frac{1}{n} \sum_{i=1}^n A_i}{\frac{1}{n} \sum_{i=1}^n A_i} \mathbb{E}[Y_i^{(1)}] - \frac{\frac{1}{n} \sum_{i=1}^n (1 - A_i)}{\frac{1}{n} \sum_{i=1}^n (1 - A_i)} \mathbb{E}[Y_i^{(0)}]\right] \quad \{Y_i^{(1)}, Y_i^{(0)}\} \perp\!\!\!\perp A_i \\ &= \mathbb{E}\left[\mathbf{1}_{\sum_{i=1}^n A_i > 0} \mathbb{E}[Y_i^{(1)}] - \mathbf{1}_{\sum_{i=1}^n 1 - A_i > 0} \mathbb{E}[Y_i^{(0)}]\right] \\ &= \mathbb{E}[Y_i^{(1)}] \mathbb{E}[\mathbf{1}_{\sum_{i=1}^n A_i > 0}] - \mathbb{E}[\mathbf{1}_{\sum_{i=1}^n 1 - A_i > 0}] \mathbb{E}[Y_i^{(0)}] \\ &= (1 - (1 - \pi)^n) \mathbb{E}[Y_i^{(1)}] - (1 - \pi^n) \mathbb{E}[Y_i^{(0)}] \\ &= \mathbb{E}[Y_i^{(1)} - Y_i^{(0)}] - (1 - \pi)^n \mathbb{E}[Y_i^{(1)}] + \pi^n \mathbb{E}[Y_i^{(0)}] \\ &= \tau - (1 - \pi)^n \mathbb{E}[Y_i^{(1)}] + \pi^n \mathbb{E}[Y_i^{(0)}], \end{aligned}$$

where the second row uses linearity of expectation and the conditioning on  $\mathbf{A}$ . To summarize, the difference-in-means has a finite sample bias,

$$\mathbb{E}[\hat{\tau}_{\text{DM},n}] - \tau = \pi^n \mathbb{E}[Y_i^{(0)}] - (1 - \pi)^n \mathbb{E}[Y_i^{(1)}].$$

**Variance**

Using the law of total variance, and conditioning on the treatment assignment vector  $\mathbf{A}$ , one has

$$\text{Var}[\hat{\tau}_{\text{DM}}] = \text{Var}[\mathbb{E}[\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] + \mathbb{E}[\text{Var}[\hat{\tau}_{\text{DM}} \mid \mathbf{A}]].$$

Recall from derivations about the bias that,

$$\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}] = \mathbf{1}_{\sum_{i=1}^n A_i > 0} \mathbb{E} [Y_i^{(1)}] - \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0} \mathbb{E} [Y_i^{(0)}].$$

Note that if the number of treated was fixed, we would have  $\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}] = \tau$ , and therefore,  $\text{Var} [\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] = 0$ .

Here, one has,

$$\begin{aligned} \text{Var} [\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] &= \text{Var} \left[ \mathbf{1}_{\sum_{i=1}^n A_i > 0} \mathbb{E} [Y_i^{(1)}] - \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0} \mathbb{E} [Y_i^{(0)}] \right] \\ &= \mathbb{E} [Y_i^{(1)}]^2 \text{Var} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}] + \mathbb{E} [Y_i^{(0)}]^2 \text{Var} [\mathbf{1}_{\sum_{i=1}^n 1-A_i > 0}] \\ &\quad - 2\mathbb{E} [Y_i^{(1)}] \mathbb{E} [Y_i^{(0)}] \text{Cov} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}, \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0}]. \end{aligned}$$

Besides,

$$\begin{aligned} \text{Var} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}] &= \mathbb{E} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}^2] - \mathbb{E} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}]^2 \\ &= (1 - \pi)^n (1 - (1 - \pi)^n), \end{aligned}$$

and similarly,

$$\text{Var} [\mathbf{1}_{\sum_{i=1}^n 1-A_i > 0}] = \pi^n (1 - \pi^n).$$

On the other hand,

$$\begin{aligned} \text{Cov} [\mathbf{1}_{\sum_{i=1}^n A_i > 0}, \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0}] &= \mathbb{E} \left[ \left( \mathbf{1}_{\sum_{i=1}^n A_i > 0} - (1 - (1 - \pi)^n) \right) \left( \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0} - 1 - \pi^n \right) \right] \\ &= \mathbb{E} [\mathbf{1}_{\sum_{i=1}^n A_i > 0} \mathbf{1}_{\sum_{i=1}^n 1-A_i > 0}] - (1 - (1 - \pi)^n) (1 - \pi^n) \\ &= 1 - (1 - \pi)^n - \pi^n - (1 - \pi^n - (1 - \pi)^n - \pi^n (1 - \pi)^n) \\ &= \pi^n (1 - \pi)^n, \end{aligned}$$

such that,

$$\begin{aligned} \text{Var} [\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] &= \mathbb{E} [Y_i^{(1)}]^2 (1 - \pi)^n (1 - (1 - \pi)^n) + \mathbb{E} [Y_i^{(0)}]^2 \pi^n (1 - \pi^n) - 2\mathbb{E} [Y_i^{(1)}] \mathbb{E} [Y_i^{(0)}] \pi^n (1 - \pi)^n \\ &= \mathbb{E} [Y_i^{(1)}]^2 (1 - \pi)^n + \mathbb{E} [Y_i^{(0)}]^2 \pi^n - \left( \mathbb{E} [Y_i^{(1)}] (1 - \pi)^n + \mathbb{E} [Y_i^{(0)}] \pi^n \right)^2 \\ &\leq \mathbb{E} [Y_i^{(1)}]^2 (1 - \pi)^n + \mathbb{E} [Y_i^{(0)}]^2 \pi^n \\ &\leq \left( \mathbb{E} [Y^{(1)}]^2 + \mathbb{E} [Y^{(0)}]^2 \right) \max(\pi, 1 - \pi)^n. \end{aligned}$$

Now,

$$\begin{aligned} \text{Var} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}] &= \text{Var} \left[ \frac{1}{n} \sum_{i=1}^n \left( \frac{A_i Y_i^{(1)}}{\hat{\pi}} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \right) \mid \mathbf{A} \right] \\ &= \frac{1}{n} \text{Var} \left[ \frac{A_i Y_i^{(1)}}{\hat{\pi}} - \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \mid \mathbf{A} \right] \quad \text{iid} \\ &= \frac{1}{n} \left( \text{Var} \left[ \frac{A_i Y_i^{(1)}}{\hat{\pi}} \mid \mathbf{A} \right] + \text{Var} \left[ \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \mid \mathbf{A} \right] - 2 \text{Cov} \left[ \frac{A_i Y_i^{(1)}}{\hat{\pi}}, \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \mid \mathbf{A} \right] \right). \end{aligned}$$

Now, developing the covariance term, it is possible to show that,

$$\begin{aligned} \text{Cov} \left[ \frac{A_i Y_i^{(1)}}{\hat{\pi}}, \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \mid \mathbf{A} \right] &= -\mathbb{E} \left[ \frac{(1 - A_i) Y_i^{(0)}}{1 - \hat{\pi}} \mid \mathbf{A} \right] \mathbb{E} \left[ \frac{A_i Y_i^{(1)}}{\hat{\pi}} \mid \mathbf{A} \right] \\ &= -\frac{(1 - A_i) \mathbb{E} [Y_i^{(0)} \mid \mathbf{A}]}{1 - \hat{\pi}} \frac{A_i \mathbb{E} [Y_i^{(1)} \mid \mathbf{A}]}{\hat{\pi}} \quad \text{Linearity and conditioned on } \mathbf{A} \\ &= 0. \quad A_i(1 - A_i) = 0 \end{aligned}$$

Now, also using linearity of expectation, and the fact that we conditioned on  $\mathbf{A}$ , one has

$$\begin{aligned} \text{Var} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}] &= \frac{1}{n} \left( \left( \frac{A_i}{\hat{\pi}} \right)^2 \text{Var} [Y_i^{(1)} \mid \mathbf{A}] + \left( \frac{1-A_i}{1-\hat{\pi}} \right)^2 \text{Var} [Y_i^{(0)} \mid \mathbf{A}] \right) \\ &= \frac{1}{n} \left( \left( \frac{A_i}{\hat{\pi}} \right)^2 \text{Var} [Y_i^{(1)}] + \left( \frac{1-A_i}{1-\hat{\pi}} \right)^2 \text{Var} [Y_i^{(0)}] \right), \quad \text{using } \{Y_i^{(1)}, Y_i^{(0)}\} \perp\!\!\!\perp A_i. \end{aligned}$$

Taking the expectation of the previous term leads to,

$$\begin{aligned} \mathbb{E} [\text{Var} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] &= \mathbb{E} \left[ \frac{1}{n} \left( \left( \frac{A_i}{\hat{\pi}} \right)^2 \text{Var} [Y_i^{(1)}] + \left( \frac{1-A_i}{1-\hat{\pi}} \right)^2 \text{Var} [Y_i^{(0)}] \right) \right] \\ &= \frac{1}{n} \left( \mathbb{E} \left[ \left( \frac{A_i}{\hat{\pi}} \right)^2 \right] \text{Var} [Y_i^{(1)}] + \frac{1}{n} \mathbb{E} \left[ \left( \frac{1-A_i}{1-\hat{\pi}} \right)^2 \right] \text{Var} [Y_i^{(0)}] \right), \quad \text{by linearity.} \end{aligned}$$

Note that,

$$\begin{aligned} \mathbb{E} \left[ \left( \frac{A_i}{\hat{\pi}} \right)^2 \right] &= \mathbb{E} \left[ \frac{A_i}{(\hat{\pi})^2} \right] \\ &= \frac{1}{n} \left( \mathbb{E} \left[ \frac{A_1}{\hat{\pi}^2} \right] + \mathbb{E} \left[ \frac{A_2}{\hat{\pi}^2} \right] + \dots + \mathbb{E} \left[ \frac{A_n}{\hat{\pi}^2} \right] \right) \\ &= \mathbb{E} \left[ \frac{\hat{\pi}}{\hat{\pi}^2} \right] \\ &= \mathbb{E} \left[ \frac{\mathbf{1}_{\hat{\pi}>0}}{\hat{\pi}} \right], \end{aligned}$$

so that

$$\mathbb{E} [\text{Var} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] = \frac{1}{n} \left( \mathbb{E} \left[ \frac{\mathbf{1}_{\hat{\pi}>0}}{\hat{\pi}} \right] \text{Var} [Y_i^{(1)}] + \mathbb{E} \left[ \frac{\mathbf{1}_{(1-\hat{\pi})>0}}{1-\hat{\pi}} \right] \text{Var} [Y_i^{(0)}] \right).$$

Coming back to the law of total variance, one has,

$$\begin{aligned} \text{Var} [\hat{\tau}_{\text{DM}}] &= \text{Var} [\mathbb{E} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] + \mathbb{E} [\text{Var} [\hat{\tau}_{\text{DM}} \mid \mathbf{A}]] \\ &= \mathbb{E} [Y_i^{(1)}]^2 (1-\pi)^n + \mathbb{E} [Y_i^{(0)}]^2 \pi^n - \left( \mathbb{E} [Y_i^{(1)}] (1-\pi)^n + \mathbb{E} [Y_i^{(0)}] \pi^n \right)^2 \\ &\quad + \frac{1}{n} \left( \mathbb{E} \left[ \frac{\mathbf{1}_{\hat{\pi}>0}}{\hat{\pi}} \right] \text{Var} [Y_i^{(1)}] + \mathbb{E} \left[ \frac{\mathbf{1}_{(1-\hat{\pi})>0}}{1-\hat{\pi}} \right] \text{Var} [Y_i^{(0)}] \right) \end{aligned}$$

In particular, for any sample size,

$$\text{Var} [\hat{\tau}_{\text{DM}}] = \frac{1}{n} \left( \mathbb{E} \left[ \frac{\mathbf{1}_{\hat{\pi}>0}}{\hat{\pi}} \right] \text{Var} [Y_i^{(1)}] + \mathbb{E} \left[ \frac{\mathbf{1}_{(1-\hat{\pi})>0}}{1-\hat{\pi}} \right] \text{Var} [Y_i^{(0)}] \right) + \mathcal{O}(\max(\pi, 1-\pi)^n),$$

and more particularly,

$$\lim_{n \rightarrow \infty} n \text{Var} [\hat{\tau}_{\text{DM}}] = \frac{\text{Var} [Y^{(1)}]}{\pi} + \frac{\text{Var} [Y^{(0)}]}{1-\pi} := V_{\text{DM},\infty}.$$

□

#### 4.D.4 Variance inequality between a Horvitz-Thomson and difference-in-means

In this work we use an inequality to compare the variance of the Horvitz-Thomson with the variance of the difference-in-means under a Bernoulli design. We propose two inequalities, one for the finite sample and one for the asymptotic variance. The result in finite sample depends on another equality on Binomial law, and in particular  $\hat{\pi}$ , that we detail in Lemma 5.

**Lemma 5** (Inequality on  $\hat{\pi}$ ). *Consider a Bernoulli trial (Definition 34) and the estimated propensity score  $\hat{\pi}$  defined as,*

$$\hat{\pi} = \frac{\sum_{i=1}^n A_i}{n}.$$

Then, for all  $n \geq 1$  and for all  $\alpha \in (0, \frac{1}{2})$ ,

$$\mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] \leq \frac{1 + C_{\alpha, \pi} n^{-\alpha}}{\pi},$$

where  $C_{\alpha, \pi} = 1 + 2 \left( \frac{16}{\pi^2(1-2\alpha)} \right)^{\frac{2}{1-2\alpha}}$ .

*Proof.* Let  $\varepsilon > 0$ . (and later in the proof, we will more precisely posit  $\varepsilon = \frac{\pi}{4} n^{-\alpha}$  with  $\alpha \in (0, \frac{1}{2})$ ) The law of total expectation leads to,

$$\mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] = \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \mathbb{1}_{|\hat{\pi} - \pi| < \varepsilon} \right] + \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \mathbb{1}_{|\hat{\pi} - \pi| \geq \varepsilon} \right].$$

For the first term,

$$\begin{aligned} \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \mathbb{1}_{|\hat{\pi} - \pi| < \varepsilon} \right] &\leq \frac{1}{\pi - \varepsilon} \mathbb{E} \left[ \mathbb{1}_{\hat{\pi} > 0} \mathbb{1}_{|\hat{\pi} - \pi| < \varepsilon} \right] \\ &\leq \frac{1}{\pi - \varepsilon}, \end{aligned}$$

and for the second term,

$$\begin{aligned} \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \mathbb{1}_{|\hat{\pi} - \pi| \geq \varepsilon} \right] &\leq n \mathbb{E} \left[ \mathbb{1}_{\hat{\pi} > 0} \mathbb{1}_{|\hat{\pi} - \pi| \geq \varepsilon} \right] \\ &\leq n \mathbb{P} (|\hat{\pi} - \pi| \geq \varepsilon) \\ &\leq 2ne^{-2\varepsilon^2 n}. \end{aligned}$$

The last row is obtained through Chernoff's inequality in a similar manner as in the proof for the semi-oracle (see eq. 4.35). As a consequence, and gathering the two previous inequalities,

$$\begin{aligned} \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] &\leq \frac{1}{\pi - \varepsilon} + 2ne^{-2\varepsilon^2 n} \\ &= \frac{1}{\pi} \frac{1}{1 - \frac{\varepsilon}{\pi}} + 2ne^{-2\varepsilon^2 n}. \end{aligned}$$

One can show using function analysis, that, for all  $0 \leq x < \frac{1}{2}$ , we have

$$\frac{1}{1-x} \leq 1 + \frac{x}{1-2x}.$$

Then, as soon as  $\varepsilon$  is small enough, then  $\frac{\varepsilon}{\pi} < \frac{1}{2}$ , so that,

$$\begin{aligned} \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] &\leq \frac{1}{\pi} \frac{1}{1 - \frac{\varepsilon}{\pi}} + 2ne^{-2\varepsilon^2 n} \\ &\leq \frac{1}{\pi} \left( 1 + \frac{\frac{\varepsilon}{\pi}}{1 - 2\frac{\varepsilon}{\pi}} \right) + 2ne^{-2\varepsilon^2 n}. \end{aligned}$$

Letting  $\varepsilon = \frac{\pi}{4}n^{-\alpha}$  with  $\alpha \in (0, \frac{1}{2})$ , we have

$$\mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] \leq \frac{1}{\pi} + \frac{1}{4\pi} \frac{n^{-\alpha}}{1 - \frac{n^{-\alpha}}{2}} + 2ne^{-\frac{\pi^2}{8}n^{1-2\alpha}}$$

Now, using the fact that

$$\forall x \geq 1, \forall \alpha \in (0, \frac{1}{2}), \quad x^2 e^{-\frac{\pi^2}{8}x^{1-2\alpha}} \leq \underbrace{\left( \frac{16}{\pi^2(1-2\alpha)} \right)^{\frac{2}{1-2\alpha}}}_{C_{\alpha, \pi}},$$

allows to have

$$\begin{aligned} \mathbb{E} \left[ \frac{\mathbb{1}_{\hat{\pi} > 0}}{\hat{\pi}} \right] &\leq \frac{1}{\pi} + \frac{1}{4\pi} \frac{n^{-\alpha}}{1 - \frac{n^{-\alpha}}{2}} + 2 \frac{C_{\alpha, \pi}}{n} \\ &\leq \frac{1}{\pi} + \frac{n^{-\alpha}}{\pi} + 2 \frac{C_{\alpha, \pi}}{\pi n^\alpha} \\ &= \frac{1 + n^{-\alpha(1+2C_{\alpha, \pi})}}{\pi}. \end{aligned}$$

□

**Lemma 6** (Variance inequality). *Considering the Horvitz-Thomson estimator (Definition 22) and the difference-in-means estimator (Definition 23), with an internally valid randomized controlled trial of size  $n$  (Assumption 27), then asymptotic variance of the difference-in-means is always smaller or equal than the Horvitz-Thomson, such as*

$$V_{DM, \infty} = V_{HT} - \left( \sqrt{\frac{1-\pi}{\pi}} \mathbb{E}_R[Y^{(1)}] + \sqrt{\frac{\pi}{1-\pi}} \mathbb{E}_R[Y^{(0)}] \right)^2 \leq V_{HT}.$$

In addition, and using the previous inequality, Lemma 4 and Lemma 5, one can bound the finite sample difference-in-means's variance:

$$\begin{aligned} \text{Var} [\hat{\tau}_{DM, n}] &\leq \frac{1}{n} \left( \frac{\text{Var} [Y^{(1)}]}{\pi} + \frac{\text{Var} [Y^{(0)}]}{1-\pi} \right) + \mathcal{O}(n^{-3/2}) \\ &\leq V_{HT} + \mathcal{O}(n^{-3/2}). \end{aligned}$$

*Proof. Asymptotic inequality*

Recall that,

$$V_{HT} = \mathbb{E} \left[ \frac{(Y^{(1)})^2}{\pi} \right] + \mathbb{E} \left[ \frac{(Y^{(0)})^2}{1-\pi} \right] - \tau^2.$$

Noting that,

$$\tau^2 = \left( \mathbb{E} [Y^{(1)} - Y^{(0)}] \right)^2 = \mathbb{E} [Y^{(1)}]^2 + \mathbb{E} [Y^{(0)}]^2 - 2\mathbb{E} [Y^{(1)}] \mathbb{E} [Y^{(0)}],$$

and that for any  $a \in \{0, 1\}$ ,

$$\text{Var} [Y^{(a)}] = \mathbb{E} \left[ (Y^{(a)})^2 \right] - \mathbb{E} [Y^{(a)}]^2,$$

allows to obtain,

$$\begin{aligned} V_{\text{HT}} &= \frac{\text{Var}[Y^{(1)}]}{\pi} + \frac{\text{Var}[Y^{(0)}]}{1-\pi} - (1-\frac{1}{\pi})\mathbb{E}[Y^{(1)}]^2 - (1-\frac{1}{1-\pi})\mathbb{E}[Y^{(0)}]^2 + 2\mathbb{E}[Y^{(1)}]\mathbb{E}[Y^{(0)}] \\ &= V_{\text{DM},\infty} + \left( \sqrt{\frac{1-\pi}{\pi}}\mathbb{E}_{\text{R}}[Y^{(1)}] + \sqrt{\frac{\pi}{1-\pi}}\mathbb{E}_{\text{R}}[Y^{(0)}] \right)^2. \end{aligned}$$

### Finite sample inequality

Recall the finite sample variance of the difference-in-means from Lemma 4, and using the inequality from Lemma 5,

$$\begin{aligned} \text{Var}[\hat{\tau}_{\text{DM},n}] &= \mathbb{E}\left[ Y_i^{(1)} \right]^2 (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right]^2 \pi^n - \left( \mathbb{E}\left[ Y_i^{(1)} \right] (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right] \pi^n \right)^2 \\ &\quad + \frac{1}{n} \left( \mathbb{E}\left[ \frac{\mathbb{1}_{\hat{\pi}>0}}{\hat{\pi}} \right] \text{Var}\left[ Y_i^{(1)} \right] + \mathbb{E}\left[ \frac{\mathbb{1}_{(1-\hat{\pi})>0}}{1-\hat{\pi}} \right] \text{Var}\left[ Y_i^{(0)} \right] \right) \\ &\leq \mathbb{E}\left[ Y_i^{(1)} \right]^2 (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right]^2 \pi^n - \left( \mathbb{E}\left[ Y_i^{(1)} \right] (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right] \pi^n \right)^2 \\ &\quad + \frac{1}{n} \left( \frac{1+C_{1/4,\pi}n^{-1/4}}{\pi} \text{Var}\left[ Y_i^{(1)} \right] + \frac{1+C_{1/4,1-\pi}n^{-1/4}}{1-\pi} \text{Var}\left[ Y_i^{(0)} \right] \right), \end{aligned}$$

where Lemma 5 is applied with  $\alpha = 1/4$  and we recall that  $C_{1/4,\pi} = 1 + 2\left(\frac{32}{\pi^2}\right)^4$ . Note that, at this stage, it is possible to write that,

$$\text{Var}[\hat{\tau}_{\text{DM},n}] = \frac{1}{n} \left( \frac{\text{Var}[Y^{(1)}]}{\pi} + \frac{\text{Var}[Y^{(0)}]}{1-\pi} \right) + \mathcal{O}(n^{-3/2}). \quad (4.60)$$

But the overall goal here is to compare  $\text{Var}[\hat{\tau}_{\text{DM},n}]$  with  $\text{Var}[\hat{\tau}_{\text{HT},n}]$ .

$$\begin{aligned} \text{Var}[\hat{\tau}_{\text{DM},n}] &\leq \text{Var}[\hat{\tau}_{\text{HT},n}] - \frac{1}{n} \left( \sqrt{\frac{1-\pi}{\pi}}\mathbb{E}_{\text{R}}[Y^{(1)}] + \sqrt{\frac{\pi}{1-\pi}}\mathbb{E}_{\text{R}}[Y^{(0)}] \right) \\ &\quad + \frac{1}{n} \left( \frac{C_{1/4,\pi}n^{-1/4}}{\pi} \text{Var}\left[ Y_i^{(1)} \right] + \frac{C_{1/4,1-\pi}n^{-1/4}}{1-\pi} \text{Var}\left[ Y_i^{(0)} \right] \right) \geq 0 \\ &\quad + \mathbb{E}\left[ Y_i^{(1)} \right]^2 (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right]^2 \pi^n - \left( \mathbb{E}\left[ Y_i^{(1)} \right] (1-\pi)^n + \mathbb{E}\left[ Y_i^{(0)} \right] \pi^n \right)^2 \end{aligned}$$

□

### 4.D.5 Post-stratification estimator

The post-stratified estimator (see Definition 29) is an estimator of the average treatment effect from a RCT sample. The principle is to divide the RCT sample into strata, to compute the difference-in-means per strata, and then to average the estimand on each strata, weighting by the strata size. Indeed, the post-stratification estimator introduced in Definition 29 can be re-written as follows.

$$\hat{\tau}_{\text{PS},n} = \sum_{x \in \mathbb{X}} \frac{n_{x,1} + n_{x,0}}{n} \left( \frac{1}{n_{x,1}} \sum_{A_i=1, X_i=x} Y_i - \frac{1}{n_{x,0}} \sum_{A_i=0, X_i=x} Y_i \right), \quad \text{where } n_{x,a} = \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{1}_{A_i=a}.$$

Therefore, the post-stratification estimator can be understood as a weighted estimate of each strata level difference-in-means estimates,

$$\hat{\tau}_{\text{PS},n} = \sum_{x \in \mathbb{X}} \frac{n_x}{n} \hat{\tau}_{\text{DM},n_x}, \quad \text{where } n_x = \sum_{i=1}^n \mathbb{1}_{X_i=x}.$$

*Proof.* Recalling the definition of  $\hat{\pi}_n(x)$  (Definition 28) and denoting  $n_{x,a} = \sum_{i=1}^n \mathbb{1}_{X_i=x} \mathbb{1}_{A_i=a}$

$$\begin{aligned}
 \hat{\tau}_{\text{PS},n} &= \frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{\hat{\pi}_n(x)} - \frac{(1 - A_i) Y_i}{1 - \hat{\pi}_n(x)} \\
 &= \frac{1}{n} \sum_{i=1}^n \frac{A_i Y_i}{n_{x,1}/n_x} - \frac{(1 - A_i) Y_i}{n_{x,0}/n_x} && \text{Definition 28} \\
 &= \sum_{x \in \mathbb{X}} \frac{1}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \frac{A_i Y_i}{n_{x,1}/n_x} - \frac{(1 - A_i) Y_i}{n_{x,0}/n_x} && \text{Categorical covariates} \\
 &= \sum_{x \in \mathbb{X}} \frac{n_x}{n} \sum_{i=1}^n \mathbb{1}_{X_i=x} \frac{A_i Y_i}{n_{x,1}} - \frac{(1 - A_i) Y_i}{n_{x,0}} && \text{Re-arranging } n_x \\
 &= \sum_{x \in \mathbb{X}} \frac{n_x}{n} \hat{\tau}_{\text{DM},n_x}.
 \end{aligned}$$

□

The post-stratified estimator is extensively detailed in [Miratrix et al. \(2013\)](#), but largely focused on inference on a finite population (except in their Section 5). In particular the variance of the post-stratified estimator under a Bernoulli or a completely randomized design is given in [Miratrix et al. \(2013\)](#) (see their Equation (16)). [Imai et al. \(2008\)](#) also present derivation to compare the variance of a difference-in-means with a post-stratified estimator, quantifying the gain in precision (see Appendix A).

## 4.E (Non-exhaustive) Review of the different IPSW versions in the literature

Within the generalization literature, the IPSW can be found under slightly different forms, such as with estimated  $\pi$  or not, or with or without normalization. Here, and to help the reader navigates, we reference some of the different formulas found in the literature and in implementations.

Reference	IPSW formula	Comments
<a href="#">Huang (2022)</a>	$\frac{1}{n} \sum_{i \in \text{Trial}} \hat{w}_{n,m}(X_i) \left( \frac{Y_i A_i}{\hat{\pi}_n} - \frac{Y_i(1-A_i)}{1-\hat{\pi}_n} \right)$	$\pi$ estimated once $\hat{\pi}_n = \sum_{i=1}^n A_i/n$
<a href="#">Josey et al. (2021)</a>	$\frac{1}{n} \sum_{i \in \text{Trial}} \hat{w}_{n,m}(X_i) \left( \frac{Y_i A_i}{\hat{\pi}_n} - \frac{Y_i(1-A_i)}{1-\hat{\pi}_n} \right)$	$\pi$ estimated by any consistent estimator
<a href="#">Nie et al. (2021)</a>	$\frac{1}{n} \sum_{i \in \text{Trial}} \hat{w}_{n,m}(X_i) \left( \frac{Y_i A_i}{\pi} - \frac{Y_i(1-A_i)}{1-\pi} \right)$	Oracle $\pi$
<a href="#">Dahabreh et al. (2020)</a>	$\frac{1}{n} \sum_{i \in \text{Trial}} \hat{w}_{n,m}(X_i) \left( \frac{Y_i A_i}{\hat{\pi}_n(X)} - \frac{Y_i(1-A_i)}{1-\hat{\pi}_n(X)} \right)$	$\hat{\pi}_n(X)$ estimated with logistic regression
<a href="#">Buchanan et al. (2018)</a>	$\frac{1}{n} \sum_{i \in \text{Trial}} \hat{w}_{n,m}(X_i) \left( \frac{Y_i A_i}{\hat{\pi}_n} - \frac{Y_i(1-A_i)}{1-\hat{\pi}_n} \right)$	$\pi$ estimated once $\hat{\pi}_n = \sum_{i=1}^n A_i/n$

**Table 4.1: Non-exhaustive review of the different IPSW versions, illustrating that different approaches exist.**



## Chapter 5

# Which causal measure is easier to generalize?

This chapter corresponds to the article entitled *Risk ratio, odds ratio, risk difference... Which causal measure is easier to generalize?* [submitted](#) to *Statistics in Medicine*,

co-authored with Julie JOSSE, Gaël VAROQUAUX, and Erwan SCORNET.

### *Chapter's content*

---

In all the previous chapters, the causal effect is systematically defined as an absolute difference of the two conditional expectations of the outcome under treatment or not. This practice is consistent with the statistical literature's practice. But when coming to more applied clinical publications, one can find many more measures to report so-called treatment or causal effect: ratio, odds ratio, number needed to treat, and so on. The choice of a measure, e.g. absolute versus relative, is often debated because it leads to different appreciations of the same phenomenon. More importantly, it also implies different heterogeneity patterns of treatment effect. In addition some measures but not all have appealing properties such as collapsibility. In this Chapter, we review common measures, and their pros and cons typically brought forward. Doing so, we clarify notions of collapsibility and treatment effect heterogeneity, unifying different existing definitions. As previous chapters are focused on generalizability, this led us to think more carefully on the definition of effect heterogeneity. Covariates modulating the treatment effect are the cornerstone of the transportability assumption used in the previous chapters. Having this idea in mind, we propose to reverse the thinking: rather than starting from the measure, we propose to start from a non-parametric generative model of the outcome. Depending on the nature of the outcome, some causal measures disentangle treatment modulations from baseline risk. As our goal is the generalization of causal measures, we show that different sets of covariates are needed to generalize an effect to a different target population depending on (i) the causal measure of interest, (ii) the nature of the outcome, and (iii) the identification method itself (i.e. modeling either conditional outcomes or local effects).

---

## Contents

1	The age-old question of how to report effects . . . . .	184
2	Problem setting and key results . . . . .	185
3	Causal metrics and their properties . . . . .	190
4	Reverse the thinking: using working models . . . . .	195
5	Are some measures easier to generalize than others? . . . . .	200
6	Illustration through simulations . . . . .	202
7	Conclusion . . . . .	204
5.A	Treatment effect measures . . . . .	205
5.B	Definitions found in the literature . . . . .	208
5.C	Proofs . . . . .	210
5.D	Usual point of view for a binary outcome: logistic regression . . . . .	222
5.E	Complements on the intrication model . . . . .	224
5.F	Different points of view . . . . .	226
5.G	Comments and answers to related article . . . . .	230
5.H	Details about the simulations . . . . .	233

## 1 The age-old question of how to report effects

From the physician to the patient, the term *effect* of a drug on an outcome usually appears very spontaneously, within a casual discussion or in scientific documents. Overall, everyone agrees that an effect is a comparison between two states: treated or not. But there are various ways to report the main effect of a treatment. For example, the scale may be absolute (e.g. the number of migraine days per month is expected to diminishes by 0.8 taking Rimegepant (Edvinsson, 2021)) or relative (e.g. the probability of having a thrombosis is expected to be multiplied by 3.8 when taking oral contraceptives (Vandenbroucke et al., 1994)). Choosing one measure or the other has several consequences. First, it conveys a different impression of the same data to an external reader (Forrow et al., 1992; Guyatt et al., 2015; Xiao et al., 2022). Such subjective impression may be even more prominent in newspapers, where most effects are presented in relative rather than absolute terms, creating a heightened sense of sensationalism (Moynihan et al., 2000). Second, the treatment effect heterogeneity – i.e. different effects on sub-populations – depends on the chosen measure (Rothman, 2011, see p.199). The choice of the measure to report an effect is still actively discussed (Spiegelman and VanderWeele, 2017; Spiegelman et al., 2017; Baker and Jackson, 2018; Feng et al., 2019; Doi et al., 2020, 2022; Xiao et al., 2021, 2022; Huitfeldt et al., 2021; Lapointe-Shaw et al., 2022; Liu et al., 2022). Publications on the topic come with many diverging opinions and guidelines (see Appendix 5.F for quotes). And yet the question of the measure (or metric) of interest is not new; Sheps (1958) was already raising it in the *New England Journal of Medicine* (see also Huitfeldt et al. (2021)):

“ We wish to decide whether we shall count the failures or the successes and whether we shall make relative or absolute comparisons ” –

Beyond impression conveyed and heterogeneity captured, different causal measures lead to different generalizability towards populations (Huitfeldt et al., 2018). The problem of generalizability (or portability) encompasses a range of different scenarii, and refers to the ability of findings to be carried over to a broader population beyond the study sample.

Generalizability of trials’ findings is crucial as most often clinicians use causal effects from published trials (*i*) to estimate the expected response to treatment for a specific patient based on his/her baseline risks, and (*ii*) therefore to choose the best treatment. In this work we show that some effect measures are less sensitive than others to population’s shift between the study sample and the target population.

Section 2 starts with a didactic clinical example to introduce the question, the notation, and our main results. Reading it suffices for an executive summary of the paper. For the mathematical underpinnings, each of the following sections (Section 3-5) is dedicated to one of the three contributions exposed in Section 2. Section 3 first clarifies and discusses typical properties of causal measures such as treatment effect homogeneity, heterogeneity, and collapsibility and then explicitly links collapsibility with generalizability (*i.e.* re-weighting of local effects to get the population effect). In Section 4, we reverse the thinking; we propose to start from a non-parametric generative model of the outcome, and then observe what each measure captures. This approach leads to a new view on treatment effect heterogeneity: accounting for covariates that may act as treatment effect modulators, as opposed to those that only affect baseline levels. Section 5 presents the consequences on the generalizability of a causal measure. We show that some measures are easier to generalize, in the sense that they require adjustment only on the treatment effect modulators introduced in Section 4, and not on all shifted prognostic covariates. Section 6 illustrates the takeaways through simulations.

## 2 Problem setting and key results

### 2.1 Causal effects in the potential outcomes framework

We use the *potential outcome* framework to characterize treatment (or causal) effects. This framework has been proposed by Neyman in 1923 (English translation in [Splawa-Neyman et al., 1990](#)), and popularized by Donald Rubin in the 70's ([Imbens and Rubin, 2015](#); [Hernan, 2020](#)). It formalizes the concept of an intervention by studying two possible values  $Y_i^{(1)}$  and  $Y_i^{(0)}$  for the outcome of interest (say the pain level of headache) for the two different situations where the individual  $i$  has been exposed to the treatment ( $A_i = 1$ ) or not ( $A_i = 0$ ) –we will only consider binary exposure. The treatment has a causal effect if the potential outcomes are different, that is testing the assumption:

$$Y_i^{(1)} \stackrel{?}{=} Y_i^{(0)}. \quad (5.1)$$

Unfortunately, one cannot observe the two worlds for a single individual. Statistically, it can still be possible to compare the *expected* values of each potential outcome  $Y^{(a)}$  but it requires a population-level approach, broadening from a specific individual. The paradigmatic example is a randomized experiment (called Randomized Controlled Trial –RCT– in clinical research or A/B test in marketing): randomly assigning the treatment to half of the individuals enables the average comparison of the two situations. Doing so, the previous question of interest amounts to *comparing* or *contrasting* two expectations:

$$\mathbb{E} \left[ Y^{(1)} \right] \stackrel{?}{=} \mathbb{E} \left[ Y^{(0)} \right], \quad (5.2)$$

where  $\mathbb{E}[Y^{(a)}]$  is the expected counterfactual outcome had all individuals in the *population* received the treatment level  $a$ . This quantity is defined with respect to a population: statistically the expectation is taken on a distribution, which we denote  $P_S$  (reflecting the source or study sample from which evidence comes from, for example a RCT). Many methodological efforts have focused on estimating the two expectations (namely  $\hat{\mathbb{E}} \left[ Y^{(1)} \right]$  and  $\hat{\mathbb{E}} \left[ Y^{(0)} \right]$ ). Our focus is different: we propose theoretical guidance for choosing among different measures to *compare* those two expectations at the population level, e.g. ratio, difference, or odds. What are the properties of these measures? How do they impact the conclusions of a study?

### 2.2 Comparing two averaged situations: different treatment effect measures

We focus on two types of outcomes: continuous (e.g. headache pain level) and binary (e.g. death). Binary outcomes are frequent in medical questions, often related to the occurrence of an event.

**Continuous outcome** For continuous outcomes, a common measure is the absolute difference (usually referred to as the Risk Difference - RD):

$$\tau_{\text{RD}} := \mathbb{E} \left[ Y^{(1)} \right] - \mathbb{E} \left[ Y^{(0)} \right].$$

A null effect corresponds to  $\tau_{RD} = 0$ . If the outcomes are of constant sign and different from 0 one can also consider relative measures<sup>1</sup> such as the ratio (Risk Ratio - RR), or the (Excess Risk Ratio - ERR):

$$\tau_{RR} := \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]}, \quad \tau_{ERR} := \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{\mathbb{E}[Y^{(0)}]} = \tau_{RR} - 1.$$

A null effect now corresponds to  $\tau_{RR} = 1$  or  $\tau_{ERR} = 0$ . Note that the ranges of the three metrics are very different, for e.g. if  $\mathbb{E}[Y^{(1)}] = 200$  and  $\mathbb{E}[Y^{(0)}] = 100$ . Then  $\tau_{RD} = 100$ , while  $\tau_{RR} = 2$  and  $\tau_{ERR} = 1$ .

**Binary outcome** Due to the binary nature of the outcome, the two expectations of eq. 5.2 can now also be understood as the probability of the event to occur,  $\mathbb{P}[Y^{(a)} = 1] = \mathbb{E}[Y^{(a)}]$ , and as a consequence  $\mathbb{P}[Y^{(a)} = 0] = 1 - \mathbb{E}[Y^{(a)}]$ . As long as the phenomenon is non-deterministic (i.e.  $1 > \mathbb{P}[Y^{(a)} = 1] > 0$ ), previous relative measures  $\tau_{RR}$  and  $\tau_{ERR}$  can also be used with binary outcomes. But others measures exist when the outcome is binary. For example the Risk Ratio (RR) can be *reversed*, rather counting the null events. It is called the Survival Ratio (SR). The Odds Ratio (OR) is another very common measure, in particular as it serves as a link between follow-up studies and case-control studies (Greenland, 1987; King and Zeng, 2002). Another measure called the Number Needed to Treat (NNT) has been proposed more recently (Laupacis et al., 1988); it helps the interpretation of the Risk Difference by counting how many individuals should be treated to observe one individual answering positively to treatment. Depending on the direction of the effect, NNT can also be called Number Needed to Harm (NNH) when the events are side effects or Number of Prevented Events (NPE) when it comes to prevention. For simplicity of the exposition, in this work we only consider NNT. The exact expression of the above measures are given here:

$$\tau_{SR} := \frac{\mathbb{P}[Y^{(1)} = 0]}{\mathbb{P}[Y^{(0)} = 0]}, \quad \tau_{OR} := \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)^{-1}, \quad \tau_{NNT} := \tau_{RD}^{-1}.$$

Other measures can be found in the literature, such as the log Odds Ratio (log-OR). We recall each measure in Appendix 5.A where Figure 5.7 illustrates the differences between measures, for different values of the expected outcomes of controls and treated. We also compute all these measures on a clinical example in Section 2.3.

**Treatment effects on subgroups** Treatment effects can also be reported within subgroups of a population (i.e. stratified risks) to show how sub-populations react to the treatment. Therefore, one could also define each of the previously introduced measures on sub-populations. For the rest of the work, we denote  $X$  a set of baseline covariates<sup>2</sup>. We denote  $\tau(x)$  the treatment effect on the subpopulation  $X = x$  for any causal measure. For example  $\tau_{RD}(x)$  denotes the Risk Difference on the subgroup for which  $X = x$ . This quantity is often referred to as the Conditional Average Treatment Effect (CATE).

## 2.3 Key messages: from effect measures to generalization

### 2.3.1 An illustrative example

We consider clinical data assessing the benefit of antihypertensive therapy ( $A$ ) against stroke ( $Y$ ) (MacMahon et al., 1990; Cook and Sackett, 1995). We denote  $Y = 1$  a stroke, and  $Y = 0$  no stroke. Individuals can be categorized into two groups depending on their diastolic blood pressure: either moderate ( $X = 0$ ) or mild ( $X = 1$ ). Moderate patients have a higher baseline risk of stroke than

<sup>1</sup>Allowing situations where the outcomes can be null or change sign is at risk of having undefined ratio due to  $\mathbb{E}[Y^{(0)}] = 0$ . This is why, when considering relative measure we assume that the continuous outcome is of constant sign. Note that this is often the case in medicine. For example with blood glucose level, systolic blood pressure, etc.

<sup>2</sup>Those covariates are baseline or pre-treatment covariates. See VanderWeele and Robins (2007) for a detailed explanation.

mild patients, which corresponds to  $\mathbb{P}[Y^{(0)} = 1 \mid X = 0] \geq \mathbb{P}[Y^{(0)} = 1 \mid X = 1]$ . In particular in this example,  $X = 0$  (resp.  $X = 1$ ) corresponds to a baseline risks of 2 events for 10 individuals (resp. 15 events for 1,000 individuals). All the measures previously introduced are computed from values reported in the original articles and presented in Table 5.1.

**Table 5.1: Different treatment measure give different impressions of the phenomenon:**

The outcome is stroke in 5 years ( $Y = 1$  denoting stroke and  $Y = 0$  no stroke) and stratification is done along a binary covariate  $X$  (moderate  $X = 0$  or mild  $X = 1$ ). Each measure are computed from aggregated data taken from [MacMahon et al. \(1990\)](#); [Cook and Sackett \(1995\)](#). No confidence intervals are represented as our focus is the interpretation of the measure and not statistical significance.

	$\tau_{RD}$	$\tau_{RR}$	$\tau_{SR}$	$\tau_{NNT}$	$\tau_{OR}$
<b>All (<math>P_S</math>)</b>	-0.0452	<b>0.6</b>	1.05	22	0.57
<b>X = 1</b>	-0.006	<b>0.6</b>	1.01	167	0.6
<b>X = 0</b>	-0.08	<b>0.6</b>	1.1	13	0.545

A risk ratio below 1 means there is an inverse association: is a decreased risk of stroke in the treated group compared with the treated group. More precisely, the treated group has 0.6 times the risk of having a stroke outcome when compared with the non-treated group. On this example, one can also recover that the Odds Ratio approximates the Risk Ratio in a stratum where prevalence of the outcome is low ( $X = 1$ ), but not if the prevalence is higher ( $X = 0$ ) (derivations recalled in Appendix 5.A). The survival ratio of 1.05 captures that there is an increased chance of not having a stroke when treated compared to the control by a factor 1.05. Note that the Survival Ratio takes really different values than the Risk Ratio: it corresponds to the Risk Ratio where labels  $Y$  are swapped for occurrences and non-occurrences, illustrating that Risk Ratio is not symmetric to the choice of outcome 0 and 1 –e.g. counting the living or the dead ([Sheps, 1958](#)). This lack of symmetry is usually considered as a drawback of the survival ratio and risk ratio compared to the odds ratio. Indeed, the odds ratio is robust to a change of labels: swapping labels leads to changing the odds ratio  $\tau_{OR}$  by its inverse  $\tau_{OR}^{-1}$  (see Appendix 5.A). There is no such formula to understand the effect of a change of labels on the risk ratio or the survival ratio.

Finally, the Risk Difference translates the effect on a absolute scale: treatment reduces by 0.045 the probability to suffer from a stroke when treated<sup>3</sup>. The NNT is the number of patients you need to treat to prevent one additional bad outcome. Here the NNT is of 22, meaning that one has to treat 22 people with the drug to prevent one additional stroke. The Number Needed to Treat represents the same Risk Difference on a way bigger amplitude than the Risk Difference, especially when looking at the effect on subgroups. This is one of the interest of the NNT, making the measure more explicit than a difference of probabilities.

### 2.3.2 Contributions: considerations to choose an effect measure

**Contribution 1: A collapsible measure is needed to generalize local effects [Section 3]** If we were only provided subgroups' effects, and not the population effect ( $P_S$  or **All** on Figure 5.1), an intuitive procedure to obtain the population effect from local effects would be to average subgroups effects. More explicitly,

$$\text{Collapsibility} \quad \tau_{RD} = \underbrace{p_S(X=1)}_{\% \text{ individuals with } X=1 \text{ in } P_S} \cdot \tau_{RD}(X=1) + \underbrace{p_S(X=0)}_{\% \text{ individuals with } X=0 \text{ in } P_S} \cdot \tau_{RD}(X=0), \quad (5.3)$$

denoting  $P_S$  the source population from which the study was sampled, and  $p_S(x)$  the proportion of individual with  $X = x$  in this population. In our example study above  $p_S(X = 0)$  is 0.53 ([Cook and](#)

<sup>3</sup>When it comes to binary outcomes, such absolute effects are rather presented as reducing by 45 events over 1,000 individuals.

Sackett, 1995), thus for the risk difference the formula recovers the population effect from the subgroup effects:  $-0.47 \cdot 0.006 - 0.53 \cdot 0.08 = 0.0452$ . When a population-effect measure can be written as a weighted average of subgroup effects, it is said to be *collapsible*, and *directly collapsible* if the weights are equal to the population’s proportions. While the Risk Difference is directly collapsible, this is not true for all measures (e.g. for the Number Needed to Treat,  $0.47 \cdot 167 + 0.53 \cdot 13 = 85 \neq 22$ ). We precisely define collapsibility and which measures are collapsible (or not) in Section 3.2, summarized in Table 5.3.

Collapsibility comes into play when one is interested in the population effect on a target population  $P_T$  different from the original source population  $P_S$ , e.g. with a different proportion of individuals with diastolic pressure ( $\forall x \in \{0, 1\}, p_S(x) \neq p_T(x)$ ). Here, one must account for distributional shift across the two populations in baseline covariates that are prognostic of the outcome.

Intuitively, one would wish that the procedure from eq. 5.3 remains valid, only changing the weights for example swapping  $p_S(X = 0)$  for  $p_S(X = 1)$  (resp.  $p_T(X = 0)$  for  $p_T(X = 1)$ ). More explicitly,

$$\text{Effect on } P_T \quad \tau_{RD}^T = p_T(X = 1) \cdot \tau_{RD}^S(X = 1) + p_T(X = 0) \cdot \tau_{RD}^S(X = 0), \quad (5.4)$$

% individuals with  $X = 1$  in  $P_T$                       % individuals with  $X = 0$  in  $P_T$

where  $\tau_{RD}^T$  is the RD on the target population  $P_T$  and  $\tau_{RD}^S(x)$  are local effects in the source population  $P_S$ . This procedure can be found under various names: *standardization*, *re-weighting*, *recalibration*) (Miettinen, 1972; Rothman and Greenland, 2000; Pearl and Bareinboim, 2014). We will call it *generalization*, as it is related to the work initiated by Stuart et al. (2011). We show that procedure from eq. 5.4 is accurate, only if the causal measures are collapsible.

### Contribution 2: A measure can disentangle treatment effect from baseline risk [Section 4]

Table 5.1 shows that the choice of the measure gives different impressions of the heterogeneity of the effect, i.e. how much the effects measures change on different subgroups. Such differences can be due to different baseline risks. For example, it seems that a higher number needed to treat on the subgroup with low prevalence ( $X = 1$ ) is expected as, even without the treatment, individuals already have a low risk of stroke. Is it possible to disentangle the baseline variation with the treatment effect in itself? Surprisingly, in this example, one measure is constant (or *homogeneous*) over the strata  $X$ : the risk ratio. We will show that this measure was the only one expected to behave like this. More precisely, we will show that depending on the outcome nature and the direction of treatment effect (harmful or beneficial), there exists one treatment effect measure capable of disentangling the baseline level with the treatment effect itself: the RD for continuous outcome; either the RR or the SR (depending on the direction of the treatment) for binary outcome. All other common measures entangle baseline level and treatment effect. A by-product of this definition is a non-parametric way to define covariates being treatment effect modulators or only prognostic covariates.

### Contribution 3: Causal effect measures are not equal when facing population’s shift [Section 5]

Collapsibility is needed when generalizing local effects to another target population using eq. 5.4. But which covariates  $X$  must be accounted for in eq. 5.4 for the procedure to be valid? Current line of works usually advocate to adjust on all prognostic covariates being shifted between the two populations. Using Contribution 2, we will show that some collapsible measures are likely to be more easily generalizable than others, and in particular are likely to require less covariates to adjust on (only the treatment effect modulators, and not all shifted prognostic covariates). Illustration from Table 5.1 taken from a real clinical example is in perfect agreement with our findings. In this example, the RR is directly generalizable from  $P_R$  to  $P_T$ , while the risk difference would need to be adjusted on  $X$ . Note that Section 5 also provides the formula to generalize relative measures such as the risk ratio, while the current literature mostly focuses on risk difference.

## 2.4 Related work: many different viewpoints on effect measures

**The choice of measure, a long debate** The question of which treatment-effect measure is most appropriate (RR, SR, RD, OR, NNT, log-OR, etc) is age old (Sheps, 1958; Greenland, 1987; Laupacis



et al., 1988; Cook and Sackett, 1995; Sackett et al., 1996; Davies et al., 1998; King and Zeng, 2002; Schwartz et al., 2006; Cummings, 2009). Health authorities advise to report both absolute and relative causal effect (Schulz et al., 2010, item 17b). And yet, the question is still a heated debate: in the last 5 years, numerous publications have advocated different practices (Spiegelman and VanderWeele, 2017; Spiegelman et al., 2017; Lesko et al., 2018; Baker and Jackson, 2018; Feng et al., 2019; George et al., 2020; Doi et al., 2020, 2022; Xiao et al., 2021, 2022; Huitfeldt et al., 2021; Lapointe-Shaw et al., 2022, see Appendix 5.F for details). Most of these works focus on the interpretation of the metrics and simple properties such as symmetry (Cummings, 2009), heterogeneity of effects (Rothman, 2011; VanderWeele and Robins, 2007; Lesko et al., 2018), or collapsibility (Simpson, 1951; Whittemore, 1978; Miettinen and Cook, 1981; Greenland, 1987; Greenland et al., 1999; Cummings, 2009; Greenland and Pearl, 2011; Hernàn et al., 2011; Martinussen and Vansteelandt, 2013; Sjölander et al., 2016; Huitfeldt et al., 2019; Daniel et al., 2020; Liu et al., 2022; Didelez and Stensrud, 2022) –some works discuss the paradoxes induced by a lack of collapsibility without using this exact term, e.g. in oncology (Ding et al., 2016; Liu et al., 2022). We shed new light on this debate with a framing on generalization and non-parametric generative models of the outcome (Section 4).

**Connecting to the generalization literature** The problem of external validity is a growing concern in clinical research (Rothwell, 2007; Rothman et al., 2013; Berkowitz et al., 2018; Deeks, 2002), related to various methodological questions (Cook et al., 2002; Pearl and Bareinboim, 2011a). We focus on external validity concerns due to shifted baseline covariates between the trial’s population and the target population, following the line of work initiated in Imai et al. (2008) (see their definition of *sample* effect versus *population* effect), or Corollary 1 of Pearl and Bareinboim (2014)). Generalization by standardization (eq. 5.4, *i.e.* re-weighting local effects) has been proposed before in epidemiology (Rothman and Greenland, 2000), and in an even older line of work in the demography literature (Yule, 1934). Note that eq. 5.4 is very close to procedure from eq. 5.3 which can be linked to post-stratification (Imbens, 2011; Miratrix et al., 2013). Post-stratification is used to lower variance on a randomized controlled trial and therefore has no explicit link with generalization, despite using a similar statistical procedure. Today, almost all statistical papers dealing with generalization focus on the estimation procedures that generalizes the risk difference  $\tau_{RD}$  (Stuart et al., 2011; Tipton, 2013; O’Muircheartaigh and Hedges, 2013; Kern et al., 2016; Lesko et al., 2017; Nguyen et al., 2018; Gatsonis and Sally, 2017; Buchanan et al., 2018; Dahabreh et al., 2020) (reviewed in Colnet et al. (2020); Degtiar and Rose (2023)), seldom mentioning other measures. Other works focus on the generalization of the distribution of the treated outcome  $\mathbb{E}[Y^{(1)}]$  (Pearl and Bareinboim, 2011a, 2014; Cinelli and Pearl, 2020). A notable exception, Huitfeldt et al. (2018), details which choice of variables enables the standardization procedure for binary outcomes. We extensively generalize the thought process of Huitfeldt et al. (2018) revealing the interplay with choice of measure and role of covariates in heterogeneous settings, as well as continuous outcomes.

**Building up on causal research** By writing the outcomes as generated by a non-parametric process disentangling the baseline from the treatment effect (in the spirit of Robinson (1988); Nie and Wager (2020); Gao and Hastie (2021)), we extend the usual assumptions for generalization. In particular, Pearl and Bareinboim (2014) state that their assumptions for generalization are “*the worst case analysis where every variable may potentially be an effect-modifier*”. Our work proposes more optimistic situations, by introducing a notion of effect-modifier without parametric assumptions. This enables the description of situations where fewer covariates are required for the generalization of certain measures, depending on the nature of the outcome Cinelli and Pearl (2020) have proposed similar ideas, assuming monotonicity of the effect (*i.e.* the effect being either harmful or beneficial for everyone) and the absence of shifted treatment effect modifiers, in order to generalize  $\mathbb{E}[Y^{(1)}]$ . More precisely they assumption that what they call *probabilities of causation*  $\mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1]$  are invariant across populations. We relax this assumption to allow more general situations. Doing so, we also extend work from Huitfeldt et al. (2018, 2019), showing how those probabilities are linked with the causal measures of interest. Interestingly, all our derivations retrieves Sheps (1958) intuition and results when the outcome is binary (which was the only situation described by Sheps). Our work

also proposes conclusions for a continuous outcome which was not treated by Sheps (1958); Cinelli and Pearl (2020); Huitfeldt et al. (2021).

### 3 Causal metrics and their properties

This section uses notations introduced in Section 2, in particular the potential outcomes  $Y^{(0)}$ ,  $Y^{(1)}$  (which can be either binary or continuous), the binary treatment  $A$ , and the baseline covariates  $X$ . By default, all expectations are assumed to refer to a source population  $P_S$ . Only when generalizing (see Section 3.3 or Section 5), we also consider a target population  $P_T$ . For example  $\tau_{RR}^T$  denotes the RR on the target population.

In this section, we ground formally concepts such as homogeneity and heterogeneity of treatment effect, but also collapsibility, and its link to generalization. Those concepts are already described in the literature, via numerous and slightly different definitions (see Section 5.B). We unify existing definitions. For clarity, all definitions, assumptions, and lemmas that do not contain an explicit reference in the title are original.

#### 3.1 Treatment effect heterogeneity depends on the measure chosen

Homogeneity or heterogeneity is linked to how the effects on subgroups of the population change. If the effect amplitude and/or direction is different in some subgroups (not due to sampling noise as we only consider the true population's values), the treatment effect is said to be heterogeneous. In the literature, one can find several informal definitions of heterogeneity of a treatment effect but formal definitions are scarce. From now on, we let  $\mathbb{X}$  be the covariate space.

**Definition 35** (Treatment effect homogeneity). *A causal effect measure  $\tau$  is said to be homogeneous, if*

$$\forall x_1, x_2 \in \mathbb{X}, \quad \tau(x_1) = \tau(x_2) = \tau.$$

**Definition 36** (Treatment effect heterogeneity - VanderWeele and Robins (2007)). *Assuming a causal measure  $\tau$  and a baseline covariate  $X$ , a treatment effect is said to be heterogeneous with respect to  $X$  if,*

$$\exists x_1, x_2 \in \mathbb{X}, \quad \tau(x_1) \neq \tau(x_2).$$

Heterogeneity and homogeneity are properties defined with respect to (i) baseline covariates and (ii) a measure. Claiming *heterogeneity or homogeneity of a treatment effect* should always be completed by the information about the considered covariates and the measure under study. For instance in the illustrative example from Table 5.1, the treatment effect on the Risk Difference scale is heterogeneous with respect to the baseline diastolic blood pressure level  $X$ , while the treatment effect on the Risk Ratio scale is homogeneous with respect to  $X$ . Below we link homogeneity of treatment effect with the generalizability of a causal measure.

#### 3.2 Not all measures are collapsible

**Intuition** Collapsibility is intuitively linked to heterogeneity. Indeed, to investigate for heterogeneity, one looks up the treatment effect on subgroups of the population. Collapsibility is the opposite process, where local information is aggregated to obtain a global information (i.e. on a population). One might expect the global effect on a population to be an average of the subgroups effects, with weights corresponding to proportions of each subgroup in the target population of interest as in eq. 5.3. Counter-intuitively, this procedure is valid only for certain causal effect measures. For example, if the treatment effect is reported as an Odds Ratio, it is possible to find bewildering situations, such as that of the synthetic example detailed on Table 5.2. On this example, the Odds Ratio is measured on the overall population (Table 5.2 (a)) and on the two subpopulations if female ( $F = 1$ ) or not ( $F = 0$ ) (Table 5.2 (b)). Here, the drug's effect (on the OR scale) is found almost equal on both males (0.166) and females (0.167); however the average effect on the overall population appears much



more efficient (0.26). The value Odds Ratio at the population level is not even *between* that of Odds Ratio of sub-populations. The situation mimics a randomized controlled trial conducted with exact population proportions and with  $F$  being a baseline covariate, so the phenomenon observed is not an effect of confounding.

**Table 5.2: Non-collapsibility of the odds ratio on a toy example:** The tables below represent the exact proportion of an hypothetical population, considering two treatment level  $A \in \{0, 1\}$  and a binary outcome. The proportion are as if a randomized controlled trial was conducted on this population. This population can be stratified in two strata  $F \in \{0, 1\}$ . The odds ratio can be measured on the overall population (a), or on each of the sub-population, namely  $F = 0$  or  $F = 1$  (b). Surprisingly, on each sub-population the odds ratios are similar, but on the overall population the odds ratio is almost two times bigger than on each sub-population. This example is largely inspired from Greenland (1987), but several similar examples can be found elsewhere, for example in Hernan (2020) (see their Fine point 4.3) or in Greenland et al. (1999) (see their Table 1). Another didactic example is provided in Daniel et al. (2020) (see their Figure 1), with a geometrical argument.

(a) Overall population,  $\tau_{OR} \approx 0.26$

	Y=0	Y=1
A=1	1005	95
A=0	1074	26

(b)  $\tau_{OR|F=1} \approx 0.167$  and  $\tau_{OR|F=0} \approx 0.166$

F=1	Y=0	Y=1	F=0	Y=0	Y=1
A=1	40	60	A=1	965	35
A=0	80	20	A=0	994	6

This apparent paradox is due to what is called non-collapsibility<sup>4</sup> of the Odds Ratio. That the average effect on a population could not be written as a weighted sum of effects on sub-populations is somehow going against the “*implicit assumptions that drive our causal intuitions*” (Pearl (2000), page 180). On the contrary, an effect measure is said to be collapsible when the population effect measure can be expressed as a weighted average of the stratum-specific measures. Note that non-collapsibility and confounding are two different concepts, as explained in several papers e.g. in Greenland et al. (1999)<sup>5</sup>.

**Formalizing the problem** In various formal definitions found in the literature (see Section 5.B), collapsibility relates to the possibility of writing the marginal effect as a weighted sum of conditional effects on each subgroups. Yet two definitions coexist, depending on whether weights are forced to be equal to the proportion of individuals in each subgroup or not. We outline various definitions and their links:

**Definition 37** (Direct collapsibility - adapted from Pearl (2000)). *Let  $\tau$  be a measure of effect and  $P(Y^{(0)}, Y^{(1)}, X)$  a joint distribution with  $X$  a set of baseline covariate.  $\tau$  is said to be directly collapsible, if*

$$\mathbb{E}[\tau(X)] = \tau.$$

Some authors present a concept called strict collapsibility (see Definition 53 in Appendix), which corresponds to our definition of homogeneity (Definition 35) (Greenland et al., 1999; Liu et al., 2022; Didelez and Stensrud, 2022). A homogeneous treatment effect along  $X$  has indeed its marginal effect equal to all subgroups effects. Our direct collapsibility definition encompasses such phenomenons.

**Lemma 7** (Direct collapsibility of the risk difference (RD) – (Greenland et al., 1999)). *The Risk Difference  $\tau_{RD}$  is directly collapsible.*

This result has been much discussed; it grounds eq.5.3 in the illustrative example. In the literature, more flexible definitions of collapsibility can be found, keeping the intuition of the population effect being a weighted sum of effects on subpopulation, with certain constraints on the weights such as positivity and normalization.

<sup>4</sup>This definition and phenomenon has been observed long ago by Simpson. See also the Hernan et al. (2011) for a discussion of Simpson’s original paper with modern statistical framework. Note that Pearl (2000) (page 176) mentions that collapsibility has been discussed earlier, for example by Pearson in 1899.

<sup>5</sup>“*the two concepts are distinct: confounding may occur with or without noncollapsibility and noncollapsibility may occur with or without confounding.*”

**Definition 38** (Collapsibility - adapted from [Huitfeldt et al. \(2019\)](#)). Let  $\tau$  be a measure of effect and  $X$  a set of baseline covariates. The measure  $\tau$  is said to be collapsible if there exist weights  $g(X, P(X, Y^{(0)}))$  such that for all distributions  $P(X, Y^{(0)}, Y^{(1)})$  we have

$$\mathbb{E} \left[ g(X, P(X, Y^{(0)})) \tau(X) \right] = \tau, \quad \text{with } g \geq 0, \text{ and } \mathbb{E} \left[ g(X, P(X, Y^{(0)})) \right] = 1.$$

Note that here weights depends on the density of  $X$  and the distribution of controls  $P(X, Y^{(0)})$ . The direct collapsibility is therefore a specific case of the more general version of collapsibility from Definition 38, where  $g(X, P(X, Y^{(0)}))$  corresponds to 1. This definition enables more treatment effect measures to be collapsible.

**Lemma 8** (Collapsibility of the risk ratio and survival ratio - extending [Huitfeldt et al. \(2019\)](#)). The risk ratio and survival ratio are collapsible measures. In particular, assume that almost surely  $0 < \mathbb{E}[Y^{(0)}|X] < 1$ . Then, the conditional risk ratio and conditional survival ratio are defined and satisfy

$$\mathbb{E} \left[ \tau_{RR}(X) \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right] = \tau_{RR} \quad \text{and} \quad \mathbb{E} \left[ \tau_{SR}(X) \frac{1 - \mathbb{E} [Y^{(0)} | X]}{1 - \mathbb{E} [Y^{(0)}]} \right] = \tau_{SR}.$$

Appendix 5.C.1 gives proofs along with other measures. [Huitfeldt et al. \(2019\)](#) or [Ding et al. \(2016\)](#) (see their Equation 2.3) also recall these results but only for a binary outcome and categorical baseline covariate<sup>6</sup>. Lemma 8 extends the derivations for any type of covariate  $X$  and outcome  $Y$  (continuous or binary). Note Lemma 8 is consistent with the illustrative example in Table 5.1 where

$$\tau_{RR} = \mathbb{E} \left[ \tau_{RR}(X) \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right] = \mathbb{E} \left[ 0.6 \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right] = 0.6 \cdot \underbrace{\mathbb{E} \left[ \frac{\mathbb{E} [Y^{(0)} | X]}{\mathbb{E} [Y^{(0)}]} \right]}_{=1} = 0.6.$$

**Lemma 9** (Non-collapsibility of the OR, log-OR, and NNT). The odds ratio  $\tau_{OR}$ , log odds ratio  $\tau_{\log-OR}$ , and Number Needed to Treat  $\tau_{NNT}$  are non-collapsible measures.

The proof is in Appendix 5.C.1. Note that the proof for the Odds Ratio and the log Odds Ratio are not new (in particular we recall the one from [Daniel et al. \(2020\)](#)). While the non-collapsibility of the odds ratio has been reported multiple times (see references above and the example from Table 5.2), we have not found references stating results about the NNT. While the NNT is not-collapsible, this measure does not show the same paradoxical behavior as the OR (see Table 5.2). When considering the OR, the marginal effect  $\tau$  can indeed be smaller or bigger than the range of local effects  $\tau(x)$ .

**Definition 39** (Logic-respecting measure – [Liu et al. \(2022\)](#)). A measure  $\tau$  is said to be logic-respecting if

$$\tau \in \left[ \min_x(\tau(x)), \max_x(\tau(x)) \right].$$

**Lemma 10** (All collapsible measures are logic-respecting, but not the opposite). Several properties can be noted:

- (i) All collapsible measures are logic-respecting measures.
- (ii) The Number Needed to Treat is a logic-respecting measure.
- (iii) The OR and the log-OR are not logic-respecting measures.

Proof is in Appendix 5.C.2. The numerous mentions of paradoxes with the OR are probably more driven the fact that it is not logic-respecting than by its non-collapsibility. This also probably explains why some definitions of collapsibility proposed in the literature do not explicitly separate the notion of collapsibility and logic-respecting measure as they do not detail how weights are defined (see for example Definitions 55 or 56 in Appendix). All properties of this section are summarized in Table 5.3.

<sup>6</sup>Note that it is possible to find this result under slightly forms such as in [Huitfeldt et al. \(2018\)](#); [Didelez and Stensrud \(2022\)](#), with a categorical  $X$  and using Bayes formula,  $\tau_{RR} = \sum_x \tau_{RR}(x) \mathbb{E} [X = x | Y^{(0)} = 1]$ .


Measure	Collapsible	Logic-respecting
Risk Difference (RD)	Yes	Yes
Number Needed to Treat (NNT)	No	Yes
Risk Ratio (RR)	Yes	Yes
Survival Ratio (SR)	Yes	Yes
Odds Ratio (OR)	No	No

**Table 5.3: Causal measures and their properties:** highlighting the properties of collapsibility (Definition 38) and logic respecting (Definition 39). An exhaustive table is available in Appendix (see Table 5.5).

### 3.3 Generalizability or portability of a causal measure

As highlighted above (Section 2), an RCT conducted in a population  $P_S$  allows for the estimation of a treatment effect  $\tau^S$  on this population. What would the result be if the individuals in the trial were rather sampled from a population  $P_T$  with different baseline covariates distribution? This question is linked to external validity, and more precisely to a sub-problem of external validity being *generalizability* or *transportability*. We say that findings from a trial sampled from  $P_S$  can be generalized to  $P_T$  when  $\tau^T$  can be estimated without running a trial on  $P_T$ , but only using data from the RCT and baseline information on the target population  $P_T$  (the covariates  $X$ , and sometimes also the control outcome  $Y^{(0)}$ ), as summarized on Figure 5.1.

**Figure 5.1: Generalization in practice:** We typically consider a situation where the treatment effect is estimated from a Randomized Controlled Trial (RCT) where individuals are sampled from a population  $P_S$ . When willing to extend these findings to  $P_T$ , we assume to have access to a representative sample of the patients of interest, with information on their covariates  $P_T(X)$ , and also maybe the outcome under no treatment  $P_T(X, Y^{(0)})$ .



There exists two identification strategies, generalizing (i) the conditional outcomes or (ii) the local effect measure itself, leading to different assumptions required for generalizing. For both strategies we consider the settings where information gathered on the source population covers at least the support of the target population.

**Assumption 30** (Overlap or positivity). *The support of the target population is included in the source population:  $\text{supp}(P_T) \subset \text{supp}(P_S)$ .*

#### 3.3.1 Generalizing via a conditional-outcome model

The rational is to generalize conditional expectations of the potential outcomes  $\mathbb{E}_S [Y^{(a)} | X]$  to the target population. This procedure is valid only under the following assumption.

**Assumption 31** (Transportability or S-ignorability or Exchangeability between populations). *for all  $x$  in the support of both populations ( $\forall x \in \text{supp}(P_T) \cap \text{supp}(P_S)$ ,  $\forall a \in \{0, 1\}$ ),*

$$\mathbb{E}_S [Y^{(a)} | X = x] = \mathbb{E}_T [Y^{(a)} | X = x].$$

This assumption<sup>7</sup> boils down to:  $X$  contains all the baseline covariates that are *both* shifted between the two populations  $P_R$  and  $P_T$  and prognostic of the outcome. Such assumption enables the identification of  $\tau^T$  using information from  $P_S(X, A, Y)$  and only the covariates information in the target population  $P_T(X)$ .

**Proposition 5** (Generalizing conditional outcomes). *Consider two populations  $P_S$  and  $P_T$  satisfying Assumptions 30 and 31. Then, the conditional outcomes are generalizable:*

$$\begin{aligned} \forall a \in \{0, 1\} \quad \mathbb{E}_T \left[ Y^{(a)} \right] &= \mathbb{E}_T \left[ \mathbb{E}^S \left[ Y^{(a)} \mid X \right] \right] && \text{G-formula} \\ &= \mathbb{E}_S \left[ \frac{p_T(X)}{p_S(X)} \mathbb{E}_S \left[ Y^{(a)} \mid X \right] \right] \end{aligned}$$

where  $\frac{p_T(X)}{p_S(X)}$  corresponds to the density ratio between the source and target populations. Doing so, any causal measure  $\tau^T$  can be identified from  $P_S(X, A, Y)$  and  $P_T(X)$  as any causal measure on the target population can be computed from the generalized outcomes  $\mathbb{E}_T \left[ Y^{(0)} \right]$  and  $\mathbb{E}_T \left[ Y^{(1)} \right]$ .

Appendix 5.C.3 derives this result. The first formula of proposition 5 connects to a classic estimation strategy, plug-in g-formula (see Colnet et al., 2020, for a review on the Risk Difference). Yet under these assumptions, estimation can also be performed by re-weighting the observations (Stuart et al., 2011).

### 3.3.2 Generalizing a collapsible measure via local effects

When the measure is collapsible, rather than using a conditional outcome model, one can rely on the local effects  $\tau^R(x)$  to get the target population's effect  $\tau^T$ , such as in Equation 5.4. Importantly Assumption 31 can then be relaxed into a new, less restrictive, Assumption 32.

**Assumption 32** (Transportability of the treatment effect). *for all  $x$  in the support of both populations ( $\forall x \in \text{supp}(P_T) \cap \text{supp}(P_S)$ ),*

$$\tau^S(x) = \tau^T(x).$$

Here, the transportability assumption<sup>8</sup> can be phrased as:  $X$  contains all the baseline covariates that are *both* shifted between the two populations  $P_R$  and  $P_T$  and treatment effect modulators.

**Proposition 6** (Generalizing local effects). *Consider two population  $P_S$  and  $P_T$  and a causal measure satisfying Assumptions 30 and 32. If  $\tau$  is collapsible,*

$$\begin{aligned} \tau^T &= \mathbb{E}_T \left[ g_T(Y^{(0)}, X) \tau^S(X) \right] \\ &= \mathbb{E}_S \left[ \frac{p_T(X)}{p_S(X)} g_T(Y^{(0)}, X) \tau^S(X) \right] && \text{Re-weighting.} \end{aligned}$$

where  $\frac{p_T(X)}{p_S(X)}$  corresponds to the density ratio between the source and target populations and  $g_T(Y^{(0)}, X)$  corresponds to the collapsibility weights of  $\tau$  on the target population. Doing so, any collapsible causal measure can be identified from  $P_S(X, A, Y)$  and  $P_T(X, Y^{(0)})$  (if not directly collapsible).

Appendix 5.C.3 derives this result. Here the first formula suggests the classical re-weighting estimation strategy also called IPSW (see Colnet et al. (2020) for a review on the Risk Difference).

<sup>7</sup>This assumption is also commonly found expressed as  $Y^{(0)}, Y^{(1)} \perp\!\!\!\perp I \mid X$ , where  $I$  is an indicator of the population membership (Stuart et al., 2011; Pearl, 2015; Lesko et al., 2017). Such assumptions can also be expressed using selection diagram (Pearl and Bareinboim, 2011a).

<sup>8</sup>This assumption is also commonly found expressed as  $Y^{(0)} - Y^{(1)} \perp\!\!\!\perp I \mid X$  when it comes to the generalization of the risk difference ( $I$  being an indicator of the population membership). Note that the transportability assumptions conveys the idea of some homogeneity assumption (close to the spirit of Definition 35). This is highlighted by Huitfeldt et al. (2018) who refer to Assumptions 31 and 32 as “different homogeneity conditions to operationalize standardization”.

### 3.3.3 One assumption needs less covariates than the other

The two above sections (3.3.1 and 3.3.2) mirror each other with two different strategies relying on two different assumptions. However, it is very important to note that **Assumption 32 is lighter than Assumption 31** as highlighted in [Nguyen et al. \(2018\)](#); [Huitfeldt and Stensrud \(2018\)](#); [Colnet et al. \(2022a\)](#). As a consequence, using local effects – Proposition 6 – as opposed to conditionnal-outcomes – Proposition 5 – may allow generalizing a causal measure *with less covariates*. This is at the cost of generalizing only collapsible measures (RD, RR, SR – Table 5.3), and having access to  $Y^{(0)}$  in the target population if the measure is not directly collapsible such as the RR and SR.

**Final comment** The two procedures are equivalent when it comes to the Risk Difference, thanks to the direct generalization of this measure and linearity of expectation,

$$\tau_{RD}^T = \mathbb{E}_T \left[ g_T(Y^{(0)}, X) \tau_{RD}^S(X) \right] = \mathbb{E}_T \left[ 1 \cdot \tau_{RD}^S(X) \right] = \mathbb{E}_T \left[ \mathbb{E}_S \left[ Y^{(1)} \mid X = x \right] \right] - \mathbb{E}_T \left[ \mathbb{E}_S \left[ Y^{(0)} \mid X = x \right] \right].$$

We discuss how to transform identification into estimation in the simulations' part (see Section 5.H.1)

## 4 Reverse the thinking: using working models

We now propose to reverse the thinking: rather than starting from a given metric, we propose to reason from generic generative models (for continuous and binary outcomes). Such models allow us to disentangle covariates that affect only baseline level from those that modulate treatment effects. Such phenomenon will be used later on in Section 5 to determine which measures are easier to generalize. Note that our generative models are very general, since no parametric assumptions are made. As the models depend on the nature of the outcome considered, this section is organized accordingly.

### 4.1 Continuous outcomes

Considering a continuous outcome, using the binary nature of  $A$  it is possible to decompose the response  $Y$  in two parts: baseline level and modification induced by the treatment. Such decomposition is generic and does not rely on any parametric assumptions.

**Lemma 11.** *Assuming that  $\mathbb{E}[|Y^{(1)}| \mid X] < \infty$  and  $\mathbb{E}[|Y^{(0)}| \mid X] < \infty$ , there exists two functions  $b, m : \mathcal{X} \rightarrow \mathbb{R}$  such that*

$$Y^{(a)} = b(X) + a m(X) + \varepsilon_a,$$

where  $b(X) := \mathbb{E}[Y^{(0)} \mid X]$ ,  $m(X) := \mathbb{E}[Y^{(1)} - Y^{(0)} \mid X]$  and a noise  $\varepsilon_A$  satisfying  $\mathbb{E}[\varepsilon_A \mid X] = 0$  almost surely.

Proof is in appendix 5.C.4.1. This result is related to the Robinson decomposition ([Robinson, 1988](#)). This model allows to interpret the difference between the distributions of treated and control groups as the alteration  $m(X)$  of a generative model  $b(X)$  by the treatment. The function  $b$  corresponds to the **baseline**, and  $m$  to the **modifying function** due to treatment. Figure 5.2 gives the intuition backing Lemma 11. Note that a very weak assumption suffices: a bounded outcome  $Y$  –which is expected in clinical applications.


From this non-parametric model, one can observe what each causal metric captures of these functions.

**Lemma 12** (Expression of the causal measures). *Under the assumptions of Lemma 11, we have*

$$\tau_{RD} = \mathbb{E}[m(X)], \quad \tau_{RR} = 1 + \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}, \quad \text{and} \quad \tau_{ERR} = \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}.$$

Proof is in appendix 5.C.4.2. Lemma 12 illustrates how the relative measures  $\tau_{RR}$  and  $\tau_{ERR}$  depend on both the effect  $m(X)$  **and** the baseline  $b(X)$ . On the contrary,  $\tau_{RD}$  is independent of the baseline.

**Figure 5.2: Intuition behind Lemma 11:** This illustration highlights that, for a given set of baseline covariates  $X$ , one can assume that there exist two functions accounting for the expected outcome value for any individual with baseline characteristics  $X$ . Then, it is possible to denote  $m(X)$  as the alteration or modification of the baseline  $b(X) := \mathbb{E}[Y^{(0)} | X]$  response.



**Comment: Linear generative model** A decomposition such as in Lemma 5.C.4.1 is often used in the literature. For example, many applied works or introductory books (Angrist and Pischke, 2008) propose completely linear models such as

$$\mathbb{E}[Y | X, A] = \beta_0 + \langle \beta, \mathbf{X} \rangle + A m, \tag{5.5}$$

where  $m(X) := m$  is a constant and  $b(X)$  a linear model of the covariates. Assuming this model as the true generative model, Lemma 12 leads to


$$\tau_{RD} = m, \quad \tau_{RR} = 1 + \frac{m}{\beta_0 + \langle \beta, \mathbb{E}[X] \rangle}, \quad \text{and} \quad \tau_{ERR} = \frac{m}{\beta_0 + \langle \beta, \mathbb{E}[X] \rangle}.$$

As expected, one can recover that under such model,  $\tau_{RD}$  is homogeneous according to Definition 35, while  $\tau_{RR}$  and  $\tau_{ERR}$  are not.

## 4.2 Binary outcomes

With binary outcomes, one cannot simply write the outcome model as a function of the baseline plus the treatment alteration, due to the fact that the probability of an event ( $Y = 0$  or  $Y = 1$ ) is bounded by zero and one. Figure 5.3 illustrates the situation. As a consequence, another non-parametric generative model than Lemma 11 is needed to disentangle baseline risk with treatment effect.

**Figure 5.3: Intuition for a binary outcome:** Symmetric illustration than the one proposed in Figure 5.2, but highlighting that for a binary outcome the quantity to consider is rather the conditional probabilities of the counterfactual events  $\mathbb{P}[Y^{(a)} = 1 | X]$ . The two probabilities are bounded by 0 and 1.



### 4.2.1 Intuition of the entanglement model

To illustrate the workings of a binary-outcome model that disentangles the baseline risk with the effect of a treatment, we borrow the intuitive example of the Russian Roulette from Huitfeldt (2019), further used by Cinelli and Pearl (2020). When playing the Russian Roulette, everyone has the same probability of 1/6 to die each time they play. We know this because of the intrinsic mechanism of the Russian Roulette. Now, assume that we have not access to this information. In biology, medicine, or economy this is often the case, as the systems under study are too complex. Therefore, one has to empirically estimate this effect. Consider a hypothetical randomized trial to estimate the effect of the Russian Roulette: a random set of individuals is forced to play Russian Roulette, and the others just wait. For logistic reasons, the experiment is done on a certain time frame. During this time frame, individuals can die from other reasons, such as diseases or poor health conditions. For an individual



with characteristics  $x$ , denoting  $b(x)$  his/her probability to die without the Russian Roulette, and counting a death as  $Y = 1$  and survival  $Y = 0$ , one has:

$$\mathbb{P} \left[ Y^{(a)} = 1 \mid X = x \right] = b(x) + a \underbrace{(1 - b(x))}_{\text{Entanglement}} \frac{1}{6}. \quad (5.6)$$

This equation <sup>9</sup> simply states the fact that each individual  $X = x$  has a certain probability to die  $b(x)$  by default. When getting treatment, an individual can also die from Russian Roulette if affected in the treated group  $a = 1$ , but only if not dead otherwise (see the multiplication by  $(1 - b(x))$ , while in the continuous outcome this was just the sum of the two effects). In this equation, one can explicitly observe that the effect is *entangled* with the baseline, due to the binary nature of the outcome. As a consequence, the risk difference no longer captures the modification as it was the case for a continuous outcome (see Lemma 12), but rather:

$$\tau_{\text{RD}} = \frac{1}{6} (1 - \mathbb{E}[b(x)]), \quad \text{and in particular} \quad \lim_{\mathbb{E}[b(x)] \rightarrow 1} \tau_{\text{RD}} = 0.$$

The risk difference measured depends on the population's baseline. In a population with a high baseline, the measured effect vanishes along the risk difference scale. In other words, it seems that when considering the RD, the effect of the treatment can only be observed on people that would not have died otherwise. This could seem a bit odd, as the Russian Roulette example contains the idea of an *homogeneous* treatment effect, that should not vary over different populations. Still, one measure, the survival ratio, shows an interesting property,

$$\tau_{\text{SR}} = 1 - \frac{\mathbb{E} \left[ (1 - b(X)) \frac{1}{6} \right]}{\mathbb{E} [1 - b(X)]} = \frac{5}{6}.$$

The Survival Ratio thus captures the idea of homogeneity: no matter the baseline risk, the Russian Roulette acts in the same way for everyone, as noticed by [Huitfeldt \(2019\)](#). Appendix 5.E explores this example in details.

#### 4.2.2 Formal analysis

The intuitive model presented in eq. 5.6 does not allow catching all phenomena. In particular, we want to describe positive or deleterious effects of the treatment while Equation 5.6 only describes harmful situations. In addition, we want a model able to encode situations where there is heterogeneity of the treatment effect. E.g. stressed out people could have a higher effect of the Russian Roulette because the prospect of playing would create cardiac arrests. Or on a more concrete example: the seat belts could be protective for taller individuals but less protective (or even deleterious) for smaller individuals because of the design.

**Lemma 13** (Entanglement Model). *Considering a binary outcome  $Y$ , assume that*

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) := \mathbb{P} \left[ Y^{(a)} = 1 \mid X = x \right].$$

*Introducing*

$$m_g(x) := \mathbb{P} \left[ Y^{(1)} = 0 \mid Y^{(0)} = 1, X = x \right] \quad \text{and} \quad m_b(x) := \mathbb{P} \left[ Y^{(1)} = 1 \mid Y^{(0)} = 0, X = x \right],$$

*allows to have*

$$\mathbb{P} \left[ Y^{(a)} = 1 \mid X = x \right] = b(x) + a \left( (1 - b(x)) m_b(x) - b(x) m_g(x) \right), \quad \text{where } b(x) := p_0(x).$$

<sup>9</sup>This equation comes from  $\mathbb{P} \left[ Y^{(a)} = 1 \mid X = x \right] = \mathbb{P} \left[ Y^{(0)} = 1 \mid X = x \right] \cup \mathbb{P} \left[ Y^{(1)} = 1 \mid X = x \right] = b(X) + 1/6 - (1/6) \cdot b(X)$ .

Proof is available in Appendix 5.C.4.3. Usually  $Y = 1$  denotes death or deleterious events, therefore the subscripts  $b$  (resp.  $g$ ) stands for *bad* (resp. *good*) events.  $m_b$  (resp.  $m_g$ ) corresponds to the probability that a person who was previously not destined (resp. destined) to experience the outcome, does (resp. does not) experience the outcome in response to treatment. They represent the outcome switch depending on the position at baseline<sup>10</sup>. It is possible to propose an equivalent of Lemma 12.

**Lemma 14** (Expression of the causal measures). *Ensuring conditions of Lemma 13 leads to,*

$$\begin{aligned}\tau_{RD} &= \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)], & \tau_{NNT} &= \frac{1}{\mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]} \\ \tau_{RR} &= 1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]}, & \tau_{SR} &= 1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]}, \\ \tau_{OR} &= \frac{\mathbb{E}[b(X)] + \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)] - \mathbb{E}[(1 - b(X)) m_b(X)] + \mathbb{E}[b(X) m_g(X)]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]}.\end{aligned}$$

Proof is detailed in appendix 5.C.4.4. At first sight Lemma 14 appears to be very complex. Still, this allows to recover some intuitions. For example, if the treatment is always beneficial ( $m_b(x) = 0$ ), and assuming that  $m_g(x)$  is lower bounded by a positive constant (i.e there is always a positive effect, even if small), then

$$\tau_{NNT} = \frac{1}{-\mathbb{E}[b(X) m_g(X)]}, \quad \text{such that, } \lim_{\mathbb{E}[b(X)] \rightarrow 0} |\tau_{NNT}| = \infty.$$

Recall that in the illustrative example of Table 5.1, the Number Needed to Treat is way higher on the population with a low baseline. If the population is at low risk, the effect of a beneficial treatment is indeed perceived as very small<sup>11</sup> because individuals have already no reason to suffer from the outcome. Lemma 14 can be simplified under some situations, in particular when only monotonous effects are involved.

### 4.2.3 Notion of monotonous effect

We introduce the assumption of monotonous effects, where either  $\forall x, m_b(x) = 0$  or  $\forall x, m_g(x) = 0$  (Huitfeldt et al., 2018; Cinelli and Pearl, 2020). Such situations corresponds to situation where the treatment is only beneficial or deleterious<sup>12</sup>, but cannot be both. If the treatment is always beneficial (i.e.  $\forall x, m_b(x) = 0$ ) then the probability  $p_1(x)$  is lower than the baseline. Respectively, if the treatment is always deleterious (i.e.  $\forall x, m_g(x) = 0$ ) then the probability  $p_1(x)$  is higher than the baseline. This can be summarized in,

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + \underbrace{a(1 - b(x)) m_b(x)}_{\nearrow} - \underbrace{a b(x) m_g(x)}_{\searrow},$$

where arrows indicate whether each term of the equation is increasing or decreasing the probability of occurrences. This equation highlights that the entanglement is not the same depending on the nature of the treatment (deleterious or not). A beneficial effect ( $m_b(x) = 0$ ) is more visible on a high baseline population ( $b(x)$  close to 1). On the opposite, a deleterious effect ( $m_g(x) = 0$ ) is visible only on the population with low baseline ( $1 - b(x)$  close to 1). In other words, an effect increasing the probability of occurrences acts only on individuals on which occurrences has not already happened yet.

<sup>10</sup>Such parameters can be found to be close to the “*counterfactual outcome state transition*” (COST) in Huitfeldt et al. (2018). For example  $m_b$  would correspond to the quantity denoted  $1 - H$ . Also note that the intrication model also allows to apprehend what has been done by Cinelli and Pearl (2020), where the quantity they introduce being  $PS_{01} := \mathbb{P}[Y^{(1)} = 1 \mid Y^{(0)} = 0]$  corresponds to  $m_b$ . While their work mostly rely on the formalism of selection diagram, they define  $PS_{01}$  (and therefore  $m_b$ ) as the probability of fatal treatment among those who would survive had they not been assigned to for treatment. And conversely,  $PS_{10} := \mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1]$  (corresponding to  $m_g$ ) stands for the probability that the treatment is sufficient to save a person who would die if defined. As far as we understand, in both of these works these probabilities are not taken conditionally to  $X$ .

<sup>11</sup>We recall that a high NNT corresponds to a small effect.

<sup>12</sup>In particular, the Russian Roulette corresponds to a situation where  $\forall x, m_g(x) = 0$  (Russian Roulette makes no good).



**Lemma 15** (Risk Ratio and Survival Ratio under a monotonous effect). *Ensuring conditions of Lemma 13,*

- Assuming that the treatment is beneficial (i.e.  $\forall x, m_b(x) = 0$ ), then

$$\tau_{RR} = 1 - \frac{\mathbb{E}[b(X)m_g(X)]}{\mathbb{E}[b(X)]}.$$

- Assuming that the treatment is harmful (i.e.  $\forall x, m_g(x) = 0$ ), then

$$\tau_{SR} = 1 - \frac{\mathbb{E}[(1 - b(X))m_b(X)]}{\mathbb{E}[1 - b(X)]}.$$

Lemma 15 is still disappointing as it does not allow to disentangle baseline risk and treatment effect ( $m_b(\cdot)$  or  $m_g(\cdot)$ ) such as for the continuous outcome situation. Still, looking at local effect  $x$ , for example on the Risk Ratio scale, one has

$$\tau_{RR}(x) = 1 - \frac{b(x)m_g(x)}{b(x)} = 1 - m_g(x).$$

Therefore, if willing to compute subgroup effects on covariates  $X$  affecting only the baseline level  $b(\cdot)$ , one would observe a constant effect. This explains the illustrative example from Table 5.1, where the Risk Ratio is constant over strata with varying baseline (here diastolic blood pressure).

These results formalize what has been proposed several times in the literature, for example by Sheps (1958), and later by Huitfeldt et al. (2018, 2021), or with what has been called the *Generalised Relative Risk Reduction* (Baker and Jackson, 2018). In particular, Sheps finishes her paper with the following quote

“ A beneficial or harmful effect may be estimated from the proportions of persons affected. The absolute measure does not provide a measure of this sort. The choice of an appropriate measure resolves itself largely into the choice of an appropriate base or denominator for a relative comparisons. [...] the appropriate denominator consists of the number of persons who could have been affected by the factor in question”.

This recommendation is consistent with Lemma 15. In other words, direction of the effect dictates on which labels the relative comparison should be made to obtain a treatment effect measure as less as possible entangled by the baseline. If the effect is harmful, this will be the SR (like the Russian Roulette). If the effect is beneficial, this is the RR. The comment of Sheps about absolute measure holds for binary outcome, but we showed that RD has good properties when considering a continuous outcome. Doing so, we justified and extended the scope of her conclusions. In other words, depending on the direction of the effect (harmful or beneficial) it is possible to define an equivalent of the Risk Difference for the continuous outcome, but in the world of binary outcome. Such definitions also enable a meaningful interpretation of what constitutes a homogeneous treatment effect when dealing with binary outcomes..

#### 4.2.4 What about non-monotonous effect?

While the situation of monotonous effect can lead to simpler expression of RR or SR, the situation remains complex when it comes to treatment being both beneficial and harmful (such as the seat belt example, and depending on the individuals). In fact, in such a situation  $m_b(X)$  and  $m_g(X)$  are not identifiable (Pearl, 2000; Huitfeldt et al., 2018). As a consequence, the interesting model to consider would be

$$\mathbb{P}\left[Y^{(a)} = 1 \mid X = x\right] = b(x) + a\tau(x), \quad \text{where } \tau(x) := (1 - b(x))m_b(x) - b(x)m_g(x).$$

This expression is close to the generative model for a continuous outcomes (Lemma 11). Still,  $\tau(x)$  now contains covariates linked to both baseline level and the treatment effect modulators. In such a situation, all measures now depend on the baseline level, and it is no longer possible to find a measure that decomposes baseline from the effect.

### 4.2.5 Why not a logistic model?

A common practice is to adopt a logistic regression model (or any model encapsulating a function taking values in  $\mathbb{R}$ ), for example a logistic model such as:

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 | X)}{\mathbb{P}(Y^{(a)} = 0 | X)} \right) = \beta_0 + \langle \boldsymbol{\beta}, \mathbf{X} \rangle + Am. \quad (5.7)$$

where  $\beta_0$ ,  $\boldsymbol{\beta}$  and  $m$  are the coefficients of a linear model. When the generative model from Equation 5.7 holds, some nice properties arise. Notably, one can show that this implies constant conditional odds ratio  $\tau_{\text{log-OR}}(x) = m$  and  $\tau_{\text{OR}}(x) = e^m$ . Beyond eq. 5.7 it is possible to encapsulate non-parametric functions in the logit. Such decomposition is present in the literature (Gao and Hastie, 2021) (and see Section 5.D, and in particular Lemma 17 for details). But interpretation of all other metrics than the conditional odds ratio is clearly not obvious (see Lemma 18 in Section 5.D) In other words, it seems that such logistic models are rather forcing all covariates and treatment to interact through the link function, preventing any simple interpretation of the causal measure (except conditional OR). This is even more problematic as the odds ratio is a non logic-respecting measure. Finally, the logistic model is a very restrictive model, unable to describe accurately many real-life situation; for instance the Russian Roulette – thought being simple – cannot take simple or intuitive expressions in the logistic model approach:

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 | X = x)}{\mathbb{P}(Y^{(a)} = 0 | X = x)} \right) = \ln \left( \frac{b(x)}{1 - b(x)} \right) + A \ln \left( \frac{(\frac{1}{6} + b(x))}{1 - (\frac{1}{6} + b(x))(1 - b(x))} \cdot \frac{1 - b(x)}{b(x)} \right),$$

is the equivalent to Equation 5.6. More details are provided in Appendix 5.D.3.

## 5 Are some measures easier to generalize than others?

Section 3 exposes two transportability assumptions depending on which conditional quantity from the source population is generalized: the conditional outcome (Assumption 31) or the local effect (Assumption 32). The first approach assuming having observed all covariates being prognostic and shifted in the two populations, while the second approach only requires to adjust on all covariates modulating treatment effect and shifted. By disentangling the baseline level and the treatment effect, Section 4 paves the way toward establishing which transportability assumption is more likely to hold, depending on the outcome nature and the causal measure considered. Recall that Assumption 32 means

$$\forall x \in \text{supp}(P_T) \cap \text{supp}(P_S), \quad \tau^R(x) = \tau^T(x).$$

If the outcome is continuous, Lemma 12 ensures  $\tau_{\text{RD}}(x) = m(x)$ . Therefore, if considering a continuous outcome, Assumption 32 is satisfied as soon as we adjust on the shifted covariates implied in  $m(\cdot)$  (regardless of the covariates implied in the baseline level  $b(\cdot)$ ).

To formalize which covariates are implied in local treatment effect, we introduce notations to distinguish covariates status, either intervening on the baseline level or modulating the effect.

**Definition 40** (Two kind of covariates). *Recall that  $b : \mathcal{X} \rightarrow \mathbb{R}$  and  $m : \mathcal{X} \rightarrow \mathbb{R}$  are defined in Lemma 11 for a continuous outcome or in Lemma 13 (here,  $m$  referring for  $m_b$  and  $m_g$ ). For all  $J \subset \{1, \dots, d\}$ , we let  $X_J$  the subvector of  $X$  composed of components of  $X$  indexed by  $J$ . Accordingly, we let  $X_B$  (resp.  $X_M$ ) the minimal set of variables involved in the function  $b$  (resp. the function  $m$ ), such that, for all  $x \in \mathbb{R}$ ,*

$$\mathbb{E}[b(X) | X = x] = \mathbb{E}[b(X) | X_B = x_B] \quad \text{and} \quad \mathbb{E}[m(X) | X = x] = \mathbb{E}[m(X) | X_M = x_M].$$

Then, within the set of baseline covariate  $X$ , some covariates may be shifted between the two populations or not.

**Definition 41** (Shifted covariates set). We let  $Sh \subset \{1, \dots, d\}$  the set of indices corresponding to the components of  $X$  that are shifted between the source and the target population, that is, for all integrable function  $f : \mathcal{X} \rightarrow \mathbb{R}$ , almost surely,

$$\mathbb{E}^S[f(X)|X_{Sh}] = \mathbb{E}^T[f(X)|X_{Sh}]$$

Generalizing conditional outcomes requires to have access to all shifted prognostic covariates.

**Theorem 13.** Under the assumptions of Lemma 11 or 13, for any causal measure, generalization of the conditional outcomes is possible if one has access to all shifted covariates of  $X_{BUM}$ , provided such a set satisfies the overlap assumption (Assumption 30).

To illustrate what are the different covariate sets, we introduce the data generative model of the simulations (see Section 6), where we assume that six covariates are prognostic and that data are generated as

$$Y = b(X_1, X_2, X_3, X_4, X_5, X_6) + A m(X_1, X_2, X_5) + \varepsilon. \quad (5.8)$$

Doing so,  $B = (1, 2, 3, 4, 5, 6)$ , and  $M = (1, 2, 5)$ . In addition, the two populations are constructed such that  $X_1, \dots, X_4$  are shifted covariates, but not  $X_5, X_6$ . Figure 5.4 illustrates what shifted and non-shifted means. Theorem 13 states that generalization of the conditional outcomes is possible when observing  $X_1, \dots, X_4$ .

Having access to all shifted prognostic covariates in the two data samples seems challenging (and maybe too optimistic). This situation could explain all the numerous recent research works about sensitivity analysis when necessary covariates are not observed or partially observed when generalizing (Nguyen et al., 2018; Nie et al., 2021; Colnet et al., 2022a). In such a context, Assumption 32 is appealing as it potentially reduces the needed covariates. In fact, not all measures can be easier to generalize than others.




Figure 5.4:  $2 \in \text{Shift}$ , and  $6 \notin \text{Shift}$ .

**Theorem 14.** Consider a continuous outcome  $Y$ . Under the assumptions of Lemma 11, observing all shifted covariates of  $X_M$  is sufficient for generalizing  $\tau_{RD}$ , provided such a set of covariates satisfies the overlap assumption (Assumption 30).

Theorem 14 reveals that Assumption 32 is expected to be more likely to hold for the Risk Difference only. Back to eq. 5.8, one would require only  $X_1$  and  $X_2$  to generalize the Risk Difference. Willing to generalize Risk Ratio or Excess Risk Ratio would still require  $X_1, X_2, X_3, X_4$  for identification, no matter the approach (generalizing conditional outcomes or local effects).

**Theorem 15.** Consider a binary outcome  $Y$ . Under Assumptions of Lemma 13, if the effect is beneficial (resp. harmful), having access to all covariates  $X_{M \cap Sh}$  that are shifted and treatment effect modifiers and to the distribution  $\mathbb{E}^T[Y^{(0)} | X_{M \cap Sh}]$  in the target population is sufficient for generalizing  $\tau_{RR}$  (resp.  $\tau_{SR}$ ), provided such a set of covariates satisfies the overlap assumption (Assumption 30).

In the simulations (Section 6) we enrich the example of the Russian Roulette assuming that the effect of the Russian Roulette itself is modulated by baseline covariates. We adapt the generative model of eq. 5.6 into

$$\mathbb{P}[Y^{(a)} = 1 | X = x] = b(X_1, X_2, X_3) + a(1 - b(X_1, X_2, X_3)) m_b(X_2, X_3), \quad (5.9)$$


where  $X_1 = \text{lifestyle}$ ,  $X_2 = \text{stress}$ , and  $X_3 = \text{gender}$ , a situation where individuals' baseline risk of death depends on their lifestyle, stress, and gender. We assume that the effect of the Russian Roulette can be modulated by stress (imagine individuals having a heart attack as soon as the gun is approaching their head) and gender (the executioner being more merciful when facing a women). We further assume that **gender** is the only covariate with no shift between the two populations. Therefore Theorem 15 tells us that the Survival Ratio can be generalized to another target population having

at hand only **stress**, without adjusting on **lifestyle** and **gender**. Willing to generalize all other measures (no matter the method) would require **lifestyle** and **stress**.

Finally, note that if some measures are easier to generalize (i.e. needs less baseline covariates to adjust on), then a by-product of this result is that they should be less sensitive to a population's shift. Spiegelman and VanderWeele (2017) does mention that empirically the Risk Ratio seems to be more constant accross populations. The illustrative example (Table 5.1) in introduction perfectly illustrates this phenomenon too.

## 6 Illustration through simulations

We use synthetic simulations to illustrate Theorems 13, 14, and 15: that is different covariates sets are required to retrieve the target population effect depending on (i) the causal measure of interest, (ii) the nature of the outcome, and (iii) the method to generalize. Appendix 5.H.1 gives comments on how to transform identification formula (see Propositions 5 and 6) into estimation. The code to reproduce the simulations is available on [github](#) (see repository [BenedicteColnet/ratio-versus-difference](#)).



**Figure 5.5: Results of the simulations for a continuous outcomes:** where generative corresponds to eq. 5.8. Column 1 corresponds to generalizing conditional outcome, column 2 corresponds to generalizing local effect with the proper collapsibility weights. For these two approaches we use different covariates set, with **shifted treatment effect modulators** ( $X_1, X_2$ ), **shifted prognostic covariates** ( $X_1, X_2, X_3$ , and  $X_4$ ), and all **prognostic covariates** ( $X_1, X_2, X_3, X_4, X_4$  and  $X_6$ ). According to Theorems 13 and 14, only the Risk Difference can be generalized with a restricted covariates set. Simulations are performed with 1000 repetitions, a source sample size of 500 and target sample size of 1,000. Estimation is performed with plug-in g-formula modeling all responses with an OLS approach.


### 6.1 Continuous outcome

We propose a situation where the continuous outcome is generated from six baseline prognostic covariates  $X_1, \dots, X_6$  as detailed in eq. 5.8. More precisely,  $B = (1, 2, 3, 4, 5, 6)$ , and  $M = (1, 2, 5)$ , while only

covariates  $X_1, X_2, X_3, X_4$  are shifted between  $P_S$  and  $P_T$ . Both  $b(\cdot)$  and  $m(\cdot)$  are linear functions of the covariates. We adopt a plug-in g-formula estimation approach. Figure 5.5 presents results. As the outcome  $Y$  is continuous, and according to Theorem 14, we expect that only the Risk Difference  $\tau_{RD}$  can be generalized using the shifted treatment effect modulators, namely  $X_1$  and  $X_2$ . For this, both procedures (generalizing the conditional outcomes or the local effects) are equivalent due to the linearity of the expectation (the second row of Figure 5.5 is identical across procedures). We indeed observe that only the RD can be recovered with the smaller covariates set composed of shifted treatment effect modulators. All other causal measures require access to all shifted covariates of  $X_{BUM}$ . Note that adding only shifted covariates seems to increase variance, while adding all prognostic covariates lead to more precision, in accordance with what is proposed in Colnet et al. (2022b) for the risk difference.

## 6.2 Binary outcome

For the binary outcome, we extend the Russian Roulette situation, introducing effects' heterogeneity. See eq. 5.9 for the generative model chosen with three prognostic covariates: **lifestyle**, **gender**, and **stress**. We assume that the source population  $P_S$  contains the same proportion of men and women as in the target population  $P_T$ , but that the two other covariates (**lifestyle** and **stress**) are shifted. In particular, we suppose that  $P_S$  is composed of more people with a good lifestyle but are very stressed, while in  $P_T$  individuals have a poor lifestyle but a low stress. We therefore expect the effect of the Russian Roulette to be higher in the source population than in the target population due to both different baseline level and heterogeneity of treatment effect.



**Figure 5.6: Simulation with binary outcome  $Y$ :** for a monotonous and deleterious effect. Therefore conditions of Lemma 15 are satisfied, allowing to generalize the Survival Ratio with fewer covariates, and in particular only **shifted treatment effect modulators**, here stress. Adding all **shifted prognostic covariates** (stress and lifestyle), or even more with all **prognostic covariates** (stress, lifestyle, and gender) enables generalization of all causal measures by generalization of the conditional outcome or re-weighting of local effect if possible (only for collapsible measures, namely RR, SR, and RD). On this simulation, estimation is done with IPSW estimator, source (resp. target) sample being of size  $n = 5\,000$  (resp.  $m = 20\,000$ ), with 1 000 repetitions.

Doing so, Theorem 15 states that the Survival Ratio is identifiable having at hand only the covariate **stress** when generalizing local effects, while all other causal measures require to have access to

all shifted prognostic covariates (**stress** and **lifestyle**). Simulations indeed confirm the model and results are exposed on Figure 5.6, where the true effect is recovered with a smaller subset of covariates only for the SR. Adding all shifted prognostic covariates allows to recover all effect measures, in particular generalizing conditional outcomes. Generalizing local effects work only for collapsible measure, information on  $Y^{(0)}$  and with the appropriate weights (see RR, SR, and RD).

## 7 Conclusion

The choice of a population-level measure of treatment effect has been much debated. We bring a new argument: a well-chosen measure is easier to generalize to a population different from that of the initial study or to sub-populations, crucial to make decisions based on this measure. Indeed, as the probability of different outcomes often varies across individuals, the average treatment effect typically depends on the population considered. A *collapsible* measure –such as the risk difference, the risk ratio or the survival ratio but not the odds ratio– can be computed from local effects, on strata of the population. Reweighting these strata then adapts the measure to a new population. Stratification must be done along the individual’s characteristics that modulate the probability of outcomes: treatment-effect modifying covariates. But less stratification is needed for a good choice of population-level measure, one that is not affected by covariates that modulated only the baseline risk, common to treated and non-treated individuals. We showed that if the outcome is continuous, then the Risk Difference only depends on the expectation of the modification, while the Risk Ratio or Excess Risk Ratio highly depends on the baseline (Lemma 12 and Theorem 14). But if the outcome is binary, relative measures such as the Risk Ratio or the Survival Ratio can remove the baseline level (Lemma 15 and Theorem 15). The Risk Ratio is the appropriate measure when the effect is beneficial (i.e. reduces events), while the Survival Ratio has better properties when the effect is harmful (i.e. increases events). If the treatment is beneficial and harmful at the same time, none of the measures can remove the baseline level. Likewise, in the absence of the control outcome in the target population, any measure of treatment effect can be generalized through the conditional outcome, which however typically requires more covariates (Theorem 13).

So, which is the best measure to summarize a causal effect across a population but facilitate reasoning at the individual level? It depends. For continuous outcomes, the Risk Difference is not modulated by a varying baseline risk. For binary outcomes, prefer a Risk Ratio for beneficial effects and a Survival Ratio for harmful ones.



## Appendix of Chapter 5

### 5.A Treatment effect measures

This section completes Section 2 (and more specially Section 2.2) by exposing the different treatment (or causal) effect measures.

#### 5.A.1 A formal definition of a treatment or causal effect measure

In this section we recall the definition of all measures used in this paper or that can be found in applied medical work. As all of these measures correspond to a combination of the two potential outcomes expectations, such that the concept of causal effect measures could be written in a general way. This is not exposed in the main article, but a causal measure can be defined in a general way.

**Definition 42** (Causal effect measures – Pearl (2000)). *Assuming a certain joint distribution of potential outcomes  $P(Y^{(0)}, Y^{(1)})$ , which implies that a certain treatment  $A$  of interest is considered, we denote  $\tau^P$  any functional of the joint distribution of potential outcomes. More precisely,*

$$\mathcal{P} \rightarrow \mathbb{R} \quad (5.10)$$

$$P(Y^{(0)}, Y^{(1)}) \mapsto \tau^P \quad (5.11)$$

This definition is also valid for any subpopulation, as for any baseline covariate  $X$ ,  $\tau^P(X)$  is defined as a functional of  $P(Y^{(0)}, Y^{(1)} | X)$ . Note that this definition could admit many more causal measures than the one presented in this work. Introducing a definition is meant for (i) generality of the definition and (ii) to highlight what kind of mathematical object is a causal measure. For instance, this definition highlights the fact that a so-called treatment or causal effect naturally depends on *the population considered*. The notation  $\tau^P$  highlights this dependency. For lighter notation, and when there is no doubt on the population of interest, we will also denote this quantity without the superscript  $\tau$ .

*Why do we say that those measures are causal?* Note that the same definition could have been made on the distribution  $P(A, Y)$ , comparing expectation on two distributions:  $P(Y | A = 1)$  and  $P(Y | A = 0)$ . For example, within the statistical community, the odds ratio is often known as the strength of the association between two events,  $A = 1$  and  $A = 0$  and therefore defined as:

$$OR := \frac{P(Y = 1 | A = 1)}{P(Y = 0 | A = 1)} \cdot \frac{P(Y = 0 | A = 0)}{P(Y = 1 | A = 0)}.$$

In such a situation, the OR measure would be an associational measure and not a causal measure, except if there is no confounding in the distribution considered (for e.g. in the case of a Randomized Controlled Trial). To avoid discussion about confounding, in this paper we never consider distribution such as  $Y | A, X$  or  $Y | A$ . We rather consider  $Y^{(a)} | X$ . For any new reader discovering the potential outcomes framework, we refer to the first chapters of Imbens and Rubin (2015) for a clear and complete exposition of this notations inherited from Neyman. Note that Didelez and Stensrud (2022) make the same distinction when discussing collapsibility questions.


#### 5.A.2 Common treatment effect measures

As highlighted by Definition 42, many measures could be proposed. Here we detail common measures found in applied works and propose an illustration for the case of binary outcomes (Figure 5.7). Most of the time, the distinction is made on whether or not the measure is an absolute or a relative effect.

##### 5.A.2.1 Absolute measures


**Definition 43** (Risk Difference (RD)). *The risk difference is a causal effect measure defined as the difference of the expectations (also called risks),*

$$\tau_{RD} = \mathbb{E} \left[ Y^{(1)} \right] - \mathbb{E} \left[ Y^{(0)} \right].$$



**Figure 5.7:** Plots<sup>a</sup> of the ranges of the different metrics as a function of the proportion of events in control group, namely  $\mathbb{E}[Y^{(0)}]$  (x-axis), and of the proportion of events in treated group, namely  $\mathbb{E}[Y^{(1)}]$  (y-axis). See Subfigure 5.8a. As both the colors and the different scale illustrate, the ranges of the effect considerably differ with the metric chosen. Note that for the NNT (Figure 5.7b) we only represented the quarter of the plot when an event encodes death.

<sup>a</sup>Similar plots can be found under the name "L'Abbé plots" (L'abbé et al., 1987; Jiménez et al., 1997; Deeks, 2002) in research works related to meta-analysis. In this domain those plots help representing estimates from different studies.





RD is also named Absolute Risk Reduction (ARR), Absolute Effect (AE), Absolute Difference (AD), or Excess Risk (ER).

**Definition 44** (Number Needed to Treat (NNT)). *The number needed to treat (NNT) is a causal effect measure defined as the average number of individuals or observations who need to be treated to prevent one additional outcome,*

$$\tau_{NNT} = \frac{1}{\mathbb{E}[Y^{(1)} = 1] - \mathbb{E}[Y^{(0)} = 1]}$$

The Number Needed to Treat (NNT) has been proposed as a measure rather recently (Laupacis et al., 1988). A harmful treatment is usually called the Number Needed to Harm (NNH) and made positive.

### 5.A.2.2 Relative measures

**Definition 45** (Risk Ratio). *The risk ratio is a causal effect measure defined as the ratio of the expectations,*

$$\tau_{RR} = \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]}$$

The Risk Ratio (RR) is also named Relative Risk (RR), Relative Response (RR), or Incidence Proportion Ratio (IPR)

**Definition 46** (Survival Ratio). *The survival ratio is a causal effect measure defined as the Risk Ratio were labels are swapped,*

$$\tau_{SR} = \frac{1 - \mathbb{E}[Y^{(1)}]}{1 - \mathbb{E}[Y^{(0)}]}$$

It is possible to introduce a measure that captures both the Risk Difference, but normalized by the baseline.

**Definition 47** (Excess relative risk (ERR)).

$$\tau_{ERR} = \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{\mathbb{E}[Y^{(0)}]}$$

The Excess relative risk (ERR) has been proposed by Cole and MacMahon (1971). Note that,

$$\tau_{ERR} = \tau_{RR} - 1.$$

**Definition 48** (Relative Susceptibility (RS)).

$$\tau_{RS} := \frac{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]}{1 - \mathbb{E}[Y^{(0)}]}.$$

Note that,

$$\tau_{RS} = 1 - \tau_{SR}.$$

Finally, another measure is often used based on odds. Odds are a way of representing probability in particular for betting. For example a throw with a die will produce a one with odds 1:5. The odds is the ratio of the probability that the event occurs to the probability it does not.

**Definition 49** (Odds Ratio (OR)). *The odds ratio is a causal effect measure defined as the ratio of the odds of the treated and control groups,*

$$\tau_{OR} := \frac{\mathbb{P}[Y^{(1)} = 1]}{1 - \mathbb{P}[Y^{(1)} = 1]} \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{1 - \mathbb{P}[Y^{(0)} = 1]} \right)^{-1}.$$

Odds Ratio (OR) is sometimes named Marginal Causal Odds Ratio (MCOR). This is by opposition to a conditional Odds Ratio, being defined as,

$$\tau_{\text{OR}}(X) := \frac{\mathbb{E}[Y^{(1)} = 1 \mid X = x]}{1 - \mathbb{E}[Y^{(1)} = 1 \mid X = x]} \left( \frac{\mathbb{E}[Y^{(0)} = 1 \mid X = x]}{1 - \mathbb{E}[Y^{(0)} = 1 \mid X = x]} \right)^{-1},$$

often used due to its homogeneity when considering a logistic generative model of the outcome (see Section 5.C.1.3 for a detailed proof). The OR is known to approximate the RR at low baseline (see for example the illustrative example of Table 5.1).

*Proof.*  $\mathbb{P}[Y^{(1)} = 1] \leq \mathbb{P}[Y^{(0)} = 1] \ll 1 \implies \tau_{\text{OR}} = \frac{\mathbb{P}[Y^{(1)}=1]}{1-\mathbb{P}[Y^{(1)}=1]} \cdot \frac{1-\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=1]} \approx \frac{\mathbb{P}[Y^{(1)}=1]}{1} \cdot \frac{1}{\mathbb{P}[Y^{(0)}=1]} = \tau_{\text{RR}}$ . □

These derivations can be found as late as in the 50's in case-control studies about lung cancer (Cornfield et al., 1951). Also note that,

$$\tau_{\text{OR}} = \tau_{\text{RR}} \cdot \tau_{\text{SR}}^{-1}.$$

*Proof.*

$$\begin{aligned} \tau_{\text{OR}} &= \frac{\mathbb{P}[Y^{(1)} = 1]}{1 - \mathbb{P}[Y^{(1)} = 1]} \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{1 - \mathbb{P}[Y^{(0)} = 1]} \right)^{-1} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)^{-1} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \frac{\mathbb{P}[Y^{(0)} = 0]}{\mathbb{P}[Y^{(0)} = 1]} \\ &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(0)} = 1]} \frac{\mathbb{P}[Y^{(0)} = 0]}{\mathbb{P}[Y^{(1)} = 0]} \\ &= \tau_{\text{RR}} \cdot \tau_{\text{SR}}^{-1} \end{aligned}$$

□

One can observe on Figure 5.7 (see subplots Figures 5.7e and 5.7f) the range on which the OR varies depends on the direction of the effect. Therefore, the OR is often presented encapsulated in a logarithm.

**Definition 50** (Log Odds Ratio (log-OR)).

$$\tau_{\text{log-OR}} := \log \left( \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \right) - \log \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)$$

## 5.B Definitions found in the literature

This section completes Section 3 (and in particular Sections 3.1 and 3.2) with formalization of homogeneity of effects, heterogeneity of effects, and collapsibility we have found in the literature. Doing so, we highlight that definitions can be more or less formal, and therefore can lead to different apprehension of phenomenons, in particular collapsibility. The Definitions we propose in Section 3 aims to account for the intuitions behind all previously proposed definitions, while uniformizing them.

### 5.B.1 Effect modification

*This section supports definitions proposed in Section 3.1.*

Note that effect modification or heterogeneity is mentioned in many places, but now always clearly defined.

We searched the National Library of Medicine Books, National Library of Medicine Catalog, Current Index to Statistics database, ISI web of science, and websites of 25 major regulatory agencies and organizations for papers and guidelines on study design, analysis and interpretation of treatment effect heterogeneity. Because there is not standard terminology for this topic, a structured search strategy was not sensitive nor specific and we found many resources through “snowball” searching, that is, reviewing citations in, and citations of, key methodological and policy papers. – (Lesko et al., 2018)


### 5.B.1.1 Definitions found in the literature

**Definition 51** (Rothman (2011), page 51). *Suppose we divide our cohort into two or more distinct categories, or strata. In each stratum, we can construct an effect measure of our choosing. These stratum-specific effect measures may or may not equal on another. Rarely would we have any reason to suppose that they do equal one another. If indeed they are not equal, we say that the effect measure is heterogeneous or modified across strata. If they are equal we say that the measure is homogeneous, constant, or uniform across strata. A major point about effect-measure modification is that, if effects are present, it will usually be the case that only one or none of the effect measures will be uniform across strata.*

**Definition 52** (VanderWeele and Robins (2007)). *We say that a variable  $Q$  is a treatment effect modifier for the causal risk difference of  $A$  on  $Y$  if  $Q$  is not affected by  $A$  and if there exist two levels of  $A$ ,  $a_0$  and  $a_1$ , such that  $\mathbb{E}[Y^{(a_1)} | Q = q] - \mathbb{E}[Y^{(a_0)} | Q = q]$  is not constant in  $q$ .*

### 5.B.1.2 Effect heterogeneity depends on the chosen scale: an illustration

A treatment effect heterogeneity depends on the causal measure  $\tau$  chosen (the scale). This idea is well-known in epidemiology (Rothman, 2011; Lesko et al., 2018). To be convinced by such phenomenon, the drawing in Figure 5.9 illustrates what could be two data generative models leading to two different homogeneity and heterogeneity patterns.



**Figure 5.9: Heterogeneity of a treatment effect depends on the scale:** Illustrative schematics where the data generative model on the left leads to a constant treatment effect on the absolute scale (RD) when conditioning on  $X$ , while on the data generative model on the right leads to an homogeneous treatment effect on the relative scale (RR). In both of the situations, homogeneity of treatment effect of one scale (RR or RD) leads to heterogeneity on the other scale. Note that a similar schematic is presented in Rothman (2011) (see their Figure 11–1, p. 199)

## 5.B.2 Different definitions of collapsibility in the literature

*This section supports definitions proposed in Section 3.2.*

### 5.B.2.1 Unformal definitions

We have found many unformal definitions in the literature, such as:

In a single study with a non-confounding stratification variable, if the stratum-specific effects are homogenous, then they are expected to be the same as the crude effect, a desirable property known as collapsibility of an effect measure. – (Xiao et al., 2022)

RR but, not OR, have a mathematical property called collapsibility; this means the size of the risk ratio will not change if adjustment is made for a variable that is not a confounder. – (Cummings, 2009)

and

Collapsibility means that in the absence of confounding, a weighted average of stratum-specific ratios (e.g., using Mantel-Haenszel methods) will equal the ratio from a single 2 by 2 table of the pooled (collapsed) counts from the stratum-specific tables. This means that a crude (unadjusted) ratio will not change if we adjust for a variable that is not a confounder. – (Cummings, 2009)

### 5.B.2.2 Formal definitions

**Definition 53** (Strict collapsibility Greenland et al. (1999)). *We say a measure of association between  $Y^{(0)}$  and  $Y^{(1)}$  is strictly collapsible across  $X$  if it is constant across the strata (subtables) and this constant value equals the value obtained from the marginal table.*

Similar definition as Definition 53 have been proposed in Liu et al. (2022); Didelez and Stensrud (2022).

**Definition 54** (Pearl (2000)). *Let  $\tau(P(Y^{(0)}, Y^{(1)}))$  be any functional that measures the association between  $Y^{(0)}$  and  $Y^{(1)}$  in the joint distribution  $P(Y^{(0)}, Y^{(1)})$ . We say that  $\tau$  is collapsible on a variable  $V$  if*

$$\mathbb{E} \left[ \tau \left( P \left( Y^{(0)}, Y^{(1)} \mid V \right) \right) \right] = \tau \left( P \left( Y^{(0)}, Y^{(1)} \right) \right)$$

Note that in his book, Judea Pearl rather present the definition of collapsibility with respect two any two covariates, not necessarily potential outcomes. Indeed, collapsibility is a statistical concept at first. As in this work we are explicitly concerned with causal metrics, this definition has been written here with potential outcomes.

**Definition 55** (Huitfeldt et al. (2019)). *Let  $\tau(P(Y^{(0)}, Y^{(1)}))$  be any function of the parameters  $Y^{(0)}$  and  $Y^{(1)}$  in the joint distribution  $P(Y^{(0)}, Y^{(1)})$ . We say that  $\tau$  is collapsible on a variable  $V$  with weights  $w_v$  if,*

$$\frac{\sum_v w_v \tau \left( P \left( Y^{(0)}, Y^{(1)} \mid V = v \right) \right)}{\sum_v w_v} = \tau \left( P \left( Y^{(0)}, Y^{(1)} \right) \right)$$

**Definition 56** (Didelez and Stensrud (2022)). *Let  $\tau = \tau(P(Y^{(0)}, Y^{(1)}))$  be a measure of association between  $Y^{(0)}$  and  $Y^{(1)}$ ; that is,  $\tau$  is a functional of the joint distribution  $P(Y^{(0)}, Y^{(1)})$ . Let  $\tau_x = \tau(Y, A \mid X = x)$  be a measure of conditional association between  $Y$  and  $A$  given  $X = x$ ; that is,  $\tau_x$  is a functional of the conditional distribution  $P(Y, A \mid X = x)$ . The measure  $\tau$  is called collapsible over  $X$ , if  $\tau$  is a weighted average of  $\tau_x$  for  $x \in \mathbb{X}$ . Strict collapsibility demands that  $\tau = \tau_x$ .*

## 5.C Proofs

In this section we detail all the derivations needed to understand the results of this article.

### 5.C.1 Collapsibility

*Note that not all proofs are novel work. Collapsibility results have been reported multiple times as explained in the main paper. For clarity we still recall them. We indicate when the proofs are not novel or when similar proofs exist elsewhere. When we indicate nothing, this means that we have not found those results in other published work.*

### 5.C.1.1 Proof of Lemma 7

*N.B:* The proof for the direct collapsibility of the RD is not a novel contribution.

*Proof.*

$$\begin{aligned}
 \tau_{\text{RD}} &= \mathbb{E} \left[ Y^{(1)} - Y^{(0)} \right] && \text{By definition} \\
 &= \mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} - Y^{(0)} \mid X \right] \right] && \text{Law of total expectation} \\
 &= \mathbb{E} \left[ \tau_{\text{RD}}(X) \right].
 \end{aligned}$$

□

**Remark** To observe the phenomenon as weighting, one can also write this last quantity as an integral.

$$\begin{aligned}
 \mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} - Y^{(0)} \mid X \right] \right] &= \int_{\mathbf{X}} \mathbb{E} \left[ Y^{(1)} - Y^{(0)} \mid X \right] f(x) dx && \text{Re-writing} \\
 &= \int_{\mathbf{X}} \tau_{\text{RD}}(x) f(x) dx.
 \end{aligned}$$

Here, one can observe that weights are the density of  $x$  in the population. Most of the time (Pearl and Bareinboim, 2011a; Huitfeldt et al., 2018; Didelez and Stensrud, 2022) express such quantity on categorical covariates  $X$ , therefore using a sum.

### 5.C.1.2 Proof of Lemma 8

*N.B:* The proof for the collapsibility of the RR and SR are extensions of Huitfeldt et al. (2019).

**General comment** In this subsection we detail the proof for collapsibility of the RR, and SR. Before detailing the proof, we want to highlight why the RR (and SR) is not directly collapsible.

$$\begin{aligned}
 \tau_{\text{RR}} &= \frac{\mathbb{E} \left[ Y^{(1)} \right]}{\mathbb{E} \left[ Y^{(0)} \right]} \\
 &= \frac{\mathbb{E} \left[ \mathbb{E} \left[ Y^{(1)} \mid X \right] \right]}{\mathbb{E} \left[ \mathbb{E} \left[ Y^{(0)} \mid X \right] \right]} \\
 &\neq \mathbb{E} \left[ \frac{\mathbb{E} \left[ Y^{(1)} \mid X \right]}{\mathbb{E} \left[ Y^{(0)} \mid X \right]} \right],
 \end{aligned}$$

in all generality. For example, assuming that  $\mathbb{E} \left[ Y^{(0)} \mid X \right]$  and  $\mathbb{E} \left[ Y^{(1)} \mid X \right]$  are independent, we have

$$\mathbb{E} \left[ \frac{\mathbb{E} \left[ Y^{(1)} \mid X \right]}{\mathbb{E} \left[ Y^{(0)} \mid X \right]} \right] = \mathbb{E} \left[ Y^{(1)} \right] \mathbb{E} \left[ \frac{1}{\mathbb{E} \left[ Y^{(0)} \mid X \right]} \right] > \frac{\mathbb{E} \left[ Y^{(1)} \right]}{\mathbb{E} \left[ Y^{(0)} \right]} = \tau_{\text{RR}},$$

by Jensen inequality, assuming additionally that  $\mathbb{E} \left[ Y^{(0)} \mid X \right] > 0$ .

## Risk Ratio (RR)

*Proof.*

$$\begin{aligned}
 \tau_{\text{RR}} &= \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]} && \text{By definition of the RR} \\
 &= \frac{\mathbb{E}[\mathbb{E}[Y^{(1)} | X]]}{\mathbb{E}[Y^{(0)}]} && \text{Law of total expectation used on } \mathbb{E}[Y^{(1)}] \\
 &= \frac{\mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)}|X]}{\mathbb{E}[Y^{(0)}|X]} \mathbb{E}[Y^{(0)} | X]\right]}{\mathbb{E}[Y^{(0)}]} && \mathbb{E}[Y^{(0)} | X] \neq 0 \text{ almost surely} \\
 &= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} | X] \mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)} | X] \mathbb{E}[Y^{(0)}]}\right] && \mathbb{E}[Y^{(0)}] \text{ is a constant} \\
 &= \mathbb{E}\left[\tau_{\text{RR}}(X) \frac{\mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]}\right]. && \frac{\mathbb{E}[Y^{(1)} | X]}{\mathbb{E}[Y^{(0)} | X]} := \tau_{\text{RR}}(X)
 \end{aligned}$$

□

### Survival Ratio (SR)

*Proof.*

$$\begin{aligned}
 \tau_{\text{SR}} &= \frac{1 - \mathbb{E}[Y^{(1)}]}{1 - \mathbb{E}[Y^{(0)}]} && \text{By definition of the SR} \\
 &= \frac{1 - \mathbb{E}[\mathbb{E}[Y^{(1)} | X]]}{1 - \mathbb{E}[Y^{(0)}]} && \text{Law of total expectation} \\
 &= \frac{\mathbb{E}\left[\frac{1 - \mathbb{E}[Y^{(1)}|X]}{1 - \mathbb{E}[Y^{(0)}|X]} (1 - \mathbb{E}[Y^{(0)} | X])\right]}{1 - \mathbb{E}[Y^{(0)}]} && 1 - \mathbb{E}[Y^{(0)} | X] \neq 0 \text{ almost surely} \\
 &= \mathbb{E}\left[\tau_{\text{SR}}(X) \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right] && 1 - \mathbb{E}[Y^{(0)}] \text{ is a constant}
 \end{aligned}$$

□

The Excess Risk Ratio (ERR) (resp. Risk Susceptibility) collapsibility are proven using the same derivations than RR (resp. SR).

### Excess Risk Ratio (ERR)

*Proof.*

$$\begin{aligned}
 \tau_{\text{ERR}} &= \frac{\mathbb{E}[Y^{(1)} - Y^{(0)}]}{\mathbb{E}[Y^{(0)}]} \\
 &= \frac{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} | X]]}{\mathbb{E}[Y^{(0)}]} \\
 &= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]}\right] \\
 &= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X] \mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}] \mathbb{E}[Y^{(0)} | X]}\right] \\
 &= \mathbb{E}\left[\tau_{\text{ERR}}(X) \frac{\mathbb{E}[Y^{(0)} | X]}{\mathbb{E}[Y^{(0)}]}\right]
 \end{aligned}$$

□

**Risk Susceptibility (RS)***Proof.*

$$\begin{aligned}
\tau_{\text{RS}} &= \frac{\mathbb{E}[Y^{(1)} - Y^{(0)}]}{1 - \mathbb{E}[Y^{(0)}]} \\
&= \frac{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} | X]]}{1 - \mathbb{E}[Y^{(0)}]} \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right] \\
&= \mathbb{E}\left[\frac{\mathbb{E}[Y^{(1)} - Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]} \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)} | X]}\right] \\
&= \mathbb{E}\left[\tau_{\text{RS}}(X) \frac{1 - \mathbb{E}[Y^{(0)} | X]}{1 - \mathbb{E}[Y^{(0)}]}\right]
\end{aligned}$$

□

**5.C.1.3 Proof of Lemma 9: Non-collapsibility of the OR, log-OR, and NNT**

**Odds Ratio (OR).** According to the first point of Lemma 10, all collapsible measure are logic-respecting. However, according to the third point of Lemma 10, OR is not logic-respecting. Therefore OR is not collapsible.

**Log Odds Ratio (log-OR).** The same reasoning as above holds for the log Odds Ratio.

**Number Needed to Treat (NNT).**

*Proof.* Recall that

$$\tau_{\text{NNT}} = \frac{1}{\mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]} \quad \text{and} \quad \tau_{\text{NNT}}(X) = \frac{1}{\mathbb{E}[Y^{(1)}|X] - \mathbb{E}[Y^{(0)}|X]}. \quad (5.12)$$

Assume that the NNT causal measure is collapsible, that is there exist weights  $g(X, P(X, Y^{(0)}))$  such that for all distributions  $P(X, Y^{(0)}, Y^{(1)})$  we have

$$\mathbb{E}\left[g(X, P(X, Y^{(0)})) \tau_{\text{NNT}}(X)\right] = \tau_{\text{NNT}}, \quad \text{with } g \geq 0, \text{ and } \mathbb{E}\left[g(X, P(X, Y^{(0)}))\right] = 1. \quad (5.13)$$

Note that

$$\tau_{\text{NNT}} = \frac{1}{\mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}(X)}\right]}, \quad (5.14)$$

which, combined with the previous equation, leads to

$$\mathbb{E}\left[g(X, P(X, Y^{(0)})) \tau_{\text{NNT}}(X)\right] = \frac{1}{\mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}(X)}\right]}. \quad (5.15)$$

Assuming that  $\tau_{\text{NNT}}(X) \geq 0$ , by Jensen inequality, we have

$$\mathbb{E}\left[g(X, P(X, Y^{(0)})) \tau_{\text{NNT}}(X)\right] \leq \mathbb{E}[\tau_{\text{NNT}}(X)] \quad (5.16)$$

$$\mathbb{E}\left[\left(g(X, P(X, Y^{(0)})) - 1\right) \tau_{\text{NNT}}(X)\right] \leq 0. \quad (5.17)$$

Fix  $\varepsilon > 0$ . Assume now that there exists a measurable set  $B \subset \mathcal{X}$  with positive measure, such that for all  $x \in B$ ,  $g(X, P(X, Y^{(0)})) > 1 + \varepsilon$ . By choosing the distribution of  $Y^{(1)}$  such that

$\mathbb{E}[Y^{(1)}|X]$  is arbitrary close to  $\mathbb{E}[Y^{(0)}|X]$  on  $B$ , one has that  $\tau_{\text{NNT}}(X)$  is arbitrary large, so that  $(g(X, P(X, Y^{(0)})) - 1) \tau_{\text{NNT}}(X)$  is arbitrary large on  $B$ , which contradicts eq. 5.17. This proves that  $g(X, P(X, Y^{(0)})) \leq 1$  almost surely. Since  $\mathbb{E}[g(X, P(X, Y^{(0)}))] = 1$ , this implies that almost surely  $g(X, P(X, Y^{(0)})) = 1$ . Thus, one should have

$$\mathbb{E}[\tau_{\text{NNT}}(X)] = \frac{1}{\mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}(X)}\right]}, \quad (5.18)$$

which, according to Jensen inequality, holds only if  $\tau_{\text{NNT}}(X)$  is constant. Thus the Number Needed to Treat satisfies the collapsibility equation eq. 5.13 only in the specific case of homogeneous treatment effect. This proves that the NNT is not collapsible.  $\square$

## 5.C.2 Proof of Lemma 10 (about logic-respecting measures)

### 5.C.2.1 All collapsible measures are logic respecting

*Proof.* We recall from Definition 38 that a measure  $\tau$  is said to be collapsible (directly or not), if there exist positive weights  $g(Y^{(0)}, X)$  verifying  $\mathbb{E}[g(Y^{(0)}, X)] = 1$ , such that

$$\tau = \mathbb{E}\left[g(Y^{(0)}, X)\tau(X)\right].$$

Then,

$$\begin{aligned} \tau &\leq \mathbb{E}\left[g(Y^{(0)}, X) \max_x(\tau(X))\right] \\ \tau &\leq \mathbb{E}\left[g(Y^{(0)}, X)\right] \max_x(\tau(x)) \\ \tau &\leq \max_x(\tau(x)) \end{aligned}$$

using the properties of the weights. Similarly, one can show that,

$$\mathbb{E}\left[g(Y^{(0)}, X) \min_x(\tau(x))\right] \leq \tau.$$

This proves that  $\tau$  is logic-respecting, according to Definition 39.  $\square$

### 5.C.2.2 Number Needed to Treat is a logic-respecting measure

*Proof.* First, note that,

$$\begin{aligned} \tau_{\text{NNT}} &= \frac{1}{\mathbb{E}[Y^{(1)} - Y^{(0)}]} \\ &= \frac{1}{\mathbb{E}[\mathbb{E}[Y^{(1)} - Y^{(0)} | X]]} && \text{Law of total expectation} \\ &= \mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}(X)}\right]^{-1}. && \tau_{\text{NNT}}(X) := 1/\mathbb{E}[Y^{(1)} - Y^{(0)} | X] \end{aligned}$$

By definition,  $\min_x(\tau_{\text{NNT}}(x)) \leq \tau_{\text{NNT}}(X)$  almost surely, such that taking the inverse and the expectation leads to

$$\mathbb{E}\left[\frac{1}{\tau_{\text{NNT}}(X)}\right] \leq \mathbb{E}\left[\frac{1}{\min_x(\tau_{\text{NNT}}(x))}\right] = \frac{1}{\min_x(\tau_{\text{NNT}}(x))},$$

which implies

$$\min_x(\tau_{\text{NNT}}(x)) \leq \tau_{\text{NNT}}.$$



The exact same reasoning leads to

$$\tau_{\text{NNT}} \leq \max_x (\tau_{\text{NNT}}(x)).$$

Consequently,

$$\min_x (\tau_{\text{NNT}}(x)) \leq \tau_{\text{NNT}} \leq \max_x (\tau_{\text{NNT}}(x)),$$

which concludes the proof.  $\square$

### 5.C.2.3 OR and log-OR are not logic-respecting

Proving that the OR is not logic-respecting can be done with a counter-example as in Table 5.2. Previous works propose to understand non-collapsibility through the non-linearity of a function linking the baseline (control) and response functions. This link function is named the *characteristic collapsibility function* (CCF) and have been proposed by [Neuhaus S and Jewell \(1993\)](#) and is nicely recalled in [Daniel et al. \(2020\)](#) (see their Appendix 1A). This proof relies on Jensen inequality. The proof we recall here is largely inspired from these works, but written within the formalism of our paper.

*Proof.* Assume a generative model such as

$$\text{logit} \left( \mathbb{P}(Y^{(a)} = 1 \mid X, A = a) \right) = b(X) + a m, \quad (5.19)$$

where  $b(X)$  can be any function of the vector  $X$  to  $\mathbb{R}$ , and where  $m$  is a non-null constant. Without loss of generality, one can further assume that  $m > 0$ . Under such model, one has a property on the conditional log-OR or OR, being that:

$$\tau_{\text{log-OR}}(X) = \log \left( \frac{\mathbb{P}(Y^{(1)} = 1 \mid X)}{1 - \mathbb{P}(Y^{(1)} = 1 \mid X)} \cdot \left( \frac{\mathbb{P}(Y^{(0)} = 1 \mid X)}{1 - \mathbb{P}(Y^{(0)} = 1 \mid X)} \right)^{-1} \right) = b(X) + m - b(X) = m, \quad (5.20)$$

or similarly that

$$\tau_{\text{OR}}(X) = e^{b(X)+m} \cdot e^{-b(X)} = e^m.$$

In other words, for any  $x$  the OR  $\tau_{\text{OR}}(x)$  (resp. log-OR) is the same and equal to  $e^m$  (resp.  $m$ ).

Now, we propose to go from this conditional causal measure to the marginal measure. When looking for the marginal OR, one can first estimate  $\mathbb{P}(Y^{(1)} = 1)$  and  $\mathbb{P}(Y^{(0)} = 1)$ , and then compute the OR. To do so, we propose to rewrite  $\mathbb{P}(Y^{(1)} = 1 \mid X)$  as a function of  $\mathbb{P}(Y^{(0)} = 1 \mid X)$ . From eq. 5.19 one has,

$$\text{logit} \left( \mathbb{P}(Y^{(0)} = 1 \mid X) \right) = b(X),$$

so that

$$\text{logit} \left( \mathbb{P}(Y^{(1)} = 1 \mid X) \right) = \text{logit} \left( \mathbb{P}(Y^{(0)} = 1 \mid X) \right) + m, \quad (5.21)$$

which is equivalent to


$$\mathbb{P}(Y^{(1)} = 1 \mid X) = \text{expit} \left( \text{logit} \left( \mathbb{P}(Y^{(0)} = 1 \mid X) \right) + m \right). \quad (5.22)$$

Letting, for all  $z \in [0, 1]$ ,

$$f(z) = \text{expit} (\text{logit} (z) + m), \quad (5.23)$$

we have

$$\mathbb{P}(Y^{(1)} = 1 \mid X) = f \left( \mathbb{P}(Y^{(0)} = 1 \mid X) \right). \quad (5.24)$$



**Figure 5.10:** Implementation of the formulae from eq. 5.24 for different values of  $m$ . This illustrates the concavity of the function linking  $\mathbb{P}(Y^{(0)} = 1 | X)$  to  $\mathbb{P}(Y^{(1)} = 1 | X)$  when assuming the generative model of eq. 5.19.

Note that the function  $f$  is concave for positive  $m$  (it is possible to derive it, but we propose an illustration on Figure 5.10 to help to be convinced). Then, using Jensen inequality, we obtain,

$$\begin{aligned}
 \mathbb{P}(Y^{(1)} = 1) &= \mathbb{E} \left[ \mathbb{P}(Y^{(1)} = 1 | X) \right] \\
 &= \mathbb{E} \left[ f \left( \mathbb{P}(Y^{(0)} = 1 | X) \right) \right] \\
 &< f \left( \mathbb{E} \left[ \mathbb{P}(Y^{(0)} = 1 | X) \right] \right) \\
 &= \text{expit} \left( \text{logit} \left( \mathbb{E} \left[ \mathbb{P}(Y^{(0)} = 1 | X) \right] \right) + m \right) && \text{Jensen and } m > 0 \\
 &= \text{expit} \left( \text{logit} \left( \mathbb{P}(Y^{(0)} = 1) \right) + m \right),
 \end{aligned}$$

and because the logit is a monotonous function, then,

$$\text{logit} \left( \mathbb{P}(Y^{(1)} = 1) \right) < \text{logit} \left( \mathbb{P}(Y^{(0)} = 1) \right) + m,$$

so that

$$\text{logit} \left( \mathbb{P}(Y^{(1)} = 1) \right) - \text{logit} \left( \mathbb{P}(Y^{(0)} = 1) \right) = \tau_{\log\text{-OR}} < m,$$

where  $m = \tau_{\log\text{-OR}}(x)$  (see eq. 5.20). This allows to conclude that there exist a data generative process for which the odds ratio at the population level can not be written as a positively weighted sum of conditional odds ratio.

Note that the example provided in Table 5.2 is for a negative  $m$ , showing constant effect on the two substrata and a higher effect on the marginal population.  $\square$

### 5.C.3 Proofs related to generalizability

#### 5.C.3.1 Proof of Proposition 5

*Proof.* Consider  $a \in \{0, 1\}$ , then

$$\begin{aligned}
 \mathbb{E}_T \left[ Y^{(a)} \right] &= \mathbb{E}_T \left[ \mathbb{E}_T \left[ Y^{(a)} | X = x \right] \right] && \text{Total expectation} \\
 &= \mathbb{E}_T \left[ \mathbb{E}_S \left[ Y^{(a)} | X = x \right] \right] && \text{G-formula identification – Assumptions 31} \\
 &= \mathbb{E}_R \left[ \frac{p_T(X)}{p_S(X)} \mathbb{E}_S \left[ Y^{(a)} | X = x \right] \right] && \text{Identification by re-weighting – Assumptions 30}
 \end{aligned}$$

$\square$

### 5.C.3.2 Proof of Proposition 6

*Proof.* If  $\tau$  is collapsible, then there exists weights  $g_T(Y^{(0)}, X)$  (defined on  $P_T$ ) such that

$$\begin{aligned} \tau^T &= \mathbb{E}_T \left[ g_T(Y^{(0)}, X) \tau^T(X) \right] && \text{Collapsibility} \\ &= \mathbb{E}_T \left[ g_T(Y^{(0)}, X) \tau^R(X) \right] && \text{G-formula identification – Assumption 32} \\ &= \mathbb{E}_R \left[ \frac{p_T(X)}{p_R(X)} g_T(Y^{(0)}, X) \tau^R(X) \right] && \text{Identification by re-weighting – Assumption 30.} \end{aligned}$$

□

### 5.C.4 Proofs related to non-parametric generative models (Section 4)

*As we have not found elsewhere the approach of writing non-parametric models and to relate them to measures of effect, to the best of our knowledge, all proofs in this subsection are novel.*

#### 5.C.4.1 Proof of Lemma 11 (continuous outcomes)

*Proof.* By assumption, we know that  $\mathbb{E}[|Y^{(1)}| | X] < \infty$ . Therefore, one can write

$$Y^{(0)} = f(0, X) + \varepsilon_0,$$

where  $f(0, X) = \mathbb{E}[Y^{(0)} | X]$  and  $\mathbb{E}[\varepsilon_0 | X] = 0$  almost surely. In the exact same way, we have

$$Y^{(1)} = f(1, X) + \varepsilon_1,$$

where  $f(1, X) = \mathbb{E}[Y^{(1)} | X]$  and  $\mathbb{E}[\varepsilon_1 | X] = 0$  almost surely. Note that the two previous equations are equivalent to

$$Y^{(A)} = \underbrace{f(0, X)}_{:=b(X)} + A \underbrace{(f(1, X) - f(0, X))}_{:=m(X)} + \underbrace{A\varepsilon_1 + (1 - A)\varepsilon_0}_{:=\varepsilon_A}.$$

Note that

$$\begin{aligned} \mathbb{E}[\varepsilon_A | X] &= \mathbb{E}[A\varepsilon_1 + (1 - A)\varepsilon_0 | X] \\ &= \mathbb{E}[A\mathbb{E}[\varepsilon_1 | A, X] | X] + \mathbb{E}[(1 - A)\mathbb{E}[\varepsilon_0 | A, X] | X] \\ &= \mathbb{E}[A\mathbb{E}[\varepsilon_1 | X] | X] + \mathbb{E}[(1 - A)\mathbb{E}[\varepsilon_0 | X] | X] \\ &= \mathbb{E}[A | X] \mathbb{E}[\varepsilon_1 | X] + \mathbb{E}[(1 - A) | X] \mathbb{E}[\varepsilon_0 | X] \\ &= 0, \end{aligned}$$

and

$$\begin{aligned} \mathbb{E}[\varepsilon_A | X, A] &= \mathbb{E}[A\varepsilon_1 + (1 - A)\varepsilon_0 | X, A] \\ &= A\mathbb{E}[\varepsilon_1 | A, X] + (1 - A)\mathbb{E}[\varepsilon_0 | A, X] \\ &= 0. \end{aligned}$$

Consequently, we have

$$Y^{(A)} = b(X) + A m(X) + \varepsilon_A,$$

with  $\mathbb{E}[\varepsilon_A | X, A] = 0$  almost surely and

$$\begin{aligned} b(X) &= \mathbb{E}[Y^{(0)} | X], \\ m(X) &= \mathbb{E}[Y^{(1)} | X] - \mathbb{E}[Y^{(0)} | X] = \mathbb{E}[Y^{(1)} - Y^{(0)} | X]. \end{aligned}$$

□

### 5.C.4.2 Proof of Lemma 12

*Proof.* Assume that  $Y$  is a continuous outcome. Under the conditions of Lemma 11, we have

$$Y^{(a)} = b(X) + a m(X) + \varepsilon_a,$$

where  $b(X) := \mathbb{E}[Y^{(0)} | X]$ ,  $m(X) := \mathbb{E}[Y^{(1)} - Y^{(0)} | X]$  and a noise  $\varepsilon_A$  satisfying  $\mathbb{E}[\varepsilon_A | X] = 0$  almost surely. With these relations in mind, one can compute each of the causal measures.

#### Risk Difference

$$\begin{aligned} \tau_{\text{RD}} &= \mathbb{E}[Y^{(1)} - Y^{(0)}] && \text{By definition} \\ &= \mathbb{E}[b(X) + m(X) + \varepsilon_1 - b(X) - \varepsilon_0] \\ &= \mathbb{E}[m(X)] + \mathbb{E}[\varepsilon_1] - \mathbb{E}[\varepsilon_0] \\ &= \mathbb{E}[m(X)] && \mathbb{E}[\varepsilon_a] = 0 \end{aligned}$$

#### Risk Ratio

$$\begin{aligned} \tau_{\text{RR}} &= \frac{\mathbb{E}[Y^{(1)}]}{\mathbb{E}[Y^{(0)}]} && \text{By definition} \\ &= 1 + \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}. \end{aligned}$$

#### Excess Risk Ratio

$$\tau_{\text{ERR}} = \frac{\mathbb{E}[m(X)]}{\mathbb{E}[b(X)]}.$$

□

### 5.C.4.3 Proof of Lemma 13 (binary outcomes)

*Proof.* Consider a binary outcome  $Y$ . We further assume that,

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) := \mathbb{P}[Y^{(a)} = 1 | X = x],$$

which means that the outcome is non-deterministic. Using the law of total expectation, one has

$$\begin{aligned} p_1(x) &= \mathbb{P}[Y^{(1)} = 1 | X = x] \\ &= \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 0, X = x] \mathbb{P}[Y^{(0)} = 0 | X = x] \\ &\quad + \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 1, X = x] \mathbb{P}[Y^{(0)} = 1 | X = x] \\ &= \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 0, X = x] (1 - p_0(x)) + \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 1, X = x] p_0(x). \end{aligned}$$

Denoting  $m_g(x) := \mathbb{P}[Y^{(1)} = 0 | Y^{(0)} = 1, X = x]$  and  $m_b(x) := \mathbb{P}[Y^{(1)} = 1 | Y^{(0)} = 0, X = x]$ , we finally obtain

$$\begin{aligned} p_1(x) &= m_b(x)(1 - p_0(x)) + (1 - m_g(x))p_0(x) \\ &= p_0(x) + m_b(x)(1 - p_0(x)) - p_0(x)m_g(x). \end{aligned}$$

Therefore, for all  $a \in \{0, 1\}$ ,

$$p_a(x) = p_0(x) + a(m_b(x)(1 - p_0(x)) - p_0(x)m_g(x)).$$

□

### 5.C.4.4 Proof of Lemma 14

*Proof.* Consider a binary outcome  $Y$ . Under the assumptions of Lemma 13, there exist probabilities  $b(x)$ ,  $m_g(x)$ , and  $m_b(x)$  such that

$$\mathbb{P}\left[Y^{(a)} = 1 \mid X = x\right] = b(x) + a \left( (1 - b(x)) m_b(x) - b(x) m_g(x) \right).$$

Using such a decomposition, one has

$$\begin{aligned} \tau_{\text{RD}} &= \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))] - \mathbb{E}[b(X)] \\ &= \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)], \\ \tau_{\text{NNT}} &= \frac{1}{\mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}, \\ \tau_{\text{RR}} &= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{\mathbb{E}[b(X)]} \\ &= 1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]}, \\ \tau_{\text{SR}} &= \frac{1 - \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{1 - \mathbb{E}[b(X)]} \\ &= \frac{\mathbb{E}[1 - b(X) - ((1 - b(X)) m_b(X) + b(X) m_g(X))]}{\mathbb{E}[1 - b(X)]} \\ &= 1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]}, \\ \tau_{\text{OR}} &= \frac{\mathbb{P}[Y^{(1)} = 1]}{\mathbb{P}[Y^{(1)} = 0]} \left( \frac{\mathbb{P}[Y^{(0)} = 1]}{\mathbb{P}[Y^{(0)} = 0]} \right)^{-1} \\ &= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{1 - \mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]} \left( \frac{\mathbb{E}[b(X)]}{1 - \mathbb{E}[b(X)]} \right)^{-1} \\ &= \frac{\mathbb{E}[b(X) + ((1 - b(X)) m_b(X) - b(X) m_g(X))]}{\mathbb{E}[1 - b(X) - ((1 - b(X)) m_b(X) + b(X) m_g(X))]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]} \\ &= \frac{\mathbb{E}[b(X)] + \mathbb{E}[(1 - b(X)) m_b(X)] - \mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)] - \mathbb{E}[(1 - b(X)) m_b(X)] + \mathbb{E}[b(X) m_g(X)]} \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[b(X)]} \\ &= \left( 1 + \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[b(X)]} - \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[b(X)]} \right) \left( 1 - \frac{\mathbb{E}[(1 - b(X)) m_b(X)]}{\mathbb{E}[1 - b(X)]} + \frac{\mathbb{E}[b(X) m_g(X)]}{\mathbb{E}[1 - b(X)]} \right)^{-1}. \end{aligned}$$

□

### 5.C.5 Proofs of Section 5

#### 5.C.5.1 Proof of Theorem 13

*Proof. Continuous outcome.* Consider a continuous outcome  $Y$ . Under assumptions of Lemma 11,

$$Y^{(a)} = b(X) + a m(X) + \varepsilon_a,$$

where  $b(X) := \mathbb{E}[Y^{(0)} \mid X]$ ,  $m(X) := \mathbb{E}[Y^{(1)} - Y^{(0)} \mid X]$  and  $\varepsilon_A$  satisfies  $\mathbb{E}[\varepsilon_A \mid X] = 0$ .

Let  $a \in \{0, 1\}$ ,

$$\begin{aligned} \mathbb{E}_{\text{T}}[Y^{(a)}] &= \mathbb{E}_{\text{T}}[Y^{(a)}] \\ &= \mathbb{E}_{\text{T}}[b(X) + a m(X) + \varepsilon_a] && \text{Lemma 11} \\ &= \mathbb{E}_{\text{T}}[b(X)] + a \mathbb{E}_{\text{T}}[m(X)]. \end{aligned}$$

Generalizing conditional outcomes to the target population means that we can compute  $\mathbb{E}_T[Y^{(a)}]$  for  $a \in \{0, 1\}$ , which is equivalent to computing

$$\mathbb{E}_T[b(X)], \quad \text{and} \quad \mathbb{E}_T[m(X)], \quad (5.25)$$

that is generalizing  $b(X)$  and  $m(X)$ . According to Definitions 40 and 41, we have

$$\mathbb{E}_T[b(X)] = \mathbb{E}_T[\mathbb{E}_T[b(X) \mid X_{\text{Sh}}]] \quad (5.26)$$

$$= \mathbb{E}_T[\mathbb{E}_S[b(X) \mid X_{\text{Sh}}]] \quad (5.27)$$

$$= \mathbb{E}_T[\mathbb{E}_S[b(X) \mid X_{B \cap \text{Sh}}]], \quad (5.28)$$

and similarly,

$$\mathbb{E}_T[m(X)] = \mathbb{E}_T[\mathbb{E}^T[m(X) \mid X_{\text{Sh}}]] \quad (5.29)$$

$$= \mathbb{E}_T[\mathbb{E}_S[m(X) \mid X_{\text{Sh}}]] \quad (5.30)$$

$$= \mathbb{E}_T[\mathbb{E}_S[m(X) \mid X_{M \cap \text{Sh}}]]. \quad (5.31)$$

Having access to  $X_{(M \cup B) \cap \text{Sh}}$  that is all shifted covariates that are treatment effect modifiers or related to the baseline risk is then sufficient to generalize  $b$  and  $m$  and thus to generalize  $\mathbb{E}_T[Y^{(a)}]$  for all  $a \in \{0, 1\}$ .

**Binary outcome.** Consider a binary outcome  $Y \in \{0, 1\}$ , and let

$$m_g(x) := \mathbb{P}[Y^{(1)} = 0 \mid Y^{(0)} = 1, X = x] \quad \text{and} \quad m_b(x) := \mathbb{P}[Y^{(1)} = 1 \mid Y^{(0)} = 0, X = x].$$

Under Assumptions of Lemma 13, we have, for all  $a \in \{0, 1\}$ ,

$$\mathbb{P}[Y^{(a)} = 1 \mid X = x] = b(x) + a m(x),$$

with  $b(x) = p_0(x)$  and

$$m(x) = (1 - b(x)) m_b(x) - b(x) m_g(x).$$

For all  $a \in \{0, 1\}$ , we have, as above,

$$\begin{aligned} \mathbb{E}_T[Y^{(a)}] &= \mathbb{E}_T[\mathbb{P}[Y^{(a)} = 1 \mid X]] \\ &= \mathbb{E}_T[b(X) + a m(X),] \\ &= \mathbb{E}_T[b(X)] + a \mathbb{E}_T[m(X),]. \end{aligned}$$

Having access to  $X_{(M \cup B) \cap \text{Sh}}$  that is all shifted covariates that are treatment effect modifiers or related to the baseline risk is then sufficient to generalize  $b$  and  $m$  and thus to generalize  $\mathbb{E}_T[Y^{(a)}]$  for all  $a \in \{0, 1\}$ . □

### 5.C.5.2 Proof of Theorem 14

*Proof.* In this proof  $Y$  is assumed continuous. We consider a set of baseline shifted covariates  $X_M$  defined in Definitions 40 and 41.

**Risk Difference** We start by proving that Assumption 32 is satisfied for  $\tau_{\text{RD}}(X_{M \cap \text{Sh}})$ . We have

$$\begin{aligned} \tau_{\text{RD}}^T(X_{M \cap \text{Sh}}) &= \mathbb{E}_T[Y^{(1)} - Y^{(0)} \mid X_{M \cap \text{Sh}}] \\ &= \mathbb{E}_T[m(X) \mid X_{M \cap \text{Sh}}] && \text{Lemma 11} \\ &= \mathbb{E}_T[m(X) \mid X_{\text{Sh}}] && \text{Definition 40} \\ &= \mathbb{E}_S[m(X) \mid X_{\text{Sh}}] && \text{Definition 41} \\ &= \mathbb{E}_S[m(X) \mid X_{M \cap \text{Sh}}] && \text{Definition 40} \\ &= \tau_{\text{RD}}^S(X_{M \cap \text{Sh}}). \end{aligned}$$

Thus, Assumption 32 is verified for  $\tau_{\text{RD}}$  with covariates  $X_{M \cap \text{Sh}}$ . Furthermore, by assumption in Theorem 14, Assumption 30 is verified with covariates  $X_{M \cap \text{Sh}}$ . Thus, by Proposition 6,  $\tau_{\text{RD}}$  is generalizable with covariates  $X_{M \cap \text{Sh}}$ .

Below, we give insights explaining why the risk ratio does not satisfy a similar property. Indeed, in the same manner as above, the risk ratio satisfies

$$\begin{aligned} \tau_{\text{RR}}^{\text{S}}(X_{M \cap \text{Sh}}) &= \frac{\mathbb{E}_{\text{S}} [Y^{(1)} \mid X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{S}} [Y^{(0)} \mid X_{M \cap \text{Sh}}]} \\ &= \frac{\mathbb{E}_{\text{S}} [b(X) + m(X) \mid X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{S}} [b(X) \mid X_{M \cap \text{Sh}}]} && \text{Lemma 11} \\ &= 1 + \frac{\mathbb{E}_{\text{T}} [m(X) \mid X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{S}} [b(X) \mid X_{M \cap \text{Sh}}]}. && \text{Definitions 41} \end{aligned}$$

For Assumption 30 to hold, we need  $\tau_{\text{RR}}^{\text{S}}(X_{M \cap \text{Sh}}) = \tau_{\text{RR}}^{\text{T}}(X_{M \cap \text{Sh}})$ , which, given the previous calculation, is equivalent to

$$\mathbb{E}_{\text{S}} [b(X) \mid X_{M \cap \text{Sh}}] = \mathbb{E}_{\text{T}} [b(X) \mid X_{M \cap \text{Sh}}],$$

which has no reason to be valid in general, since in all generality,  $X_{M \cap \text{Sh}} \not\subseteq X_{B \cap \text{Sh}}$ . A similar reasoning holds for the Excess Risk Ratio (ERR), as it is defined as a function of  $\tau_{\text{RR}}$ .  $\square$

### 5.C.5.3 Proof of Theorem 15

*Proof.* Recall that we consider a binary output  $Y \in \{0, 1\}$ . Recall that, by Lemma 13, we have, for all  $a \in \{0, 1\}$ ,

$$\mathbb{P} [Y^{(a)} = 1 \mid X = x] = b(x) + a ((1 - b(x)) m_b(x) - b(x) m_g(x)),$$

with  $b(x) = p_0(x)$ . The proof of Lemma 13 can be adapted for any subset of covariates of  $X$ , so that

$$\mathbb{E} [Y^{(a)} \mid X_{M \cap \text{Sh}}] = b(X_{M \cap \text{Sh}}) + a ((1 - b(X_{M \cap \text{Sh}})) m_b(X_{M \cap \text{Sh}}) - b(X_{M \cap \text{Sh}}) m_g(X_{M \cap \text{Sh}})),$$

with

$$\begin{aligned} b(X_{M \cap \text{Sh}}) &= \mathbb{P} [Y^{(0)} = 1 \mid X_{M \cap \text{Sh}}] \\ m_g(X_{M \cap \text{Sh}}) &= \mathbb{P} [Y^{(1)} = 0 \mid Y^{(0)} = 1, X_{M \cap \text{Sh}}] \\ m_b(X_{M \cap \text{Sh}}) &= \mathbb{P} [Y^{(1)} = 1 \mid Y^{(0)} = 0, X_{M \cap \text{Sh}}]. \end{aligned}$$

**First case.** Assume that, for all  $x$ ,  $m_b(x) = 0$ . According to the calculation above, we have

$$\tau_{\text{RR}}^{\text{S}}(X_{M \cap \text{Sh}}) = \frac{\mathbb{E}_{\text{S}} [Y^{(1)} \mid X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{S}} [Y^{(0)} \mid X_{M \cap \text{Sh}}]} \tag{5.32}$$

$$= \frac{b(X_{M \cap \text{Sh}}) - b(X_{M \cap \text{Sh}}) m_g(X_{M \cap \text{Sh}})}{b(X_{M \cap \text{Sh}})} \tag{5.33} \quad \text{Lemma 13}$$

$$= 1 - m_g(X_{M \cap \text{Sh}}) \tag{5.34}$$

$$= 1 - \mathbb{P}_{\text{S}} [Y^{(1)} = 0 \mid Y^{(0)} = 1, X_{M \cap \text{Sh}}] \tag{5.35}$$

$$= 1 - \mathbb{P}_{\text{S}} [Y^{(1)} = 0 \mid Y^{(0)} = 1, X_{\text{Sh}}] \tag{5.36} \quad \text{Definition 40}$$

$$= 1 - \mathbb{P}_{\text{T}} [Y^{(1)} = 0 \mid Y^{(0)} = 1, X_{\text{Sh}}] \tag{5.37} \quad \text{Definition 41}$$

$$= 1 - \mathbb{P}_{\text{T}} [Y^{(1)} = 0 \mid Y^{(0)} = 1, X_{M \cap \text{Sh}}] \tag{5.38} \quad \text{Definition 40}$$

$$= \tau_{\text{RR}}^{\text{T}}(X_{M \cap \text{Sh}}). \tag{5.39}$$

Following the proof of Lemma 8, we have

$$\begin{aligned}
 \tau_{\text{RR}}^{\text{T}} &= \frac{\mathbb{E}_{\text{T}} [Y^{(1)}]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} && \text{By definition of the RR} \\
 &= \frac{\mathbb{E}_{\text{T}} [\mathbb{E}_{\text{T}} [Y^{(1)} | X_{M \cap \text{Sh}}]]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} && \text{Law of total expectation used on } \mathbb{E}_{\text{T}} [Y^{(1)}] \\
 &= \frac{\mathbb{E}_{\text{T}} \left[ \frac{\mathbb{E}_{\text{T}} [Y^{(1)} | X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]} \mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}] \right]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} && \mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}] \neq 0 \text{ almost surely} \\
 &= \mathbb{E}_{\text{T}} \left[ \tau_{\text{RR}}^{\text{T}}(X_{M \cap \text{Sh}}) \frac{\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} \right] \\
 &= \mathbb{E}_{\text{T}} \left[ \tau_{\text{RR}}^{\text{S}}(X_{M \cap \text{Sh}}) \frac{\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} \right] && \text{By eq. 5.39} \\
 &= \mathbb{E}_{\text{S}} \left[ \tau_{\text{RR}}^{\text{S}}(X_{M \cap \text{Sh}}) \frac{\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]}{\mathbb{E}_{\text{T}} [Y^{(0)}]} \frac{p_{\text{T}}(X_{M \cap \text{Sh}})}{p_{\text{S}}(X_{M \cap \text{Sh}})} \right] && \text{Since Assumption 30 holds}
 \end{aligned}$$

Thus,  $\tau_{\text{RR}}$  is generalizable with covariates  $X_{M \cap \text{Sh}}$  when  $m_b = 0$ , if one has access to  $\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]$ .

**Second case.** Assume that, for all  $x$ ,  $m_g(x) = 0$ . As above, we have

$$\begin{aligned}
 \tau_{\text{SR}}^{\text{S}}(X_{M \cap \text{Sh}}) &= \frac{1 - \mathbb{E}_{\text{S}} [Y^{(1)} | X_{M \cap \text{Sh}}]}{1 - \mathbb{E}_{\text{S}} [Y^{(0)} | X_{M \cap \text{Sh}}]} \\
 &= \frac{1 - b(X_{M \cap \text{Sh}}) - (1 - b(X_{M \cap \text{Sh}}))m_b(X_{M \cap \text{Sh}})}{1 - b(X_{M \cap \text{Sh}})} && \text{Lemma 13} \\
 &= 1 - m_b(X_{M \cap \text{Sh}}) \\
 &= 1 - \mathbb{P}_{\text{S}} [Y^{(1)} = 1 | Y^{(0)} = 0, X_{M \cap \text{Sh}}] \\
 &= 1 - \mathbb{P}_{\text{S}} [Y^{(1)} = 1 | Y^{(0)} = 0, X_{\text{Sh}}] && \text{Definition 40} \\
 &= 1 - \mathbb{P}_{\text{T}} [Y^{(1)} = 1 | Y^{(0)} = 0, X_{\text{Sh}}] && \text{Definition 41} \\
 &= 1 - \mathbb{P}_{\text{T}} [Y^{(1)} = 1 | Y^{(0)} = 0, X_{M \cap \text{Sh}}] && \text{Definition 40} \\
 &= \tau_{\text{RR}}^{\text{T}}(X_{M \cap \text{Sh}}).
 \end{aligned}$$

As above, one can use the arguments in the proof of Lemma 8 to show that

$$\tau_{\text{SR}}^{\text{T}} = \mathbb{E}_{\text{S}} \left[ \tau_{\text{SR}}^{\text{S}}(X_{M \cap \text{Sh}}) \frac{1 - \mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]}{1 - \mathbb{E}_{\text{T}} [Y^{(0)}]} \frac{p_{\text{T}}(X_{M \cap \text{Sh}})}{p_{\text{S}}(X_{M \cap \text{Sh}})} \right],$$

which proves that  $\tau_{\text{SR}}^{\text{T}}$  is generalizable with covariates  $X_{M \cap \text{Sh}}$  when  $m_g = 0$ , if one has access to  $\mathbb{E}_{\text{T}} [Y^{(0)} | X_{M \cap \text{Sh}}]$ . □

## 5.D Usual point of view for a binary outcome: logistic regression

### 5.D.1 A very general generative model

The general habit when considering binary outcome is to consider a logistic regression model (see in the main document the example of a typical log-linear model in Equation 5.40). While such log-linear model rely on parametric assumptions, one would wish to keep the logistic approach but with



no modeling assumption in the spirit of what is done for a continuous outcome  $Y$  (see Lemma 11). Positing very weak assumptions allows to write the response model with a “baseline” function and a “modification” function, encapsulated in a link function, usually a logit. Doing so, it is possible to model the outcome non-parametrically.

**Lemma 16** (Logit generative model for a binary outcome). *Considering a binary outcome  $Y$ , assume that*

$$\forall x \in \mathbb{X}, \forall a \in \{0, 1\}, \quad 0 < p_a(x) < 1, \quad \text{where } p_a(x) = \mathbb{P}(Y^{(a)} = 1 \mid X = x).$$

*Then, there exist two functions  $b, m : \mathcal{X} \rightarrow \mathbb{R}$  such that*

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = b(X) + a m(X).$$

Similarly than for the continuous outcomes, the assumption allowing the existence of such functions is very weak, only asking for the counterfactual probabilities to be distinct from 0 and 1. The notations have been chosen to reflect the previous idea of a *baseline*  $b(x)$  and the *modification*  $m(x)$  induced by the treatment  $A$ . Still, we point out that in this model,  $p_0(x) \neq b(x)$ , and that due to the link function,  $b(x)$  and  $m(x)$  can not be disentangled.

*Proof.* Consider  $a \in \{0, 1\}$ , and assume that there exists a function  $p_a : \mathbb{R}^d \rightarrow ]0, 1[$  such that,

$$\mathbb{P}(Y^{(a)} = 1 \mid X) = p_a(X).$$

Because  $p_a$  takes values in  $]0, 1[$  the odds can be considered, so that,

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = \ln \left( \frac{p_a(X)}{1 - p_a(X)} \right).$$

Denoting,

$$b(X) := \ln \left( \frac{p_0(X)}{1 - p_0(X)} \right),$$

and

$$m(X) := \ln \left( \frac{p_1(X)}{1 - p_1(X)} \right) - \ln \left( \frac{p_0(X)}{1 - p_0(X)} \right) = \ln \left( \frac{p_1(X)}{1 - p_1(X)} \frac{1 - p_0(X)}{p_0(X)} \right),$$

one can write the log-odds as

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = b(X) + A m(X).$$

Note that another link function could have been chosen, which impacts how  $b(x)$  and  $m(x)$  are defined.  $\square$

**Comment on the usual practice** In many papers it is possible to find this very common assumption

$$\ln \left( \frac{\mathbb{P}(Y^{(a)} = 1 \mid X)}{\mathbb{P}(Y^{(a)} = 0 \mid X)} \right) = \beta_0 + \langle \boldsymbol{\beta}, \mathbf{X} \rangle + A m, \quad (5.40)$$

which corresponds to a linear function  $b(X)$  and a constant function  $m(X)$  (Daniel et al., 2020). In particular, it is easy to derive from eq. 5.40 that for any  $X \in \mathbb{X}$ , one has  $\tau_{\log\text{-OR}}(x) = m$  and  $\tau_{\text{OR}}(x) = e^m$ . And more generally,

**Lemma 17** (Conditional log odds ratio). *Ensuring conditions of Lemma 16 leads to,*

$$\mathbb{E}[\tau_{\log\text{-OR}}(X)] := \mathbb{E} \left[ \ln \left( \frac{\mathbb{P}(Y^{(1)} = 1 \mid X)}{\mathbb{P}(Y^{(1)} = 0 \mid X)} \frac{\mathbb{P}(Y^{(0)} = 0 \mid X)}{\mathbb{P}(Y^{(0)} = 1 \mid X)} \right) \right] = \mathbb{E}[m(X)].$$

This result is apparently satisfying, where  $\mathbb{E}[\tau_{\log\text{-OR}}(X)]$  somehow only grasps the modification function. Still, note that due to non-collapsibility of the odds ratio, this does not imply that  $\tau_{\log\text{-OR}} = \tau$  (i.e.  $\tau_{\text{OR}} = e^\tau$ ) because  $\mathbb{E}[\tau_{\log\text{-OR}}(X)] \neq \tau_{\log\text{-OR}}$  (except if treatment effect is null or if the outcome does not depend on  $X$ , that is  $b(X)$  and  $m(X)$  are both scalars). As an intermediary conclusion, the working model from Lemma 16 leads to complex expression of causal measures, except for  $\mathbb{E}[\tau_{\log\text{-OR}}(X)]$ , but with the default that this measure shows bad property of non-collapsibility.

### 5.D.2 The equivalent of Lemma 12

**Lemma 18.** *Ensuring conditions of Lemma 16 leads to,*

$$\begin{aligned} \tau_{RD} &= \mathbb{E} \left[ \frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] - \mathbb{E} \left[ \frac{e^{b(X)}}{1 + e^{b(X)}} \right] & \tau_{RR} &= \mathbb{E} \left[ \frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \left( \mathbb{E} \left[ \frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} \\ \tau_{ERR} &= \mathbb{E} \left[ \frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \left( \mathbb{E} \left[ \frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} - 1 & \tau_{SR} &= \mathbb{E} \left[ \left( 1 + e^{b(X)+m(X)} \right)^{-1} \right] \left( \mathbb{E} \left[ \left( 1 + e^{b(X)} \right)^{-1} \right] \right)^{-1} \\ \tau_{NNT} &= \left( \mathbb{E} \left[ \frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] - \mathbb{E} \left[ \frac{e^{b(X)}}{1 + e^{b(X)}} \right] \right)^{-1} & \tau_{OR} &= \frac{\mathbb{E} \left[ \frac{e^{b(X)+m(X)}}{1 + e^{b(X)+m(X)}} \right] \mathbb{E} \left[ \frac{1}{1 + e^{b(X)}} \right]}{\mathbb{E} \left[ \frac{1}{1 + e^{b(X)+m(X)}} \right] \mathbb{E} \left[ \frac{e^{b(X)}}{1 + e^{b(X)}} \right]} \end{aligned}$$

For example the rather simple expression of RD for the continuous outcome now shows bewildering and complex forms when having a binary outcome. For example, a working model such that  $m(x) = m$  is a constant don't lead to any measures to be constant. All expressions from Lemma 18 now involve both  $b(\cdot)$  and  $m(x)$ . All other metrics show complex relation between the two functions.

### 5.D.3 Link between the intrication model and the logistic model

Denoting  $b_1(X)$  and  $m_1(X)$  the functions for the intrication model, and  $b_2(X)$  and  $m_2(X)$  for the logistic model, one has:

$$b_2(X) = \ln \left( \frac{b_1(X)}{1 - b_1(X)} \right)$$

and

$$m_2(X) = \ln \left( \frac{(m_1(X) + b_1(X))(1 - b_1(X))}{1 - (m_1(X) + b_1(X))(1 - b_1(X))} \right) - \ln \left( \frac{b_1(X)}{1 - b_1(X)} \right)$$

Taking the case of the Russian Roulette, one has

$$b_1(X) := p_0(X), \quad m_1(X) = \frac{1}{6}$$

so that

$$b_2(X) := \ln \left( \frac{X}{1 - X} \right)$$

and

$$m_2(X) := \ln \left( \frac{\left( \frac{1}{6} + p_0(X) \right)}{1 - \left( \frac{1}{6} + p_0(X) \right)(1 - p_0(X))} \right) - \ln \left( \frac{p_0(X)}{1 - p_0(X)} \right).$$

Despite a rather simple example, it is non-intuitive to encode it into the logistic model due to the link function.

## 5.E Complements on the intrication model

### Origin of the example

*Here we provide more details on how the Russian Roulette is stated in [Cinelli and Pearl \(2020\)](#). Note that the first reference we have found of this problem is in [Huitfeldt \(2019\)](#). This section is just meant to recall how the problem was initially introduced by [Huitfeldt \(2019\)](#).*

Suppose the city of Los Angeles decides to run a randomized control trial. Running the experiment, the mayor of Los Angeles discovers that ‘‘Russian Roulette’’ is harmful: among those assigned to play Russian Roulette, 17.5% of the people died, as compared to only 1% among those who were not assigned to play the game (people can die due to other causes during the trial, for example, prior poor health conditions). This example is a good toy example as the mechanism is well-known, with a chance

of one over six to die when playing. Even if it seems counter-intuitive, we consider the treatment as being forced to play to the Russian roulette (we consider the player plays only one time). We denote  $\Pi$  the population from Los Angeles. In that case, we can already note that the RR is 17.5 and the ATE is 0.165 (outcome being  $Y$  equals to 1 if death before the end of the period). With this notation  $\mathbb{E}[Y^{(0)}|pop = \Pi] = 0.01$  and  $\mathbb{E}[Y^{(1)}|pop = \Pi] = 0.175$

After hearing the news about the Los Angeles experiment, the mayor of New York City (a dictator, and we propose to denote the population of New York City  $\Pi^*$ ) wonders what the overall mortality rate would be if the city forced everyone to play Russian Roulette. Currently, the practice of Russian Roulette is forbidden in New York, and its mortality rate is at 5% (4% higher than LA, being  $\mathbb{E}[Y^{(0)}|pop = \Pi^*] = 0.05$ ). The mayor thus asks the city's statistician to decide whether and how one could use the data from Los Angeles to predict the mortality rate in New York, once the new policy is implemented. But in fact, knowing the mechanism of the Russian roulette we can already compute the value of interest being  $\mathbb{E}[Y^{(1)}|pop = \Pi^*]$ . Results are presented in Table 5.4. Here we used the fact that mortality is a consequence of two "independent" processes (the game of Russian Roulette and prior health conditions of the individual), and while the first factor remains unaltered across cities, the second intensifies by a known amount (5% vs 1%). Moreover, we can safely assume that the two processes interact disjunctively, namely, that death occurs if and only if at least one of the two processes takes effect. We can also - within the two cities - compute the associated RR, ATE and survival ratio (SR). We can observe they are not the same, but only the survival ratio comparing how many people dies with treatment on how many people would have died without treatment, transport the *mechanism* of the Russian Roulette (note that  $\frac{5}{6} \sim 0.83$ ).

Population	Los Angeles ( $\Pi$ )	New York city ( $\Pi^*$ )
$\mathbb{E}[Y^{(0)}]$	0.01	0.05
$\mathbb{E}[Y^{(1)}]$	$\frac{1}{6}0.99 + 0.01 = 0.175$	$\frac{1}{6}0.95 + 0.05 = 0.208$
RR	17.5	4.16
ATE	0.165	0.158
SR	0.83	0.83

**Table 5.4:** Summary of the different values. Note that none of the transport equation is applied, everything is computed within each population taking into account a distinct mechanism between the two reasons to die. SR corresponds to the survival ratio.

### A limit case, when $b(x) \ll m(x)$

We recall the intuitive model we have proposed in eq. 5.6.

$$\mathbb{P}[Y^{(a)} = 1 | X = x] = b(x) + a \underbrace{(1 - b(x))}_{\text{Intrication}} \frac{1}{6}.$$

Comparing the entanglement model from eq. 5.6, one can observe that, compared to the working model of the continuous outcome (Lemma 11) the baseline and the effect of the treatment are entangled. Interestingly, if  $b(x) \ll m(x)$  (in particular, the baseline is close to 0) then it is possible to have:

$$\text{If, } p_0(x) \ll 1, \quad \text{then, } \mathbb{P}[Y^{(a)} | X = x] \approx b(x) + a m(x),$$

such that we retrieved the intuition of the continuous outcome model, and remove the entanglement as expected.

Application of Lemma 14 for the Russian Roulette example gives:

$$\tau_{RD} = \frac{1}{6} (1 - \mathbb{E}[b(x)]), \quad \tau_{NNT} = \frac{6}{1 - \mathbb{E}[b(x)]}, \quad \tau_{RR} = \frac{5}{6} + \frac{1}{\mathbb{E}[b(x)]} \frac{1}{6}, \quad \tau_{SR} = \frac{5}{6},$$

and  $\tau_{OR} = \left( 1 + \frac{\mathbb{E}[(1 - b(X))]}{\mathbb{E}[b(X)]} \frac{1}{6} \right) \frac{\mathbb{E}[1 - b(X)]}{\mathbb{E}[(1 - b(X))]} \frac{6}{7}.$

## 5.F Different points of view

*This section gathers quotes from research papers or books. The aim is to illustrate how diverse opinions are.*

### General remarks about the choice of measure

Physicians, consumers, and third-party payers may be more enthusiastic about long-term preventive treatments when benefits are stated as relative, rather than absolute, reductions in the risk of adverse events. Medical-journal editors have said that reporting only relative reductions in risk is usually inadequate in scientific articles and have urged the news media to consider the importance of discussing both absolute and relative risks. For example, a story reporting that in patients with myocardial infarction, a new drug reduces the mortality rate at two years from 10 percent to 7 percent may help patients weigh both the 3 percent absolute and the 30 percent relative reduction in risk against the costs of the drug and its side effects. – (Moynihan et al., 2000)

In general, giving only the absolute or only the relative benefits does not tell the full story; it is more informative if both researchers and the media make data available in both absolute and relative terms. – (Moynihan et al., 2000)

The promotion of a measure often reflects personal preferences – those who are keen to promote the use of research in practice emphasize issues of interpretability of risk ratios and risk differences, those who are keen to ensure mathematical rules are always obeyed emphasize the limitations and inadequacies of the same measures. – (Deeks, 2002)

Failing to report NNT may influence the interpretation of study results. For example reporting RR alone may lead a reader to believe that a treatment effect is larger than it really is. – (Nuovo et al., 2002)

As *evidence-based practitioners*, we must decide which measure of association deserves our focus. Does it matter? The answer is yes. The same results, when presented in different ways, may lead to different treatment decisions. – (Guyatt et al., 2015)

You must, however, distinguish between the RR and the RD. The reason is that the RR is generally far larger than the RD, and presentations of results in the form of RR (or RRR) can convey a misleading message. – (focusing on binary outcome) (Guyatt et al., 2015)

Standard measures of effect, including the risk ratio, the odds ratio, and the risk difference, are associated with a number of well-described shortcomings, and no consensus exists about the conditions under which investigators should choose one effect measure over another. – (Huitfeldt et al., 2018)

Additive treatment effect heterogeneity is also most informative for guiding public health policy that aims to maximize the benefit or minimize the harm of an exposure by targeting subgroups. The relative scale (risk ratios or odds ratios) can tend to overstate treatment benefits or harms. – (Lesko et al., 2018)

The way to express and measure risk may appear to be a pure technicality. In fact, it is a crucial element of the risk-benefit balance that underlies the dominant medical discourse on contraception. Its influence on the perception and communication of risk is decisive, especially among people without a solid statistical education, like most patients and doctors who prescribe the pill (mostly generalists and gynaecologists). The dispute over *Non-rare thrombophilia* (NRT) screening sets an important difference between the absolute risk, the number of events occurring per time unit and the relative risk, which is the ratio between two absolute risks. Practically, whereas the relative risk may sound alarming, the absolute risk looks more reassuring. – (Turrini and Bourgain, 2021)

We believe if an efficacy measure is

- well defined,
- understandable by human,
- desired by patients and clinicians,
- proven to be logic-respecting<sup>13</sup>,
- readily implementable computationally,

them it is worthy of consideration. – (Liu et al., 2022)

### The odds ratio as a complex measure to interpret

Odds ratios and parameters of multivariate models will often be useful in serving as or in constructing the estimates, but should not be treated as the end product of a statistical analysis of epidemiologic data or as summaries of effect in themselves. – (Greenland, 1987)

The concept of the odds ratio is now well-established in epidemiology, largely because it serves as a link between results obtainable from follow-up studies and those obtainable from case-control studies. [...] This ubiquity, along with certain technical considerations, has led some authors to treat the odds ratio as perhaps a “universal” measure of epidemiologic effect, in that they would estimate odds ratios in follow-up studies as well as case-control studies; others have expressed reservations about the utility of the odds ratio as something other than an estimate of an incidence ratio. I believe that such controversy as exists regarding the use of the odds ratio arises from its inherent disadvantages compared with the other measures for biological inference, and its inherent advantages for statistical inference. – (Greenland, 1987)

There is a problem with odds: unlike risks, they are difficult to understand. – (Davies et al., 1998)

Another measure often used to summarise effects of treatment is the odds ratio. This is defined as the odds of an event in the active treatment group divided by the odds of an event in the control group. Though this measure has several statistical advantages and is used extensively in epidemiology, we will not pursue it here as it is not helpful in clinical decision making. – (Cook and Sackett, 1995)

In logit and other multiplicative intercept models (but not generally), OR also has the attractive feature of being invariant with respect to the values at which control variables are held constant. The disadvantage of OR is understanding what it means, and when OR is not the quantity of interest then its ‘advantages’ are not sufficient to recommend its use. Some statisticians seem comfortable with OR as their ultimate quantity of interest, but this is not common. Even more unusual is to find anyone who feels more comfortable with OR than the other quantities defined above; we have found no author who claims to be more comfortable communicating with the general public using an odds ratio. – (King and Zeng, 2002)

The OR lacks any interpretation as an average. – (Cummings, 2009)

As is well established, the odds ratio is not a parameter of interest in public health research. – (Spiegelman and VanderWeele, 2017)

Because of the exaggeration present, it is important to avoid representing ORs as RRs, and similarly, it is important to recognize that a reported OR rarely provides a good approximation of relative risks but rather simply provides a measure of correlation. – (George et al., 2020)

---

<sup>13</sup>see Definition 39.

We agree with Liu et al. (2020) that (causal) odds ratios and hazard ratios are problematic as causal contrasts. The non-collapsibility of these parameters is a mathematical property which makes their interpretation awkward, and this is amplified for hazard by their conditioning on survival. Thus they are also unsuitable measures for transportability between different populations (Martinussen & Vansteelandt, 2013). It is particularly concerning that meta-analyses pool odds ratios or hazard ratios from different studies each possibly using different variables for adjustment where the issue of non-collapsibility is typically ignored. – (Didelez and Stensrud, 2022)

ORs are notoriously difficult to interpret. When people hear “odds” they think of “risks” and this leads to the common misinterpretation of the OR as a RR by scientists and the public, which is a serious concern. For example, an OR of 2 is not generally a doubling of risk (if the risk in the control group is 20% and the OR is 2, then the risk in the treated group is 33.3% not 40%). In contrast, the RD and RR offer clearer interpretations. – (Xiao et al., 2022)

The admitted mathematical niceties of the OR are not reason enough to accept such a confusing state of affairs. Of course, when the outcome is rare, the OR approximates the RR and is, therefore, approximately collapsible.– (Xiao et al., 2022)

Because of the interpretability issues and lack of collapsibility, we urge researchers to avoid ORs when either the RD or RR is available. – (Xiao et al., 2022)

Odds ratios provoke similar discomfort—only 19% of learners and 25% of speakers at an annual meeting of the Canadian Society of Internal Medicine (CSIM) understood odds ratios well enough to explain them to others. – (Lapointe-Shaw et al., 2022)

### **The OR is a better metric to use than RR**

The results demonstrate the need to a) end the primary use of the RR in clinical trials and meta-analyses as its direct interpretation is not meaningful; b) replace the RR by the OR; and c) only use the post-intervention risk recalculated from the OR for any expected level of baseline risk in absolute terms for purposes of interpretation such as the number needed to treat. – (Doi et al., 2020)

We can no longer accept the commonly argued for view that the relative risk is easier to understand. Once we realize that the RR depends more on prevalence than the exposure-outcome association, its interpretation becomes much more difficult to comprehend than the odds ratio. It is well known that, for common events, large values of the risk ratio are impossible and this should have rung the alarm bells much earlier regarding whether the RR is more a measure of prevalence than a measure of effect. However this was not the main focus of the derivation outlined previously and the latter was aimed at demonstrating why the OR is a true measure of effect against which the RR can be compared. – (Doi et al., 2020)

Our response to this is that, although this is certainly a problem, there is an even bigger problem – *the RR is not a portable measure of effect*. By “portable” we mean a numerical value that is not dependent on baseline risk and not transportability in causal inference. — (Doi et al., 2022)

### **Relative versus absolute measures**

In reviewing the different ways that benefit and harm can be expressed, we conclude that the RD is superior to the RR because it incorporates both the baseline risk and the magnitude of the risk reduction. – (Laupacis et al., 1988)



For clinical decision making, however, it is more meaningful to use the measure “number needed to treat.” This measure is calculated on the inverse of the absolute risk reduction. It has the advantage that it conveys both statistical and clinical significance to the doctor. Furthermore, it can be used to extrapolate published findings to a patient at an arbitrary specified baseline risk when the relative risk reduction associated with treatment is constant for all levels of risk. – (Cook and Sackett, 1995)

Medical journals need to be conscious that they will contribute to scaremongering newspaper headlines if they do not request authors to quantify Adverse Drug Reactions (ADR) into best estimates of absolute numbers. – (Mills, 1999)

As a relative measure of effect, the RR is most directly estimated by the multiplicative model when it fits the data. The risk difference is an absolute measure of effect, most directly estimated by the additive model when it fits the data. – (Spiegelman and VanderWeele, 2017)

### About portability or generalizability of causal effects

The numbers needed to treat method still presents a problem when applying the results of a published randomised trial in patients at one baseline risk to a particular patient at a different risk. – (Cook and Sackett, 1995)

Some authors prefer odds ratios because they believe a constant (homogeneous) odds ratio may be more plausible than a constant risk ratio when outcomes are common. – (Cummings, 2009)

All of this assumes a constant RR across risk groups; fortunately, a more or less constant RR is usually the case, and we suggest you make that assumption unless there is evidence that suggests it is incorrect. – (Guyatt et al., 2015)

Although further and more formal quantitative work evaluating the relative degree of heterogeneity for risk ratio versus risk differences may be important, the previously mentioned considerations do seem to provide some indication that, for whatever reason, risk ratio modification is uncommon. – (Spiegelman and VanderWeele, 2017)

It is commonly believed that the risk ratio is a more homogeneous effect measure than the risk difference, but recent methodological discussion has questioned the evidence for the conventional wisdom. – (Huitfeldt et al., 2018)

In the real world of clinical medicine, doctors are usually given information about the effects of a drug on the risk ratio scale (the probability of the outcome if treated, divided by the probability of the outcome if untreated). With information on the risk ratio, a doctor may make a prediction for what will happen to the patient if treated, by multiplying the risk ratio and patient’s risk if untreated (which is predicted informally based on observable markers for the patient’s condition). – (Huitfeldt, 2019)

In this article we will show that the RR is not a measure of the magnitude of the intervention-outcome association alone because it has a stronger relationship with prevalence and therefore is not generalizable beyond the baseline risk of the population in which it is computed. – (Doi et al., 2020)

It is possible that no effect measure is “portable” in a meta-analysis. In cases where portability of the effect measure is challenging to satisfy, we suggest presenting the conditional effect based on the baseline risk using a bivariate generalized linear mixed model. The bivariate generalized linear mixed model can be used to account for correlation between the effect measure and baseline disease risk. Furthermore, in addition to the overall (or marginal) effect, we recommend that investigators also report the effects conditioning on the baseline risk. – (Xiao et al., 2022)

Despite some concerns, the RR has been widely used because it is considered a measure with “portability” across varying outcome prevalence, especially when the outcome is rare.  
– (Doi et al., 2022)

## 5.G Comments and answers to related article

As highlighted by the length of the references or even by Section 5.F: the literature on the choice of causal measures is prolific. In this Section, we propose comments or answers to previous articles in order to show how our contributions either complete what was said or shed lights on a different apprehension of the problem.

### 5.G.1 Comments of Cook and Sackett (1995)

Cook and Sackett (1995)’s widely cited paper promotes the usage of absolute measure versus relative measure for clinical decision. In particular they advocate the NNT as it is easier to interpret than a difference of probabilities (RD). For example, we quote such a section:

*For example, an estimated relative risk reduction of 50% might be statistically significant and clinically important for patients at moderate to high risk of a particular adverse event. However, for patients with a low probability of an event the risk reduction might not be sufficient to warrant the toxicity and cost of active treatment. This is the main criticism of relative measures of treatment effect for the purposes of clinical decision making.*

We agree on the fact that for a binary outcome an absolute measure better (such as the NNT) incorporates the baseline level, and therefore may be more informative for a patient (see for example Lemma 18). In this article authors use clinical data on which the risk ratio is constant across subgroups, and the treatment effect is beneficial. Interestingly, this what we show with the intrication model, that if one measure is more likely to be constant across different populations or subgroup: this is the RR (or the SR depending on the direction of the effect). These qualitative observations are completely coherent with Lemmas 14 and 15.

### 5.G.2 Comments of Cummings (2009)

Cummings (2009) propose a review of how the OR and the RR differ. In particular, they review typical arguments for pro and cons, while providing examples. In this section, we want to comment how the intrication model (Lemma 13) allows to formalize many of their arguments and examples.

*Some authors prefer odds ratios because they believe a constant (homogeneous) odds ratio may be more plausible than a constant risk ratio when outcomes are common. Risk range from 0 to 1. Risk ratios greater than 1 have an upper limit constrained by the risk when not exposed. For example the risk when not exposed is 0.5, the risk ratio when exposed cannot exceed  $2 : 5 \cdot 2 = 1$ . In a population with an average risk ratio of 2 for outcome Y among those exposed to X, assuming that the risk for Y if not exposed to X varies from .1 to .9, the average risk ratio must be less than 2 for those with risks greater than 0.5 when not exposed. Because the average risk ratio for the entire population is 2, the average risk ratio must be more than 2 for those with risks less than .5 when not exposed. Therefore, a risk ratio of 2 cannot be constant (homogeneous) for all individuals in a population if risk when not exposed is sometimes greater than .5. More generally, if the average risk ratio is greater than 1 in a population, the individual risk ratios cannot be constant (homogeneous) for all persons if any of them have risks when not exposed that exceed  $1/\text{average risk ratio}$ .*

The authors claim that if  $\tau_{\text{RR}} > 1$ , then

- The RR has an upper limit linked to the risk of the unexposed ( $p_0(x) = b(x)$ ),



- Or, the RR cannot be constant on every individuals if their risk is above a certain threshold being equal to 1/average risk ratio.


The intrication model perfectly describes such a situation, and we propose to illustrate why. As authors consider that  $\tau_{RR} > 1$ , then we use Lemma 13 with  $\forall x, m_g(x) = 0$ . More specifically, the authors mention that for  $\tau_{RR} > 1$  (that we rather model as  $\forall x, m_g(x) = 0$ ), it is not possible to have a constant RR on each subgroup. We recall that,

$$\forall x, \tau_{RR}(x) = 1 + \frac{1 - b(x)}{b(x)} m_b(x) \tag{5.41}$$

If  $\tau_{RR}(x)$  is assumed constant, one can plot the probability  $m_b(x)$  as a function of  $b(x)$  and observe that indeed this quantity is bounded and/or that  $m_b(x)$  can not exist for all baseline  $b(x)$ . We illustrate this equation on Figure 5.11.

**Figure 5.11: Illustration of the impossibility of having a constant  $\tau_{RR}(x) > 1$  if allowing all ranges for baseline risks**


$p_0(x)$ : This plot illustrates eq. 5.41 for several constant values of  $\tau_{RR}(x)$  (from 1.2 to 4), showing how the baseline risk  $p_0(x)$  implies different values of  $m_b(x)$ . If the baseline risk is too high, then there is no plausible  $m_b(x)$  (the upper limit is highlighted with the dashed red line). The dark vertical dashed line illustrate the precise example of Cummings (2009) with  $\tau_{RR}(x) = 2$ .



We want to add that, as the treatment effect is assumed to increase the occurrence of the event, then a better measure to use (at least if willing to maximise the chance to have a constant value for each individuals as claimed by the author) is the survival ratio (see Theorem 15). In particular, the Figure 5.11 can be adapted when considering a constant SR (see Figure 5.12). One can observe that all ranges of the baseline risks are allowed.

**Figure 5.12: Illustration of the possibility to have a constant  $\tau_{SR}(x) < 1$  when allowing all ranges for baseline risks**

$p_0(x)$ : This plot illustrates how several constant values of  $\tau_{SR}(x)$  (from 0.2 to 0.9) is allowed for any baseline values  $p(x)$ . Note that this implies a constant  $m_b(x)$ .



Then, authors add the following comment.

*Odds range from 0 to infinity. Odds ratios greater than 1 have no upper limit, regardless of the outcome odds for persons not exposed. If we multiply any unexposed outcome odds by an exposure odds ratio greater than 1 and convert the resulting odds when exposed to a risk, that risk will fall between 0 and 1. Thus, it is always hypothetically possible for an odds ratio to be constant for all individuals in a population.*

We agree that it is always hypothetically possible for an odds ratio to be constant for all individuals (this corresponds to Lemma 17, and  $m(x) = m$  in the logistic working models). But note that this does not mean that the odds ratio at the individual level is then the same for the population level due to non-collapsibility.

***Possibility of Constancy for Risk Ratios Less Than 1.** For both risk and odds, the lower limit is 0. For any level of risk or odds under no exposure, multiplication by a risk or odds ratio less than 1 will produce a risk or odds given exposure that is possible: 0 to 1 for risks and 0 to infinity for odds. Thus, a constant risk or odds ratio is possible for ratios less than 1. If the risk ratio comparing exposed persons with those not exposed is greater than 1, the ratio can be inverted to be less than 1 by comparing persons not exposed with those exposed. Therefore, a constant risk ratio less than 1 is hypothetically possible. This argument has been used to rebut the criticism of the risk ratio in the previous argument.*

To us, this argument is a consequence of Lemma 15 accounting for the fact that a RR less than 1 is comparable to  $m_b(x) = 0$ .

### 5.G.3 Comment on Appendix 3 of Huitfeldt et al. (2018)

Many of our insight can also be found in Huitfeldt et al. (2018) (and in particular in their Appendix). Differences come from the way the model is introduced, along with the dependency in  $X_B$  and  $X_M$  we highlight in the intrication model (and with the fact that we also deal with continuous outcomes). In this section, we transpose their example from Appendix 3. What we want to highlight is that our notations and framework enable another view of the problem. First, we quote the authors.

For illustration, we will consider an example concerning the effect of treatment with antibiotics ( $A$ ), on mortality ( $Y$ ). We will suppose that response to treatment is fully determined by bacterial susceptibility to that antibiotic ( $X$ ). In the following, we will suppose that attribute  $X$  has the same prevalence in populations  $s$  and  $t$  (for example because the two populations share the same bacterial gene pool) and that treatment with  $A$  has no effect in the absence of  $X$ . Further, suppose that this attribute is independent of the baseline risk of the outcome (for example, old people at high risk of death may have the same strains of the bacteria as young people at low risk).

Within the intrication model, and denoting  $X = 0$  the absence of the mutation, this means that:

- “attribute  $X$  has the same prevalence in populations  $s$  and  $t$ ” which corresponds to Definition 41;
- “treatment with  $A$  has no effect in the absence of  $X$ ”  $m_b(X = 0) = m_g(X = 0) = 0$ ,
- “Further, suppose that this attribute is independent of the baseline risk of the outcome” Here, we think that this assumption could be easily transposed in our intrication model, clearly decomposing  $X_B$  and  $X_M$ .

### 5.G.4 Comment on the research work from Cinelli & Pearl

The way Cinelli and Pearl (2020) deals with the problem is to encode the assumption of the problem with selection diagrams. In particular selection diagrams are an extension of DAGs with selection nodes, those nodes are used by the analyst to indicate which local mechanisms are suspected to differ between two environments (in our example, the mortality mechanism is suspected to differ between Los Angeles and New York, but not the mechanism).

A first difference to our work is that authors rather want to predict in a target population  $P_T$ ,  $\mathbb{E}_T[Y^{(1)}]$  from  $\mathbb{E}_T[Y^{(0)}]$  and  $PS_{01}$  and  $PS_{10}$  detailed below. Another difference is that authors mostly reason marginally, while in our work we link subpopulations with larger populations relying on collapsibility.

Cinelli and Pearl introduce the following quantities:

$$\text{PS}_{01} := \mathbb{P} \left[ Y^{(1)} = 1 \mid Y^{(0)} = 0 \right], \quad \text{and} \quad \text{PS}_{10} := \mathbb{P} \left[ Y^{(1)} = 0 \mid Y^{(0)} = 1 \right].$$

Those quantity corresponds to  $m_b$  and  $m_g$  defined in Lemma 13, considering those quantities are not depending on  $X$ . Therefore, their equation,

$$\mathbb{P}^{\Pi^*} \left[ Y^{(1)} = 1 \right] = (1 - \text{PS}_{10})\mathbb{P}^{\Pi^*} \left[ Y^{(0)} = 1 \right] + \text{PS}_{01}(1 - \mathbb{P}^{\Pi^*} \left[ Y^{(0)} = 1 \right]),$$

is completely equivalent to the intrication model, noting that  $\mathbb{P}^{\Pi^*} \left[ Y^{(0)} = 1 \right]$  corresponds to  $\mathbb{E}_{\mathcal{T}} [b(x)]$ . The intrication model rather highlight the dependencies to covariates (i.e. characteristics), while their equation rather models the fact that only the baseline risk is necessary to be known if

$$Y^{(1)} \perp\!\!\!\perp I \mid Y^{(0)},$$

where  $I$  is the indicator of population's membership and if effect is monotonous (and they denote  $Y^{(1)} \leq Y^{(0)}$  or conversely depending on the direction assumed).

In our work, such assumption is equivalent with assuming monotonicity (either  $m_b(x) = 0$  or  $m_g(x) = 0$ ) and that all treatment effect modifiers are not shifted.

Authors then propose to soften their assumptions deriving bounds on the target quantity  $\mathbb{P}^{\Pi^*} \left[ Y^{(1)} = 1 \right]$ . Our work rather keeps on targeting causal measure themselves, and assume that we have access to the shifted covariates of  $X_M$ . We think this could be stated as,

$$Y^{(1)} \perp\!\!\!\perp I \mid Y^{(0)}, X_M,$$

along with the monotonicity assumption.

## 5.H Details about the simulations

### 5.H.1 Comments on estimation

In this paper, we have been focusing on identification rather than estimation. In this simulation, we illustrate the two approaches that can be taken when transforming identification formula (see Propositions 5 and 6) into estimation: Plug-in g-formula or Inverse Propensity Sampling Weighting (IPSW). Existing consistency results of these approaches for the Risk Difference are reviewed in Colnet et al. (2020). We assume that the data sampled from  $P_S$  is a randomized trial  $\mathcal{R}$  of size  $n$  and the data sampled from  $P_T$  is a cohort  $\mathcal{T}$  of size  $m$  which contains covariates information  $X$  and possibly  $Y^{(0)}$ .

#### 5.H.1.1 Plug-in formula

When considering *generalization of the conditional outcome*, the plug-in g-formula consists in estimating the two surface responses  $\mathbb{E} \left[ Y^{(a)} \mid X \right]$  using the RCT data from  $P_T$ . We denote  $\hat{\mu}_{a,n}(X)$  the estimates ( $n$  is added to indicate that estimation is performed on the trial). Any approach can be proposed, for e.g. OLS or non-parametric learners. These models are then used on the target sample to estimate the averaged expected responses,

$$\hat{\mathbb{E}}_{\mathcal{T}} \left[ Y^{(a)} \right] = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{\mu}_{a,n}(X), \quad (5.42)$$

where  $m$  denotes the target sample size. Doing so this estimate depends on the two sample sizes,  $n$  and  $m$ . Finally,  $\hat{\mathbb{E}}_{\mathcal{T}} \left[ Y^{(0)} \right]$  and  $\hat{\mathbb{E}}_{\mathcal{T}} \left[ Y^{(1)} \right]$  are then used to estimate any causal measures on the target population: RD, RR, OR, and so on. Consistency of procedure eq.5.42 has been proven for any consistent estimator  $\hat{\mu}_a$  of  $\mathbb{E} \left[ Y^{(a)} \mid X \right]$  in Colnet et al. (2022a).

*Generalizing local effects* using a plug-in formula suggests to estimate the local treatment effect (or CATE)  $\hat{\tau}_n(x)$  using  $\mathcal{S}$ . This can be done using the previously introduced  $\hat{\mu}_a(X)$  too (this is called T-learner), and then making a difference or a ratio of the two depending on the causal measure someone

wants to generalize. Then, one has to estimate  $\hat{g}_m(X, P(X, Y^{(0)}))$  using  $\mathcal{T}$ , for exemple using a linear model (or any other model). Finally, one can obtain the target treatment effect with

$$\hat{\tau} = \frac{1}{m} \sum_{i \in \mathcal{T}} \hat{g}_m(X_i, P(X_i, Y_i^{(0)})) \hat{\tau}_n(X_i), \quad (5.43)$$

where  $m$  denotes the target sample size. Note that eq. 5.43 relies on the estimation of  $\tau(X)$  directly. While the estimation of the conditional risk difference is well described in the literature (Wager and Athey, 2018; Nie and Wager, 2020) (to name a few), estimation of conditional ratios is way less described. We have found only one recent work dealing with such questions (Yadlowsky et al., 2021). Consistency of such procedure for another metric than the Risk Difference is an open research question.

### 5.H.1.2 Inverse Propensity Sampling Weighting (IPSW)

IPSW uses the ratio of densities to re-weight individual observation in the trial. Denoting  $r(X) := \frac{p_{\mathcal{T}}(X)}{p_{\mathcal{S}}(X)}$  the density ratio, one has first to learn this ratio  $\hat{r}_{n,m}(X)$  using both data set  $\mathcal{S}$  and  $\mathcal{T}$ . One can *generalize conditional outcomes* doing:

$$\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(a)}] = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}_{n,m}(X_i) A_i Y_i.$$

Those estimates ( $\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(0)}]$  and  $\hat{\mathbb{E}}_{\mathcal{T}} [Y^{(a1)}]$ ) are then used to estimate any causal measures on the target population.

Now, considering *generalizing local effects* using a re-weighting approach rather suggest to also estimate  $\hat{g}_m(X, P(X, Y^{(0)}))$  using  $\mathcal{T}$  (for example using a linear model). Then, for e.g when considering the Risk Difference, this consists in doing

$$\hat{\tau}_{\text{RD}} = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}(X_i) (A_i Y_i - (1 - A_i) Y_i),$$

or when considering the Risk Ratio, a procedure could be

$$\ln(\hat{\tau}_{\text{RR}}) = \frac{1}{n} \sum_{i \in \mathcal{S}} \hat{r}(X_i) (\ln(A_i Y_i) - \ln((1 - A_i) Y_i)) \hat{g}_m(X_i, P(X_i, Y_i^{(0)})).$$

We use these weighting approaches for the simulation with a binary outcomes. As the purpose is not estimation, we propose a simulation with categorical covariates only, in particular to propose an estimation of  $\hat{r}_{n,m}(X)$  as in Colnet et al. (2022b).  $\hat{g}_m(X, P(X, Y^{(0)}))$  is estimating by computing the empirical mean of  $\mathbb{E}[Y^{(0)} | X]$  in each category.

## 5.H.2 Continuous outcomes

**Data generative process** We assume that the outcome is generated linearly from six covariates in the two populations

$$Y(a) = 0.05X_1 + 0.04X_2 + 2X_3 + X_4 + 2X_5 - 2X_6 + a \cdot (1.5X_1 + 2X_2 + X_5) + \epsilon \text{ with } \epsilon \sim \mathcal{N}(0, 2). \quad (5.44)$$

The two data samples are directly sampled from two different baseline distributions.

Covariates  $X_1, X_2, X_3$  are generated from

$$\mathcal{N} \left( \left( \begin{bmatrix} 6 \\ 5 \\ 8 \end{bmatrix}, \begin{bmatrix} 1 & 0 & 0.5 \\ 0 & 1 & 0.2 \\ 0.5 & 0.2 & 1 \end{bmatrix} \right) \right)$$

in  $P_{\mathcal{S}}$ , and in

$$\mathcal{N} \left( \left( \begin{bmatrix} 15 \\ 7 \\ 10 \end{bmatrix}, \begin{bmatrix} 1 & 0 & 0.5 \\ 0 & 1 & 0.2 \\ 0.5 & 0.2 & 1 \end{bmatrix} \right) \right)$$

for  $P_T$ .  $X_4$  is such that  $X_4 \sim \mathcal{B}(1, 0.8)$  in  $P_S$  and  $X_4 \sim \mathcal{B}(1, 0.3)$  in  $P_T$ . Then,  $X_5$  and  $X_6$  are non-shifted covariates, where  $X_5 \sim \mathcal{B}(1, 0.8)$  and  $X_6 \sim \mathcal{N}(4, 1)$  in both populations.

Within the trial sample of size  $n$  we generate the treatment according to a Bernoulli distribution with probability equals to 0.5.

**Estimation** For this simulation we applied a plug-in g-formula approach, using Ordinary Least Squares (OLS) to estimate  $\hat{\mu}_{a,n}$  and  $\hat{g}_m(X, P(X, Y^{(0)}))$ .  $\hat{\tau}_n$  is estimated combining  $\hat{\mu}_{a,n}$  as a difference or ratio or else (T-learner).

### 5.H.3 Binary outcomes

**Data generative process** For this simulation the baseline covariates are categorical to ease the estimation strategy. The data generative model is build on top of eq. 5.6, and adapted to give,

$$\mathbb{P} \left[ Y^{(a)} = 1 \mid X = x \right] = b(X_1, X_2, X_3) + a (1 - b(X_1, X_2, X_3)) m_b(X_2, X_3),$$

where  $X_1 = \text{lifestyle}$ ,  $X_2 = \text{stress}$ , and  $X_3 = \text{gender}$ .

Each of the three covariates are sampled following a Bernoulli distribution. In  $P_S$ , one has  $X_1 \sim \mathcal{B}(1, 0.4)$ ,  $X_2 \sim \mathcal{B}(1, 0.8)$ , and  $X_3 \sim \mathcal{B}(1, 0.5)$ . In  $P_T$ , one has  $X_1 \sim \mathcal{B}(1, 0.6)$ ,  $X_2 \sim \mathcal{B}(1, 0.2)$ , and  $X_3 \sim \mathcal{B}(1, 0.5)$ .

The outcome is defined such as,

$$b(X) = \text{ifelse}(X_1 = 1, 0.2, 0.05) \cdot \text{ifelse}(X_2 = 1, 2, 1) \cdot \text{ifelse}(X_3 = 1, 0.5, 1),$$

where `ifelse` corresponds to the function with the same name in R. And,

$$m_b(X) = \text{ifelse}(X_2 = 1, 1/4, \text{ifelse}(X_3 = 1, 1/10, 1/6)).$$

Within the trial sample of size  $n$  we generate the treatment according to a Bernoulli distribution with probability equals to 0.5.

**Estimation** We estimate the density ratio as in Colnet et al. (2022b), namely

$$\forall x \in \mathcal{X}, \hat{p}_{T,m}(x) := \frac{1}{m} \sum_{i \in \mathcal{T}} \mathbb{1}_{X_i=x} \quad \text{and} \quad \hat{p}_{R,n}(x) := \frac{1}{n} \sum_{i \in \mathcal{R}} \mathbb{1}_{X_i=x}.$$

As the covariates are categorical, we apply the same strategy: estimate the local effect in each combination of categories.

Name	Outcome type	Definition	Collapsibility	Logic respecting	Invariant to encoding	Covariate set for generalization
Risk Difference (RD)	Continuous	$\tau_{RD} := \mathbb{E}[Y^{(1)}] - \mathbb{E}[Y^{(0)}]$	Directly collapsible	Logic-respecting	Not applicable	$X_{M \cap Sh}$
Risk Ratio (RR)	Continuous	$\tau_{RR} := \mathbb{E}[Y^{(1)}] / \mathbb{E}[Y^{(0)}]$	Collapsible	Logic-respecting	Not applicable	$X_{(M \cup B) \cap Sh}$
Excess Risk Ratio (ERR)	Continuous	$\tau_{ERR} := \tau_{RD} / \mathbb{E}[Y^{(0)}] = \tau_{RR} - 1$	Collapsible	Logic-respecting	Not applicable	$X_{(M \cup B) \cap Sh}$
Risk Difference (RD)	Binary	$\tau_{RD} := \mathbb{P}[Y^{(1)} = 1] - \mathbb{P}[Y^{(0)} = 1]$	Directly collapsible	Logic-respecting	Multiplied by $-1$	$X_{(M \cup B) \cap Sh}$
Number Needed to Treat (NNT)	Binary	$\tau_{RD} := 1 / (\mathbb{P}[Y^{(1)} = 1] - \mathbb{P}[Y^{(0)} = 1])$	<b>Not</b> collapsible	Logic-respecting	Multiplied by $-1$	$X_{(M \cup B) \cap Sh}$
Risk Ratio (RR)	Binary	$\tau_{RR} := \mathbb{P}[Y^{(1)} = 1] / \mathbb{P}[Y^{(0)} = 1]$	Collapsible	Logic-respecting	$= \tau_{SR}$	If $m_b(x) = 0$ , $X_{M \cap Sh}$
Survival Ratio (SR)	Binary	$\tau_{SR} := \mathbb{P}[Y^{(1)} = 0] / \mathbb{P}[Y^{(0)} = 0]$	Collapsible	Logic-respecting	$= \tau_{RR}$	If $m_g(x) = 0$ , $X_{M \cap Sh}$
Excess Risk Ratio (ERR)	Binary	$\tau_{ERR} := \tau_{RD} / \mathbb{P}[Y^{(0)} = 1] = \tau_{RR} - 1$	Collapsible	Logic-respecting	$= \tau_{SR} - 1$	If $m_b(x) = 0$ , $X_{M \cap Sh}$
Relative Susceptibility (RS)	Binary	$\tau_{RS} := \tau_{RD} / \mathbb{P}[Y^{(0)} = 0] = 1 - \tau_{SR}$	Collapsible	Logic-respecting	$= 1 - \tau_{RR}$	If $m_g(x) = 0$ , $X_{M \cap Sh}$
Odds Ratio (OR)	Binary	$\tau_{OR} := \frac{\mathbb{P}[Y^{(1)}=1]}{\mathbb{P}[Y^{(1)}=0]} \left( \frac{\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=0]} \right)^{-1} = \tau_{RR} \cdot \tau_{SR}^{-1}$	Non collapsible	<b>Not</b> logic-respecting	Reciprocal	$X_{(M \cup B) \cap Sh}$
Log Odds Ratio (log-OR)	Binary	$\tau_{\log-OR} := \log \left( \frac{\mathbb{P}[Y^{(1)}=1]}{\mathbb{P}[Y^{(1)}=0]} \right) - \log \left( \frac{\mathbb{P}[Y^{(0)}=1]}{\mathbb{P}[Y^{(0)}=0]} \right)$	Non collapsible	<b>Not</b> logic-respecting	Multiplied by $-1$	$X_{(M \cup B) \cap Sh}$

**Table 5.5: Typical causal measures reported in clinical practice:** The upper part of the Table mentions the three typical measures found when the outcome is ordinal or continuous, and the lower part mentions measures for binary outcomes. For each measure we provide the explicit formulae, and properties such as collapsibility (see Definitions 37 and 38), invariance to encoding (also called symmetry in the literature), and whether the covariate set for generalization by standardization is extended or not. All these properties are defined in this article, and proved for each of the measures.

# Chapter 6

## Conclusion

**The scientific context of this thesis** This thesis is part of the current movement aiming to strengthen how clinical evidence is built. The ongoing advances of the scientific community are using modern tools – namely data availability and computational power. One of the recent emphasis in the literature is how different data sources can complement each other. In the scope of that question, this thesis tackles the very precise and practical question of the generalization of trial findings toward a target population. In other words, we proposed methodological and theoretical results to procedures targeting the following question: “*What average treatment effect would have this trial given, if the individuals were rather sampled in the target population of interest ?*”.

**Navigating new methods questions** This work is tremendously shaped and guided by application, in particular by the clinical questions driving our clinician collaborators who work on the Traumabase registry. We were given a question from clinical research, and therefore started an extensive review of the existing methods combining two data samples. As the domain is quite recent, we had to implement all the methods and test them through simulations. The practical application of these methods led us to discover more questions than we had initially anticipated. We became interested in obtaining theoretical guarantees and guidance pertaining to these novel procedures. The specificity of clinical research is indeed to seek for guarantees as the conclusions impact individuals’s health. This led us to develop a sensitivity analysis to address the challenge of partially observed covariates, as we faced such a situation. We drew inspiration from previous seminal sensitivity analyses, while adapting them to the specific research question at hand. For instance: incorporating specific sensitivity parameters for population shift and accounting for all missing data patterns due to the presence of several data sets (see Chapter 3).

However, even in a scenario where all covariates are observed, we asked questions regarding the general statistical behavior of an estimator which depends on two data samples sizes. How do the relative sizes of the data sets impact the performances? Can we have finite sample guarantees? What is the impact on these properties when a user adds too many covariates in the adjustment set? We provided answers to all of these questions for the most intuitive estimator – re-weighting the trial individuals with density ratio (see Chapter 4).

At the start of this research journey, one of our clinician collaborators piqued our interest with a question about a common practice in statistical papers: the focus on absolute difference when considering a causal effect. The ratio or the odds ratio seem indeed to be preferred measures in the medical field. This question motivated us to delve deeper into the significance of causal measures, which led to extensive new readings. The specific prism that generalization offers led us to propose a contribution about identification of transported causal effect. We found that so-called transportability assumptions change depending on the considered causal measure (see Chapter 5). And a by-product of this work is a new proposal to qualify homogeneity of an effect: not through the measure itself, but through a non-parametric generative process of the outcome. Results from this framework align with the empirical practices from different fields such as clinical or econometrical research.

**What are the scientific perspectives?** We foresee three perspectives to our work. **(1)** The most direct extensions could come from softening certain assumptions used in some theorems. For example the results of Chapter 3 could be extended with a non-linear effect modification in the covariates. Similarly, one could extend the theoretical results from Chapter 4 to answer the following question: How are the results from Chapter 4 evolving when considering a set of covariates containing continuous covariates? Another promising area of research lies in the characterization of estimation procedures, for measures beyond the difference. Chapter 5 indeed focuses on identification, with simulations providing a preliminary foundation for estimation. However, there is a substantial amount of work that needs to be done to rigorously define and theoretically characterize estimation strategies. **(2)** Meta-analysis also emerges as a potential exploration avenue in light of the findings from our research. Meta-analysis is all about combining results from different studies, but usually already aggregated effects. In the light of the external validity questions and the generalization of trial findings, we would find relevant to have a precise understanding of what a meta-analysis targets, and how generalization approach can lead to another way of linking studies results. As meta-analysis is considered by most as the best evidence one can reach (see Figure 1.6), such work could impact the community at large. **(3)** Lastly, in the introduction we highlighted that as of today and in practice, generalizability of a study is usually discussed by what undermines external validity. An example commonly cited by clinicians is the comparison of Tables 1 from different studies, which may raise concerns whether differences in recruited populations prevent any extrapolation or not. Somehow, generalization procedures allow going one step further, by turning a population's shift into an estimated *transported* expected effect. Applying the generalization on more clinical questions is a crucial step in validating the relevance and real-world applicability of the methods described in this thesis. As illustrated for the IPW methods (see Figure 1.5) there can be a considerable time between a statistical innovation and its adoption. As statisticians, yes we can propose theoretical foundations. But collaborations are key in this upcoming phase.

**What personal convictions have backed this approach?** Any action is influenced by one's subjective approach and interests. In the following final thesis lines, I<sup>1</sup> would like to explain how some of my convictions have influenced this work. First, it is not an exaggeration to say that most (if not all) research questions I tackled in this work comes from the application. People working in companies would not be surprised, as they are used to be driven by the customers. But many argue that science is supposed to be driven by something else. Something that lies above us, related to knowledge, and maybe truth. While I do believe that without this appeal to understand the world, humanity would be deprived of its essence, I also think that statistical research has to be confronted with real data and those who actually use it. Why statistics especially? To quote Brad Efron: “[...] *statisticians have quite an advantage in the dean's office because we deal with lots of different fields, while most other academics deal only with their own field.*” (Holmes et al., 2003). This quote highlights that statisticians' work is supposedly meant for other fields. Statistics could surely be developed for itself, but would therefore be a different science, as only real data can finally answer scientific and practical questions. While I also think that I could have done way more applied collaborations, this explains why I was constantly driven by applications during this thesis. Doing so is at the risk of tackling less impressive questions, and to rather prefer *simpler* set-ups (at least for a statistician).

Second, as a person trained primarily as an engineer, one of my main surprise when I entered the statistics field is that: when facing real data, then reality is usually very finite (i.e. small to very small data), while statistical books are full of large sample results. How do finite samples impact the asymptotic results, which are traditionally used to guide applications? This is why I decided to focus on a different set of assumptions that is usually done (e.g. adjusting on categorical covariates) to be able to derive finite sample bias and variance. Reality is certainly not as simple as categories, but I hope that this characterization helps to provide a fair model. Another surprise was the constant presence of assumptions about data generating processes, while little is known about the true nature of those processes This explains how I tried to do the so-called parametric assumptions as little as

---

<sup>1</sup>As a very personal note, this last paragraph uses “I”.



---

possible (e.g. Chapter 3 with consistency proofs for any learners or the semi-synthetic simulation's section; or Chapter 5 proposing non-parametric models).

Finally, as a student, I struggled with the ability to reproduce proofs and simulations. I had many troubles finding how existing results were proven. All my research works – and especially proofs – are written so that any student with a Master level should be able to follow the derivations. I hope that the time invested in detailing the proofs will be valuable for others.

## Bibliography

- Ackerman, B., C. R. Lesko, J. Siddique, R. Susukida, and E. A. Stuart (2021). Generalizing randomized trial findings to a target population using complex survey population data. *Statistics in medicine* 40(5), 1101–1120.
- Ahn, E. and H. Kang (2018). Introduction to systematic review and meta-analysis. *Korean journal of anesthesiology* 71(2), 103–112.
- Ali, M. S., R. H. Groenwold, S. V. Belitser, W. R. Pestman, A. W. Hoes, K. C. Roes, A. de Boer, and O. H. Klungel (2015). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *Journal of clinical epidemiology* 68(2), 122–131.
- Altman, D. G., K. F. Schulz, D. Moher, M. Egger, F. Davidoff, D. Elbourne, P. C. Gøtzsche, T. Lang, and C. Group (2001). The revised consort statement for reporting randomized trials: explanation and elaboration. *Annals of internal medicine* 134(8), 663–694.
- Andrews, I. and E. Oster (2019, 2018). A simple approximation for evaluating external validity bias. *Economics Letters* 178, 58–62. Working Paper.
- Angrist, J. D., G. W. Imbens, and D. B. Rubin (1996). Identification of causal effects using instrumental variables. *Journal of the American statistical Association* 91(434), 444–455.
- Angrist, J. D. and J.-S. Pischke (2008, December). *Mostly Harmless Econometrics: An Empiricist’s Companion*. Princeton University Press.
- Arnould, L., C. Boyer, and E. Scornet (2021, 18–24 Jul). Analyzing the tree-layer structure of deep forests. In M. Meila and T. Zhang (Eds.), *Proceedings of the 38th International Conference on Machine Learning*, Volume 139 of *Proceedings of Machine Learning Research*, pp. 342–350. PMLR.
- Aronow, P. M. and C. Samii (2017). Estimating average causal effects under general interference, with application to a social network experiment.
- Athey, S., R. Chetty, and G. Imbens (2020). Combining experimental and observational data to estimate treatment effects on long term outcomes. *arXiv preprint arXiv:2006.09676*.
- Athey, S. and G. W. Imbens (2017, May). The state of applied econometrics: Causality and policy evaluation. *Journal of Economic Perspectives* 31(2), 3–32.
- Athey, S., G. W. Imbens, and S. Wager (2018, September). Approximate residual balancing: debiased inference of average treatment effects in high dimensions. *Journal of the Royal Statistical Society Series B* 80(4), 597–623.
- Athey, S., J. Tibshirani, and S. Wager (2019). Generalized random forests. *The Annals of Statistics* 47(2), 1148–1178.
- Austin, P. and E. Stuart (2015, December). Moving towards best practice when using inverse probability of treatment weighting (iptw) using the propensity score to estimate causal treatment effects in observational studies. *Statistics in Medicine* 34(28), 3661–3679.
- Bach, P., V. Chernozhukov, M. S. Kurz, and M. Spindler (2021). DoubleML – An object-oriented implementation of double machine learning in R. [arXiv:2103.09603](https://arxiv.org/abs/2103.09603) [stat.ML].
- Bach, P., V. Chernozhukov, M. S. Kurz, and M. Spindler (2022). DoubleML – An object-oriented implementation of double machine learning in Python. *Journal of Machine Learning Research* 23(53), 1–6.
- Baker, R. and D. Jackson (2018). A new measure of treatment effect for random-effects meta-analysis of comparative binary outcome data. *arXiv preprint arXiv:1806.03471*.

- Bareinboim, E., S. Lee, V. Honavar, and J. Pearl (2013, 01). Transportability from multiple environments with limited experiments.
- Bareinboim, E. and J. Pearl (2012a). Controlling selection bias in causal inference. In N. D. Lawrence and M. Girolami (Eds.), *Proceedings of the Fifteenth International Conference on Artificial Intelligence and Statistics*, Volume 22 of *Proceedings of Machine Learning Research*, La Palma, Canary Islands, pp. 100–108. PMLR.
- Bareinboim, E. and J. Pearl (2012b). Transportability of causal effects: Completeness results. In *Proceedings of the Twenty-Sixth AAAI Conference on Artificial Intelligence*, AAAI'12, pp. 698–704. AAAI Press.
- Bareinboim, E. and J. Pearl (2013). A general algorithm for deciding transportability of experimental results. *Journal of Causal Inference* 1(1), 107–134.
- Bareinboim, E. and J. Pearl (2016). Causal inference and the data-fusion problem. *Proceedings of the National Academy of Sciences* 113(27), 7345–7352.
- Bareinboim, E., J. Tian, and J. Pearl (2014, Jun.). Recovering from selection bias in causal and statistical inference. *Proceedings of the AAAI Conference on Artificial Intelligence* 28(1).
- Begg, C. B. and D. H. Y. Leung (2000). On the use of surrogate end points in randomized trials. *Journal of the Royal Statistical Society. Series A (Statistics in Society)* 163(1), 15–28.
- Berkowitz, S. A., J. B. Sussman, D. E. Jonas, and S. Basu (2018). Generalizing intensive blood pressure treatment to adults with diabetes mellitus. *Journal of the American College of Cardiology* 72(11), 1214–1223. SPECIAL FOCUS ISSUE: BLOOD PRESSURE.
- Bernard, C. (1865). *Introduction à l'étude de la médecine expérimentale*. Number 2. JB Baillière.
- Biau, G. (2012). Analysis of a random forests model. *Journal of Machine Learning Research* 13(38), 1063–1095.
- Blanco, C., M. Olfson, R. D. Goodwin, E. Ogburn, M. R. Liebowitz, E. V. Nunes, and D. S. Hasin (2008). Generalizability of clinical trial results for major depression to community samples: results from the national epidemiologic survey on alcohol and related conditions. *Journal of Clinical Psychiatry* 69(8), 1276–1280.
- Blunt, C. (2015). *Hierarchies of evidence in evidence-based medicine*. Ph. D. thesis, London School of Economics and Political Science.
- Box, G. E. P. (1949, 12). A general distribution theory for a class of likelihood criteria. *Biometrika* 36(3-4), 317–346.
- Brenner, A., M. Arribas, J. Cuzick, V. Jairath, S. Stanworth, K. Ker, H. Shakur-Still, and I. Roberts (2018). Outcome measures in clinical trials of treatments for acute severe haemorrhage. *Trials* 19, 533.
- Brookhart, M. A., S. Schneeweiss, K. J. Rothman, R. J. Glynn, J. Avorn, and T. Stürmer (2006). Variable selection for propensity score models. *Am J Epidemiol* 163, 1149–1156.
- Buchanan, A. L., M. G. Hudgens, S. R. Cole, K. R. Mollan, P. E. Sax, E. S. Daar, A. A. Adimora, J. J. Eron, and M. J. Mugavero (2018). Generalizing evidence from randomized trials using inverse probability of sampling weights. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 181, 1193–1209.
- Campbell, D. T. (1957). Factors relevant to the validity of experiments in social settings. *Psychological Bulletin* 54(4), 297–312.

- Carpenter, J. R. and M. G. Kenward (2007). Missing data in randomised controlled trials: a practical guide.
- Chambers, J. M. (2022). Data, science, and global disasters. *Statistical Science* 37(2), 284–288.
- Chattopadhyay, A., E. R. Cohn, and J. R. Zubizarreta (2022). One-step weighting to generalize and transport treatment effect estimates to a target population.
- Chemla, D. and P. Abastado (2012). Pierre-charles-alexandre louis: un pionnier de la médecine fondée sur les preuves. *La Lettre du cardiologue* (451), 29–32.
- Chen, R., G. Chen, and M. Yu (2021, 08). A generalizability score for aggregate causal effect. *Bio-statistics*.
- Chen, X., H. Hong, and D. Nekipelov (2007). Measurement error models.
- Chen, X., H. Hong, and E. Tamer (2005, 02). Measurement error models with auxiliary data. *Review of Economic Studies* 72, 343–366.
- Chernozhukov, V., D. Chetverikov, M. Demirer, E. Duflo, C. Hansen, W. Newey, and J. Robins (2017, 06). Double/debiased machine learning for treatment and structural parameters. *The Econometrics Journal* 21.
- Chernozhukov, V., D. Chetverikov, M. Demirer, E. Duflo, C. Hansen, W. Newey, and J. Robins (2018a, 01). Double/debiased machine learning for treatment and structural parameters. *The Econometrics Journal* 21(1), C1–C68.
- Chernozhukov, V., D. Chetverikov, M. Demirer, E. Duflo, C. Hansen, W. Newey, and J. Robins (2018b). Double/debiased machine learning for treatment and structural parameters. *The Econometrics Journal* 21(1), C1–C68.
- Chu, J., W. Lu, and S. Yang (2022). Targeted optimal treatment regime learning using summary statistics. *arXiv preprint arXiv:2201.06229*.
- Cinelli, C., A. Forney, and J. Pearl (2022). A crash course in good and bad controls. *Sociological Methods & Research*.
- Cinelli, C. and C. Hazlett (2020, February). Making sense of sensitivity: extending omitted variable bias. *Journal of the Royal Statistical Society Series B* 82(1), 39–67.
- Cinelli, C. and J. Pearl (2020). Generalizing experimental results by leveraging knowledge of mechanisms. *European Journal of Epidemiology*.
- Cochran, W. G. (1968). The effectiveness of adjustment by subclassification in removing bias in observational studies. *Biometrics* 24, 295–313.
- Cole, P. and B. MacMahon (1971). Attributable risk percent in case-control studies. *British journal of preventive & social medicine* 25(4), 242.
- Cole, S. R. and E. A. Stuart (2010). Generalizing evidence from randomized clinical trials to target populations: The actg 320 trial. *American Journal of Epidemiology* 172, 107–115.
- Colnet, B., J. Josse, G. Varoquaux, and E. Scornet (2022a, 11). Causal effect on a target population: A sensitivity analysis to handle missing covariates. *Journal of Causal Inference* 10, 372–414.
- Colnet, B., J. Josse, G. Varoquaux, and E. Scornet (2022b). Reweighting the rct for generalization: finite sample analysis and variable selection. *arXiv preprint arXiv:2208.07614*.
- Colnet, B., I. Mayer, G. Chen, A. Dieng, R. Li, G. Varoquaux, J.-P. Vert, J. Josse, and S. Yang (2020). Causal inference methods for combining randomized trials and observational studies: a review.

- Concato, J., N. Shah, and R. Horwitz (2000). Randomized, controlled trials, observational studies, and the hierarchy of research designs. *The New England journal of medicine* 342, 1887–1892.
- Cook, R. J. and D. L. Sackett (1995). The number needed to treat: a clinically useful measure of treatment effect. *Bmj* 310(6977), 452–454.
- Cook, T. D., D. T. Campbell, and W. Shadish (2002). *Experimental and quasi-experimental designs for generalized causal inference*. Houghton Mifflin Boston, MA.
- Cooper, G. (1995). Causal discovery from data in the presence of selection bias. In *Proceedings of the Fifth International Workshop on Artificial Intelligence and Statistics*, pp. 140–150.
- Cornfield, J. et al. (1951). A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. *Journal of the National Cancer Institute*, 1269–1275.
- Cornfield, J., W. Haenszel, E. C. Hammond, A. M. Lilienfeld, M. B. Shimkin, and E. L. Wynder (1959, 01). Smoking and Lung Cancer: Recent Evidence and a Discussion of Some Questions. *JNCI: Journal of the National Cancer Institute* 22(1), 173–203.
- Correa, J. D., J. Tian, and E. Bareinboim (2018). Generalized adjustment under confounding and selection biases. In *Thirty-Second AAAI Conference on Artificial Intelligence*.
- CRASH-3 (2019). Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. *The Lancet* 394(10210), 1713–1723.
- Cro, S., T. P. Morris, B. C. Kahan, V. R. Cornelius, and J. R. Carpenter (2020). A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic.
- Crofton, J. (2006). The mrc randomized trial of streptomycin and its legacy: a view from the clinical front line. *Journal of the Royal Society of Medicine* 99(10), 531–534.
- Crofton, J. and D. Mitchison (1948). Streptomycin resistance in pulmonary tuberculosis. *British medical journal* 2(4588), 1009.
- Cummings, P. (2009, 05). The Relative Merits of Risk Ratios and Odds Ratios. *Archives of Pediatrics & Adolescent Medicine* 163(5), 438–445.
- Dagan, N., N. Barda, E. Kepten, O. Miron, S. Perchik, M. A. Katz, M. A. Hernán, M. Lipsitch, B. Reis, and R. D. Balicer (2021). Bnt162b2 mrna covid-19 vaccine in a nationwide mass vaccination setting. *New England Journal of Medicine* 384(15), 1412–1423.
- Dahabreh, I. J., S. J. A. Haneuse, J. M. Robins, S. E. Robertson, A. L. Buchanan, E. A. Stuart, and M. A. Hernán (2021). Study designs for extending causal inferences from a randomized trial to a target population. *American journal of epidemiology* 190(8), 1632–1642.
- Dahabreh, I. J., S. E. Robertson, J. A. Steingrimsson, E. A. Stuart, and M. A. Hernán (2020). Extending inferences from a randomized trial to a new target population. *Statistics in Medicine* 39(14), 1999–2014.
- Dahabreh, I. J., S. E. Robertson, E. J. T. Tchetgen, E. A. Stuart, and M. A. Hernán (2019). Generalizing causal inferences from individuals in randomized trials to all trial-eligible individuals. *Biometrics* 75, 685–694.
- Dahabreh, I. J., J. M. Robins, S. J. Haneuse, and M. A. Hernán (2019). Generalizing causal inferences from randomized trials: counterfactual and graphical identification. *arXiv preprint arXiv:1906.10792*.

- Dahabreh, I. J., J. M. Robins, S. J.-P. A. Haneuse, I. Saeed, S. E. Robertson, E. A. Stuart, and M. A. Hernán (2019). Sensitivity analysis using bias functions for studies extending inferences from a randomized trial to a target population.
- Dahabreh, I. J., J. M. Robins, and M. A. Hernán (2020). Benchmarking observational methods by comparing randomized trials and their emulations. *Epidemiology* 31(5), 614–619.
- D’Amour, A., P. Ding, A. Feller, L. Lei, and J. Sekhon (2017, 11). Overlap in observational studies with high-dimensional covariates. *Journal of Econometrics* 221.
- Daniel, R., J. Zhang, and D. Farewell (2020, 12). Making apples from oranges: Comparing non-collapsible effect estimators and their standard errors after adjustment for different covariate sets. *Biometrical Journal* 63.
- Davies, H. T. O., I. K. Crombie, and M. Tavakoli (1998). When can odds ratios mislead? *Bmj* 316(7136), 989–991.
- Dawid, P., M. Humphreys, and M. Musio (2019). Bounding causes of effects with mediators. Technical Report 1907.00399, arXiv.
- Deaton, A. and N. Cartwright (2018). Understanding and misunderstanding randomized controlled trials. *Social Science & Medicine* 210, 2–21. Randomized Controlled Trials and Evidence-based Policy: A Multidisciplinary Dialogue.
- Deaton, A., S. C. Case, N. Côté, J. Drèze, W. Easterly, R. Khera, L. Pritchett, and C. R. Reddy (2019). Randomization in the tropics revisited: a theme and eleven variations. *Randomized controlled trials in the field of development: A critical perspective*. Oxford University Press. Forthcoming.
- Deeks, J. (2002, June). Issues in the selection of a summary statistic in meta-analysis of clinical trials with binary outcomes. *Statistics in Medicine* 21(11), 1575–1600.
- Degtiar, I., T. Layton, J. Wallace, and S. Rose (2021). Conditional cross-design synthesis estimators for generalizability in medicaid.
- Degtiar, I. and S. Rose (2023). A review of generalizability and transportability. *Annual Review of Statistics and Its Application* 10, 501–524.
- Dempster, A. P., N. M. Laird, and D. B. Rubin (1977). Maximum likelihood from incomplete data via the em algorithm. *J. R. Stat. Soc. Ser. B.*, 1–38.
- Dewan, Y., E. Komolafe, J. Mejia-Mantilla, P. Perel, I. Roberts, and H. Shakur-Still (2012, 06). CRASH-3: Tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. *Trials* 13, 87.
- Didelez, V., S. Kreiner, and N. Keiding (2010). Graphical Models for Inference Under Outcome-Dependent Sampling. *Statistical Science* 25(3), 368 – 387.
- Didelez, V. and M. J. Stensrud (2022). On the logic of collapsibility for causal effect measures. *Biometrical Journal* 64(2), 235–242.
- Ding, P., A. Feller, and L. Miratrix (2016, June). Randomization inference for treatment effect variation. *Journal of the Royal Statistical Society Series B* 78(3), 655–671.
- Ding, Y., H.-M. Lin, and J. C. Hsu (2016). Subgroup mixable inference on treatment efficacy in mixture populations, with an application to time-to-event outcomes. *Statistics in medicine* 35(10), 1580–1594.
- Doi, S., L. Furuya-Kanamori, C. Xu, L. Lin, T. Chivese, and L. Thalib (2020, 11). Questionable utility of the relative risk in clinical research: A call for change to practice. *Journal of Clinical Epidemiology*.

- Doi, S. A., L. Furuya-Kanamori, C. Xu, T. Chivese, L. Lin, O. A. Musa, G. Hindy, L. Thalib, and F. E. Harrell Jr (2022). The odds ratio is “portable” across baseline risk but not the relative risk: Time to do away with the log link in binomial regression. *Journal of Clinical Epidemiology* 142, 288–293.
- Doi, S. A., L. Furuya-Kanamori, C. Xu, L. Lin, T. Chivese, and L. Thalib (2022). Controversy and debate: Questionable utility of the relative risk in clinical research: Paper 1: A call for change to practice. *Journal of Clinical Epidemiology* 142, 271–279.
- Dong, L., S. Yang, X. Wang, D. Zeng, and J. Cai (2020). Integrative analysis of randomized clinical trials with real world evidence studies. *arXiv preprint arXiv:2003.01242*.
- Dorie, V., M. Harada, N. Carnegie, and J. Hill (2016, September). A flexible, interpretable framework for assessing sensitivity to unmeasured confounding. *Statistics in Medicine* 35(20), 3453–3470.
- Doutreligne, M., A. Degremont, P.-A. Jachiet, A. Lamer, and X. Tannier (2023). Good practices for clinical data warehouse implementation: a case study in france.
- D’Amour, A., P. Ding, A. Feller, L. Lei, and J. Sekhon (2021). Overlap in observational studies with high-dimensional covariates. *Journal of Econometrics* 221(2), 644–654.
- Edvinsson, L. (2021). Oral rimegepant for migraine prevention. *The Lancet* 397(10268), 4–5.
- Efron, B. and D. V. Hinkley (1978). Assessing the accuracy of the maximum likelihood estimator: Observed versus expected fisher information. *Biometrika* 65(3), 457–482.
- Egami, N. and E. Hartman (2021, 08). Covariate selection for generalizing experimental results: Application to a large-scale development program in uganda\*. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 184.
- Evans, A. (2001). Benjamin guy babington: founding president of the london epidemiological society. *International journal of epidemiology* 30 2, 226–30.
- Eyler, J. M. (2004). The changing assessments of john snow’s and william farr’s cholera studies. *A History of Epidemiologic Methods and Concepts*, 129–139.
- Farr, W. (1839). Letter to the registrar general. *First annual report of the Registrar General*.
- Farr, W. (1864). *English Life Tables: Tables of Lifetimes, Annuities, and Premiums: With an Introduction*. HM Stationery Office.
- FDA (2018, December). Framework for fda’s real-world evidence program.
- Feng, C., B. Wang, and W. Hongyue (2019, 07). The relations among three popular indices of risks. *Statistics in Medicine* 38.
- Forrow, L., W. C. Taylor, and R. M. Arnold (1992). Absolutely relative: How research results are summarized can affect treatment decisions. *The American Journal of Medicine* 92(2), 121–124.
- Franks, A., A. D’Amour, and A. Feller (2019, 04). Flexible sensitivity analysis for observational studies without observable implications. *Journal of the American Statistical Association*, 1–38.
- Frieden, T. (2017, 08). Evidence for health decision making - beyond randomized, controlled trials. *New England Journal of Medicine* 377, 465–475.
- Friendly, M. and M. Sigal (2020). Visualizing tests for equality of covariance matrices. *The American Statistician* 74(2), 144–155.
- Gao, Z. and T. Hastie (2021). Estimating heterogeneous treatment effects for general responses. *arXiv preprint arXiv:2103.04277*.

- Gatsonis, C. and M. C. Sally (2017). *Methods in Comparative Effectiveness Research*, pp. 177–199. Chapman & Hall.
- Geneletti, S., S. Richardson, and N. Best (2008, 05). Adjusting for selection bias in retrospective, case–control studies. *Biostatistics* 10(1), 17–31.
- George, A., T. S. Stead, and L. Ganti (2020). What’s the risk: Differentiating risk ratios, odds ratios, and hazard ratios? *Cureus* 12.
- Godwin, M., L. Ruhland, I. Casson, S. MacDonald, D. Delva, R. Birtwhistle, M. Lam, and R. Seguin (2003). Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. *BMC medical research methodology* 3, 1–7.
- Gordon, B. R., F. Zettelmeyer, N. Bhargava, and D. Chapsky (2019, March). A Comparison of Approaches to Advertising Measurement: Evidence from Big Field Experiments at Facebook. *Marketing Science* 38(2), 193–225.
- Green, L. and R. Glasgow (2006, 04). Evaluating the relevance, generalization, and applicability of research issues in external validation and translation methodology. *Evaluation & the health professions* 29, 126–53.
- Greenland, S. (1987, 05). Interpretation and choice of effect measures in epidemiologic analyses. *American Journal of Epidemiology* 125(5), 761–768.
- Greenland, S. and J. Pearl (2011, 12). Adjustments and their consequences—collapsibility analysis using graphical models. *International Statistical Review / Revue Internationale de Statistique* 79.
- Greenland, S., J. M. Robbins, and J. Pearl (1999, 01). Confounding and collapsibility in causal inference. *Statistical Science* 14, 29–46.
- Grose, E., S. Wilson, J. Barkun, K. Bertens, G. Martel, F. Balaa, and J. Abou Khalil (2020). Use of propensity score methodology in contemporary high-impact surgical literature. *Journal of the American College of Surgeons* 230(1), 101–112.
- Guo, F. R. and E. Perković (2022). Efficient least squares for estimating total effects under linearity and causal sufficiency. *The Journal of Machine Learning Research* 23(1), 4503–4543.
- Guo, R., L. Cheng, J. Li, P. R. Hahn, and H. Liu (2020). A survey of learning causality with data: Problems and methods. *ACM Computing Surveys (CSUR)* 53(4), 1–37.
- Guo, W., S. Wang, P. Ding, Y. Wang, and M. I. Jordan (2021). Multi-source causal inference using control variates. *arXiv preprint arXiv:2103.16689*.
- Guyatt, G., D. Rennie, M. O. Meade, and D. J. Cook (2015). *Users’ Guides to the Medical Literature : A Manual for Evidence-Based Clinical Practice*. New York: McGraw-Hill Education.
- Guyatt, G. H., D. L. Sackett, J. C. Sinclair, R. Hayward, D. J. Cook, R. J. Cook, E. Bass, H. Gerstein, B. Haynes, A. Holbrook, et al. (1995). Users’ guides to the medical literature: Ix. a method for grading health care recommendations. *Jama* 274(22), 1800–1804.
- Hahn, J. (1998). On the role of the propensity score in efficient semiparametric estimation of average treatment effects. *Econometrica* 66(2), 315–332.
- Hahn, J. (2004, 02). Functional restriction and efficiency in causal inference. *The Review of Economics and Statistics* 86, 73–76.
- Hahn, J., P. Todd, and W. Van der Klaauw (2001). Identification and estimation of treatment effects with a regression-discontinuity design. *Econometrica* 69(1), 201–209.



- Hahn, P. R., J. S. Murray, C. M. Carvalho, et al. (2020). Bayesian regression tree models for causal inference: regularization, confounding, and heterogeneous effects. *Bayesian Analysis*.
- Hainmueller, J. (2012). Entropy balancing for causal effects: A multivariate reweighting method to produce balanced samples in observational studies. *Political Analysis* 20, 25–46.
- Harshaw, C., J. A. Middleton, and F. Sävje (2021). Optimized variance estimation under interference and complex experimental designs.
- Hartman, E. (2021). *Generalizing Experimental Results*, pp. 385–410. Cambridge University Press.
- Hartman, E., R. Grieve, R. Ramsahai, and J. S. Sekhon (2015). From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 178(3), 757–778.
- He, Z., X. Tang, X. Yang, Y. Guo, T. George, N. Charness, K. Hem, W. Hogan, and J. Bian (2020, 02). Clinical trial generalizability assessment in the big data era: A review. *Clinical and Translational Science* 13.
- Henckel, L., E. Perković, and M. H. Maathuis (2019). Graphical criteria for efficient total effect estimation via adjustment in causal linear models.
- Henry, J., Y. Pylypchuk, T. Searcy, V. Patel, et al. (2016). Adoption of electronic health record systems among us non-federal acute care hospitals: 2008–2015. *ONC data brief* 35(35), 2008–2015.
- Hernan, MA Robins, J. (2020). *Causal Inference: What If*. Boca Raton: Chapman & Hall/CRC.
- Hernán, M., D. Clayton, and N. Keiding (2011, 03). The simpson’s paradox unraveled. *International journal of epidemiology* 40, 780–5.
- Hernán, M. and J. Robins (2006, 08). Instruments for causal inference: An epidemiologist’s dream? *Epidemiology (Cambridge, Mass.)* 17, 360–72.
- Hernán, M. A., S. R. Cole, J. Margolick, M. Cohen, and J. M. Robins (2005). Structural accelerated failure time models for survival analysis in studies with time-varying treatments. *Pharmacoepidemiology and Drug Safety* 14, 477–491.
- Hernán, M. A. and J. M. Robins (2016). Using big data to emulate a target trial when a randomized trial is not available. *American journal of epidemiology* 183(8), 758–764.
- Hernán, M. A. and T. J. VanderWeele (2011). Compound treatments and transportability of causal inference. *Epidemiology* 22, 368.
- Hill, J. L. (2011). Bayesian nonparametric modeling for causal inference. *Journal of Computational and Graphical Statistics* 20(1), 217–240.
- Hirano, K., G. Imbens, and G. Ridder (2003, 02). Efficient estimation of average treatment effects using the estimated propensity score. *Econometrica* 71, 1161–1189.
- Hobbs, B. P., D. J. Sargent, and B. P. Carlin (2012). Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. *Bayesian Analysis* 7(3), 639 – 674.
- Holmes, S., C. Morris, R. Tibshirani, and B. Efron (2003). Bradley efron: A conversation with good friends. *Statistical Science*, 268–281.
- Horvitz, D. G. and D. J. Thompson (1952). A generalization of sampling without replacement from a finite universe. *Journal of the American Statistical Association* 47(260), 663–685.

- Hotz, J., G. Imbens, and J. Mortimer (2005). Predicting the efficacy of future training programs using past experiences at other locations. *Journal of Econometrics* 125(1-2), 241–270.
- Hu, Y., S. Li, and S. Wager (2022). Average direct and indirect causal effects under interference. *Biometrika* 109(4), 1165–1172.
- Huang, M. (2022). Sensitivity analysis in the generalization of experimental results.
- Huang, M., N. Egami, E. Hartman, and L. Miratrix (2021). Leveraging population outcomes to improve the generalization of experimental results.
- Huang, Y. and M. Valtorta (2006). Pearl’s calculus of intervention is complete. In *Proceedings of the Twenty-Second Conference on Uncertainty in Artificial Intelligence*, UAI’06, Arlington, Virginia, USA, pp. 217–224. AUAI Press.
- Huitfeldt, A. (2019). Effect heterogeneity and external validity in medicine. Available in: <https://www.lesswrong.com/posts/wwbrvumMWhDfeo652>.
- Huitfeldt, A., M. P. Fox, E. J. Murray, A. Hr’objartsson, and R. M. Daniel (2021). Shall we count the living or the dead?
- Huitfeldt, A., A. Goldstein, and S. A. Swanson (2018). The choice of effect measure for binary outcomes: Introducing counterfactual outcome state transition parameters. *Epidemiologic methods* 7(1).
- Huitfeldt, A., M. Stensrud, and E. Suzuki (2019, 01). On the collapsibility of measures of effect in the counterfactual causal framework. *Emerging Themes in Epidemiology* 16.
- Huitfeldt, A. and M. J. Stensrud (2018). Re: generalizing study results: a potential outcomes perspective. *Epidemiology* 29(2), e13–e14.
- Huitfeldt, A., S. Swanson, M. Stensrud, and E. Suzuki (2019, 12). Effect heterogeneity and variable selection for standardizing causal effects to a target population. *European Journal of Epidemiology* 34.
- Hünermund, P. and E. Bareinboim (2019). Causal inference and data-fusion in econometrics. *arXiv preprint arXiv:1912.09104*.
- Ichino, A., T. Nannicini, and F. Mealli (2008, 04). From temporary help jobs to permanent employment: What can we learn from matching estimators and their sensitivity? *Journal of Applied Econometrics* 23, 305–327.
- Imai, K., G. King, and E. A. Stuart (2008). Misunderstandings between experimentalists and observationalists about causal inference. *Journal of the royal statistical society: series A (statistics in society)* 171(2), 481–502.
- Imbens, G. (2003). Sensitivity to exogeneity assumptions in program evaluation. *The American Economic Review*.
- Imbens, G. (2014). Instrumental variables: an econometrician’s perspective. Technical report, National Bureau of Economic Research.
- Imbens, G. W. (2011). Experimental design for unit and cluster randomid trials. *International Initiative for Impact Evaluation Paper*.
- Imbens, G. W. and D. B. Rubin (2015). *Causal Inference in Statistics, Social, and Biomedical Sciences*. Cambridge UK: Cambridge University Press.
- Jeong, S. and H. Namkoong (2022, February). Assessing External Validity Over Worst-case Subpopulations. *arXiv:2007.02411 [cs, econ, stat]*. arXiv: 2007.02411.

- Jiang, W., J. Josse, M. Lavielle, and T. Group (2020). Logistic regression with missing covariates—parameter estimation, model selection and prediction within a joint-modeling framework. *Computational Statistics & Data Analysis* 145, 106907.
- Jiménez, F. J., E. Guallar, and J. M. Martin-Moreno (1997). A graphical display useful for meta-analysis. *European Journal of Public Health* 7, 101–105.
- Johnson, A. E., T. J. Pollard, L. Shen, L.-w. H. Lehman, M. Feng, M. Ghassemi, B. Moody, P. Szolovits, L. Anthony Celi, and R. G. Mark (2016). Mimic-iii, a freely accessible critical care database. *Scientific data* 3(1), 1–9.
- Jolani, S., T. Debray, H. Koffijberg, S. van Buuren, and K. Moons (2015). Imputation of systematically missing predictors in an individual participant data meta-analysis: a generalized approach using mice. *Statistics in medicine* 34(11), 1841–1863.
- Josey, K. P., S. A. Berkowitz, D. Ghosh, and S. Raghavan (2021, May). Transporting experimental results with entropy balancing. *Statistics in Medicine* 40(19), 4310–4326.
- Josse, J., N. Prost, E. Scornet, and G. Varoquaux (2019). On the consistency of supervised learning with missing values. *arXiv preprint arXiv:1902.06931*.
- Jung, Y., J. Tian, and E. Bareinboim (2020a). Estimating causal effects using weighting-based estimators. In *Proceedings of the AAAI Conference on Artificial Intelligence*, Volume 34, pp. 10186–10193.
- Jung, Y., J. Tian, and E. Bareinboim (2020b). Learning causal effects via weighted empirical risk minimization. In H. Larochelle, M. Ranzato, R. Hadsell, M. F. Balcan, and H. Lin (Eds.), *Advances in Neural Information Processing Systems*, Volume 33, pp. 12697–12709. Curran Associates, Inc.
- Jung, Y., J. Tian, and E. Bareinboim (2021, May). Estimating identifiable causal effects through double machine learning. *Proceedings of the AAAI Conference on Artificial Intelligence* 35(13), 12113–12122.
- Kallus, N., X. Mao, and M. Udell (2018). Causal inference with noisy and missing covariates via matrix factorization. In *Advances in neural information processing systems*, pp. 6921–6932.
- Kallus, N., A. M. Puli, and U. Shalit (2018). Removing hidden confounding by experimental grounding. In *Advances in Neural Information Processing Systems*, pp. 10888–10897.
- Karvanen, J., S. Tikka, and A. Hyttinen (2020). Do-search: a tool for causal inference and study design with multiple data sources. *Epidemiology* 32(1), 111–119.
- Keiding, N. and T. A. Louis (2016). Perils and potentials of self-selected entry to epidemiological studies and surveys. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 179, 319–376.
- Kennedy, E. H. (2016). Semiparametric theory and empirical processes in causal inference. In *Statistical Causal Inferences and Their Applications in Public Health Research*, pp. 141–167. Springer.
- Kennedy-Martin, T., S. Curtis, D. Faries, S. Robinson, and J. Johnston (2015). A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. *Trials* 16, 1–14.
- Kenward, M. (2013). The handling of missing data in clinical trials. *Clinical Investigation* 3(3), 241–250.
- Kern, H. L., E. A. Stuart, J. Hill, and D. P. Green (2016). Assessing methods for generalizing experimental impact estimates to target populations. *Journal of research on educational effectiveness* 9(1), 103–127.

- King, G. and L. Zeng (2002). Estimating risk and rate levels, ratios and differences in case-control studies. *Statistics in medicine* 21(10), 1409–1427.
- Knaus, M. C., M. Lechner, and A. Strittmatter (2021). Machine learning estimation of heterogeneous causal effects: Empirical monte carlo evidence. *The Econometrics Journal* 24(1), 134–161.
- Kreif, N. and K. DiazOrdaz (2019). Machine learning in policy evaluation: new tools for causal inference. *ArXiv abs/1903.00402*.
- Krieger, N. (1994). Epidemiology and the web of causation: has anyone seen the spider? *Social science & medicine* 39(7), 887–903.
- Krueger, A. B. (1999a). Experimental estimates of education production functions. *The quarterly journal of economics* 114(2), 497–532.
- Krueger, A. B. (1999b). Experimental Estimates of Education Production Functions. *The Quarterly Journal of Economics* 114(2), 497–532.
- Künzel, S. R., J. S. Sekhon, P. J. Bickel, and B. Yu (2019). Metalearners for estimating heterogeneous treatment effects using machine learning. *Proceedings of the national academy of sciences* 116(10), 4156–4165.
- Künzel, S. R., S. J. Walter, and J. S. Sekhon (2019). Causaltoolbox—estimator stability for heterogeneous treatment effects. *Observational Studies* 5(2), 105–117.
- Künzel, S., J. Sekhon, P. Bickel, and B. Yu (2017, 06). Meta-learners for estimating heterogeneous treatment effects using machine learning. *Proceedings of the National Academy of Sciences* 116.
- Laan, M. and S. Rose (2011, 01). *Targeted Learning: Causal Inference for Observational and Experimental Data*.
- L’abbé, K. A., A. S. Detsky, and K. O’rourke (1987). Meta-analysis in clinical research. *Annals of internal medicine* 107 2, 224–33.
- Lane-Clayton, J. E. et al. (1926). A further report on cancer of the breast with special reference to its associated antecedent conditions. *A Further Report on Cancer of the Breast with Special Reference to its Associated Antecedent Conditions*. (32).
- Langmuir, A. D. (1976). William farr: founder of modern concepts of surveillance. *International journal of epidemiology* 5(1), 13–18.
- Lapointe-Shaw, L., G. Babe, P. C. Austin, A. P. Costa, and A. Jones (2022, Nov.). Reporting risk: from math to meaning. *Canadian Journal of General Internal Medicine* 17(4), 59–66.
- Laupacis, A., D. L. Sackett, and R. S. Roberts (1988). An assessment of clinically useful measures of the consequences of treatment. *New England Journal of Medicine* 318(26), 1728–1733. PMID: 3374545.
- Lauritzen, S. L. and T. S. Richardson (2008). Discussion of mccullagh: Sampling bias and logistic models. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 70(4), 671.
- Lê, S., J. Josse, and F. Husson (2008). FactoMineR: A package for multivariate analysis. *Journal of Statistical Software* 25(1), 1–18.
- Lee, D., S. Ghosh, and S. Yang (2022). Transporting survival of an HIV clinical trial to the external target populations. *arXiv preprint arXiv:2210.02571*.
- Lee, D., S. Yang, and X. Wang (2022). Doubly robust estimators for generalizing treatment effects on survival outcomes from randomized controlled trials to a target population. *Journal of Causal Inference* (accepted).

- Lee, S., J. Correa, and E. Bareinboim (2020a, Apr.). General transportability – synthesizing observations and experiments from heterogeneous domains. *Proceedings of the AAAI Conference on Artificial Intelligence* 34(06), 10210–10217.
- Lee, S., J. D. Correa, and E. Bareinboim (2020b, 22–25 Jul). General identifiability with arbitrary surrogate experiments. In R. P. Adams and V. Gogate (Eds.), *Proceedings of The 35th Uncertainty in Artificial Intelligence Conference*, Volume 115 of *Proceedings of Machine Learning Research*, pp. 389–398. PMLR.
- Lefebvre, G., J. Delaney, and R. Platt (2008, 08). Impact of mis-specification of the treatment model on estimates from a marginal structural model. *Statistics in medicine* 27, 3629–42.
- Lesko, C. R., A. L. Buchanan, D. Westreich, J. K. Edwards, M. G. Hudgens, and S. R. Cole (2017). Generalizing study results: a potential outcomes perspective. *Epidemiology (Cambridge, Mass.)* 28(4), 553.
- Lesko, C. R., S. R. Cole, H. I. Hall, D. Westreich, W. C. Miller, J. J. Eron, J. Li, M. J. Mugavero, and for the CNICS Investigators (2016, 01). The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. *International Journal of Epidemiology* 45(1), 140–150.
- Lesko, C. R., N. C. Henderson, and R. Varadhan (2018). Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research. *Journal of clinical epidemiology* 100, 22–31.
- Li, F., A. L. Buchanan, and S. R. Cole (2021). Generalizing trial evidence to target populations in non-nested designs: Applications to aids clinical trials.
- Li, F., H. Hong, and E. A. Stuart (2021). A note on semiparametric efficient generalization of causal effects from randomized trials to target populations. *Communications in Statistics - Theory and Methods* 0(0), 1–32.
- Li, P. and E. A. Stuart (2019). Best (but oft-forgotten) practices: missing data methods in randomized controlled nutrition trials. *The American journal of clinical nutrition* 109(3), 504–508.
- Liberati, A., D. Altman, J. Tetzlaff, and C. Mulrow (2009). Gøtzsche pc, ioannidis jp, et al. the prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 62(10), e1–34.
- Ling, A. Y., M. E. Montez-Rath, P. Carita, K. Chandross, L. Lucats, Z. Meng, B. Sebastien, K. Kaphahn, and M. Desai (2022). A critical review of methods for real-world applications to generalize or transport clinical trial findings to target populations of interest.
- Linstone, H. and M. Turoff (1975, 01). *The Delphi Method: Techniques and Applications*, Volume 18.
- Lipsitch, M., E. J. T. Tchetgen, and T. Cohen (2010). Negative controls: A tool for detecting confounding and bias in observational studies. *Epidemiology* 21, 383–388.
- Liu, R., S. Rizzo, S. Whipple, N. Pal, A. Lopez Pineda, M. Lu, B. Arnieri, Y. Lu, W. Capra, R. Copping, and J. Zou (2021, 04). Evaluating eligibility criteria of oncology trials using real-world data and ai. *Nature* 592.
- Liu, Y., B. Wang, H. Tian, and J. C. Hsu (2022). Rejoinder for discussions on correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials. *Biometrical Journal* 64(2), 246–255.
- Liu, Y., B. Wang, M. Yang, J. Hui, H. Xu, S. Kil, and J. C. Hsu (2022). Correct and logical causal inference for binary and time-to-event outcomes in randomized controlled trials. *Biometrical Journal* 64(2), 198–224.

- Lodi, S., A. Phillips, J. Lundgren, R. Logan, S. Sharma, S. Cole, A. Babiker, M. Law, H. Chu, D. Byrne, A. Horban, J. Sterne, K. Porter, C. Sabin, D. Costagliola, S. Abgrall, M. Gill, G. Touloumi, A. Pacheco, and M. Hernán (2019, 05). Effect estimates in randomized trials and observational studies: Comparing apples with apples. *American Journal of Epidemiology* 188.
- Lodi, S., A. Phillips, J. Lundgren, R. Logan, S. Sharma, S. R. Cole, A. Babiker, M. Law, H. Chu, D. Byrne, et al. (2019). Effect estimates in randomized trials and observational studies: comparing apples with apples. *American journal of epidemiology* 188(8), 1569–1577.
- Louis, P. C. A. (1828). *Recherches sur les effets de la saignée dans plusieurs maladies inflammatoires*. Migneret.
- Louizos, C., U. Shalit, J. M. Mooij, D. Sontag, R. Zemel, and M. Welling (2017). Causal effect inference with deep latent-variable models. In *Advances in Neural Information Processing Systems*, pp. 6446–6456.
- Lu, Y., D. O. Scharfstein, M. M. Brooks, K. Quach, and E. H. Kennedy (2019). Causal inference for comprehensive cohort studies. *arXiv preprint arXiv:1910.03531*.
- Lunceford, J. K. and M. Davidian (2004). Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. In *Statistics in Medicine*, pp. 2937–2960.
- MacMahon, S., R. Peto, R. Collins, J. Godwin, J. Cutler, P. Sorlie, R. Abbott, J. Neaton, A. Dyer, and J. Stamler (1990). Blood pressure, stroke, and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *The Lancet* 335(8692), 765–774.
- Mansukhani, R., L. Frimley, H. Shakur-Still, L. Sharples, and I. Roberts (2020, 07). Accuracy of time to treatment estimates in the crash-3 clinical trial: impact on the trial results. *Trials* 21.
- Marquis de Laplace, P. S. (1825). *Essai philosophique sur les probabilités*. Bachelier.
- Martel Garcia, F. and L. Wantchekon (2010). Theory, external validity, and experimental inference: Some conjectures. *The ANNALS of the American Academy of Political and Social Science* 628(1), 132–147.
- Martinussen, T. and S. Vansteelandt (2013). On collapsibility and confounding bias in cox and aalen regression models. *Lifetime data analysis* 19(3), 279–296.
- Mayer, I., S. Aude, N. Tierney, N. Vialaneix, and J. Josse (2019). R-miss-tastic: a unified platform for missing values methods and workflows. *R journal*.
- Mayer, I., J. Josse, and Traumabase Group (2021). Generalizing treatment effects with incomplete covariates: identifying assumptions and multiple imputation algorithms. *arXiv preprint arXiv:2104.12639*.
- Mayer, I., E. Sverdrup, T. Gauss, J.-D. Moyer, S. Wager, and J. Josse (2020). Doubly robust treatment effect estimation with missing attributes. *Ann. Appl. Statist.* 14(3), 1409–1431.
- Mayer, I., P. Zhao, N. Greifer, N. Huntington-Klein, and J. Josse (2022). Cran task view: Causal inference.
- Meinshausen, N. (2018). Causality from a distributional robustness point of view. In *2018 IEEE Data Science Workshop (DSW)*, pp. 6–10. IEEE.
- Miettinen, O. S. (1972). Standardization of risk ratios. *American Journal of Epidemiology* 96(6), 383–388.

- Miettinen, O. S. and E. F. Cook (1981, 10). Confounding: Essence and Detection. *American Journal of Epidemiology* 114(4), 593–603.
- Mills, A. (1999, 11). Clinical implications. Avoiding problems in clinical practice after the pill scare. *Human Reproduction Update* 5(6), 639–653.
- Miratrix, L. W., J. S. Sekhon, A. G. Theodoridis, and L. F. Campos (2017). Worth weighting? how to think about and use weights in survey experiments.
- Miratrix, L. W., J. S. Sekhon, and B. Yu (2013). Adjusting treatment effect estimates by post-stratification in randomized experiments. *Journal of the Royal Statistical Society Series B* 75, 369–396.
- Moher, D., D. J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D. F. Stroup (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the quorum statement. *The Lancet* 354(9193), 1896–1900.
- Morabia, A. (2006). Pierre-charles-alexandre louis and the evaluation of bloodletting. *Journal of the Royal Society of Medicine* 99(3), 158–160.
- Morabia, A. (2018). Claude bernard, statistics and comparative trials. *Journal of the Royal Society of Medicine* 111(9), 335–336.
- Moynihan, R., L. Bero, D. Ross-Degnan, D. Henry, K. Lee, J. Watkins, C. Mah, and S. B. Soumerai (2000). Coverage by the news media of the benefits and risks of medications. *New England journal of medicine* 342(22), 1645–1650.
- National Research Council (2012). The prevention and treatment of missing data in clinical trials. *N Engl J Med* 367, 1355–1360.
- Neuhaus S, J. M. and N. P. Jewell (1993, 12). A geometric approach to assess bias due to omitted covariates in generalized linear models. *Biometrika* 80(4), 807–815.
- Neyman, J. (1923). Sur les applications de la thar des probabilités aux expériences Agaricales: Essay de principe. English translation of excerpts by Dabrowska, D. and Speed, T. *Statistical Science* 5, 465–472.
- Nguyen, T., B. Ackerman, I. Schmid, S. Cole, and E. Stuart (2018, 12). Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details. *PLOS ONE* 13, e0208795.
- Nguyen, T. Q., C. Ebnesaajjad, S. R. Cole, E. A. Stuart, et al. (2017). Sensitivity analysis for an unobserved moderator in rct-to-target-population generalization of treatment effects. *The Annals of Applied Statistics* 11(1), 225–247.
- Nie, X., G. Imbens, and S. Wager (2021). Covariate balancing sensitivity analysis for extrapolating randomized trials across locations.
- Nie, X. and S. Wager (2020, 09). Quasi-oracle estimation of heterogeneous treatment effects. *Biometrika* 108(2), 299–319.
- Nuovo, J., J. Melnikow, and D. Chang (2002, 06). Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials. *JAMA* 287(21), 2813–2814.
- Ogburn, E. L., O. Sofrygin, I. Diaz, and M. J. Van der Laan (2022). Causal inference for social network data. *Journal of the American Statistical Association*, 1–15.
- Ogburn, E. L. and T. J. VanderWeele (2014). Causal diagrams for interference.

- O’Kelly, M. and B. Ratitch (2014). *Clinical trials with missing data: a guide for practitioners*. John Wiley & Sons.
- O’Muircheartaigh, C. and L. Hedges (2013, 11). Generalizing from unrepresentative experiments: A stratified propensity score approach. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 63.
- O’Muircheartaigh, C. and L. V. Hedges (2014). Generalizing from unrepresentative experiments: a stratified propensity score approach. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 63, 195–210.
- Pearl, J. (1993). [Bayesian Analysis in Expert Systems]: Comment: graphical models, causality and intervention. *Statistical Science* 8(3), 266–269.
- Pearl, J. (1995). Causal diagrams for empirical research. *Biometrika* 82(4), 669–688.
- Pearl, J. (2000). *Causality: Models, Reasoning, and Inference*. Cambridge University Press.
- Pearl, J. (2009a). Causal inference in statistics: An overview. *Statistics Surveys* 3, 96 – 146.
- Pearl, J. (2009b). *Causality* (2 ed.). Cambridge: Cambridge University Press.
- Pearl, J. (2015). Generalizing experimental findings. *Journal of Causal Inference* 3(2), 259–266.
- Pearl, J. and E. Bareinboim (2011a). Transportability of causal and statistical relations: A formal approach. In *Proceedings of the Twenty-Fifth AAAI Conference on Artificial Intelligence, AAAI’11*, pp. 247–254. AAAI Press.
- Pearl, J. and E. Bareinboim (2011b, Aug.). Transportability of causal and statistical relations: A formal approach. *Proceedings of the AAAI Conference on Artificial Intelligence* 25(1).
- Pearl, J. and E. Bareinboim (2014). External Validity: From Do-Calculus to Transportability Across Populations. *Statistical Science* 29(4), 579 – 595.
- Pearl, J. and D. Mackenzie (2018). *The book of why: the new science of cause and effect*. Basic books.
- Peters, J., D. Janzing, and B. Schölkopf (2017). *Elements of causal inference*. The MIT Press.
- Pocock, S. J. (1976). The combination of randomized and historical controls in clinical trials. *Journal of Chronic Diseases* 29(3), 175–188.
- Pool, R., C. M. Montgomery, N. S. Morar, O. Mweemba, A. Ssali, M. Gafos, S. Lees, J. Stadler, A. Nunn, A. Crook, et al. (2010). Assessing the accuracy of adherence and sexual behaviour data in the mdp301 vaginal microbicides trial using a mixed methods and triangulation model. *PloS one* 5(7), e11632.
- Powers, S., J. Qian, K. Jung, A. Schuler, N. H. Shah, T. Hastie, and R. Tibshirani (2018). Some methods for heterogeneous treatment effect estimation in high dimensions. *Statistics in medicine* 37(11), 1767–1787.
- Prentice, R. (1989, April). Surrogate endpoints in clinical trials: definition and operational criteria. *Statistics in medicine* 8(4), 431–440.
- R Core Team (2021). *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing.
- Resche-Rigon, M., I. White, J. Bartlett, S. A. Peters, and S. Thompson (2013, 07). Multiple imputation for handling systematically missing confounders in meta-analysis of individual participant data. *Statistics in medicine* 32.



- Richardson, T. S. and J. M. Robins (2013). Single world intervention graphs (swigs): A unification of the counterfactual and graphical approaches to causality. *Center for the Statistics and the Social Sciences, University of Washington Series. Working Paper 128*(30), 2013.
- Robins, J. (1986). A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect. *Mathematical Modelling* 7, 1393–1512.
- Robins, J. M. (2000). Marginal structural models versus structural nested models as tools for causal inference. In *Statistical Models in Epidemiology, the Environment, and Clinical Trials*, pp. 95–133. Springer, New York.
- Robins, J. M., S. D. Mark, and W. Newey (1992). Estimating exposure effects by modelling the expectation of exposure conditional on confounders. *Biometrics* 48 2, 479–95.
- Robins, J. M., A. Rotnitzky, and L. P. Zhao (1994). Estimation of regression coefficients when some regressors are not always observed. *Journal of the American Statistical Association* 89(427), 846–866.
- Robinson, P. (1988). Root-  $n$ -consistent semiparametric regression. *Econometrica* 56(4), 931–54.
- Rosenbaum, P. (2005, 10). *Sensitivity Analysis in Observational Studies*, Volume 4.
- Rosenbaum, P. R. and D. B. Rubin (1983a). Assessing the sensitivity to an unobserved binary covariate in an observational study with binary outcome. *Journal of the Royal Statistical Society: Series B (Methodological)* 45(2), 212–218.
- Rosenbaum, P. R. and D. B. Rubin (1983b). The central role of the propensity score in observational studies for causal effects. *Biometrika* 70(1), 41–55.
- Rosenbaum, P. R. and D. B. Rubin (1984). Reducing bias in observational studies using subclassification on the propensity score. *J Am Stat Assoc* 79, 516–524.
- Ross, S. M. (2020). *Introduction to probability and statistics for engineers and scientists*. Academic press.
- Rothenhäusler, D., N. Meinshausen, P. Bühlmann, and J. Peters (2021). Anchor regression: Heterogeneous data meet causality. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 83(2), 215–246.
- Rothman, K. J. (2011). *Epidemiology: an introduction* (2 ed.). Oxford University Press.
- Rothman, K. J., J. E. Gallacher, and E. E. Hatch (2013, 08). Why representativeness should be avoided. *International Journal of Epidemiology* 42(4), 1012–1014.
- Rothman, K. J. and S. Greenland (2000). *Modern Epidemiology* (2 ed.). Lippincott Williams and Wilkins.
- Rothwell, P. (2007, 01). External validity of randomised controlled trials: “to whom do the results of this trial apply?”. *Lancet* 365, 82–93.
- Rotnitzky, A. and E. Smucler (2020). Efficient adjustment sets for population average causal treatment effect estimation in graphical models. *Journal of Machine Learning Research* 21(188), 1–86.
- Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. *Journal of Educational Psychology* 66, 688–701.
- Rubin, D. B. (1976). Inference and missing data. *Biometrika* 63, 581–592.
- Rubin, D. B. (1990). Formal modes of statistical inference for causal effects. *Quality Engineering* 36, 185–188.

- Rudolph, K. E., N. M. Schmidt, M. M. Glymour, R. Crowder, J. Galin, J. Ahern, and T. L. Osypuk (2018, March). Composition or context: Using transportability to understand drivers of site differences in a large-scale housing experiment. *Epidemiology (Cambridge, Mass.)* 29(2), 199–206.
- Rudolph, K. E. and M. J. van der Laan (2017). Robust estimation of encouragement design intervention effects transported across sites. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 79, 1509–1525.
- Sackett, D. L., J. J. Deeks, and D. G. Altman (1996). Down with odds ratios! *Evidence Based Medicine* 1, 164 – 166.
- Saul, B. C. and M. G. Hudgens (2020). The calculus of m-estimation in R with geex. *Journal of Statistical Software* 92(2), 1–15.
- Scharfstein, D. O., A. Rotnitzky, and J. M. Robins (1999). Adjusting for nonignorable drop-out using semiparametric nonresponse models. *J Am Stat Assoc* 94, 1096–1120.
- Schmidli, H., S. Gsteiger, S. Roychoudhury, A. O’Hagan, D. Spiegelhalter, and B. Neuenschwander (2014, December). Robust meta-analytic-predictive priors in clinical trials with historical control information. *Biometrics* 70(4), 1023–1032.
- Schnitzer, M., J. Lok, and S. Gruber (2015, 07). Variable selection for confounder control, flexible modeling and collaborative targeted minimum loss-based estimation in causal inference. *The international journal of biostatistics* 12.
- Schulz, K. F., D. G. Altman, D. Moher, and C. Group\* (2010). Consort 2010 statement: updated guidelines for reporting parallel group randomized trials. *Annals of internal medicine* 152(11), 726–732.
- Schwartz, L. M., S. Woloshin, E. L. Dvorin, and H. G. Welch (2006, December). Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. *BMJ (Clinical research ed.)* 333(7581), 1248.
- Seaman, S. and I. White (2014). Inverse probability weighting with missing predictors of treatment assignment or missingness. *Comm. Statist. Theory Methods* 43, 3499–3515.
- Shakur-Still, H., I. Roberts, R. Bautista, J. Caballero, T. Coats, Y. Dewan, H. El-Sayed, G. Tamar, S. Gupta, J. Herrera, B. Hunt, P. Iribhogbe, M. Izurieta, H. Khamis, E. Komolafe, M. Marrero, J. Mejía-Mantilla, J. J. Miranda, C. Uribe, and S. Yutthakasemsunt (2009, 11). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. *Lancet* 376, 23–32.
- Sheps, M. C. (1958). Shall we count the living or the dead? *New England Journal of Medicine* 259(25), 1210–1214. PMID: 13622912.
- Shpitser, I. and J. Pearl (2006). Identification of joint interventional distributions in recursive semi-markovian causal models. In *Proceedings of the 21st National Conference on Artificial Intelligence - Volume 2*, AAAI’06, pp. 1219–1226. AAAI Press.
- Simpson, E. H. (1951). The interpretation of interaction in contingency tables. *Journal of the Royal Statistical Society: Series B (Methodological)* 13(2), 238–241.
- Singal, A. G., P. D. Higgins, and A. K. Waljee (2014). A primer on effectiveness and efficacy trials. *Clinical and translational gastroenterology* 5(1), e45.
- Sjölander, A., E. Dahlqvist, and J. Zetterqvist (2016, May). A note on the noncollapsibility of rate differences and rate ratios. *Epidemiology (Cambridge, Mass.)* 27(3), 356–359.
- Smucler, E., F. Sapienza, and A. Rotnitzky (2021, 03). Efficient adjustment sets in causal graphical models with hidden variables. *Biometrika* 109(1), 49–65.

- Snowden, J. M., S. Rose, and K. M. Mortimer (2011). Implementation of g-computation on a simulated data set: demonstration of a causal inference technique. *American journal of epidemiology* 173(7), 731–738.
- Spiegelman, D., P. Khudyakov, M. Wang, and T. Vanderweele (2017, 11). Evaluating public health interventions: 7. let the subject matter choose the effect measure: Ratio, difference, or something else entirely. *American journal of public health* 108, e1–e4.
- Spiegelman, D. and T. J. VanderWeele (2017). Evaluating public health interventions: 6. modeling ratios or differences? let the data tell us. *American Journal of Public Health* 107, 1087–1091.
- Splawa-Neyman, J., D. M. Dabrowska, and T. P. Speed (1990). On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9. *Statistical Science* 5(4), 465 – 472.
- Stefanski, L. A. and D. D. Boos (2002). The calculus of m-estimation. *The American Statistician* 56(1), 29–38.
- Stuart, E. A. (2010). Matching methods for causal inference: A review and a look forward. *Statist. Sci.* 25, 1–21.
- Stuart, E. A., B. Ackerman, and D. Westreich (2018). Generalizability of randomized trial results to target populations: Design and analysis possibilities. *Research on social work practice* 28(5), 532–537.
- Stuart, E. A., C. P. Bradshaw, and P. J. Leaf (2015). Assessing the generalizability of randomized trial results to target populations. *Prevention Science* 16, 475–485.
- Stuart, E. A., S. R. Cole, C. P. Bradshaw, and P. J. Leaf (2011). The use of propensity scores to assess the generalizability of results from randomized trials. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 174, 369–386.
- Stuart, E. A. and A. Rhodes (2017). Generalizing treatment effect estimates from sample to population: A case study in the difficulties of finding sufficient data. *Evaluation Review* 41(4), 357–388. PMID: 27491758.
- Student (1908). The probable error of a mean. *Biometrika* 6(1), 1–25.
- Sugiyama, M. and M. Kawanabe (2012). *Machine Learning in Non-stationary Environments: Introduction to Covariate Shift Adaptation*. MIT press.
- Susukida, R., R. Crum, E. Stuart, C. Ebnesajjad, and R. Mojtabai (2016, 01). Assessing sample representativeness in randomized control trials: Application to the national institute of drug abuse clinical trials network. *Addiction* 111, n/a–n/a.
- Tan, Z. (2006). A distributional approach for causal inference using propensity scores. *Journal of the American Statistical Association* 101(476), 1619–1637.
- Textor, J., J. Hardt, and S. Knüppel (2011). Dagitty: a graphical tool for analyzing causal diagrams. *Epidemiology* 22(5), 745.
- Thistlethwaite, D. L. and D. T. Campbell (1960). Regression-discontinuity analysis: An alternative to the ex post facto experiment. *Journal of Educational psychology* 51(6), 309.
- Tian, J. and J. Pearl (2000). Probabilities of causation: Bounds and identification. *Annals of Mathematics and Artificial Intelligence* 28(1), 287–313.
- Tibshirani, J., S. Athey, and S. Wager (2020). *grf: Generalized Random Forests*. R package version 1.2.0.

- Tikka, S., A. Hyttinen, and J. Karvanen (2019). Causal effect identification from multiple incomplete data sources: A general search-based approach. *arXiv preprint arXiv:1902.01073*.
- Tikka, S. and J. Karvanen (2017). Identifying causal effects with the R package *causaleffect*. *Journal of Statistical Software* 76(12), 1–30.
- Tipton, E. (2013). Improving generalizations from experiments using propensity score subclassification: Assumptions, properties, and contexts. *Journal of Educational and Behavioral Statistics* 38, 239–266.
- Tipton, E., K. Hallberg, L. Hedges, and W. Chan (2016, 07). Implications of small samples for generalization: Adjustments and rules of thumb. *Evaluation Review* 41.
- Tulchinsky, T. H. (2018). John snow, cholera, the broad street pump; waterborne diseases then and now. *Case studies in public health*, 77.
- Turrini, M. and C. Bourgain (2021, August). Appraising screening, making risk in/visible. The medical debate over Non-Rare Thrombophilia (NRT) testing before prescribing the pill. *Sociology of Health and Illness* 43(7), 1627–1642.
- Twala, B., M. Jones, and D. J. Hand (2008). Good methods for coping with missing data in decision trees. *Pattern Recognition Letters* 29(7), 950–956.
- van Buuren, S. (2018). *Flexible Imputation of Missing Data. Second Edition*. Boca Raton, FL: Chapman and Hall/CRC.
- Van Eijk, R. P., H.-J. Westeneng, S. Nikolakopoulos, I. E. Verhagen, M. A. Van Es, M. J. Eijkemans, and L. H. Van Den Berg (2019). Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. *Neurology* 92(5), e451–e460.
- Vandenbroucke, J., T. Koster, F. Rosendaal, E. Briët, P. Reitsma, and R. Bertina (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor v leiden mutation. *The Lancet* 344(8935), 1453–1457. Originally published as Volume 2, Issue 8935.
- VanderWeele, T. J. and J. M. Robins (2007, September). Four types of effect modification: a classification based on directed acyclic graphs. *Epidemiology (Cambridge, Mass.)* 18(5), 561–568.
- Vansteelandt, S. and N. Keiding (2011, 03). Invited Commentary: G-Computation—Lost in Translation? *American Journal of Epidemiology* 173(7), 739–742.
- Veitch, V. and A. Zaveri (2020). Sense and sensitivity analysis: Simple post-hoc analysis of bias due to unobserved confounding. *Advances in Neural Information Processing Systems* 33, 10999–11009.
- Velentgas, P., N. A. Dreyer, P. Nourjah, S. R. Smith, and M. Torchia (2013). Developing a protocol for observational comparative effectiveness research: A user’s guide.
- Wager, S. (2020). Stats 361: Causal inference.
- Wager, S. and S. Athey (2018). Estimation and inference of heterogeneous treatment effects using random forests. *Journal of the American Statistical Association* 113(523), 1228–1242.
- Wendling, T., K. Jung, A. Callahan, A. Schuler, N. Shah, and B. Gallego (2018, 06). Comparing methods for estimation of heterogeneous treatment effects using observational data from health care databases. *Statistics in Medicine* 37.
- Westreich, D., J. Edwards, C. Lesko, E. Stuart, and S. Cole (2017a, 05). Transportability of trial results using inverse odds of sampling weights. *American journal of epidemiology* 186.
- Westreich, D., J. K. Edwards, C. R. Lesko, S. R. Cole, and E. A. Stuart (2018, 10). Target Validity and the Hierarchy of Study Designs. *American Journal of Epidemiology* 188(2), 438–443.

- Westreich, D., J. K. Edwards, C. R. Lesko, E. Stuart, and S. R. Cole (2017b). Transportability of trial results using inverse odds of sampling weights. *American journal of epidemiology* 186(8), 1010–1014.
- Westreich, D., J. Lessler, and M. Jonsson Funk (2010, 08). Propensity score estimation: Neural networks, support vector machines, decision trees (cart), and meta-classifiers as alternatives to logistic regression. *Journal of clinical epidemiology* 63, 826–33.
- Whittemore, A. S. (1978). Collapsibility of multidimensional contingency tables. *Journal of the Royal Statistical Society. Series B (Methodological)* 40(3), 328–340.
- Winkelstein Jr, W. (2004). Vignettes of the history of epidemiology: Three firsts by janet elizabeth lane-clayton. *American journal of epidemiology* 160(2), 97–101.
- Witte, J. and V. Didelez (2018, 10). Covariate selection strategies for causal inference: Classification and comparison. *Biometrical Journal* 61.
- Witte, J., L. Henckel, M. H. Maathuis, and V. Didelez (2020). On efficient adjustment in causal graphs. *The Journal of Machine Learning Research* 21(1), 9956–10000.
- Wooldridge, J. (2016). Should instrumental variables be used as matching variables? *Research in Economics* 70(2), 232–237.
- Wooldridge, J. M. (2015). *Introductory econometrics: A modern approach*. Cengage learning.
- Wu, L. and S. Yang (2022a). Integrative r-learner of heterogeneous treatment effects combining experimental and observational studies. *Proceedings of the 1st Conference on Causal Learning and Reasoning*.
- Wu, L. and S. Yang (2022b). Transfer learning of individualized treatment rules from experimental to real-world data. *Journal of Computation and Graphical Statistics* (doi.org/10.1080/10618600.2022.2141752).
- Xiao, M., Y. Chen, S. Cole, R. MacLehose, D. Richardson, and H. Chu (2022). Is or “portable” in meta-analysis? time to consider bivariate generalized linear mixed model. *Journal of clinical epidemiology* 142, 280.
- Xiao, M., H. Chu, S. Cole, Y. Chen, R. MacLehose, D. Richardson, and S. Greenland (2021). Odds ratios are far from “portable”: A call to use realistic models for effect variation in meta-analysis.
- Yadlowsky, S., F. Pellegrini, F. Lionetto, S. Braune, and L. Tian (2021). Estimation and validation of ratio-based conditional average treatment effects using observational data. *Journal of the American Statistical Association* 116(533), 335–352.
- Yang, S. and P. Ding (2020). Combining multiple observational data sources to estimate causal effects. *Journal of American Statistical Association* 115, 1540–1554.
- Yang, S. and J. K. Kim (2020). Statistical data integration in survey sampling: A review. *Japanese Journal of Statistics and Data Science* 3, 625–650.
- Yang, S., J. K. Kim, and R. Song (2020a). Doubly robust inference when combining probability and non-probability samples with high-dimensional data. *Journal of the Royal Statistical Society, Series B* 82, 445–465.
- Yang, S., J. K. Kim, and R. Song (2020b). Doubly robust inference when combining probability and non-probability samples with high dimensional data. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 82.

- Yang, S. and X. Wang (2022). RWD-integrated randomized clinical trial analysis. *ASA Biopharmaceutical Report Real World Evidence (Editors: Herbert Pang, Ling Wang, Kristi L. Griffiths)* 29, 15–21.
- Yang, S., X. Wang, and D. Zeng (2022). Elastic integrative analysis of randomized trial and real-world data for treatment heterogeneity estimation. *Journal of the Royal Statistical Society: Series B* (accepted).
- Yang, S., D. Zeng, and X. Wang (2020). Improved inference for heterogeneous treatment effects using real-world data subject to hidden confounding. *arXiv preprint arXiv:2007.12922*.
- Yao, L., Z. Chu, S. Li, Y. Li, J. Gao, and A. Zhang (2021). A survey on causal inference. *ACM Transactions on Knowledge Discovery from Data (TKDD)* 15(5), 1–46.
- Yule, G. U. (1934). On some points relating to vital statistics, more especially statistics of occupational mortality. *Journal of the Royal Statistical Society* 97(1), 1–84.
- Zhong, Y., E. H. Kennedy, L. M. Bodnar, and A. I. Naimi (2021, 07). Aipw: An r package for augmented inverse probability weighted estimation of average causal effects. *American Journal of Epidemiology*.
- Zivich, P., M. Klose, S. Cole, J. Edwards, and B. Shook-Sa (2022, 03). Delicatessen: M-estimation in python.

**Titre :** Généralisation d'un effet causal depuis une étude randomisée vers une population cible : contributions théoriques et méthodologiques

**Mots clés :** Inférence causale, Validité Externe, Apprentissage statistique.

**Résumé :** La médecine moderne, aussi dite médecine fondée sur les preuves, place les essais contrôlés randomisés (ECRs) au premier plan de la preuve clinique. En effet, la randomisation permet une estimation de l'effet causal du traitement, au lieu de la simple association ou corrélation. Cependant, de plus en plus de limites sont trouvées aux ECRs, du fait de leurs stricts critères d'éligibilité, des conditions de réalisation, des périodes de temps trop restreintes qu'ils couvrent, ou encore de leur petite taille d'échantillon. Toutes ces raisons entament ce que l'on appelle la validité externe des résultats. L'utilisation de données observationnelles – ou dites de vie réelle – constitue une potentielle solution. Les autorités sanitaires comme le régulateur américain (*Food and Drug Administration*) ou encore la *Haute Autorité de la Santé* (HAS) soutiennent ces nouvelles pratiques. Mais les données de vie réelle ne sont pas non plus une panacée, car leur analyse repose sur des hypothèses non vérifiables pour la plupart. Des travaux plus récents proposent de combiner les deux sources de données, afin de renforcer les faiblesses de l'une par les forces de l'autre. Ainsi, cette thèse propose d'abord une revue de toutes les méthodes existantes sur le sujet, que ce soit pour déconfondre une base de données observationnelles à partir de données expérimentales ou bien pour généraliser à d'autres populations une étude randomisée. Ce travail de thèse propose en-

suite d'approfondir ce dernier aspect, en utilisant la représentativité des données de vie réelle pour répondre les résultats d'un ECR. Cette thèse étudie les propriétés théoriques de ces méthodes, telles que les propriétés d'estimation à taille finie ou asymptotique (biais et variance). Ces résultats permettent d'obtenir des recommandations pratiques pour la recherche clinique, notamment concernant la sélection de covariables. Cette thèse propose également une analyse de sensibilité lorsque les covariables sont partiellement ou totalement observées. La plupart des travaux existants définissent l'effet d'un traitement comme une différence absolue. Pourtant, d'autres métriques, comme le ratio, sont préférées dans la recherche clinique. Par conséquent, cette thèse ouvre également la voie à la généralisation de toutes les mesures causales, et non pas seulement de l'une d'entre elles. Ce faisant, nous relierons la généralisation à une préoccupation plutôt ancienne de la causalité, à savoir la collapsibilité d'une mesure. Nous proposons également une autre façon d'appréhender ce que l'on appelle l'hétérogénéité d'un effet. Ceci nous permet de montrer que les méthodes pour généraliser un effet causal dépendent de la nature de l'outcome (continu ou binaire) ainsi que de la nature de la mesure d'intérêt (ratio ou différence). Tous les travaux de cette thèse sont développés en lien avec la recherche clinique, notamment via le consortium français de la Traumabase.

**Title** : Generalizing a causal effect from a trial to a target population : methodological and theoretical contributions

**Keywords** : Causal inference, External validity, Machine-Learning.

**Abstract** : Modern evidence-based medicine places Randomized Controlled Trials (RCTs) at the forefront of clinical evidence. Randomization enables the estimation of the average treatment effect (ATE) by eliminating the confounding effects of spurious or unwanted associated factors. More recently, concerns have been raised on the limited scope of RCTs : stringent eligibility criteria, unrealistic real-world compliance, short timeframe, limited sample size, etc. All these possible limitations threaten the external validity of RCT studies to other situations or populations. The usage of complementary non-randomized data, referred to as *observational* or from the *real world*, brings promises as additional sources of evidence. Today, there is a growing incentive to rely on this new data, which is also endorsed by health authorities such as the *Food and Drug Administration* (FDA) in the U.S. and the *Haute Autorité de la Santé* (HAS) in France. Combining both data types – randomized and observational – is a new venue that could make the most of both worlds. First, this thesis proposes a review of all the existing methods combining several data types to build clinical evidence. Then, the thesis is focused on improving the external validity of RCTs. In other words, how can we use representative sample of the

target population of interest to *re-weight* or to *generalize* the trial's findings? Such methods are quite recent and have been proposed in the early 2010's. This thesis investigates theoretical properties of these methods, such as finite and large sample properties (bias and variance) of the estimation, which helps to provide practical guidelines about covariates selection and the impact of both samples' sizes. This thesis also proposes a sensitivity analysis when covariates are either partially or totally unobserved. Most – if not all – current statistical works concern the generalization of the effect on the scale of the absolute difference, while our clinicians collaborators pointed to us the need to encompass several causal measures (e.g. ratio, odds ratio, number needed to treat). Therefore, this thesis also opens the door to the generalization of all causal measures of interest. Doing so, we link generalization with a rather old concern of causality, namely collapsibility of a measure. We also propose a new framing to apprehend heterogeneity of a treatment effect. Finally, it turns out that assumptions required for generalization depend on the nature of the outcome and the causal measure of interest. All our research questions are motivated by clinical applications, and in particular by the Traumabase consortium.